{"config":{"lang":["en"],"separator":"[\\s\\-]+","pipeline":["stopWordFilter"],"fields":{"title":{"boost":1000.0},"text":{"boost":1.0},"tags":{"boost":1000000.0}}},"docs":[{"location":"","title":"ZJE Collection","text":"<p>Welcome \u2014 this site is generated from the repository's ZJE courses folder, from my own notes. This website is open-sourced, which means you can feel free to download or fork. </p> <p>If you have any further question, find me in xhs@\u751f\u6210\u4e00\u53ea\u5934\u4e0a\u6234\u82b1\u82b1\u7684\u5c0fmomo\uff1bor via email: c1556613010@outlook.com and you are very welcomed to contribute to this repo, like filling the gap of other courses.</p> <p>\u2764\ufe0f If you find this website helpful, please give it a star!</p> \u2b50 Star on GitHub <p>Your support means a lot! \ud83d\ude4f</p>"},{"location":"#credit-to","title":"Credit to","text":"<ul> <li>Yicheng_22: contributed to IBMS3</li> <li>Tianze_22: contributed to the recovery of files</li> <li>Xiaoran_22: contributed to multiple courses</li> <li>Yue_22: contributed to multiple courses</li> <li>Boxiang_21: contributed to multiple courses</li> </ul> <p>Thank you all! If you find anything wrong, please tell me and I will fix the errors.</p> <p>Browse the sections below, you can go through everything online:</p> <ul> <li>Code Cheatsheet</li> </ul>"},{"location":"#courses-by-year","title":"Courses by Year","text":""},{"location":"#year-1","title":"Year 1","text":"<ul> <li>CHEM1: CHEM1/</li> <li>IBI1: IBI1/</li> <li>IBMS1: IBMS1/</li> <li>ICMB1: ICMB1/</li> <li>MATH1: MATH1/</li> </ul>"},{"location":"#year-2","title":"Year 2","text":"<ul> <li>ADS2: ADS2/</li> <li>BG2: BG2/</li> <li>BaO2: BaO2/</li> <li>DST2: DST2/</li> <li>GP2: GP2/</li> <li>IFBS2: IFBS2/</li> <li>MI2: MI2/</li> </ul>"},{"location":"#year-3","title":"Year 3","text":"<ul> <li>BMI3: BMI3/</li> <li>CBSB3: CBSB3/</li> <li>IBMS3: IBMS3/</li> <li>IN3: IN3/</li> <li>MBE3: MBE3/</li> <li>PoN3: PoN3/</li> </ul>"},{"location":"#year-4","title":"Year 4","text":"<ul> <li>BIA4: BIA4/</li> <li>IBMS4: IBMS4/</li> <li>IID_4: IID_4/</li> </ul> <p>Note: individual course folders remain at the repo root under <code>ZJE_Collection/</code>. Use the Year pages (Year1\u2013Year4) for a compact view, or click a course above to open its page.</p> <p>Notes:</p> <ul> <li>PDFs are kept in-place; check file sizes before publishing widely.</li> <li>Filenames with spaces are preserved; consider renaming for cleaner URLs.</li> </ul>"},{"location":"#click-to-download-here","title":"Click to Download Here!","text":"<ul> <li>Download the entire repository as a ZIP: Download repo ZIP</li> <li>Course material ZIPs are hosted externally (Google Drive / Zenodo). See:<ul> <li>Zips Index</li> <li>Zip contents overview</li> </ul> </li> </ul>"},{"location":"#_1","title":"\u8d21\u732e\u6307\u5357","text":"<p>\u540c\u5b66\uff0c\u4f60\u7ec8\u4e8e\u4e5f\u8981\u8fc8\u51fa\u8d21\u732e\u5230\u5f00\u6e90\u793e\u533a\u7684\u8fd9\u4f1f\u5927\u4e00\u6b65\u4e86\uff01\u611f\u8c22\u4f60\u7684\u652f\u6301\uff01\u5728\u6b64\u4e4b\u524d\uff0c\u8bf7\u5148\u9605\u8bfb\uff1a</p> <p>!! 1. \u5047\u8bbe\u6211\u7684\u6587\u4ef6\u683c\u5f0f\u5b8c\u5168\u662fmarkdown\uff1a\u90a3\u4e48\u7f51\u7ad9\u539f\u751f\u652f\u6301\u663e\u793a\uff1b\u8bf7\u786e\u4fdd\u4e00\u4ef6\u4e8b\u60c5\uff0c\u4f60\u7684\u56fe\u50cf\u4e0d\u662f\u5b8c\u5168\u5b58\u5728\u672c\u5730\u3002\u6211\u7684\u5de5\u4f5c\u6d41\u662f\u56fe\u50cf\u4f1a\u81ea\u52a8\u4e0a\u4f20\u5230\u67d0\u4e00\u4e2a\u56fe\u50cf\u7f51\u7ad9\u5e76\u4e14\u81ea\u52a8\u7f16\u7801\u6210\u7f51\u7ad9\u94fe\u63a5\uff0c\u6240\u4ee5\u4e0d\u5f71\u54cd\u4e0a\u4f20\uff1b\u5426\u5219\uff0c\u8bf7\u770b\u7b2c\u4e8c\u6761\u3002</p> <ol> <li> <p>\u5047\u8bbe\u6211\u7684\u6587\u4ef6\u683c\u5f0f\u5b8c\u5168\u662fpdf\uff1a\u975e\u5e38\u597d\uff0c\u8fd9\u4e2a\u7f51\u7ad9\u4e5f\u539f\u751f\u652f\u6301\u3002Markdown\u5982\u679c\u56fe\u50cf\u90fd\u5728\u672c\u5730\uff0c\u4e5f\u8bf7\u5148\u8f6c\u6362\u6210pdf\u683c\u5f0f\uff0c\u6709\u5f88\u591a\u7f51\u7ad9\u53ef\u4ee5\u505a\u8fd9\u4ef6\u4e8b\uff0cObsidian\u4e5f\u53ef\u4ee5\u3002\u53ea\u8981\u662fPdf\u90fd\u53ef\u4ee5\uff01\u7f51\u7ad9\u4e4b\u540e\u4f1a\u81ea\u52a8\u538b\u7f29pdf\uff0c\u901a\u8fc7\u7f51\u9875\u76f4\u63a5\u53ef\u4ee5\u4e0b\u8f7dzip\u5408\u96c6\u3002</p> </li> <li> <p>\u5047\u8bbe\u4f60\u7684\u6587\u4ef6\u683c\u5f0f\u5f88\u5947\u602a\uff1a\u6682\u65f6\u6ca1\u6709\u6392\u67e5\u6240\u6709\u683c\u5f0f\uff0c\u4f46\u662f\u601d\u7ef4\u5bfc\u56fe\uff0cOneNote\uff0c\u7b49\u6bd4\u8f83\u8f6f\u4ef6\u72ec\u6709\u7684\u683c\u5f0f\u57fa\u672c\u4e0d\u80fd\u7f51\u9875\u76f4\u63a5\u67e5\u770b\u3002\u6b64\u65f6\u6700\u597d\u7684\u65b9\u6cd5\u6709\u4e24\u4e2a\uff0c\u7b2c\u4e00\u4e2a\uff0c\u662f\u76f4\u63a5\u4e0a\u4f20\u5230\u4f60\u81ea\u5df1\u7684\u67d0\u4e00\u4e2a\u4e91\u76d8\uff0c\u786e\u4fdd\u5171\u4eab\u94fe\u63a5\u540e\uff0c\u53ef\u4ee5\u5199\u4e00\u4e2a\u7b80\u5355\u7684\u6982\u8ff0\uff0c\u7136\u540e\u628a\u6982\u8ff0\u548c\u94fe\u63a5\u53d1\u9001\u7ed9\u6211\u3002\u7b2c\u4e8c\u4e2a\uff0c\u662f\u548c\u6211\u8054\u7cfb\uff0c\u6587\u4ef6\u4f20\u8f93\u7ed9\u6211\u540e\uff0c\u6211\u4f1a\u5e2e\u4f60\u4e0a\u4f20\u5230\u6211\u7684Google Drive\uff08\u901a\u5e38\u66f4\u63a8\u8350\uff0c\u56e0\u4e3a\u6211\u4f1a\u8fdb\u884c\u7edf\u4e00\u6574\u7406\uff09\u3002</p> </li> <li> <p>\u6211\u60f3\u8d21\u732e\u8bfe\u4e0a\u7684\u4f5c\u4e1a\u548c\u671f\u672b\u8003\u8bd5\u5185\u5bb9\uff0c\u53ef\u4ee5\u5417\uff1a\u5f88\u9057\u61be\uff0c\u8fd9\u4e2a\u5176\u5b9e\u662f\u4e00\u4e2a\u5b66\u6821\u4e0d\u592a\u5141\u8bb8\u7684\u4e8b\uff0c\u4e3a\u4e86\u7f51\u7ad9\u6301\u7eed\u8fd0\u884c\uff08\u672c\u4ebaxhs\u5df2\u7ecf\u88abE\u5f00\u76d2\u4e86\uff09\uff0c\u6682\u65f6\u4e0d\u652f\u6301\u516c\u5f00\u3002\u4e3b\u8981\u6b22\u8fce\u5927\u5bb6\u5206\u4eab\u671f\u672b\u603b\u7ed3\u7684\u7b14\u8bb0\uff0c\u6216\u8005\u8bfe\u7a0b\u4e2d\u5b66\u4e60\u603b\u7ed3\u7684\u7b14\u8bb0\uff1b\u96f6\u788e\u7684\u4e0a\u8bfe\u7684\u8bb0\u5f55\u7b49\uff0c\u4e5f\u5176\u5b9e\u4e0d\u662f\u5f88\u63a8\u8350\uff0c\u4ee5\u4e3a\u4fe1\u606f\u4e0d\u96c6\u4e2d\u7684\u8bdd\u6bd4\u8f83\u96be\u4ee5\u7528\u4e8e\u590d\u4e60\u3002</p> </li> <li> <p>\u6211\u5f88\u60f3\u8d21\u732e\uff0c\u4f46\u662f\u4e0d\u77e5\u9053\u8be5\u600e\u4e48\u505a\uff1a\u6ca1\u4e8b\uff0c\u6b22\u8fce\u8054\u7cfb\u6211\uff0c\u6709\u4efb\u4f55\u4e0d\u660e\u767d\u7684\u5730\u65b9\u6216\u8005\u4f60\u60f3\u5206\u4eab\u8bfe\u7a0b\u4e4b\u5916\u7684\u77e5\u8bc6\u7b14\u8bb0\uff01</p> </li> <li> <p>\u8bfe\u7a0b\u7b14\u8bb0\u91cd\u590d\u4e86\uff1a \u662f\u7684\uff0c\u968f\u7740\u8d21\u732e\u8005\u8d8a\u6765\u8d8a\u591a\uff0c\u8fd9\u662f\u80af\u5b9a\u4f1a\u53d1\u751f\u7684\u3002\u4f46\u662f\u6211\u76f8\u4fe1\u6ca1\u6709\u4efb\u4f55\u4eba\u7684\u7b14\u8bb0\u662f\u5b8c\u7f8e\u7684\uff0c\u53cd\u8fc7\u6765\u8bf4\uff0c\u4e0d\u7ba1\u8c01\u63d0\u4f9b\u7b14\u8bb0\uff0c\u603b\u80fd\u5e26\u6765\u65b0\u7684\u89c6\u89d2\uff01\u7f51\u7ad9\u5df2\u7ecf\u5728\u5c3d\u529b\u5efa\u8bbe\u5206\u7c7b\u4f53\u7cfb\u3002</p> </li> </ol>"},{"location":"AUTHORS/","title":"AUTHORS / \u8d21\u732e\u8005","text":"<p>Current maintainers / \u5f53\u524d\u7ef4\u62a4\u8005 - Yiru, 2022</p> <p>Current contributors / \u5f53\u524d\u8d21\u732e\u8005 - Xiaoran, Yaqi, Yifei, et al. 2022 \u2014 \u5df2\u8d21\u732e\u975e\u5e38\u8be6\u5c3d\u5b9d\u8d35\u7684\u8d44\u6599\uff0c\u5c24\u5176\u5173\u4e8eBMS\u65b9\u5411\u7684\u8bfe\u7a0b\u3002\u6ce8\u610f\u5230\u4e86\u6587\u4ef6\u540d\u4e2d\u6709\u5176\u4ed6\u53ef\u80fd\u7684\u8d21\u732e\u8005\uff0c\u611f\u8c22\u5927\u5bb6\u3002 - Yue,22 - \u7ee7\u7eed\u8865\u5168\u4e86BMS\u65b9\u5411\u7684\u8bfe\u7a0b\uff0c\u65e5\u76ca\u5b8c\u5584\uff01 - Boxiang, 22 - \u7ee7\u7eed\u8865\u5168\u4e86\u57fa\u7840\u8bfe\u7a0b\u548cBMI\u65b9\u5411\u7684\u8bfe\u7a0b\uff01\u611f\u8c22\u5b66\u957f\uff01 - Zhouyue, 2023 - \u7ba1\u7406\u4e86\u975e\u5e38\u68d2\u7684\u4fe1\u606f\u6c47\u603b\u7ad9 zjers.com</p> <p>\u5982\u4f55\u6dfb\u52a0 / How to add yourself - \u5728\u63d0\u4ea4 PR \u65f6\uff0c\u8bf7\u5728 <code>AUTHORS.md</code> \u4e2d\u4ee5\u4e00\u884c\u683c\u5f0f\u6dfb\u52a0\uff1a<code>- &lt;github_handle&gt; \u2014 &lt;brief description&gt;</code>\u3002 - \u6211\u4eec\u4f1a\u5728\u5408\u5e76\u65f6\u786e\u8ba4\u5e76\u4fdd\u7559\u63d0\u4ea4\u8005\u7f72\u540d\u3002</p> <p>\u6ce8\uff1a\u82e5\u4f60\u5e0c\u671b\u4fdd\u6301\u533f\u540d\uff0c\u53ef\u5728\u7b14\u8bb0\u5143\u6570\u636e\u4e2d\u4f7f\u7528\u533f\u540d\u6807\u8bc6\uff0c\u4f46\u8bf7\u5728 PR \u63cf\u8ff0\u4e2d\u63d0\u4f9b\u53ef\u9a8c\u8bc1\u8054\u7cfb\u65b9\u5f0f\u3002</p>"},{"location":"CONTRIBUTING/","title":"CONTRIBUTING\uff08\u8d21\u732e\u6307\u5357\uff09","text":"<p>\u8c22\u8c22\u4f60\u60f3\u4e3a\u672c\u4ed3\u5e93\u8d21\u732e\u7b14\u8bb0\u548c\u8d44\u6599\uff01\u4e3a\u4fdd\u6301\u5185\u5bb9\u6574\u6d01\u4e0e\u53ef\u7528\u6027\uff0c\u8bf7\u6309\u4e0b\u9762\u6b65\u9aa4\u548c\u7ea6\u5b9a\u63d0\u4ea4\uff1a</p> <ol> <li>\u57fa\u672c\u6d41\u7a0b / Basic flow</li> <li>Fork \u672c\u4ed3\u5e93\uff0c\u521b\u5efa feature \u5206\u652f\uff08<code>notes/&lt;course&gt;-&lt;yourname&gt;-&lt;year&gt;</code>\uff09\u3002</li> <li>\u5728\u4f60\u7684\u5206\u652f\u4e2d\u6dfb\u52a0\u6216\u4fee\u6539\u6587\u4ef6\uff0c\u4f7f\u7528 <code>templates/note_template.md</code> \u4f5c\u4e3a\u7b14\u8bb0\u6a21\u677f\u3002</li> <li> <p>\u63d0\u4ea4\u5e76\u53d1\u8d77 Pull Request\uff0c\u586b\u5199 PR \u6a21\u677f\uff08.github/PULL_REQUEST_TEMPLATE.md\uff09\u3002</p> </li> <li> <p>\u6587\u4ef6\u4e0e\u547d\u540d\u89c4\u8303 / File &amp; naming conventions</p> </li> <li>\u7b14\u8bb0\u6587\u4ef6\uff1a\u4fdd\u5b58\u5728\u5bf9\u5e94\u8bfe\u7a0b\u76ee\u5f55\u4e0b\uff0c\u6587\u4ef6\u540d\u5e94\u5305\u542b\u8bfe\u7a0b\u540d + \u4f5c\u8005\u540e\u7f00\uff0c\u4f8b\u5982 <code>Topic 1 Innate Immune system (zl_2023).md</code>\u3002</li> <li>ZIP \u6587\u4ef6\uff1a\u8bf7\u5305\u542b\u8d21\u732e\u8005\u6807\u8bc6\u4e0e\u5e74\u4efd\uff0c\u4f8b <code>pon\u590d\u4e60\u8d44\u6599_lxrwyqlxf_2022.zip</code>\u3002</li> </ol> <p>\u91cd\u8981\uff1a\u672c\u4ed3\u5e93\u4e0d\u518d\u63a5\u6536 ZIP \u6587\u4ef6\u672c\u4f53\uff08\u592a\u5927\uff0c\u4e0d\u9002\u5408\u653e\u5728 GitHub\uff09\u3002</p> <ul> <li>\u8bf7\u5c06 ZIP \u4e0a\u4f20\u5230 Google Drive\uff08\u6216 Zenodo \u7b49\u5916\u90e8\u5b58\u50a8\uff09\u3002</li> <li> <p>\u5728 <code>ZJE_Collection/ZIPS_INDEX.md</code> \u4e2d\u8865\u5145\u6761\u76ee/\u72b6\u6001\uff0c\u5e76\u5728 <code>ZJE_Collection/zip_contents/</code> \u4e2d\u6dfb\u52a0\u5bf9\u5e94\u7684\u201c\u5185\u5bb9\u9875\u201d\uff08\u53ef\u5199\u660e ZIP \u5185\u5305\u542b\u54ea\u4e9b\u6587\u4ef6\uff0c\u6216\u8bfe\u7a0b\u8303\u56f4\uff09\u3002</p> </li> <li> <p>\u5982\u679c\u5305\u542b\u4e00\u4e9b\u6bd4\u8f83\u96be\u4ee5\u7f51\u7ad9\u76f4\u63a5\u8bfb\u53d6\u7684\u683c\u5f0f\uff0c\u53ef\u4ee5\u4f7f\u7528zip\u4f5c\u4e3a\u4e0a\u4f20\u9014\u5f84\uff0c\u5982\u679c\u7279\u522b\u5e0c\u671b\u76f4\u63a5\u5728\u7f51\u4e0a\u53ef\u4ee5\u9605\u8bfb\uff0cmd\u683c\u5f0f\u6216\u8005pdf\u683c\u5f0f\u53ef\u80fd\u6700\u597d\u3002</p> </li> </ul> <p>\u9644\uff1a\u66f4\u591a\u6a21\u677f\u89c1 <code>templates/note_template.md</code>\u3002</p> <p>\u611f\u8c22\u8d21\u732e\uff01 \u2014 CHENyiru &amp; contributors</p>"},{"location":"ZIPS_INDEX/","title":"ZIP contributions index","text":"<p>This file lists zip archives included in the collection, the inferred contributor, and a contents page.</p> <p>All large ZIP archives are hosted externally (not stored in this Git repo).</p> <p>Google Drive folder (all uploads): https://drive.google.com/drive/folders/1_ttbZASdiHPW9xt0GSjVjFHF5MAPk2fv?usp=drive_link</p> <p>For per-zip contents pages, see zip_contents overview.</p>"},{"location":"ZIPS_INDEX/#quick-index","title":"Quick index","text":"Package (Drive file name) Contributor Detail page BG\u5bfc\u56fe\u5408\u96c6_lxrwyqlxf.zip Xiaoran_etal BG\u5bfc\u56fe\u5408\u96c6_lxrwyqlxf \u601d\u7ef4\u5bfc\u56feIFBS_lxr.zip Xiaoran_etal \u601d\u7ef4\u5bfc\u56feIFBS_lxr IN_lxfwyqlxr.zip Xiaoran_etal IN_lxfwyqlxr MBE_lxrwyalxf.zip Xiaoran_etal MBE_lxrwyalxf pon\u590d\u4e60\u8d44\u6599_lxrwyqlxf.zip Xiaoran_etal pon\u590d\u4e60\u8d44\u6599_lxrwyqlxf IFBS\uff08theme34).zip Yue IFBS\uff08theme34) pon.zip Yue pon BG2_sum_Yiru.zip Yiru BG2_sum_Yiru Code_Cheatsheet_Yiru.zip Yiru Code_Cheatsheet_Yiru GP2_sum_Yiru.zip Yiru GP2_sum_Yiru IBMS3_full_Yiru.zip Yiru IBMS3_full_Yiru IID_4_full_Yiru.zip Yiru IID_4_full_Yiru MBE3_sum_Yiru.zip Yiru MBE3_sum_Yiru PoN3_full_Yiru.zip Yiru PoN3_full_Yiru"},{"location":"ADS2/","title":"ADS2","text":""},{"location":"ADS2/#external-links","title":"External links","text":"<ul> <li>Hal (2022-2023): https://drive.google.com/file/d/1Fl2WtzDZoyEqi3MLvilNCOUIeTbQTl-Y/view?usp=sharing</li> </ul>"},{"location":"BG2/","title":"BG2","text":""},{"location":"BG2/#contributors","title":"Contributors","text":"<ul> <li>Yiru: notes and PDFs</li> </ul>"},{"location":"BG2/#files","title":"Files","text":"<ul> <li>Browse Yiru materials: Yiru/</li> </ul>"},{"location":"BG2/#external-links","title":"External links","text":"<ul> <li>Hal (2022-2023): https://drive.google.com/file/d/1M41n2IJuvcm_0eYSWqiJpg2-tatguquG/view?usp=sharing</li> </ul>"},{"location":"BG2/Yiru/","title":"BG2","text":"<p>Files:</p> <ul> <li>calculation.pdf</li> <li>Collection of disease.pdf</li> <li>Collection of technology.pdf</li> </ul>"},{"location":"BIA4/","title":"BIA4","text":""},{"location":"BIA4/#external-links","title":"External links","text":"<ul> <li>Hal (2024-2025): https://drive.google.com/file/d/1QkXJCPLbmC3-H4PLHZLA6fEQm3eZzXAL/view?usp=sharing</li> </ul>"},{"location":"BMI3/","title":"BMI3","text":""},{"location":"BMI3/#external-links","title":"External links","text":"<ul> <li>Hal (2023-2024): https://drive.google.com/file/d/1QB0Z1TYR2U0DTcqwliKIKlJaJ68Umau2/view?usp=sharing</li> </ul>"},{"location":"BaO2/","title":"BaO2","text":""},{"location":"BaO2/#contributors","title":"Contributors","text":"<ul> <li>Yue: PDF materials</li> </ul>"},{"location":"BaO2/#files","title":"Files","text":"<ul> <li>Browse Yue PDFs: Yue/</li> </ul>"},{"location":"BaO2/Yue/","title":"BaO2 \u2014 Yue","text":"<p>Materials contributed by Yue:</p> <ul> <li>BaO\uff08\u975e\u5b8c\u6574\uff09.pdf \u2014 Download/view</li> </ul> <p>If you prefer a URL-safe filename, I can rename the PDF to <code>BaO_partial.pdf</code> and update links.</p>"},{"location":"CBSB3/","title":"CBSB3","text":"<p>! Please notice, this course has been replaced by CMML3 since 2022 class.</p>"},{"location":"CBSB3/#external-links","title":"External links","text":"<ul> <li>Hal (2023-2024): https://drive.google.com/file/d/1aiyIviT2sEW57mjtEKqtddtFxK4n8C4I/view?usp=sharing</li> </ul>"},{"location":"CHEM1/","title":"CHEM","text":""},{"location":"CHEM1/#external-links","title":"External links","text":"<ul> <li>Hal (2021-2022): https://drive.google.com/file/d/12qrRLagEU9GqZkHguhvcXjDtLmpt5xw9/view?usp=sharing</li> </ul>"},{"location":"Code_Cheatsheet/","title":"Code Cheatsheet","text":"<p>This folder contains short cheat-sheets and summaries for common programming tasks.</p> <p>Yiru's files:</p> <ul> <li>base-r-cheat-sheet.pdf</li> <li>data-visualization.pdf</li> <li>JAVA_Sum_yiru.pdf</li> <li>java-cheat-sheet-comprehensive-guide.pdf</li> <li>R\u6570\u636e\u79d1\u5b66 ( etc.) (Z-Library).pdf</li> <li>SQL-cheat-sheet.pdf</li> </ul>"},{"location":"DST2/","title":"DST2","text":""},{"location":"DST2/#external-links","title":"External links","text":"<ul> <li>Hal (2022-2023): https://drive.google.com/file/d/165q4ynH7l4o_Sc8no5C8sqM7MSWMvVye/view?usp=sharing</li> </ul>"},{"location":"GP2/","title":"GP2","text":""},{"location":"GP2/#contributors","title":"Contributors","text":"<ul> <li>Yiru: notes and PDFs</li> </ul>"},{"location":"GP2/#files","title":"Files","text":"<ul> <li>Browse Yiru materials: Yiru/</li> </ul>"},{"location":"GP2/#external-links","title":"External links","text":"<ul> <li>Hal (2022-2023): https://drive.google.com/file/d/1P4oNZSKyOg9kB8Ie05srfcW8GpwyFp08/view?usp=sharing</li> </ul>"},{"location":"GP2/Yiru/","title":"GP2","text":"<p>Files:</p> <ul> <li>GP\u63d0\u7eb2.pdf</li> </ul>"},{"location":"IBI1/","title":"IBI1","text":""},{"location":"IBI1/#external-links","title":"External links","text":"<ul> <li>Hal (2021-2022): https://drive.google.com/file/d/19O7639tb0HM0yrQC_iWNIh360JaLW4al/view?usp=sharing</li> </ul>"},{"location":"IBMS1/","title":"IBMS1","text":""},{"location":"IBMS1/#external-links","title":"External links","text":"<ul> <li>Hal (2021-2022): https://drive.google.com/file/d/1lDYh5ghRXBE8z3et_ShQg3WCjwoq7egi/view?usp=sharing</li> </ul>"},{"location":"IBMS3/","title":"IBMS3","text":""},{"location":"IBMS3/#contributors","title":"Contributors","text":"<ul> <li>Yiru: main materials</li> <li>Xiaoran_etal: additional materials</li> </ul>"},{"location":"IBMS3/#files","title":"Files","text":"<ul> <li>Browse Yiru materials: Yiru/</li> <li>Browse Xiaoran_etal materials: Xiaoran_etal/</li> </ul>"},{"location":"IBMS3/#external-links","title":"External links","text":"<ul> <li>Hal (2023-2024): https://drive.google.com/file/d/1_0Snof-NLIY3lqJHfND0-KcFXpHnJM2W/view?usp=sharing</li> </ul>"},{"location":"IBMS3/Yiru/","title":"IBMS3","text":"<p>Files and subfolders:</p> <ul> <li>\u4e00\u5b9e\u9a8c\u65b9\u6cd5\u901f\u67e5.pdf</li> <li>\u8003\u524d\u6574\u7406(1).pdf</li> <li>Experimental Design &amp; Ethics.pdf</li> <li>IBMS Dry Lab \u7b54\u9898\u603b\u7ed3.pdf</li> <li>IBMS Wet Lab \u7b54\u9898\u603b\u7ed3.pdf</li> </ul> <p>Subfolders:</p> <ul> <li>detailed/</li> </ul>"},{"location":"IBMS3/Yiru/detailed/","title":"IBMS3 / detailed","text":"<p>Files and subfolders in <code>detailed</code>:</p> <ul> <li>\u4e00\u5b9e\u9a8c\u65b9\u6cd5\u901f\u67e5.md</li> <li>0. Model selection.md</li> <li>1. Experiment Methods.md</li> <li>2. Group settings.md</li> <li>4. Statistical analysis; Computational methods.md</li> <li>4.5 Visualization.md</li> <li>5. Ethics.md</li> <li>6. Critical thinking.md</li> </ul> <p>Subfolders:</p> <ul> <li>experiments_case/</li> <li>from_yicheng/</li> </ul>"},{"location":"IBMS3/Yiru/detailed/0.%20Model%20selection/","title":"0. Model selection","text":"<p>\u2022 What model system is used? Why is this system appropriate for the study\u2019s goals (e.g., relevance to human biology, ease of manipulation)? \u2022 What are alternative model systems? Compare their pros/cons (cost, ethical concerns, translatability). \u2022   Are there ethical considerations in using this system?  Models: - In silico model - Cell line model - Mouse model(animal model) - Human model</p>"},{"location":"IBMS3/Yiru/detailed/0.%20Model%20selection/#3r-for-animal-model","title":"3R for animal model","text":"<p>And the choice should follow the 3Rs principle: Replacement, Reduction, and Refinement  - Replacement: we should use alternatives to replace live animals when possible, like cell cultures, computer models - Reduction: we should minimizing the number of animals used while maintaining scientific validity - Refinement: we should optimize procedures to minimize pain and distress, improving animal welfare through better housing, enrichment, and less invasive techniques</p>"},{"location":"IBMS3/Yiru/detailed/0.%20Model%20selection/#in-silico-models","title":"In silico models","text":"<ul> <li>Advantage:<ul> <li>useful for predicting gene functions, drug interaction, pathway by calculation</li> <li>cost-effective</li> <li>rapid for initial screening</li> </ul> </li> <li>Disadvantages<ul> <li>Limited by accuracy of algorithms, and limited by existing knowledge and datasets</li> <li>Can only be used to raise up hypotheses or identify wet lab results</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/0.%20Model%20selection/#cell-line-model","title":"Cell line model","text":"<ul> <li>Cell line models use cultured cells (often immortalised) to study biological processes in controlled environments</li> <li>Advantages: <ul> <li>More biologically relevant than computational models</li> <li>Controlled experimental environment</li> <li>Relatively inexpensive compared to animal/human studies</li> <li>Amenable to high-throughput screening</li> <li>Allows for genetic manipulation and specific pathway analysis</li> <li>Reproducible results from homogeneous populations</li> <li>Can be used in pilot experiment to decide which method or does of drug could be the best.</li> </ul> </li> <li>Disadvantages:<ul> <li>Lack complex tissue interactions and physiological context</li> <li>May not represent in vivo behavior accurately</li> <li>Cell lines can drift genetically over passages</li> <li>Limited to cellular responses rather than organism-level effects</li> <li>May not reflect normal cell behavior (especially cancer cell lines)</li> <li>Cannot study systemic responses or organ interactions</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/0.%20Model%20selection/#mouse-model","title":"Mouse model","text":"<ul> <li>8 weeks -- young and adult mouse</li> <li>Advantages:<ul> <li>Whole organism with intact physiological systems</li> <li>Significant genetic similarity to humans (~85%)</li> <li>Well-characterized biology and available genetic tools</li> <li>Allows study of complex disease processes and treatments</li> <li>Enables tissue interactions and systemic responses</li> <li>Established protocols and research precedents</li> </ul> </li> <li>Disadvantages:<ul> <li>Expensive to maintain and require specialized facilities</li> <li>Significant ==ethical== considerations and regulatory requirements</li> <li>Physiological differences from humans affect translatability</li> <li>Longer experimental timelines than in vitro studies</li> <li>Genetic homogeneity in lab strains may not reflect human diversity</li> <li>Limited sample sizes due to cost and ethical considerations</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/0.%20Model%20selection/#human-models","title":"Human Models","text":"<ul> <li>Advantages<ul> <li>Directly relevant to human health and disease</li> <li>No species translation concerns</li> <li>Captures human-specific biological responses</li> <li>Most valuable for clinical applications</li> <li>Reflects human genetic and physiological diversity</li> </ul> </li> <li>Disadvantages:<ul> <li>Highest ethical scrutiny and regulatory requirements</li> <li>Most expensive and logistically complex</li> <li>Limited experimental manipulation possibilities</li> <li>Significant variability between individuals</li> <li>Longer timelines for study completion</li> <li>Recruitment and retention challenges</li> <li>Limited ability to control for confounding variables</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/0.%20Model%20selection/#zebrafish-model","title":"Zebrafish Model","text":"<ul> <li>Advantages:</li> <li>Transparent embryos allow real-time visualization of development</li> <li>Rapid development and short generation time</li> <li>High fecundity (hundreds of embryos per mating)</li> <li>External fertilization and development</li> <li>~70% genetic similarity to humans</li> <li>Amenable to genetic manipulation (CRISPR, transgenesis)</li> <li>Relatively low cost compared to mammalian models</li> <li>Less stringent ethical regulations than mammalian models</li> <li>Disadvantages:</li> <li>Evolutionary distance from humans limits some applications</li> <li>Physiological differences in some organ systems</li> <li>Limited behavioral complexity compared to mammals</li> <li>Some human disease mechanisms not conserved</li> <li>Regenerative abilities not shared with humans</li> </ul>"},{"location":"IBMS3/Yiru/detailed/0.%20Model%20selection/#rat-model","title":"Rat Model","text":"<ul> <li>Advantages:</li> <li>Larger size than mice allows for more complex surgical procedures</li> <li>Better for behavioral and cognitive studies than mice</li> <li>More similar to humans in some physiological and metabolic aspects</li> <li>Superior model for certain disease areas (cardiovascular, neurological)</li> <li>Well-established in toxicology and drug development</li> <li>More sophisticated social behaviors than mice</li> <li>Disadvantages:</li> <li>More expensive than mice</li> <li>Fewer genetic tools available compared to mice</li> <li>Require more space and resources</li> <li>Similar ethical considerations as mice</li> <li>Still significant translational gaps to humans</li> </ul>"},{"location":"IBMS3/Yiru/detailed/0.%20Model%20selection/#non-human-primate-models","title":"Non-Human Primate Models","text":"<ul> <li>Advantages:</li> <li>Closest evolutionary relationship to humans</li> <li>Similar brain structure and cognitive abilities</li> <li>Comparable immune system and disease susceptibility</li> <li>Most predictive for human drug responses and safety</li> <li>Critical for specific research areas (neuroscience, infectious disease)</li> <li>Similar reproductive physiology</li> <li>Disadvantages:</li> <li>Highest ethical concerns among animal models</li> <li>Extremely costly to maintain</li> <li>Stringent regulatory requirements</li> <li>Long lifespan complicates longitudinal studies</li> <li>Limited availability and specialized facility requirements</li> <li>Public controversy surrounding their use</li> </ul>"},{"location":"IBMS3/Yiru/detailed/0.%20Model%20selection/#drosophila-fruit-fly-model","title":"Drosophila (Fruit Fly) Model","text":"<ul> <li>Advantages:</li> <li>Rapid generation time (10-12 days)</li> <li>Extensive genetic tools available</li> <li>Low cost and easy maintenance</li> <li>~60% of human disease genes have fly counterparts</li> <li>Minimal ethical concerns</li> <li>High-throughput screening capability</li> <li>Well-characterized developmental biology</li> <li>Disadvantages:</li> <li>Significant evolutionary distance from humans</li> <li>Simplified organ systems</li> <li>Invertebrate physiology differs substantially from mammals</li> <li>Limited behavioural complexity</li> <li>Restricted ability to model complex human diseases</li> </ul>"},{"location":"IBMS3/Yiru/detailed/1.%20Experiment%20Methods/","title":"1. Experiment Methods","text":"<ul> <li>RNA editing-based RNA-seq: Like STAMP, the RBP is fused to catalytic domain like APOBEC. AFter overexpression of the RBP-APOBEC, RNA were extracted for RNA-esq</li> </ul> <p>DNA Assessment: 1. PCR: Amplifies specific DNA sequences for identification. Uses thermal cycling to exponentially replicate target DNA segments through repeated denaturation, annealing, and extension steps.</p> <ol> <li> <p>qPCR: Quantifies DNA amplification in real-time using fluorescence. Incorporates fluorescent markers that increase signal proportionally to DNA amplification, enabling precise quantification during the reaction.</p> </li> <li> <p>Southern blotting: Detects specific DNA sequences in a sample using labeled probes. Transfers DNA fragments from gel to membrane, then uses radioactive or chemiluminescent probes for sequence-specific detection.</p> </li> </ol> <p>RNA Assessment: 1. RT-PCR: Amplifies cDNA from limited RNA molecules. Converts RNA to complementary DNA(cDNA) using reverse transcriptase before PCR amplification, enabling analysis of low-quantity RNA samples.</p> <ol> <li>Northern blotting: Detects specific RNA sequences in a sample. Separates RNA by size through gel electrophoresis and uses labeled probes to identify specific RNA transcripts.</li> </ol> <p>Protein-DNA Interactions: 1. ChIP-seq: Identifies DNA-protein interactions through immunoprecipitation and sequencing. Crosslinks proteins to DNA, fragments the chromatin, and uses specific antibodies to isolate protein-DNA complexes for sequencing analysis.</p> <ol> <li> <p>Footprinting assay: Reveals protein-DNA binding sites by protecting bound DNA from degradation. Uses enzymatic or chemical reagents to cleave unbound DNA regions, leaving a \"footprint\" where proteins are bound.</p> </li> <li> <p>EMSA: Detects protein-DNA interactions based on mobility shifts in gel electrophoresis. Demonstrates protein binding by showing a slower migration of protein-DNA complexes compared to free DNA fragments.</p> </li> <li> <p>CUT&amp;RUN: Provides high-resolution chromatin profiling with low sample input. Uses antibody-targeted micrococcal nuclease to cleave and release protein-bound DNA fragments for precise mapping.</p> </li> </ol> <p>Protein Analysis: 1. Western blotting: Detects specific proteins using antibodies after gel electrophoresis. Transfers separated proteins to a membrane and uses specific antibodies to visualize and quantify target proteins.</p> <ol> <li> <p>Co-IP: Identifies protein-protein interactions using specific antibodies. Immunoprecipitates a protein of interest along with its interacting partners, allowing detection of protein complexes.</p> </li> <li> <p>Pull-down assay: Captures protein interactions using recombinant \"bait\" proteins. Uses tagged proteins to selectively isolate and identify interacting proteins from complex mixtures.</p> </li> <li> <p>Mass Spectrometry: Analyzes protein identity, abundance, interactions, and modifications. Ionizes proteins and separates them based on mass-to-charge ratio to provide comprehensive protein characterization.</p> </li> <li> <p>FRET: Measures protein-protein interactions in live cells using fluorescence energy transfer. Detects proximity between two fluorescently labeled proteins through energy transfer when they are close together.</p> </li> <li> <p>ELISA: The\u00a0enzyme-linked immunosorbent assay. More sensitive than WB. To detect the presence of a ligand in a liquid sample using antibodies directed aganist the ligand to be measured. Can be used to detect antibodies. </p> </li> </ol> <p>Gene Expression Sequencing: 8. Microarray: Measures expression of multiple genes through hybridization. Uses DNA probes on a chip to simultaneously detect and quantify expression levels of thousands of genes.</p> <ol> <li> <p>RNA-seq: Provides high-throughput, quantitative gene expression profiling. Converts RNA to cDNA and uses next-generation sequencing to comprehensively analyze transcriptome composition.</p> </li> <li> <p>Single-cell RNA-seq: Analyzes gene expression in individual cells. Enables detailed examination of gene expression variations across heterogeneous cell populations.</p> </li> <li> <p>Long-read sequencing: Sequences full-length transcripts. Provides complete transcript information, including splice variants and structural details missed by short-read sequencing. (\u53ea\u6709\u8fd9\u4e2a\u4e5f\u53ef\u4ee5\u7528\u5728DNA\u6d4b\u5e8f)</p> </li> <li> <p>Spatial transcriptomics: Maps gene expression in tissue context. Preserves spatial information of gene expression within tissue sections, revealing cellular interactions and localization.</p> </li> </ol> <p>Epigenetics Sequencing: 1. Bisulfite sequencing: Maps DNA methylation by converting unmethylated cytosines to uracil. Allows comprehensive analysis of DNA methylation patterns across the genome.</p> <ol> <li> <p>immunoprecipitation-based MeDIP: Enriches methylated DNA using antibodies. Selectively captures methylated DNA fragments for downstream analysis.</p> </li> <li> <p>ChIP-seq: Identifies genome-wide protein-DNA interactions. Combines chromatin immunoprecipitation with sequencing to map protein binding sites across the entire genome.</p> </li> <li> <p>ATAC-seq: Assesses chromatin accessibility using Tn5 transposase. Identifies open chromatin regions by inserting sequencing adapters into accessible DNA regions.</p> </li> <li> <p>MNase-seq: Maps nucleosome positions by digesting linker DNA. Provides high-resolution information about nucleosome positioning and chromatin structure.</p> </li> <li> <p>DNase-seq: Identifies open chromatin regions. Uses DNase I enzyme to cleave accessible chromatin, revealing regulatory elements.</p> </li> <li> <p>FAIRE-seq: Maps active regulatory elements. Isolates nucleosome-free DNA regions to identify active regulatory sequences.</p> </li> <li> <p>Small RNA-seq: Profiles small non-coding RNAs. Enables comprehensive analysis of microRNAs, siRNAs, and other small regulatory RNA molecules.</p> </li> <li> <p>m6A sequencing: Maps RNA methylation sites. Identifies and quantifies N6-methyladenosine modifications in RNA molecules,using immunoprepitation</p> </li> </ol> <p>mRNA Visualization and Analysis: 1. FISH: Visualizes specific RNA sequences using fluorescent probes. Allows direct observation of RNA localization within cells or tissues.</p> <ol> <li> <p>Molecular Beacon: Detects RNA with high specificity using hairpin probes. Uses conformational changes in fluorescent probes to detect target RNA sequences.</p> </li> <li> <p>MCP-MS2 system: RBP-based method Visualizes RNA in live cells using RNA-binding proteins, with fluorescent protein. Enables real-time tracking of RNA dynamics in living cells.</p> </li> <li> <p>Using Molecular dyes, like HBC. Can track and visualize RNA in living cells with activated fluorescence dye.</p> </li> <li> <p>RIP, RNA immunoprecipitation: Identifies RNAs bound to specific proteins. Immunoprecipitates RNA-protein complexes to study RNA-protein interactions.</p> </li> <li> <p>CLIP, crosslink immunoprecipitation: Maps protein-RNA interactions at nucleotide resolution. Crosslinking protein and RNA suing UV light. Provides precis$PO_4^{3+}$mapping of protein binding sites on RNA molecules.</p> </li> <li> <p>RNA editing-based RNA-seq: detecting RNA-protein binding site by comparing RNA editing sites with template DNA sequences. </p> </li> </ol> <p>Chromosome Structure: 1. Hi-C: Maps genome-wide chromatin interactions. Captures three-dimensional chromosome organization and long-range genomic interactions. 2. Chromosome Conformation Capture (3C): Original method for studying chromatin interactions. Provides fundamental approach to understanding chromosome folding and gene regulation. 3. 4C (Circular Chromosome Conformation Capture): Focuses on interactions between a specific genomic region and genome-wide chromatin contacts. Provides detailed analysis of a single locus's spatial interactions. 4. 5C (Carbon Copy Chromosome Conformation Capture): Simultaneously analyzes interactions between multiple predetermined genomic regions.  Gene Editing: 5. Homologous Recombination: Replaces genes through DNA repair mechanisms. Uses cellular DNA repair machinery to introduce precise genetic modifications.</p> <ol> <li> <p>ZFNs: Edits genes using zinc finger nucleases. Creates targeted DNA double-strand breaks to facilitate gene modification.</p> </li> <li> <p>TALENs: Edits genes using transcription activator-like effector nucleases. Provides precise genome editing through customizable DNA-binding domains.</p> </li> <li> <p>CRISPR-Cas9: Edits genes using guide RNA and Cas9 nuclease. Offers versatile and efficient genome editing with high precision.</p> <ol> <li>CRISPRi (CRISPR interference) uses a \"dead\" Cas9 (dCas9) fused to a repressor domain. This complex can bind to DNA sequences but does not cut the DNA; instead, it blocks transcription, effectively silencing gene expression.</li> <li>CRISPRa (CRISPR activation) also uses dCas9, but it is fused to an activator domain to enhance transcription.</li> </ol> </li> <li> <p>RNAi: Silences genes using small interfering RNAs. Targets specific mRNA sequences for degradation to reduce gene expression.</p> </li> <li> <p>Gene overexpression: Increases gene expression using viral vectors or mRNA delivery. Introduces additional copies or enhances expression of specific genes.</p> </li> <li> <p>Epigenome engineering: Modifies epigenetic marks using CRISPR-based systems. Allows targeted manipulation of DNA methylation and histone modifications.</p> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/1.%20Experiment%20Methods/#other-system-build","title":"Other system build","text":"<ul> <li>Luciferase reporter assay (\u68c0\u6d4bTE\u548cpromoter\u5173\u7cfb)<ul> <li>is a method to detect the relationship between Transcription element and gene promoter</li> <li>Example:<ul> <li>Luciferase reporter assays validate that these changes are due to direct transcriptional regulation by gene X on the specific promoters or enhancers. We constructed reporter vectors containing the putative target promoters upstream of the firefly luciferase gene. A Herpes Simplex Virus thymidine kinase (HSV-TK) promoter-driven Renilla luciferase was co-transfected as an internal control to normalize for transfection efficiency. Cells with and without gene X expression were transfected with these constructs, and the ratio of firefly to Renilla luciferase activity was measured. The significant reduction in normalized luciferase activity in cells lacking gene X confirms its direct role in activating transcription from these promoters.</li> </ul> </li> </ul> </li> <li>Antisense oligonucleotides (ASOs)<ul> <li>ASOs are short, synthetic, single-stranded RNA or DNA sequences designed to bind to specific mRNA sequences, thereby modulating protein expression and potentially treating disease</li> </ul> </li> <li>FUCCI: Fluorescence Ubiquitin cell cycle indicator<ul> <li>is a powerful cell visualization technique using two fluorescent proteins (mCherry-hCdt1 showing red in G1 and mVenus-hGem showing green in S/G2/M phases) that enables real-time tracking of cell cycle progression, while EdU (5-ethynyl-2'-deoxyuridine), a thymidine analog incorporated into DNA during active synthesis, complements FUCCI by specifically marking S-phase cells, together providing comprehensive analysis of cell proliferation dynamics through fluorescence microscopy without requiring cell fixation, allowing researchers to precisely quantify cell cycle duration, identify proliferating cell populations, and assess the effects of experimental treatments on cell division.</li> </ul> </li> <li>DREADD:Designer Receptors Exclusively Activated by Designer Drugs: <ul> <li>A chemogenetic technique using engineered receptors exclusively activated by designer drugs, enabling temporary control of specific neuronal populations; researchers need it to manipulate neural activity over extended periods without tethering animals; it's preferable when studying prolonged behavioral effects or deep brain regions; implementation involves injecting viral vectors encoding Cre-dependent DREADDs into target brain regions of transgenic mice, followed by systemic administration of activator drugs like CNO when manipulation is desired.</li> </ul> </li> <li> <p>Optogenetics: </p> <ul> <li>A neuromodulation technique using light-sensitive ion channels to control neuronal firing with millisecond precision; neuroscientists need it to establish causal relationships between neural activity and behavior with high temporal resolution; it's optimal when studying rapid circuit dynamics and precise timing-dependent processes; implementation requires viral delivery of opsin genes to target neurons, surgical implantation of fiber optics, and controlled light delivery through laser or LED systems during behavioral experiments.</li> </ul> </li> <li> <p>CRISPR screen</p> <ul> <li>CRISPR screening is a powerful genomic technique that systematically disrupts genes across the entire genome to identify those involved in specific biological processes or disease mechanisms; it utilizes CRISPR-Cas9 technology to deliver guide RNAs (gRNAs) targeting thousands of different genes into a population of cells, creating a pooled library of knockout cells that can be subjected to selective pressure or phenotypic analysis.</li> <li>The experimental workflow involves designing and synthesizing a gRNA library targeting all genes of interest, packaging these guides into lentiviral vectors, transducing target cells at low multiplicity of infection to ensure single integrations, applying a selective pressure or condition (such as drug treatment or growth conditions), and then using next-generation sequencing to quantify the relative abundance of each gRNA before and after selection.</li> <li>Analysis identifies genes whose disruption leads to enrichment (conferring advantage under selection) or depletion (causing disadvantage) in the selected population compared to controls; this reveals genes essential for survival, resistance mechanisms, or specific cellular processes depending on the selection applied, with statistical methods accounting for multiple guide efficiencies and off-target effects.</li> <li>CRISPR screens have revolutionized functional genomics by enabling unbiased, genome-wide loss-of-function studies in mammalian cells, identifying novel therapeutic targets, resistance mechanisms to cancer therapies, host factors for viral infection, and components of cellular pathways, with variations including CRISPR activation/repression screens that modulate gene expression rather than disrupting genes, and in vivo screens that operate in animal models to capture complex physiological contexts.</li> </ul> </li> <li>Flow cytometry</li> <li></li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/","title":"2. Group settings","text":""},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#control","title":"Control","text":"<p>We should set control group: - Negative control     - that we know there won't be any further effects; like water - Positive control     - that we know there will be some expected effects; like when we try to test a new drug, we will use known drug as control - Internal control     - Test a standard control in a same sample, for normalization     - Like normalize western blot results using beta-actin as a loading control</p>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#replicates","title":"Replicates","text":"<p>We should set replicates to reduce the effect of uncontrolled variation - Technical replicate     - Same action, redo in a same sample     - to remove the random effect of technique itself - Biological replicate     - use multiple samples, reduce the effect of sample itself     - \u5b9e\u9645\u4e0a\uff0c\u9664\u4e86\u76f4\u63a5\u63d0\u51fa\u7684\u4e3a\u4e86\u6d88\u9664\u6d4b\u5e8f/\u6d4b\u6837\u7b49\u5f71\u54cd\u800c\u8fdb\u884c\u7684\u91cd\u590d\uff0c\u6211\u4eec\u90fd\u5e94\u8be5</p>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#sample-from-population","title":"Sample from population","text":"<ul> <li>Blinding measurement<ul> <li>Mostly, we should do double-blind; because the information of expereiment will also influence people being tested</li> </ul> </li> <li>representativeness: the sampled samples should be random selected from population</li> <li>Independence of observations: we should avoid correct cases, making sure statistical independence<ul> <li>\u6bd4\u5982\u4e0d\u8981\u5728\u540c\u4e00\u4e2a\u5b9e\u9a8c\u4e2d\u5305\u542b\u5144\u5f1f  </li> </ul> </li> <li>Randomisation and stratification<ul> <li>When grouping samples, we should both consider randomisation, and consider the differences between cases, do stratification</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#other-influence-factors","title":"Other influence factors","text":"<ul> <li>We should also consider the sex<ul> <li>female are more likely to show side-effect than male</li> <li>researcher are more likely to use male model; and when do statistical analysis, they seldomly separate male and female<ul> <li>==which could be a drawback==  </li> </ul> </li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#internal-control","title":"==Internal control==","text":""},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#designing-internal-controls-in-experimental-research","title":"Designing Internal Controls in Experimental Research","text":""},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#introduction-to-internal-controls","title":"Introduction to Internal Controls","text":"<p>Internal controls are critical experimental elements that validate results, normalize measurements, account for technical variation, and ensure experimental integrity. A well-designed internal control strategy significantly enhances the reliability and reproducibility of scientific findings.</p>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#when-to-implement-internal-controls","title":"When to Implement Internal Controls","text":""},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#1-high-variability-systems","title":"1. High Variability Systems","text":"<ul> <li>Biological samples with inherent heterogeneity</li> <li>Multi-step protocols with cumulative error potential</li> <li>Experiments susceptible to environmental fluctuations</li> <li>Systems with stochastic processes</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#2-quantitative-analyses","title":"2. Quantitative Analyses","text":"<ul> <li>Gene/protein expression measurements</li> <li>Metabolite quantification</li> <li>Signal intensity assessments</li> <li>Concentration-dependent experiments</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#3-longitudinal-studies","title":"3. Longitudinal Studies","text":"<ul> <li>Time-course experiments</li> <li>Degradation-sensitive samples</li> <li>Studies with multiple collection points</li> <li>Experiments with potential drift effects</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#4-multi-operator-or-multi-site-research","title":"4. Multi-operator or Multi-site Research","text":"<ul> <li>Collaborative projects across laboratories</li> <li>Clinical trials with multiple centers</li> <li>Studies requiring standardization across platforms</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#5-method-developmentvalidation","title":"5. Method Development/Validation","text":"<ul> <li>Novel assay implementation</li> <li>Protocol optimization</li> <li>Analytical method verification</li> <li>Diagnostic test development</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#types-of-internal-controls","title":"Types of Internal Controls","text":""},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#1-endogenous-controls","title":"1. Endogenous Controls","text":"<p>Definition: Intrinsic elements within the sample that remain stable regardless of experimental conditions.</p> <p>Implementation Guidelines: - Select molecules with demonstrated expression stability - Verify stability under your specific experimental conditions - Use multiple endogenous controls when possible - Consider tissue/cell-type specificity</p> <p>Examples by Application: - RT-qPCR:    * Housekeeping genes (GAPDH, ACTB, 18S rRNA, HPRT1, TBP)   * Selection criteria: Ct values between 15-30, CV &lt; 0.5 across conditions   * Validation using geNorm, NormFinder, or BestKeeper algorithms</p> <ul> <li>Western Blotting:</li> <li>Total protein normalization (REVERT, Ponceau S)</li> <li>Structural proteins (\u03b2-actin, \u03b1-tubulin, vinculin)</li> <li> <p>Selection based on molecular weight separation from target</p> </li> <li> <p>Immunohistochemistry:</p> </li> <li>Anatomical landmarks</li> <li>Cell-type specific markers</li> <li>Autofluorescence controls</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#2-spike-in-controls","title":"2. Spike-in Controls","text":"<p>Definition: Exogenous materials added to samples at known quantities.</p> <p>Implementation Guidelines: - Add at earliest possible stage of sample processing - Use concentrations within the linear range of detection - Select spike-ins with minimal cross-reactivity - Consider multiple spike-ins at different concentrations</p> <p>Examples by Application: - RNA-seq:   * ERCC RNA spike-in mixes (92 synthetic RNAs)   * Addition ratios: 1:100 to 1:1000 of total RNA   * Use Mix 1 and Mix 2 to evaluate differential expression accuracy</p> <ul> <li>Mass Spectrometry:</li> <li>Isotope-labeled peptides/proteins</li> <li>Addition at consistent concentrations (typically 10-50 fmol)</li> <li> <p>Selection criteria: stability, ionization efficiency, unique mass</p> </li> <li> <p>Microbiome Analysis:</p> </li> <li>Synthetic DNA sequences</li> <li>Mock communities of known composition</li> <li>Addition at 2-5% of estimated sample biomass</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#3-negative-controls","title":"3. Negative Controls","text":"<p>Definition: Samples that should produce no signal or response.</p> <p>Implementation Guidelines: - Process identically to experimental samples - Include at multiple stages of the workflow - Use matrix-matched materials when possible - Include in every experimental batch</p> <p>Examples by Application: - PCR/qPCR:   * No-template controls (water instead of DNA/RNA)   * RT-minus controls (reverse transcription without enzyme)   * Non-target sequence controls</p> <ul> <li>Cell-based Assays:</li> <li>Vehicle-only treatments</li> <li>Untransfected cells</li> <li>Isotype antibody controls</li> <li> <p>Empty vector transfections</p> </li> <li> <p>Immunoassays:</p> </li> <li>Buffer-only samples</li> <li>Isotype-matched irrelevant antibodies</li> <li>Blocking peptide controls</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#4-positive-controls","title":"4. Positive Controls","text":"<p>Definition: Samples known to produce specific, expected results.</p> <p>Implementation Guidelines: - Use well-characterized materials - Include across the dynamic range when possible - Verify stability and consistency between experiments - Document expected performance metrics</p> <p>Examples by Application: - Diagnostic Tests:   * Certified reference materials   * Previously validated clinical samples   * Synthetic positive constructs</p> <ul> <li>Cell Function Assays:</li> <li>Known inducer of cell death for viability assays</li> <li>Standard agonists for receptor activation</li> <li> <p>Well-characterized cell lines</p> </li> <li> <p>Molecular Detection:</p> </li> <li>Plasmids containing target sequences</li> <li>Commercially available positive control materials</li> <li>Previously validated positive samples</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#5-technical-replicates","title":"5. Technical Replicates","text":"<p>Definition: Multiple measurements of the same sample.</p> <p>Implementation Guidelines: - Determine appropriate number based on expected variability - Distribute across experimental setup (e.g., different wells, runs) - Use to calculate coefficient of variation - Consider nested designs for multi-step processes</p>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#experimental-design-considerations","title":"Experimental Design Considerations","text":""},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#1-sample-randomization","title":"1. Sample Randomization","text":"<ul> <li>Randomize sample processing order</li> <li>Distribute controls across experimental batches</li> <li>Avoid systematic positioning (e.g., controls always in first well)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#2-blinding-procedures","title":"2. Blinding Procedures","text":"<ul> <li>Code samples to prevent operator bias</li> <li>Blind analysis when possible</li> <li>Reveal controls only during data normalization</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#3-control-frequency","title":"3. Control Frequency","text":"<ul> <li>Include controls in each experimental batch</li> <li>Consider higher frequency for critical or variable steps</li> <li>Balance comprehensiveness with practical constraints</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#4-control-validation","title":"4. Control Validation","text":"<ul> <li>Pre-validate control performance before main experiment</li> <li>Document acceptance criteria for controls</li> <li>Establish procedures for failed controls</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#application-specific-control-strategies","title":"Application-Specific Control Strategies","text":""},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#1-molecular-biology-experiments","title":"1. Molecular Biology Experiments","text":"<p>RT-qPCR: - Minimum 3 reference genes validated for stability - Include RT-minus, no-template, and positive controls - Standard curve samples spanning 5-log concentration range - Inter-run calibrators for multi-plate experiments</p> <p>RNA-seq: - ERCC spike-ins at consistent ratios - Technical replicates for subset of samples - Housekeeping genes for cross-validation - Include samples previously analyzed by other methods</p> <p>CRISPR Genome Editing: - Non-targeting guide RNA controls - Indel detection controls with known efficiency - Positive selection markers - Wild-type cells processed in parallel</p>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#2-cell-based-assays","title":"2. Cell-Based Assays","text":"<p>Cell Viability/Cytotoxicity: - Untreated cells (100% viability reference) - Known cytotoxic agent (positive control) - Cells killed by heat/detergent (0% viability) - Vehicle-only controls</p> <p>Transfection Experiments: - Reporter gene to monitor efficiency - Empty vector controls - Mock transfection (reagent without DNA/RNA) - Positive control plasmid with known expression</p> <p>Flow Cytometry: - Unstained cells - Single-color compensation controls - Fluorescence-minus-one (FMO) controls - Isotype controls for antibody specificity</p>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#3-animal-studies","title":"3. Animal Studies","text":"<p>Gene Knockout Models: - Wild-type littermates - Heterozygous animals - Sham-operated controls - Sex-balanced grouping</p> <p>Drug Studies: - Vehicle-only treatment - Dose-response design - Known effective compound as benchmark - Time-matched controls</p>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#4-clinical-research","title":"4. Clinical Research","text":"<p>Biomarker Studies: - Healthy control samples - Disease control samples (related but different condition) - Historical reference ranges - Pooled normal samples</p> <p>Therapeutic Trials: - Placebo controls - Standard-of-care comparators - Dose escalation controls - Washout period designs</p>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#troubleshooting-control-failures","title":"Troubleshooting Control Failures","text":""},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#1-identification-of-failure-patterns","title":"1. Identification of Failure Patterns","text":"<ul> <li>Systematic vs. random control failures</li> <li>Batch-specific issues</li> <li>Operator-dependent variations</li> <li>Instrument-related problems</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#2-mitigation-strategies","title":"2. Mitigation Strategies","text":"<ul> <li>Redundant control systems</li> <li>Statistical correction methods</li> <li>Sample re-processing protocols</li> <li>Decision trees for control failure scenarios</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#documentation-and-reporting","title":"Documentation and Reporting","text":""},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#1-control-selection-justification","title":"1. Control Selection Justification","text":"<ul> <li>Document selection criteria</li> <li>Reference literature supporting choices</li> <li>Describe validation procedures</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#2-control-performance-metrics","title":"2. Control Performance Metrics","text":"<ul> <li>Report control values/ranges</li> <li>Include control variability statistics</li> <li>Document control acceptance criteria</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#3-control-based-data-exclusion","title":"3. Control-Based Data Exclusion","text":"<ul> <li>Pre-establish exclusion criteria</li> <li>Document any excluded data points</li> <li>Report impact of exclusions on conclusions</li> </ul>"},{"location":"IBMS3/Yiru/detailed/2.%20Group%20settings/#conclusion","title":"Conclusion","text":"<p>Properly designed internal controls are fundamental to experimental rigor and reproducibility. They should be thoughtfully selected, validated, and implemented based on the specific experimental context. The investment in comprehensive control strategies ultimately enhances data quality, reliability, and scientific credibility.</p>"},{"location":"IBMS3/Yiru/detailed/4.%20Statistical%20analysis%3B%20Computational%20methods/","title":"4. Statistical analysis; Computational methods","text":""},{"location":"IBMS3/Yiru/detailed/4.%20Statistical%20analysis%3B%20Computational%20methods/#normalization","title":"Normalization","text":"<ul> <li>Could be data-wise normalization: like gene expression, gene counts</li> <li>Could caused by experimental: like in qRT-PCR, when we test a targeted gene, in parallel, the mRNA level of a housekeeping gene, like ACTB or GAPDH will be also measured--&gt; for normalization<ul> <li>The mRNA level of Gene X will be normalized to the level of housekeeping gene in each sample</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.%20Statistical%20analysis%3B%20Computational%20methods/#statistical-analysis","title":"Statistical analysis","text":"<ul> <li>t test<ul> <li>Compares means between two groups. Independent t-tests compare different subjects (e.g., drug vs. placebo), while paired t-tests analyze the same subjects before and after intervention (e.g., pre/post-treatment blood pressure).</li> </ul> </li> <li>Chi-square tests<ul> <li>Analyzes relationships between categorical variables. Commonly used to compare proportions across groups, such as response rates between treatment arms or disease prevalence across populations.</li> </ul> </li> <li>ANOVA (analysis of variance)<ul> <li>Extends t-tests to compare means across multiple groups. One-way ANOVA compares one factor (e.g., multiple drug doses), while factorial ANOVA examines interactions between factors (e.g., drug and gender effects).</li> </ul> </li> <li>Linear regression<ul> <li>Models relationships between continuous variables. In biomedicine, used to predict outcomes based on predictors (e.g., how BMI relates to cholesterol) or adjust for confounding factors.</li> </ul> </li> <li>Logistic regression<ul> <li>Predicts binary outcomes (e.g., disease/no disease) based on predictor variables. Essential for developing risk prediction models and analyzing case-control studies.</li> </ul> </li> <li>Survival analysis<ul> <li>Analyzes time-to-event data with censored observations</li> <li>Kaplan-meier curves: visualize survival probabilities over time</li> <li>Log-rank test: compare survival between groups</li> <li>Cox proportional hazards: Assess multiple variables' impact on survival time</li> </ul> </li> <li>Non-Parametric Tests<ul> <li>Used when data doesn't follow normal distribution:<ul> <li>Mann-Whitney U test: Non-parametric alternative to t-test</li> <li>Kruskal-Wallis test: Non-parametric alternative to ANOVA</li> <li>Wilcoxon signed-rank test: Non-parametric paired comparison</li> </ul> </li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.%20Statistical%20analysis%3B%20Computational%20methods/#gwas-genome-wide-association-studies","title":"GWAS Genome-wide association studies","text":"<ul> <li> <p>GWAS Application: From Experimental Design to Results</p> </li> <li> <p>Experimental Design:</p> <ul> <li>A case-control study investigating genetic associations with Type 2 Diabetes (T2D) in diverse populations, recruiting 5,000 diagnosed T2D patients and 5,000 matched healthy controls with detailed phenotypic data including clinical measurements, family history, and environmental exposure information; participants provide informed consent for genotyping and data sharing under appropriate ethical approvals.</li> </ul> </li> <li> <p>Upstream Process:</p> <ul> <li>Blood samples collected from all participants undergo DNA extraction following standardized protocols to ensure high-quality genomic material; extracted DNA is quantified, quality-checked, and genotyped using a high-density SNP array platform covering 800,000+ genetic variants across the genome; rigorous quality control measures include monitoring call rates, Hardy-Weinberg equilibrium testing, and technical replicates to ensure data integrity before proceeding to analysis.</li> </ul> </li> <li> <p>Downstream Analysis:</p> <ul> <li>Initial quality filtering removes samples with low genotyping rates (&lt;98%) and SNPs with poor call rates, minor allele frequencies &lt;1%, or significant deviation from Hardy-Weinberg equilibrium; population stratification is addressed using principal component analysis and ancestry-informative markers; association testing employs logistic regression models adjusting for age, sex, BMI, and ancestry components, with genome-wide significance threshold set at p&lt;5\u00d710^-8; identified signals undergo replication testing in independent cohorts and fine-mapping to pinpoint causal variants.</li> </ul> </li> <li> <p>Expected Results:</p> <ul> <li>The study identifies several genomic loci significantly associated with T2D risk, including both previously known and novel genetic associations; pathway enrichment analysis reveals biological processes related to insulin signaling, glucose metabolism, and pancreatic beta-cell function; polygenic risk scores developed from significant variants demonstrate predictive value for disease risk beyond traditional clinical factors; functional annotation of associated variants provides insights into potential regulatory mechanisms, guiding follow-up experimental studies to validate biological effects and explore therapeutic implications for personalized medicine approaches.</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.%20Statistical%20analysis%3B%20Computational%20methods/#eqtl-expression-quantitative-trait-locus","title":"eQTL, expression quantitative trait locus","text":"<p>eQTL (Expression Quantitative Trait Locus) Analysis</p> <p>Experimental Design: A study investigating genetic variants affecting gene expression in liver tissue, recruiting 300 individuals undergoing liver biopsies during bariatric surgery or routine clinical procedures; participants provide informed consent for genetic testing and tissue collection; detailed clinical data including liver function tests, metabolic parameters, and medication history are recorded to account for potential confounding factors in downstream analyses.</p> <p>Upstream Process: Liver tissue samples undergo simultaneous DNA and RNA extraction; DNA samples are genotyped using a genome-wide SNP array capturing 1 million variants; RNA is processed for RNA-sequencing with appropriate quality controls including RNA integrity number assessment; RNA-seq libraries are prepared and sequenced to a depth of 30 million paired-end reads per sample; tissue processing, nucleic acid extraction, and sequencing follow standardized protocols to minimize batch effects and technical variation.</p> <p>Downstream Analysis: Genotype data undergo quality control filtering for call rates, minor allele frequency, and Hardy-Weinberg equilibrium; RNA-seq data are processed through alignment to the reference genome, quantification of gene expression levels, and normalization to account for sequencing depth and composition biases; eQTL mapping employs linear regression models testing associations between genotypes and expression levels of genes within 1Mb of each variant (cis-eQTLs), adjusting for age, sex, principal components of genetic ancestry, and technical covariates; statistical significance is determined using permutation-based methods with FDR control.</p> <p>Expected Results: The analysis identifies thousands of significant cis-eQTLs where genetic variants correlate with expression levels of nearby genes; integration with GWAS data reveals that disease-associated variants often function as eQTLs, providing mechanistic insights into how genetic risk factors influence disease through gene regulation; tissue-specific eQTL effects help explain why certain variants affect disease risk in specific organs; colocalization analysis distinguishes shared causal variants from coincidental overlaps between GWAS and eQTL signals; findings contribute to functional annotation of the genome and help prioritize genes for therapeutic targeting based on their genetic regulation profiles.</p>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/","title":"\u751f\u7269\u533b\u5b66\u53ef\u89c6\u5316\u56fe\u8868\u7d22\u5f15 / Biomedical Visualization Chart Index","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#gene-expression-data-visualization","title":"\u57fa\u56e0\u8868\u8fbe\u6570\u636e\u53ef\u89c6\u5316 / Gene Expression Data Visualization","text":"<ul> <li>\u70ed\u56fe / Heatmap: \u4f7f\u7528\u989c\u8272\u5f3a\u5ea6\u5c55\u793a\u591a\u4e2a\u57fa\u56e0\u5728\u591a\u4e2a\u6837\u672c\u4e2d\u7684\u8868\u8fbe\u6c34\u5e73\u77e9\u9635 / Matrix showing gene expression levels across samples using color intensity</li> <li>\u706b\u5c71\u56fe / Volcano Plot: \u540c\u65f6\u5c55\u793a\u57fa\u56e0\u8868\u8fbe\u53d8\u5316\u7684\u663e\u8457\u6027\u548c\u5e45\u5ea6\u7684\u6563\u70b9\u56fe / Scatter plot showing both significance and magnitude of gene expression changes</li> <li>MA\u56fe / MA Plot: \u5c55\u793a\u5e73\u5747\u8868\u8fbe\u5f3a\u5ea6\u4e0e\u8868\u8fbe\u53d8\u5316\u5173\u7cfb\u7684\u6563\u70b9\u56fe / Scatter plot showing relationship between mean expression and fold change</li> <li>PCA/MDS\u56fe / PCA/MDS Plot: \u5c06\u9ad8\u7ef4\u8868\u8fbe\u6570\u636e\u964d\u7ef4\u52302D/3D\u7a7a\u95f4\u5c55\u793a\u6837\u672c\u5173\u7cfb / Projects high-dimensional expression data to 2D/3D to show sample relationships</li> <li>\u7bb1\u7ebf\u56fe / Box Plot: \u5c55\u793a\u4e0d\u540c\u6761\u4ef6\u4e0b\u57fa\u56e0\u8868\u8fbe\u5206\u5e03\u7684\u7bb1\u5f62\u56fe / Shows distribution of expression values across conditions with boxes and whiskers</li> <li>\u76f8\u5173\u6027\u6563\u70b9\u56fe / Correlation Scatter Plot: \u5c55\u793a\u4e24\u4e2a\u57fa\u56e0\u8868\u8fbe\u6c34\u5e73\u76f8\u5173\u6027\u7684\u6563\u70b9\u56fe / Scatter plot showing correlation between expression levels of two genes</li> <li>\u7ebf\u56fe / Line Plot: \u5c55\u793a\u57fa\u56e0\u8868\u8fbe\u968f\u65f6\u95f4\u53d8\u5316\u7684\u6298\u7ebf\u56fe / Shows gene expression changes over time with connected lines</li> <li>\u65f6\u5e8f\u70ed\u56fe / Time-series Heatmap: \u6309\u65f6\u95f4\u987a\u5e8f\u6392\u5217\u7684\u70ed\u56fe\uff0c\u5c55\u793a\u8868\u8fbe\u968f\u65f6\u95f4\u53d8\u5316 / Heatmap with samples ordered by time to show temporal patterns</li> <li>\u8f68\u8ff9\u56fe / Trajectory Plot: \u5c55\u793a\u7ec6\u80de\u72b6\u6001\u968f\u65f6\u95f4\u6f14\u53d8\u7684\u8def\u5f84\u56fe / Shows path of cellular states changing over time</li> <li>\u6d41\u56fe / Stream Plot: \u5c55\u793a\u7ec6\u80de\u7c7b\u578b\u6216\u57fa\u56e0\u6a21\u5757\u6bd4\u4f8b\u968f\u65f6\u95f4\u53d8\u5316\u7684\u9762\u79ef\u56fe / Area chart showing proportions of cell types or gene modules changing over time</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#single-cell-and-spatial-omics-data","title":"\u5355\u7ec6\u80de\u4e0e\u7a7a\u95f4\u7ec4\u5b66\u6570\u636e / Single-cell and Spatial Omics Data","text":"<ul> <li>\u964d\u7ef4\u56fe / Dimensionality Reduction Plot: \u4f7f\u7528t-SNE/UMAP\u7b49\u65b9\u6cd5\u5c55\u793a\u5355\u7ec6\u80de\u805a\u7c7b / Shows cell clusters using t-SNE/UMAP or similar methods</li> <li>\u7279\u5f81\u56fe / Feature Plot: \u5728\u964d\u7ef4\u56fe\u4e0a\u53e0\u52a0\u57fa\u56e0\u8868\u8fbe\u6c34\u5e73\u7684\u6563\u70b9\u56fe / Overlays gene expression levels on dimensionality reduction plots</li> <li>\u70b9\u56fe / Dot Plot: \u540c\u65f6\u5c55\u793a\u57fa\u56e0\u8868\u8fbe\u6bd4\u4f8b\u548c\u5f3a\u5ea6\u7684\u70b9\u9635\u56fe / Shows both percentage of expressing cells and expression intensity</li> <li>\u5c0f\u63d0\u7434\u56fe / Violin Plot: \u5c55\u793a\u57fa\u56e0\u5728\u4e0d\u540c\u7ec6\u80de\u7c7b\u578b\u4e2d\u8868\u8fbe\u5206\u5e03\u7684\u6982\u7387\u5bc6\u5ea6\u56fe / Shows distribution of gene expression across cell types</li> <li>\u7ec6\u80de-\u7ec6\u80de\u4e92\u4f5c\u7f51\u7edc / Cell-Cell Interaction Network: \u5c55\u793a\u7ec6\u80de\u7c7b\u578b\u95f4\u9884\u6d4b\u7684\u4fe1\u53f7\u901a\u8def\u4e92\u4f5c / Shows predicted signaling interactions between cell types</li> <li>\u8f68\u8ff9\u63a8\u65ad\u56fe / Trajectory Inference Plot: \u5c55\u793a\u7ec6\u80de\u5206\u5316\u6216\u72b6\u6001\u8f6c\u53d8\u8def\u5f84 / Shows developmental or state transition paths between cell states</li> <li>\u7a7a\u95f4\u7279\u5f81\u56fe / Spatial Feature Plot: \u5728\u7ec4\u7ec7\u5750\u6807\u4e0a\u53e0\u52a0\u57fa\u56e0\u8868\u8fbe\u7684\u7a7a\u95f4\u56fe / Overlays gene expression on tissue coordinates</li> <li>\u7a7a\u95f4\u805a\u7c7b\u56fe / Spatial Clustering Map: \u57fa\u4e8e\u8868\u8fbe\u76f8\u4f3c\u6027\u5bf9\u7ec4\u7ec7\u533a\u57df\u8fdb\u884c\u805a\u7c7b / Colors tissue regions based on expression similarity clusters</li> <li>\u7a7a\u95f4\u5171\u8868\u8fbe\u7f51\u7edc / Spatial Co-expression Network: \u5c55\u793a\u5177\u6709\u76f8\u4f3c\u7a7a\u95f4\u5206\u5e03\u7684\u57fa\u56e0\u7f51\u7edc / Network of genes with similar spatial distribution patterns</li> <li>\u7ec6\u80de\u7c7b\u578b\u89e3\u5377\u79ef\u56fe / Cell Type Deconvolution Map: \u5c55\u793a\u7ec4\u7ec7\u4e2d\u9884\u6d4b\u7684\u7ec6\u80de\u7c7b\u578b\u6bd4\u4f8b / Shows predicted cell type proportions across tissue</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#genomic-and-epigenomic-data","title":"\u57fa\u56e0\u7ec4\u4e0e\u8868\u89c2\u57fa\u56e0\u7ec4\u6570\u636e / Genomic and Epigenomic Data","text":"<ul> <li>\u66fc\u54c8\u987f\u56fe / Manhattan Plot: \u5c55\u793a\u5168\u57fa\u56e0\u7ec4\u5173\u8054\u7814\u7a76\u7684\u7edf\u8ba1\u663e\u8457\u6027 / Shows statistical significance across entire genome in association studies</li> <li>\u68d2\u68d2\u7cd6\u56fe / Lollipop Plot: \u5c55\u793a\u57fa\u56e0\u6216\u86cb\u767d\u5e8f\u5217\u4e0a\u7684\u53d8\u5f02\u4f4d\u70b9 / Shows variants along a gene or protein sequence</li> <li>\u80bf\u7624\u56fe\u8c31 / Oncoprint: \u5c55\u793a\u591a\u4e2a\u6837\u672c\u4e2d\u7684\u57fa\u56e0\u6539\u53d8\u77e9\u9635 / Matrix showing genetic alterations across samples</li> <li>\u73af\u5f62\u56fe / Circos Plot: \u5c55\u793a\u57fa\u56e0\u7ec4\u533a\u57df\u95f4\u5173\u7cfb\u7684\u73af\u5f62\u56fe / Circular representation showing relationships between genomic regions</li> <li>\u96e8\u6ef4\u56fe / Rainfall Plot: \u5c55\u793a\u57fa\u56e0\u7ec4\u4f4d\u7f6e\u4e0e\u76f8\u90bb\u53d8\u5f02\u8ddd\u79bb\u5173\u7cfb\u7684\u6563\u70b9\u56fe / Plots genomic position versus distance to neighboring variants</li> <li>\u57fa\u56e0\u7ec4\u6d4f\u89c8\u5668\u8f68\u9053 / Genome Browser Track: \u6cbf\u67d3\u8272\u4f53\u5c55\u793a\u57fa\u56e0\u7ec4\u7279\u5f81\u7684\u7ebf\u6027\u56fe / Linear representation of genomic features along chromosomes</li> <li>\u4fe1\u53f7\u5206\u5e03\u70ed\u56fe / Heatmap Metaplot: \u5c55\u793a\u4fe1\u53f7\u5728\u57fa\u56e0\u7ec4\u7279\u5f81\u5468\u56f4\u5206\u5e03\u7684\u70ed\u56fe / Heatmap showing signal distribution around genomic features</li> <li>\u67d3\u8272\u8d28\u4e92\u4f5c\u56fe / Chromatin Interaction Map: \u5c55\u793a\u57fa\u56e0\u7ec4\u533a\u57df\u95f4\u4e92\u4f5c\u9891\u7387\u7684\u70ed\u56fe / Heatmap showing interaction frequency between genomic regions</li> <li>\u5cf0\u4fe1\u53f7\u805a\u5408\u56fe / Aggregated Peak Plot: \u5c55\u793a\u57fa\u56e0\u7ec4\u7279\u5f81\u5468\u56f4\u7684\u5e73\u5747\u4fe1\u53f7\u5206\u5e03 / Shows average signal profiles around genomic features</li> <li>\u67d3\u8272\u8d28\u72b6\u6001\u56fe / Chromatin State Map: \u5c55\u793a\u9884\u6d4b\u7684\u67d3\u8272\u8d28\u72b6\u6001\u5206\u5e03 / Visualizes predicted chromatin states across genomic regions</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#protein-and-structural-data","title":"\u86cb\u767d\u8d28\u4e0e\u7ed3\u6784\u6570\u636e / Protein and Structural Data","text":"<ul> <li>\u86cb\u767d\u4e92\u4f5c\u7f51\u7edc / Protein-Protein Interaction Network: \u5c55\u793a\u86cb\u767d\u8d28\u4e4b\u95f4\u7269\u7406\u6216\u529f\u80fd\u4e92\u4f5c\u7684\u7f51\u7edc\u56fe / Network showing physical or functional interactions between proteins</li> <li>\u86cb\u767d\u7ed3\u6784\u56fe / Protein Structure Visualization: \u5c55\u793a\u86cb\u767d\u8d28\u4e09\u7ef4\u7ed3\u6784\u7684\u7acb\u4f53\u56fe / 3D representation of protein structure</li> <li>\u7ed3\u6784\u57df\u67b6\u6784\u56fe / Domain Architecture Plot: \u5c55\u793a\u86cb\u767d\u8d28\u7ed3\u6784\u57df\u7ec4\u7ec7\u7684\u7ebf\u6027\u56fe / Linear representation of protein domains and functional regions</li> <li>\u5e8f\u5217\u6807\u5fd7\u56fe / Sequence Logo Plot: \u5c55\u793a\u591a\u5e8f\u5217\u6bd4\u5bf9\u4e2d\u7684\u5e8f\u5217\u4fdd\u5b88\u6027 / Visualizes sequence conservation in multiple sequence alignments</li> <li>\u7ffb\u8bd1\u540e\u4fee\u9970\u56fe / Post-translational Modification Map: \u5c55\u793a\u86cb\u767d\u8d28\u4fee\u9970\u4f4d\u70b9\u5206\u5e03 / Shows locations and types of protein modifications</li> <li>\u62c9\u6c0f\u56fe / Ramachandran Plot: \u5c55\u793a\u86cb\u767d\u8d28\u9aa8\u67b6\u4e8c\u9762\u89d2\u5206\u5e03 / Shows distribution of backbone dihedral angles in protein structures</li> <li>\u63a5\u89e6\u56fe / Contact Map: \u5c55\u793a\u86cb\u767d\u8d28\u7ed3\u6784\u4e2d\u6c28\u57fa\u9178\u6b8b\u57fa\u95f4\u63a5\u89e6\u7684\u77e9\u9635 / Matrix showing residue-residue contacts within protein structures</li> <li>\u5206\u5b50\u52a8\u529b\u5b66\u8f68\u8ff9\u56fe / Molecular Dynamics Trajectory Plot: \u5c55\u793a\u86cb\u767d\u8d28\u6784\u8c61\u968f\u65f6\u95f4\u53d8\u5316 / Visualizes protein motion and conformational changes over time</li> <li>\u914d\u4f53-\u86cb\u767d\u4e92\u4f5c\u56fe / Ligand-Protein Interaction Diagram: \u5c55\u793a\u914d\u4f53\u4e0e\u86cb\u767d\u7ed3\u5408\u4f4d\u70b9\u4e92\u4f5c / 2D representation of interactions between protein and bound molecules</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#pathway-and-network-analysis","title":"\u901a\u8def\u4e0e\u7f51\u7edc\u5206\u6790 / Pathway and Network Analysis","text":"<ul> <li>\u901a\u8def\u56fe / Pathway Diagram: \u5c55\u793a\u751f\u7269\u901a\u8def\u4e2d\u5206\u5b50\u4e92\u4f5c\u7684\u56fe\u5f62\u8868\u793a / Graphical representation of biological pathways with molecular interactions</li> <li>\u5bcc\u96c6\u56fe\u8c31 / Enrichment Map: \u5c55\u793a\u5bcc\u96c6\u901a\u8def\u53ca\u5176\u5173\u7cfb\u7684\u7f51\u7edc\u56fe / Network visualization of enriched pathways and their relationships</li> <li>\u6851\u57fa\u56fe / Sankey Diagram: \u5c55\u793a\u96c6\u5408\u95f4\u5173\u7cfb\u7684\u6d41\u56fe / Flow diagram showing relationships between sets or categories</li> <li>\u96c6\u5408\u4ea4\u53c9\u56fe / UpSet Plot: \u5c55\u793a\u591a\u4e2a\u96c6\u5408\u4ea4\u96c6\u7684\u66ff\u4ee3\u7ef4\u6069\u56fe / Alternative to Venn diagrams for visualizing set intersections</li> <li>\u57fa\u56e0\u8c03\u63a7\u7f51\u7edc / Gene Regulatory Network: \u5c55\u793a\u8f6c\u5f55\u8c03\u63a7\u5173\u7cfb\u7684\u6709\u5411\u7f51\u7edc / Directed network showing transcriptional regulation relationships</li> <li>\u76f8\u5173\u6027\u7f51\u7edc / Correlation Network: \u5c55\u793a\u57fa\u56e0\u8868\u8fbe\u76f8\u5173\u6027\u7684\u7f51\u7edc\u56fe / Network where edges represent correlation strength between nodes</li> <li>\u6a21\u5757\u68c0\u6d4b\u56fe / Module Detection Visualization: \u5c55\u793a\u7f51\u7edc\u4e2d\u529f\u80fd\u6a21\u5757\u7684\u793e\u533a\u7ed3\u6784 / Highlights densely connected subnetworks representing functional modules</li> <li>\u4e2d\u5fc3\u6027\u53ef\u89c6\u5316 / Network Centrality Visualization: \u7a81\u51fa\u663e\u793a\u57fa\u4e8e\u7f51\u7edc\u62d3\u6251\u5ea6\u91cf\u7684\u91cd\u8981\u8282\u70b9 / Highlights important nodes based on network topology metrics</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#clinical-and-phenotypic-data","title":"\u4e34\u5e8a\u4e0e\u8868\u578b\u6570\u636e / Clinical and Phenotypic Data","text":"<ul> <li>\u751f\u5b58\u66f2\u7ebf / Kaplan-Meier Curve: \u5c55\u793a\u4e0d\u540c\u7ec4\u522b\u968f\u65f6\u95f4\u7684\u751f\u5b58\u6982\u7387 / Shows survival probability over time for different groups</li> <li>\u68ee\u6797\u56fe / Forest Plot: \u5c55\u793a\u591a\u4e2a\u56e0\u7d20\u7684\u98ce\u9669\u6bd4\u53ca\u7f6e\u4fe1\u533a\u95f4 / Shows hazard ratios and confidence intervals for multiple factors</li> <li>\u7ade\u4e89\u98ce\u9669\u7d2f\u79ef\u53d1\u751f\u7387\u56fe / Competing Risk Cumulative Incidence: \u5c55\u793a\u591a\u79cd\u7ade\u4e89\u6027\u7ed3\u5c40\u7684\u6982\u7387 / Shows probability of different competing outcomes over time</li> <li>\u65f6\u95f4\u4f9d\u8d56ROC\u66f2\u7ebf / Time-dependent ROC Curve: \u5c55\u793a\u4e0d\u540c\u65f6\u95f4\u70b9\u7684\u8bca\u65ad\u6027\u80fd / Shows diagnostic performance at different time points</li> <li>\u60a3\u8005\u65f6\u95f4\u7ebf\u56fe / Patient Timeline Plot: \u5c55\u793a\u4e2a\u4f53\u60a3\u8005\u4e34\u5e8a\u4e8b\u4ef6\u5e8f\u5217 / Shows sequence and timing of clinical events for individual patients</li> <li>\u7011\u5e03\u56fe / Waterfall Plot: \u5c55\u793a\u4e2a\u4f53\u60a3\u8005\u53cd\u5e94\u5e45\u5ea6\u7684\u6761\u5f62\u56fe / Bar chart showing response magnitude for individual patients</li> <li>\u8718\u86db\u56fe / Spider Plot: \u5c55\u793a\u4e2a\u4f53\u60a3\u8005\u968f\u65f6\u95f4\u7684\u53cd\u5e94\u8f68\u8ff9 / Shows trajectory of response over time for individual patients</li> <li>\u5217\u7ebf\u56fe / Nomogram: \u57fa\u4e8e\u591a\u53d8\u91cf\u9884\u6d4b\u7ed3\u5c40\u7684\u56fe\u5f62\u8ba1\u7b97\u5de5\u5177 / Graphical calculation tool for predicting outcomes based on multiple variables</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#multi-omics-integration","title":"\u591a\u7ec4\u5b66\u6574\u5408 / Multi-omics Integration","text":"<ul> <li>\u591a\u7ec4\u5b66\u70ed\u56fe / Multi-omics Heatmap: \u5c55\u793a\u591a\u79cd\u7ec4\u5b66\u6570\u636e\u6a21\u5f0f\u7684\u5e76\u5217\u70ed\u56fe / Juxtaposed or integrated heatmaps showing patterns across data types</li> <li>\u591a\u7ec4\u5b66\u73af\u5f62\u56fe / Circos Multi-omics Plot: \u6574\u5408\u591a\u79cd\u7ec4\u5b66\u6570\u636e\u7684\u73af\u5f62\u53ef\u89c6\u5316 / Circular visualization integrating multiple data types</li> <li>\u964d\u7ef4\u53cc\u6807\u56fe / Dimension Reduction Biplot: \u5c06\u6837\u672c\u548c\u7279\u5f81\u540c\u65f6\u6295\u5f71\u5230\u964d\u7ef4\u7a7a\u95f4 / Projects both samples and features onto reduced dimensional space</li> <li>\u591a\u7ec4\u5b66\u6851\u57fa\u56fe / Sankey Multi-omics Diagram: \u5c55\u793a\u591a\u7ec4\u5b66\u5c42\u7ea7\u95f4\u7279\u5f81\u5173\u7cfb\u7684\u6d41\u56fe / Flow diagram showing relationships between features across omics layers</li> <li>\u591a\u7ec4\u5b66\u805a\u7c7b\u70ed\u56fe / Multi-omics Clustering Heatmap: \u57fa\u4e8e\u591a\u7ec4\u5b66\u6574\u5408\u5206\u6790\u7684\u6837\u672c\u805a\u7c7b / Shows sample clustering based on integrated analysis of multiple data types</li> <li>\u7279\u5f81\u91cd\u8981\u6027\u56fe / Feature Importance Plot: \u5c55\u793a\u6765\u81ea\u4e0d\u540c\u7ec4\u5b66\u7684\u7279\u5f81\u5bf9\u5206\u7c7b\u7684\u8d21\u732e / Shows contribution of features from different omics to classification</li> <li>\u9a71\u52a8\u6539\u53d8\u53ef\u89c6\u5316 / Driver Alteration Visualization: \u5c55\u793a\u8de8\u7ec4\u5b66\u5c42\u7ea7\u7684\u5173\u952e\u5206\u5b50\u6539\u53d8 / Shows key molecular alterations driving phenotypes across omics layers</li> <li>\u591a\u6a21\u6001\u5bcc\u96c6\u53ef\u89c6\u5316 / Multi-modal Enrichment Visualization: \u5c55\u793a\u591a\u79cd\u6570\u636e\u7c7b\u578b\u7684\u901a\u8def\u5bcc\u96c6 / Shows pathway enrichment across multiple data types</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#i-gene-expression-data-visualization","title":"I. Gene Expression Data Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#1-differential-expression-analysis","title":"1. Differential Expression Analysis","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#heatmaps","title":"Heatmaps","text":"<ul> <li>Description: Matrix visualization that uses color intensity to represent expression values, with rows typically representing genes and columns representing samples.</li> <li>Best for: Visualizing patterns across multiple genes and samples simultaneously.</li> <li>Variants:</li> <li>Clustered heatmap: Includes hierarchical clustering dendrograms to group similar samples/genes.</li> <li>Annotated heatmap: Includes color bars for sample/gene metadata (e.g., treatment, tissue type).</li> <li>Z-score heatmap: Normalizes expression values for each gene to highlight relative changes.</li> <li>Biclustered heatmap: Simultaneously clusters both rows and columns to identify gene modules.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#volcano-plots","title":"Volcano Plots","text":"<ul> <li>Description: Scatter plot showing statistical significance (-log10 p-value) versus magnitude of change (log2 fold change).</li> <li>Best for: Identifying genes with both statistical and biological significance.</li> <li>Variants:</li> <li>Enhanced volcano: Includes gene labels for top hits and customizable significance thresholds.</li> <li>Interactive volcano: Allows hovering/clicking on points to reveal gene details.</li> <li>Quadrant volcano: Divides plot into regions based on up/down-regulation and significance.</li> <li>3D volcano: Adds a third dimension (e.g., expression level) represented by point size or color.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#ma-plots","title":"MA Plots","text":"<ul> <li>Description: Scatter plot of log-ratio (M) versus mean average (A) values, showing relationship between expression intensity and fold change.</li> <li>Best for: Identifying intensity-dependent biases in differential expression.</li> <li>Variants:</li> <li>Smoothed MA plot: Includes a trend line showing average fold change across expression levels.</li> <li>Highlighted MA plot: Colors points based on statistical significance.</li> <li>Density MA plot: Uses color to show point density in crowded regions.</li> <li>Paired MA plot: Shows multiple comparisons side-by-side for the same gene set.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#pcamds-plots","title":"PCA/MDS Plots","text":"<ul> <li>Description: Dimensionality reduction techniques that project high-dimensional expression data onto 2D/3D space.</li> <li>Best for: Visualizing overall sample relationships and identifying batch effects.</li> <li>Variants:</li> <li>Biplot PCA: Shows both sample positions and gene loadings in the same plot.</li> <li>3D PCA: Adds a third principal component for more detailed separation.</li> <li>Ellipse PCA: Adds confidence ellipses around sample groups.</li> <li>Animated PCA: Shows rotation through different principal components.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#box-and-whisker-plots","title":"Box-and-Whisker Plots","text":"<ul> <li>Description: Shows distribution of expression values across sample groups with median, quartiles, and outliers.</li> <li>Best for: Comparing expression distributions between conditions.</li> <li>Variants:</li> <li>Notched boxplot: Includes notches indicating confidence interval around median.</li> <li>Violin plot: Combines boxplot with kernel density estimate for distribution shape.</li> <li>Raincloud plot: Combines boxplot, violin plot, and individual data points.</li> <li>Grouped boxplot: Shows multiple genes side-by-side across conditions.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#scatter-plots-with-trend-lines","title":"Scatter Plots with Trend Lines","text":"<ul> <li>Description: Shows relationship between expression of two genes with optional trend lines.</li> <li>Best for: Examining correlation between genes or comparing expression across conditions.</li> <li>Variants:</li> <li>Hexbin scatter: Uses hexagonal binning for dense data visualization.</li> <li>Contour scatter: Adds density contours to highlight data distribution.</li> <li>Marginal histogram scatter: Includes histograms along axes for distribution context.</li> <li>LOESS smoothed scatter: Adds locally estimated scatterplot smoothing curve.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#2-time-series-expression-data","title":"2. Time-series Expression Data","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#line-plots","title":"Line Plots","text":"<ul> <li>Description: Shows expression changes over time with lines connecting time points.</li> <li>Best for: Visualizing temporal expression patterns of selected genes.</li> <li>Variants:</li> <li>Multi-gene line plot: Shows multiple genes with different colors/patterns.</li> <li>Shadowed line plot: Includes confidence intervals or standard error bands.</li> <li>Stacked line plot: Shows cumulative expression patterns.</li> <li>Faceted line plot: Creates small multiples for different genes or conditions.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#heatmap-with-time-ordering","title":"Heatmap with Time Ordering","text":"<ul> <li>Description: Heatmap with samples ordered by time point to show temporal patterns.</li> <li>Best for: Visualizing global expression changes over time across many genes.</li> <li>Variants:</li> <li>Clustered time heatmap: Clusters genes with similar temporal patterns.</li> <li>Interpolated time heatmap: Uses color gradient to smooth between time points.</li> <li>Standardized time heatmap: Z-score normalizes each gene across time points.</li> <li>Annotated time heatmap: Includes pathway or functional annotations.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#trajectory-plots","title":"Trajectory Plots","text":"<ul> <li>Description: Shows progression of cellular states in reduced dimensional space.</li> <li>Best for: Single-cell RNA-seq time course experiments.</li> <li>Variants:</li> <li>Pseudotime trajectory: Orders cells by developmental or response progression.</li> <li>Branched trajectory: Shows bifurcations in cell fate decisions.</li> <li>RNA velocity trajectory: Includes arrows indicating future state predictions.</li> <li>Annotated trajectory: Overlays cell type or state information.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#stream-plots","title":"Stream Plots","text":"<ul> <li>Description: Area plots showing how proportions of cell types or gene modules change over time.</li> <li>Best for: Visualizing compositional changes in cell populations.</li> <li>Variants:</li> <li>Stacked stream plot: Shows absolute numbers stacked vertically.</li> <li>Normalized stream plot: Shows relative proportions that sum to 100%.</li> <li>Smoothed stream plot: Uses spline interpolation between time points.</li> <li>Highlighted stream plot: Emphasizes specific cell types or gene modules.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#slope-graphs","title":"Slope Graphs","text":"<ul> <li>Description: Connects expression values between two time points with straight lines.</li> <li>Best for: Comparing expression changes between specific time points.</li> <li>Variants:</li> <li>Multi-condition slope graph: Uses color to distinguish experimental conditions.</li> <li>Highlighted slope graph: Emphasizes specific genes of interest.</li> <li>Ranked slope graph: Orders genes by expression at each time point.</li> <li>Filtered slope graph: Shows only genes with significant changes.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#ii-single-cell-and-spatial-omics-data","title":"II. Single-Cell and Spatial Omics Data","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#1-single-cell-rna-seq-visualization","title":"1. Single-Cell RNA-seq Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#dimensionality-reduction-plots","title":"Dimensionality Reduction Plots","text":"<ul> <li>Description: Reduces high-dimensional expression data to 2D/3D for visualization.</li> <li>Best for: Identifying cell clusters and visualizing cell type relationships.</li> <li>Variants:</li> <li>t-SNE plot: Preserves local structure, good for revealing clusters.</li> <li>UMAP plot: Preserves both local and global structure, faster than t-SNE.</li> <li>PHATE plot: Emphasizes progression and continuum between cell states.</li> <li>FDG plot: Force-directed graph layout based on expression similarity.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#feature-plots","title":"Feature Plots","text":"<ul> <li>Description: Overlays gene expression values on dimensionality reduction plots.</li> <li>Best for: Visualizing expression patterns of marker genes across cell populations.</li> <li>Variants:</li> <li>Multi-feature plot: Shows several genes in small multiples.</li> <li>Gradient feature plot: Uses color intensity for expression level.</li> <li>Binary feature plot: Highlights cells above expression threshold.</li> <li>Ridge feature plot: Adds vertical dimension showing expression distribution.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#dot-plots","title":"Dot Plots","text":"<ul> <li>Description: Shows both percentage of expressing cells (dot size) and average expression level (color intensity).</li> <li>Best for: Comparing marker gene expression across cell types.</li> <li>Variants:</li> <li>Hierarchical dot plot: Orders cell types by similarity.</li> <li>Pathway dot plot: Groups genes by functional pathway.</li> <li>Comparative dot plot: Shows differences between conditions.</li> <li>Annotated dot plot: Includes significance indicators.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#violin-plots","title":"Violin Plots","text":"<ul> <li>Description: Shows distribution of gene expression across cell types/clusters.</li> <li>Best for: Comparing expression distributions between cell populations.</li> <li>Variants:</li> <li>Split violin plot: Compares distributions between two conditions.</li> <li>Multi-gene violin plot: Shows several genes across cell types.</li> <li>Ridgeline violin plot: Overlaps distributions for space efficiency.</li> <li>Box-violin hybrid: Combines violin with boxplot statistics.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#cell-cell-interaction-networks","title":"Cell-Cell Interaction Networks","text":"<ul> <li>Description: Network visualization showing predicted interactions between cell types.</li> <li>Best for: Analyzing cellular communication and signaling pathways.</li> <li>Variants:</li> <li>Circos interaction plot: Shows interactions between cell types in circular layout.</li> <li>Heatmap interaction plot: Shows interaction strength between cell pairs.</li> <li>Chord diagram: Visualizes interaction flow between cell populations.</li> <li>Sankey diagram: Shows signaling pathway flow between cell types.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#trajectory-inference-visualizations","title":"Trajectory Inference Visualizations","text":"<ul> <li>Description: Shows developmental or differentiation paths between cell states.</li> <li>Best for: Understanding cellular transitions and lineage relationships.</li> <li>Variants:</li> <li>Tree plot: Shows hierarchical differentiation paths.</li> <li>Subway map plot: Shows parallel differentiation trajectories.</li> <li>Stream plot: Shows density of cells along differentiation paths.</li> <li>State transition graph: Shows probability of transitions between states.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#2-spatial-transcriptomics-visualization","title":"2. Spatial Transcriptomics Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#spatial-feature-plots","title":"Spatial Feature Plots","text":"<ul> <li>Description: Overlays gene expression on tissue coordinates/images.</li> <li>Best for: Visualizing spatial expression patterns in tissue context.</li> <li>Variants:</li> <li>Spot-based spatial plot: Shows expression in discrete capture spots.</li> <li>Cell-based spatial plot: Shows single-cell resolution expression.</li> <li>Contour spatial plot: Uses isolines to show expression gradients.</li> <li>3D spatial plot: Shows expression in three-dimensional tissue context.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#spatial-clustering-maps","title":"Spatial Clustering Maps","text":"<ul> <li>Description: Colors tissue regions based on expression similarity clusters.</li> <li>Best for: Identifying tissue domains with similar expression profiles.</li> <li>Variants:</li> <li>Hard boundary clustering: Shows discrete cluster assignments.</li> <li>Soft boundary clustering: Uses color blending for gradual transitions.</li> <li>Hierarchical spatial clustering: Shows nested tissue domains.</li> <li>Spatially-aware clustering: Incorporates physical proximity in clustering.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#spatial-co-expression-networks","title":"Spatial Co-expression Networks","text":"<ul> <li>Description: Visualizes gene-gene correlations with spatial context.</li> <li>Best for: Identifying spatially regulated gene programs.</li> <li>Variants:</li> <li>Spatial correlation network: Shows co-expressed genes in spatial domains.</li> <li>Module spatial plot: Shows expression of gene modules across tissue.</li> <li>Spatial gene-gene heatmap: Correlates genes with similar spatial patterns.</li> <li>Spatial enrichment map: Shows pathway enrichment in spatial domains.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#cell-type-deconvolution-maps","title":"Cell Type Deconvolution Maps","text":"<ul> <li>Description: Visualizes predicted cell type proportions across tissue.</li> <li>Best for: Inferring cellular composition in spatial transcriptomics data.</li> <li>Variants:</li> <li>Pie chart spatial map: Shows cell type proportions at each location.</li> <li>Stacked bar spatial map: Shows absolute counts of each cell type.</li> <li>Cell type probability map: Shows likelihood of specific cell type.</li> <li>Dominant cell type map: Colors regions by most abundant cell type.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#iii-genomic-and-epigenomic-data","title":"III. Genomic and Epigenomic Data","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#1-variant-analysis-visualization","title":"1. Variant Analysis Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#manhattan-plots","title":"Manhattan Plots","text":"<ul> <li>Description: Plots genomic position (x-axis) versus statistical significance (y-axis).</li> <li>Best for: Genome-wide association studies (GWAS) and similar analyses.</li> <li>Variants:</li> <li>Multi-trait Manhattan: Shows multiple phenotypes in different colors.</li> <li>Annotated Manhattan: Labels significant loci with gene names.</li> <li>QQ Manhattan: Includes quantile-quantile plot to assess statistical inflation.</li> <li>Regional Manhattan: Zooms in on specific genomic region of interest.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#lollipop-plots","title":"Lollipop Plots","text":"<ul> <li>Description: Shows variants along a gene or protein sequence with stems indicating significance.</li> <li>Best for: Visualizing mutation hotspots and functional domains.</li> <li>Variants:</li> <li>Domain-annotated lollipop: Includes protein domain information.</li> <li>Multi-sample lollipop: Uses color to distinguish variants from different samples.</li> <li>Frequency lollipop: Sizes lollipops by variant frequency.</li> <li>Functional impact lollipop: Colors by predicted functional effect.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#oncoprints","title":"Oncoprints","text":"<ul> <li>Description: Matrix showing genetic alterations across samples.</li> <li>Best for: Comparing mutation profiles across cancer samples.</li> <li>Variants:</li> <li>Multi-omics oncoprint: Integrates mutations, CNVs, and expression.</li> <li>Clinical oncoprint: Includes patient metadata and outcomes.</li> <li>Pathway oncoprint: Groups genes by functional pathway.</li> <li>Clustered oncoprint: Orders samples by similarity of alteration profile.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#circos-plots","title":"Circos Plots","text":"<ul> <li>Description: Circular representation of genomic data showing relationships between regions.</li> <li>Best for: Visualizing structural variants, translocations, and interactions.</li> <li>Variants:</li> <li>Multi-track circos: Includes multiple data types (CNV, expression, etc.).</li> <li>Chord circos: Shows connections between genomic regions.</li> <li>Heatmap circos: Includes heatmaps along circular tracks.</li> <li>Histogram circos: Shows quantitative data as radial histograms.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#rainfall-plots","title":"Rainfall Plots","text":"<ul> <li>Description: Plots genomic position versus distance to neighboring variants.</li> <li>Best for: Identifying hypermutated regions or mutation clusters.</li> <li>Variants:</li> <li>Mutation type rainfall: Colors points by mutation type (e.g., C&gt;T, A&gt;G).</li> <li>Sample rainfall: Compares mutation distributions across samples.</li> <li>Kataegis rainfall: Highlights regions of localized hypermutation.</li> <li>Annotated rainfall: Includes gene annotations for relevant regions.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#2-epigenomic-data-visualization","title":"2. Epigenomic Data Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#genome-browser-tracks","title":"Genome Browser Tracks","text":"<ul> <li>Description: Linear representation of genomic features along chromosomes.</li> <li>Best for: Integrating multiple data types at specific genomic loci.</li> <li>Variants:</li> <li>Multi-sample tracks: Compares samples side-by-side.</li> <li>Signal tracks: Shows continuous signal (e.g., ChIP-seq, ATAC-seq).</li> <li>Annotation tracks: Shows genes, regulatory elements, etc.</li> <li>Interaction tracks: Shows chromatin interactions (e.g., Hi-C, ChIA-PET).</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#heatmap-metaplots","title":"Heatmap Metaplots","text":"<ul> <li>Description: Heatmap showing signal distribution around genomic features.</li> <li>Best for: Visualizing patterns around transcription start sites, enhancers, etc.</li> <li>Variants:</li> <li>K-means clustered metaplot: Groups features by signal pattern.</li> <li>Multi-condition metaplot: Compares signal across experimental conditions.</li> <li>Composite metaplot: Combines multiple signal types.</li> <li>Differential metaplot: Highlights differences between conditions.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#chromatin-interaction-maps","title":"Chromatin Interaction Maps","text":"<ul> <li>Description: Heatmap showing interaction frequency between genomic regions.</li> <li>Best for: Visualizing 3D genome organization from Hi-C or similar data.</li> <li>Variants:</li> <li>Multi-resolution contact map: Shows different zoom levels.</li> <li>Differential contact map: Highlights changes between conditions.</li> <li>Virtual 4C plot: Shows interactions from specific viewpoint.</li> <li>Triangular contact map: Shows TADs and domain boundaries.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#aggregated-peak-analysis","title":"Aggregated Peak Analysis","text":"<ul> <li>Description: Shows average signal profiles around genomic features.</li> <li>Best for: Comparing epigenetic marks around regulatory elements.</li> <li>Variants:</li> <li>Profile plot: Shows average signal with confidence intervals.</li> <li>Heatmap profile: Shows individual features stacked as heatmap rows.</li> <li>K-means profile: Clusters features by signal pattern.</li> <li>Multi-mark profile: Compares different epigenetic marks.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#chromatin-state-maps","title":"Chromatin State Maps","text":"<ul> <li>Description: Visualizes predicted chromatin states across genomic regions.</li> <li>Best for: Interpreting combinatorial patterns of epigenetic marks.</li> <li>Variants:</li> <li>Genome browser state track: Shows states along linear genome.</li> <li>State enrichment plot: Shows state enrichment near genomic features.</li> <li>State transition map: Shows changes in states between conditions.</li> <li>State composition plot: Shows proportion of genome in each state.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#iv-protein-and-structural-data-continued","title":"IV. Protein and Structural Data (continued)","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#1-protein-analysis-visualization-continued","title":"1. Protein Analysis Visualization (continued)","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#protein-protein-interaction-networks-continued","title":"Protein-Protein Interaction Networks (continued)","text":"<ul> <li>Variants (continued):</li> <li>Clustered network: Groups proteins by functional modules or complexes.</li> <li>Weighted network: Uses edge thickness to indicate interaction confidence.</li> <li>Dynamic network: Shows changes in interactions across conditions.</li> <li>Hierarchical network: Organizes proteins by cellular compartment or function.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#protein-structure-visualization","title":"Protein Structure Visualization","text":"<ul> <li>Description: 3D representation of protein structure showing atomic or residue-level details.</li> <li>Best for: Understanding protein function, mutation effects, and binding sites.</li> <li>Variants:</li> <li>Ribbon diagram: Shows secondary structure elements (\u03b1-helices, \u03b2-sheets).</li> <li>Surface representation: Shows molecular surface and binding pockets.</li> <li>Ball-and-stick model: Emphasizes atomic bonds and interactions.</li> <li>Ensemble visualization: Shows multiple conformational states.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#domain-architecture-plots","title":"Domain Architecture Plots","text":"<ul> <li>Description: Linear representation of protein domains and functional regions.</li> <li>Best for: Comparing domain organization across protein families.</li> <li>Variants:</li> <li>Multi-protein domain plot: Aligns related proteins by domain structure.</li> <li>Mutation-annotated domain plot: Shows mutation locations relative to domains.</li> <li>Exon-mapped domain plot: Shows relationship between exons and domains.</li> <li>Interactive domain plot: Allows exploration of domain features.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#sequence-logo-plots","title":"Sequence Logo Plots","text":"<ul> <li>Description: Visualizes sequence conservation in multiple sequence alignments.</li> <li>Best for: Identifying conserved motifs and binding sites.</li> <li>Variants:</li> <li>Information content logo: Scales letter height by conservation.</li> <li>Probability logo: Shows frequency of each residue at each position.</li> <li>Difference logo: Highlights differences between two sequence sets.</li> <li>3D structure-mapped logo: Projects conservation onto structural elements.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#post-translational-modification-maps","title":"Post-translational Modification Maps","text":"<ul> <li>Description: Shows locations and types of protein modifications.</li> <li>Best for: Understanding regulation of protein function.</li> <li>Variants:</li> <li>Linear PTM map: Shows modifications along protein sequence.</li> <li>Structure-mapped PTM: Projects modifications onto 3D structure.</li> <li>Quantitative PTM map: Shows modification abundance across conditions.</li> <li>Temporal PTM map: Shows dynamic changes in modifications over time.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#2-structural-biology-visualization","title":"2. Structural Biology Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#ramachandran-plots","title":"Ramachandran Plots","text":"<ul> <li>Description: Shows distribution of backbone dihedral angles in protein structures.</li> <li>Best for: Assessing protein structure quality and conformational preferences.</li> <li>Variants:</li> <li>Residue-specific Ramachandran: Highlights specific amino acids.</li> <li>Density Ramachandran: Uses contours to show preferred regions.</li> <li>Multi-structure Ramachandran: Compares angles across protein structures.</li> <li>Secondary structure Ramachandran: Colors points by secondary structure.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#contact-maps","title":"Contact Maps","text":"<ul> <li>Description: Matrix showing residue-residue contacts within protein structures.</li> <li>Best for: Comparing protein folds and identifying structural domains.</li> <li>Variants:</li> <li>Distance map: Uses color to represent inter-residue distances.</li> <li>Difference contact map: Highlights structural changes between states.</li> <li>Native contact map: Shows contacts present in native structure.</li> <li>Evolution-based contact map: Integrates evolutionary coupling information.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#molecular-dynamics-trajectory-analysis","title":"Molecular Dynamics Trajectory Analysis","text":"<ul> <li>Description: Visualizes protein motion and conformational changes over time.</li> <li>Best for: Understanding protein flexibility and function.</li> <li>Variants:</li> <li>RMSD plot: Shows structural deviation over simulation time.</li> <li>Principal component projection: Shows major modes of motion.</li> <li>Free energy landscape: Maps conformational space by energy.</li> <li>Residue fluctuation plot: Shows flexibility of individual residues.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#ligand-protein-interaction-diagrams","title":"Ligand-Protein Interaction Diagrams","text":"<ul> <li>Description: 2D representation of interactions between protein and bound molecules.</li> <li>Best for: Understanding binding mechanisms and drug design.</li> <li>Variants:</li> <li>2D interaction diagram: Shows hydrogen bonds, hydrophobic interactions, etc.</li> <li>Interaction fingerprint: Compares interactions across multiple ligands.</li> <li>Interaction network: Shows residue interaction network around binding site.</li> <li>Pharmacophore map: Highlights key features for molecular recognition.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#v-pathway-and-network-analysis","title":"V. Pathway and Network Analysis","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#1-pathway-visualization","title":"1. Pathway Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#pathway-diagrams","title":"Pathway Diagrams","text":"<ul> <li>Description: Graphical representation of biological pathways with genes/proteins as nodes.</li> <li>Best for: Visualizing molecular interactions in biological processes.</li> <li>Variants:</li> <li>Expression-overlaid pathway: Maps expression data onto pathway components.</li> <li>Multi-condition pathway: Shows pathway changes across conditions.</li> <li>Mutation-annotated pathway: Highlights mutated components.</li> <li>Flux pathway: Shows metabolic flux through pathways.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#enrichment-maps","title":"Enrichment Maps","text":"<ul> <li>Description: Network visualization of enriched pathways and their relationships.</li> <li>Best for: Interpreting functional enrichment analysis results.</li> <li>Variants:</li> <li>Clustered enrichment map: Groups related pathways.</li> <li>Edge-weighted enrichment map: Shows pathway similarity strength.</li> <li>Multi-dataset enrichment map: Compares enrichment across conditions.</li> <li>Temporal enrichment map: Shows pathway enrichment changes over time.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#alluvialsankey-diagrams","title":"Alluvial/Sankey Diagrams","text":"<ul> <li>Description: Flow diagram showing relationships between sets or categories.</li> <li>Best for: Visualizing pathway cross-talk or gene set overlaps.</li> <li>Variants:</li> <li>Gene-pathway Sankey: Shows gene membership across pathways.</li> <li>Multi-omics Sankey: Connects findings across data types.</li> <li>Temporal Sankey: Shows changes in pathway activity over time.</li> <li>Hierarchical Sankey: Shows nested pathway relationships.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#upset-plots","title":"Upset Plots","text":"<ul> <li>Description: Alternative to Venn diagrams for visualizing set intersections.</li> <li>Best for: Comparing membership across multiple gene sets or pathways.</li> <li>Variants:</li> <li>Interactive UpSet plot: Allows selection of specific intersections.</li> <li>Quantitative UpSet plot: Sizes bars by statistical significance.</li> <li>Connected UpSet plot: Shows relationships between intersections.</li> <li>Attribute-enriched UpSet: Colors intersections by additional metadata.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#2-network-analysis-visualization","title":"2. Network Analysis Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#gene-regulatory-networks","title":"Gene Regulatory Networks","text":"<ul> <li>Description: Directed network showing transcriptional regulation relationships.</li> <li>Best for: Understanding gene expression control mechanisms.</li> <li>Variants:</li> <li>TF-centered regulatory network: Focuses on specific transcription factors.</li> <li>Inferred regulatory network: Shows predicted regulatory relationships.</li> <li>Layered regulatory network: Organizes by regulatory hierarchy.</li> <li>Condition-specific regulatory network: Shows context-dependent regulation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#correlation-networks","title":"Correlation Networks","text":"<ul> <li>Description: Network where edges represent correlation strength between nodes.</li> <li>Best for: Identifying co-expressed genes or co-regulated processes.</li> <li>Variants:</li> <li>Thresholded correlation network: Shows only strong correlations.</li> <li>Signed correlation network: Distinguishes positive and negative correlations.</li> <li>Partial correlation network: Controls for indirect correlations.</li> <li>Differential correlation network: Shows changes in correlations between conditions.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#module-detection-visualizations","title":"Module Detection Visualizations","text":"<ul> <li>Description: Highlights densely connected subnetworks representing functional modules.</li> <li>Best for: Identifying biological processes from network structure.</li> <li>Variants:</li> <li>Community detection map: Colors nodes by module membership.</li> <li>Module eigengene plot: Shows module activity across samples.</li> <li>Module preservation plot: Compares module structure across datasets.</li> <li>Module-trait correlation heatmap: Relates modules to phenotypic traits.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#network-centrality-visualizations","title":"Network Centrality Visualizations","text":"<ul> <li>Description: Highlights important nodes based on network topology metrics.</li> <li>Best for: Identifying key regulators or hub genes.</li> <li>Variants:</li> <li>Degree centrality map: Sizes nodes by number of connections.</li> <li>Betweenness centrality map: Highlights nodes that bridge network regions.</li> <li>Eigenvector centrality map: Emphasizes connections to other important nodes.</li> <li>Multi-metric centrality plot: Compares different centrality measures.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#vi-clinical-and-phenotypic-data","title":"VI. Clinical and Phenotypic Data","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#1-survival-analysis-visualization","title":"1. Survival Analysis Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#kaplan-meier-curves","title":"Kaplan-Meier Curves","text":"<ul> <li>Description: Shows survival probability over time for different groups.</li> <li>Best for: Comparing survival outcomes between patient cohorts.</li> <li>Variants:</li> <li>Annotated Kaplan-Meier: Includes confidence intervals and risk tables.</li> <li>Multi-group Kaplan-Meier: Compares multiple patient subgroups.</li> <li>Landmark Kaplan-Meier: Analyzes survival from specific time points.</li> <li>Restricted mean survival time plot: Alternative to hazard ratio comparison.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#forest-plots","title":"Forest Plots","text":"<ul> <li>Description: Shows hazard ratios and confidence intervals for multiple factors.</li> <li>Best for: Visualizing results from Cox regression or similar analyses.</li> <li>Variants:</li> <li>Subgroup forest plot: Analyzes effect in different patient subgroups.</li> <li>Multi-endpoint forest plot: Compares effects on different outcomes.</li> <li>Interaction forest plot: Shows effect modification by other factors.</li> <li>Time-dependent forest plot: Shows changes in hazard ratios over time.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#competing-risk-cumulative-incidence","title":"Competing Risk Cumulative Incidence","text":"<ul> <li>Description: Shows probability of different competing outcomes over time.</li> <li>Best for: Analyzing events where multiple outcomes can occur.</li> <li>Variants:</li> <li>Stacked cumulative incidence: Shows all competing outcomes together.</li> <li>Cause-specific cumulative incidence: Focuses on specific outcome.</li> <li>Multi-group cumulative incidence: Compares incidence across patient groups.</li> <li>Conditional cumulative incidence: Shows incidence given survival to specific time.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#time-dependent-roc-curves","title":"Time-dependent ROC Curves","text":"<ul> <li>Description: Shows diagnostic performance at different time points.</li> <li>Best for: Evaluating predictive biomarkers for time-to-event outcomes.</li> <li>Variants:</li> <li>Multi-timepoint ROC: Compares ROC curves at different follow-up times.</li> <li>AUC timeline plot: Shows changes in AUC over follow-up time.</li> <li>Integrated time-dependent ROC: Summarizes performance across time range.</li> <li>Comparative time-dependent ROC: Compares multiple predictors.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#2-clinical-data-visualization","title":"2. Clinical Data Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#patient-timeline-plots","title":"Patient Timeline Plots","text":"<ul> <li>Description: Shows sequence and timing of clinical events for individual patients.</li> <li>Best for: Visualizing disease progression and treatment history.</li> <li>Variants:</li> <li>Swimmer plot: Shows duration of response for individual patients.</li> <li>Event timeline: Shows discrete events along patient history.</li> <li>Treatment timeline: Focuses on therapy administration periods.</li> <li>Biomarker timeline: Integrates quantitative measurements over time.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#waterfall-plots","title":"Waterfall Plots","text":"<ul> <li>Description: Bar chart showing response magnitude for individual patients.</li> <li>Best for: Visualizing treatment response heterogeneity.</li> <li>Variants:</li> <li>Annotated waterfall: Includes patient characteristics as annotations.</li> <li>Sorted waterfall: Orders patients by response magnitude.</li> <li>Grouped waterfall: Organizes patients by subgroups.</li> <li>Before-after waterfall: Shows changes from baseline.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#spider-plots","title":"Spider Plots","text":"<ul> <li>Description: Shows trajectory of response measurements over time for individual patients.</li> <li>Best for: Visualizing dynamics of treatment response.</li> <li>Variants:</li> <li>Color-coded spider: Distinguishes patient subgroups.</li> <li>Landmark spider: Highlights specific timepoints of interest.</li> <li>Annotated spider: Includes treatment changes or events.</li> <li>Normalized spider: Shows percent change from baseline.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#nomograms","title":"Nomograms","text":"<ul> <li>Description: Graphical calculation tool for predicting outcomes based on multiple variables.</li> <li>Best for: Creating clinically useful prediction models.</li> <li>Variants:</li> <li>Cox nomogram: Based on proportional hazards model.</li> <li>Logistic nomogram: Predicts binary outcomes.</li> <li>Competing risk nomogram: Accounts for multiple possible outcomes.</li> <li>Dynamic nomogram: Interactive tool with adjustable parameters.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#vii-multi-omics-integration","title":"VII. Multi-omics Integration","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#1-multi-omics-data-integration","title":"1. Multi-omics Data Integration","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#multi-omics-heatmaps","title":"Multi-omics Heatmaps","text":"<ul> <li>Description: Juxtaposed or integrated heatmaps showing patterns across data types.</li> <li>Best for: Comparing patterns across different molecular layers.</li> <li>Variants:</li> <li>Stacked multi-omics heatmap: Aligns multiple data types for same samples.</li> <li>Integrated clustering heatmap: Uses joint clustering across data types.</li> <li>Correlation heatmap: Shows relationships between features across omics.</li> <li>Block heatmap: Organizes by data type and sample clusters.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#circos-multi-omics-plots","title":"Circos Multi-omics Plots","text":"<ul> <li>Description: Circular visualization integrating multiple data types.</li> <li>Best for: Showing relationships between genomic features and other omics data.</li> <li>Variants:</li> <li>Multi-track circos: Shows different omics in concentric rings.</li> <li>Link-enhanced circos: Shows connections between features across omics.</li> <li>Histogram circos: Uses bar heights to show quantitative multi-omics data.</li> <li>Heatmap circos: Incorporates heatmaps in circular layout.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#dimension-reduction-biplots","title":"Dimension Reduction Biplots","text":"<ul> <li>Description: Projects both samples and features onto reduced dimensional space.</li> <li>Best for: Identifying relationships between molecular features and sample groups.</li> <li>Variants:</li> <li>Multi-omics MOFA plot: Uses multi-omics factor analysis.</li> <li>Joint PCA biplot: Integrates multiple data types in PCA.</li> <li>Canonical correlation biplot: Shows maximally correlated projections.</li> <li>Multi-block PLS biplot: Uses partial least squares for integration.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#sankey-multi-omics-diagrams","title":"Sankey Multi-omics Diagrams","text":"<ul> <li>Description: Flow diagram showing relationships between features across omics layers.</li> <li>Best for: Visualizing multi-omics pathway analysis results.</li> <li>Variants:</li> <li>Vertical multi-omics Sankey: Flows from genome to transcriptome to proteome.</li> <li>Horizontal multi-omics Sankey: Shows relationships within each omics layer.</li> <li>Pathway-centric Sankey: Organizes by biological pathways.</li> <li>Sample-flow Sankey: Shows how samples cluster across different omics.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#2-integrative-analysis-visualization","title":"2. Integrative Analysis Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#multi-omics-clustering-heatmaps","title":"Multi-omics Clustering Heatmaps","text":"<ul> <li>Description: Shows sample clustering based on integrated analysis of multiple data types.</li> <li>Best for: Identifying molecular subtypes from multi-omics data.</li> <li>Variants:</li> <li>SNF clustering heatmap: Based on similarity network fusion.</li> <li>iCluster heatmap: Uses integrative clustering approach.</li> <li>MOFA clustering: Based on multi-omics factor analysis.</li> <li>Consensus clustering heatmap: Shows agreement across clustering solutions.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#feature-importance-plots","title":"Feature Importance Plots","text":"<ul> <li>Description: Shows contribution of features from different omics to classification or prediction.</li> <li>Best for: Understanding which molecular features drive sample classification.</li> <li>Variants:</li> <li>SHAP multi-omics plot: Uses Shapley values for feature importance.</li> <li>Random forest importance plot: Shows feature importance from RF models.</li> <li>Elastic net coefficient plot: Shows non-zero coefficients from regularized models.</li> <li>Omics-stratified importance: Groups features by data type.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#driver-alteration-visualizations","title":"Driver Alteration Visualizations","text":"<ul> <li>Description: Shows key molecular alterations driving phenotypes across omics layers.</li> <li>Best for: Identifying causal mechanisms in disease.</li> <li>Variants:</li> <li>Multi-omics oncoprint: Integrates mutations, CNV, and expression.</li> <li>Causal network graph: Shows inferred causal relationships.</li> <li>eQTL effect plot: Shows genetic variants affecting expression.</li> <li>Mediator analysis plot: Shows molecular mediators of genetic effects.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#multi-modal-enrichment-visualizations","title":"Multi-modal Enrichment Visualizations","text":"<ul> <li>Description: Shows pathway or functional enrichment across multiple data types.</li> <li>Best for: Understanding biological processes affected across molecular layers.</li> <li>Variants:</li> <li>Multi-omics enrichment map: Network of enriched pathways across omics.</li> <li>Stacked enrichment bar plot: Compares enrichment across data types.</li> <li>Enrichment overlap diagram: Shows common and unique enriched terms.</li> <li>Hierarchical enrichment treemap: Organizes enrichment by ontology structure.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#viii-specialized-visualization-techniques-continued","title":"VIII. Specialized Visualization Techniques (continued)","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#1-machine-learning-model-visualization-continued","title":"1. Machine Learning Model Visualization (continued)","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#model-performance-visualizations-continued","title":"Model Performance Visualizations (continued)","text":"<ul> <li>Description: Shows predictive performance of machine learning models.</li> <li>Best for: Evaluating and comparing prediction models.</li> <li>Variants:</li> <li>ROC curves: Plots sensitivity vs. 1-specificity across thresholds.</li> <li>Precision-recall curves: Alternative to ROC for imbalanced datasets.</li> <li>Calibration plots: Shows agreement between predicted and actual probabilities.</li> <li>Learning curves: Shows performance as a function of training set size.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#feature-importance-visualizations","title":"Feature Importance Visualizations","text":"<ul> <li>Description: Shows contribution of features to model predictions.</li> <li>Best for: Interpreting complex models and identifying key predictors.</li> <li>Variants:</li> <li>SHAP summary plot: Shows feature impact on model output.</li> <li>Permutation importance plot: Shows performance drop when features are shuffled.</li> <li>Partial dependence plots: Shows relationship between features and predictions.</li> <li>Feature interaction heatmaps: Shows pairwise feature interactions.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#classifier-decision-boundary-plots","title":"Classifier Decision Boundary Plots","text":"<ul> <li>Description: Shows how a classifier separates classes in feature space.</li> <li>Best for: Understanding classification model behavior.</li> <li>Variants:</li> <li>2D decision boundary: Shows boundary in two-feature space.</li> <li>Decision surface heatmap: Uses color to show probability across feature space.</li> <li>Margin plot: Highlights samples near decision boundary.</li> <li>Multi-class decision boundary: Shows boundaries between multiple classes.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#confusion-matrix-visualizations","title":"Confusion Matrix Visualizations","text":"<ul> <li>Description: Shows agreement between predicted and actual classes.</li> <li>Best for: Detailed analysis of classification performance.</li> <li>Variants:</li> <li>Normalized confusion matrix: Shows proportions instead of counts.</li> <li>Hierarchical confusion matrix: Groups related classes.</li> <li>Difference confusion matrix: Compares performance between models.</li> <li>Interactive confusion matrix: Allows exploration of misclassified examples.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#2-network-medicine-visualization","title":"2. Network Medicine Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#disease-gene-networks","title":"Disease-Gene Networks","text":"<ul> <li>Description: Shows relationships between diseases and associated genes.</li> <li>Best for: Understanding genetic relationships between diseases.</li> <li>Variants:</li> <li>Bipartite disease-gene network: Shows connections between diseases and genes.</li> <li>Disease similarity network: Links diseases by shared genetic basis.</li> <li>Gene-centric disease network: Focuses on genes associated with multiple diseases.</li> <li>Hierarchical disease network: Organizes by disease taxonomy.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#drug-target-networks","title":"Drug-Target Networks","text":"<ul> <li>Description: Shows relationships between drugs and their molecular targets.</li> <li>Best for: Drug repurposing and understanding polypharmacology.</li> <li>Variants:</li> <li>Bipartite drug-target network: Shows direct drug-protein interactions.</li> <li>Drug similarity network: Links drugs by shared targets or mechanisms.</li> <li>Target-centric drug network: Focuses on proteins targeted by multiple drugs.</li> <li>Drug-pathway network: Integrates pathway information with drug targets.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#symptom-disease-networks","title":"Symptom-Disease Networks","text":"<ul> <li>Description: Shows relationships between clinical symptoms and diseases.</li> <li>Best for: Differential diagnosis and phenotypic analysis.</li> <li>Variants:</li> <li>Bipartite symptom-disease network: Shows symptom-disease associations.</li> <li>Symptom co-occurrence network: Links symptoms that frequently co-occur.</li> <li>Disease comorbidity network: Shows diseases that frequently co-occur.</li> <li>Temporal symptom network: Shows progression of symptoms over time.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#multi-scale-biological-networks","title":"Multi-scale Biological Networks","text":"<ul> <li>Description: Integrates molecular, cellular, and phenotypic data in network representation.</li> <li>Best for: Understanding disease mechanisms across biological scales.</li> <li>Variants:</li> <li>Hierarchical multi-scale network: Organizes by biological scale.</li> <li>Causal multi-scale network: Shows causal relationships across scales.</li> <li>Functional multi-scale network: Organizes by biological function.</li> <li>Dynamic multi-scale network: Shows changes across time or disease progression.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#3-metabolomics-visualization","title":"3. Metabolomics Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#metabolite-pathway-maps","title":"Metabolite Pathway Maps","text":"<ul> <li>Description: Shows metabolites in context of biochemical pathways.</li> <li>Best for: Understanding metabolic alterations in disease.</li> <li>Variants:</li> <li>Expression-overlaid pathway: Maps concentration changes onto pathways.</li> <li>Flux pathway map: Shows metabolic flux through pathways.</li> <li>Time-series pathway map: Shows dynamic changes in metabolism.</li> <li>Comparative pathway map: Shows differences between conditions.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#metabolite-correlation-networks","title":"Metabolite Correlation Networks","text":"<ul> <li>Description: Network showing correlations between metabolite levels.</li> <li>Best for: Identifying co-regulated metabolites and metabolic modules.</li> <li>Variants:</li> <li>WGCNA metabolite network: Uses weighted correlation network analysis.</li> <li>Gaussian graphical model network: Shows direct metabolite associations.</li> <li>Biochemical-distance network: Incorporates knowledge of reaction steps.</li> <li>Multi-condition correlation network: Shows changes in correlations across conditions.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#mass-spectrometry-visualizations","title":"Mass Spectrometry Visualizations","text":"<ul> <li>Description: Shows mass spectrometry data for metabolite identification.</li> <li>Best for: Analyzing complex metabolomic datasets.</li> <li>Variants:</li> <li>Mirror plots: Compares experimental and reference spectra.</li> <li>Chromatogram plots: Shows separation of metabolites by retention time.</li> <li>Ion map: 2D visualization of m/z versus retention time.</li> <li>Fragmentation tree: Shows hierarchical fragmentation patterns.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#metabolite-set-enrichment-visualizations","title":"Metabolite Set Enrichment Visualizations","text":"<ul> <li>Description: Shows enrichment of metabolite sets in biological pathways.</li> <li>Best for: Functional interpretation of metabolomics data.</li> <li>Variants:</li> <li>Metabolite set enrichment bar plot: Shows enriched pathways.</li> <li>Metabolite enrichment network: Shows relationships between enriched pathways.</li> <li>Metabolite over-representation map: Shows metabolite distribution across pathways.</li> <li>Joint pathway analysis: Integrates metabolomics with other omics data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#ix-emerging-visualization-techniques","title":"IX. Emerging Visualization Techniques","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#1-interactive-and-dynamic-visualizations","title":"1. Interactive and Dynamic Visualizations","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#interactive-web-applications","title":"Interactive Web Applications","text":"<ul> <li>Description: Browser-based tools allowing user-driven exploration of data.</li> <li>Best for: Sharing complex datasets with collaborators or the public.</li> <li>Variants:</li> <li>Shiny apps: R-based interactive visualizations.</li> <li>Plotly dashboards: JavaScript-based interactive plots.</li> <li>D3.js visualizations: Custom interactive data visualizations.</li> <li>Tableau dashboards: Business intelligence-style interactive reports.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#dynamic-animations","title":"Dynamic Animations","text":"<ul> <li>Description: Shows changes in data over time through animation.</li> <li>Best for: Visualizing temporal processes or comparing multiple conditions.</li> <li>Variants:</li> <li>Time-lapse plots: Shows data changing over time.</li> <li>Transition animations: Smoothly morphs between different data views.</li> <li>Animated trajectories: Shows movement through data space.</li> <li>Storytelling animations: Guides viewer through sequential data insights.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#virtual-reality-data-exploration","title":"Virtual Reality Data Exploration","text":"<ul> <li>Description: Immersive 3D visualization of complex biological data.</li> <li>Best for: Exploring highly dimensional or spatial datasets.</li> <li>Variants:</li> <li>VR protein structures: Allows manipulation of 3D molecular structures.</li> <li>VR genome browsers: Navigates 3D genome organization.</li> <li>VR pathway maps: Walks through 3D representations of biological pathways.</li> <li>VR single-cell landscapes: Explores high-dimensional single-cell data in 3D space.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#real-time-data-monitoring","title":"Real-time Data Monitoring","text":"<ul> <li>Description: Continuously updated visualizations as new data arrives.</li> <li>Best for: Clinical monitoring or ongoing experimental data collection.</li> <li>Variants:</li> <li>Clinical dashboard: Shows patient vital signs and lab values.</li> <li>Experiment monitoring: Tracks experimental measurements in real-time.</li> <li>Sequencing run visualizations: Shows quality metrics during sequencing.</li> <li>Alert-based visualizations: Highlights deviations from expected patterns.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#2-ai-assisted-visualization","title":"2. AI-assisted Visualization","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#dimension-reduction-for-complex-data","title":"Dimension Reduction for Complex Data","text":"<ul> <li>Description: Uses advanced AI techniques to visualize high-dimensional data.</li> <li>Best for: Exploring complex relationships in large datasets.</li> <li>Variants:</li> <li>UMAP plots: Non-linear dimension reduction preserving global and local structure.</li> <li>VAE latent space visualization: Shows learned representations from variational autoencoders.</li> <li>Self-organizing maps: Uses unsupervised neural networks for visualization.</li> <li>Graph neural network embeddings: Visualizes learned node representations.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#attention-mechanism-visualizations","title":"Attention Mechanism Visualizations","text":"<ul> <li>Description: Shows what parts of input data AI models focus on for predictions.</li> <li>Best for: Interpreting deep learning model decisions.</li> <li>Variants:</li> <li>Attention heatmaps: Shows attention weights across input features.</li> <li>Saliency maps: Highlights input regions important for classification.</li> <li>Class activation maps: Shows regions contributing to specific class predictions.</li> <li>Attention flow diagrams: Shows how attention propagates through model layers.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#generative-model-visualizations","title":"Generative Model Visualizations","text":"<ul> <li>Description: Shows data generated or completed by AI models.</li> <li>Best for: Understanding data distributions and model capabilities.</li> <li>Variants:</li> <li>GAN output galleries: Shows examples generated by generative adversarial networks.</li> <li>Latent space interpolation: Shows smooth transitions between data points.</li> <li>Conditional generation plots: Shows generated data under different conditions.</li> <li>Data imputation visualizations: Shows AI-completed missing data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#uncertainty-visualization","title":"Uncertainty Visualization","text":"<ul> <li>Description: Shows confidence or uncertainty in AI predictions.</li> <li>Best for: Assessing reliability of model outputs.</li> <li>Variants:</li> <li>Confidence interval plots: Shows prediction ranges with uncertainty.</li> <li>Ensemble prediction plots: Shows variation across multiple models.</li> <li>Bayesian posterior plots: Shows distribution of possible parameter values.</li> <li>Uncertainty heatmaps: Maps prediction uncertainty across feature space.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#3-integrated-multi-view-visualizations","title":"3. Integrated Multi-view Visualizations","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#coordinated-multiple-views","title":"Coordinated Multiple Views","text":"<ul> <li>Description: Multiple linked visualizations showing different aspects of the same data.</li> <li>Best for: Exploring complex datasets from multiple perspectives.</li> <li>Variants:</li> <li>Brushing and linking: Selection in one view highlights corresponding data in others.</li> <li>Overview+detail views: Combines broad overview with detailed inspection.</li> <li>Cross-filtered dashboards: Allows filtering data across multiple visualizations.</li> <li>Multi-scale views: Shows data at different levels of granularity.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#integrated-genomic-views","title":"Integrated Genomic Views","text":"<ul> <li>Description: Combines multiple genomic data types in coordinated visualization.</li> <li>Best for: Comprehensive analysis of genomic regions.</li> <li>Variants:</li> <li>Multi-omics genome browser: Shows multiple data tracks aligned to genome.</li> <li>Circular-linear genome view: Combines circular overview with linear detail.</li> <li>3D-1D genome integration: Links 3D structure with linear genomic features.</li> <li>Comparative genomics viewer: Aligns multiple species or samples.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#clinical-molecular-integrated-views","title":"Clinical-Molecular Integrated Views","text":"<ul> <li>Description: Combines clinical data with molecular profiling in unified visualization.</li> <li>Best for: Translational research connecting molecular mechanisms to clinical outcomes.</li> <li>Variants:</li> <li>Patient-molecular profile dashboard: Links patient data with molecular features.</li> <li>Survival-molecular correlation view: Connects molecular features to outcomes.</li> <li>Treatment response-biomarker view: Links therapy response to molecular markers.</li> <li>Phenotype-genotype network: Shows relationships between clinical and molecular features.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#spatial-molecular-integrated-views","title":"Spatial-Molecular Integrated Views","text":"<ul> <li>Description: Combines spatial tissue information with molecular profiles.</li> <li>Best for: Understanding tissue architecture and molecular heterogeneity.</li> <li>Variants:</li> <li>H&amp;E-molecular overlay: Maps molecular data onto histology images.</li> <li>Spatial transcriptomics viewer: Shows gene expression in spatial context.</li> <li>Multi-channel IF viewer: Shows multiple protein markers in tissue context.</li> <li>3D tissue reconstruction: Reconstructs molecular profiles in three dimensions.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#x-visualization-best-practices","title":"X. Visualization Best Practices","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#1-design-principles","title":"1. Design Principles","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#color-selection-strategies","title":"Color Selection Strategies","text":"<ul> <li>Description: Choosing appropriate color schemes for different data types.</li> <li>Best practices:</li> <li>Use perceptually uniform colormaps (viridis, magma, plasma) for continuous data</li> <li>Use colorblind-friendly palettes for categorical data</li> <li>Reserve red/blue for opposing conditions (up/down, high/low)</li> <li>Use sequential color scales for quantities without natural midpoint</li> <li>Use diverging color scales for data with meaningful midpoint</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#annotation-and-labeling","title":"Annotation and Labeling","text":"<ul> <li>Description: Adding context and explanation to visualizations.</li> <li>Best practices:</li> <li>Label axes clearly with units</li> <li>Use informative titles that explain the main finding</li> <li>Add annotations highlighting key features</li> <li>Include legends explaining all visual encodings</li> <li>Consider direct labeling instead of legends when possible</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#layout-optimization","title":"Layout Optimization","text":"<ul> <li>Description: Arranging multiple plots or elements effectively.</li> <li>Best practices:</li> <li>Create logical reading flow (typically left-to-right, top-to-bottom)</li> <li>Group related visualizations</li> <li>Maintain consistent scales across related plots</li> <li>Use white space effectively to separate logical sections</li> <li>Consider data-to-ink ratio to minimize clutter</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#accessibility-considerations","title":"Accessibility Considerations","text":"<ul> <li>Description: Making visualizations accessible to all viewers.</li> <li>Best practices:</li> <li>Use colorblind-friendly palettes</li> <li>Ensure sufficient contrast between elements</li> <li>Avoid relying solely on color to convey information</li> <li>Make text large enough to be legible</li> <li>Provide alternative text descriptions for complex figures</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#2-technical-implementation","title":"2. Technical Implementation","text":""},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#reproducible-visualization-workflows","title":"Reproducible Visualization Workflows","text":"<ul> <li>Description: Creating visualizations that can be regenerated from raw data.</li> <li>Best practices:</li> <li>Use code-based visualization tools (R, Python) rather than manual tools</li> <li>Document all preprocessing steps</li> <li>Version control visualization code</li> <li>Use consistent random seeds for reproducible results</li> <li>Share both code and data when possible</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#file-format-selection","title":"File Format Selection","text":"<ul> <li>Description: Choosing appropriate formats for different use cases.</li> <li>Best practices:</li> <li>Use vector formats (SVG, PDF) for publication figures</li> <li>Use PNG for web display with transparency</li> <li>Consider EPS for journal submissions</li> <li>Use HTML+JavaScript for interactive visualizations</li> <li>Balance resolution and file size for presentations</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#software-tool-selection","title":"Software Tool Selection","text":"<ul> <li>Description: Choosing appropriate visualization tools for different needs.</li> <li>Best options:</li> <li>R (ggplot2, plotly, Bioconductor) for statistical and bioinformatics visualization</li> <li>Python (matplotlib, seaborn, plotly) for data science and machine learning</li> <li>D3.js for custom interactive web visualizations</li> <li>Cytoscape for network visualization</li> <li>IGV/UCSC Genome Browser for genomic data</li> </ul>"},{"location":"IBMS3/Yiru/detailed/4.5%20Visualization/#automation-and-templating","title":"Automation and Templating","text":"<ul> <li>Description: Creating reusable visualization templates for consistent reporting.</li> <li>Best practices:</li> <li>Create function libraries for common plot types</li> <li>Use parameterized reports (R Markdown, Jupyter) for reproducible documents</li> <li>Develop consistent style guides for organizational visualizations</li> <li>Create reusable templates for regular analyses</li> <li>Implement automated quality checks for visualizations</li> </ul> <p>This comprehensive guide covers the vast landscape of visualization techniques in biomedical research, from basic expression analysis to cutting-edge AI-assisted visualization approaches. By selecting the most appropriate visualization technique for your specific data type and research question, you can effectively communicate complex findings and gain deeper insights from your biomedical data.</p>"},{"location":"IBMS3/Yiru/detailed/5.%20Ethics/","title":"5. Ethics","text":""},{"location":"IBMS3/Yiru/detailed/5.%20Ethics/#answer","title":"Answer:","text":"<p>Ethics: All animal experiments would be performed according to the guidelines set by the Institutional Animal Care and Use Committee (IACUC) to ensure ethical treatment of the animals. All animal handling and procedures would be done in accordance with institutional guidelines and regulations to minimize any distress or discomfort.</p>"},{"location":"IBMS3/Yiru/detailed/5.%20Ethics/#animal-experimentation-ethics","title":"Animal Experimentation ethics","text":"<ul> <li>3Rs Principle<ul> <li>Reduction: minimize animal use via power calculations</li> <li>Replacement: Explore alternatives like in vitro models or computational simulations</li> <li>Refinement: Optimize procedures to reduce suffering (like standardized handling protocols for mice, using carbon dioxide to sacrifice mouse)</li> </ul> </li> <li>Ethical review<ul> <li>Mandatory approval processes for animal studies</li> <li>Model Limitations: Acknowledge species-specific differences</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/5.%20Ethics/#ethical-decision-making-frameworks","title":"Ethical Decision-Making Frameworks","text":"<ul> <li>Ethical Theories<ul> <li>Utilitarianism: Balance scientific progress with societal benefit (e.g., gene therapy trials) .</li> <li>Deontology: Adhere to moral rules (e.g., informed consent in human studies) .</li> </ul> </li> <li>Case Analysis<ul> <li>Hydroxychloroquine Controversy: Flaws in non-randomized trials, ethical approval violations, and conflicting conclusions .</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/5.%20Ethics/#alternative-methods-innovation","title":"Alternative Methods &amp; Innovation","text":"<ul> <li>Advanced Models<ul> <li>Organoids, microfluidics, and AI-driven drug discovery to reduce animal reliance .</li> </ul> </li> <li>Open Science<ul> <li>Data sharing via platforms like EDAs (European Data Archive) to enhance reproducibility.</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/5.%20Ethics/#data-sharing-ethic","title":"Data sharing ethic","text":"<ul> <li>The data used in current experiment and analysis, could be released to public database for sharing and reproductivity, if the privacy of donor could be defended </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/","title":"6. Critical thinking","text":"<p>\u4ee5\u4e0b\u662f\u9488\u5bf9\u60a8\u5217\u51fa\u7684\u5206\u5b50\u751f\u7269\u5b66\u5b9e\u9a8c\u6280\u672f\u548c\u8ba1\u7b97\u65b9\u6cd5\u7684Critical Thinking\u5206\u6790\uff0c\u5305\u62ec\u6f5c\u5728\u504f\u5dee(Bias)\u548c\u6539\u8fdb\u65b9\u5411(Improvements)\uff1a</p>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#dna","title":"DNA\u8bc4\u4f30\u65b9\u6cd5","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-pcrqpcr","title":"1. PCR/qPCR","text":"<ul> <li>Bias: </li> <li>\u5f15\u7269\u4e8c\u805a\u4f53\u548c\u975e\u7279\u5f02\u6027\u6269\u589e\u5bfc\u81f4\u5047\u9633\u6027</li> <li>\u6269\u589e\u6548\u7387\u5dee\u5f02\u5f71\u54cd\u5b9a\u91cf\u51c6\u786e\u6027\uff08qPCR\uff09</li> <li>\u5bf9\u6291\u5236\u5242\u654f\u611f\uff08\u5982\u8840\u6db2\u4e2d\u7684\u809d\u7d20\uff09</li> <li>Improvements: </li> <li>\u4f7f\u7528\u6570\u5b57PCR(dPCR)\u63d0\u9ad8\u7edd\u5bf9\u5b9a\u91cf\u7cbe\u5ea6</li> <li>\u52a0\u5165\u5185\u53c2\u57fa\u56e0(\u5982GAPDH)\u6821\u6b63</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-southernnorthern-blotting","title":"2. Southern/Northern Blotting","text":"<ul> <li>Bias: </li> <li>\u4f4e\u901a\u91cf\uff0c\u4e00\u6b21\u53ea\u80fd\u68c0\u6d4b\u5c11\u91cf\u76ee\u6807</li> <li>\u9700\u8981\u5927\u91cf\u8d77\u59cb\u6750\u6599\uff08\u5c24\u5176Northern\u5bf9RNA\u964d\u89e3\u654f\u611f\uff09</li> <li>\u6742\u4ea4\u63a2\u9488\u53ef\u80fd\u4e0e\u975e\u76ee\u6807\u5e8f\u5217\u4ea4\u53c9\u53cd\u5e94</li> <li>Improvements: </li> <li>\u7ed3\u5408\u6bdb\u7ec6\u7ba1\u7535\u6cf3\u63d0\u9ad8\u5206\u8fa8\u7387</li> <li>\u7528\u8367\u5149\u6807\u8bb0\u66ff\u4ee3\u653e\u5c04\u6027\u6807\u8bb0</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#rna","title":"RNA\u8bc4\u4f30\u65b9\u6cd5","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-rt-pcr","title":"1. RT-PCR","text":"<ul> <li>Bias: </li> <li>\u53cd\u8f6c\u5f55\u6548\u7387\u53d7RNA\u4e8c\u7ea7\u7ed3\u6784\u5f71\u54cd</li> <li>\u5f15\u7269\u8bbe\u8ba1\u504f\u5411\u5df2\u77e5\u5e8f\u5217\uff0c\u96be\u68c0\u6d4b\u65b0\u5f02\u6784\u4f53</li> <li>Improvements: </li> <li>\u4f7f\u7528\u968f\u673a\u516d\u805a\u4f53+oligo(dT)\u6df7\u5408\u5f15\u7269</li> <li>\u52a0\u5165\u5916\u6e90RNA spike-in\u63a7\u5236</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-rna-seq","title":"2. RNA-seq","text":"<ul> <li>Bias: </li> <li>3'\u7aef\u504f\u597d\u6027\uff08\u5c24\u5176\u5355\u7ec6\u80deRNA-seq\uff09</li> <li>GC\u542b\u91cf\u504f\u5dee\u5f71\u54cd\u6d4b\u5e8f\u6df1\u5ea6</li> <li>rRNA\u53bb\u9664\u4e0d\u5f7b\u5e95</li> <li>Improvements: </li> <li>\u4f7f\u7528UMI\u6d88\u9664PCR\u91cd\u590d</li> <li>\u957f\u8bfb\u957f\u6d4b\u5e8f(PacBio)\u89e3\u51b3\u526a\u63a5\u5f02\u6784\u4f53\u95ee\u9898</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#-dnarna","title":"\u86cb\u767d\u8d28-DNA/RNA\u76f8\u4e92\u4f5c\u7528","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-chip-seqcutrun","title":"1. ChIP-seq/CUT&amp;RUN","text":"<ul> <li>Bias: </li> <li>\u6297\u4f53\u7279\u5f02\u6027\u95ee\u9898\uff08\u5047\u9633\u6027\u7ed3\u5408\uff09</li> <li>\u4ea4\u8054\u6548\u7387\u5f71\u54cd\u4fe1\u53f7\u5f3a\u5ea6</li> <li>\u5bf9\u5f31\u7ed3\u5408\u4f4d\u70b9\u7075\u654f\u5ea6\u4f4e</li> <li>Improvements: </li> <li>\u4f7f\u7528\u591a\u514b\u9686\u6297\u4f53\u6df7\u5408\u63d0\u9ad8\u8986\u76d6\u5ea6</li> <li>CUT&amp;Tag\u66ff\u4ee3\u51cf\u5c11\u7ec6\u80de\u7528\u91cf</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-emsa","title":"2. EMSA","text":"<ul> <li>Bias: </li> <li>\u4ec5\u4f53\u5916\u9a8c\u8bc1\uff0c\u65e0\u6cd5\u53cd\u6620\u7ec6\u80de\u5185\u73af\u5883</li> <li>\u65e0\u6cd5\u533a\u5206\u76f4\u63a5/\u95f4\u63a5\u7ed3\u5408</li> <li>Improvements: </li> <li>\u7ed3\u5408\u8d85\u8fc1\u79fb(supershift)\u9a8c\u8bc1\u7279\u5b9a\u86cb\u767d</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#_1","title":"\u86cb\u767d\u8d28\u5206\u6790\u65b9\u6cd5","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-western-blot","title":"1. Western Blot","text":"<ul> <li>Bias: </li> <li>\u6297\u4f53\u4ea4\u53c9\u53cd\u5e94\u6027</li> <li>\u7ebf\u6027\u52a8\u6001\u8303\u56f4\u7a84\uff08\u7ea610^2\uff09</li> <li>Improvements: </li> <li>\u7528\u8d28\u8c31\u9a8c\u8bc1\u6297\u4f53\u7279\u5f02\u6027</li> <li>\u8fd1\u7ea2\u5916\u8367\u5149\u68c0\u6d4b\u63d0\u9ad8\u7075\u654f\u5ea6</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-co-ipms","title":"2. Co-IP/MS","text":"<ul> <li>Bias: </li> <li>\u65e0\u6cd5\u533a\u5206\u76f4\u63a5/\u95f4\u63a5\u4e92\u4f5c</li> <li>\u9ad8\u4e30\u5ea6\u86cb\u767d\u63a9\u76d6\u4f4e\u4e30\u5ea6\u4fe1\u53f7</li> <li>Improvements: </li> <li>\u4ea4\u8054\u8d28\u8c31(XL-MS)\u6355\u83b7\u77ac\u6001\u4e92\u4f5c</li> <li>\u4eb2\u548c\u7eaf\u5316\u540e\u5b9a\u91cf(SILAC)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#_2","title":"\u8868\u89c2\u9057\u4f20\u5b66\u6280\u672f","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-bisulfite-sequencing","title":"1. Bisulfite Sequencing","text":"<ul> <li>Bias: </li> <li>DNA\u964d\u89e3\uff08\u4e9a\u786b\u9178\u6c22\u76d0\u5904\u7406\uff09</li> <li>\u65e0\u6cd5\u533a\u52065mC/5hmC</li> <li>Improvements: </li> <li>OxBS-seq\u7279\u5f02\u6027\u68c0\u6d4b5hmC</li> <li>\u5355\u7ec6\u80de\u7532\u57fa\u5316\u6d4b\u5e8f</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-atac-seq","title":"2. ATAC-seq","text":"<ul> <li>Bias: </li> <li>\u5bf9\u6838\u5c0f\u4f53\u5b9a\u4f4d\u5206\u8fa8\u7387\u6709\u9650(~200bp)</li> <li>\u8f6c\u5ea7\u9176\u504f\u597d\u6027(GC-rich\u533a\u57df)</li> <li>Improvements: </li> <li>\u7ed3\u5408MNase-seq\u63d0\u9ad8\u6838\u5c0f\u4f53\u5b9a\u4f4d\u7cbe\u5ea6</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#_3","title":"\u57fa\u56e0\u7f16\u8f91\u4e0e\u7b5b\u9009","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-crispr-cas9","title":"1. CRISPR-Cas9","text":"<ul> <li>Bias: </li> <li>\u8131\u9776\u6548\u5e94\uff08\u5c24\u5176\u4f4e\u6548sgRNA\uff09</li> <li>\u975e\u540c\u6e90\u672b\u7aef\u8fde\u63a5(NHEJ)\u5f15\u5165\u4e0d\u53ef\u63a7indel</li> <li>Improvements: </li> <li>\u4f7f\u7528\u9ad8\u4fdd\u771fCas9\u53d8\u4f53(eSpCas9)</li> <li>\u5355\u78b1\u57fa\u7f16\u8f91\u907f\u514dDSB</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-crispr-screen","title":"2. CRISPR Screen","text":"<ul> <li>Bias: </li> <li>\u6587\u5e93\u8986\u76d6\u4e0d\u5747\u5bfc\u81f4\u5047\u9634\u6027</li> <li>\u591a\u57fa\u56e0\u534f\u540c\u6548\u5e94\u88ab\u5ffd\u7565</li> <li>Improvements: </li> <li>\u7ec4\u5408\u7b5b\u9009(Combi-Seq)</li> <li>\u52a8\u6001\u8ffd\u8e2a\u5355\u7ec6\u80de\u8c31\u7cfb</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#_4","title":"\u8ba1\u7b97\u751f\u7269\u5b66\u65b9\u6cd5","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-gwaseqtl","title":"1. GWAS/eQTL","text":"<ul> <li>Bias: </li> <li>\u4eba\u7fa4\u5206\u5c42\u5bfc\u81f4\u5047\u9633\u6027</li> <li>\u65e0\u6cd5\u786e\u5b9a\u56e0\u679c\u53d8\u5f02</li> <li>Improvements: </li> <li>\u5b5f\u5fb7\u5c14\u968f\u673a\u5316\u9a8c\u8bc1\u56e0\u679c\u5173\u7cfb</li> <li>\u8de8\u79cd\u65cfmeta\u5206\u6790</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2","title":"2. \u6df1\u5ea6\u5b66\u4e60\u6a21\u578b","text":"<ul> <li>Bias: </li> <li>\u5bf9\u751f\u7269\u53ef\u89e3\u91ca\u6027\u5dee\uff08\u9ed1\u7bb1\u95ee\u9898\uff09</li> <li>\u4f9d\u8d56\u8bad\u7ec3\u6570\u636e\u8d28\u91cf</li> <li>Improvements: </li> <li>\u6ce8\u610f\u529b\u673a\u5236\u53ef\u89c6\u5316\u5173\u952e\u7279\u5f81</li> <li>\u8fc1\u79fb\u5b66\u4e60\u89e3\u51b3\u5c0f\u6837\u672c\u95ee\u9898</li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#_5","title":"\u901a\u7528\u6539\u8fdb\u7b56\u7565","text":"<ol> <li>\u5b9e\u9a8c\u8bbe\u8ba1\uff1a</li> <li>\u589e\u52a0\u751f\u7269\u5b66\u91cd\u590d(n\u22653)</li> <li>\u4f7f\u7528\u6b63\u4ea4\u65b9\u6cd5\u9a8c\u8bc1\uff08\u5982WB\u9a8c\u8bc1RNA-seq\uff09</li> <li>\u6570\u636e\u5206\u6790\uff1a</li> <li>\u4e25\u683c\u591a\u91cd\u68c0\u9a8c\u6821\u6b63\uff08FDR&lt;0.05\uff09</li> <li>\u516c\u5f00\u4ee3\u7801\u548c\u539f\u59cb\u6570\u636e(FAIR\u539f\u5219)</li> <li>\u6280\u672f\u6574\u5408\uff1a</li> <li>\u591a\u7ec4\u5b66\u8054\u5408\u5206\u6790\uff08\u5982ATAC+RNA-seq\uff09</li> <li>\u6d3b\u7ec6\u80de\u6210\u50cf\u52a8\u6001\u9a8c\u8bc1</li> </ol>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#_6","title":"\u5173\u952e\u603b\u7ed3","text":"<ul> <li>\u7075\u654f\u5ea6 vs \u7279\u5f02\u6027\uff1a\u51e0\u4e4e\u6240\u6709\u6280\u672f\u90fd\u9762\u4e34\u6b64\u6743\u8861\uff08\u5982CRISPR\u7684\u8131\u9776\uff09</li> <li>\u8fd8\u539f\u8bba\u5c40\u9650\uff1a\u4f53\u5916\u5b9e\u9a8c\u65e0\u6cd5\u5b8c\u5168\u6a21\u62df\u4f53\u5185\u73af\u5883\uff08\u5efa\u8bae\u7c7b\u5668\u5b98\u6a21\u578b\uff09</li> <li>\u6280\u672f\u8fed\u4ee3\uff1a\u957f\u8bfb\u957f\u6d4b\u5e8f\u3001\u7a7a\u95f4\u7ec4\u5b66\u7b49\u65b0\u6280\u672f\u6b63\u5728\u89e3\u51b3\u4f20\u7edf\u504f\u5dee</li> </ul> <p>\u5982\u9700\u5bf9\u67d0\u4e00\u6280\u672f\u6df1\u5165\u8ba8\u8bba\uff0c\u53ef\u63d0\u4f9b\u5177\u4f53\u65b9\u5411\u3002</p> <p>Here is the organized critical analysis of each listed methodology in English, including potential biases and improvement strategies:</p>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#dna-assessment-methods","title":"DNA Assessment Methods","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-pcrqpcr_1","title":"1. PCR/qPCR","text":"<ul> <li>Bias:  </li> <li>Primer dimer formation and nonspecific amplification (false positives).  </li> <li>Variable amplification efficiency affecting quantification accuracy (qPCR).  </li> <li>Sensitivity to inhibitors (e.g., heparin in blood samples).  </li> <li>Improvements:  </li> <li>Use digital PCR (dPCR) for absolute quantification.  </li> <li>Include internal reference genes (e.g., GAPDH) for normalization.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-southern-blotting","title":"2. Southern Blotting","text":"<ul> <li>Bias:  </li> <li>Low throughput (limited to single-target detection).  </li> <li>High RNA degradation risk (Northern blotting).  </li> <li>Cross-hybridization with non-target sequences.  </li> <li>Improvements:  </li> <li>Combine with capillary electrophoresis for higher resolution.  </li> <li>Replace radioactive probes with fluorescence-based detection.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#rna-assessment-methods","title":"RNA Assessment Methods","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-rt-pcr_1","title":"1. RT-PCR","text":"<ul> <li>Bias:  </li> <li>Reverse transcription efficiency affected by RNA secondary structures.  </li> <li>Primer bias against novel isoforms/unknown sequences.  </li> <li>Improvements:  </li> <li>Use random hexamer + oligo(dT) hybrid primers.  </li> <li>Add exogenous RNA spike-ins for quality control.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-rna-seq_1","title":"2. RNA-seq","text":"<ul> <li>Bias:  </li> <li>3'-end bias (especially in single-cell RNA-seq).  </li> <li>GC content bias influencing sequencing depth.  </li> <li>Incomplete rRNA depletion.  </li> <li>Improvements:  </li> <li>Implement unique molecular identifiers (UMIs) to remove PCR duplicates.  </li> <li>Use long-read sequencing (PacBio) to resolve splice isoforms.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#protein-dnarna-interaction-methods","title":"Protein-DNA/RNA Interaction Methods","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-chip-seqcutrun_1","title":"1. ChIP-seq/CUT&amp;RUN","text":"<ul> <li>Bias:  </li> <li>Antibody specificity issues (false-positive binding).  </li> <li>Crosslinking efficiency impacting signal strength.  </li> <li>Low sensitivity for weak binding sites.  </li> <li>Improvements:  </li> <li>Combine multiple antibodies to improve coverage.  </li> <li>Adopt CUT&amp;Tag for lower input requirements.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-emsa_1","title":"2. EMSA","text":"<ul> <li>Bias:  </li> <li>Limited to in vitro conditions (no cellular context).  </li> <li>Unable to distinguish direct vs. indirect binding.  </li> <li>Improvements:  </li> <li>Combine with supershift assays to confirm protein identity.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#protein-analysis-methods","title":"Protein Analysis Methods","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-western-blot_1","title":"1. Western Blot","text":"<ul> <li>Bias:  </li> <li>Antibody cross-reactivity.  </li> <li>Narrow linear dynamic range (~10\u00b2-fold).  </li> <li>Improvements:  </li> <li>Validate antibodies with mass spectrometry.  </li> <li>Use near-infrared fluorescence for enhanced sensitivity.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-co-ipms_1","title":"2. Co-IP/MS","text":"<ul> <li>Bias:  </li> <li>Inability to differentiate direct vs. indirect interactions.  </li> <li>Signal masking by high-abundance proteins.  </li> <li>Improvements:  </li> <li>Apply crosslinking mass spectrometry (XL-MS) to capture transient interactions.  </li> <li>Use SILAC labeling for quantitative analysis.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#epigenetic-sequencing","title":"Epigenetic Sequencing","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-bisulfite-sequencing_1","title":"1. Bisulfite Sequencing","text":"<ul> <li>Bias:  </li> <li>DNA degradation during bisulfite treatment.  </li> <li>Indistinguishable 5mC/5hmC signals.  </li> <li>Improvements:  </li> <li>Use oxidative bisulfite sequencing (OxBS-seq) for 5hmC detection.  </li> <li>Implement single-cell methylation sequencing.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-atac-seq_1","title":"2. ATAC-seq","text":"<ul> <li>Bias:  </li> <li>Limited nucleosome positioning resolution (~200 bp).  </li> <li>Transposase preference for GC-rich regions.  </li> <li>Improvements:  </li> <li>Integrate MNase-seq for precise nucleosome mapping.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#gene-editing-screening","title":"Gene Editing &amp; Screening","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-crispr-cas9_1","title":"1. CRISPR-Cas9","text":"<ul> <li>Bias:  </li> <li>Off-target effects (especially with low-efficiency sgRNAs).  </li> <li>Uncontrolled indels via NHEJ repair.  </li> <li>Improvements:  </li> <li>Use high-fidelity Cas9 variants (e.g., eSpCas9).  </li> <li>Apply base editing to avoid double-strand breaks.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-crispr-screen_1","title":"2. CRISPR Screen","text":"<ul> <li>Bias:  </li> <li>Library coverage bias leading to false negatives.  </li> <li>Oversimplification of gene synergy effects.  </li> <li>Improvements:  </li> <li>Perform combinatorial CRISPR screening (Combi-Seq).  </li> <li>Track single-cell lineages dynamically.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#computational-methods","title":"Computational Methods","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#1-gwaseqtl_1","title":"1. GWAS/eQTL","text":"<ul> <li>Bias:  </li> <li>Population stratification causing false positives.  </li> <li>Difficulty in identifying causal variants.  </li> <li>Improvements:  </li> <li>Apply Mendelian randomization for causal inference.  </li> <li>Conduct cross-ancestry meta-analyses.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#2-deep-learning-models","title":"2. Deep Learning Models","text":"<ul> <li>Bias:  </li> <li>Poor biological interpretability (\"black box\" issue).  </li> <li>Dependency on training data quality.  </li> <li>Improvements:  </li> <li>Visualize key features via attention mechanisms.  </li> <li>Use transfer learning for small datasets.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#universal-improvement-strategies","title":"Universal Improvement Strategies","text":"<ol> <li>Experimental Design:  </li> <li>Include biological replicates (n \u2265 3).  </li> <li>Validate with orthogonal methods (e.g., WB for RNA-seq results).  </li> <li>Data Analysis:  </li> <li>Apply strict multiple testing correction (FDR &lt; 0.05).  </li> <li>Follow FAIR principles (Findable, Accessible, Interoperable, Reusable).  </li> <li>Technology Integration:  </li> <li>Multi-omics integration (e.g., ATAC-seq + RNA-seq).  </li> <li>Live-cell imaging for dynamic validation.  </li> </ol>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#key-takeaways","title":"Key Takeaways","text":"<ul> <li>Sensitivity-Specificity Tradeoff: Inherent to most technologies (e.g., CRISPR off-targets).  </li> <li>Reductionism Limitations: In vitro models cannot fully replicate in vivo complexity (consider organoid models).  </li> <li>Emerging Solutions: Long-read sequencing, spatial omics, and single-cell technologies address traditional biases.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#critical-thinking-sections-for-molecular-biology-experiments","title":"Critical Thinking Sections for Molecular Biology Experiments","text":""},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#dna-assessment-techniques","title":"DNA Assessment Techniques:","text":"<ol> <li>PCR</li> <li>Limitations: Cannot quantify initial DNA amount, prone to contamination, limited size range of amplicons, potential primer-dimer formation.</li> <li>Controls Needed: Positive control (known template), negative control (no template), internal control for inhibition.</li> <li> <p>Alternative Approaches: Digital PCR for absolute quantification, long-range PCR for larger fragments.</p> </li> <li> <p>qPCR</p> </li> <li>Limitations: Requires careful primer design, affected by PCR inhibitors, amplification efficiency variations.</li> <li>Data Analysis Considerations: Proper threshold setting, appropriate reference genes, efficiency corrections for accurate quantification.</li> <li> <p>Validation Requirements: Standard curves, melt curve analysis, no-template controls.</p> </li> <li> <p>Southern Blotting</p> </li> <li>Limitations: Low throughput, labor-intensive, requires large DNA amounts, limited sensitivity.</li> <li>Critical Parameters: Probe specificity, transfer efficiency, blocking effectiveness.</li> <li>Modern Alternatives: qPCR, digital PCR, or NGS approaches that offer higher sensitivity and throughput.</li> </ol>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#rna-assessment-techniques","title":"RNA Assessment Techniques:","text":"<ol> <li>RT-PCR</li> <li>Limitations: Reverse transcriptase variability, RNA degradation risks, genomic DNA contamination.</li> <li>Controls Required: No-RT controls, reference gene normalization, RNA quality assessment.</li> <li> <p>Optimization Factors: RNA preservation methods, DNase treatment, RT enzyme selection.</p> </li> <li> <p>Northern Blotting</p> </li> <li>Limitations: Low sensitivity, time-consuming, requires substantial RNA input.</li> <li>Critical Considerations: RNA integrity, efficient transfer, probe specificity.</li> <li>Modern Alternatives: RNA-seq, NanoString, or RT-qPCR for higher sensitivity and throughput.</li> </ol>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#protein-dna-interaction-techniques","title":"Protein-DNA Interaction Techniques:","text":"<ol> <li>ChIP-seq</li> <li>Limitations: Antibody specificity issues, high background, formaldehyde crosslinking biases.</li> <li>Controls Required: Input DNA, IgG controls, spike-in normalization.</li> <li> <p>Validation Approaches: Replicate concordance, motif enrichment analysis, orthogonal techniques like CUT&amp;RUN.</p> </li> <li> <p>Footprinting Assay</p> </li> <li>Limitations: Limited to in vitro interactions, requires optimization for each protein-DNA pair.</li> <li>Critical Parameters: Nuclease concentration, incubation time, protein concentration.</li> <li> <p>Alternative Methods: In vivo techniques like ChIP-seq or CUT&amp;RUN for physiological context.</p> </li> <li> <p>EMSA</p> </li> <li>Limitations: Semi-quantitative, artificial binding conditions, limited to small DNA fragments.</li> <li>Controls Needed: Unlabeled competitor DNA, non-specific competitor, supershift controls.</li> <li> <p>Optimization Factors: Binding buffer composition, protein:DNA ratio, gel percentage.</p> </li> <li> <p>CUT&amp;RUN</p> </li> <li>Limitations: Antibody specificity dependencies, optimization required for each target.</li> <li>Critical Considerations: Nuclease concentration, antibody selection, cell permeabilization.</li> <li>Advantages Over ChIP: Lower background, reduced input requirements, higher resolution.</li> </ol>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#protein-analysis-techniques","title":"Protein Analysis Techniques:","text":"<ol> <li>Western Blotting</li> <li>Limitations: Semi-quantitative, antibody cross-reactivity, limited dynamic range.</li> <li>Controls Required: Loading controls, molecular weight markers, positive/negative controls.</li> <li> <p>Optimization Factors: Transfer conditions, blocking reagents, antibody dilutions.</p> </li> <li> <p>Co-IP</p> </li> <li>Limitations: Non-physiological buffer conditions, transient interactions may be missed.</li> <li>Controls Needed: IgG control, input samples, reciprocal IP validation.</li> <li> <p>Critical Parameters: Lysis conditions, antibody specificity, washing stringency.</p> </li> <li> <p>Pull-down Assay</p> </li> <li>Limitations: Artificial conditions, tag interference with interactions, non-specific binding.</li> <li>Controls Required: Tag-only controls, competitive inhibition controls.</li> <li>Validation Approaches: Reciprocal pull-downs, dose-dependent competition, orthogonal methods.</li> </ol>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#gene-expression-sequencing","title":"Gene Expression Sequencing:","text":"<ol> <li>RNA-seq</li> <li>Limitations: 3' bias in some protocols, GC content biases, batch effects.</li> <li>Quality Controls: RNA integrity assessment, spike-in controls, technical replicates.</li> <li> <p>Analysis Considerations: Appropriate normalization methods, batch correction, differential expression statistics.</p> </li> <li> <p>Single-cell RNA-seq</p> </li> <li>Limitations: Dropout events, cell capture biases, amplification biases.</li> <li>Critical Parameters: Cell viability, doublet rate, sequencing depth.</li> <li>Analytical Challenges: Dimensionality reduction choices, clustering parameters, trajectory inference assumptions.</li> </ol>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#epigenetics-sequencing","title":"Epigenetics Sequencing:","text":"<ol> <li>ATAC-seq</li> <li>Limitations: Open chromatin doesn't always indicate functional activity, cell type heterogeneity effects.</li> <li>Controls Required: Naked DNA controls, mitochondrial DNA exclusion, technical replicates.</li> <li> <p>Validation Approaches: Correlation with DNase-seq, functional validation of identified regions (as in the example question).</p> </li> <li> <p>ChIP-seq for Histone Modifications</p> </li> <li>Limitations: Antibody specificity concerns, crosslinking biases, batch effects.</li> <li>Controls Needed: Input normalization, spike-in controls, validation with different antibodies.</li> <li>Interpretation Challenges: Correlative vs. causative relationships, combinatorial modification effects.</li> </ol>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#gene-editing","title":"Gene Editing:","text":"<ol> <li>CRISPR-Cas9</li> <li>Limitations: Off-target effects, PAM site requirements, delivery efficiency.</li> <li>Controls Required: Non-targeting gRNAs, wild-type cells, validation of edits.</li> <li> <p>Optimization Factors: gRNA design, delivery method, timing of analysis post-editing.</p> </li> <li> <p>RNAi</p> </li> <li>Limitations: Off-target effects, incomplete knockdown, transient effects.</li> <li>Controls Needed: Scrambled siRNA controls, multiple siRNAs per target, rescue experiments.</li> <li>Validation Requirements: Protein-level knockdown confirmation, phenotype specificity tests.</li> </ol>"},{"location":"IBMS3/Yiru/detailed/6.%20Critical%20thinking/#example-critical-analysis-similar-to-question-1","title":"Example Critical Analysis (Similar to Question 1):","text":"<p>For investigating if an ATAC-seq identified open chromatin region is an enhancer for gene X:</p> <ol> <li> <p>Experimental Method: CRISPR interference (CRISPRi) using dCas9-KRAB to selectively repress the potential enhancer region, followed by gene X expression analysis.</p> </li> <li> <p>Alternative Approaches: </p> </li> <li>CRISPR deletion of the region followed by expression analysis</li> <li>Reporter assays with the region cloned upstream of a minimal promoter</li> <li> <p>Chromosome conformation capture (3C/4C) to detect physical interactions with the gene promoter</p> </li> <li> <p>Controls Required:</p> </li> <li>Cells with non-targeting gRNA</li> <li>Targeting a known non-regulatory region</li> <li> <p>Targeting the promoter as a positive control</p> </li> <li> <p>Potential Confounding Factors:</p> </li> <li>The region might regulate other nearby genes instead of/in addition to gene X</li> <li>Compensatory mechanisms might mask enhancer function</li> <li> <p>Cell type-specific enhancer activity might be missed</p> </li> <li> <p>Validation Strategy:</p> </li> <li>Test multiple independent gRNAs targeting different parts of the region</li> <li>Perform rescue experiments by re-introducing the enhancer</li> <li> <p>Test enhancer activity in multiple cell types relevant to gene X function</p> </li> <li> <p>Quantification and Statistics:</p> </li> <li>Normalize gene X expression to multiple reference genes</li> <li>Use appropriate statistical tests (t-test or ANOVA) with correction for multiple comparisons</li> <li>Calculate effect size to determine biological significance beyond statistical significance</li> </ol>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/","title":"MBE","text":""},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#dna-mbe-dna-assessment","title":"DNA\u8bc4\u4f30\u65b9\u6cd5  --==MBE DNA assessment==","text":"<ol> <li>PCR (Polymerase Chain Reaction) </li> <li>\u539f\u7406\uff1a\u901a\u8fc7\u70ed\u5faa\u73af\uff08\u53d8\u6027\u3001\u9000\u706b\u3001\u5ef6\u4f38\uff09\u6307\u6570\u7ea7\u6269\u589e\u7279\u5b9aDNA\u7247\u6bb5\u3002  </li> <li>\u5e94\u7528\uff1a\u57fa\u56e0\u514b\u9686\u3001\u75c5\u539f\u4f53\u68c0\u6d4b\u3001\u9057\u4f20\u75be\u75c5\u8bca\u65ad\u3002  </li> <li> <p>\u82f1\u6587\uff1aAmplifies specific DNA sequences using thermal cycling and DNA polymerase.  </p> </li> <li> <p>==qPCR (Quantitative PCR) ==.    --&gt; \u68c0\u6d4b\u6570\u91cf\uff0c\u8868\u8fbe\u91cf  </p> </li> <li>\u539f\u7406\uff1a\u5b9e\u65f6\u76d1\u6d4b\u8367\u5149\u4fe1\u53f7\u5f3a\u5ea6\u4ee5\u91cf\u5316DNA\u6269\u589e\u8fc7\u7a0b\u3002  </li> <li>\u5e94\u7528\uff1a\u57fa\u56e0\u8868\u8fbe\u5206\u6790\u3001\u75c5\u539f\u4f53\u8f7d\u91cf\u6d4b\u5b9a\u3002  </li> <li> <p>\u82f1\u6587\uff1aQuantifies DNA amplification in real-time using fluorescent dyes or probes.  </p> </li> <li> <p>==Southern Blotting==   --&gt; \u63d0\u4f9b\u7ed3\u6784\u4fe1\u606f</p> </li> <li>\u539f\u7406\uff1a\u51dd\u80f6\u7535\u6cf3\u5206\u79bbDNA\u540e\u8f6c\u79fb\u81f3\u819c\uff0c\u7528\u6807\u8bb0\u63a2\u9488\u6742\u4ea4\u68c0\u6d4b\u76ee\u6807\u5e8f\u5217\u3002  </li> <li>\u5e94\u7528\uff1a\u57fa\u56e0\u62f7\u8d1d\u6570\u5206\u6790\u3001\u9650\u5236\u6027\u7247\u6bb5\u957f\u5ea6\u591a\u6001\u6027\uff08RFLP\uff09\u68c0\u6d4b\u3002  </li> <li>\u82f1\u6587\uff1aDetects specific DNA sequences via hybridization with labeled probes after gel electrophoresis.  </li> </ol>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#rna-mbe-rna-assessment","title":"RNA\u8bc4\u4f30\u65b9\u6cd5  -- ==MBE RNA assessment==","text":"<ol> <li>==RT-PCR (Reverse Transcription-PCR)  ==</li> <li>\u539f\u7406\uff1a\u53cd\u8f6c\u5f55RNA\u4e3acDNA\u540e\u8fdb\u884cPCR\u6269\u589e\u3002  </li> <li>\u5e94\u7528\uff1a\u4f4e\u4e30\u5ea6RNA\u68c0\u6d4b\u3001\u75c5\u6bd2RNA\u5b9a\u91cf\u3002  </li> <li> <p>\u82f1\u6587\uff1aConverts RNA to cDNA using reverse transcriptase before PCR amplification.  </p> </li> <li> <p>==Northern Blotting  ==</p> </li> <li>\u539f\u7406\uff1a\u51dd\u80f6\u7535\u6cf3\u5206\u79bbRNA\u540e\u8f6c\u79fb\u81f3\u819c\uff0c\u7528\u6807\u8bb0\u63a2\u9488\u68c0\u6d4b\u76ee\u6807\u8f6c\u5f55\u672c\u3002  </li> <li>\u5e94\u7528\uff1a\u57fa\u56e0\u8868\u8fbe\u5206\u6790\u3001RNA\u526a\u63a5\u7814\u7a76\u3002  </li> <li>\u82f1\u6587\uff1aDetects specific RNA sequences via hybridization with labeled probes after gel electrophoresis.  </li> </ol>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-dna-mbe-protein-dna-interaction","title":"\u86cb\u767d\u8d28-DNA\u76f8\u4e92\u4f5c\u7528  --==MBE Protein-DNA interaction==","text":"<ol> <li>==ChIP-seq (Chromatin Immunoprecipitation Sequencing)  ==</li> <li>\u539f\u7406\uff1a\u4ea4\u8054\u86cb\u767d-DNA\u590d\u5408\u7269\uff0c\u514d\u75ab\u6c89\u6dc0\u540e\u6d4b\u5e8f\u5206\u6790\u7ed3\u5408\u4f4d\u70b9\u3002  </li> <li>\u5e94\u7528\uff1a\u8f6c\u5f55\u56e0\u5b50\u7ed3\u5408\u56fe\u8c31\u3001\u8868\u89c2\u9057\u4f20\u8c03\u63a7\u7814\u7a76\u3002  </li> <li> <p>\u82f1\u6587\uff1aIdentifies genome-wide protein-DNA interactions by immunoprecipitating chromatin fragments.  </p> </li> <li> <p>Footprinting Assay </p> </li> <li>\u539f\u7406\uff1a\u86cb\u767d\u7ed3\u5408\u533a\u57df\u4fdd\u62a4DNA\u514d\u53d7\u9176\u5207\u6216\u5316\u5b66\u4fee\u9970\uff0c\u901a\u8fc7\u6d4b\u5e8f\u63ed\u793a\u7ed3\u5408\u4f4d\u70b9\u3002  </li> <li>\u5e94\u7528\uff1a\u7cbe\u786e\u7ed8\u5236\u86cb\u767d\u8d28-DNA\u76f8\u4e92\u4f5c\u7528\u754c\u9762\u3002  </li> <li> <p>\u82f1\u6587\uff1aReveals protein-DNA binding sites by detecting protected regions from enzymatic/chemical cleavage.  </p> </li> <li> <p>EMSA (Electrophoretic Mobility Shift Assay) </p> </li> <li>\u539f\u7406\uff1a\u86cb\u767d-DNA\u590d\u5408\u7269\u5728\u51dd\u80f6\u4e2d\u8fc1\u79fb\u901f\u7387\u53d8\u6162\uff0c\u901a\u8fc7\u7535\u6cf3\u533a\u5206\u7ed3\u5408\u4e0e\u6e38\u79bbDNA\u3002  </li> <li>\u5e94\u7528\uff1a\u5b9a\u6027\u68c0\u6d4b\u86cb\u767d-DNA\u76f8\u4e92\u4f5c\u7528\u3002  </li> <li> <p>\u82f1\u6587\uff1aDetects protein-DNA interactions based on retarded migration of complexes in gel electrophoresis.  </p> </li> <li> <p>CUT&amp;RUN (Cleavage Under Targets and Release Using Nuclease) </p> </li> <li>\u539f\u7406\uff1a\u6297\u4f53\u9776\u5411\u5fae\u7403\u83cc\u6838\u9178\u9176\u5207\u5272\u86cb\u767d\u7ed3\u5408\u7684DNA\u7247\u6bb5\uff0c\u4f4e\u8d77\u59cb\u91cf\u5373\u53ef\u9ad8\u5206\u8fa8\u7387 mapping\u3002  </li> <li>\u5e94\u7528\uff1a\u67d3\u8272\u8d28\u53ef\u53ca\u6027\u5206\u6790\u3001\u8f6c\u5f55\u56e0\u5b50\u7ed3\u5408\u56fe\u8c31\u3002  </li> <li>\u82f1\u6587\uff1aHigh-resolution chromatin profiling using antibody-targeted nuclease digestion.  </li> </ol>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-mbe-protein-assessment","title":"\u86cb\u767d\u8d28\u5206\u6790\u65b9\u6cd5  --==MBE Protein assessment==","text":"<ol> <li>==Western Blotting  ==</li> <li>\u539f\u7406\uff1a\u51dd\u80f6\u7535\u6cf3\u5206\u79bb\u86cb\u767d\u540e\u8f6c\u819c\uff0c\u7528\u6297\u4f53\u68c0\u6d4b\u76ee\u6807\u86cb\u767d\u3002  </li> <li>\u5e94\u7528\uff1a\u86cb\u767d\u8868\u8fbe\u5b9a\u91cf\u3001\u7ffb\u8bd1\u540e\u4fee\u9970\u5206\u6790\u3002  </li> <li> <p>\u82f1\u6587\uff1aDetects specific proteins using antibodies after gel electrophoresis and membrane transfer.  </p> </li> <li> <p>==Co-IP (Co-Immunoprecipitation)== --&gt; detection in vivo env</p> </li> <li>\u539f\u7406\uff1a\u6297\u4f53\u6c89\u6dc0\u76ee\u6807\u86cb\u767d\u53ca\u5176\u4e92\u4f5c\u86cb\u767d\uff0c\u8d28\u8c31\u9274\u5b9a\u590d\u5408\u7269,\u9700\u8981\u63a5\u7740\u7528MS  </li> <li>\u5e94\u7528\uff1a\u86cb\u767d\u8d28\u4e92\u4f5c\u7f51\u7edc\u7814\u7a76\u3002  </li> <li> <p>\u82f1\u6587\uff1aIdentifies protein-protein interactions by co-precipitating interacting partners with specific antibodies.  </p> </li> <li> <p>==Pull-down Assay==  --&gt; in vitro, some new interaction like drugs</p> </li> <li>\u539f\u7406\uff1a\u91cd\u7ec4\u201c\u8bf1\u9975\u201d\u86cb\u767d\uff08\u5982GST\u6807\u7b7e\uff09\u6355\u83b7\u4e92\u4f5c\u86cb\u767d\uff0c\u8d28\u8c31\u9274\u5b9a\u3002  </li> <li>\u5e94\u7528\uff1a\u9a8c\u8bc1\u5df2\u77e5\u4e92\u4f5c\u6216\u7b5b\u9009\u65b0\u4e92\u4f5c\u86cb\u767d\u3002  </li> <li>\u82f1\u6587\uff1aCaptures protein interactions using recombinant tagged proteins as bait.  </li> <li> <p>\u4e5f\u53ef\u4ee5\u7528\u6765\u8bbe\u8ba1\u6210RNA pull down\uff0c DNA pull down</p> </li> <li> <p>==Mass Spectrometry (MS)  ==</p> </li> <li>\u539f\u7406\uff1a\u79bb\u5b50\u5316\u86cb\u767d\u540e\u6309\u8d28\u8377\u6bd4\u5206\u79bb\uff0c\u6570\u636e\u5e93\u6bd4\u5bf9\u9274\u5b9a\u86cb\u767d\u3002  </li> <li>\u5e94\u7528\uff1a\u86cb\u767d\u8d28\u7ec4\u5b66\u3001\u7ffb\u8bd1\u540e\u4fee\u9970\u5206\u6790\u3002  </li> <li> <p>\u82f1\u6587\uff1aAnalyzes protein identity, abundance, and modifications based on mass-to-charge ratios.  </p> </li> <li> <p>FRET (Fluorescence Resonance Energy Transfer) </p> </li> <li>\u539f\u7406\uff1a\u4e24\u4e2a\u8367\u5149\u6807\u8bb0\u86cb\u767d\u8fd1\u8ddd\u79bb\u65f6\u53d1\u751f\u80fd\u91cf\u8f6c\u79fb\uff0c\u68c0\u6d4b\u4e92\u4f5c\u3002  </li> <li>\u5e94\u7528\uff1a\u6d3b\u7ec6\u80de\u5185\u52a8\u6001\u86cb\u767d\u4e92\u4f5c\u76d1\u6d4b\u3002  </li> <li> <p>\u82f1\u6587\uff1aMeasures protein-protein interactions in live cells via energy transfer between fluorescently labeled proteins.  </p> </li> <li> <p>==ELISA==</p> <ul> <li>\u539f\u7406\uff1a\u9176\u8054\u514d\u75ab\u5206\u6790\uff0c\u548cWB\u7c7b\u4f3c</li> <li>\u68c0\u6d4b\u86cb\u767d\u8d28\uff0c\u6bd4\u5982antibody</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#gene-expression-sequencing-mbe-gene-expression-analysis-technologies","title":"Gene Expression Sequencing -- MBE Gene Expression Analysis Technologies","text":"<ol> <li>RNA-seq (RNA Sequencing) </li> <li>\u539f\u7406\uff1a\u53cd\u8f6c\u5f55RNA\u4e3acDNA\u540e\u9ad8\u901a\u91cf\u6d4b\u5e8f\uff0c\u91cf\u5316\u57fa\u56e0\u8868\u8fbe\u3002  </li> <li>\u5e94\u7528\uff1a\u5dee\u5f02\u8868\u8fbe\u5206\u6790\u3001\u65b0\u8f6c\u5f55\u672c\u53d1\u73b0\u3002  </li> <li> <p>\u82f1\u6587\uff1aHigh-throughput transcriptome profiling by sequencing cDNA derived from RNA.  </p> </li> <li> <p>Single-cell RNA-seq </p> </li> <li>\u539f\u7406\uff1a\u5355\u7ec6\u80de\u6c34\u5e73\u5206\u6790\u57fa\u56e0\u8868\u8fbe\uff0c\u63ed\u793a\u7ec6\u80de\u5f02\u8d28\u6027\u3002  </li> <li>\u5e94\u7528\uff1a\u80bf\u7624\u5fae\u73af\u5883\u3001\u5e72\u7ec6\u80de\u5206\u5316\u7814\u7a76\u3002  </li> <li> <p>\u82f1\u6587\uff1aAnalyzes gene expression in individual cells to characterize cellular heterogeneity.  </p> </li> <li> <p>Spatial Transcriptomics </p> </li> <li>\u539f\u7406\uff1a\u4fdd\u7559\u7ec4\u7ec7\u7a7a\u95f4\u4fe1\u606f\u7684\u57fa\u56e0\u8868\u8fbe\u56fe\u8c31\u3002  </li> <li>\u5e94\u7528\uff1a\u7ec4\u7ec7\u53d1\u80b2\u3001\u80bf\u7624\u7a7a\u95f4\u5f02\u8d28\u6027\u7814\u7a76\u3002  </li> <li> <p>\u82f1\u6587\uff1aMaps gene expression within tissue sections while preserving spatial context.  </p> </li> <li> <p>Microarray</p> </li> <li>\u539f\u7406\uff1a\u57fa\u4e8e\u7279\u5b9a\u63a2\u9488\u4e0e\u9776\u6807\u5e8f\u5217\u6742\u4ea4\u7684\u8868\u8fbe\u91cf\u68c0\u6d4b\u6280\u672f\u3002</li> <li>\u5e94\u7528\uff1a\u591a\u57fa\u56e0\u8868\u8fbe\u8c31\u5206\u6790\u3001\u4e34\u5e8a\u8bca\u65ad\u3002</li> <li> <p>\u82f1\u6587\uff1aMeasures expression of multiple genes through hybridization to DNA probes on a chip.</p> </li> <li> <p>Long-read Sequencing</p> </li> <li>\u539f\u7406\uff1a\u6d4b\u5e8f\u5b8c\u6574\u8f6c\u5f55\u672c\uff0c\u4fdd\u7559\u526a\u63a5\u53d8\u4f53\u548c\u7ed3\u6784\u4fe1\u606f\u3002</li> <li>\u5e94\u7528\uff1a\u590d\u6742\u8f6c\u5f55\u672c\u7ed3\u6784\u5206\u6790\u3001\u65b0\u578b\u526a\u63a5\u53d8\u4f53\u53d1\u73b0\u3002</li> <li>\u82f1\u6587\uff1aSequences full-length transcripts to identify splice variants and structural details.</li> </ol>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#epigenetic-sequencing-mbe-epigenetic-sequencing","title":"Epigenetic Sequencing -- MBE Epigenetic Sequencing","text":"<ol> <li>Bisulfite Sequencing </li> <li>\u539f\u7406\uff1a\u4e9a\u786b\u9178\u6c22\u76d0\u8f6c\u5316\u672a\u7532\u57fa\u5316\u80de\u5627\u5576\u4e3a\u5c3f\u5627\u5576\uff0c\u6d4b\u5e8f\u540e\u6bd4\u5bf9\u5206\u6790\u7532\u57fa\u5316\u6a21\u5f0f\u3002  </li> <li>\u5e94\u7528\uff1aDNA\u7532\u57fa\u5316\u56fe\u8c31\u6784\u5efa\u3002  </li> <li> <p>\u82f1\u6587\uff1aMaps DNA methylation by converting unmethylated cytosines to uracil.  </p> </li> <li> <p>ATAC-seq (Assay for Transposase-Accessible Chromatin with sequencing) </p> </li> <li>\u539f\u7406\uff1aTn5\u8f6c\u5ea7\u9176\u63d2\u5165\u5f00\u653e\u67d3\u8272\u8d28\u533a\u57df\u5e76\u6dfb\u52a0\u6d4b\u5e8f\u63a5\u5934\u3002  </li> <li>\u5e94\u7528\uff1a\u67d3\u8272\u8d28\u53ef\u53ca\u6027\u5206\u6790\u3001\u8c03\u63a7\u5143\u4ef6\u5b9a\u4f4d\u3002  </li> <li> <p>\u82f1\u6587\uff1aIdentifies accessible chromatin regions using transposase insertion and sequencing.  </p> </li> <li> <p>m6A Sequencing </p> </li> <li>\u539f\u7406\uff1a\u514d\u75ab\u6c89\u6dc0\u542bN6-\u7532\u57fa\u817a\u82f7\u7684RNA\u7247\u6bb5\u540e\u6d4b\u5e8f\u3002  </li> <li>\u5e94\u7528\uff1aRNA\u7532\u57fa\u5316\u4fee\u9970\u529f\u80fd\u7814\u7a76\u3002  </li> <li> <p>\u82f1\u6587\uff1aMaps N6-methyladenosine (m6A) modifications in RNA using immunoprecipitation.  </p> </li> <li> <p>ChIP-seq (Chromatin Immunoprecipitation Sequencing)</p> </li> <li>\u539f\u7406\uff1a\u4f7f\u7528\u7279\u5f02\u6027\u6297\u4f53\u5bcc\u96c6\u76ee\u6807\u86cb\u767d\u7ed3\u5408\u7684DNA\u533a\u57df\u540e\u6d4b\u5e8f\u3002</li> <li>\u5e94\u7528\uff1a\u8f6c\u5f55\u56e0\u5b50\u7ed3\u5408\u4f4d\u70b9\u548c\u7ec4\u86cb\u767d\u4fee\u9970\u5206\u6790\u3002</li> <li> <p>\u82f1\u6587\uff1aIdentifies genome-wide protein-DNA interactions by immunoprecipitation followed by sequencing.</p> </li> <li> <p>MeDIP-seq (Methylated DNA Immunoprecipitation Sequencing)</p> </li> <li>\u539f\u7406\uff1a\u4f7f\u7528\u62975-\u7532\u57fa\u80de\u5627\u5576\u6297\u4f53\u5bcc\u96c6\u7532\u57fa\u5316DNA\u7247\u6bb5\u540e\u6d4b\u5e8f\u3002</li> <li>\u5e94\u7528\uff1a\u5168\u57fa\u56e0\u7ec4\u7532\u57fa\u5316\u5206\u6790\uff0c\u764c\u75c7\u8868\u89c2\u9057\u4f20\u5b66\u7814\u7a76\u3002</li> <li> <p>\u82f1\u6587\uff1aEnriches methylated DNA using antibodies specific to 5-methylcytosine for sequencing.</p> </li> <li> <p>MNase-seq (Micrococcal Nuclease Sequencing)</p> </li> <li>\u539f\u7406\uff1a\u5fae\u7403\u83cc\u6838\u9178\u9176\u6d88\u5316\u8fde\u63a5\u5b50DNA\uff0c\u4fdd\u7559\u6838\u5c0f\u4f53DNA\u540e\u6d4b\u5e8f\u3002</li> <li>\u5e94\u7528\uff1a\u6838\u5c0f\u4f53\u5b9a\u4f4d\u548c\u67d3\u8272\u8d28\u7ed3\u6784\u5206\u6790\u3002</li> <li> <p>\u82f1\u6587\uff1aMaps nucleosome positions by digesting linker DNA with micrococcal nuclease.</p> </li> <li> <p>DNase-seq (DNase I Hypersensitive Sites Sequencing)</p> </li> <li>\u539f\u7406\uff1aDNase I\u9176\u5207\u5f00\u653e\u67d3\u8272\u8d28\u533a\u57df\u540e\u6d4b\u5e8f\u3002</li> <li>\u5e94\u7528\uff1a\u8bc6\u522b\u8c03\u63a7\u5143\u4ef6\u548c\u8f6c\u5f55\u56e0\u5b50\u7ed3\u5408\u4f4d\u70b9\u3002</li> <li> <p>\u82f1\u6587\uff1aIdentifies open chromatin regions using DNase I enzyme digestion followed by sequencing.</p> </li> <li> <p>FAIRE-seq (Formaldehyde-Assisted Isolation of Regulatory Elements)</p> </li> <li>\u539f\u7406\uff1a\u901a\u8fc7\u7532\u919b\u4ea4\u8054\u548c\u915a-\u6c2f\u4eff\u63d0\u53d6\u5206\u79bb\u65e0\u6838\u5c0f\u4f53\u533a\u57df\u540e\u6d4b\u5e8f\u3002</li> <li>\u5e94\u7528\uff1a\u9274\u5b9a\u6d3b\u6027\u8c03\u63a7\u5143\u4ef6\u548c\u5f00\u653e\u67d3\u8272\u8d28\u533a\u57df\u3002</li> <li> <p>\u82f1\u6587\uff1aMaps active regulatory elements by isolating nucleosome-free DNA regions.</p> </li> <li> <p>Small RNA-seq</p> </li> <li>\u539f\u7406\uff1a\u5206\u79bb\u5e76\u6d4b\u5e8f\u5c0f\u5206\u5b50\u975e\u7f16\u7801RNA\u3002</li> <li>\u5e94\u7528\uff1amiRNA\u3001siRNA\u548cpiRNA\u8868\u8fbe\u8c31\u5206\u6790\u3002</li> <li>\u82f1\u6587\uff1aProfiles small non-coding RNAs such as microRNAs, siRNAs, and other regulatory RNA molecules.</li> </ol>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#mrna-mbe-mrna-visualisation-and-analysis-technologies","title":"mRNA\u53ef\u89c6\u5316\u4e0e\u5206\u6790  --==MBE mRNA visualisation and analysis technologies==","text":"<ol> <li>FISH (Fluorescence In Situ Hybridisation) </li> <li>\u539f\u7406\uff1a\u8367\u5149\u6807\u8bb0\u63a2\u9488\u4e0e\u7ec6\u80de\u5185RNA\u6742\u4ea4\uff0c\u663e\u5fae\u955c\u89c2\u5bdf\u5b9a\u4f4d\u3002  </li> <li>\u5e94\u7528\uff1aRNA\u4e9a\u7ec6\u80de\u5b9a\u4f4d\u3001\u75c5\u6bd2RNA\u68c0\u6d4b\u3002  </li> <li> <p>\u82f1\u6587\uff1aVisualizes RNA localization in cells/tissues using fluorescent probes.  </p> </li> <li> <p>CLIP (Crosslinking and Immunoprecipitation) </p> </li> <li>\u539f\u7406\uff1a\u7d2b\u5916\u7ebf\u4ea4\u8054\u86cb\u767d-RNA\u590d\u5408\u7269\uff0c\u514d\u75ab\u6c89\u6dc0\u540e\u6d4b\u5e8f\u3002  </li> <li>\u5e94\u7528\uff1aRNA\u7ed3\u5408\u86cb\u767d\u9776\u70b9\u9274\u5b9a\u3002  </li> <li>\u82f1\u6587\uff1aMaps protein-RNA interactions at nucleotide resolution using UV crosslinking.  </li> </ol>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-mbe-chromosome-structure-detection","title":"\u67d3\u8272\u4f53\u7ed3\u6784\u5206\u6790  --==MBE Chromosome structure detection==","text":"<ol> <li>Hi-C </li> <li>\u539f\u7406\uff1a\u7532\u919b\u4ea4\u8054\u67d3\u8272\u8d28\uff0c\u9176\u5207\u540e\u8fde\u63a5\u5e76\u6d4b\u5e8f\uff0c\u6784\u5efa\u5168\u57fa\u56e0\u7ec4\u4e92\u4f5c\u56fe\u8c31\u3002  </li> <li>\u5e94\u7528\uff1a\u4e09\u7ef4\u57fa\u56e0\u7ec4\u7ed3\u6784\u7814\u7a76\u3001\u957f\u7a0b\u8c03\u63a7\u5143\u4ef6\u53d1\u73b0\u3002  </li> <li>\u82f1\u6587\uff1aMaps genome-wide chromatin interactions to study 3D chromosome organization.  </li> <li>3C-5C<ul> <li>\u662f\u4e0d\u540c\u7684\u6280\u672f\uff0c\u6709\u591a\u79cd\u7684\u5206\u8fa8\u7387</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-mbe-gene-editing","title":"\u57fa\u56e0\u7f16\u8f91\u6280\u672f\u00a0-- MBE Gene Editing","text":"<ol> <li> <p>CRISPR-Cas9\u00a0--&gt; gene knockout</p> <ul> <li>\u539f\u7406\uff1asgRNA\u5f15\u5bfcCas9\u6838\u9178\u9176\u5207\u5272\u76ee\u6807DNA\uff0c\u901a\u8fc7\u540c\u6e90\u91cd\u7ec4\u6216\u975e\u540c\u6e90\u672b\u7aef\u8fde\u63a5\u5b9e\u73b0\u7f16\u8f91\u3002</li> <li>\u5e94\u7528\uff1a\u57fa\u56e0\u6572\u9664\u3001\u6572\u5165\u3001\u78b1\u57fa\u7f16\u8f91\u3002</li> <li>\u82f1\u6587\uff1aPrecision genome editing using guide RNA and Cas9 nuclease.</li> <li> <p>RNAi (RNA Interference)\u00a0--&gt; gene knockdown</p> </li> <li> <p>\u539f\u7406\uff1asiRNA\u6216shRNA\u9776\u5411\u964d\u89e3mRNA\uff0c\u6291\u5236\u57fa\u56e0\u8868\u8fbe\u3002</p> </li> <li>\u5e94\u7528\uff1a\u57fa\u56e0\u529f\u80fd\u7814\u7a76\u3001\u75be\u75c5\u6cbb\u7597\u3002</li> <li>\u82f1\u6587\uff1aSilences gene expression by targeting mRNA for degradation.</li> <li> <p>CRISPRi (CRISPR Interference)\u00a0--&gt; gene repression</p> </li> <li> <p>\u539f\u7406\uff1a\u5931\u6d3b\u7684dCas9\u4e0e\u8f6c\u5f55\u6291\u5236\u7ed3\u6784\u57df(\u5982KRAB)\u878d\u5408\uff0c\u7ed3\u5408\u76ee\u6807\u57fa\u56e0\u542f\u52a8\u5b50\u6291\u5236\u8f6c\u5f55\u3002</p> </li> <li>\u5e94\u7528\uff1a\u53ef\u9006\u57fa\u56e0\u6c89\u9ed8\u3001\u5fc5\u9700\u57fa\u56e0\u7814\u7a76\u3001\u591a\u57fa\u56e0\u8c03\u63a7\u3002</li> <li>\u82f1\u6587\uff1aRepresses gene expression using catalytically dead Cas9 without altering DNA sequence.</li> <li> <p>CRISPRa (CRISPR Activation)\u00a0--&gt; gene activation</p> </li> <li> <p>\u539f\u7406\uff1a\u5931\u6d3b\u7684dCas9\u4e0e\u8f6c\u5f55\u6fc0\u6d3b\u7ed3\u6784\u57df(\u5982VP64\u3001p65)\u878d\u5408\uff0c\u7ed3\u5408\u76ee\u6807\u57fa\u56e0\u542f\u52a8\u5b50\u589e\u5f3a\u8f6c\u5f55\u3002</p> </li> <li>\u5e94\u7528\uff1a\u5185\u6e90\u57fa\u56e0\u6fc0\u6d3b\u3001\u7ec6\u80de\u91cd\u7f16\u7a0b\u3001\u589e\u76ca\u529f\u80fd\u7b5b\u9009\u3002</li> <li>\u82f1\u6587\uff1aEnhances gene expression by recruiting transcriptional activators to target promoters.</li> <li>CRISPR-based Epigenetic Editing\u00a0--&gt; epigenome modification</li> <li>\u539f\u7406\uff1adCas9\u4e0e\u8868\u89c2\u9057\u4f20\u4fee\u9970\u9176(\u5982DNMT3A\u3001TET1\u3001HDAC)\u878d\u5408\uff0c\u9776\u5411\u6539\u53d8\u7279\u5b9a\u4f4d\u70b9\u7684\u8868\u89c2\u9057\u4f20\u72b6\u6001\u3002</li> <li>\u5e94\u7528\uff1aDNA\u7532\u57fa\u5316\u7f16\u8f91\u3001\u7ec4\u86cb\u767d\u4fee\u9970\u8c03\u63a7\u3001\u8868\u89c2\u9057\u4f20\u75be\u75c5\u7814\u7a76\u3002</li> <li>\u82f1\u6587\uff1aModifies epigenetic marks at specific genomic loci using dCas9 fused to epigenetic effectors.  </li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#crispr-screen-mbe-crispr-screen-disease-gene-factor","title":"CRISPR screen\u5e94\u7528\u5728\u75be\u75c5\u5173\u8054\u57fa\u56e0 --==MBE CRISPR screen disease gene factor==","text":"<ul> <li>\u76ee\u7684\uff1a\u60f3\u8981\u77e5\u9053\u54ea\u4e00\u4e2a\u57fa\u56e0\u548c\u75be\u75c5\u7684\u53d1\u75c5/\u6613\u611f\u6027\u6709\u5173\u7cfb</li> <li>\u901a\u8fc7CRISPRCas9\u8fdb\u884c\u57fa\u56e0\u6572\u9664\u7684\u7b5b\u9009</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#epigenome-engineering-mbe-epigenome-engineering-discussion","title":"Epigenome Engineering --==MBE  Epigenome Engineering Discussion==","text":"<ul> <li>\u539f\u7406\uff1aCRISPR-dCas9\u878d\u5408\u8868\u89c2\u4fee\u9970\u9176\uff08\u5982DNMT3A\uff09\uff0c\u9776\u5411\u8c03\u63a7\u8868\u89c2\u9057\u4f20\u6807\u8bb0\u3002  </li> <li>\u5e94\u7528\uff1aDNA\u7532\u57fa\u5316\u3001\u7ec4\u86cb\u767d\u4fee\u9970\u529f\u80fd\u7814\u7a76\u3002  </li> <li>\u82f1\u6587\uff1aTargets epigenetic modifications (e.g., DNA methylation) using CRISPR-based systems.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#crispr-screen-mbe-cripsr-screen-drug-resistence","title":"CRISPR screen\u5e94\u7528\u5728\u836f\u7269\u8010\u836f\u6027\u5173\u8054\u57fa\u56e0 --MBE CRIPSR screen drug resistence","text":"<ul> <li>\u76ee\u7684\uff1a\u60f3\u8981\u77e5\u9053\u54ea\u4e00\u4e2a\u57fa\u56e0\u548c\u836f\u7269\u7684\u8010\u836f\u6027\u6709\u5173</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#semester-1","title":"Semester 1","text":"<ol> <li>RNA Editing-based RNA-seq </li> <li>\u539f\u7406\uff1aRBP-APOBEC\u878d\u5408\u86cb\u767d\u8bf1\u5bfcRNA\u7f16\u8f91\uff0c\u901a\u8fc7\u6d4b\u5e8f\u5dee\u5f02\u5b9a\u4f4d\u7ed3\u5408\u4f4d\u70b9\u3002  </li> <li>\u5e94\u7528\uff1aRNA\u7ed3\u5408\u86cb\u767d\u9776\u70b9\u9274\u5b9a\u3002  </li> <li>\u82f1\u6587\uff1aDetects RBP binding sites by analyzing RNA editing events induced by RBP-APOBEC fusion proteins.  </li> </ol>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#aso-s1-antisense-oligonucleotides","title":"ASO --==S1 Antisense oligonucleotides==","text":"<ul> <li>\u539f\u7406\uff1aASO \u53ef\u4ee5downregulate gene expression</li> <li>\u53ef\u4ee5\u7528\u5728\u68c0\u6d4bcellular \u8868\u578b\u53d8\u5316\u548c\u57fa\u56e0\u7684\u5173\u7cfb </li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-s1w3tu-flow-cytometry-for-immunology","title":"\u6d41\u5f0f\u7ec6\u80de\u672f --==S1.W3.tu Flow cytometry for immunology==","text":"<ul> <li>\u539f\u7406\uff1a\u6d41\u5f0f\u7ec6\u80de\u672f\u68c0\u6d4b\u7684\u662f\u5355\u4e2a\u7ec6\u80de\u7684\u8868\u9762\u6216\u8005\u80de\u5185\u86cb\u767d\u5206\u5e03\u548c\u6c34\u5e73\uff0c\u662f\u4e00\u79cd\u57fa\u4e8e\u6fc0\u5149\u7684\u6280\u672f\uff0c</li> <li>\u5e38\u7528\u5728\u514d\u75ab\u5206\u578b\u548c\u7ec6\u80de\u5206\u9009\uff1b \u6bd4\u5982\u75be\u75c5X\u5bf9\u4e8e\u514d\u75ab\u7ec6\u80desubset\u7684\u5f71\u54cd\u662f\u4ec0\u4e48</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-s1w3tu-flow-cytometry-for-biomedical","title":"\u6d41\u5f0f\u7ec6\u80de\u672f --==S1.W3.tu Flow cytometry for biomedical==","text":"<ul> <li>\u5bf9\u4e8e\u6d41\u5f0f\u7ec6\u80de\u672f\u7684\u66f4\u52a0\u76f4\u89c2\u7684\u89e3\u91ca</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#wb-and-elisa-wb-and-elisa","title":"WB and ELISA --==WB and ELISA==","text":"<ul> <li>\u539f\u7406\uff1aWestern ploting\u662f\u4e00\u79cd\u5e38\u89c4\u7684\u86cb\u767d\u8d28\u5206\u6790\u6280\u672f\uff0c\u901a\u5e38\u7528\u4e8e\u9274\u5b9a\u7279\u5b9a\u86cb\u767d\u8d28\u5e76\u5bf9\u86cb\u767d\u8d28\u8fdb\u884c\u5b9a\u6027\u548c\u534a\u5b9a\u91cf\u5206\u6790; ELISA\u7528\u4e8e\u68c0\u6d4b\u6eb6\u6db2\u4e2d\u7684\u86cb\u767d\u8d28\u6210\u5206\uff0c\u591a\u7528\u7684\u5316\u5b66\u53cd\u5e94\u663e\u8272\uff0c\u5b9a\u91cf\u5206\u6790</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#modification-s1w8-gene-modified-mouse","title":"\u57fa\u56e0modification\u76f8\u5173\u6280\u672f\u548c\u5b9e\u9a8c\u6d41\u7a0b  --==S1.W8 Gene modified mouse==","text":"<ul> <li>\u539f\u7406\uff1aCre/loxP system \u6216\u8005\u5176\u4ed6\u57fa\u56e0\u7f16\u8f91\u6280\u672f\u53ef\u4ee5\u83b7\u5f97\u7279\u5b9a\u57fa\u56e0\u7f16\u8f91\u7684\u8001\u9f20\u6a21\u578b\uff0c\u7528\u4e8e\u6784\u5efa\u75be\u75c5\u6216\u8005\u8868\u578b\u6a21\u578b</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-s1w10chendi-aging-research-in-c-elegans","title":"\u8870\u8001\u673a\u5236\u7814\u7a76\uff0c\u7ebf\u866b\u6a21\u578b --==S1W10.ChenDI Aging research in C elegans==","text":"<ul> <li>\u901a\u8fc7\u6784\u5efa\u7a81\u53d8\u4f53\u7ebf\u866b\uff0c\u548c\u5efa\u7acb\u9488\u5bf9\u9776\u5411\u76ee\u6807\u57fa\u56e0\u7684RNAi \u63a2\u7d22\u7ebf\u866b\u8870\u8001</li> <li>\u540c\u65f6\u8fd0\u7528\u4e86Survival analysis</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#structural-variation-s1w12lianggong-long-read-sequencing-genomic-structural-variation","title":"\u57fa\u56e0\u7ec4\u7684Structural Variation \u68c0\u6d4b -- ==S1.W12.LiangGong Long read sequencing, Genomic Structural Variation==","text":"<ul> <li>\u68c0\u6d4b\u7ed3\u6784\u53d8\u5f02\uff0c\u6bd4\u5982\u91cd\u590d\u6269\u589e\uff0c\u6613\u4f4d\uff0c\u5012\u4f4d\u7b49\u7b49</li> <li>\u4e3b\u8981\u901a\u8fc7\u7b2c\u4e09\u4ee3\u6d4b\u5e8f\u83b7\u5f97DNA\u6d4b\u5e8f</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#gwas-s1w13liunan-gwas","title":"GWAS\u5e94\u7528 --==S1.W13.LiuNan GWAS==","text":"<ul> <li>GWAS\u4e3b\u8981\u7528\u4e8e\u8bc6\u522b\u75be\u75c5\u6216\u8005\u8868\u578b\u76f8\u5173\u7684SNPs</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#hemoglobin-s1w13liunan-hemoglobin-switching","title":"Hemoglobin\u8f6c\u53d8\u7814\u7a76\u6848\u4f8b  --==S1.W13.LiuNan Hemoglobin Switching==","text":"<ul> <li>\u901a\u8fc7\u57fa\u56e0\u7f16\u8f91--&gt;\u529f\u80fd\u9a8c\u8bc1--&gt; \u5206\u5b50\u673a\u5236\u7814\u7a76\uff08\u6b64\u5904\u662f\u8868\u89c2\u9057\u4f20\u673a\u5236\uff09\uff0c\u6784\u5efa\u4e86\u7814\u7a76\u7684pipeline</li> <li>\u7814\u7a76\u4e86BCL11A\u5728\u80ce\u513f\u8840\u7ea2\u86cb\u767d(HbF)\u5411\u6210\u4eba\u8840\u7ea2\u86cb\u767d(HbA)\u8f6c\u6362\u4e2d\u7684\u8c03\u63a7\u673a\u5236</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-s1w13liunan-luciferase-reporter-assay","title":"\u53cc\u8367\u5149\u9176\u57fa\u56e0\u62a5\u544a\u5206\u6790 --==S1.W13.LiuNan Luciferase reporter assay==","text":"<ul> <li> <p>\u539f\u7406\uff1a\u68c0\u6d4bTE\u662f\u5426\u901a\u8fc7\u57fa\u56e0\u7684promoter\u76f4\u63a5\u8c03\u63a7\u57fa\u56e0\uff08\u68c0\u6d4bTE\u548c\u57fa\u56e0\u8c03\u63a7\u7684\u5173\u7cfb\uff09 \u8367\u5149\u7d20\u9176\u62a5\u544a\u57fa\u56e0\u68c0\u6d4b\u7cfb\u7edf\u7684\u4f5c\u7528\u4e3b\u8981\u6709\u4ee5\u4e0b\u51e0\u70b9\uff1a</p> </li> <li> <p>\u9a8c\u8bc1\u8f6c\u5f55\u56e0\u5b50\u4e0e\u57fa\u56e0\u542f\u52a8\u5b50\u4e4b\u95f4\u7684\u76f4\u63a5\u8c03\u63a7\u5173\u7cfb</p> </li> <li>\u91cf\u5316\u8f6c\u5f55\u6d3b\u6027\u7684\u53d8\u5316</li> <li>\u9274\u5b9a\u542f\u52a8\u5b50\u6216\u589e\u5f3a\u5b50\u533a\u57df\u4e2d\u7684\u5173\u952e\u8c03\u63a7\u5143\u4ef6</li> <li>\u7814\u7a76\u4fe1\u53f7\u901a\u8def\u5bf9\u7279\u5b9a\u57fa\u56e0\u8868\u8fbe\u7684\u5f71\u54cd</li> </ul> <p>\u4f7f\u7528HSV-TK\uff08\u5355\u7eaf\u75b1\u75b9\u75c5\u6bd2\u80f8\u82f7\u6fc0\u9176\uff09\u542f\u52a8\u5b50\u9a71\u52a8\u7684\u6d77\u80be\u8367\u5149\u7d20\u9176\u4f5c\u4e3a\u5185\u53c2\uff0c\u53ef\u4ee5\uff1a</p> <ol> <li>\u63d0\u4f9b\u5185\u90e8\u5bf9\u7167\uff0c\u6821\u6b63\u8f6c\u67d3\u6548\u7387\u5dee\u5f02</li> <li>\u6d88\u9664\u7ec6\u80de\u6570\u91cf\u3001\u7ec6\u80de\u6d3b\u529b\u7b49\u5b9e\u9a8c\u6761\u4ef6\u5dee\u5f02\u5e26\u6765\u7684\u8bef\u5dee</li> <li>\u589e\u5f3a\u5b9e\u9a8c\u7ed3\u679c\u7684\u53ef\u9760\u6027\u548c\u91cd\u590d\u6027</li> </ol> <p>\u8fd9\u4e2a\u53cc\u8367\u5149\u7d20\u9176\u7cfb\u7edf\u8ba9\u6211\u4eec\u80fd\u591f\u51c6\u786e\u5730\u6d4b\u91cf\u76ee\u6807\u8f6c\u5f55\u56e0\u5b50\u5bf9\u7279\u5b9a\u542f\u52a8\u5b50\u7684\u8c03\u63a7\u4f5c\u7528\uff0c\u4ece\u800c\u6df1\u5165\u4e86\u89e3\u57fa\u56e0\u8868\u8fbe\u8c03\u63a7\u7684\u5206\u5b50\u673a\u5236\u3002</p>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#pro-seq-s1w13liunan-pro-seq","title":"Pro-seq --==S1.W13.LiuNan Pro-seq==","text":"<ul> <li>Pro-seq\u662f\u5bf9\u4e8e\u4f20\u7edfRNA-seq\u7684\u6539\u8fdb\uff0c\u53ef\u4ee5\u5bcc\u96c6\u5e76\u4e14\u6d4b\u51fa\u521a\u521a\u88abRNA\u805a\u5408\u9176\u8f6c\u5f55\u51fa\u6765\u7684\u65b0RNA</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-s1w14wangqun-immunotherapy-development","title":"\u514d\u75ab\u7597\u6cd5\u5f00\u53d1 --==S1.W14.WangQun Immunotherapy development==","text":"<ul> <li>\u4e3b\u8981\u5173\u6ce8\u6dcb\u5df4\u7624\u7684\u514d\u75ab\u7597\u6cd5</li> <li>\u6d89\u53ca\u5230\u529f\u80fd\u57fa\u56e0\u7ec4\u7684\u9776\u70b9\u7b5b\u9009\uff0c\u4e34\u5e8a\u524d\u7684\u6a21\u578b\u5efa\u7acb\uff0cCAR-T\u7ec6\u80de\u5f00\u53d1\uff0c\u548c\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7814\u7a76\uff0c\u4ee5\u53ca\u6700\u540e\u7684\u4e34\u5e8a\u8bd5\u9a8c\u8bbe\u8ba1\u548c\u5206\u6790</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-s2-comprehensive-design-framework-for-computational-methods-in-biomedicine","title":"\u8ba1\u7b97\u751f\u7269\u5b66\u7814\u7a76\u8303\u5f0f --==S2 Comprehensive Design Framework for Computational Methods in Biomedicine","text":"<p>== - \u4ecb\u7ecd\u4f7f\u7528\u8ba1\u7b97\u6a21\u578b\u5982\u4f55\u8fd0\u7528\u5728\u751f\u7269\u5b66\u6570\u636e\u4e0a - \u5173\u4e8e\u5404\u4e2a\u6a21\u578b\u548c\u8ba1\u7b97\u65b9\u6cd5\u7684\u9009\u62e9\uff0c\u9002\u7528\u6027</p>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#transformer-based-s2w11seminar-dl-for-genomic-modeling","title":"Transformer-based \u6a21\u578b --==S2.W1.1.Seminar DL for genomic modeling ==","text":"<ul> <li>\u5177\u4f53\u7684\u6df1\u5ea6\u5b66\u4e60\u67b6\u6784\u5728mRNA translation\u548cRNA-binding </li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#histone-modificationchromatin-regulation-s2w32-structural-study-of-epigenetic-regulation-in-transcription","title":"Histone modification\u548cChromatin regulation --==S2.W3.2 Structural study of epigenetic regulation in transcription==","text":"<ul> <li>\u7ed3\u6784\u751f\u7269\u5b66\uff1a\u4e86\u89e3\u7ec4\u86cb\u767d\u4fee\u9970\u7684\u7ed3\u6784\u57fa\u7840\u53ca\u5176\u5728\u8f6c\u5f55\u8c03\u63a7\u4e2d\u7684\u4f5c\u7528\uff0c\u4e3a\u57fa\u7840\u8868\u89c2\u9057\u4f20\u673a\u5236\u7814\u7a76\u548c\u6f5c\u5728\u6cbb\u7597\u9776\u70b9\u5f00\u53d1\u63d0\u4f9b\u89c1\u89e3</li> <li>\u53ef\u4ee5\u4e86\u89e3\u548c\u75be\u75c5\u7684\u5173\u8054</li> <li>\u548c\u51b7\u51bb\u7535\u955c\u7b49\u5148\u8fdb\u6280\u672f\u6709\u5173</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-s2w22seminar-precision-medicine-with-computational-biology","title":"\u7cbe\u51c6\u533b\u7597\u548c\u8ba1\u7b97\u751f\u7269\u5b66 --==S2W2.2.Seminar Precision medicine with computational biology==","text":"<ul> <li>\u7814\u7a76cancer\u4e2d\u7684\u4f53\u7ec6\u80de\u7a81\u53d8</li> <li>\u9884\u6d4b\u591a\u79cd\u57fa\u56e0\u7ed3\u6784\u53d8\u5f02\uff0c\u5305\u62ecframeshift, non-synonymous, slice site</li> <li>\u9884\u6d4btissue-specific splicing alterations, \u548csingle nucleotide variants \u6709\u5173</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-s2w3-antibody-de-novo-design","title":"\u6297\u539f\u8ba1\u7b97\u8bbe\u8ba1 -- ==S2W3 Antibody de novo design","text":"<p>== - \u7b97\u6cd5\u8bbe\u8ba1\u6297\u539f\u7684\u6d41\u7a0b - \u5305\u542bwet lab\u9a8c\u8bc1\u5f00\u53d1</p>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-s2w4-survival-analysis","title":"\u751f\u5b58\u5206\u6790 --==S2W4 Survival Analysis","text":"<p>== - Kaplan-Meier curve - Log-rank test</p>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-s2w43-host-microbial-interactions-and-lipid-metabolism","title":"\u5fae\u751f\u7269\u7ec4\u5b66 --==S2W4.3 Host-microbial Interactions and Lipid Metabolism==","text":"<ul> <li>\u7ed9\u5c0f\u9f20\u7279\u5b9a\u83cc\u7fa4</li> <li>\u8bc4\u4f30\u4ee3\u8c22\u548c\u8868\u578b</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#-s2w5-adipose-tissue-in-cold-thermogenesis","title":"\u8102\u80aa\u7ec6\u80de\u548c\u6e29\u5ea6\u7684\u5173\u7cfb  --==S2W5 Adipose tissue in cold thermogenesis","text":"<p>== - \u901a\u8fc7\u5c0f\u9f20\u6a21\u578b\u548c\u51b7\u66b4\u9732\uff0c\u68c0\u67e5\u5bf9\u8102\u80aa\u7ec4\u7ec7\u7684\u5f71\u54cd\uff0c\u5e76\u4e14\u8fdb\u884c\u57fa\u56e0\u8868\u8fbe\u5206\u6790\uff0c\u86cb\u767d\u5206\u6790\u7b49</p>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#fluorescence-ubiquitin-cell-cycle-indicator-fucci-extra-fucci","title":"Fluorescence Ubiquitin Cell Cycle Indicator (FUCCI) -- ==EXTRA FUCCI==","text":"<p>FUCCI\u7cfb\u7edf\u662f\u4e00\u79cd\u5f3a\u5927\u7684\u7ec6\u80de\u5468\u671f\u53ef\u89c6\u5316\u5de5\u5177\uff1a 1. \u57fa\u672c\u539f\u7406\uff1a\u5229\u7528\u4e24\u79cd\u4e0e\u7ec6\u80de\u5468\u671f\u86cb\u767d\u878d\u5408\u7684\u8367\u5149\u86cb\u767d    - mVenus-hGem(1/110)\uff1a\u9ec4\u7eff\u8272\u8367\u5149\uff0c\u5728S/G2/M\u671f\u8868\u8fbe    - mCherry-hCdt1(30/120)\uff1a\u7ea2\u8272\u8367\u5149\uff0c\u5728G1\u671f\u8868\u8fbe 1. \u7ec6\u80de\u5468\u671f\u5224\u65ad\uff1a    - \u7ea2\u8272\u7ec6\u80de\uff1aG1\u671f    - \u7eff\u8272\u7ec6\u80de\uff1aS/G2/M\u671f    - \u7ea2\u7eff\u53cc\u8272\u7ec6\u80de\uff1a\u5904\u4e8e\u8fc7\u6e21\u671f</p> <ol> <li>EdU\u68c0\u6d4b\u6cd5\uff1a</li> <li>EdU\u662f\u80f8\u82f7\u7c7b\u4f3c\u7269\uff0c\u80fd\u5728DNA\u5408\u6210\u65f6(S\u671f)\u63ba\u5165DNA</li> <li>\u901a\u8fc7\u70b9\u51fb\u5316\u5b66\u53cd\u5e94\u53ef\u88ab\u8367\u5149\u6807\u8bb0\u7269\u68c0\u6d4b</li> <li>\u4f18\u52bf\uff1a\u65e0\u9700DNA\u53d8\u6027\uff0c\u4fdd\u7559\u7ec6\u80de\u7ed3\u6784\u5b8c\u6574\u6027</li> <li>\u53ef\u4e0eFUCCI\u7cfb\u7edf\u7ed3\u5408\u4f7f\u7528\uff0c\u63d0\u4f9b\u66f4\u7cbe\u786e\u7684S\u671f\u68c0\u6d4b</li> </ol> <p>\u8fd9\u4e24\u79cd\u6280\u672f\u7ed3\u5408\u4f7f\u7528\u53ef\u4ee5\u5b9e\u65f6\u76d1\u6d4b\u7ec6\u80de\u5468\u671f\u8fdb\u7a0b\u3001\u8861\u91cf\u7ec6\u80de\u589e\u6b96\u6d3b\u6027\uff0c\u5e76\u7814\u7a76\u7ec6\u80de\u5468\u671f\u8c03\u63a7\u56e0\u5b50\u7684\u4f5c\u7528\uff0c\u5728\u80bf\u7624\u7814\u7a76\u3001\u836f\u7269\u7b5b\u9009\u548c\u53d1\u80b2\u751f\u7269\u5b66\u7b49\u9886\u57df\u5177\u6709\u5e7f\u6cdb\u5e94\u7528\u3002</p>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#dreadd-extra-dreadd-neuronal-method","title":"DREADD \u7cfb\u7edf -- ==EXTRA DREADD, neuronal method==","text":"<ul> <li>DREADD\u662f\u4e00\u79cd\u86cb\u767d\u8d28\uff0c\u53ef\u4ee5\u7528\u6765\u8c03\u63a7\u52a8\u7269\u6a21\u578b\u7684\u795e\u7ecf\u6d3b\u52a8</li> <li>\u4e3b\u8981\u901a\u8fc7\u548cG-protein receptor \u53cd\u5e94</li> </ul>"},{"location":"IBMS3/Yiru/detailed/%E4%B8%80%E5%AE%9E%E9%AA%8C%E6%96%B9%E6%B3%95%E9%80%9F%E6%9F%A5/#eqtl-extra-eqtl","title":"eQTL -- ==EXTRA eQTL==","text":"<ul> <li>GWAS\u5206\u6790\u4e2d\uff0c\u5927\u90e8\u5206\u663e\u8457\u7684SNP\u4f4d\u70b9\u90fd\u4f4d\u4e8e\u975e\u7f16\u7801\u533a\uff0c\u800ceQTL\u53ef\u4ee5\u5c06SNP\u4f4d\u70b9\u548c\u57fa\u56e0\u7f16\u7801\uff08\u57fa\u56e0\u8868\u8fbe\u4f4d\u70b9\uff09\u8054\u7cfb\u8d77\u6765\uff0c\u53ef\u4ee5\u8fdb\u4e00\u6b65\u7b5b\u9009\u57fa\u56e0</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/","title":"IBMS3 / detailed / experiments_case","text":"<p>Files in <code>experiments_case</code>:</p> <ul> <li>MBE Chromosome structure detection.md</li> <li>MBE CRISPR screen disease gene factor.md</li> <li>MBE CRISPR_screen_drug_resistence.md</li> <li>MBE DNA assessment.md</li> <li>MBE Epigenetic sequencing.md</li> <li>MBE Epigenome Engineering Discussion.md</li> <li>MBE Gene editing.md</li> <li>MBE Gene expression analysis technologies.md</li> <li>MBE mRNA visualization and analysis technologies.md</li> <li>MBE Protein assessment.md</li> <li>MBE Protein-DNA interaction.md</li> <li>MBE RNA assessment.md</li> <li>MBE RNA editing-based RNA-seq.md</li> <li>MBE RNA-seq.md</li> <li>S1 Antisense oligonucleotides.md</li> <li>S1.W10.ChenDi Aging research in C elegans.md</li> <li>S1.W12.LiangGong Long read sequencing, Genomic Structural Variation.md</li> <li>S1.W13.LiuNan Dual-Luciferase reporter assay.md</li> <li>S1.W13.LiuNan GWAS.md</li> <li>S1.W13.LiuNan Hemoglobin Switching.md</li> <li>S1.W13.LiuNan Pro-seq.md</li> <li>S1.W14.WangQun Immunotherapy development.md</li> <li>S1.W3.tu.  Flow Cytometry for immunology.md</li> <li>S1.W3.tu. Flow cytometry in Biomedical.md</li> <li>S1.W5.tu WB and ELISA.md</li> <li>S1.W8.Laura Gene modified mouse.md</li> <li>S2 Comprehensive Design Framework for Computational Methods in Biomedicine.md</li> <li>S2.W1.1.Seminar DL for genomic modeling.md</li> <li>S2.W3.2 Structural study of epigenetic regulation in transcription.md</li> <li>S2.W5 GFP reporter model.md</li> <li>S2W2.2.Seminar Precision medicine with computational biology.md</li> <li>S2W3 Antibody de novo design.md</li> <li>S2W4 Survival Analysis.md</li> <li>S2W4.3 Host-microbial Interactions and Lipid Metabolism.md</li> <li>S2W5 Adipose tissue in cold thermogenesis.md</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20DREADD%2C%20neuronal%20method/","title":"EXTRA DREADD, neuronal method","text":"<p>Revised Experimental Design: DREADD-Based Investigation of Microglial Regulation of Sleep</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20DREADD%2C%20neuronal%20method/#1-experimental-purpose-and-rationale","title":"1. Experimental Purpose and Rationale","text":"<p>This study investigates the causal role of microglial Gi signaling in sleep regulation, addressing a fundamental question in neuroimmunology: How do brain immune cells influence sleep architecture? We hypothesize that selective activation of inhibitory Gi pathways in microglia modulates non-rapid eye movement (NREM) sleep duration.</p> <p>The experimental approach uses two complementary strategies: - Chemogenetic activation of Gi signaling via DREADD technology - Pharmacological modulation of endogenous P2Y12 receptors (a native Gi-coupled receptor on microglia)</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20DREADD%2C%20neuronal%20method/#2-model-system","title":"2. Model System","text":"<p>We utilize adult mice (12-16 weeks old, mixed sex: 5M/3F) for several advantages: - Genetic tractability allowing cell-type specific DREADD expression - Well-characterized sleep architecture similar to humans - Established protocols for EEG/EMG sleep monitoring</p> <p>Transgenic CX3CR1-CreERT2 mice are crossed with hM4Di-floxed mice to achieve microglia-specific expression of the inhibitory DREADD receptor. Expression is validated using immunohistochemistry and confocal microscopy.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20DREADD%2C%20neuronal%20method/#3-experimental-design-and-methods","title":"3. Experimental Design and Methods","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20DREADD%2C%20neuronal%20method/#phase-1-chemogenetic-modulation-of-microglial-gi-signaling","title":"Phase 1: Chemogenetic Modulation of Microglial Gi Signaling","text":"<ul> <li>Groups: hM4Di-expressing mice vs. CreERT2-negative littermate controls (n=8/group)</li> <li>Treatments: CNO (5mg/kg, i.p.) vs. saline vehicle</li> <li>Design: Within-subject crossover design with 72h washout between treatments</li> <li>Timing: Drug administration at ZT6 (6 hours after lights on) during the mouse rest phase</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20DREADD%2C%20neuronal%20method/#phase-2-pharmacological-modulation-of-endogenous-p2y12-receptors","title":"Phase 2: Pharmacological Modulation of Endogenous P2Y12 Receptors","text":"<ul> <li>Groups: Wild-type mice (n=8/group)</li> <li>Treatments: P2Y12 agonist (2MeSADP), P2Y12 antagonist (PSB0739), or ACSF vehicle</li> <li>Administration: Intracerebroventricular injection via pre-implanted cannula</li> <li>Design: Between-subject design with counterbalanced treatment order</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20DREADD%2C%20neuronal%20method/#measurements","title":"Measurements","text":"<ul> <li>Primary outcome: EEG/EMG-based sleep architecture (24h continuous recording)</li> <li>NREM sleep duration and fragmentation</li> <li>REM sleep duration</li> <li>Wake time and transitions</li> <li>Secondary outcomes: </li> <li>Spectral power analysis of NREM delta waves (0.5-4Hz)</li> <li>Microglial morphology via post-mortem immunohistochemistry</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20DREADD%2C%20neuronal%20method/#4-controls-and-potential-confounds","title":"4. Controls and Potential Confounds","text":"<ul> <li>Genetic controls: CreERT2-negative littermates to control for genetic background</li> <li>Treatment controls: Vehicle injections (saline or ACSF)</li> <li>Circadian controls: Standardized timing of interventions (ZT6-ZT9)</li> <li>Sex as biological variable: Balanced male/female ratio with sex as a factor in analysis</li> <li>Off-target effects: CNO dose optimization to minimize conversion to clozapine</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20DREADD%2C%20neuronal%20method/#5-data-analysis","title":"5. Data Analysis","text":"<ul> <li>Sleep staging: Automated scoring with manual verification by blinded observers</li> <li>Statistical approach: Two-way repeated measures ANOVA (genotype \u00d7 treatment)</li> <li>Multiple comparisons: Bonferroni correction to maintain family-wise error rate</li> <li>Power analysis: n=8/group provides 85% power to detect 20% change in NREM sleep duration (\u03b1=0.05)</li> <li>Data visualization: Combined bar plots (group means \u00b1 SEM) with overlaid individual data points</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20DREADD%2C%20neuronal%20method/#6-expected-outcomes-and-significance","title":"6. Expected Outcomes and Significance","text":"<p>We anticipate that microglial Gi activation will increase NREM sleep duration and consolidation. This would establish a novel causal link between microglial signaling state and sleep regulation, potentially revealing new therapeutic targets for sleep disorders.</p> <p>The complementary approach using both DREADD technology and pharmacological manipulation of endogenous receptors strengthens the validity of our findings by demonstrating convergent evidence for the role of microglial Gi signaling in sleep regulation.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20FUCCI/","title":"EXTRA FUCCI","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20FUCCI/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How does treatment X affect cell cycle progression dynamics in real-time at the single-cell level?</li> <li>Design Rationale: FUCCI system allows visualization of G1 (red) and S/G2/M (green) phases while EdU pulse-labeling specifically identifies S-phase cells, enabling comprehensive analysis of cell cycle perturbations</li> <li>Follow-up Studies: Combine with drug treatments, genetic manipulations, or microenvironmental changes to investigate mechanisms regulating cell cycle progression in normal versus disease states</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20FUCCI/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cell lines stably expressing FUCCI reporters (e.g., RPE-1, U2OS, or cancer cell lines relevant to research question)</li> <li>Rationale: Immortalized cell lines provide consistent expression of FUCCI reporters and controlled experimental conditions for high-resolution imaging</li> <li>Alternatives:</li> <li>Primary cells with FUCCI (pros: physiological relevance; cons: transfection difficulties, limited lifespan)</li> <li>FUCCI transgenic mice (pros: in vivo context; cons: complex, expensive, limited imaging depth)</li> <li>Organoids with FUCCI (pros: 3D tissue architecture; cons: imaging challenges, variable reporter expression)</li> <li>Ethical Considerations: Cell line authentication, proper biosafety practices, responsible resource usage for long-term imaging experiments</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20FUCCI/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques:</li> <li>Live-cell time-lapse confocal microscopy (quantitative)</li> <li>EdU click chemistry detection (quantitative)</li> <li>Automated image analysis for cell tracking and fluorescence quantification</li> <li>Technical Replicates: Multiple fields of view per condition (minimum 5-10)</li> <li>Potential Biases:</li> <li>Phototoxicity (minimize laser power and acquisition frequency)</li> <li>FUCCI reporter expression variability (use clonal cell lines)</li> <li>Cell density effects on proliferation (standardize seeding density)</li> <li>EdU toxicity (optimize concentration for minimal impact on cell cycle)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20FUCCI/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Control: Untreated FUCCI-expressing cells with EdU pulse</li> <li>Experimental: Treatment X at various concentrations/timepoints with EdU pulse</li> <li>Positive control: Cell cycle inhibitor with known mechanism (e.g., CDK4/6 inhibitor for G1 arrest)</li> <li>Technical control: Non-FUCCI expressing cells for autofluorescence baseline</li> <li>Controlled Variables: Temperature, CO2, humidity, media composition, imaging parameters</li> <li>Biological Replicates: Minimum 3 independent experiments on different days</li> <li>Modified Design: Include synchronization (e.g., double thymidine block) to start from uniform cell cycle phase, then release into treatment conditions</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20FUCCI/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: </li> <li>Single-cell tracking across time points</li> <li>Fluorescence intensity quantification for red/green FUCCI signals and EdU</li> <li>Cell cycle phase duration calculations</li> <li>Cell lineage mapping for mother-daughter relationships</li> <li>Statistical Analysis:</li> <li>Distribution analysis of cell cycle phase durations</li> <li>Comparison of means using appropriate tests (t-test or ANOVA)</li> <li>Correlation analysis between cell cycle parameters</li> <li>Survival analysis for time-to-division data</li> <li>Data Presentation:</li> <li>Representative time-lapse image sequences</li> <li>Cell cycle phase distribution pie charts</li> <li>Cumulative frequency plots of phase durations</li> <li>Cell lineage trees with color-coded cell cycle phases</li> <li>Scatter plots of individual cell measurements with population means</li> <li>Validation Methods:</li> <li>Flow cytometry for population-level cell cycle analysis</li> <li>Immunostaining for endogenous cell cycle markers (e.g., Ki67, PCNA)</li> <li>BrdU incorporation as alternative S-phase marker</li> <li>Cell synchronization release experiments to confirm phase transitions</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20Fluorescence%20Polarization/","title":"EXTRA Fluorescence Polarization","text":"<p>\u8fd9\u4e2a\u6280\u672f\u5e38\u7528\u4e8e\uff1a - \u6d4b\u5b9a\u86cb\u767d\u8d28\u548c\u914d\u4f53\u7684\u7ed3\u5408\u4eb2\u548c\u529b - \u7b5b\u9009\u80fd\u591f\u4e0e\u7279\u5b9a\u86cb\u767d\u8d28\u7ed3\u5408\u7684\u5c0f\u5206\u5b50 - \u7814\u7a76\u86cb\u767d\u8d28-DNA\uff0c\u86cb\u767d\u8d28-\u86cb\u767d\u8d28\u7b49\u5206\u5b50\u95f4\u76f8\u4e92\u4f5c\u7528 \u968f\u7740\u52a0\u5165\u7684\u86cb\u767d\u8d28\u6d53\u5ea6\u589e\u52a0\uff0c\u8d8a\u6765\u8d8a\u591a\u7684\u8367\u5149\u6807\u8bb0\u5206\u5b50\u88ab\u7ed3\u5408\uff0c\u6574\u4f53\u8367\u5149\u504f\u632f\u503c\u4e0a\u5347\uff0c\u76f4\u5230\u8fbe\u5230\u9971\u548c\uff08\u6240\u6709\u8367\u5149\u5206\u5b50\u90fd\u88ab\u7ed3\u5408\uff09\u3002 fluorescence polarization (FP)  1. Fluorescently Labeled Ligand: A small ligand (such as a DNA sequence) is labeled with a fluorescent dye. Due to its small size, the labeled ligand will rotate quickly in solution, causing depolarization of light. This means that the light emitted after the ligand absorbs polarized light will not be polarized, resulting in low fluorescence polarization (FP). 2. Polarized Light: Polarized light is light waves that vibrate in one plane. When polarized light is used to excite the fluorescent dye, it will emit light in a similar polarization if the dye (and therefore the ligand) is not rotating or rotating slowly. 3. Binding Event: When a protein (in this example, ZnF456) binds to the ligand, it forms a larger complex. This larger complex rotates more slowly than the ligand alone. Slow rotation maintains the polarization of the emitted light, resulting in a higher FP measurement. 4. Increasing Protein Concentration: By adding increasing amounts of the protein to the fluorescently labeled ligand, the experiment can measure how much of the ligand is bound by the protein based on the increase in FP. The greater the protein concentration, the more ligand is bound, until a saturation point is reached where all the ligand is bound, and further increases in protein concentration do not increase FP. 5. Plotting FP Against Protein Concentration: The graph (labeled D in your image) plots the FP value against the concentration of protein. As the concentration of protein increases, the FP increases until it plateaus, indicating that all the ligand is bound. The half-maximal binding affinity (Kd) can be estimated from the point at which the FP is half of its maximum value. According to the annotation on the image, ZnF456 binds to the DNA sequence TGACC with a Kd of 20-30 nM, which indicates a relatively high binding affinity. The graph shows three curves: one for ZnF456 motif (the specific DNA sequence it binds to), one for a different DNA sequence (23 motif), and one for a scrambled sequence. The strong increase in FP for the ZnF456 motif indicates that the protein has a high affinity for this specific DNA sequence. The other sequences show lower FP increases, indicating less binding. The EDTA control is likely used to chelate metal ions and thereby inhibit the binding activity of the protein, as zinc fingers often require zinc ions to maintain their structure and binding activity.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20eQTL/","title":"eQTL\u5206\u6790\u53ca\u5176\u4e0eGWAS\u8054\u5408\u5206\u6790","text":"<p>eQTL(\u8868\u8fbe\u6570\u91cf\u6027\u72b6\u4f4d\u70b9)\u5206\u6790\u662f\u7814\u7a76\u9057\u4f20\u53d8\u5f02\u5982\u4f55\u5f71\u54cd\u57fa\u56e0\u8868\u8fbe\u7684\u65b9\u6cd5\u3002\u5c06eQTL\u4e0eGWAS\u8054\u5408\u5206\u6790\u53ef\u4ee5\u5e2e\u52a9\u89e3\u91ca\u75be\u75c5\u76f8\u5173\u53d8\u5f02\u7684\u529f\u80fd\u673a\u5236\u3002</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20eQTL/#eqtl","title":"eQTL\u5206\u6790\u57fa\u672c\u6b65\u9aa4","text":"<ol> <li>\u6570\u636e\u6536\u96c6</li> <li>\u57fa\u56e0\u578b\u6570\u636e\uff1aSNP\u82af\u7247\u6216\u6d4b\u5e8f\u6570\u636e</li> <li>\u57fa\u56e0\u8868\u8fbe\u6570\u636e\uff1aRNA-seq\u6216\u82af\u7247\u6570\u636e</li> <li> <p>\u6837\u672c\u4fe1\u606f\uff1a\u4eba\u53e3\u5b66\u7279\u5f81\u3001\u6279\u6b21\u7b49\u534f\u53d8\u91cf</p> </li> <li> <p>\u6570\u636e\u9884\u5904\u7406</p> </li> <li>\u57fa\u56e0\u578b\u6570\u636e\uff1a\u8d28\u63a7\u3001\u7f3a\u5931\u503c\u586b\u5145\u3001\u8fde\u9501\u4e0d\u5e73\u8861\u8ba1\u7b97</li> <li>\u8868\u8fbe\u6570\u636e\uff1a\u6807\u51c6\u5316\u3001\u6279\u6b21\u6548\u5e94\u6821\u6b63\u3001\u79bb\u7fa4\u503c\u5904\u7406</li> <li> <p>\u8f6c\u5f55\u672c\u5b9a\u91cf\uff1a\u5982\u4f7f\u7528Salmon\u3001RSEM\u7b49\u5de5\u5177</p> </li> <li> <p>eQTL\u6620\u5c04</p> </li> <li>\u8fd1\u7aefeQTL(cis-eQTL)\uff1a\u53d8\u5f02\u4f4d\u70b9\u9760\u8fd1\u76ee\u6807\u57fa\u56e0(\u901a\u5e38\u00b11Mb)</li> <li>\u8fdc\u7aefeQTL(trans-eQTL)\uff1a\u53d8\u5f02\u4f4d\u70b9\u8fdc\u79bb\u76ee\u6807\u57fa\u56e0\u6216\u5728\u4e0d\u540c\u67d3\u8272\u4f53\u4e0a</li> <li> <p>\u4f7f\u7528\u7ebf\u6027\u56de\u5f52\u6216\u6df7\u5408\u6a21\u578b\u68c0\u6d4bSNP\u4e0e\u57fa\u56e0\u8868\u8fbe\u7684\u5173\u8054</p> </li> <li> <p>\u591a\u91cd\u68c0\u9a8c\u6821\u6b63</p> </li> <li>FDR\u63a7\u5236</li> <li>\u7f6e\u6362\u6d4b\u8bd5</li> <li> <p>\u8003\u8651\u591a\u7ec4\u7ec7\u3001\u591a\u6761\u4ef6\u5206\u6790\u7684\u6821\u6b63</p> </li> <li> <p>\u5e38\u7528\u8f6f\u4ef6</p> </li> <li>MatrixEQTL\uff1a\u5feb\u901feQTL\u5206\u6790\u5de5\u5177</li> <li>FastQTL\uff1a\u9488\u5bf9\u5927\u6570\u636e\u96c6\u4f18\u5316</li> <li>QTLtools\uff1a\u7efc\u5408\u5de5\u5177\u5305</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20eQTL/#gwaseqtl","title":"GWAS\u4e0eeQTL\u8054\u5408\u5206\u6790","text":"<ol> <li>\u5171\u5b9a\u4f4d\u5206\u6790(Colocalization)</li> <li>\u68c0\u6d4bGWAS\u4fe1\u53f7\u4e0eeQTL\u4fe1\u53f7\u662f\u5426\u5171\u4eab\u76f8\u540c\u7684\u56e0\u679c\u53d8\u5f02</li> <li> <p>\u5de5\u5177\uff1acoloc\u3001HEIDI\u3001eCAVIAR\u3001FINEMAP</p> </li> <li> <p>\u8f6c\u5f55\u7ec4\u5e7f\u6cdb\u5173\u8054\u7814\u7a76(TWAS)</p> </li> <li>\u5229\u7528eQTL\u9884\u6d4b\u57fa\u56e0\u8868\u8fbe\uff0c\u7136\u540e\u4e0e\u8868\u578b\u5173\u8054</li> <li> <p>\u5de5\u5177\uff1aPrediXcan\u3001FUSION\u3001S-PrediXcan</p> </li> <li> <p>Mendelian Randomization(MR)</p> </li> <li>\u4f7f\u7528eQTL\u4f5c\u4e3a\u5de5\u5177\u53d8\u91cf\u8bc4\u4f30\u57fa\u56e0\u8868\u8fbe\u4e0e\u75be\u75c5\u7684\u56e0\u679c\u5173\u7cfb</li> <li> <p>\u5de5\u5177\uff1aMR-Base\u3001TwoSampleMR</p> </li> <li> <p>\u529f\u80fd\u6ce8\u91ca\u548c\u5bcc\u96c6\u5206\u6790</p> </li> <li>\u6574\u5408ENCODE\u3001Roadmap\u7b49\u529f\u80fd\u7ec4\u5b66\u6570\u636e</li> <li> <p>\u4f7f\u7528FUMA\u3001GARFIELD\u7b49\u5de5\u5177\u8fdb\u884c\u5bcc\u96c6\u5206\u6790</p> </li> <li> <p>\u591a\u7ec4\u7ec7\u6574\u5408\u5206\u6790</p> </li> <li>\u4f7f\u7528GTEx\u7b49\u591a\u7ec4\u7ec7eQTL\u6570\u636e</li> <li>\u8bc6\u522b\u7ec4\u7ec7\u7279\u5f02\u6027\u6216\u5171\u4eab\u7684\u8c03\u63a7\u673a\u5236</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20eQTL/#_1","title":"\u5b9e\u9645\u5e94\u7528\u6848\u4f8b","text":"<ol> <li>\u80ba\u529f\u80fdGWAS\u4e0e\u80ba\u7ec4\u7ec7eQTL\u8054\u5408\u5206\u6790</li> <li>\u8bc6\u522bGWAS\u4fe1\u53f7\u5171\u5b9a\u4f4d\u7684\u57fa\u56e0</li> <li> <p>\u53d1\u73b0\u6f5c\u5728\u7684\u81f4\u75c5\u57fa\u56e0\u548c\u8c03\u63a7\u673a\u5236</p> </li> <li> <p>\u7cbe\u795e\u75be\u75c5GWAS\u4e0e\u8111\u7ec4\u7ec7eQTL\u6574\u5408</p> </li> <li>\u8bc6\u522b\u7279\u5b9a\u8111\u533a\u7684\u8c03\u63a7\u53d8\u5f02</li> <li>\u63ed\u793a\u795e\u7ecf\u7cbe\u795e\u75be\u75c5\u7684\u5206\u5b50\u673a\u5236</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20eQTL/#_2","title":"\u5206\u6790\u6ce8\u610f\u4e8b\u9879","text":"<ol> <li>\u8003\u8651\u7ec4\u7ec7\u7279\u5f02\u6027\u548c\u7ec6\u80de\u7c7b\u578b\u7279\u5f02\u6027</li> <li>\u6574\u5408\u8868\u89c2\u9057\u4f20\u5b66\u6570\u636e\u589e\u5f3a\u89e3\u91ca\u529b</li> <li>\u8003\u8651\u6837\u672c\u91cf\u548c\u7edf\u8ba1\u529f\u6548</li> <li>\u9a8c\u8bc1\u5173\u952e\u53d1\u73b0(\u5982\u4f53\u5916\u529f\u80fd\u5b9e\u9a8c)</li> </ol> <p>\u901a\u8fc7eQTL\u548cGWAS\u7684\u8054\u5408\u5206\u6790\uff0c\u53ef\u4ee5\u5c06\u7edf\u8ba1\u5173\u8054\u8f6c\u5316\u4e3a\u751f\u7269\u5b66\u673a\u5236\uff0c\u4e3a\u75be\u75c5\u7684\u7406\u89e3\u548c\u5e72\u9884\u63d0\u4f9b\u66f4\u7cbe\u786e\u7684\u5206\u5b50\u9776\u70b9\u3002</p> <p>Designing an eQTL Study to Identify Genetic Regulators of Brain Gene Expression in Neurodegenerative Disease</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20eQTL/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<p>Scientific Question: How do genetic variants influence gene expression in different brain regions affected by neurodegenerative disease, and do disease-associated variants act through region-specific gene regulation?</p> <p>This experiment directly tests this question by correlating genome-wide genotypes with transcriptome-wide gene expression across multiple brain regions from the same individuals, comparing patterns between patients with neurodegenerative disease and neurologically normal controls.</p> <p>Purpose of Design: While previous eQTL studies have examined brain tissue, most have focused on single brain regions or used bulk tissue. This design advances the field by analyzing multiple disease-relevant brain regions from the same individuals, enabling the detection of region-specific eQTLs and their potential role in selective vulnerability to neurodegeneration.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20eQTL/#2-model-system","title":"2. Model System","text":"<p>Model System: Post-mortem human brain tissue from individuals with neurodegenerative disease (Alzheimer's and Parkinson's) and neurologically normal controls, focusing on five key regions: prefrontal cortex, hippocampus, substantia nigra, cerebellum, and putamen.</p> <p>Appropriateness: Human brain tissue is essential for this study as gene regulation is highly tissue-specific and species-specific. Brain region-specific eQTLs cannot be accurately modeled in other systems, and the disease context is critical for identifying dysregulated expression patterns.</p> <p>Alternative Models: - Induced pluripotent stem cell (iPSC)-derived neurons: Allow for experimental manipulation but lack brain region context and mature neural networks - Organoids: Provide 3D tissue architecture but remain simplified models with variable reproducibility - Animal models: Enable controlled genetic manipulation but have different regulatory landscapes than humans - Blood eQTLs: More accessible but poorly reflect brain-specific regulation</p> <p>Ethical Considerations:  - Respectful handling of post-mortem tissue and informed consent from donors or next-of-kin - Appropriate brain bank protocols and ethical approvals - Consideration of donor wishes regarding data sharing and future research - Responsible return of research results to scientific community and donor families</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20eQTL/#3-measurement-approach","title":"3. Measurement Approach","text":"<p>Techniques: - Whole genome sequencing (30x coverage) for comprehensive genotyping - RNA-sequencing (paired-end, 100M reads/sample) for gene expression quantification - Single-nucleus RNA-sequencing on subset of samples for cell-type specific eQTLs - ATAC-seq to assess chromatin accessibility in the same regions - DNA methylation profiling using EPIC arrays</p> <p>Choice Rationale: This multi-omic approach allows correlation between genetic variation, gene expression, and epigenetic regulation. WGS captures all potential regulatory variants, while deep RNA-seq enables detection of alternative splicing QTLs in addition to expression QTLs.</p> <p>Technical Replicates:  - 10% of samples processed in duplicate for RNA-seq quality control - Technical standards included in each sequencing batch - Randomization of disease and control samples across processing batches</p> <p>Potential Biases and Mitigation: - Post-mortem interval effects: Record PMI and include as covariate; exclude samples with PMI &gt;24 hours - RNA degradation: Measure RIN scores and exclude samples with RIN &lt;6 - Batch effects: Implement batch correction algorithms; use technical controls - Cell-type composition: Estimate cell-type proportions using deconvolution methods and include as covariates - Medication effects: Record treatment history and analyze as potential confounder</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20eQTL/#4-group-setting","title":"4. Group Setting","text":"<p>Experimental Groups: - 150 Alzheimer's disease cases - 150 Parkinson's disease cases - 200 neurologically normal controls - All groups with 5 brain regions per individual (total ~2,500 samples)</p> <p>Controlled Variables: - Age at death (matched within 5-year ranges) - Sex (balanced distribution) - Post-mortem interval (&lt;24 hours) - Ancestry (principal components included in analysis) - Brain pH (measured and included as covariate) - Agonal state (recorded and included as covariate)</p> <p>Negative Controls: - Cerebellum as minimally affected region in Alzheimer's disease - Prefrontal cortex as less affected region in Parkinson's disease - Permutation-based null distributions for statistical testing</p> <p>Biological Replicates:  With 150-200 individuals per group across 5 brain regions, the study is powered to detect eQTLs explaining &gt;5% of expression variance at FDR&lt;0.05. This sample size enables identification of both common and moderately rare variant effects on gene expression.</p> <p>Modified Design Suggestion: Include longitudinal samples from brain banks with multiple tissue collections at different disease stages to capture dynamic changes in eQTL effects during disease progression.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/EXTRA%20eQTL/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<p>Data Processing: - RNA-seq alignment using STAR, quantification with Salmon - Quality control: removal of low-quality samples (low mapping rate, high duplication) - Normalization for library size and composition using TMM method - Adjustment for technical covariates (RIN, batch, PMI) - Variant calling from WGS using GATK pipeline</p> <p>Statistical Tests: - Linear regression models testing associations between genotypes and normalized expression values - Adjustment for age, sex, ancestry PCs, and estimated cell-type proportions - Multiple testing correction using Benjamini-Hochberg FDR - Significance threshold: FDR &lt; 0.05 - Bayesian colocalization analysis to identify shared causal variants between eQTLs and GWAS signals - Differential eQTL analysis comparing disease vs. control</p> <p>Data Presentation: - Circular plots showing genome-wide distribution of significant eQTLs - Heat maps displaying region-specificity of eQTL effects - Box plots showing genotype-expression relationships for top eQTLs - Network visualizations of eQTL-gene interactions in disease-relevant pathways - Venn diagrams comparing eQTLs across brain regions</p> <p>Result Confirmation: - Replication in independent brain tissue datasets - Cross-validation within dataset using leave-one-out approaches - Validation of top eQTLs using qPCR in subset of samples - Functional validation of selected eQTLs using CRISPR editing in neural cell models - Integration with existing eQTL databases (GTEx, CommonMind, AMP-AD)</p> <p>This design enables comprehensive mapping of the genetic architecture of gene expression in the human brain, with special emphasis on regions affected by neurodegenerative disease, potentially revealing mechanisms by which disease-associated variants exert their effects through altered gene regulation.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR%20screen%20disease%20gene%20factor/","title":"MBE CRISPR screen disease gene factor","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR%20screen%20disease%20gene%20factor/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Which human genes are essential for virus X infection and replication?</li> <li>Design Rationale: Genome-wide CRISPR screen enables identification of host dependency factors required for viral entry, replication, assembly, or release</li> <li>Follow-up Studies: Investigate mechanism of top hits, develop small molecule inhibitors targeting key host factors, test for broad-spectrum activity against related viruses</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR%20screen%20disease%20gene%20factor/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cell line susceptible to virus X infection (e.g., Huh7 cells for hepatitis C virus)</li> <li>Rationale: Permissive cell lines that support complete viral lifecycle while maintaining high Cas9 editing efficiency provide ideal platform for identifying host factors</li> <li>Alternatives:</li> <li>Primary human cells (pros: physiological relevance; cons: difficult to scale, variable editing)</li> <li>Immortalized cells from target organs (pros: tissue-specific factors; cons: may have altered cellular pathways)</li> <li>Reporter virus systems (pros: biosafety, high-throughput; cons: may miss late-stage factors)</li> <li>Ethical Considerations: Biosafety protocols for viral work, cell line authentication, appropriate containment levels</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR%20screen%20disease%20gene%20factor/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques:</li> <li>Lentiviral delivery of genome-wide sgRNA library to Cas9-expressing cells</li> <li>Viral challenge with optimized MOI</li> <li>Cell survival/death assay or FACS-based sorting of infected vs. uninfected cells</li> <li>Next-generation sequencing of sgRNA abundance pre/post-selection</li> <li>Technical Replicates: Duplicate NGS library preparations, multiple infection timepoints</li> <li>Potential Biases:</li> <li>Viral stock variations (standardize preparation, titration)</li> <li>Infection efficiency differences (optimize viral MOI)</li> <li>Cell death from Cas9 toxicity (include essential gene controls)</li> <li>Off-target effects (use libraries with minimal predicted off-targets)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR%20screen%20disease%20gene%20factor/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: sgRNA library-transduced cells infected with virus X</li> <li>Control 1: Uninfected sgRNA library cells (baseline sgRNA distribution)</li> <li>Control 2: Non-targeting sgRNA library with viral infection</li> <li>Control 3: Time-matched uninfected cells for growth-related effects</li> <li>Controlled Variables: Cell density, viral dose, infection duration, sgRNA library coverage</li> <li>Biological Replicates: 3-4 independent library transductions and viral challenges</li> <li>Modified Design: Include CRISPR screens with multiple viral strains to identify strain-specific vs. conserved host factors</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR%20screen%20disease%20gene%20factor/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: </li> <li>sgRNA read counting from sequencing data</li> <li>Normalization to library depth</li> <li>Enrichment/depletion calculation relative to uninfected controls</li> <li>Gene-level significance using MAGeCK or similar algorithms</li> <li>Statistical Analysis:</li> <li>False discovery rate control for multiple testing</li> <li>Comparison with published essential gene datasets</li> <li>Pathway and network analysis of hits</li> <li>Comparison with known viral interactors from proteomics data</li> <li>Data Presentation:</li> <li>Manhattan plots of gene significance across the genome</li> <li>Cellular pathway maps highlighting hit clusters</li> <li>Validation data for top hits showing infection rates with individual knockouts</li> <li>Comparison with previous genetic screens or interactome studies</li> <li>Validation Methods:</li> <li>Individual gene knockout confirmation</li> <li>Viral replication assays with knockout cell lines</li> <li>Rescue experiments with cDNA expression</li> <li>Protein-protein interaction studies with viral components</li> <li>Small molecule inhibition of identified pathways</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR_screen_drug_resistence/","title":"Experimental Design: Genome-Wide CRISPR Screen for Drug Resistance Mechanisms","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR_screen_drug_resistence/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Which genes, when knocked out, confer resistance to drug X in cancer cell line Y?</li> <li>Design Rationale: Genome-wide CRISPR-Cas9 knockout screen allows unbiased identification of genes whose loss enables cell survival under drug selection pressure</li> <li>Follow-up Studies: Validate top hits with individual knockouts, investigate mechanism of resistance for key genes, test combinations of drug X with inhibitors targeting resistance pathways</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR_screen_drug_resistence/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cancer cell line relevant to drug X's therapeutic application (e.g., A375 melanoma cells for BRAF inhibitor screen)</li> <li>Rationale: Cancer cell lines provide stable Cas9 expression, consistent growth, and clinically relevant drug responses while enabling high-throughput screening</li> <li>Alternatives:</li> <li>Patient-derived xenografts (pros: better clinical relevance; cons: more variable, complex, expensive)</li> <li>Primary patient cells (pros: direct clinical relevance; cons: limited expansion, variable Cas9 efficiency)</li> <li>Immortalized non-cancer cells (pros: define cancer-specific vs. general mechanisms; cons: may lack disease context)</li> <li>Ethical Considerations: Cell line authentication, appropriate biosafety practices, responsible use of patient-derived materials if applicable</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR_screen_drug_resistence/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques:</li> <li>Lentiviral delivery of genome-wide gRNA library</li> <li>Next-generation sequencing of gRNA abundance</li> <li>Drug dose-response assays for validation</li> <li>Western blotting and RT-qPCR for mechanism studies</li> <li>Technical Replicates: Duplicate NGS library preparations</li> <li>Potential Biases:</li> <li>Variable Cas9 editing efficiency (use cells with validated high Cas9 activity)</li> <li>Lentiviral MOI variations (maintain &gt;500x library coverage throughout)</li> <li>gRNA design efficiency differences (use validated libraries with multiple guides per gene)</li> <li>PCR amplification bias (minimize PCR cycles, use UMIs if possible)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR_screen_drug_resistence/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Treatment: Cells with gRNA library exposed to drug X at IC70-IC90 concentration</li> <li>Control 1: Cells with gRNA library without drug treatment (T0 reference)</li> <li>Control 2: Cells with gRNA library grown in parallel without drug (time-matched control)</li> <li>Control 3: Cells with non-targeting gRNA library with drug treatment</li> <li>Controlled Variables: Cell passage number, Cas9 expression level, library coverage, drug concentration, treatment duration</li> <li>Biological Replicates: 3-4 independent infections and selections</li> <li>Modified Design: Include multiple drug concentrations to identify dose-dependent resistance mechanisms, or combine with CRISPRa screen to identify both loss- and gain-of-function resistance mechanisms</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20CRISPR_screen_drug_resistence/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: </li> <li>gRNA counting from raw NGS reads</li> <li>Normalization for sequencing depth</li> <li>Guide-level fold-change calculation (treatment vs. control)</li> <li>Gene-level enrichment scores using algorithms like MAGeCK or BAGEL</li> <li>Statistical Analysis:</li> <li>False discovery rate correction for multiple hypothesis testing</li> <li>Robust rank aggregation for combining multiple guides per gene</li> <li>Gene set enrichment analysis for pathway-level insights</li> <li>Principal component analysis to assess replicate consistency</li> <li>Data Presentation:</li> <li>Volcano plots showing gene enrichment/depletion significance</li> <li>Ranked bar charts of top hits with statistical significance</li> <li>Pathway enrichment bubble plots</li> <li>Validation data for selected hits showing individual knockout phenotypes</li> <li>Network visualization of functionally related hits</li> <li>Validation Methods:</li> <li>Individual CRISPR knockout of top hits</li> <li>Rescue experiments with cDNA expression</li> <li>Dose-response curves with and without gene knockout</li> <li>Combinatorial drug testing targeting resistance pathways</li> <li>Protein-protein interaction studies to elucidate mechanisms</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/","title":"MBE Chromosome structure detection","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How does three-dimensional genome organization influence gene regulation and cellular function?</li> <li>Design Rationale: Chromosome conformation capture technologies reveal spatial organization of chromatin, regulatory interactions, and topological domains</li> <li>Follow-up Studies: Correlation with gene expression, epigenetic marks, functional validation of regulatory interactions, dynamic changes during development or disease</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, primary cells, tissue samples, embryos</li> <li>Rationale: These systems provide sufficient material for capturing chromatin interactions while maintaining native nuclear architecture</li> <li>Alternatives:</li> <li>In vitro nuclear preparations (pros: enriched nuclei; cons: potential disruption of architecture)</li> <li>Single-cell approaches (pros: cellular heterogeneity; cons: technical noise)</li> <li>Tissue sections (pros: spatial context; cons: fixation artifacts)</li> <li>Ethical Considerations: Standard considerations for cell and tissue sources, potential insights into disease mechanisms</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>Crosslinking to preserve chromatin interactions</li> <li>Restriction enzyme digestion</li> <li>Proximity ligation of interacting fragments</li> <li>DNA purification and analysis</li> <li>Technical Replicates: Multiple libraries recommended due to complexity of protocols</li> <li>Potential Biases:</li> <li>Restriction enzyme bias (site distribution)</li> <li>Crosslinking efficiency variations</li> <li>PCR amplification bias</li> <li>Mapping biases in repetitive regions</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples under experimental condition of interest</li> <li>Control 1: Untreated/baseline samples</li> <li>Control 2: Technical controls (random ligation controls)</li> <li>Control 3: Biological reference samples for normalization</li> <li>Controlled Variables: Cell cycle stage, fixation conditions, cell density</li> <li>Biological Replicates: Minimum 2-3 biological replicates; more for heterogeneous samples</li> <li>Modified Design: Time-course analysis, cell type comparisons, treatment effects</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Interaction matrix generation</li> <li>Normalization for technical biases</li> <li>Identification of significant interactions</li> <li>Domain calling (TADs, compartments)</li> <li>Presentation Approaches:</li> <li>Heatmaps at various resolutions</li> <li>Virtual 4C plots for specific viewpoints</li> <li>Circos plots for genome-wide interactions</li> <li>3D models of chromatin folding</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature 3C (Chromosome Conformation Capture) 4C (Circular Chromosome Conformation Capture) 5C (Carbon Copy Chromosome Conformation Capture) Hi-C Primary Application One-to-one interactions One-to-all interactions Many-to-many interactions All-to-all interactions Scope Focused (few loci) Viewpoint-centric Regional (multiple loci) Genome-wide Resolution High (restriction fragment) High at viewpoint High within region Variable (10kb-1Mb) Coverage Limited (targeted) Genome-wide from viewpoint Selected regions Genome-wide Throughput Low Medium High for target regions Very high Input Material Low (millions of cells) Low to moderate Moderate High (millions of cells) Complexity Low Moderate High Very high Cost Low Moderate Moderate to high High Sequencing Depth Low (targeted) Moderate High for covered regions Very high Analysis Complexity Simple Moderate Moderate to high Very high Best For \u2022 Testing specific interactions\u2022 Validating predictions\u2022 Focused hypothesis testing\u2022 Quantitative comparison \u2022 Single locus regulation\u2022 Enhancer-promoter mapping\u2022 Identifying all contacts for a region\u2022 Detailed viewpoint analysis \u2022 Regulatory landscapes\u2022 Complex locus organization\u2022 Multiple candidate interactions\u2022 Medium-scale mapping \u2022 Global architecture\u2022 TAD identification\u2022 Compartment analysis\u2022 Comprehensive interaction maps Limitations \u2022 Limited to predefined regions\u2022 Labor-intensive for multiple loci\u2022 No global context\u2022 Primer design challenges \u2022 Limited to single viewpoint\u2022 Uneven coverage away from viewpoint\u2022 Complex library preparation\u2022 Viewpoint bias \u2022 Limited to predefined regions\u2022 Primer design complexity\u2022 Coverage gaps\u2022 Labor-intensive design \u2022 Lower resolution\u2022 High sequencing costs\u2022 Complex computational analysis\u2022 High cell input requirements"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Hypothesis Generation:</li> <li>Begin with Hi-C for global chromosome architecture</li> <li> <p>Identify domains, compartments, and potential regulatory hubs</p> </li> <li> <p>Focused Investigation:</p> </li> <li>Use 4C to explore all interactions from key regulatory elements</li> <li>Apply 5C to comprehensively map interactions across candidate regions</li> <li> <p>Validate specific interactions with 3C for quantitative assessment</p> </li> <li> <p>Functional Validation:</p> </li> <li>Correlate interactions with gene expression data</li> <li>Integrate with epigenetic marks (ChIP-seq, ATAC-seq)</li> <li> <p>Perform genetic perturbation of interaction sites</p> </li> <li> <p>Integrated Approach: Design multi-platform studies for comprehensive characterization:</p> </li> <li>Hi-C to map global architecture and identify domains</li> <li>4C to explore key regulatory elements in detail</li> <li>5C to comprehensively analyze complex regulatory regions</li> <li>3C to validate and quantify specific interactions of interest</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#8-technology-specific-considerations","title":"8. Technology-Specific Considerations","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#3c-chromosome-conformation-capture","title":"3C (Chromosome Conformation Capture)","text":"<ul> <li>Design Considerations:</li> <li>Primer design critical for efficiency and specificity</li> <li>Control for primer efficiency with BAC templates</li> <li> <p>Quantitative PCR for accurate interaction measurement</p> </li> <li> <p>Applications:</p> </li> <li>Validation of predicted interactions</li> <li>Quantitative comparison between conditions</li> <li> <p>Focused analysis of specific regulatory elements</p> </li> <li> <p>Variations:</p> </li> <li>Real-time PCR vs. traditional PCR detection</li> <li>Multiplexed 3C for multiple simultaneous interactions</li> <li>Nested 3C for improved specificity</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#4c-circular-chromosome-conformation-capture","title":"4C (Circular Chromosome Conformation Capture)","text":"<ul> <li>Design Considerations:</li> <li>Viewpoint selection critical (regulatory elements, promoters)</li> <li>Secondary restriction enzyme choice affects resolution</li> <li> <p>Inverse PCR conditions optimization important</p> </li> <li> <p>Applications:</p> </li> <li>Enhancer-promoter interaction mapping</li> <li>Identifying novel regulatory contacts</li> <li> <p>Comparing interaction profiles between conditions</p> </li> <li> <p>Variations:</p> </li> <li>4C-seq with high-throughput sequencing</li> <li>r3C-seq with reduced complexity</li> <li>e4C with enhanced sensitivity</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#5c-carbon-copy-chromosome-conformation-capture","title":"5C (Carbon Copy Chromosome Conformation Capture)","text":"<ul> <li>Design Considerations:</li> <li>Primer design complexity (hundreds of primers)</li> <li>Balanced primer pool important for even coverage</li> <li> <p>Optimization of multiplex PCR conditions</p> </li> <li> <p>Applications:</p> </li> <li>Comprehensive mapping of complex loci</li> <li>Regulatory landscapes of developmental genes</li> <li> <p>Comparing multiple regions simultaneously</p> </li> <li> <p>Variations:</p> </li> <li>5C with next-generation sequencing</li> <li>Targeted 5C for specific pathways</li> <li>Condition-specific 5C designs</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#hi-c","title":"Hi-C","text":"<ul> <li>Design Considerations:</li> <li>Biotin incorporation efficiency</li> <li>Streptavidin bead enrichment optimization</li> <li> <p>Sequencing depth vs. resolution trade-off</p> </li> <li> <p>Applications:</p> </li> <li>Global chromatin organization</li> <li>Topologically associating domain (TAD) identification</li> <li>A/B compartment analysis</li> <li> <p>Long-range interaction discovery</p> </li> <li> <p>Variations:</p> </li> <li>In situ Hi-C for improved signal-to-noise</li> <li>Capture Hi-C for targeted regions</li> <li>Micro-C with micrococcal nuclease for nucleosome-level resolution</li> <li>HiChIP/PLAC-seq for protein-centric interactions</li> <li>Single-cell Hi-C for cellular heterogeneity</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Chromosome%20structure%20detection/#9-integration-with-other-technologies","title":"9. Integration with Other Technologies","text":"<ul> <li>Epigenomic Integration:</li> <li>ChIP-seq data to correlate interactions with histone marks</li> <li>ATAC-seq to identify accessible regions at interaction sites</li> <li> <p>DNA methylation data to assess regulatory potential</p> </li> <li> <p>Transcriptomic Integration:</p> </li> <li>RNA-seq to correlate interactions with gene expression</li> <li>eQTL analysis to link genetic variation to interaction changes</li> <li> <p>Nascent RNA analysis for direct regulatory effects</p> </li> <li> <p>Imaging Validation:</p> </li> <li>DNA FISH to validate specific interactions</li> <li>Super-resolution microscopy for fine-scale organization</li> <li>Live-cell imaging for dynamic changes</li> </ul> <p>This integrated framework provides researchers with a structured approach to selecting and combining chromosome conformation capture technologies. The complementary use of these methods, from genome-wide to locus-specific, enables a comprehensive understanding of chromatin architecture and its functional implications in gene regulation.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/","title":"MBE DNA assessment","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Is gene X present, altered, or differentially expressed in condition Y compared to controls?</li> <li>Design Rationale: DNA detection and quantification techniques allow identification of specific sequences, structural variations, and abundance changes</li> <li>Follow-up Studies: Functional validation of detected variants, expression analysis, correlation with phenotypic outcomes</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human tissue samples from patients with condition Y and matched controls</li> <li>Rationale: Patient-derived samples provide direct clinical relevance while allowing sufficient DNA extraction for multiple analytical approaches</li> <li>Alternatives:</li> <li>Cell lines (pros: abundant material, controlled conditions; cons: may not reflect in vivo context)</li> <li>Animal models (pros: controlled genetics; cons: species differences)</li> <li>Synthetic DNA (pros: precise control; cons: lacks biological context)</li> <li>Ethical Considerations: IRB approval, informed consent, sample de-identification, responsible data sharing</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>High-quality DNA extraction</li> <li>Appropriate sample storage</li> <li>Consistent quantification methods</li> <li>Inclusion of reference standards</li> <li>Technical Replicates: Triplicate measurements for each sample and technique</li> <li>Potential Biases:</li> <li>Sample quality variations (standardize extraction protocols)</li> <li>Batch effects (include inter-run calibrators)</li> <li>Amplification bias (optimize primer design)</li> <li>Probe specificity (validate with known controls)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples from subjects with condition Y</li> <li>Control 1: Matched samples from healthy subjects</li> <li>Control 2: Positive controls with known sequence variants</li> <li>Control 3: Negative controls (no template controls)</li> <li>Controlled Variables: DNA quantity, quality metrics, reagent lots, instrument calibration</li> <li>Biological Replicates: Minimum 20-30 subjects per group for adequate statistical power</li> <li>Modified Design: Include family members for hereditary conditions or longitudinal sampling for progressive conditions</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Quality control metrics</li> <li>Normalization to reference genes/sequences</li> <li>Statistical comparison between groups</li> <li>Correlation with clinical parameters</li> <li>Presentation Approaches:</li> <li>Gel/blot images with size markers</li> <li>Amplification curves and threshold cycles</li> <li>Quantitative comparisons with error bars</li> <li>Correlation plots with clinical outcomes</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature PCR qPCR Southern Blotting Primary Use Qualitative detection of specific sequences Precise quantification of target DNA Detection of specific sequences and structural variations Sensitivity Moderate (detects ~10-100 copies) High (detects 1-10 copies) Moderate (50-100 ng of genomic DNA) Specificity Good, primer-dependent Very good, primer and probe-dependent Excellent, especially for complex rearrangements Quantification Semi-quantitative at best Highly quantitative Semi-quantitative Throughput High High Low Time Required 2-3 hours 2-3 hours 1-3 days Cost Low Moderate High Equipment Basic thermal cycler qPCR instrument Multiple specialized equipment Technical Expertise Basic Moderate Advanced Best For \u2022 Rapid presence/absence detection\u2022 Genotyping\u2022 Initial screening\u2022 Amplifying targets for sequencing \u2022 Precise copy number quantification\u2022 Gene expression studies\u2022 Pathogen load determination\u2022 Allelic discrimination \u2022 Complex structural variations\u2022 Large insertions/deletions\u2022 Repetitive sequence analysis\u2022 Confirming ambiguous PCR results Limitations \u2022 Limited quantification\u2022 Potential for false positives\u2022 Size constraints \u2022 Limited fragment size information\u2022 Requires careful assay design\u2022 Potential amplification bias \u2022 Labor intensive\u2022 Low throughput\u2022 Requires large DNA amounts\u2022 Radioactive hazards (for some probes)"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Initial Screening: Use standard PCR for rapid, cost-effective detection of target sequences</li> <li>Precise Quantification: Follow with qPCR for accurate measurement of differences between groups</li> <li>Structural Validation: Employ Southern blotting to confirm complex structural variations or repetitive sequence changes</li> <li>Integrated Approach: Use all three methods for comprehensive characterization of important targets:</li> <li>PCR to rapidly screen multiple samples</li> <li>qPCR to precisely quantify differences</li> <li>Southern blotting to validate structural context and complex variations</li> </ul> <p>This multi-technique approach provides complementary data that overcomes the limitations of any single method while maximizing confidence in results for critical findings.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#complete-experimental-protocols-qpcr-and-southern-blot","title":"Complete Experimental Protocols: qPCR and Southern Blot","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#qpcr-quantitative-polymerase-chain-reaction-protocol","title":"qPCR (Quantitative Polymerase Chain Reaction) Protocol","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#i-sample-preparation","title":"I. Sample Preparation","text":"<ol> <li>RNA Extraction</li> <li>Harvest cells or tissue samples (50-100 mg tissue or 1-5\u00d710^6 cells)</li> <li>Add 1 mL TRIzol reagent and homogenize</li> <li>Incubate at room temperature for 5 minutes</li> <li>Add 0.2 mL chloroform, shake vigorously for 15 seconds</li> <li>Incubate at room temperature for 3 minutes</li> <li>Centrifuge at 12,000\u00d7g for 15 minutes at 4\u00b0C</li> <li>Transfer aqueous phase to a new tube</li> <li>Add 0.5 mL isopropanol, incubate for 10 minutes</li> <li>Centrifuge at 12,000\u00d7g for 10 minutes at 4\u00b0C</li> <li>Discard supernatant and wash RNA pellet with 75% ethanol</li> <li> <p>Air-dry pellet and resuspend in RNase-free water</p> </li> <li> <p>DNA Removal and RNA Quality Assessment</p> </li> <li>Treat RNA with DNase I (1 unit/\u03bcg RNA) for 30 minutes at 37\u00b0C</li> <li>Inactivate DNase at 65\u00b0C for 10 minutes with EDTA</li> <li>Measure RNA concentration using spectrophotometer (NanoDrop)</li> <li>Verify RNA quality by checking A260/A280 ratio (1.8-2.0 is optimal)</li> <li> <p>Run 1 \u03bcg RNA on a 1% agarose gel to check integrity (28S and 18S rRNA bands)</p> </li> <li> <p>cDNA Synthesis</p> </li> <li>Prepare reaction mixture:<ul> <li>1 \u03bcg total RNA</li> <li>1 \u03bcL oligo(dT) primer (50 \u03bcM) or random hexamers (50 ng/\u03bcL)</li> <li>1 \u03bcL dNTP mix (10 mM each)</li> <li>Nuclease-free water to 13 \u03bcL</li> </ul> </li> <li>Heat at 65\u00b0C for 5 minutes, then chill on ice</li> <li>Add:<ul> <li>4 \u03bcL 5\u00d7 First-Strand Buffer</li> <li>1 \u03bcL DTT (0.1 M)</li> <li>1 \u03bcL RNase inhibitor (40 units/\u03bcL)</li> <li>1 \u03bcL reverse transcriptase (200 units/\u03bcL)</li> </ul> </li> <li>Incubate at 42\u00b0C for 50 minutes</li> <li>Inactivate at 70\u00b0C for 15 minutes</li> <li>Store cDNA at -20\u00b0C</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#ii-primer-design-and-validation","title":"II. Primer Design and Validation","text":"<ol> <li>Primer Design</li> <li>Design primers using software (e.g., Primer3, NCBI Primer-BLAST)</li> <li>Parameters:<ul> <li>Amplicon length: 70-150 bp</li> <li>Primer length: 18-25 nucleotides</li> <li>GC content: 40-60%</li> <li>Melting temperature (Tm): 58-62\u00b0C</li> <li>Avoid secondary structures and primer-dimers</li> </ul> </li> <li>Check primer specificity using BLAST</li> <li> <p>Order primers from commercial supplier</p> </li> <li> <p>Primer Validation</p> </li> <li>Prepare standard PCR reaction:<ul> <li>12.5 \u03bcL 2\u00d7 PCR master mix</li> <li>1 \u03bcL forward primer (10 \u03bcM)</li> <li>1 \u03bcL reverse primer (10 \u03bcM)</li> <li>1 \u03bcL cDNA template</li> <li>9.5 \u03bcL nuclease-free water</li> </ul> </li> <li>Run PCR: 95\u00b0C for 3 min; 35 cycles of (95\u00b0C for 30 sec, 60\u00b0C for 30 sec, 72\u00b0C for 30 sec); 72\u00b0C for 5 min</li> <li> <p>Run PCR product on 2% agarose gel to verify single band of expected size</p> </li> <li> <p>Primer Efficiency Test</p> </li> <li>Prepare a 5-fold serial dilution of cDNA (1:1, 1:5, 1:25, 1:125, 1:625)</li> <li>Run qPCR for each dilution in triplicate</li> <li>Plot Ct values against log(dilution factor)</li> <li>Calculate efficiency: E = 10^(-1/slope) - 1 (optimal: 90-110%)</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#iii-qpcr-setup-and-run","title":"III. qPCR Setup and Run","text":"<ol> <li>Reaction Preparation</li> <li>For SYBR Green-based detection:<ul> <li>10 \u03bcL 2\u00d7 SYBR Green master mix</li> <li>0.6 \u03bcL forward primer (10 \u03bcM)</li> <li>0.6 \u03bcL reverse primer (10 \u03bcM)</li> <li>1 \u03bcL cDNA template</li> <li>7.8 \u03bcL nuclease-free water</li> </ul> </li> <li>For probe-based detection (TaqMan):<ul> <li>10 \u03bcL 2\u00d7 TaqMan master mix</li> <li>1 \u03bcL gene-specific primer-probe mix (20\u00d7)</li> <li>1 \u03bcL cDNA template</li> <li>8 \u03bcL nuclease-free water</li> </ul> </li> <li>Prepare master mix for all reactions plus 10% extra</li> <li>Dispense 19 \u03bcL master mix into each well of a 96-well plate</li> <li>Add 1 \u03bcL cDNA to appropriate wells</li> <li>Seal plate with optical adhesive film</li> <li> <p>Centrifuge plate briefly to eliminate air bubbles</p> </li> <li> <p>Controls Setup</p> </li> <li>No template control (NTC): replace cDNA with water</li> <li>No reverse transcriptase control (NRT): cDNA synthesis without RT</li> <li>Positive control: sample known to express target gene</li> <li> <p>Reference gene controls: primers for housekeeping genes (GAPDH, \u03b2-actin, 18S rRNA)</p> </li> <li> <p>qPCR Cycling Conditions</p> </li> <li>For SYBR Green:<ul> <li>Initial denaturation: 95\u00b0C for 10 minutes</li> <li>40 cycles of:</li> <li>Denaturation: 95\u00b0C for 15 seconds</li> <li>Annealing/extension: 60\u00b0C for 1 minute</li> <li>Melt curve analysis: 60-95\u00b0C (0.3\u00b0C increments)</li> </ul> </li> <li>For TaqMan:<ul> <li>Initial denaturation: 95\u00b0C for 10 minutes</li> <li>40 cycles of:</li> <li>Denaturation: 95\u00b0C for 15 seconds</li> <li>Annealing/extension: 60\u00b0C for 1 minute</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#iv-data-analysis","title":"IV. Data Analysis","text":"<ol> <li>Quality Control</li> <li>Check amplification plots for smooth, sigmoidal curves</li> <li>Verify single peak in melt curve analysis (SYBR Green only)</li> <li>Confirm NTC and NRT controls show no amplification</li> <li> <p>Check replicate consistency (Ct standard deviation &lt;0.3)</p> </li> <li> <p>Relative Quantification</p> </li> <li>Determine Ct values for target and reference genes</li> <li>Calculate \u0394Ct = Ct(target) - Ct(reference)</li> <li>For comparing experimental vs. control:<ul> <li>Calculate \u0394\u0394Ct = \u0394Ct(experimental) - \u0394Ct(control)</li> <li>Calculate fold change = 2^(-\u0394\u0394Ct)</li> </ul> </li> <li> <p>Apply statistical analysis (t-test or ANOVA)</p> </li> <li> <p>Result Interpretation and Reporting</p> </li> <li>Create bar graphs showing relative expression levels</li> <li>Include error bars (standard deviation or standard error)</li> <li>Indicate statistical significance (p-values)</li> <li>Report primer sequences, efficiency, and reference genes used</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#southern-blot-protocol","title":"Southern Blot Protocol","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#i-dna-extraction-and-preparation","title":"I. DNA Extraction and Preparation","text":"<ol> <li>Genomic DNA Extraction</li> <li>Harvest cells or tissue samples (100-200 mg tissue or 5-10\u00d710^6 cells)</li> <li>Add 500 \u03bcL lysis buffer (10 mM Tris-HCl pH 8.0, 100 mM NaCl, 25 mM EDTA, 0.5% SDS)</li> <li>Add proteinase K to 100 \u03bcg/mL final concentration</li> <li>Incubate at 55\u00b0C overnight with gentle shaking</li> <li>Add equal volume of phenol:chloroform:isoamyl alcohol (25:24:1)</li> <li>Mix thoroughly and centrifuge at 12,000\u00d7g for 10 minutes</li> <li>Transfer aqueous phase to a new tube</li> <li>Add 0.1 volume of 3M sodium acetate (pH 5.2) and 2 volumes of 100% ethanol</li> <li>Incubate at -20\u00b0C for 30 minutes</li> <li>Centrifuge at 12,000\u00d7g for 15 minutes at 4\u00b0C</li> <li> <p>Wash pellet with 70% ethanol, air-dry, and resuspend in TE buffer</p> </li> <li> <p>DNA Quality Assessment</p> </li> <li>Measure DNA concentration using spectrophotometer (NanoDrop)</li> <li>Check A260/A280 ratio (1.8-2.0 is optimal)</li> <li> <p>Run 1 \u03bcg DNA on a 0.8% agarose gel to check integrity (high molecular weight band)</p> </li> <li> <p>Restriction Enzyme Digestion</p> </li> <li>Prepare digestion reaction:<ul> <li>10-20 \u03bcg genomic DNA</li> <li>5 \u03bcL 10\u00d7 restriction enzyme buffer</li> <li>3-5 units restriction enzyme per \u03bcg DNA</li> <li>Nuclease-free water to 50 \u03bcL</li> </ul> </li> <li>Incubate at appropriate temperature (usually 37\u00b0C) for 4-16 hours</li> <li>Add 1/10 volume 3M sodium acetate and 2.5 volumes ethanol</li> <li>Incubate at -20\u00b0C for 30 minutes</li> <li>Centrifuge at 12,000\u00d7g for 15 minutes at 4\u00b0C</li> <li>Wash pellet with 70% ethanol, air-dry, and resuspend in TE buffer</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#ii-gel-electrophoresis-and-transfer","title":"II. Gel Electrophoresis and Transfer","text":"<ol> <li>Agarose Gel Preparation</li> <li>Prepare 0.7-0.8% agarose gel in 1\u00d7 TAE buffer</li> <li>Add ethidium bromide (0.5 \u03bcg/mL) or other DNA stain</li> <li> <p>Pour gel and allow to solidify</p> </li> <li> <p>Sample Loading and Electrophoresis</p> </li> <li>Mix DNA samples with 6\u00d7 loading dye</li> <li>Load samples alongside DNA molecular weight marker</li> <li>Run gel at 20-30V overnight (12-16 hours) for good separation</li> <li>Document gel with UV transilluminator</li> <li> <p>Trim excess gel and mark orientation</p> </li> <li> <p>Gel Processing</p> </li> <li>Depurination: soak gel in 0.25M HCl for 10 minutes with gentle shaking</li> <li>Rinse briefly with distilled water</li> <li>Denaturation: soak gel in denaturation solution (0.5M NaOH, 1.5M NaCl) for 30 minutes</li> <li>Rinse briefly with distilled water</li> <li> <p>Neutralization: soak gel in neutralization solution (0.5M Tris-HCl pH 7.5, 1.5M NaCl) for 30 minutes</p> </li> <li> <p>Capillary Transfer Setup</p> </li> <li>Cut nylon membrane to gel size and pre-wet in 10\u00d7 SSC</li> <li>Place a glass plate across a container filled with 10\u00d7 SSC</li> <li>Place a wick (Whatman 3MM paper) over the glass plate with ends in buffer</li> <li>Place gel upside down on the wick</li> <li>Place membrane on top of gel (avoid bubbles)</li> <li>Place 3 sheets of Whatman paper on membrane</li> <li>Stack paper towels (5-8 cm high) on top</li> <li>Place weight (~500g) on top</li> <li> <p>Allow transfer to proceed overnight (12-16 hours)</p> </li> <li> <p>Post-Transfer Processing</p> </li> <li>Disassemble transfer setup and mark membrane orientation</li> <li>Rinse membrane briefly in 2\u00d7 SSC</li> <li>Crosslink DNA to membrane using UV crosslinker (120 mJ/cm\u00b2) or bake at 80\u00b0C for 2 hours</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#iii-probe-preparation-and-hybridization","title":"III. Probe Preparation and Hybridization","text":"<ol> <li>Probe Synthesis</li> <li> <p>For radioactive labeling (P32):</p> <ul> <li>Prepare reaction mixture:</li> <li>25-50 ng DNA template</li> <li>5 \u03bcL random primers</li> <li>Nuclease-free water to 34 \u03bcL</li> <li>Denature at 95\u00b0C for 5 minutes, chill on ice</li> <li>Add:</li> <li>5 \u03bcL 10\u00d7 buffer</li> <li>5 \u03bcL dNTP mix (minus dCTP)</li> <li>5 \u03bcL [\u03b1-32P]dCTP (50 \u03bcCi)</li> <li>1 \u03bcL Klenow fragment (5 units)</li> <li>Incubate at 37\u00b0C for 1 hour</li> <li>Purify labeled probe using spin column</li> </ul> </li> <li> <p>For non-radioactive labeling (DIG):</p> <ul> <li>Use DIG High Prime DNA Labeling Kit following manufacturer's protocol</li> <li>Denature DNA template, add labeling mix, incubate</li> <li>Stop reaction and purify labeled probe</li> </ul> </li> <li> <p>Probe Denaturation</p> </li> <li>Heat probe at 95\u00b0C for 5 minutes</li> <li> <p>Chill immediately on ice for 5 minutes</p> </li> <li> <p>Membrane Pre-hybridization</p> </li> <li>Place membrane in hybridization tube</li> <li>Add pre-hybridization solution (containing blocking agent, SDS, SSC, formamide)</li> <li> <p>Incubate at 42\u00b0C (for formamide-containing buffer) or 65\u00b0C for 1-3 hours with rotation</p> </li> <li> <p>Hybridization</p> </li> <li>Add denatured probe to fresh hybridization solution</li> <li>Replace pre-hybridization solution with probe-containing solution</li> <li>Hybridize overnight (12-16 hours) at appropriate temperature</li> <li>For radioactive probes: 42\u00b0C with formamide or 65\u00b0C without</li> <li>For DIG-labeled probes: follow manufacturer's recommendations</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#iv-washing-and-detection","title":"IV. Washing and Detection","text":"<ol> <li>Post-Hybridization Washes</li> <li>Low stringency wash: 2\u00d7 SSC, 0.1% SDS at room temperature, 2 \u00d7 5 minutes</li> <li>High stringency wash: 0.1\u00d7 SSC, 0.1% SDS at 65\u00b0C, 2 \u00d7 15 minutes</li> <li> <p>Adjust wash stringency based on probe specificity requirements</p> </li> <li> <p>Detection Methods</p> </li> <li> <p>For radioactive probes:</p> <ul> <li>Air-dry membrane</li> <li>Expose to X-ray film in cassette with intensifying screens at -80\u00b0C</li> <li>Develop film after appropriate exposure time (hours to days)</li> <li>Alternatively, use phosphorimager for quantitative detection</li> </ul> </li> <li> <p>For DIG-labeled probes:</p> <ul> <li>Block membrane in blocking solution for 30 minutes</li> <li>Incubate with anti-DIG antibody conjugated to alkaline phosphatase</li> <li>Wash to remove unbound antibody</li> <li>Apply chemiluminescent substrate (e.g., CDP-Star)</li> <li>Expose to X-ray film or use imaging system</li> </ul> </li> <li> <p>Signal Analysis</p> </li> <li>Analyze band patterns and sizes relative to molecular weight markers</li> <li>Compare with expected restriction fragment patterns</li> <li>For quantitative analysis, use densitometry software</li> <li>Document results with appropriate image acquisition</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20DNA%20assessment/#v-membrane-stripping-and-reprobing-optional","title":"V. Membrane Stripping and Reprobing (Optional)","text":"<ol> <li>Stripping Procedure</li> <li> <p>For radioactive probes:</p> <ul> <li>Incubate membrane in stripping solution (0.1% SDS, 0.1\u00d7 SSC)</li> <li>Heat to 95-100\u00b0C and let cool to room temperature</li> <li>Repeat if necessary</li> <li>Verify complete stripping by re-exposing to film</li> </ul> </li> <li> <p>For DIG-labeled probes:</p> <ul> <li>Wash membrane in sterile water</li> <li>Incubate twice in 0.2M NaOH, 0.1% SDS at 37\u00b0C for 15 minutes</li> <li>Rinse in 2\u00d7 SSC</li> </ul> </li> <li> <p>Reprobing</p> </li> <li>Return to pre-hybridization step</li> <li>Continue with new probe as described above</li> </ol> <p>These detailed protocols provide comprehensive step-by-step instructions for performing qPCR and Southern blot analyses, covering all aspects from sample preparation through data analysis and interpretation.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/","title":"Experimental Design: Epigenetic Analysis Technologies","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How do epigenetic modifications regulate gene expression and chromatin structure in different biological contexts?</li> <li>Design Rationale: Epigenetic sequencing techniques reveal DNA methylation patterns, histone modifications, chromatin accessibility, nucleosome positioning, and RNA modifications</li> <li>Follow-up Studies: Integration with transcriptome data, functional validation of regulatory elements, epigenetic editing, developmental trajectory analysis</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, primary cells, tissue samples, embryos, patient biopsies</li> <li>Rationale: These systems provide sufficient material while maintaining native epigenetic landscapes relevant to development or disease</li> <li>Alternatives:</li> <li>In vitro differentiation models (pros: controlled progression; cons: artificial conditions)</li> <li>Animal models (pros: developmental context; cons: species differences)</li> <li>Patient-derived xenografts (pros: human relevance; cons: altered microenvironment)</li> <li>Ethical Considerations: Informed consent for human samples, developmental stage considerations, transgenerational effects</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>Careful sample preservation to maintain epigenetic marks</li> <li>Cross-linking conditions optimization</li> <li>Antibody validation for IP-based methods</li> <li>Appropriate enzymatic digestion parameters</li> <li>Technical Replicates: Multiple replicates to account for technical variability in enzymatic or antibody-based methods</li> <li>Potential Biases:</li> <li>Antibody specificity (validate with knockout controls)</li> <li>Enzymatic bias (optimize digestion conditions)</li> <li>PCR duplication (use UMIs when possible)</li> <li>GC content bias (normalize in computational analysis)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples from experimental condition of interest</li> <li>Control 1: Matched untreated/baseline samples</li> <li>Control 2: Technical controls (input DNA, IgG controls for IP methods)</li> <li>Control 3: Spike-in controls for quantitative comparisons</li> <li>Controlled Variables: Cell cycle stage, developmental time point, tissue processing method</li> <li>Biological Replicates: Minimum 3 biological replicates; more for heterogeneous samples</li> <li>Modified Design: Time-course analysis, multiple cell types, disease progression stages</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Quality control metrics (library complexity, mapping rates)</li> <li>Peak calling or methylation calling algorithms</li> <li>Differential analysis between conditions</li> <li>Integration with gene expression data</li> <li>Presentation Approaches:</li> <li>Genome browser tracks for visual comparison</li> <li>Heatmaps centered on features of interest</li> <li>Metaplots showing average profiles around features</li> <li>Enrichment analyses for functional interpretation</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#6-technique-comparison-dna-methylation-and-chromatin-structure","title":"6. Technique Comparison - DNA Methylation and Chromatin Structure","text":"Feature Bisulfite Sequencing MeDIP-seq ChIP-seq ATAC-seq MNase-seq Primary Target DNA methylation DNA methylation Protein-DNA interactions Chromatin accessibility Nucleosome positioning Resolution Single-base 100-300 bp 150-300 bp &lt;50 bp Single-nucleosome Coverage Genome-wide Enriched regions Protein binding sites Accessible regions Nucleosome-occupied Sensitivity Very high Moderate Moderate to high High Moderate Specificity Very high Antibody-dependent Antibody-dependent High High Input Material 50-500 ng 100-1000 ng 1-10 million cells 50,000-100,000 cells 1-5 million cells Cost High Moderate Moderate to high Moderate Moderate Technical Complexity High Moderate Moderate to high Low to moderate Moderate to high Best For \u2022 Comprehensive methylome\u2022 Single-CpG resolution\u2022 Quantitative analysis\u2022 Allele-specific methylation \u2022 Cost-effective methylation\u2022 Low input samples\u2022 Enriched methylated regions\u2022 Hypermethylated regions \u2022 Histone modifications\u2022 Transcription factor binding\u2022 Enhancer mapping\u2022 Protein-DNA interactions \u2022 Global accessibility\u2022 Low cell numbers\u2022 Regulatory element mapping\u2022 Footprinting \u2022 Nucleosome positioning\u2022 Chromatin structure\u2022 Linker regions\u2022 Phasing analysis Limitations \u2022 Incomplete conversion\u2022 Cannot distinguish 5mC from 5hmC\u2022 PCR bias\u2022 High sequencing cost \u2022 Low resolution\u2022 Qualitative rather than quantitative\u2022 Antibody specificity\u2022 CpG density bias \u2022 Antibody quality dependent\u2022 High cell input\u2022 Background signal\u2022 Indirect binding detection \u2022 Mitochondrial contamination\u2022 Tn5 sequence bias\u2022 Fragment size selection\u2022 Cellular heterogeneity \u2022 Digestion variability\u2022 High cell input\u2022 Complex analysis\u2022 Enzyme accessibility bias"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#7-technique-comparison-chromatin-accessibility-and-rna-modifications","title":"7. Technique Comparison - Chromatin Accessibility and RNA Modifications","text":"Feature DNase-seq FAIRE-seq Small RNA-seq m6A-seq Primary Target Open chromatin Open regulatory regions Small non-coding RNAs RNA methylation Resolution 50-150 bp 200-300 bp Single-base 100-200 bp Coverage Accessible regions Nucleosome-depleted Small RNA population Modified transcripts Sensitivity High Moderate High Moderate Specificity High Moderate Very high Antibody-dependent Input Material 1-10 million cells 1-5 million cells 100-1000 ng RNA 100-300 \u03bcg RNA Cost Moderate Low to moderate Moderate High Technical Complexity Moderate to high Moderate Moderate High Best For \u2022 Regulatory elements\u2022 Transcription factor footprints\u2022 Cell-type specific elements\u2022 Enhancer mapping \u2022 Active regulatory regions\u2022 Nucleosome depletion\u2022 Complementary to DNase-seq\u2022 Simple protocol \u2022 miRNA profiling\u2022 piRNA discovery\u2022 siRNA characterization\u2022 Non-coding RNA regulation \u2022 RNA modification maps\u2022 Epitranscriptome analysis\u2022 mRNA regulation\u2022 Modification dynamics Limitations \u2022 High cell input\u2022 Enzyme efficiency\u2022 Sensitivity to conditions\u2022 Complex analysis \u2022 Lower signal-to-noise\u2022 Variable efficiency\u2022 Lower resolution\u2022 Limited sensitivity \u2022 Size selection bias\u2022 Adapter ligation bias\u2022 Secondary structure effects\u2022 Quantification challenges \u2022 Antibody specificity\u2022 IP efficiency\u2022 Low resolution\u2022 High input requirements"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#8-complementary-usage-strategy","title":"8. Complementary Usage Strategy","text":"<ul> <li>DNA Methylation Analysis: </li> <li>Use bisulfite sequencing for comprehensive, single-base resolution methylation mapping</li> <li> <p>Employ MeDIP-seq for cost-effective screening of methylated regions</p> </li> <li> <p>Chromatin Structure Analysis:</p> </li> <li>Apply ATAC-seq for global accessibility with low input requirements</li> <li>Use DNase-seq for detailed footprinting of transcription factor binding</li> <li>Implement MNase-seq for precise nucleosome positioning</li> <li> <p>Utilize FAIRE-seq as a complementary approach for open chromatin</p> </li> <li> <p>Protein-DNA Interactions:</p> </li> <li>Employ ChIP-seq for mapping specific histone modifications and transcription factor binding</li> <li> <p>Integrate with accessibility data to identify functional binding events</p> </li> <li> <p>RNA Regulation:</p> </li> <li>Use Small RNA-seq to profile regulatory non-coding RNAs</li> <li> <p>Apply m6A-seq to map RNA modifications affecting transcript processing and stability</p> </li> <li> <p>Integrated Approach: Design multi-platform studies for comprehensive epigenetic characterization:</p> </li> <li>Bisulfite sequencing to establish DNA methylation landscape</li> <li>ChIP-seq for key histone modifications (H3K4me3, H3K27me3, H3K27ac, etc.)</li> <li>ATAC-seq to map accessible chromatin regions</li> <li>Integration with transcriptome data to correlate epigenetic features with gene expression</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#9-technology-specific-considerations","title":"9. Technology-Specific Considerations","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#dna-methylation-methods","title":"DNA Methylation Methods","text":"<ul> <li>Bisulfite Sequencing:</li> <li>Variants include WGBS (whole genome), RRBS (reduced representation), and targeted approaches</li> <li>Alternative methods (oxBS-seq, TAB-seq) can distinguish 5mC from 5hmC</li> <li> <p>Non-bisulfite methods (TAPS, EM-seq) reduce DNA degradation</p> </li> <li> <p>MeDIP-seq:</p> </li> <li>Antibody selection critical (5mC vs. 5hmC specificity)</li> <li>Quantification requires normalization for CpG density</li> <li>Cost-effective for large-scale comparative studies</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#chromatin-accessibility-methods","title":"Chromatin Accessibility Methods","text":"<ul> <li>ATAC-seq:</li> <li>Optimization for cell number and transposition conditions</li> <li>Single-cell protocols available for heterogeneous samples</li> <li> <p>Mitochondrial filtering essential in analysis</p> </li> <li> <p>DNase-seq:</p> </li> <li>Enzyme concentration titration critical for optimal results</li> <li>Digital genomic footprinting possible with deep sequencing</li> <li> <p>Higher input requirements than ATAC-seq</p> </li> <li> <p>MNase-seq:</p> </li> <li>Digestion conditions affect nucleosome detection</li> <li>Can reveal subnucleosomal particles with light digestion</li> <li> <p>Paired-end sequencing recommended for precise positioning</p> </li> <li> <p>FAIRE-seq:</p> </li> <li>Simplest protocol but lower signal-to-noise ratio</li> <li>Complements protein-based methods</li> <li>Useful for samples where crosslinking is challenging</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#protein-dna-interactions","title":"Protein-DNA Interactions","text":"<ul> <li>ChIP-seq:</li> <li>Antibody validation critical (specificity, lot testing)</li> <li>Fixation conditions affect efficiency</li> <li>Spike-in normalization recommended for quantitative comparisons</li> <li>Variants include CUT&amp;RUN and CUT&amp;Tag for lower input requirements</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenetic%20sequencing/#rna-modification-methods","title":"RNA Modification Methods","text":"<ul> <li>Small RNA-seq:</li> <li>Size selection critically important</li> <li>Adapter design affects capture efficiency</li> <li> <p>Special considerations for highly modified RNAs</p> </li> <li> <p>m6A-seq:</p> </li> <li>IP efficiency varies between experiments</li> <li>Single-base resolution variants available (miCLIP)</li> <li>Integration with RNA structure data enhances interpretation</li> </ul> <p>This integrated framework provides researchers with a comprehensive approach to epigenetic analysis, enabling the selection of appropriate technologies based on research questions, sample availability, and resource constraints. The complementary use of multiple methods strengthens findings by overcoming the limitations of individual approaches.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenome%20Engineering%20Discussion/","title":"MBE Epigenome Engineering Discussion","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenome%20Engineering%20Discussion/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Epigenome engineering explores how specific epigenetic modifications affect gene expression and cellular function without altering DNA sequence. The experimental design directly tests this by using CRISPR-dCas9 fused to epigenetic enzymes to target precise genomic locations.</li> <li>Repeated Designs: Researchers often repeat similar designs to test different epigenetic modifiers (DNMT3A vs TET for methylation/demethylation), target different genomic regions, or study effects across different cell types to understand context-dependent regulation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenome%20Engineering%20Discussion/#2-model-system","title":"2. Model System","text":"<ul> <li>Current Systems: Commonly uses cell culture models (e.g., HEK293, iPSCs, cancer cell lines) which allow for efficient transfection of CRISPR components and controlled experimental conditions.</li> <li>Alternatives: Mouse models offer in vivo context but are more complex and expensive. Organoids provide 3D tissue-like environments but with increased variability. Drosophila or zebrafish can be used for developmental studies.</li> <li>Ethical Considerations: Cell line work has minimal ethical concerns, though patient-derived cells require proper consent. Animal models raise standard animal welfare considerations.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenome%20Engineering%20Discussion/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques: Combines sequencing approaches (BS-seq, ChIP-seq, RNA-seq, ATAC-seq) providing quantitative measurements of epigenetic marks, chromatin accessibility, and gene expression changes.</li> <li>Method Selection: These methods offer genome-wide coverage and quantitative precision compared to alternatives like immunofluorescence or PCR-based approaches.</li> <li>Technical Replicates: Multiple sequencing reads per genomic region serve as technical replicates, with quality filters applied to ensure reliable signal detection.</li> <li>Potential Biases: Off-target binding of dCas9, variable transfection efficiency, and cell-cycle effects can introduce biases, minimized through proper controls and normalization.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenome%20Engineering%20Discussion/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups: Typically includes dCas9-enzyme treated samples versus controls (untreated, dCas9-only without enzyme, or catalytically dead enzyme).</li> <li>Negative Controls: dCas9 without effector domains, non-targeting gRNAs, and catalytically inactive enzyme fusions serve as negative controls.</li> <li>Biological Replicates: 3-4 biological replicates are standard, generally sufficient for statistical power in controlled cell culture experiments.</li> <li>Modified Design: Adding time-course measurements would reveal dynamics and persistence of epigenetic modifications; testing combinatorial modifications would explore synergistic effects.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Epigenome%20Engineering%20Discussion/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: Raw sequencing data undergoes quality filtering, alignment to reference genome, and normalization before quantifying epigenetic changes at target sites.</li> <li>Statistical Tests: Differential modification analysis uses tools like DESeq2 or edgeR, with multiple testing correction (FDR) to identify significant changes.</li> <li>Data Presentation: Results typically appear as genome browser tracks, heatmaps of modification patterns across targets, and correlation plots between epigenetic changes and gene expression.</li> <li>Validation Methods: Findings are confirmed through orthogonal techniques like targeted bisulfite sequencing, ChIP-qPCR, and functional assays (luciferase reporters, phenotypic readouts) to establish causal relationships.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/","title":"MBE Gene editing","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How do specific genes or regulatory elements contribute to cellular function, development, and disease?</li> <li>Design Rationale: Gene editing and expression modulation technologies enable precise manipulation of the genome and gene expression to establish causality</li> <li>Follow-up Studies: Phenotypic analysis, mechanistic investigations, therapeutic applications, genetic interaction mapping</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, primary cells, organoids, model organisms, patient-derived cells</li> <li>Rationale: These systems allow genetic manipulation while maintaining relevant biological context for functional analysis</li> <li>Alternatives:</li> <li>In vitro biochemical systems (pros: mechanistic detail; cons: lack cellular context)</li> <li>Ex vivo tissue cultures (pros: tissue architecture; cons: limited viability)</li> <li>In vivo models (pros: physiological relevance; cons: delivery challenges, ethical considerations)</li> <li>Ethical Considerations: Off-target effects, germline editing concerns, animal welfare, consent for human cells</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>Validation of editing efficiency</li> <li>Off-target analysis</li> <li>Phenotypic readouts</li> <li>Molecular characterization</li> <li>Technical Replicates: Multiple transfection/transduction experiments, multiple edited clones</li> <li>Potential Biases:</li> <li>Delivery method efficiency</li> <li>Cell type-specific editing outcomes</li> <li>Clonal selection artifacts</li> <li>Off-target effects</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Cells/organisms with targeted genetic modification</li> <li>Control 1: Wild-type/unmodified cells</li> <li>Control 2: Mock-treated cells (transfection reagents only)</li> <li>Control 3: Non-targeting guide RNA or scrambled siRNA controls</li> <li>Controlled Variables: Cell passage number, transfection conditions, selection methods</li> <li>Biological Replicates: Minimum 3 independent editing experiments; multiple clones for stable modifications</li> <li>Modified Design: Multiplexed editing, inducible systems, combinatorial modifications</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Editing efficiency quantification</li> <li>Off-target analysis</li> <li>Expression level verification</li> <li>Phenotypic measurements</li> <li>Presentation Approaches:</li> <li>Sequencing traces showing edits</li> <li>Western blots/qPCR for expression changes</li> <li>Phenotypic assay results</li> <li>Off-target analysis plots</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#6-technique-comparison-genome-editing-methods","title":"6. Technique Comparison - Genome Editing Methods","text":"Feature Homologous Recombination ZFNs (Zinc Finger Nucleases) TALENs CRISPR-Cas9 Mechanism Endogenous DNA repair Engineered nuclease + DNA repair Engineered nuclease + DNA repair RNA-guided nuclease + DNA repair Design Complexity High (homology arms) Very high (protein engineering) High (protein assembly) Low (guide RNA design) Efficiency Very low (0.1-1%) Moderate (1-10%) Moderate (1-10%) High (1-90%, system-dependent) Specificity Very high High Very high Moderate to high (guide-dependent) Size of Edit Unlimited (replacement) Small to large Small to large Small to large Multiplexing Difficult Difficult Difficult Easy Time to Implement Months Months Weeks to months Days to weeks Cost High Very high High Low Best For \u2022 Precise gene replacement\u2022 Knock-in of large sequences\u2022 Clean modifications\u2022 ES cell modifications \u2022 Targeted gene disruption\u2022 Editing in specific contexts\u2022 When high specificity is critical\u2022 Historic datasets \u2022 Highly specific editing\u2022 Modification of methylated regions\u2022 Alternative to CRISPR\u2022 Reduced off-target concerns \u2022 Rapid genetic screening\u2022 Multiplexed editing\u2022 Versatile applications\u2022 Complex genetic manipulations Limitations \u2022 Extremely low efficiency\u2022 Labor intensive\u2022 Limited to dividing cells\u2022 Complex construct design \u2022 Difficult protein design\u2022 Limited targeting range\u2022 High cost\u2022 Technical expertise required \u2022 Complex assembly\u2022 Large protein size limits delivery\u2022 Time-consuming design\u2022 Lower efficiency than CRISPR \u2022 Off-target concerns\u2022 PAM site requirements\u2022 Delivery challenges for large Cas9\u2022 Immune responses in vivo"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#7-technique-comparison-expression-modulation-methods","title":"7. Technique Comparison - Expression Modulation Methods","text":"Feature RNAi CRISPRi CRISPRa Gene Overexpression Epigenome Engineering Mechanism mRNA degradation Transcriptional repression Transcriptional activation Increased gene dosage Modification of epigenetic marks Target mRNA DNA (promoters/enhancers) DNA (promoters/enhancers) Coding sequence DNA/histones Effect Level Post-transcriptional Transcriptional Transcriptional Post-transcriptional Transcriptional Duration Transient (siRNA)Stable (shRNA) Stable while expressed Stable while expressed Variable (transient to stable) Potentially heritable Completeness Partial knockdown Near-complete silencing possible Variable activation Controlled by promoter/enhancer Variable and context-dependent Specificity Moderate (off-targets) High (guide-dependent) High (guide-dependent) Very high (gene-specific) High (site-specific) Ease of Design Easy Easy Moderate Easy Moderate to complex Best For \u2022 Rapid gene inhibition\u2022 Transient effects\u2022 Dose-dependent studies\u2022 Non-coding RNAs \u2022 Gene silencing\u2022 Regulatory element analysis\u2022 Non-coding regions\u2022 Stable repression \u2022 Upregulating endogenous genes\u2022 Enhancer activation\u2022 Screening enhancers\u2022 Complex gene regulation \u2022 Rescue experiments\u2022 Protein function studies\u2022 Dominant effects\u2022 Dose-response analysis \u2022 Chromatin state manipulation\u2022 Imprinting studies\u2022 Heritable modifications\u2022 Regulatory element analysis Limitations \u2022 Incomplete knockdown\u2022 Off-target effects\u2022 Variable efficiency\u2022 Interferon responses \u2022 Requires continuous expression\u2022 Variable across genomic contexts\u2022 Limited to accessible regions\u2022 Delivery challenges \u2022 Context-dependent efficiency\u2022 Chromatin state dependent\u2022 Limited by endogenous potential\u2022 Delivery challenges \u2022 Non-physiological levels\u2022 Ectopic expression artifacts\u2022 Toxicity concerns\u2022 Delivery limitations \u2022 Context-dependent effects\u2022 Complex readouts\u2022 Variable stability\u2022 Technical complexity"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#8-complementary-usage-strategy","title":"8. Complementary Usage Strategy","text":"<ul> <li>Gene Function Analysis:</li> <li>Use CRISPR-Cas9 for complete gene knockout</li> <li>Apply RNAi for dose-dependent or transient knockdown</li> <li> <p>Implement gene overexpression for rescue experiments</p> </li> <li> <p>Regulatory Element Analysis:</p> </li> <li>Employ CRISPRi to silence specific regulatory elements</li> <li>Use CRISPRa to activate enhancers or promoters</li> <li> <p>Apply epigenome engineering to modify chromatin states</p> </li> <li> <p>Therapeutic Development:</p> </li> <li>CRISPR-Cas9 for correction of pathogenic mutations</li> <li>RNAi for targeting disease-causing gene products</li> <li> <p>Gene overexpression for replacement of deficient proteins</p> </li> <li> <p>Integrated Approach: Design multi-platform studies for comprehensive characterization:</p> </li> <li>CRISPR-Cas9 to generate complete knockouts for core phenotypic analysis</li> <li>RNAi for temporal or partial inhibition studies</li> <li>CRISPRi/a for regulatory element mapping</li> <li>Overexpression for structure-function and rescue studies</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#9-technology-specific-considerations","title":"9. Technology-Specific Considerations","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#crispr-cas9-system","title":"CRISPR-Cas9 System","text":"<ul> <li>Guide RNA Design:</li> <li>Optimize for on-target efficiency and minimal off-targets</li> <li>Consider chromatin accessibility at target site</li> <li> <p>Account for PAM requirements of specific Cas variants</p> </li> <li> <p>Delivery Methods:</p> </li> <li>Plasmid transfection (simple, transient)</li> <li>Viral vectors (efficient, stable integration)</li> <li> <p>RNP delivery (rapid, reduced off-targets)</p> </li> <li> <p>Variants and Adaptations:</p> </li> <li>Cas9 nickase for reduced off-targets</li> <li>High-fidelity Cas9 variants (SpCas9-HF1, eSpCas9)</li> <li>Cas12a/Cpf1 for alternative PAM requirements</li> <li>Base editors for precise nucleotide changes</li> <li>Prime editors for targeted insertions and deletions</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#rnai-technology","title":"RNAi Technology","text":"<ul> <li>Design Considerations:</li> <li>siRNA vs. shRNA selection based on duration needs</li> <li>Seed region optimization to reduce off-targets</li> <li> <p>Pooled vs. individual siRNAs</p> </li> <li> <p>Validation Approaches:</p> </li> <li>Multiple independent siRNAs targeting different regions</li> <li>Rescue experiments with RNAi-resistant constructs</li> <li>Dose-response analysis</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#crispri-and-crispra","title":"CRISPRi and CRISPRa","text":"<ul> <li>Component Selection:</li> <li>dCas9 fusion partners (KRAB, VP64, p65, HSF1)</li> <li>Guide RNA positioning relative to TSS</li> <li> <p>Single guides vs. multiple guides for synergistic effects</p> </li> <li> <p>Applications:</p> </li> <li>Tiling of regulatory regions to map functional elements</li> <li>Multiplexed activation/repression for pathway analysis</li> <li>Inducible systems for temporal control</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#gene-overexpression","title":"Gene Overexpression","text":"<ul> <li>Vector Selection:</li> <li>Viral (lentivirus, AAV, adenovirus) based on cell type</li> <li>Inducible promoters for controlled expression</li> <li> <p>Tagged constructs for tracking and purification</p> </li> <li> <p>Considerations:</p> </li> <li>Expression level optimization</li> <li>Codon optimization for efficient translation</li> <li>Subcellular targeting signals if needed</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20editing/#epigenome-engineering","title":"Epigenome Engineering","text":"<ul> <li>Effector Domains:</li> <li>DNA methyltransferases (DNMT3A, DNMT3B)</li> <li>Histone modifiers (p300, LSD1, EZH2)</li> <li> <p>Combinations for synergistic effects</p> </li> <li> <p>Target Selection:</p> </li> <li>CpG islands for DNA methylation</li> <li>Promoters vs. enhancers</li> <li>Boundary elements and insulators</li> </ul> <p>This comprehensive framework provides researchers with a structured approach to selecting and implementing gene editing and expression modulation technologies. The complementary use of these methods enables precise dissection of gene function and regulatory mechanisms in diverse biological contexts.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/","title":"MBE Gene expression analysis technologies","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How do gene expression patterns vary across conditions, cell types, or spatial locations within tissues?</li> <li>Design Rationale: Transcriptome analysis techniques reveal comprehensive gene expression profiles, alternative splicing events, and spatial distribution of transcripts</li> <li>Follow-up Studies: Functional validation of differentially expressed genes, pathway analysis, biomarker identification, therapeutic target discovery</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, tissue samples, patient biopsies, single-cell suspensions</li> <li>Rationale: These systems provide RNA of sufficient quality and quantity while maintaining biological relevance</li> <li>Alternatives:</li> <li>In vitro cell models (pros: controlled conditions, homogeneity; cons: may not reflect in vivo complexity)</li> <li>Animal models (pros: system-level responses; cons: species differences, ethical considerations)</li> <li>Organoids (pros: 3D structure, cell-cell interactions; cons: incomplete tissue architecture)</li> <li>Ethical Considerations: Patient consent for clinical samples, minimizing animal use, responsible data sharing and privacy</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>High-quality RNA extraction and preservation</li> <li>RNA integrity verification</li> <li>Library preparation optimization</li> <li>Inclusion of spike-in controls</li> <li>Technical Replicates: Multiple technical replicates for microarrays; sequencing depth considerations for RNA-seq approaches</li> <li>Potential Biases:</li> <li>RNA degradation (use RIN scores to assess quality)</li> <li>Batch effects (include batch controls)</li> <li>PCR amplification bias (UMIs for single-cell approaches)</li> <li>3' bias in degraded samples (assess coverage uniformity)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples from experimental condition of interest</li> <li>Control 1: Matched untreated/baseline samples</li> <li>Control 2: Technical controls (spike-ins, housekeeping genes)</li> <li>Control 3: Biological reference standards when available</li> <li>Controlled Variables: RNA quality, batch processing, sequencing platform, analysis pipeline</li> <li>Biological Replicates: Minimum 3-5 biological replicates per condition; higher numbers for heterogeneous samples</li> <li>Modified Design: Time-course analysis, dose-response relationships, multiple tissue regions</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Quality control metrics (read depth, mapping rates, coverage)</li> <li>Normalization strategies appropriate to technique</li> <li>Differential expression analysis with statistical thresholds</li> <li>Pathway and functional enrichment analysis</li> <li>Presentation Approaches:</li> <li>Heatmaps for expression patterns</li> <li>Volcano plots for significance visualization</li> <li>PCA/t-SNE/UMAP for dimensionality reduction</li> <li>Spatial maps for regional expression patterns</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature Microarray RNA-seq Single-cell RNA-seq Long-read Sequencing Spatial Transcriptomics Primary Use Global gene expression profiling Comprehensive transcriptome analysis Cell-type specific expression patterns Full-length transcript analysis Spatial mapping of gene expression Sensitivity Moderate (limited dynamic range) High (wide dynamic range) Moderate (limited by dropout effects) Moderate (lower throughput) Moderate (depends on platform) Specificity Good for known transcripts Excellent for known and novel transcripts Good for abundant transcripts Excellent for isoform discrimination Good for targeted gene panels Quantification Relative abundance through hybridization Digital counts of transcript abundance Digital counts at single-cell resolution Accurate isoform quantification Regional expression quantification Throughput High (thousands of genes) Very high (entire transcriptome) High (thousands of cells) Moderate (fewer reads, longer lengths) Moderate (spatial resolution trade-off) Resolution Gene-level only Gene and transcript-level Single-cell Full transcript structure Tissue region/cell location Cost Low to moderate Moderate High High Very high RNA Input Required 50-500 ng 10-1000 ng Single-cell (pg range) 50-1000 ng Tissue sections Technical Expertise Moderate Moderate to advanced Advanced Advanced Very advanced Best For \u2022 Well-characterized systems\u2022 Large sample comparisons\u2022 Cost-effective screening\u2022 Established gene sets \u2022 Discovering novel transcripts\u2022 Detecting rare transcripts\u2022 Alternative splicing analysis\u2022 Comprehensive profiling \u2022 Heterogeneous samples\u2022 Rare cell type identification\u2022 Developmental trajectories\u2022 Cellular diversity studies \u2022 Isoform identification\u2022 Fusion transcript detection\u2022 Complex structural variants\u2022 Complete transcript sequences \u2022 Tissue architecture analysis\u2022 Cell-cell communication\u2022 Niche-specific expression\u2022 Disease boundary mapping Limitations \u2022 Limited to known sequences\u2022 Cross-hybridization issues\u2022 Narrow dynamic range\u2022 No novel transcript discovery \u2022 Complex data analysis\u2022 Computational requirements\u2022 Short-read assembly challenges\u2022 Batch effects \u2022 Low RNA capture efficiency\u2022 High dropout rates\u2022 Expensive per sample\u2022 Limited splicing information \u2022 Lower throughput\u2022 Higher error rates\u2022 More expensive\u2022 Specialized analysis required \u2022 Limited gene coverage\u2022 Resolution constraints\u2022 Expensive technology\u2022 Complex data integration"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Initial Profiling: Use microarrays for cost-effective screening of known genes across many samples</li> <li>Comprehensive Analysis: Follow with RNA-seq for in-depth transcriptome characterization including novel transcripts</li> <li>Heterogeneity Assessment: Apply single-cell RNA-seq to dissect cellular subpopulations and rare cell types</li> <li>Structural Validation: Employ long-read sequencing to resolve complex isoforms and structural variants</li> <li>Contextual Understanding: Integrate spatial transcriptomics to map expression patterns within tissue architecture</li> <li>Integrated Approach: Design multi-platform studies for comprehensive characterization:</li> <li>RNA-seq for global transcriptome profiling</li> <li>Single-cell RNA-seq to resolve cellular heterogeneity</li> <li>Long-read sequencing to characterize full-length transcripts of interest</li> <li>Spatial transcriptomics to map key findings to tissue context</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#8-technology-specific-considerations","title":"8. Technology-Specific Considerations","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#microarray","title":"Microarray","text":"<ul> <li>Design Optimization: Probe selection affects specificity and coverage</li> <li>Hybridization Conditions: Critical for signal-to-noise ratio</li> <li>Data Normalization: Essential for cross-array comparisons</li> <li>Legacy Data: Valuable historical datasets available for meta-analysis</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#rna-seq","title":"RNA-seq","text":"<ul> <li>Library Preparation: Stranded vs. unstranded, poly(A) selection vs. ribo-depletion</li> <li>Sequencing Depth: Tailored to research question (15-30M reads for differential expression)</li> <li>Read Length: Longer reads improve mapping and transcript assembly</li> <li>Spike-in Controls: Essential for absolute quantification</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#single-cell-rna-seq","title":"Single-cell RNA-seq","text":"<ul> <li>Cell Isolation: Dissociation protocols affect cell representation</li> <li>Droplet vs. Well-based: Trade-off between cell number and coverage depth</li> <li>Doublet Rate: Quality control to remove multi-cell captures</li> <li>Computational Deconvolution: Advanced algorithms for cell type identification</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#long-read-sequencing","title":"Long-read Sequencing","text":"<ul> <li>Platform Selection: PacBio (higher accuracy) vs. Oxford Nanopore (longer reads)</li> <li>Error Correction: Critical for accurate transcript annotation</li> <li>Hybrid Approaches: Combining with short-read data for error correction</li> <li>Direct RNA Sequencing: Captures native modifications but with lower throughput</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Gene%20expression%20analysis%20technologies/#spatial-transcriptomics","title":"Spatial Transcriptomics","text":"<ul> <li>Resolution Range: From tissue regions to subcellular localization</li> <li>Coverage vs. Resolution: Trade-off between gene number and spatial detail</li> <li>Image Integration: Correlating expression with histological features</li> <li>Cell Type Deconvolution: Computational methods to resolve mixed signals</li> </ul> <p>This integrated framework provides a comprehensive approach to transcriptome analysis, leveraging the strengths of each technology while addressing their individual limitations. The complementary use of these methods enables researchers to build a multi-dimensional understanding of gene expression across biological systems.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein%20assessment/","title":"MBE Protein assessment","text":"<ul> <li>\u8868\u8fbe\u5c42\u9762\uff1aWestern Blotting\uff08WB\uff09\u548c ELISA \u9002\u5408\u68c0\u6d4b\u86cb\u767d\u8d28\u4e30\u5ea6\u53d8\u5316\u6216\u7ffb\u8bd1\u540e\u4fee\u9970\uff08PTM\uff09\u3002</li> <li>\u76f8\u4e92\u4f5c\u7528\u5c42\u9762\uff1aCo-IP\u3001Pull-Down \u548c\u8d28\u8c31\uff08MS\uff09\u7528\u4e8e\u89e3\u6790\u86cb\u767d\u590d\u5408\u7269\u7ec4\u6210\u3002</li> <li>\u52a8\u6001\u5c42\u9762\uff1aFRET \u53ef\u5b9e\u65f6\u76d1\u6d4b\u6d3b\u7ec6\u80de\u4e2d\u86cb\u767d\u4e92\u4f5c\u7684\u65f6\u7a7a\u52a8\u6001\u3002</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein%20assessment/#_1","title":"\u6280\u672f\u4e92\u8865\u6027\u793a\u4f8b","text":"<ul> <li>WB \u2192 Co-IP \u2192 MS\uff1a     \u5148\u7528 WB \u786e\u8ba4\u86cb\u767d\u8868\u8fbe\u6c34\u5e73\uff0c\u518d\u901a\u8fc7 Co-IP \u5bcc\u96c6\u590d\u5408\u7269\uff0c\u6700\u540e\u7528 MS \u9274\u5b9a\u4e92\u4f5c\u86cb\u767d\u3002</li> <li>Pull-Down \u2192 FRET\uff1a     \u4f53\u5916\u9a8c\u8bc1\u76f4\u63a5\u4e92\u4f5c\u540e\uff0c\u7528 FRET \u5728\u6d3b\u7ec6\u80de\u4e2d\u9a8c\u8bc1\u52a8\u6001\u8fc7\u7a0b\u3002</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein%20assessment/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Are specific proteins expressed, modified, or forming complexes under particular cellular conditions?</li> <li>Design Rationale: Protein analysis techniques enable detection, quantification, and characterization of protein-protein interactions critical for understanding cellular pathways</li> <li>Follow-up Studies: Functional validation of protein interactions, structure-function analysis, development of targeted interventions</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein%20assessment/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, tissue lysates, purified protein preparations</li> <li>Rationale: These systems provide sufficient protein yield while maintaining native conformations and interactions</li> <li>Alternatives:</li> <li>In vitro reconstituted systems (pros: defined components; cons: may lack cellular context)</li> <li>In vivo animal models (pros: physiological relevance; cons: complex background, ethical considerations)</li> <li>Patient samples (pros: clinical relevance; cons: limited availability, heterogeneity)</li> <li>Ethical Considerations: Responsible antibody production, ethical sourcing of biological materials, data reproducibility</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein%20assessment/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>Optimized protein extraction methods</li> <li>Appropriate buffer conditions to maintain native interactions</li> <li>Validated antibodies or detection reagents</li> <li>Inclusion of appropriate controls</li> <li>Technical Replicates: Minimum triplicate measurements for quantitative assessments</li> <li>Potential Biases:</li> <li>Antibody cross-reactivity (validate with knockouts/knockdowns)</li> <li>Extraction efficiency variations (standardize protocols)</li> <li>Artificial interactions during lysis (crosslinking strategies)</li> <li>Overexpression artifacts (use endogenous levels when possible)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein%20assessment/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples from treatment conditions of interest</li> <li>Control 1: Untreated/baseline samples</li> <li>Control 2: Negative controls (non-specific antibodies, irrelevant proteins)</li> <li>Control 3: Positive controls (known interactors or expression levels)</li> <li>Controlled Variables: Protein concentration, lysis conditions, incubation times, detection parameters</li> <li>Biological Replicates: Minimum 3-5 independent experiments for statistical validity</li> <li>Modified Design: Include time-course analysis, dose-response relationships, or genetic perturbations</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein%20assessment/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Normalization to loading controls or reference proteins</li> <li>Statistical comparison between experimental conditions</li> <li>Quantification of band intensities or signal strength</li> <li>Correlation with functional outcomes</li> <li>Presentation Approaches:</li> <li>Representative blot/gel images with molecular weight markers</li> <li>Quantitative graphs with error bars</li> <li>Network diagrams for interaction studies</li> <li>Co-localization images for spatial information</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein%20assessment/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature Western Blotting Co-IP Pull-Down Assay Mass Spectrometry FRET ELISA Primary Use Protein detection and semi-quantification Endogenous protein-protein interactions Direct protein-protein binding Comprehensive protein identification and quantification Real-time protein interactions in living cells Sensitive protein quantification Sensitivity Moderate (nanogram range) Moderate (depends on antibody) Moderate (depends on bait affinity) High (picogram range) Moderate (requires sufficient fluorophore expression) Very high (picogram to femtogram range) Specificity Good, antibody-dependent Good, antibody-dependent Good, depends on bait purity Very good with proper controls Good for direct interactions (&lt;10nm) Excellent (sandwich format) Quantification Semi-quantitative Qualitative to semi-quantitative Qualitative to semi-quantitative Highly quantitative with proper controls Quantitative for interaction dynamics Highly quantitative Throughput Low to moderate Low Low High Low to moderate High Time Required 1-2 days 1-2 days 1-2 days 2-3 days (including analysis) Hours to days (construct preparation) Hours Cost Moderate Moderate Moderate High High (equipment) Moderate Equipment Gel apparatus, transfer system, imaging Basic lab equipment Basic lab equipment Mass spectrometer, LC system Specialized fluorescence microscope Plate reader Technical Expertise Moderate Moderate Moderate Advanced Advanced Basic to moderate Best For \u2022 Protein expression levels\u2022 Post-translational modifications\u2022 Confirming specific proteins\u2022 Relative comparison between conditions \u2022 Endogenous protein complexes\u2022 Verification of interactions\u2022 Identifying components of complexes\u2022 Native interaction conditions \u2022 Direct binding partners\u2022 Testing specific interactions\u2022 In vitro confirmation\u2022 Domain mapping \u2022 Unbiased interaction discovery\u2022 Comprehensive proteome analysis\u2022 PTM identification\u2022 Complex composition \u2022 Real-time interaction kinetics\u2022 Spatial localization of interactions\u2022 Conformational changes\u2022 Living cell studies \u2022 Precise protein quantification\u2022 Biomarker detection\u2022 High-throughput screening\u2022 Clinical samples Limitations \u2022 Limited quantification\u2022 Antibody availability\u2022 Single protein focus\u2022 Size limitations \u2022 Non-specific binding\u2022 Transient interactions may be missed\u2022 Requires good antibodies\u2022 Indirect interactions indistinguishable \u2022 Artificial conditions\u2022 Overexpression artifacts\u2022 May miss weak interactions\u2022 Limited to binary interactions \u2022 Expensive equipment\u2022 Complex data analysis\u2022 Sample preparation critical\u2022 Low abundance proteins challenging \u2022 Requires protein tagging\u2022 Background fluorescence\u2022 Limited to close interactions\u2022 Complex setup \u2022 Limited to soluble proteins\u2022 Antibody pair requirement\u2022 Limited structural information\u2022 No interaction details"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein%20assessment/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Expression Analysis: Begin with Western blotting to confirm protein expression and basic modifications</li> <li>Interaction Screening: Use Co-IP or pull-down assays to identify potential interacting partners</li> <li>Comprehensive Mapping: Apply mass spectrometry for unbiased identification of complex components</li> <li>Dynamic Analysis: Employ FRET to study real-time interaction kinetics in living cells</li> <li>Quantitative Assessment: Utilize ELISA for precise quantification of specific proteins</li> <li>Integrated Approach: Combine techniques for robust validation:</li> <li>Western blotting to confirm protein expression</li> <li>Co-IP to identify native protein complexes</li> <li>Pull-down to verify direct interactions</li> <li>Mass spectrometry to comprehensively map interaction networks</li> <li>FRET to validate interactions in living cells</li> <li>ELISA to precisely quantify changes in protein abundance</li> </ul> <p>This multi-technique strategy leverages the strengths of each method while compensating for individual limitations, providing a comprehensive understanding of protein interactions that is critical for elucidating cellular pathways and disease mechanisms.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein-DNA%20interaction/","title":"MBE Protein DNA interaction","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein-DNA%20interaction/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: What are the genomic binding sites of transcription factor X, and how do these binding patterns change in response to condition Y?</li> <li>Design Rationale: Protein-DNA interaction techniques reveal where regulatory proteins bind across the genome, helping elucidate gene regulation mechanisms</li> <li>Follow-up Studies: Functional validation of binding sites, correlation with gene expression changes, investigation of co-factors and chromatin modifications</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein-DNA%20interaction/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cell lines expressing the transcription factor of interest, with and without exposure to condition Y</li> <li>Rationale: Cell lines provide controlled experimental conditions, consistent expression of the factor, and sufficient material for multiple analytical approaches</li> <li>Alternatives:</li> <li>Primary cells (pros: physiological relevance; cons: limited material, variability)</li> <li>Animal tissues (pros: in vivo context; cons: species differences)</li> <li>In vitro reconstituted systems (pros: defined components; cons: lacks chromatin context)</li> <li>Ethical Considerations: Cell line authentication, appropriate antibody validation, responsible data sharing</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein-DNA%20interaction/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>Protein expression verification</li> <li>Antibody validation</li> <li>Appropriate controls for each technique</li> <li>Consistent sample processing</li> <li>Technical Replicates: Duplicate or triplicate experiments for each condition</li> <li>Potential Biases:</li> <li>Antibody specificity (validate with knockout/knockdown)</li> <li>Crosslinking efficiency (optimize protocols)</li> <li>Fragmentation bias (control fragment size distribution)</li> <li>Sequencing depth variation (normalize appropriately)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein-DNA%20interaction/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Cells expressing transcription factor X in condition Y</li> <li>Control 1: Cells expressing transcription factor X in baseline condition</li> <li>Control 2: Cells lacking transcription factor X (knockout/knockdown)</li> <li>Control 3: Technique-specific controls (IgG, input DNA, etc.)</li> <li>Controlled Variables: Cell density, treatment conditions, protein expression levels, sample processing</li> <li>Biological Replicates: Minimum 2-3 independent experiments</li> <li>Modified Design: Include time-course or dose-response elements to capture dynamic binding changes</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein-DNA%20interaction/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Peak/binding site identification</li> <li>Motif analysis</li> <li>Genomic feature annotation</li> <li>Comparison between conditions</li> <li>Presentation Approaches:</li> <li>Genome browser tracks</li> <li>Heatmaps of binding intensity</li> <li>Motif logos</li> <li>Venn diagrams of binding site overlap</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein-DNA%20interaction/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature ChIP-seq Footprinting EMSA CUT&amp;RUN Primary Use Genome-wide mapping of protein binding sites High-resolution analysis of protein-DNA contacts Verification of direct protein-DNA interactions High-resolution mapping with minimal sample input Genomic Scale Genome-wide Limited regions Single locus Genome-wide Resolution 100-300 bp 1-10 bp ~20-30 bp 10-50 bp Required Sample High (millions of cells) Moderate (thousands to millions) Low (recombinant protein and oligos) Very low (hundreds to thousands of cells) Antibody Needed Yes No No (can use for supershifts) Yes In vivo Relevance High (captures native chromatin) Moderate to high Low (in vitro binding) High (native chromatin) Throughput High Low Low High Time Required 2-3 days 1-2 days 4-6 hours 1-2 days Technical Difficulty Moderate to high High Low to moderate Moderate Equipment Needs Sequencer, sonicator/fragmenter Sequencer or capillary electrophoresis Electrophoresis equipment Sequencer Best For \u2022 Global binding patterns\u2022 Discovering new targets\u2022 Comparative analysis across conditions\u2022 Integration with other genomic data \u2022 Precise binding site determination\u2022 Visualizing multiple factors at one locus\u2022 Determining occupancy levels\u2022 Characterizing binding dynamics \u2022 Confirming direct binding\u2022 Testing binding affinity\u2022 Evaluating sequence specificity\u2022 Identifying protein complexes (supershifts) \u2022 Rare cell types\u2022 Highly specific factor mapping\u2022 Low background profiling\u2022 High resolution binding maps Limitations \u2022 Antibody quality dependence\u2022 High cell number requirement\u2022 Crosslinking artifacts\u2022 Limited resolution \u2022 Limited to accessible regions\u2022 Labor intensive\u2022 Technically challenging\u2022 Limited throughput \u2022 In vitro conditions\u2022 Single locus at a time\u2022 Semi-quantitative\u2022 May not reflect chromatin context \u2022 Relatively new technique\u2022 Limited antibody compatibility\u2022 Specialized protocol optimization\u2022 Data analysis challenges"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein-DNA%20interaction/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein-DNA%20interaction/#sequential-approach","title":"Sequential Approach","text":"<ol> <li>ChIP-seq for Global Discovery:</li> <li>Perform first to identify genome-wide binding patterns</li> <li>Reveals overall distribution (promoters, enhancers, etc.)</li> <li> <p>Identifies condition-specific binding changes</p> </li> <li> <p>CUT&amp;RUN for High-Resolution Validation:</p> </li> <li>Follow up on key regions with higher resolution</li> <li>Validate findings with lower cell numbers</li> <li> <p>Reduce background and increase signal-to-noise</p> </li> <li> <p>Footprinting for Base-Level Resolution:</p> </li> <li>Apply to critical regulatory regions</li> <li>Determine exact nucleotide contacts</li> <li> <p>Identify binding of multiple factors at regulatory hubs</p> </li> <li> <p>EMSA for Biochemical Validation:</p> </li> <li>Confirm direct binding to specific sequences</li> <li>Test affinity of variants or mutants</li> <li>Identify co-factor requirements</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20Protein-DNA%20interaction/#optimal-application-scenarios","title":"Optimal Application Scenarios","text":"<ul> <li>Novel Factor with Unknown Targets: Start with ChIP-seq for broad discovery</li> <li>Limited Sample Availability: Use CUT&amp;RUN as primary approach</li> <li>Complex Regulatory Region: Apply footprinting for detailed architecture</li> <li>Mutation Impact Assessment: Use EMSA to test sequence variants</li> <li>Comprehensive Analysis: Combine techniques for multi-level validation:</li> <li>ChIP-seq \u2192 identify binding regions</li> <li>CUT&amp;RUN \u2192 refine binding sites</li> <li>Footprinting \u2192 determine exact contacts</li> <li>EMSA \u2192 biochemically validate direct interactions</li> </ul> <p>This integrated approach leverages the strengths of each technique while compensating for individual limitations, providing comprehensive characterization of protein-DNA interactions from genome-wide patterns to specific base contacts.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20assessment/","title":"MBE RNA assessment","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20assessment/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How does gene X expression change in response to condition Y, and what transcript variants are present?</li> <li>Design Rationale: RNA detection techniques allow quantification of expression levels and characterization of transcript structures in different conditions</li> <li>Follow-up Studies: Protein expression correlation, functional validation of transcript variants, mechanistic investigation of expression changes</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20assessment/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cell lines exposed to condition Y (e.g., drug treatment, stress, differentiation signal)</li> <li>Rationale: Cell lines provide controlled experimental conditions, reproducible responses, and sufficient RNA yield for multiple analytical approaches</li> <li>Alternatives:</li> <li>Patient tissues (pros: clinical relevance; cons: variability, limited availability)</li> <li>Animal models (pros: in vivo context; cons: species differences)</li> <li>Organoids (pros: 3D tissue architecture; cons: technical complexity)</li> <li>Ethical Considerations: Cell line authentication, appropriate handling of patient materials if used, responsible data sharing</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20assessment/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>High-quality RNA extraction with RNase inhibition</li> <li>DNase treatment to remove genomic contamination</li> <li>RNA integrity assessment (e.g., Bioanalyzer RIN scores)</li> <li>Reference gene selection for normalization</li> <li>Technical Replicates: Triplicate measurements for each sample and technique</li> <li>Potential Biases:</li> <li>RNA degradation (rapid processing, quality controls)</li> <li>Reverse transcription efficiency variation (consistent protocols)</li> <li>Amplification bias (optimize primer design)</li> <li>Batch effects (include inter-run calibrators)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20assessment/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Cells exposed to condition Y (multiple timepoints)</li> <li>Control 1: Untreated cells (time-matched)</li> <li>Control 2: Positive controls (known expression changes)</li> <li>Control 3: No-template and no-RT controls</li> <li>Controlled Variables: RNA quantity, integrity metrics, reagent lots, treatment conditions</li> <li>Biological Replicates: Minimum 3-5 independent experiments</li> <li>Modified Design: Include dose-response or time-course elements to capture dynamic expression changes</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20assessment/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Quality control metrics</li> <li>Normalization to reference genes</li> <li>Statistical comparison between conditions</li> <li>Visualization of expression changes</li> <li>Presentation Approaches:</li> <li>Gel/blot images with size markers</li> <li>Amplification curves and threshold cycles</li> <li>Fold-change calculations with error bars</li> <li>Time-course or dose-response plots</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20assessment/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature RT-PCR Northern Blotting Primary Use Sensitive detection and semi-quantification of specific RNA transcripts Visualization and size determination of specific RNA transcripts Sensitivity Very high (can detect &lt;100 copies) Moderate (requires ~5-10 \u03bcg total RNA) Specificity Good, primer-dependent Excellent, especially for transcript size variants Quantification Semi-quantitative (endpoint PCR)Highly quantitative (real-time RT-qPCR) Semi-quantitative Transcript Size Info Limited (primer-dependent) Excellent (directly visualizes transcript size) Throughput High Low Time Required 3-5 hours 1-2 days Cost Low to moderate High Equipment PCR thermocycler (or qPCR instrument) Multiple specialized equipment Technical Expertise Basic to moderate Advanced RNA Input Required Low (ng range) High (\u03bcg range) Best For \u2022 Highly sensitive detection\u2022 High-throughput screening\u2022 Small sample amounts\u2022 Quantitative expression analysis (RT-qPCR)\u2022 Specific splice variant detection \u2022 Transcript size determination\u2022 Detection of novel transcript variants\u2022 Visualization of RNA processing\u2022 Confirming transcript integrity\u2022 Detecting multiple transcripts with one probe Limitations \u2022 Limited transcript size information\u2022 Cannot detect novel variants\u2022 Potential for genomic DNA contamination\u2022 Reverse transcription variability \u2022 Labor intensive\u2022 Low throughput\u2022 Requires large RNA amounts\u2022 Less sensitive\u2022 Potential RNA degradation during procedure"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20assessment/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Initial Expression Analysis: Use RT-PCR/RT-qPCR for sensitive, high-throughput screening of expression changes across many samples and conditions</li> <li>Transcript Validation: Follow with Northern blotting for critical genes to:</li> <li>Confirm actual transcript size</li> <li>Detect unexpected transcript variants</li> <li>Validate full-length mRNA integrity</li> <li> <p>Identify processing intermediates</p> </li> <li> <p>Integrated Approach:</p> </li> <li>RT-qPCR for rapid quantification across many samples and timepoints</li> <li>Northern blotting for detailed characterization of transcript structure for key findings</li> <li>Use Northern results to design improved RT-PCR primers for specific variants</li> <li>Follow up with specialized techniques (RNA-seq, 5'/3' RACE) based on initial findings</li> </ul> <p>This complementary approach leverages the sensitivity and throughput of RT-PCR with the structural information provided by Northern blotting, providing a more complete picture of gene expression changes than either technique alone.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20editing-based%20RNA-seq/","title":"MBE RNA editing based RNA seq","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20editing-based%20RNA-seq/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: What are the direct RNA targets and precise binding sites of RNA-binding protein X in living cells?</li> <li>Design Rationale: Fusion of RNA-binding protein (RBP) to an RNA editing enzyme (APOBEC) creates a chimeric protein that marks RNA binding sites with C-to-U conversions, detectable by RNA-seq without crosslinking artifacts</li> <li>Follow-up Studies: Motif analysis of binding sites, functional validation of key targets, structural studies of RBP-RNA interactions, comparison with other RBP mapping techniques (CLIP-seq)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20editing-based%20RNA-seq/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cell line relevant to RBP function (e.g., neuronal cells for neuron-specific RBPs, cancer cells for cancer-relevant RBPs)</li> <li>Rationale: Cell lines provide controlled expression of the RBP-APOBEC fusion, high RNA yield, and consistent experimental conditions</li> <li>Alternatives:</li> <li>Primary cells (pros: physiological relevance; cons: transfection challenges, variability)</li> <li>Mouse models with inducible RBP-APOBEC (pros: in vivo context; cons: complex, expensive)</li> <li>In vitro transcribed RNAs (pros: defined sequences; cons: lacks cellular context)</li> <li>Ethical Considerations: Cell line authentication, appropriate biosafety practices, responsible use of genetic modification tools</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20editing-based%20RNA-seq/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques:</li> <li>Doxycycline-inducible expression of RBP-APOBEC fusion</li> <li>RNA extraction with DNase treatment</li> <li>Strand-specific RNA-seq with high depth</li> <li>C-to-U editing site identification</li> <li>Technical Replicates: Duplicate RNA-seq libraries</li> <li>Potential Biases:</li> <li>Expression level variations of RBP-APOBEC (use inducible system with titrated expression)</li> <li>Off-target editing (include catalytically inactive APOBEC control)</li> <li>RNA degradation artifacts (optimize RNA extraction protocol)</li> <li>Sequence context preferences of APOBEC (account for in computational analysis)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20editing-based%20RNA-seq/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Cells expressing RBP-APOBEC fusion</li> <li>Control 1: Cells expressing catalytically inactive APOBEC fusion (deaminase mutant)</li> <li>Control 2: Cells expressing APOBEC only (no RBP)</li> <li>Control 3: Cells expressing GFP-APOBEC (non-specific RNA binding)</li> <li>Control 4: Uninduced cells (baseline editing)</li> <li>Controlled Variables: Induction time, expression level, RNA quality, sequencing depth</li> <li>Biological Replicates: 3-4 independent inductions and RNA preparations</li> <li>Modified Design: Include time-course of induction to capture kinetics of editing, or RBP mutants with altered RNA-binding specificity</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA%20editing-based%20RNA-seq/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: </li> <li>Read alignment to reference genome</li> <li>C-to-U conversion identification</li> <li>Background filtering using controls</li> <li>Peak calling to identify significant binding sites</li> <li>Motif discovery in binding regions</li> <li>Statistical Analysis:</li> <li>Statistical significance of editing sites above background</li> <li>Enrichment analysis for RNA types and cellular compartments</li> <li>Correlation with RBP expression levels</li> <li>Comparison with known binding motifs or CLIP-seq data</li> <li>Data Presentation:</li> <li>Genome browser tracks showing editing sites</li> <li>Metagene plots of binding distribution across transcript regions</li> <li>Motif logos for identified binding sequences</li> <li>Venn diagrams comparing targets with other datasets</li> <li>Functional enrichment maps of target RNAs</li> <li>Validation Methods:</li> <li>RT-qPCR validation of editing at selected sites</li> <li>CLIP-seq or RIP-seq for orthogonal validation</li> <li>Functional assays for key targets (e.g., minigene reporters)</li> <li>Mutagenesis of binding sites to confirm direct interaction</li> <li>RNA structure probing to assess structural context of binding</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/","title":"MBE RNA seq","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How do gene expression patterns vary across conditions, cell types, or spatial locations within tissues?</li> <li>Design Rationale: Transcriptome analysis techniques reveal comprehensive gene expression profiles, alternative splicing events, and spatial distribution of transcripts</li> <li>Follow-up Studies: Functional validation of differentially expressed genes, pathway analysis, biomarker identification, therapeutic target discovery</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, tissue samples, patient biopsies, single-cell suspensions</li> <li>Rationale: These systems provide RNA of sufficient quality and quantity while maintaining biological relevance</li> <li>Alternatives:</li> <li>In vitro cell models (pros: controlled conditions, homogeneity; cons: may not reflect in vivo complexity)</li> <li>Animal models (pros: system-level responses; cons: species differences, ethical considerations)</li> <li>Organoids (pros: 3D structure, cell-cell interactions; cons: incomplete tissue architecture)</li> <li>Ethical Considerations: Patient consent for clinical samples, minimizing animal use, responsible data sharing and privacy</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>High-quality RNA extraction and preservation</li> <li>RNA integrity verification</li> <li>Library preparation optimization</li> <li>Inclusion of spike-in controls</li> <li>Technical Replicates: Multiple technical replicates for microarrays; sequencing depth considerations for RNA-seq approaches</li> <li>Potential Biases:</li> <li>RNA degradation (use RIN scores to assess quality)</li> <li>Batch effects (include batch controls)</li> <li>PCR amplification bias (UMIs for single-cell approaches)</li> <li>3' bias in degraded samples (assess coverage uniformity)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples from experimental condition of interest</li> <li>Control 1: Matched untreated/baseline samples</li> <li>Control 2: Technical controls (spike-ins, housekeeping genes)</li> <li>Control 3: Biological reference standards when available</li> <li>Controlled Variables: RNA quality, batch processing, sequencing platform, analysis pipeline</li> <li>Biological Replicates: Minimum 3-5 biological replicates per condition; higher numbers for heterogeneous samples</li> <li>Modified Design: Time-course analysis, dose-response relationships, multiple tissue regions</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Quality control metrics (read depth, mapping rates, coverage)</li> <li>Normalization strategies appropriate to technique</li> <li>Differential expression analysis with statistical thresholds</li> <li>Pathway and functional enrichment analysis</li> <li>Presentation Approaches:</li> <li>Heatmaps for expression patterns</li> <li>Volcano plots for significance visualization</li> <li>PCA/t-SNE/UMAP for dimensionality reduction</li> <li>Spatial maps for regional expression patterns</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature Microarray RNA-seq Single-cell RNA-seq Long-read Sequencing Spatial Transcriptomics Primary Use Global gene expression profiling Comprehensive transcriptome analysis Cell-type specific expression patterns Full-length transcript analysis Spatial mapping of gene expression Sensitivity Moderate (limited dynamic range) High (wide dynamic range) Moderate (limited by dropout effects) Moderate (lower throughput) Moderate (depends on platform) Specificity Good for known transcripts Excellent for known and novel transcripts Good for abundant transcripts Excellent for isoform discrimination Good for targeted gene panels Quantification Relative abundance through hybridization Digital counts of transcript abundance Digital counts at single-cell resolution Accurate isoform quantification Regional expression quantification Throughput High (thousands of genes) Very high (entire transcriptome) High (thousands of cells) Moderate (fewer reads, longer lengths) Moderate (spatial resolution trade-off) Resolution Gene-level only Gene and transcript-level Single-cell Full transcript structure Tissue region/cell location Cost Low to moderate Moderate High High Very high RNA Input Required 50-500 ng 10-1000 ng Single-cell (pg range) 50-1000 ng Tissue sections Technical Expertise Moderate Moderate to advanced Advanced Advanced Very advanced Best For \u2022 Well-characterized systems\u2022 Large sample comparisons\u2022 Cost-effective screening\u2022 Established gene sets \u2022 Discovering novel transcripts\u2022 Detecting rare transcripts\u2022 Alternative splicing analysis\u2022 Comprehensive profiling \u2022 Heterogeneous samples\u2022 Rare cell type identification\u2022 Developmental trajectories\u2022 Cellular diversity studies \u2022 Isoform identification\u2022 Fusion transcript detection\u2022 Complex structural variants\u2022 Complete transcript sequences \u2022 Tissue architecture analysis\u2022 Cell-cell communication\u2022 Niche-specific expression\u2022 Disease boundary mapping Limitations \u2022 Limited to known sequences\u2022 Cross-hybridization issues\u2022 Narrow dynamic range\u2022 No novel transcript discovery \u2022 Complex data analysis\u2022 Computational requirements\u2022 Short-read assembly challenges\u2022 Batch effects \u2022 Low RNA capture efficiency\u2022 High dropout rates\u2022 Expensive per sample\u2022 Limited splicing information \u2022 Lower throughput\u2022 Higher error rates\u2022 More expensive\u2022 Specialized analysis required \u2022 Limited gene coverage\u2022 Resolution constraints\u2022 Expensive technology\u2022 Complex data integration"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Initial Profiling: Use microarrays for cost-effective screening of known genes across many samples</li> <li>Comprehensive Analysis: Follow with RNA-seq for in-depth transcriptome characterization including novel transcripts</li> <li>Heterogeneity Assessment: Apply single-cell RNA-seq to dissect cellular subpopulations and rare cell types</li> <li>Structural Validation: Employ long-read sequencing to resolve complex isoforms and structural variants</li> <li>Contextual Understanding: Integrate spatial transcriptomics to map expression patterns within tissue architecture</li> <li>Integrated Approach: Design multi-platform studies for comprehensive characterization:</li> <li>RNA-seq for global transcriptome profiling</li> <li>Single-cell RNA-seq to resolve cellular heterogeneity</li> <li>Long-read sequencing to characterize full-length transcripts of interest</li> <li>Spatial transcriptomics to map key findings to tissue context</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#8-technology-specific-considerations","title":"8. Technology-Specific Considerations","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#microarray","title":"Microarray","text":"<ul> <li>Design Optimization: Probe selection affects specificity and coverage</li> <li>Hybridization Conditions: Critical for signal-to-noise ratio</li> <li>Data Normalization: Essential for cross-array comparisons</li> <li>Legacy Data: Valuable historical datasets available for meta-analysis</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#rna-seq","title":"RNA-seq","text":"<ul> <li>Library Preparation: Stranded vs. unstranded, poly(A) selection vs. ribo-depletion</li> <li>Sequencing Depth: Tailored to research question (15-30M reads for differential expression)</li> <li>Read Length: Longer reads improve mapping and transcript assembly</li> <li>Spike-in Controls: Essential for absolute quantification</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#single-cell-rna-seq","title":"Single-cell RNA-seq","text":"<ul> <li>Cell Isolation: Dissociation protocols affect cell representation</li> <li>Droplet vs. Well-based: Trade-off between cell number and coverage depth</li> <li>Doublet Rate: Quality control to remove multi-cell captures</li> <li>Computational Deconvolution: Advanced algorithms for cell type identification</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#long-read-sequencing","title":"Long-read Sequencing","text":"<ul> <li>Platform Selection: PacBio (higher accuracy) vs. Oxford Nanopore (longer reads)</li> <li>Error Correction: Critical for accurate transcript annotation</li> <li>Hybrid Approaches: Combining with short-read data for error correction</li> <li>Direct RNA Sequencing: Captures native modifications but with lower throughput</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20RNA-seq/#spatial-transcriptomics","title":"Spatial Transcriptomics","text":"<ul> <li>Resolution Range: From tissue regions to subcellular localization</li> <li>Coverage vs. Resolution: Trade-off between gene number and spatial detail</li> <li>Image Integration: Correlating expression with histological features</li> <li>Cell Type Deconvolution: Computational methods to resolve mixed signals</li> </ul> <p>This integrated framework provides a comprehensive approach to transcriptome analysis, leveraging the strengths of each technology while addressing their individual limitations. The complementary use of these methods enables researchers to build a multi-dimensional understanding of gene expression across biological systems.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/","title":"MBE mRNA visualization and analysis technologies","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How are mRNAs localized, transported, and regulated through interactions with proteins in cells and tissues?</li> <li>Design Rationale: RNA visualization and interaction analysis techniques reveal spatial distribution, dynamics, and protein-binding properties of transcripts</li> <li>Follow-up Studies: Functional validation of RNA localization patterns, characterization of RNA-protein regulatory networks, investigation of RNA transport mechanisms</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, primary cells, tissue sections, organoids, model organisms</li> <li>Rationale: These systems allow observation of native RNA distribution and dynamics while providing sufficient material for biochemical analyses</li> <li>Alternatives:</li> <li>In vitro reconstituted systems (pros: defined components; cons: artificial context)</li> <li>Fixed vs. live specimens (trade-off between spatial resolution and dynamic information)</li> <li>Transgenic models (pros: tagged RNAs; cons: potential artifacts from tagging)</li> <li>Ethical Considerations: Minimal invasiveness for live imaging, fixation protocols, genetic manipulation considerations</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>RNA preservation during sample preparation</li> <li>Probe/tag specificity validation</li> <li>Signal-to-noise optimization</li> <li>Appropriate controls for non-specific binding</li> <li>Technical Replicates: Multiple fields of view, technical replicates for biochemical methods</li> <li>Potential Biases:</li> <li>Probe accessibility in structured RNAs</li> <li>Fixation artifacts in FISH approaches</li> <li>Tag-induced alterations in RNA behavior</li> <li>Crosslinking efficiency variations in CLIP methods</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples under experimental condition of interest</li> <li>Control 1: Untreated/baseline samples</li> <li>Control 2: Technical controls (non-specific probes, IgG controls for IP)</li> <li>Control 3: Competing or blocking controls to validate specificity</li> <li>Controlled Variables: Cell cycle stage, cell density, fixation conditions, imaging parameters</li> <li>Biological Replicates: Minimum 3 biological replicates; more for heterogeneous samples</li> <li>Modified Design: Time-course analysis, drug treatments, genetic perturbations</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Image segmentation and quantification</li> <li>Colocalization analysis</li> <li>Tracking of RNA movement in live cells</li> <li>Binding site identification and motif analysis</li> <li>Presentation Approaches:</li> <li>Representative images with scale bars</li> <li>Quantitative measurements of localization or binding</li> <li>Tracking plots for dynamic studies</li> <li>Genome browser tracks for binding site data</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#6-technique-comparison-visualization-methods","title":"6. Technique Comparison - Visualization Methods","text":"Feature FISH Molecular Beacon MCP-MS2 System Molecular Dyes (HBC) Primary Application Fixed cell/tissue RNA localization Specific RNA detection Live cell RNA dynamics Live cell RNA tracking Detection Principle Hybridization with labeled probes Conformational change upon hybridization MS2 stem-loops bound by fluorescent MCP Fluorescence activation upon RNA binding Temporal Resolution Snapshot (fixed) Real-time possible Real-time Real-time Spatial Resolution High (20-200 nm with super-resolution) Moderate Moderate (diffraction-limited) Moderate to high Multiplexing Capability High (10-1000s with sequential FISH) Moderate (spectral limitations) Limited (few spectrally distinct FPs) Limited (spectral limitations) Single Molecule Detection Yes (smFISH) Yes Yes Variable Live Cell Compatibility No (fixed samples) Yes Yes Yes Sample Preparation Fixation, permeabilization Minimal (cell-permeable probes) Genetic engineering required Cell-permeable dyes Technical Complexity Moderate to high Moderate High (construct design) Moderate Best For \u2022 Precise spatial mapping\u2022 Tissue sections\u2022 Quantitative analysis\u2022 Multiple RNA targets \u2022 Rapid RNA detection\u2022 Homogeneous assays\u2022 Real-time monitoring\u2022 Specific sequence detection \u2022 RNA trafficking\u2022 Real-time dynamics\u2022 Long-term imaging\u2022 Single molecule tracking \u2022 Dynamic RNA tracking\u2022 No genetic modification\u2022 Global RNA visualization\u2022 Rapid implementation Limitations \u2022 Fixed samples only\u2022 Background fluorescence\u2022 Probe accessibility\u2022 Time-consuming protocol \u2022 Probe design complexity\u2022 Background issues\u2022 Limited to accessible regions\u2022 Signal strength \u2022 Requires genetic modification\u2022 Potential functional interference\u2022 Limited multiplexing\u2022 Tag size effects \u2022 Limited specificity\u2022 Variable binding properties\u2022 Potential toxicity\u2022 Off-target interactions"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#7-technique-comparison-rna-protein-interaction-methods","title":"7. Technique Comparison - RNA-Protein Interaction Methods","text":"Feature RIP CLIP RNA Editing-Based RNA-seq Primary Application RNA-protein interactions Precise protein binding sites RNA-protein interactions in vivo Detection Principle Immunoprecipitation of RNP complexes UV crosslinking and immunoprecipitation Detecting RNA editing events at protein binding sites Resolution Transcript-level Nucleotide-level Near nucleotide-level Crosslinking Optional (native RIP) Required (UV crosslinking) Not required (detects natural editing) Stringency Lower (potential for reassociation) Higher (covalent bonds) High (detects in vivo events) Input Material Moderate (millions of cells) High (millions of cells) Moderate to high Complexity Low to moderate High Very high Bioinformatic Analysis Moderate Complex Very complex Best For \u2022 Initial screening\u2022 Strong interactions\u2022 Global RNA partners\u2022 Simple implementation \u2022 Precise binding sites\u2022 Motif discovery\u2022 Direct interactions\u2022 Regulatory element mapping \u2022 Natural binding events\u2022 In vivo interactions\u2022 No crosslinking artifacts\u2022 Novel binding site discovery Limitations \u2022 Indirect binding detection\u2022 Reassociation artifacts\u2022 Lower resolution\u2022 Background binding \u2022 UV crosslinking bias\u2022 Complex protocol\u2022 High input requirements\u2022 Crosslinking efficiency \u2022 Limited to editing sites\u2022 Complex data analysis\u2022 Lower efficiency\u2022 Requires deep sequencing"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#8-complementary-usage-strategy","title":"8. Complementary Usage Strategy","text":"<ul> <li>Spatial Analysis:</li> <li>Use FISH for high-resolution mapping in fixed samples</li> <li>Apply molecular beacons for specific sequence detection</li> <li> <p>Implement MCP-MS2 or molecular dyes for live-cell dynamics</p> </li> <li> <p>Interaction Analysis:</p> </li> <li>Begin with RIP for global RNA partners of a protein</li> <li>Follow with CLIP for precise binding site mapping</li> <li> <p>Validate with RNA editing-based approaches for in vivo confirmation</p> </li> <li> <p>Combined Approaches:</p> </li> <li>Correlate localization patterns with binding protein distribution</li> <li>Link binding sites to functional outcomes in gene expression</li> <li> <p>Integrate with structural information for mechanistic insights</p> </li> <li> <p>Integrated Approach: Design multi-platform studies for comprehensive characterization:</p> </li> <li>FISH to map spatial distribution of target RNAs</li> <li>Live imaging (MCP-MS2 or dyes) to track dynamic behavior</li> <li>CLIP to identify protein binding sites on RNAs of interest</li> <li>Functional validation through perturbation of identified elements</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#9-technology-specific-considerations","title":"9. Technology-Specific Considerations","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#fish-approaches","title":"FISH Approaches","text":"<ul> <li>Single Molecule FISH (smFISH):</li> <li>Multiple short probes for single transcript detection</li> <li>Quantitative analysis possible with spot counting</li> <li> <p>Super-resolution variants (STORM, STED) for nanoscale localization</p> </li> <li> <p>Multiplexed FISH:</p> </li> <li>Sequential hybridization for increased targets (seqFISH)</li> <li>Combinatorial labeling strategies (MERFISH)</li> <li>Expansion microscopy for improved resolution</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#live-cell-rna-imaging","title":"Live Cell RNA Imaging","text":"<ul> <li>MCP-MS2 System:</li> <li>Requires genetic modification of target RNA</li> <li>MS2 stem-loops can affect RNA behavior</li> <li> <p>Enables long-term tracking of specific transcripts</p> </li> <li> <p>Molecular Dyes:</p> </li> <li>Various chemical structures with different properties</li> <li>Can target specific RNA features or global RNA</li> <li>Potential for photoactivation or photoswitching</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#rna-protein-interaction-methods","title":"RNA-Protein Interaction Methods","text":"<ul> <li>RIP Variants:</li> <li>Native vs. crosslinked conditions</li> <li>RIP-Chip or RIP-Seq for genome-wide analysis</li> <li> <p>Tandem affinity purification for increased specificity</p> </li> <li> <p>CLIP Variants:</p> </li> <li>HITS-CLIP: High-throughput sequencing of CLIP</li> <li>PAR-CLIP: Photoactivatable ribonucleoside-enhanced CLIP</li> <li>iCLIP: Individual-nucleotide resolution CLIP</li> <li>eCLIP: Enhanced CLIP with improved efficiency</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#rna-editing-based-approaches","title":"RNA Editing-Based Approaches","text":"<ul> <li>Types of Editing:</li> <li>A-to-I editing most common (ADAR enzymes)</li> <li>C-to-U editing (APOBEC enzymes)</li> <li> <p>Requires careful analysis to distinguish from sequencing errors</p> </li> <li> <p>Analysis Considerations:</p> </li> <li>Comparison to genomic sequence essential</li> <li>Statistical models for identifying true editing events</li> <li>Integration with RNA structure prediction</li> </ul> <p>This comprehensive framework provides researchers with a structured approach to selecting and combining RNA visualization and interaction analysis techniques. The integration of spatial, temporal, and molecular information enables a deeper understanding of RNA biology in cellular contexts.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/","title":"S1 Antisense oligonucleotides","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Can ASOs effectively and specifically downregulate target gene expression in disease-relevant cells/tissues?</li> <li>Design Rationale: The experiment will measure target mRNA/protein reduction, assess off-target effects, and evaluate cellular phenotypic changes after ASO treatment</li> <li>Follow-up Studies: In vivo biodistribution, pharmacokinetics, and efficacy studies would follow promising in vitro results to advance therapeutic potential</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cell lines expressing the target gene (patient-derived cells when available) and animal disease models for in vivo validation</li> <li>Rationale: Patient-derived cells provide disease-relevant context; cell lines offer reproducibility; animal models allow assessment of delivery, biodistribution and systemic effects</li> <li>Alternatives:</li> <li>Organoids (pros: 3D tissue architecture, patient-specific; cons: complex, variable)</li> <li>Xenograft models (pros: human cells in vivo; cons: immunocompromised host)</li> <li>iPSC-derived cells (pros: patient-specific; cons: maturation challenges)</li> <li>Ethical Considerations: Informed consent for patient samples, minimizing animal use through careful experimental design, humane endpoints for animal studies</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques:</li> <li>RT-qPCR for target mRNA quantification (quantitative)</li> <li>Western blot for protein reduction (semi-quantitative)</li> <li>RNA-seq to assess transcriptome-wide specificity (quantitative)</li> <li>Functional assays relevant to disease phenotype</li> <li>Technical Replicates: Triplicate RT-qPCR measurements; duplicate Western blots</li> <li>Potential Biases:</li> <li>Transfection/delivery efficiency variations (use fluorescently labeled ASOs to track)</li> <li>Cell passage effects (standardize passage number)</li> <li>RNA degradation (strict sample handling protocols)</li> <li>Sequence-dependent off-target effects (include scrambled sequence controls)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test groups: Multiple ASO sequences targeting different regions of target mRNA at various concentrations</li> <li>Negative controls: Scrambled ASO sequence, non-targeting ASO with similar chemistry</li> <li>Positive controls: siRNA targeting same gene, known effective ASO if available</li> <li>Untreated control: Cells without any oligonucleotide treatment</li> <li>Controlled Variables: Cell density, delivery method, incubation time, ASO chemistry</li> <li>Biological Replicates: Minimum 3 independent experiments with different cell passages or animal subjects</li> <li>Modified Design: Include dose-response curves (5-6 concentrations) to determine EC50 values and therapeutic window</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: </li> <li>RT-qPCR: \u0394\u0394Ct method normalized to housekeeping genes</li> <li>Western blot: Densitometry normalized to loading controls</li> <li>RNA-seq: DESeq2 or similar for differential expression analysis</li> <li>Statistical Analysis:</li> <li>ANOVA with Dunnett's post-hoc test comparing treatment groups to controls</li> <li>IC50/EC50 calculation for dose-response data</li> <li>False discovery rate correction for RNA-seq multiple comparisons</li> <li>Data Presentation:</li> <li>Target knockdown: Bar graphs with individual data points</li> <li>Dose-response: Sigmoidal curve plots</li> <li>Off-target effects: Volcano plots from RNA-seq data</li> <li>Phenotypic assays: Appropriate to specific readout (e.g., cell viability, protein function)</li> <li>Validation Methods:</li> <li>Alternative ASO chemistries to confirm mechanism</li> <li>Rescue experiments with overexpression of target gene</li> <li>Protein half-life studies to distinguish between transcriptional and post-transcriptional effects</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/#antisense-oligonucleotides-asos-discussion","title":"Antisense Oligonucleotides (ASOs) Discussion","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/#1-experimental-purpose_1","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: ASO experiments investigate how targeted inhibition of specific RNA molecules affects cellular processes and disease states. The design directly tests this by using complementary oligonucleotides to bind target RNAs and modulate their function or abundance.</li> <li>Repeated Designs: Researchers often repeat ASO designs to optimize chemistry (phosphorothioate, 2'-MOE, LNA modifications), test multiple target sites on the same RNA, or evaluate efficacy across different cell types or disease models.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/#2-model-system_1","title":"2. Model System","text":"<ul> <li>Current Systems: Studies typically use cell culture models for initial screening, followed by animal models (mice, rats, non-human primates) for in vivo validation before clinical translation.</li> <li>Alternatives: Patient-derived cells offer disease relevance but may be limited in availability. Organoids provide 3D context. Drosophila or zebrafish can be used for developmental studies at lower cost.</li> <li>Ethical Considerations: Animal testing raises standard welfare concerns, particularly for CNS-targeted ASOs requiring intrathecal delivery. Patient-derived materials require proper consent and privacy protections.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/#3-measurement-approach_1","title":"3. Measurement Approach","text":"<ul> <li>Techniques: Combines RT-qPCR, RNA-seq, and Western blotting to quantify target knockdown at RNA and protein levels. Functional readouts specific to the target pathway are also employed.</li> <li>Method Selection: These methods provide quantitative assessment of both direct target engagement and downstream effects, allowing correlation between molecular and phenotypic outcomes.</li> <li>Technical Replicates: Multiple PCR reactions and protein blot quantifications serve as technical replicates, with appropriate housekeeping controls for normalization.</li> <li>Potential Biases: Off-target binding, variable cellular uptake, and toxicity can introduce biases, minimized through careful sequence design, chemistry optimization, and appropriate controls.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/#4-group-setting_1","title":"4. Group Setting","text":"<ul> <li>Experimental Groups: Typically includes ASO-treated samples at multiple doses versus controls (untreated, scrambled sequence ASO with matching chemistry).</li> <li>Negative Controls: Non-targeting scrambled ASOs with identical chemical modifications serve as negative controls to account for non-specific effects.</li> <li>Biological Replicates: 3-6 biological replicates are standard, with animal studies often requiring larger numbers to account for inter-individual variability.</li> <li>Modified Design: Adding time-course measurements would reveal pharmacokinetics and duration of effect; testing combination with small molecules could identify synergistic therapeutic approaches.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1%20Antisense%20oligonucleotides/#5-data-analysis-presentation_1","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: Expression data undergoes normalization to housekeeping genes/proteins, followed by calculation of percent knockdown relative to controls.</li> <li>Statistical Tests: Dose-response relationships analyzed by ANOVA with post-hoc tests; therapeutic efficacy assessed through appropriate disease model endpoints with sufficient power calculations.</li> <li>Data Presentation: Results typically appear as bar graphs showing target knockdown efficiency, correlation plots between target reduction and phenotypic improvement, and survival/functional outcome measures in disease models.</li> <li>Validation Methods: Findings are confirmed through demonstration of sequence-specific effects (testing multiple ASOs), rescue experiments, and ultimately translation to higher species before clinical testing.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W10.ChenDi%20Aging%20research%20in%20C%20elegans/","title":"S1.W10.ChenDi Aging research in C elegans","text":"<p>\u4e00\u3001\u5b9e\u9a8c\u51c6\u5907 1.\u83cc\u682a\u51c6\u5907\uff1a\u57f9\u517b\u7528\u4e8e\u5582\u517b\u7684\u5927\u80a0\u6746\u83ccOP50\u548c\u7528\u4e8eRNAi\u7684HT115\u83cc\u682a 1. \u57f9\u517b\u57fa\u5236\u5907\uff1a\u914d\u5236NGM\u743c\u8102\u5e73\u677f\uff0c\u6839\u636e\u9700\u8981\u6dfb\u52a0\u6297\u751f\u7d20\u6216\u8bf1\u5bfc\u5242 2. \u7ebf\u866b\u540c\u6b65\u5316\uff1a\u4f7f\u7528\u6b21\u6c2f\u9178\u94a0\u5904\u7406\u6210\u5e74\u7ebf\u866b\u83b7\u53d6\u5375\uff0c\u6216\u901a\u8fc7\u65f6\u95f4\u9650\u5236\u4ea7\u5375\u83b7\u5f97\u5e74\u9f84\u540c\u6b65\u7684\u7ebf\u866b\u7fa4\u4f53</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W10.ChenDi%20Aging%20research%20in%20C%20elegans/#_1","title":"\u4e8c\u3001\u57fa\u56e0\u64cd\u4f5c","text":"<ol> <li>\u7a81\u53d8\u4f53\u6784\u5efa</li> <li>\u83b7\u53d6\u73b0\u6709\u7a81\u53d8\u4f53\u83cc\u682a(daf-2\u3001rsks-1)</li> <li>\u901a\u8fc7\u6742\u4ea4\u4ea7\u751f\u53cc\u7a81\u53d8\u4f53(daf-2 rsks-1)</li> <li> <p>\u901a\u8fc7PCR\u6216\u6d4b\u5e8f\u9a8c\u8bc1\u7a81\u53d8\u4f53\u57fa\u56e0\u578b</p> </li> <li> <p>RNA\u5e72\u6270\u7cfb\u7edf\u5efa\u7acb</p> </li> <li>\u6784\u5efa\u9776\u5411\u76ee\u6807\u57fa\u56e0(\u5982cyc-2.1)\u7684RNAi\u8d28\u7c92</li> <li>\u8f6c\u5316\u5230HT115\u7ec6\u83cc\u4e2d</li> <li> <p>\u5236\u5907RNAi\u5582\u517b\u5e73\u677f(\u542bIPTG\u548c\u6297\u751f\u7d20)</p> </li> <li> <p>\u7ec4\u7ec7\u7279\u5f02\u6027RNAi\u83cc\u682a\u51c6\u5907</p> </li> <li>\u4f7f\u7528\u80a0\u9053\u7279\u5f02\u6027(rde-1\u7a81\u53d8\u4f53\u80cc\u666f\u4e0b\u80a0\u9053\u6062\u590d)\u6216\u751f\u6b96\u7cfb\u7279\u5f02\u6027RNAi\u654f\u611f\u83cc\u682a</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W10.ChenDi%20Aging%20research%20in%20C%20elegans/#_2","title":"\u4e09\u3001\u5bff\u547d\u5206\u6790\u5b9e\u9a8c","text":"<ol> <li>\u5b9e\u9a8c\u7ec4\u8bbe\u7f6e</li> <li>\u91ce\u751f\u578bN2\u7ebf\u866b(\u5bf9\u7167\u7ec4)</li> <li>\u5355\u7a81\u53d8\u4f53(daf-2\u3001rsks-1)</li> <li>\u53cc\u7a81\u53d8\u4f53(daf-2 rsks-1)</li> <li> <p>RNAi\u5904\u7406\u7ec4(\u7a7a\u8f7d\u4f53\u5bf9\u7167\u3001\u76ee\u6807\u57fa\u56e0RNAi)</p> </li> <li> <p>\u5bff\u547d\u6d4b\u5b9a</p> </li> <li>\u5c06L4\u671f\u6216\u5e74\u8f7b\u6210\u866b\u8f6c\u79fb\u5230\u5b9e\u9a8c\u5e73\u677f(\u6bcf\u7ec430-100\u6761)</li> <li>\u6bcf2-3\u5929\u8f6c\u79fb\u5230\u65b0\u9c9c\u5e73\u677f\u5e76\u8ba1\u6570\u5b58\u6d3b\u7ebf\u866b</li> <li>\u8bb0\u5f55\u6bcf\u5929\u6b7b\u4ea1\u6570\u91cf\u76f4\u81f3\u5168\u90e8\u6b7b\u4ea1</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W10.ChenDi%20Aging%20research%20in%20C%20elegans/#_3","title":"\u56db\u3001\u5206\u5b50\u673a\u5236\u5206\u6790","text":"<ol> <li>\u86cb\u767d\u8d28\u6c34\u5e73\u5206\u6790</li> <li>\u6536\u96c6\u4e0d\u540c\u57fa\u56e0\u578b\u7ebf\u866b\u6837\u672c</li> <li>\u63d0\u53d6\u603b\u86cb\u767d</li> <li> <p>\u8fdb\u884cWestern blot\u68c0\u6d4b\u5173\u952e\u86cb\u767d(\u5982\u78f7\u9178\u5316AAK-2/AMPK)</p> </li> <li> <p>\u7ffb\u8bd1\u7ec4\u5206\u6790</p> </li> <li>\u7ebf\u866b\u88c2\u89e3\u7269\u5236\u5907</li> <li>\u591a\u805a\u6838\u7cd6\u4f53\u5206\u6790\uff1a\u5728\u8517\u7cd6\u68af\u5ea6\u4e0a\u5206\u79bb\u4e0d\u540c\u7ffb\u8bd1\u72b6\u6001\u7684mRNA</li> <li> <p>RNA\u63d0\u53d6\u548c\u6d4b\u5e8f\u5206\u6790\u5dee\u5f02\u7ffb\u8bd1\u57fa\u56e0</p> </li> <li> <p>\u5e94\u6fc0\u53cd\u5e94\u5206\u6790</p> </li> <li>\u4f7f\u7528\u8367\u5149\u62a5\u544a\u57fa\u56e0(\u5982Phsp-6::GFP\u68c0\u6d4b\u7ebf\u7c92\u4f53\u5e94\u6fc0)</li> <li>\u8367\u5149\u663e\u5fae\u955c\u6210\u50cf\u548c\u5b9a\u91cf\u5206\u6790</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W10.ChenDi%20Aging%20research%20in%20C%20elegans/#_4","title":"\u4e94\u3001\u901a\u8def\u9a8c\u8bc1\u5b9e\u9a8c","text":"<ol> <li>\u4e0a\u4e0b\u4f4d\u5206\u6790</li> <li>\u5728\u5173\u952e\u8c03\u63a7\u57fa\u56e0\u7a81\u53d8\u80cc\u666f\u4e0b(\u5982daf-16(mu86))\u6d4b\u8bd5\u5bff\u547d\u8868\u578b</li> <li> <p>\u786e\u5b9a\u901a\u8def\u7ec4\u5206\u4e4b\u95f4\u7684\u4f9d\u8d56\u5173\u7cfb</p> </li> <li> <p>\u7ec4\u7ec7\u7279\u5f02\u6027\u5b9e\u9a8c</p> </li> <li>\u4f7f\u7528\u7ec4\u7ec7\u7279\u5f02\u6027\u542f\u52a8\u5b50\u9a71\u52a8\u5173\u952e\u57fa\u56e0\u8868\u8fbe</li> <li> <p>\u5728\u4e0d\u540c\u7ec4\u7ec7\u7279\u5f02\u6027RNAi\u7cfb\u7edf\u4e2d\u6572\u4f4e\u76ee\u6807\u57fa\u56e0</p> </li> <li> <p>\u836f\u7406\u5b66\u9a8c\u8bc1</p> </li> <li>\u4f7f\u7528\u7279\u5f02\u6027\u6291\u5236\u5242(\u5982\u9776\u5411TOR\u7684\u96f7\u5e15\u9709\u7d20)\u5904\u7406\u7ebf\u866b</li> <li>\u6d4b\u91cf\u5bff\u547d\u548c\u5206\u5b50\u6807\u5fd7\u7269\u53d8\u5316</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W10.ChenDi%20Aging%20research%20in%20C%20elegans/#_5","title":"\u516d\u3001\u6570\u636e\u5206\u6790","text":"<ol> <li>\u5bff\u547d\u6570\u636e\u5206\u6790</li> <li>\u751f\u6210Kaplan-Meier\u751f\u5b58\u66f2\u7ebf</li> <li>\u4f7f\u7528log-rank\u68c0\u9a8c\u6bd4\u8f83\u4e0d\u540c\u7ec4\u95f4\u5dee\u5f02</li> <li> <p>\u8ba1\u7b97\u5e73\u5747\u548c\u6700\u5927\u5bff\u547d\u53d8\u5316</p> </li> <li> <p>\u5206\u5b50\u6570\u636e\u6574\u5408\u5206\u6790</p> </li> <li>\u7ffb\u8bd1\u7ec4\u548c\u8f6c\u5f55\u7ec4\u6570\u636e\u5dee\u5f02\u5206\u6790</li> <li>\u901a\u8def\u5bcc\u96c6\u5206\u6790\u786e\u5b9a\u5173\u952e\u8c03\u63a7\u7f51\u7edc</li> <li> <p>\u6574\u5408\u86cb\u767d\u8d28\u548cRNA\u6570\u636e\u6784\u5efa\u8c03\u63a7\u6a21\u578b</p> </li> <li> <p>\u7ed3\u679c\u9a8c\u8bc1</p> </li> <li>\u4f7f\u7528\u66ff\u4ee3\u65b9\u6cd5\u9a8c\u8bc1\u5173\u952e\u53d1\u73b0</li> <li>\u5728\u4e0d\u540c\u5b9e\u9a8c\u6761\u4ef6\u4e0b\u91cd\u590d\u6838\u5fc3\u5b9e\u9a8c</li> <li>\u4e0e\u5df2\u53d1\u8868\u6587\u732e\u6570\u636e\u6bd4\u8f83\u786e\u8ba4\u53d1\u73b0\u7684\u53ef\u9760\u6027</li> </ol> <p>\u8fd9\u79cd\u7cfb\u7edf\u6027\u7684\u5b9e\u9a8c\u6d41\u7a0b\u5141\u8bb8\u7814\u7a76\u4eba\u5458\u5168\u9762\u4e86\u89e3\u80f0\u5c9b\u7d20/IGF-1\u548cTOR\u4fe1\u53f7\u901a\u8def\u5982\u4f55\u534f\u540c\u8c03\u63a7\u7ebf\u866b\u5bff\u547d\uff0c\u5e76\u63ed\u793a\u6f5c\u5728\u7684\u5206\u5b50\u673a\u5236\u3002</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W10.ChenDi%20Aging%20research%20in%20C%20elegans/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<p>The seminar addresses the molecular mechanisms underlying lifespan extension by targeting insulin/IGF-1 and TOR signaling pathways in C. elegans. Key experiments, such as generating ==double mutants== (e.g., daf-2 rsks-1), aim to determine whether combined inhibition of these pathways synergistically enhances longevity. The design directly tests this by comparing survival curves of wild-type, single mutants, and double mutants, supported by RNAi knockdowns to validate gene-specific contributions (e.g., cyc-2.1). Repeating similar designs in subsequent figures (e.g., Figure 2) serves to confirm robustness, explore tissue-specific effects (e.g., intestinal vs. germline regulation), and refine mechanistic models, such as AMPK-mediated feedback loops.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W10.ChenDi%20Aging%20research%20in%20C%20elegans/#2-model-system","title":"2. Model System","text":"<p>Model: C. elegans is used due to its short lifespan (~20 days), genetic tractability, and conserved aging pathways with humans (e.g., insulin/IGF-1 signaling). Its transparency and ease of manipulation enable high-throughput screens and live imaging. Alternatives: - Drosophila: Larger size but limited genetic homology. - Mice: Translatable to humans but costly and ethically complex. - Yeast: Simple but lacks tissue complexity. Ethical Considerations: Minimal ethical concerns compared to vertebrates, aligning with reductionist research principles.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W10.ChenDi%20Aging%20research%20in%20C%20elegans/#3-measurement-approach","title":"3. Measurement Approach","text":"<p>Techniques: - Quantitative: Lifespan analysis, RNAi screens, polysomal profiling. - Semi-quantitative: Western blotting (e.g., phospho-AAK-2 levels), fluorescence microscopy (e.g., UPRmt reporters). Rationale: These methods balance throughput (RNAi) and precision (polysomal profiling) to identify translational changes. Technical replicates (e.g., multiple lifespan assays) and controls (empty vector RNAi) minimize variability. Biases: Confounding factors like bacterial food source or temperature are controlled, but genetic background differences (e.g., strain variations) could affect reproducibility.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W10.ChenDi%20Aging%20research%20in%20C%20elegans/#4-group-setting","title":"4. Group Setting","text":"<p>Groups: - Controls: Wild-type N2, empty vector RNAi. - Treatments: daf-2, rsks-1, daf-2 rsks-1 mutants; tissue-specific RNAi (e.g., germline vs. intestine). Variables Controlled: Age, temperature, and bacterial diet. Negative controls include daf-16 null mutants to validate DAF-16 dependency. Replicates: Typically 50\u2013100 worms per group, sufficient for statistical power (e.g., ANOVA with Bonferroni correction). A modified design could include dose-response RNAi or positive controls (e.g., dietary restriction).  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W10.ChenDi%20Aging%20research%20in%20C%20elegans/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<p>Processing: Survival curves are plotted using Kaplan-Meier analysis. Polysomal profiling data are normalized to total mRNA, and differential translation is calculated via log2 ratios. Statistics: Parametric tests (e.g., t-tests) and non-parametric tests (Mantel-Cox) are applied, with p-values adjusted for multiple comparisons. Presentation: Clear visualizations (e.g., heatmaps, survival plots) avoid misleading scaling. Results are cross-validated using orthogonal methods (e.g., Western blotting for AMPK activation and UPRmt reporters).  </p> <p>Key Takeaways: The study highlights the power of integrative approaches combining genetics, translational profiling, and tissue-specific manipulations to uncover conserved aging mechanisms. Future directions could explore cross-species translational regulation (e.g., FOXO homologs in mammals) and therapeutic targets for age-related diseases.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W12.LiangGong%20Long%20read%20sequencing%2C%20Genomic%20Structural%20Variation/","title":"S1.W12.LiangGong Long read sequencing, Genomic Structural Variation","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W12.LiangGong%20Long%20read%20sequencing%2C%20Genomic%20Structural%20Variation/#_1","title":"\u4e00\u3001\u5b9e\u9a8c\u8bbe\u8ba1\u4e0e\u6837\u672c\u51c6\u5907","text":"<ol> <li>\u7814\u7a76\u95ee\u9898\u786e\u5b9a</li> <li>\u786e\u5b9a\u76ee\u6807\u7ed3\u6784\u53d8\u5f02\u7c7b\u578b(\u5982\u91cd\u590d\u6269\u589e\u3001\u6613\u4f4d\u3001\u5012\u4f4d\u7b49)</li> <li> <p>\u9009\u62e9\u9002\u5f53\u75be\u75c5\u6a21\u578b(\u5982\u80f6\u8d28\u6bcd\u7ec6\u80de\u7624\u3001\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5)</p> </li> <li> <p>\u6837\u672c\u6536\u96c6\u4e0e\u5904\u7406</p> </li> <li>\u6536\u96c6\u75c5\u4f8b\u7ec4\u7ec7\u6837\u672c(\u80bf\u7624\u7ec4\u7ec7\u3001\u795e\u7ecf\u75c5\u53d8\u7ec4\u7ec7)\u548c\u5bf9\u7167\u6837\u672c</li> <li>\u63d0\u53d6\u9ad8\u5206\u5b50\u91cfDNA(\u907f\u514d\u673a\u68b0\u526a\u5207\u9020\u6210\u7684DNA\u65ad\u88c2)</li> <li> <p>\u8bc4\u4f30DNA\u8d28\u91cf(\u901a\u8fc7\u743c\u8102\u7cd6\u51dd\u80f6\u7535\u6cf3\u6216Qubit\u6d4b\u5b9a)</p> </li> <li> <p>\u5b9e\u9a8c\u5206\u7ec4\u8bbe\u8ba1</p> </li> <li>\u75be\u75c5vs\u5065\u5eb7\u5bf9\u7167\u7ec4</li> <li>\u4e0d\u540c\u6d4b\u5e8f\u6280\u672f\u6bd4\u8f83\u7ec4(\u77ed\u8bfb\u957fvs\u957f\u8bfb\u957f)</li> <li>\u65b9\u6cd5\u5b66\u9a8c\u8bc1\u7ec4(\u5982NLR-seq vs\u6807\u51c6\u957f\u8bfb\u957f\u534f\u8bae)</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W12.LiangGong%20Long%20read%20sequencing%2C%20Genomic%20Structural%20Variation/#_2","title":"\u4e8c\u3001\u957f\u8bfb\u957f\u6d4b\u5e8f\u5b9e\u9a8c\u6d41\u7a0b","text":"<ol> <li>\u6d4b\u5e8f\u5e73\u53f0\u9009\u62e9</li> <li>PacBio SMRT\u6d4b\u5e8f(HiFi\u6a21\u5f0f):\u9ad8\u51c6\u786e\u5ea6\u957f\u8bfb\u957f(10-25kb)</li> <li>Oxford Nanopore\u6d4b\u5e8f:\u8d85\u957f\u8bfb\u957f(\u53ef\u8fbe100kb\u4ee5\u4e0a)</li> <li> <p>\u5408\u6210\u957f\u8bfb\u957f\u6280\u672f(\u598210x Genomics)</p> </li> <li> <p>\u6587\u5e93\u6784\u5efa</p> </li> <li> <p>PacBio HiFi\u6d4b\u5e8f:</p> <ul> <li>\u5927\u7247\u6bb5DNA\u63d0\u53d6\u548c\u526a\u5207(15-20kb)</li> <li>SMRTbell\u6587\u5e93\u5236\u5907(\u52a0\u63a5\u5934\u5f62\u6210\u73af\u72b6\u6a21\u677f)</li> <li>\u5927\u5c0f\u9009\u62e9(\u901a\u8fc7BluePippin)</li> </ul> </li> <li> <p>Nanopore\u6d4b\u5e8f:</p> <ul> <li>\u8d85\u957fDNA\u63d0\u53d6(\u4f7f\u7528\u6e29\u548c\u88c2\u89e3\u65b9\u6cd5)</li> <li>\u672b\u7aef\u4fee\u590d\u548c\u63a5\u5934\u8fde\u63a5</li> <li>\u53ef\u9009\u62e9\u6027\u5730\u8fdb\u884c\u5927\u5c0f\u9009\u62e9</li> </ul> </li> <li> <p>\u6d4b\u5e8f\u8fd0\u884c</p> </li> <li>PacBio:\u4f7f\u7528SMRT Cell\u8fdb\u884c\u5faa\u73af\u6d4b\u5e8f</li> <li>Nanopore:\u4f7f\u7528MinION/GridION/PromethION\u5e73\u53f0</li> <li> <p>\u5b9e\u65f6\u6570\u636e\u91c7\u96c6\u548c\u521d\u6b65\u8d28\u91cf\u8bc4\u4f30</p> </li> <li> <p>\u8f85\u52a9\u9a8c\u8bc1\u65b9\u6cd5</p> </li> <li>\u5149\u5b66\u56fe\u8c31(Bionano)\u7528\u4e8e\u5927\u5c3a\u5ea6\u7ed3\u6784\u9a8c\u8bc1</li> <li>Hi-C\u6d4b\u5e8f\u6355\u83b7\u67d3\u8272\u8d28\u4e09\u7ef4\u4e92\u4f5c</li> <li>PCR\u548cFISH\u9a8c\u8bc1\u7279\u5b9a\u7ed3\u6784\u53d8\u5f02</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W12.LiangGong%20Long%20read%20sequencing%2C%20Genomic%20Structural%20Variation/#_3","title":"\u4e09\u3001\u6570\u636e\u5206\u6790\u6d41\u7a0b","text":"<ol> <li>\u539f\u59cb\u6570\u636e\u5904\u7406</li> <li>\u78b1\u57fa\u8bc6\u522b(Nanopore\u4f7f\u7528Guppy, PacBio\u4f7f\u7528SMRT Link)</li> <li>\u8bfb\u957f\u8d28\u91cf\u8fc7\u6ee4\u548c\u7edf\u8ba1</li> <li> <p>\u6bd4\u5bf9\u5230\u53c2\u8003\u57fa\u56e0\u7ec4(\u4f7f\u7528minimap2\u6216NGMLR)</p> </li> <li> <p>\u7ed3\u6784\u53d8\u5f02\u68c0\u6d4b</p> </li> <li>\u4f7f\u7528\u4e13\u95e8\u7684SV\u68c0\u6d4b\u5de5\u5177:<ul> <li>Sniffles\u68c0\u6d4b\u5c0f\u578b\u63d2\u5165\u7f3a\u5931</li> <li>SVIM\u68c0\u6d4b\u591a\u79cdSV\u7c7b\u578b</li> <li>Picky\u6d41\u7a0b\u5206\u6790\u590d\u6742\u91cd\u6392</li> </ul> </li> <li> <p>\u9488\u5bf9\u7279\u5b9aSV\u7c7b\u578b\u7684\u4e13\u95e8\u5de5\u5177:</p> <ul> <li>TandemTools\u5206\u6790\u4e32\u8054\u91cd\u590d</li> <li>PALMER\u68c0\u6d4b\u79fb\u52a8\u5143\u4ef6\u63d2\u5165</li> </ul> </li> <li> <p>\u7ed3\u6784\u53d8\u5f02\u6ce8\u91ca\u4e0e\u8fc7\u6ee4</p> </li> <li>\u529f\u80fd\u6ce8\u91ca(\u57fa\u56e0\u533a\u57df\u3001\u8c03\u63a7\u533a\u57df\u7b49)</li> <li>\u4e0e\u5df2\u77e5SV\u6570\u636e\u5e93\u6bd4\u5bf9(DGV, gnomAD-SV)</li> <li> <p>\u8fc7\u6ee4\u5e38\u89c1\u53d8\u5f02\u548c\u6280\u672f\u5047\u9633\u6027</p> </li> <li> <p>\u591a\u7ec4\u5b66\u6570\u636e\u6574\u5408</p> </li> <li>\u7ed3\u5408\u8f6c\u5f55\u7ec4\u6570\u636e\u5206\u6790SV\u5bf9\u57fa\u56e0\u8868\u8fbe\u7684\u5f71\u54cd</li> <li>\u6574\u5408\u8868\u89c2\u57fa\u56e0\u7ec4\u6570\u636e(\u5982\u7532\u57fa\u5316)</li> <li>\u5c06SV\u4e0e\u8868\u578b\u6216\u4e34\u5e8a\u6570\u636e\u5173\u8054</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W12.LiangGong%20Long%20read%20sequencing%2C%20Genomic%20Structural%20Variation/#_4","title":"\u56db\u3001\u7ed3\u679c\u9a8c\u8bc1\u4e0e\u5c55\u793a","text":"<ol> <li>\u751f\u7269\u4fe1\u606f\u5b66\u9a8c\u8bc1</li> <li>\u8de8\u5e73\u53f0\u6bd4\u8f83(Nanopore vs PacBio\u7ed3\u679c)</li> <li>\u4e0e\u77ed\u8bfb\u957f\u6570\u636e\u6bd4\u8f83(\u5982Illumina)</li> <li> <p>\u4f7f\u7528\u4e0d\u540c\u7b97\u6cd5\u4ea4\u53c9\u9a8c\u8bc1</p> </li> <li> <p>\u5b9e\u9a8c\u9a8c\u8bc1</p> </li> <li>PCR\u6269\u589eSV\u65ad\u70b9</li> <li>\u8367\u5149\u539f\u4f4d\u6742\u4ea4(FISH)\u9a8c\u8bc1\u5927\u578b\u91cd\u6392</li> <li> <p>\u957f\u7247\u6bb5PCR\u548cSanger\u6d4b\u5e8f\u9a8c\u8bc1\u5c0f\u578bSV</p> </li> <li> <p>\u6570\u636e\u53ef\u89c6\u5316</p> </li> <li>Circos\u56fe\u5c55\u793a\u5168\u57fa\u56e0\u7ec4SV\u5206\u5e03</li> <li>IGV\u6d4f\u89c8\u5668\u5c55\u793a\u7279\u5b9a\u533a\u57df\u7684\u8bfb\u957f\u6bd4\u5bf9</li> <li> <p>\u70ed\u56fe\u663e\u793aSV\u4e0e\u75be\u75c5\u6216\u8868\u578b\u7684\u5173\u8054</p> </li> <li> <p>\u7edf\u8ba1\u5206\u6790</p> </li> <li>\u5bcc\u96c6\u5206\u6790(GO\u672f\u8bed\u3001\u901a\u8def\u5206\u6790)</li> <li>\u751f\u5b58\u5206\u6790(\u764c\u75c7\u961f\u5217)</li> <li>\u591a\u53d8\u91cf\u5206\u6790\u8bc4\u4f30SV\u4e0e\u8868\u578b\u7684\u5173\u8054</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W12.LiangGong%20Long%20read%20sequencing%2C%20Genomic%20Structural%20Variation/#_5","title":"\u4e94\u3001\u7279\u6b8a\u5e94\u7528\u6848\u4f8b","text":"<ol> <li>\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u4e2d\u7684\u91cd\u590d\u6269\u589e\u68c0\u6d4b</li> <li>NOTCH2NLC\u57fa\u56e0GGC\u91cd\u590d\u6269\u589e\u5206\u6790</li> <li>\u4f7f\u7528\u7279\u6b8aPCR-free\u6587\u5e93\u907f\u514dPCR\u504f\u597d\u6027</li> <li> <p>\u91cd\u590d\u5e8f\u5217\u5206\u6790\u5de5\u5177(\u5982ExpansionHunter)</p> </li> <li> <p>\u764c\u75c7\u4e2d\u7684\u73af\u72b6DNA(ecDNA)\u7814\u7a76</p> </li> <li>\u7ed3\u5408\u957f\u8bfb\u957f\u6d4b\u5e8f\u4e0e\u5149\u5b66\u56fe\u8c31</li> <li>\u4f7f\u7528Circle_finder\u7b49\u5de5\u5177\u68c0\u6d4b\u73af\u72b6\u7ed3\u6784</li> <li> <p>\u5206\u6790ecDNA\u4e0e\u764c\u75c7\u8fdb\u5c55\u548c\u836f\u7269\u62b5\u6297\u7684\u5173\u7cfb</p> </li> <li> <p>\u590d\u6742\u57fa\u56e0\u7ec4\u533a\u57df\u89e3\u6790</p> </li> <li>\u9ad8\u5ea6\u91cd\u590d\u533a\u57df(\u5982\u7740\u4e1d\u7c92\u3001\u7aef\u7c92)\u7684\u6d4b\u5e8f</li> <li>\u590d\u6742\u4f2a\u57fa\u56e0\u533a\u57df\u7684\u89e3\u6790</li> <li>\u9ad8GC\u542b\u91cf\u533a\u57df\u7684\u7279\u6b8a\u5904\u7406\u65b9\u6cd5</li> </ol> <p>\u8fd9\u4e00\u7cfb\u7edf\u6027\u7684\u5b9e\u9a8c\u548c\u5206\u6790\u6d41\u7a0b\u4f7f\u7814\u7a76\u4eba\u5458\u80fd\u591f\u5168\u9762\u4e86\u89e3\u57fa\u56e0\u7ec4\u7ed3\u6784\u53d8\u5f02\u5728\u4eba\u7c7b\u75be\u75c5\u4e2d\u7684\u4f5c\u7528\uff0c\u5e76\u5145\u5206\u53d1\u6325\u957f\u8bfb\u957f\u6d4b\u5e8f\u6280\u672f\u5728\u89e3\u6790\u590d\u6742\u57fa\u56e0\u7ec4\u91cd\u6392\u65b9\u9762\u7684\u4f18\u52bf\u3002</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W12.LiangGong%20Long%20read%20sequencing%2C%20Genomic%20Structural%20Variation/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<p>The lecture addresses the scientific challenge of understanding genomic structural variations (SVs) and their roles in human diseases, particularly how long-read sequencing (LRS) technologies overcome limitations of short-read methods. Key questions include: - How do SVs contribute to disease pathogenesis (e.g., cancer, neurological disorders)? - How can LRS improve SV detection and resolve complex genomic rearrangements?  </p> <p>The experimental design focuses on demonstrating LRS capabilities through: - Technical comparisons between short-read and long-read platforms (e.g., PacBio HiFi vs. Illumina). - Case studies of disease-specific SVs (e.g., GGC repeat expansions in neuronal inclusion disease, ecDNA in glioblastoma). - Methodological advancements (e.g., NLR-seq for ultra-long reads, Picky pipeline for SV detection).  </p> <p>Repeating similar designs (e.g., in Figures 2 and 3) serves to validate reproducibility, test different contexts (e.g., cancer vs. neurological diseases), and explore variables like read length and accuracy.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W12.LiangGong%20Long%20read%20sequencing%2C%20Genomic%20Structural%20Variation/#2-model-system","title":"2. Model System","text":"<p>Model systems used: - Human cell lines (e.g., GM12878 for SV benchmarking). - Cancer models (triple-negative breast cancer, glioblastoma) with ecDNA. - Clinical samples (patient-derived tumors, neurodegenerative tissues).  </p> <p>Rationale: - Relevance to human biology and disease mechanisms. - Accessibility for genomic manipulation (e.g., CRISPR-Cas9 editing). - High throughput for large-scale SV studies.  </p> <p>Alternative systems: - Model organisms (e.g., mice, Drosophila): Lower cost, ethical simplicity, but limited translatability. - Cell-free systems: Studying isolated SVs in vitro, but lacks in vivo context.  </p> <p>Ethical considerations: - Handling human clinical data requires IRB approval and patient consent. - Balancing privacy with data sharing for genomic research. </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W12.LiangGong%20Long%20read%20sequencing%2C%20Genomic%20Structural%20Variation/#3-measurement-approach","title":"3. Measurement Approach","text":"<p>Techniques: - Long-read sequencing: PacBio SMRT (HiFi reads), Oxford Nanopore (direct RNA/DNA sequencing). - Synthetic long-reads: 10x Genomics, Illumina synthetic reads. - Associated methods: Hi-C for chromatin interactions, optical mapping, and nanopore-based methylation detection.  </p> <p>Why chosen: - Long reads resolve repetitive regions and complex SVs (e.g., inversions, translocations). - Direct detection of epigenetic modifications (e.g., 5mC, m6A). - Real-time data analysis for adaptive sampling (e.g., CRISPR-guided targeting).  </p> <p>Replicates: - Technical replicates (multiple sequencing runs per sample) ensure consistency. - Biological replicates (e.g., independent patient cohorts) validate generalizability.  </p> <p>Potential biases: - GC bias in long-read sequencing. - Cost constraints limiting sample size. - Minimized via diverse library preparation and computational correction.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W12.LiangGong%20Long%20read%20sequencing%2C%20Genomic%20Structural%20Variation/#4-group-setting","title":"4. Group Setting","text":"<p>Experimental groups: - Disease vs. control: Comparing SV profiles in cancer vs. healthy tissues. - Technology comparisons: Short-read vs. long-read datasets. - Methodological validation: Testing NLR-seq vs. vendor-standard protocols.  </p> <p>Controls: - Negative controls: Wild-type cell lines, non-diseased samples. - Positive controls: Well-characterized SVs (e.g., BRCA1 deletions).  </p> <p>Replicates: - Typically 3\u20135 biological replicates per group, sufficient for statistical power (e.g., ANOVA, Fisher\u2019s exact test).  </p> <p>Modified design: - Dose-response studies: Testing SV frequency across cancer stages. - Multi-omics integration: Combining LRS with transcriptomics/epigenomics.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W12.LiangGong%20Long%20read%20sequencing%2C%20Genomic%20Structural%20Variation/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<p>Processing: - Raw data: Basecalling (Guppy for Nanopore, SMRT Link for PacBio). - SV detection: Picky pipeline for complex rearrangements, Sniffles for small indels. - Qualitative/quantitative: SV counts, length distributions, functional annotations.  </p> <p>Statistics: - Enrichment analysis (e.g., GO terms, pathways). - Survival analysis for cancer cohorts.  </p> <p>Presentation: - Clear visualization of SV landscapes (e.g., Circos plots, heatmaps). - Representative examples of disease-specific SVs (e.g., NOTCH2NLC repeat expansions).  </p> <p>Validation: - Orthogonal methods (e.g., PCR, FISH) confirm SV breakpoints. - Cross-platform comparisons (e.g., ONT vs. PacBio).  </p> <p>Conclusion The lecture highlights LRS as a transformative tool for uncovering SVs in health and disease. Key advancements include resolving complex genomic architectures, detecting epigenetic modifications, and enabling personalized medicine. Future directions involve refining computational pipelines, integrating multi-omics data, and addressing technical limitations (e.g., cost, throughput).</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/","title":"S1.W13.LiuNan Dual Luciferase reporter assay","text":"<p>\u53cc\u8367\u5149\u7d20\u9176\u62a5\u544a\u57fa\u56e0\u5b9e\u9a8c\u8be6\u7ec6\u6d41\u7a0b</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#_1","title":"\u4e00\u3001\u5b9e\u9a8c\u51c6\u5907\u9636\u6bb5","text":"<ol> <li>\u8d28\u7c92\u6784\u5efa</li> <li> <p>\u542f\u52a8\u5b50-\u8367\u5149\u7d20\u9176\u62a5\u544a\u8f7d\u4f53\u6784\u5efa</p> <ul> <li>PCR\u6269\u589e\u76ee\u6807\u57fa\u56e0\u542f\u52a8\u5b50\u533a\u57df(\u901a\u5e38\u4e3a\u8f6c\u5f55\u8d77\u59cb\u4f4d\u70b9\u4e0a\u6e381-2kb)</li> <li>\u9176\u5207\u6d88\u5316PCR\u4ea7\u7269\u548cpGL4.10\u8f7d\u4f53(\u542b\u6709\u8424\u706b\u866b\u8367\u5149\u7d20\u9176\u57fa\u56e0\u4f46\u65e0\u542f\u52a8\u5b50)</li> <li>\u8fde\u63a5\u53cd\u5e94\u5c06\u542f\u52a8\u5b50\u7247\u6bb5\u63d2\u5165\u8f7d\u4f53</li> <li>\u8f6c\u5316\u5927\u80a0\u6746\u83ccDH5\u03b1</li> <li>\u6311\u53d6\u5355\u514b\u9686\u8fdb\u884c\u5c0f\u91cf\u63d0\u53d6\u548c\u6d4b\u5e8f\u9a8c\u8bc1</li> <li>\u5927\u91cf\u63d0\u53d6\u8d28\u7c92\u5e76\u6d4b\u5b9a\u6d53\u5ea6\u548c\u7eaf\u5ea6</li> </ul> </li> <li> <p>\u8f6c\u5f55\u5143\u4ef6(TE)\u8868\u8fbe\u8f7d\u4f53\u6784\u5efa</p> <ul> <li>PCR\u6269\u589eTE\u7f16\u7801\u5e8f\u5217</li> <li>\u5c06\u5e8f\u5217\u514b\u9686\u81f3\u8868\u8fbe\u8f7d\u4f53(\u5982pcDNA3.1)\u4e2d</li> <li>\u8f6c\u5316\u3001\u9a8c\u8bc1\u548c\u63d0\u53d6\u8d28\u7c92\u540c\u4e0a</li> </ul> </li> <li> <p>\u5bf9\u7167\u8f7d\u4f53\u51c6\u5907</p> <ul> <li>pRL-TK\u8f7d\u4f53(\u542b\u6709\u6d77\u80be\u8367\u5149\u7d20\u9176\u57fa\u56e0,\u7528\u4e8e\u5185\u53c2)</li> <li>\u7a7a\u8f7d\u4f53(\u4e0d\u542bTE\u5e8f\u5217\u7684\u8868\u8fbe\u8f7d\u4f53)</li> <li>\u9633\u6027\u5bf9\u7167(\u5df2\u77e5\u5f3a\u542f\u52a8\u5b50\u5982CMV\u9a71\u52a8\u7684\u8367\u5149\u7d20\u9176\u8f7d\u4f53)</li> </ul> </li> <li> <p>\u7ec6\u80de\u57f9\u517b\u51c6\u5907</p> </li> <li>\u9009\u62e9\u5408\u9002\u7ec6\u80de\u7cfb(\u5982HEK293T\u6216\u4e0e\u76ee\u6807\u57fa\u56e0\u8868\u8fbe\u7ec4\u7ec7\u76f8\u5173\u7684\u7ec6\u80de)</li> <li>\u7ec6\u80de\u590d\u82cf\u548c\u4f20\u4ee3</li> <li>\u7ec6\u80de\u9274\u5b9a\u548c\u652f\u539f\u4f53\u68c0\u6d4b</li> <li>\u4f18\u5316\u8f6c\u67d3\u6761\u4ef6(\u8bd5\u9a8c\u6700\u4f73\u7ec6\u80de\u5bc6\u5ea6\u548c\u8f6c\u67d3\u8bd5\u5242\u6bd4\u4f8b)</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#_2","title":"\u4e8c\u3001\u8f6c\u67d3\u5b9e\u9a8c","text":"<ol> <li>\u5b9e\u9a8c\u5206\u7ec4</li> <li>\u6d4b\u8bd5\u7ec4:\u542f\u52a8\u5b50-\u8424\u706b\u866b\u8367\u5149\u7d20\u9176\u8f7d\u4f53 + TE\u8868\u8fbe\u8f7d\u4f53 + pRL-TK</li> <li>\u9634\u6027\u5bf9\u71671:\u542f\u52a8\u5b50-\u8424\u706b\u866b\u8367\u5149\u7d20\u9176\u8f7d\u4f53 + \u7a7a\u8868\u8fbe\u8f7d\u4f53 + pRL-TK</li> <li>\u9634\u6027\u5bf9\u71672:\u65e0\u542f\u52a8\u5b50\u8424\u706b\u866b\u8367\u5149\u7d20\u9176\u8f7d\u4f53 + TE\u8868\u8fbe\u8f7d\u4f53 + pRL-TK</li> <li> <p>\u9633\u6027\u5bf9\u7167:\u5df2\u77e5\u6d3b\u6027\u542f\u52a8\u5b50-\u8424\u706b\u866b\u8367\u5149\u7d20\u9176\u8f7d\u4f53 + pRL-TK</p> </li> <li> <p>\u7ec6\u80de\u63a5\u79cd</p> </li> <li>\u8ba1\u6570\u7ec6\u80de\u5e76\u8c03\u6574\u81f3\u9002\u5f53\u6d53\u5ea6</li> <li>\u572824\u5b54\u677f\u4e2d\u63a5\u79cd\u7ec6\u80de(\u901a\u5e381-2\u00d710^5\u7ec6\u80de/\u5b54)</li> <li> <p>\u57f9\u517b\u81f370-80%\u878d\u5408\u5ea6(\u901a\u5e3824\u5c0f\u65f6)</p> </li> <li> <p>\u8f6c\u67d3\u64cd\u4f5c</p> </li> <li>\u51c6\u5907\u8f6c\u67d3\u6df7\u5408\u7269:<ul> <li>\u6bcf\u5b54450ng\u542f\u52a8\u5b50-\u8424\u706b\u866b\u8367\u5149\u7d20\u9176\u8f7d\u4f53</li> <li>450ng TE\u8868\u8fbe\u8f7d\u4f53\u6216\u7a7a\u8f7d\u4f53</li> <li>100ng pRL-TK\u8f7d\u4f53</li> <li>\u9002\u91cf\u8f6c\u67d3\u8bd5\u5242(\u5982Lipofectamine 2000)</li> </ul> </li> <li>\u6309\u7167\u8bd5\u5242\u8bf4\u660e\u4e66\u8fdb\u884c\u8f6c\u67d3</li> <li>\u6bcf\u7ec4\u8bbe\u7f6e3\u4e2a\u6280\u672f\u91cd\u590d\u5b54</li> <li> <p>\u8f6c\u67d3\u540e\u66f4\u6362\u4e3a\u5b8c\u5168\u57f9\u517b\u57fa</p> </li> <li> <p>\u8f6c\u67d3\u540e\u57f9\u517b</p> </li> <li>\u8f6c\u67d3\u540e24-48\u5c0f\u65f6\u6536\u83b7\u7ec6\u80de(\u6839\u636e\u86cb\u767d\u8868\u8fbe\u52a8\u529b\u5b66\u786e\u5b9a\u6700\u4f73\u65f6\u95f4)</li> <li>\u671f\u95f4\u53ef\u53d6\u5c11\u91cf\u7ec6\u80de\u8fdb\u884cWestern blot\u9a8c\u8bc1TE\u86cb\u767d\u8868\u8fbe</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#_3","title":"\u4e09\u3001\u8367\u5149\u7d20\u9176\u6d3b\u6027\u68c0\u6d4b","text":"<ol> <li>\u6837\u54c1\u5236\u5907</li> <li>\u5f03\u53bb\u57f9\u517b\u57fa,PBS\u6d17\u6da4\u7ec6\u80de</li> <li>\u52a0\u5165\u9002\u91cf\u7ec6\u80de\u88c2\u89e3\u7f13\u51b2\u6db2(\u5982Passive Lysis Buffer)</li> <li>\u5ba4\u6e29\u9707\u8361\u88c2\u89e310-15\u5206\u949f</li> <li>\u6536\u96c6\u88c2\u89e3\u6db2\u81f3\u79bb\u5fc3\u7ba1</li> <li>\u79bb\u5fc3\u53bb\u9664\u7ec6\u80de\u788e\u7247(12,000g, 2\u5206\u949f)</li> <li> <p>\u53d6\u4e0a\u6e05\u6db2\u8fdb\u884c\u68c0\u6d4b</p> </li> <li> <p>\u53cc\u8367\u5149\u7d20\u9176\u6d3b\u6027\u6d4b\u5b9a</p> </li> <li>\u4f7f\u7528\u53cc\u8367\u5149\u7d20\u9176\u62a5\u544a\u57fa\u56e0\u68c0\u6d4b\u7cfb\u7edf(Promega)</li> <li>\u541120\u03bcl\u7ec6\u80de\u88c2\u89e3\u6db2\u4e2d\u52a0\u5165100\u03bcl\u8424\u706b\u866b\u8367\u5149\u7d20\u9176\u5e95\u7269</li> <li>\u7acb\u5373\u5728\u53d1\u5149\u68c0\u6d4b\u4eea\u4e0a\u6d4b\u91cf\u8424\u706b\u866b\u8367\u5149\u7d20\u9176\u6d3b\u6027(2\u79d2\u79ef\u5206\u65f6\u95f4)</li> <li>\u52a0\u5165100\u03bcl\u6d77\u80be\u8367\u5149\u7d20\u9176\u5e95\u7269(Stop &amp; Glo\u8bd5\u5242)</li> <li> <p>\u7acb\u5373\u6d4b\u91cf\u6d77\u80be\u8367\u5149\u7d20\u9176\u6d3b\u6027(2\u79d2\u79ef\u5206\u65f6\u95f4)</p> </li> <li> <p>\u5e73\u884c\u9a8c\u8bc1\u5b9e\u9a8c</p> </li> <li> <p>Western blot:</p> <ul> <li>\u6536\u83b7\u90e8\u5206\u8f6c\u67d3\u7ec6\u80de\u88c2\u89e3\u63d0\u53d6\u86cb\u767d</li> <li>SDS-PAGE\u5206\u79bb\u86cb\u767d</li> <li>\u8f6c\u819c\u3001\u5c01\u95ed\u3001\u5b75\u80b2\u6297\u4f53</li> <li>\u68c0\u6d4bTE\u86cb\u767d\u8868\u8fbe\u6c34\u5e73\u548c\u5185\u53c2\u86cb\u767d(\u5982GAPDH)</li> </ul> </li> <li> <p>RT-qPCR:</p> <ul> <li>\u63d0\u53d6\u8f6c\u67d3\u7ec6\u80de\u603bRNA</li> <li>\u53cd\u8f6c\u5f55\u5408\u6210cDNA</li> <li>\u5b9e\u65f6\u5b9a\u91cfPCR\u68c0\u6d4b\u8424\u706b\u866b\u8367\u5149\u7d20\u9176mRNA\u6c34\u5e73</li> <li>\u4e0e\u5185\u53c2\u57fa\u56e0\u76f8\u5bf9\u5b9a\u91cf</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#_4","title":"\u56db\u3001\u6570\u636e\u5206\u6790","text":"<ol> <li>\u6570\u636e\u6807\u51c6\u5316</li> <li>\u8ba1\u7b97\u6bcf\u4e2a\u6837\u54c1\u7684\u8424\u706b\u866b/\u6d77\u80be\u8367\u5149\u7d20\u9176\u6d3b\u6027\u6bd4\u503c(F/R)</li> <li> <p>\u6807\u51c6\u5316\u6d88\u9664\u8f6c\u67d3\u6548\u7387\u5dee\u5f02\u5f71\u54cd</p> </li> <li> <p>\u76f8\u5bf9\u6d3b\u6027\u8ba1\u7b97</p> </li> <li>\u8ba1\u7b97\u6d4b\u8bd5\u7ec4\u76f8\u5bf9\u4e8e\u9634\u6027\u5bf9\u71671\u7684\u6d3b\u6027\u500d\u6570\u53d8\u5316</li> <li> <p>\u516c\u5f0f:\u6d4b\u8bd5\u7ec4F/R \u00f7 \u9634\u6027\u5bf9\u7167F/R</p> </li> <li> <p>\u7edf\u8ba1\u5206\u6790</p> </li> <li>\u8ba1\u7b97\u6bcf\u7ec43\u4e2a\u72ec\u7acb\u751f\u7269\u5b66\u91cd\u590d\u7684\u5e73\u5747\u503c\u548c\u6807\u51c6\u5dee/\u6807\u51c6\u8bef</li> <li>\u4f7f\u7528Student's t\u68c0\u9a8c\u6216ANOVA\u5206\u6790\u7ec4\u95f4\u5dee\u5f02\u663e\u8457\u6027</li> <li> <p>\u901a\u5e38p&lt;0.05\u88ab\u8ba4\u4e3a\u5177\u6709\u7edf\u8ba1\u5b66\u610f\u4e49</p> </li> <li> <p>\u56fe\u8868\u5236\u4f5c</p> </li> <li>\u7ed8\u5236\u67f1\u72b6\u56fe\u663e\u793a\u5404\u7ec4\u76f8\u5bf9\u8367\u5149\u7d20\u9176\u6d3b\u6027</li> <li>\u8bef\u5dee\u7ebf\u8868\u793a\u6807\u51c6\u5dee\u6216\u6807\u51c6\u8bef</li> <li>\u6807\u6ce8\u7edf\u8ba1\u663e\u8457\u6027(p&lt;0.05, p&lt;0.01, **p&lt;0.001)</li> <li>\u5305\u62ec\u5355\u72ec\u6570\u636e\u70b9\u589e\u52a0\u900f\u660e\u5ea6</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#_5","title":"\u4e94\u3001\u7ed3\u679c\u9a8c\u8bc1\u4e0e\u6269\u5c55","text":"<ol> <li>\u7a81\u53d8\u4f53\u5206\u6790</li> <li>\u8bbe\u8ba1\u542f\u52a8\u5b50\u533a\u57df\u6f5c\u5728\u7ed3\u5408\u4f4d\u70b9\u7684\u70b9\u7a81\u53d8\u4f53</li> <li> <p>\u91cd\u590d\u8367\u5149\u7d20\u9176\u5b9e\u9a8c\u9a8c\u8bc1\u5173\u952e\u7ed3\u5408\u4f4d\u70b9</p> </li> <li> <p>\u5242\u91cf\u4f9d\u8d56\u6027\u5206\u6790</p> </li> <li>\u4f7f\u7528\u4e0d\u540c\u91cf\u7684TE\u8868\u8fbe\u8f7d\u4f53(\u5982100ng, 300ng, 900ng)</li> <li> <p>\u68c0\u6d4b\u542f\u52a8\u5b50\u6d3b\u6027\u4e0eTE\u8868\u8fbe\u91cf\u7684\u5173\u7cfb</p> </li> <li> <p>\u8f85\u52a9\u9a8c\u8bc1\u5b9e\u9a8c</p> </li> <li>\u67d3\u8272\u8d28\u514d\u75ab\u6c89\u6dc0(ChIP)\u9a8c\u8bc1TE\u4e0e\u542f\u52a8\u5b50\u7684\u7269\u7406\u7ed3\u5408</li> <li>\u7535\u6cf3\u8fc1\u79fb\u7387\u53d8\u52a8\u5b9e\u9a8c(EMSA)\u786e\u8ba4\u76f4\u63a5DNA-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528</li> <li>\u5728\u4e0d\u540c\u7ec6\u80de\u7cfb\u4e2d\u91cd\u590d\u5b9e\u9a8c\u9a8c\u8bc1\u8c03\u63a7\u5173\u7cfb\u7684\u666e\u904d\u6027</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#detailed-protocol-for-dual-luciferase-reporter-assay","title":"Detailed Protocol for Dual-Luciferase Reporter Assay","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#i-preparatory-phase","title":"I. Preparatory Phase","text":"<ol> <li>Plasmid Construction</li> <li> <p>Promoter-Luciferase Reporter Vector Construction</p> <ul> <li>PCR amplify target gene promoter region (typically 1-2kb upstream of TSS)</li> <li>Digest PCR product and pGL4.10 vector (containing firefly luciferase gene without promoter) with appropriate restriction enzymes</li> <li>Ligate promoter fragment into vector</li> <li>Transform into E. coli DH5\u03b1</li> <li>Pick single colonies for miniprep and sequence verification</li> <li>Perform maxiprep and determine concentration and purity</li> </ul> </li> <li> <p>Transcription Element (TE) Expression Vector Construction</p> <ul> <li>PCR amplify TE coding sequence</li> <li>Clone sequence into expression vector (e.g., pcDNA3.1)</li> <li>Transform, verify, and extract plasmid as above</li> </ul> </li> <li> <p>Control Vector Preparation</p> <ul> <li>pRL-TK vector (containing Renilla luciferase gene, for internal control)</li> <li>Empty vector (expression vector without TE sequence)</li> <li>Positive control (known strong promoter such as CMV driving luciferase)</li> </ul> </li> <li> <p>Cell Culture Preparation</p> </li> <li>Select appropriate cell line (e.g., HEK293T or tissue-relevant cell line)</li> <li>Thaw and passage cells</li> <li>Authenticate cell line and test for mycoplasma</li> <li>Optimize transfection conditions (test optimal cell density and transfection reagent ratios)</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#ii-transfection-experiment","title":"II. Transfection Experiment","text":"<ol> <li>Experimental Groups</li> <li>Test group: Promoter-firefly luciferase vector + TE expression vector + pRL-TK</li> <li>Negative control 1: Promoter-firefly luciferase vector + Empty expression vector + pRL-TK</li> <li>Negative control 2: Promoterless firefly luciferase vector + TE expression vector + pRL-TK</li> <li> <p>Positive control: Known active promoter-firefly luciferase vector + pRL-TK</p> </li> <li> <p>Cell Seeding</p> </li> <li>Count cells and adjust to appropriate concentration</li> <li>Seed cells in 24-well plates (typically 1-2\u00d710^5 cells/well)</li> <li> <p>Culture until 70-80% confluent (typically 24 hours)</p> </li> <li> <p>Transfection Procedure</p> </li> <li>Prepare transfection mixture:<ul> <li>450ng promoter-firefly luciferase vector per well</li> <li>450ng TE expression vector or empty vector</li> <li>100ng pRL-TK vector</li> <li>Appropriate amount of transfection reagent (e.g., Lipofectamine 2000)</li> </ul> </li> <li>Perform transfection according to reagent protocol</li> <li>Set up 3 technical replicate wells per group</li> <li> <p>Replace with complete culture medium after transfection</p> </li> <li> <p>Post-Transfection Culture</p> </li> <li>Harvest cells 24-48 hours post-transfection (determine optimal time based on protein expression kinetics)</li> <li>Optionally take a small aliquot of cells for Western blot to verify TE protein expression</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#iii-luciferase-activity-detection","title":"III. Luciferase Activity Detection","text":"<ol> <li>Sample Preparation</li> <li>Remove culture medium, wash cells with PBS</li> <li>Add appropriate volume of cell lysis buffer (e.g., Passive Lysis Buffer)</li> <li>Shake at room temperature for 10-15 minutes to lyse cells</li> <li>Collect lysate into centrifuge tubes</li> <li>Centrifuge to remove cell debris (12,000g, 2 minutes)</li> <li> <p>Transfer supernatant for detection</p> </li> <li> <p>Dual-Luciferase Activity Measurement</p> </li> <li>Use Dual-Luciferase Reporter Assay System (Promega)</li> <li>Add 100\u03bcl of firefly luciferase substrate to 20\u03bcl cell lysate</li> <li>Immediately measure firefly luciferase activity on a luminometer (2-second integration time)</li> <li>Add 100\u03bcl of Renilla luciferase substrate (Stop &amp; Glo reagent)</li> <li> <p>Immediately measure Renilla luciferase activity (2-second integration time)</p> </li> <li> <p>Parallel Validation Experiments</p> </li> <li> <p>Western Blot:</p> <ul> <li>Harvest a portion of transfected cells for protein extraction</li> <li>Separate proteins by SDS-PAGE</li> <li>Transfer to membrane, block, and incubate with antibodies</li> <li>Detect TE protein expression and reference protein (e.g., GAPDH)</li> </ul> </li> <li> <p>RT-qPCR:</p> <ul> <li>Extract total RNA from transfected cells</li> <li>Reverse transcribe to cDNA</li> <li>Perform real-time quantitative PCR to detect firefly luciferase mRNA levels</li> <li>Quantify relative to reference gene</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#iv-data-analysis","title":"IV. Data Analysis","text":"<ol> <li>Data Normalization</li> <li>Calculate firefly/Renilla luciferase activity ratio (F/R) for each sample</li> <li> <p>Normalization eliminates variations in transfection efficiency</p> </li> <li> <p>Relative Activity Calculation</p> </li> <li>Calculate fold change in activity of test group relative to negative control 1</li> <li> <p>Formula: Test group F/R \u00f7 Negative control F/R</p> </li> <li> <p>Statistical Analysis</p> </li> <li>Calculate mean and standard deviation/SEM from 3 independent biological replicates</li> <li>Perform Student's t-test or ANOVA to analyze significance between groups</li> <li> <p>Typically p&lt;0.05 is considered statistically significant</p> </li> <li> <p>Figure Preparation</p> </li> <li>Create bar graphs showing relative luciferase activity for each group</li> <li>Error bars represent standard deviation or SEM</li> <li>Indicate statistical significance (p&lt;0.05, p&lt;0.01, **p&lt;0.001)</li> <li>Include individual data points for transparency</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#v-result-validation-and-extension","title":"V. Result Validation and Extension","text":"<ol> <li>Mutant Analysis</li> <li>Design point mutations in potential binding sites within the promoter region</li> <li> <p>Repeat luciferase assay to validate critical binding sites</p> </li> <li> <p>Dose-Dependency Analysis</p> </li> <li>Use varying amounts of TE expression vector (e.g., 100ng, 300ng, 900ng)</li> <li> <p>Detect relationship between promoter activity and TE expression level</p> </li> <li> <p>Supplementary Validation Experiments</p> </li> <li>Chromatin Immunoprecipitation (ChIP) to verify physical interaction between TE and promoter</li> <li>Electrophoretic Mobility Shift Assay (EMSA) to confirm direct DNA-protein interaction</li> <li>Repeat experiments in different cell lines to validate the universality of the regulatory relationship</li> </ol> <p>This detailed protocol helps researchers systematically evaluate the regulatory effect of specific transcription elements on target gene promoters.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Does a specific transcription element (TE) directly regulate gene expression through interaction with a target promoter?</li> <li>Design Rationale: The dual-luciferase reporter assay provides a quantitative measure of promoter activity with and without the TE of interest, allowing direct assessment of functional regulatory relationships.</li> <li>Follow-up Studies: Additional experiments could examine dose-dependency, test multiple TEs, or investigate the effect in different cell types to establish biological relevance and specificity.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cell lines relevant to the gene's function (e.g., HEK293T for general studies, or tissue-specific lines like HepG2 for liver-expressed genes)</li> <li>Rationale: Cell culture provides a controlled environment to isolate the specific TE-promoter interaction while maintaining human genomic context</li> <li>Alternatives:</li> <li>In vivo mouse models (pros: physiological context; cons: complex, expensive, species differences)</li> <li>In vitro binding assays (pros: direct biochemical evidence; cons: lacks cellular context)</li> <li>Yeast one-hybrid (pros: high-throughput; cons: non-mammalian transcriptional machinery)</li> <li>Ethical Considerations: Cell line authentication, mycoplasma testing, and proper documentation of cell line origin</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques:</li> <li>Dual-luciferase reporter assay (quantitative)</li> <li>Western blot to confirm TE protein expression</li> <li>RT-qPCR to verify mRNA levels</li> <li>Technical Replicates: Triplicate measurements for each biological sample</li> <li>Potential Biases:</li> <li>Transfection efficiency variations (minimized by dual-reporter normalization)</li> <li>Plasmid preparation quality (controlled by using same preparation batch)</li> <li>Cell density and passage number effects (standardized seeding and culture conditions)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test condition: Cells co-transfected with TE expression vector + promoter-firefly luciferase construct + Renilla control</li> <li>Negative control 1: Empty expression vector + promoter-firefly luciferase construct + Renilla control</li> <li>Negative control 2: TE expression vector + promoterless luciferase construct + Renilla control</li> <li>Positive control: Known active promoter-luciferase construct + Renilla control</li> <li>Controlled Variables: Cell density, passage number, transfection reagent lot, incubation time</li> <li>Biological Replicates: Minimum 3 independent experiments with fresh transfections</li> <li>Modified Design: Include multiple promoter fragments of varying lengths to map the precise TE binding region</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Dual-Luciferase%20reporter%20assay/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: </li> <li>Raw luminescence values normalized (firefly/Renilla ratio)</li> <li>Fold-change calculated relative to negative control</li> <li>Statistical Analysis:</li> <li>Student's t-test or ANOVA with post-hoc tests depending on group numbers</li> <li>Sample size determined by power analysis (typically n=3-6 is sufficient for cell culture)</li> <li>Data Presentation:</li> <li>Bar graphs showing normalized luciferase activity with error bars (SEM or SD)</li> <li>Include individual data points for transparency</li> <li>Validation Methods:</li> <li>ChIP assay to confirm physical binding of TE to the promoter region</li> <li>EMSA to verify direct DNA-protein interaction</li> <li>Mutational analysis of putative binding sites in the promoter</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20GWAS/","title":"S1.W13.LiuNan GWAS","text":"<p>\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u9057\u4f20\u98ce\u9669\u56e0\u7d20\u5168\u57fa\u56e0\u7ec4\u5173\u8054\u7814\u7a76(GWAS)\u8bbe\u8ba1</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20GWAS/#_1","title":"\u4e00\u3001\u7814\u7a76\u51c6\u5907\u9636\u6bb5","text":"<ol> <li>\u7814\u7a76\u95ee\u9898\u660e\u786e</li> <li>\u786e\u5b9a\u7814\u7a76\u76ee\u6807\uff1a\u8bc6\u522b\u65e9\u53d1\u6027\u963f\u5c14\u8328\u6d77\u9ed8\u75c5(EOAD)\u7684\u9057\u4f20\u98ce\u9669\u56e0\u7d20</li> <li>\u6b21\u8981\u76ee\u6807\uff1a\u6bd4\u8f83\u65e9\u53d1\u6027\u4e0e\u665a\u53d1\u6027\u963f\u5c14\u8328\u6d77\u9ed8\u75c5(LOAD)\u7684\u9057\u4f20\u5dee\u5f02</li> <li> <p>\u5236\u5b9a\u5177\u4f53\u5047\u8bbe\uff1a\u65e9\u53d1\u6027\u60a3\u8005\u53ef\u80fd\u643a\u5e26\u4e0d\u540c\u4e8e\u665a\u53d1\u6027\u60a3\u8005\u7684\u9ad8\u98ce\u9669\u53d8\u5f02</p> </li> <li> <p>\u4f26\u7406\u5ba1\u6279\u4e0e\u60a3\u8005\u62db\u52df</p> </li> <li>\u83b7\u53d6\u591a\u4e2d\u5fc3\u4f26\u7406\u59d4\u5458\u4f1a\u6279\u51c6</li> <li>\u5236\u5b9a\u77e5\u60c5\u540c\u610f\u6d41\u7a0b(\u7279\u522b\u8003\u8651\u8ba4\u77e5\u969c\u788d\u60a3\u8005\u7684\u540c\u610f\u80fd\u529b)</li> <li>\u5efa\u7acb\u6837\u672c\u548c\u6570\u636e\u9690\u79c1\u4fdd\u62a4\u534f\u8bae</li> <li> <p>\u4ece\u591a\u4e2a\u4e34\u5e8a\u4e2d\u5fc3\u62db\u52df\u53c2\u4e0e\u8005:</p> <ul> <li>1,000\u540d\u65e9\u53d1\u6027\u60a3\u8005(\u53d1\u75c5\u5e74\u9f84&lt;65\u5c81)</li> <li>2,000\u540d\u665a\u53d1\u6027\u60a3\u8005(\u53d1\u75c5\u5e74\u9f84\u226565\u5c81)</li> <li>3,000\u540d\u5e74\u9f84\u5339\u914d\u7684\u5065\u5eb7\u5bf9\u7167</li> </ul> </li> <li> <p>\u8868\u578b\u6570\u636e\u6536\u96c6</p> </li> <li>\u8be6\u7ec6\u4e34\u5e8a\u8bc4\u4f30:<ul> <li>\u6807\u51c6\u5316\u795e\u7ecf\u5fc3\u7406\u5b66\u6d4b\u8bd5</li> <li>\u75be\u75c5\u8d77\u75c5\u5e74\u9f84\u548c\u8fdb\u5c55\u901f\u5ea6\u8bb0\u5f55</li> <li>\u5bb6\u65cf\u53f2\u8c03\u67e5</li> </ul> </li> <li>\u5f71\u50cf\u5b66\u68c0\u67e5:<ul> <li>\u7ed3\u6784\u6027MRI\u8bc4\u4f30\u8111\u840e\u7f29</li> <li>\u6dc0\u7c89\u6837\u86cb\u767dPET\u663e\u50cf</li> </ul> </li> <li>\u751f\u7269\u6807\u5fd7\u7269\u6d4b\u91cf:<ul> <li>\u8840\u6db2A\u03b242/40\u6bd4\u7387\u3001p-tau181\u3001NfL\u6c34\u5e73</li> <li>\u53ef\u80fd\u65f6\u6536\u96c6\u8111\u810a\u6db2\u6837\u672c</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20GWAS/#_2","title":"\u4e8c\u3001\u6837\u672c\u5904\u7406\u4e0e\u57fa\u56e0\u5206\u578b","text":"<ol> <li>\u6837\u672c\u6536\u96c6</li> <li>\u91c7\u96c6\u5916\u5468\u8840\u6837\u672c(EDTA\u6297\u51dd\u7ba1)</li> <li>\u6837\u672c\u7f16\u7801\u4ee5\u786e\u4fdd\u533f\u540d\u5316</li> <li> <p>\u5efa\u7acb\u6837\u672c\u8ffd\u8e2a\u7cfb\u7edf</p> </li> <li> <p>DNA\u63d0\u53d6\u4e0e\u8d28\u63a7</p> </li> <li>\u4f7f\u7528\u6807\u51c6\u8bd5\u5242\u76d2\u4ece\u5168\u8840\u4e2d\u63d0\u53d6\u57fa\u56e0\u7ec4DNA</li> <li>\u4f7f\u7528\u5206\u5149\u5149\u5ea6\u8ba1\u548c\u51dd\u80f6\u7535\u6cf3\u8bc4\u4f30DNA\u8d28\u91cf\u548c\u5b8c\u6574\u6027</li> <li> <p>\u786e\u4fddDNA\u6d53\u5ea6\u548c\u7eaf\u5ea6\u6ee1\u8db3\u6d4b\u5e8f\u8981\u6c42</p> </li> <li> <p>\u5168\u57fa\u56e0\u7ec4\u6d4b\u5e8f</p> </li> <li>\u5bf9\u6240\u6709\u6837\u672c\u8fdb\u884c30x\u8986\u76d6\u5ea6\u7684\u5168\u57fa\u56e0\u7ec4\u6d4b\u5e8f</li> <li>\u968f\u673a\u5206\u914d\u75c5\u4f8b\u548c\u5bf9\u7167\u6837\u672c\u5230\u4e0d\u540c\u6d4b\u5e8f\u6279\u6b21</li> <li>\u5305\u542b5%\u7684\u6280\u672f\u91cd\u590d\u6837\u672c\u8bc4\u4f30\u6d4b\u5e8f\u53ef\u9760\u6027</li> <li> <p>\u52a0\u5165\u6807\u51c6\u53c2\u8003\u57fa\u56e0\u7ec4\u6837\u672c\u7528\u4e8e\u8d28\u91cf\u6821\u51c6</p> </li> <li> <p>\u6570\u636e\u9884\u5904\u7406</p> </li> <li>\u539f\u59cb\u6d4b\u5e8f\u6570\u636e\u8d28\u91cf\u63a7\u5236\u548c\u8fc7\u6ee4</li> <li>\u4f7f\u7528GATK\u6700\u4f73\u5b9e\u8df5\u6d41\u7a0b\u8fdb\u884c\u53d8\u5f02\u68c0\u6d4b</li> <li>\u57fa\u4e8e\u4eba\u53e3\u7279\u5f02\u6027\u53c2\u8003\u9762\u677f\u8fdb\u884c\u57fa\u56e0\u578b\u586b\u5145</li> <li>\u5e94\u7528\u4e25\u683c\u8d28\u63a7\u6807\u51c6(\u8c03\u7528\u7387&gt;98%\u3001Hardy-Weinberg\u5e73\u8861\u7b49)</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20GWAS/#_3","title":"\u4e09\u3001\u7edf\u8ba1\u5206\u6790\u6d41\u7a0b","text":"<ol> <li>\u4eba\u53e3\u5206\u5c42\u5206\u6790</li> <li>\u4f7f\u7528\u4e3b\u6210\u5206\u5206\u6790(PCA)\u8bc4\u4f30\u6837\u672c\u9057\u4f20\u7956\u6e90</li> <li>\u8ba1\u7b97\u7956\u6e90\u4fe1\u606f\u6807\u8bb0</li> <li> <p>\u6839\u636e\u9057\u4f20\u80cc\u666f\u5bf9\u6837\u672c\u8fdb\u884c\u5206\u5c42\u6216\u8c03\u6574</p> </li> <li> <p>\u5173\u8054\u5206\u6790</p> </li> <li> <p>\u521d\u7ea7\u5206\u6790:</p> <ul> <li>\u4f7f\u7528\u903b\u8f91\u56de\u5f52\u6bd4\u8f83\u75c5\u4f8b\u4e0e\u5bf9\u7167</li> <li>\u8c03\u6574\u5e74\u9f84\u3001\u6027\u522b\u548c\u9057\u4f20\u7956\u6e90\u4e3b\u6210\u5206</li> <li>\u5168\u57fa\u56e0\u7ec4\u663e\u8457\u6027\u9608\u503c\u8bbe\u4e3ap&lt;5\u00d710^-8</li> </ul> </li> <li> <p>\u6b21\u7ea7\u5206\u6790:</p> <ul> <li>\u57fa\u4e8e\u57fa\u56e0\u7684\u7a00\u6709\u53d8\u5f02\u8d1f\u62c5\u6d4b\u8bd5</li> <li>EOAD\u4e0eLOAD\u9057\u4f20\u98ce\u9669\u6bd4\u8f83</li> <li>APOE\u57fa\u56e0\u578b\u5206\u5c42\u5206\u6790</li> <li>\u901a\u8def\u5bcc\u96c6\u5206\u6790</li> </ul> </li> <li> <p>\u9ad8\u7ea7\u9057\u4f20\u5206\u6790</p> </li> <li>\u4f7f\u7528LD\u5206\u6570\u56de\u5f52\u4f30\u8ba1\u9057\u4f20\u529b</li> <li>\u5f00\u53d1\u548c\u9a8c\u8bc1\u591a\u57fa\u56e0\u98ce\u9669\u8bc4\u5206(PRS)</li> <li>\u57fa\u56e0-\u73af\u5883\u4ea4\u4e92\u4f5c\u7528\u5206\u6790</li> <li> <p>\u529f\u80fd\u6ce8\u91ca\u548c\u9884\u6d4b\u53d8\u5f02\u6548\u5e94</p> </li> <li> <p>\u6570\u636e\u6574\u5408\u5206\u6790</p> </li> <li>\u4e0e\u5df2\u6709\u963f\u5c14\u8328\u6d77\u9ed8\u75c5GWAS\u6570\u636e\u96c6\u4ea4\u53c9\u53c2\u8003</li> <li>\u6574\u5408\u8f6c\u5f55\u7ec4\u548c\u86cb\u767d\u8d28\u7ec4\u6570\u636e</li> <li>\u4e0e\u8111\u7ec4\u7ec7\u8868\u8fbe\u5b9a\u91cf\u6027\u72b6\u4f4d\u70b9(eQTL)\u6570\u636e\u6bd4\u8f83</li> <li>\u836f\u7269\u9776\u70b9\u9884\u6d4b\u5206\u6790</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20GWAS/#_4","title":"\u56db\u3001\u7ed3\u679c\u9a8c\u8bc1\u4e0e\u5c55\u793a","text":"<ol> <li>\u751f\u7269\u4fe1\u606f\u5b66\u9a8c\u8bc1</li> <li>\u5728\u72ec\u7acb\u961f\u5217\u4e2d\u590d\u5236\u4e3b\u8981\u53d1\u73b0</li> <li>\u4e0e\u73b0\u6709\u963f\u5c14\u8328\u6d77\u9ed8\u75c5GWAS\u6570\u636e\u96c6\u6bd4\u8f83</li> <li> <p>\u68c0\u67e5\u5df2\u77e5\u529f\u80fd\u533a\u57df\u7684\u53d8\u5f02\u5bcc\u96c6</p> </li> <li> <p>\u5b9e\u9a8c\u9a8c\u8bc1</p> </li> <li>\u5728\u7ec6\u80de\u548c\u52a8\u7269\u6a21\u578b\u4e2d\u8fdb\u884c\u529f\u80fd\u9a8c\u8bc1</li> <li>\u4f7f\u7528CRISPR-Cas9\u7f16\u8f91\u9a8c\u8bc1\u5019\u9009\u57fa\u56e0\u529f\u80fd</li> <li> <p>\u86cb\u767d\u8d28\u8868\u8fbe\u548c\u4e92\u4f5c\u7814\u7a76</p> </li> <li> <p>\u6570\u636e\u53ef\u89c6\u5316</p> </li> <li>\u7ed8\u5236\u66fc\u54c8\u987f\u56fe\u663e\u793a\u5168\u57fa\u56e0\u7ec4\u7ed3\u679c</li> <li>\u4f7f\u7528\u533a\u57df\u5173\u8054\u56fe\u5c55\u793a\u91cd\u8981\u4f4d\u70b9</li> <li>\u68ee\u6797\u56fe\u6bd4\u8f83EOAD\u548cLOAD\u4e4b\u95f4\u7684\u6548\u5e94\u5927\u5c0f</li> <li>\u5206\u4f4d\u6570-\u5206\u4f4d\u6570\u56fe\u8bc4\u4f30\u7cfb\u7edf\u504f\u5dee</li> <li> <p>\u70ed\u56fe\u5c55\u793a\u901a\u8def\u5bcc\u96c6\u7ed3\u679c</p> </li> <li> <p>\u7ed3\u679c\u89e3\u91ca\u4e0e\u5e94\u7528</p> </li> <li>\u8bc4\u4f30\u65b0\u53d1\u73b0\u7684\u9057\u4f20\u53d8\u5f02\u5bf9\u75be\u75c5\u98ce\u9669\u7684\u8d21\u732e</li> <li>\u5206\u6790\u53d1\u73b0\u7684\u53d8\u5f02\u5982\u4f55\u5f71\u54cd\u75be\u75c5\u673a\u5236</li> <li>\u8ba8\u8bba\u7ed3\u679c\u5bf9\u65e9\u671f\u8bca\u65ad\u548c\u98ce\u9669\u9884\u6d4b\u7684\u6f5c\u5728\u5e94\u7528</li> <li>\u8bc4\u4f30\u7ed3\u679c\u5bf9\u836f\u7269\u5f00\u53d1\u7684\u542f\u793a</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20GWAS/#_5","title":"\u4e94\u3001\u7279\u6b8a\u8003\u8651\u4e8b\u9879","text":"<ol> <li>\u7814\u7a76\u5c40\u9650\u6027\u5206\u6790</li> <li>\u8ba8\u8bba\u6837\u672c\u91cf\u5bf9\u68c0\u6d4b\u4f4e\u9891\u53d8\u5f02\u7684\u9650\u5236</li> <li>\u8bc4\u4f30\u4eba\u53e3\u7ed3\u6784\u5bf9\u7ed3\u679c\u7684\u6f5c\u5728\u5f71\u54cd</li> <li> <p>\u8003\u8651\u8868\u578b\u5b9a\u4e49\u7684\u590d\u6742\u6027\u548c\u53ef\u80fd\u7684\u9519\u8bef\u5206\u7c7b</p> </li> <li> <p>\u6570\u636e\u5171\u4eab\u4e0e\u672a\u6765\u65b9\u5411</p> </li> <li>\u5236\u5b9a\u6570\u636e\u5171\u4eab\u8ba1\u5212\u7b26\u5408FAIR\u539f\u5219</li> <li>\u5c06\u6570\u636e\u63d0\u4ea4\u5230\u516c\u5171\u5b58\u50a8\u5e93(\u5982dbGaP)</li> <li>\u89c4\u5212\u7eb5\u5411\u968f\u8bbf\u4ee5\u8bc4\u4f30\u9057\u4f20\u56e0\u7d20\u4e0e\u75be\u75c5\u8fdb\u5c55\u7684\u5173\u7cfb</li> <li>\u8bbe\u8ba1\u9488\u5bf9\u9ad8\u98ce\u9669\u53d8\u5f02\u643a\u5e26\u8005\u7684\u9884\u9632\u6027\u5e72\u9884\u7814\u7a76</li> </ol> <p>\u8fd9\u4e00\u7cfb\u7edf\u6027\u7814\u7a76\u8bbe\u8ba1\u5c06\u5e2e\u52a9\u8bc6\u522b\u65e9\u53d1\u6027\u963f\u5c14\u8328\u6d77\u9ed8\u75c5\u7684\u7279\u5b9a\u9057\u4f20\u98ce\u9669\u56e0\u7d20\uff0c\u4e3a\u75be\u75c5\u673a\u5236\u7814\u7a76\u3001\u65e9\u671f\u8bca\u65ad\u548c\u6f5c\u5728\u6cbb\u7597\u9776\u70b9\u63d0\u4f9b\u91cd\u8981\u7ebf\u7d22\u3002</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20GWAS/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<p>Scientific Question: What genetic variants are associated with early-onset Alzheimer's disease (EOAD), and how do they differ from variants associated with late-onset disease?</p> <p>This experiment directly tests this question by comparing genetic variants across the genome between EOAD patients (onset before age 65) and age-matched controls, while also including a late-onset Alzheimer's disease (LOAD) cohort for comparative analysis.</p> <p>Purpose of Design: This design builds upon previous GWAS studies of Alzheimer's disease that primarily focused on late-onset cases. By specifically targeting early-onset cases and directly comparing them with late-onset cases, we can identify genetic variants that might be uniquely associated with early disease manifestation, potentially revealing distinct pathological mechanisms.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20GWAS/#2-model-system","title":"2. Model System","text":"<p>Model System: Human participants with clinical diagnoses of early-onset Alzheimer's disease, late-onset Alzheimer's disease, and cognitively normal controls.</p> <p>Appropriateness: Human subjects are essential for this study as we're investigating a human neurodegenerative disease with complex genetic architecture. Animal models, while valuable for functional studies, cannot fully recapitulate the genetic complexity of human Alzheimer's disease.</p> <p>Alternative Models: - Mouse models: Less expensive, allow for controlled environmental conditions, but have limited ability to model complex human genetic traits and cognitive decline - Induced pluripotent stem cells (iPSCs): Allow for study of human neurons with patient-specific genetic backgrounds, but lack whole-organism context - Population biobanks: Provide larger sample sizes but often lack detailed phenotyping for specific disease subtypes</p> <p>Ethical Considerations:  - Informed consent must address incidental findings, data sharing, and future use - Privacy protections for genetic data that may reveal disease risk - Return of clinically actionable results policy - Special considerations for participants with cognitive impairment regarding capacity to consent</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20GWAS/#3-measurement-approach","title":"3. Measurement Approach","text":"<p>Techniques: - Whole genome sequencing (WGS) at 30x coverage for comprehensive variant detection - Detailed cognitive assessments using standardized neuropsychological test batteries - Brain imaging (MRI and amyloid PET) for quantitative phenotyping - Blood biomarkers (A\u03b242/40 ratio, p-tau181, NfL) for disease staging</p> <p>Choice Rationale: WGS provides more comprehensive coverage than SNP arrays, allowing detection of rare variants and structural variations potentially important in EOAD. The multimodal phenotyping approach enables stratification of cases beyond clinical diagnosis.</p> <p>Technical Replicates:  - 5% of samples will be sequenced twice to assess technical variability - Quality control samples included in each sequencing batch - Standard reference genomes included for variant calling calibration</p> <p>Potential Biases and Mitigation: - Population stratification: Address through ancestry-informative markers and principal component analysis - Batch effects: Randomize case and control samples across sequencing runs - Phenotyping variability: Use standardized assessment protocols and train evaluators to ensure consistency - Selection bias: Recruitment from multiple centers to ensure geographic and demographic diversity</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20GWAS/#4-group-setting","title":"4. Group Setting","text":"<p>Experimental Groups: - 1,000 early-onset AD cases (onset &lt;65 years) - 2,000 late-onset AD cases (onset \u226565 years) - 3,000 age-matched controls without cognitive impairment</p> <p>Controlled Variables: - Age (matched within 5-year bands) - Sex (balanced distribution) - Ancestry (proportional representation across groups) - Education level (recorded and included as covariate) - APOE genotype (stratified analysis)</p> <p>Negative Controls: - Population-matched controls without neurological disease - Individuals with non-AD dementias to test specificity of findings</p> <p>Biological Replicates:  The sample sizes (1,000 EOAD, 2,000 LOAD, 3,000 controls) provide &gt;80% power to detect common variants (MAF&gt;5%) with odds ratios &gt;1.3 and rare variants (MAF 0.5-5%) with odds ratios &gt;1.8 at genome-wide significance (p&lt;5\u00d710^-8).</p> <p>Modified Design Suggestion: Include longitudinal follow-up of presymptomatic mutation carriers identified through family studies to capture earliest disease manifestations and enable time-to-onset analyses.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20GWAS/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<p>Data Processing: - Raw sequencing data processed through standardized bioinformatics pipeline - Variant calling using GATK best practices - Quality control filtering (call rate &gt;98%, Hardy-Weinberg equilibrium, etc.) - Imputation of missing genotypes using population-specific reference panels</p> <p>Statistical Tests: - Primary analysis: Logistic regression comparing cases vs. controls, adjusting for age, sex, and ancestry principal components - Secondary analyses: Gene-based burden tests for rare variants, pathway enrichment analysis - Heritability estimation using LD score regression - Polygenic risk score development and validation - Genome-wide significance threshold: p&lt;5\u00d710^-8 with FDR correction for multiple testing</p> <p>Data Presentation: - Manhattan plots showing genome-wide results - Regional association plots for significant loci - Forest plots comparing effect sizes between EOAD and LOAD cohorts - Quantile-quantile plots to assess systematic bias - Heat maps for pathway enrichment results</p> <p>Result Confirmation: - Replication in independent cohorts - Cross-reference with existing AD GWAS datasets - Functional validation of top hits in cellular and animal models - Integration with transcriptomic and proteomic data from brain tissue</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Hemoglobin%20Switching/","title":"S1.W13.LiuNan Hemoglobin Switching","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Hemoglobin%20Switching/#_1","title":"\u4e00\u3001\u5b9e\u9a8c\u524d\u51c6\u5907","text":"<ol> <li>\u7814\u7a76\u95ee\u9898\u786e\u5b9a</li> <li>\u660e\u786e\u7814\u7a76BCL11A\u5728\u80ce\u513f\u8840\u7ea2\u86cb\u767d(HbF)\u5411\u6210\u4eba\u8840\u7ea2\u86cb\u767d(HbA)\u8f6c\u6362\u4e2d\u7684\u8c03\u63a7\u673a\u5236</li> <li>\u786e\u5b9aBCL11A\u5982\u4f55\u6291\u5236\u03b3-\u73e0\u86cb\u767d\u57fa\u56e0\u8868\u8fbe</li> <li> <p>\u63a2\u7d22\u5e72\u9884BCL11A\u529f\u80fd\u91cd\u65b0\u6fc0\u6d3bHbF\u7684\u6cbb\u7597\u6f5c\u529b</p> </li> <li> <p>\u6a21\u578b\u7cfb\u7edf\u9009\u62e9\u4e0e\u5efa\u7acb</p> </li> <li>\u4eba\u7c7b\u7ea2\u7cfb\u7ec6\u80de\u7cfb(HUDEP-2)\u57f9\u517b\u4e0e\u7ef4\u6301</li> <li>BCL11A\u6572\u9664\u5c0f\u9f20\u6a21\u578b\u5efa\u7acb</li> <li> <p>\u6536\u96c6\u03b2-\u5730\u4e2d\u6d77\u8d2b\u8840\u548c\u9570\u72b6\u7ec6\u80de\u75c5\u60a3\u8005\u6837\u672c(\u83b7\u53d6\u4f26\u7406\u6279\u51c6\u548c\u77e5\u60c5\u540c\u610f)</p> </li> <li> <p>\u5b9e\u9a8c\u6750\u6599\u51c6\u5907</p> </li> <li>\u8bbe\u8ba1CRISPR-Cas9\u9776\u5411BCL11A\u7684gRNA</li> <li>\u51c6\u5907CUT&amp;RUN\u548cPRO-seq\u5b9e\u9a8c\u6240\u9700\u6297\u4f53\u548c\u8bd5\u5242</li> <li>\u6784\u5efa\u8367\u5149\u7d20\u9176\u62a5\u544a\u57fa\u56e0\u8f7d\u4f53(\u542b\u6709\u03b3-\u73e0\u86cb\u767d\u542f\u52a8\u5b50\u533a\u57df)</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Hemoglobin%20Switching/#_2","title":"\u4e8c\u3001\u57fa\u56e0\u7f16\u8f91\u4e0e\u529f\u80fd\u9a8c\u8bc1","text":"<ol> <li>CRISPR-Cas9\u4ecb\u5bfc\u7684BCL11A\u6572\u9664</li> <li>\u5728HUDEP-2\u7ec6\u80de\u4e2d\u8f6c\u67d3Cas9\u548c\u9776\u5411BCL11A\u7684gRNA</li> <li>\u901a\u8fc7\u9650\u5236\u6027\u5185\u5207\u9176\u5206\u6790\u548cSanger\u6d4b\u5e8f\u9a8c\u8bc1\u7f16\u8f91\u6548\u7387</li> <li> <p>\u5355\u7ec6\u80de\u514b\u9686\u6269\u589e\u83b7\u5f97\u7a33\u5b9a\u6572\u9664\u7ec6\u80de\u7cfb</p> </li> <li> <p>\u9ad8\u901a\u91cfCRISPR\u7b5b\u9009</p> </li> <li>\u8bbe\u8ba1\u9488\u5bf9\u03b3-\u73e0\u86cb\u767d\u57fa\u56e0\u8c03\u63a7\u533a\u7684gRNA\u6587\u5e93</li> <li>\u5728\u7ea2\u7cfb\u7ec6\u80de\u4e2d\u8fdb\u884c\u7b5b\u9009\u5b9e\u9a8c</li> <li> <p>\u901a\u8fc7NGS\u6d4b\u5e8f\u9274\u5b9a\u5f71\u54cd\u03b3-\u73e0\u86cb\u767d\u8868\u8fbe\u7684\u5173\u952e\u8c03\u63a7\u5143\u4ef6</p> </li> <li> <p>\u57fa\u56e0\u8868\u8fbe\u5206\u6790</p> </li> <li>RT-qPCR\u6d4b\u5b9a\u03b3-\u73e0\u86cb\u767d\u548c\u03b2-\u73e0\u86cb\u767dmRNA\u6c34\u5e73</li> <li>\u9ad8\u6548\u6db2\u76f8\u8272\u8c31(HPLC)\u6216\u8d28\u8c31\u6cd5\u68c0\u6d4bHbF\u548cHbA\u86cb\u767d\u6c34\u5e73</li> <li>RNA-seq\u5206\u6790\u5168\u8f6c\u5f55\u7ec4\u53d8\u5316</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Hemoglobin%20Switching/#_3","title":"\u4e09\u3001\u5206\u5b50\u673a\u5236\u7814\u7a76","text":"<ol> <li>\u86cb\u767d\u8d28-DNA\u76f8\u4e92\u4f5c\u7528\u5206\u6790</li> <li>CUT&amp;RUN\u5b9e\u9a8c\u786e\u5b9aBCL11A\u5728\u57fa\u56e0\u7ec4\u4e0a\u7684\u7ed3\u5408\u4f4d\u70b9</li> <li>\u6570\u636e\u5206\u6790\u9274\u5b9aBCL11A\u7ed3\u5408\u57fa\u5e8f\u548c\u9776\u57fa\u56e0</li> <li> <p>ChIP-qPCR\u9a8c\u8bc1\u5173\u952e\u7ed3\u5408\u4f4d\u70b9</p> </li> <li> <p>\u67d3\u8272\u8d28\u72b6\u6001\u5206\u6790</p> </li> <li>ATAC-seq\u8bc4\u4f30BCL11A\u6572\u9664\u524d\u540e\u7684\u67d3\u8272\u8d28\u53ef\u53ca\u6027\u53d8\u5316</li> <li>H3K27ac\u548cH3K4me3 CUT&amp;RUN\u5206\u6790\u6d3b\u6027\u589e\u5f3a\u5b50\u548c\u542f\u52a8\u5b50\u533a\u57df</li> <li> <p>4C-seq\u6216Hi-C\u5206\u6790\u67d3\u8272\u8d28\u4e09\u7ef4\u7ed3\u6784\u53d8\u5316</p> </li> <li> <p>\u8f6c\u5f55\u8c03\u63a7\u673a\u5236\u7814\u7a76</p> </li> <li>PRO-seq\u6d4b\u5b9a\u65b0\u751f\u8f6c\u5f55\u7387\u53d8\u5316</li> <li>\u8367\u5149\u7d20\u9176\u62a5\u544a\u57fa\u56e0\u5b9e\u9a8c\u9a8c\u8bc1\u542f\u52a8\u5b50\u548c\u589e\u5f3a\u5b50\u6d3b\u6027</li> <li>\u514d\u75ab\u5171\u6c89\u6dc0\u786e\u5b9aBCL11A\u4e0e\u5176\u4ed6\u8f6c\u5f55\u56e0\u5b50\u7684\u76f8\u4e92\u4f5c\u7528</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Hemoglobin%20Switching/#_4","title":"\u56db\u3001\u4f53\u5185\u529f\u80fd\u9a8c\u8bc1","text":"<ol> <li>\u5c0f\u9f20\u6a21\u578b\u7814\u7a76</li> <li>\u5206\u6790BCL11A\u6572\u9664\u5c0f\u9f20\u7684\u8840\u6db2\u5b66\u53c2\u6570</li> <li>\u6d4b\u5b9a\u5c0f\u9f20\u80da\u80ce\u548c\u6210\u5e74\u9636\u6bb5\u7684\u73e0\u86cb\u767d\u8868\u8fbe\u8c31</li> <li> <p>\u7ec4\u7ec7\u7279\u5f02\u6027\u6761\u4ef6\u6027\u6572\u9664\u7814\u7a76</p> </li> <li> <p>\u60a3\u8005\u6837\u672c\u5206\u6790</p> </li> <li>\u57fa\u56e0\u5206\u578b\u786e\u5b9aBCL11A\u76f8\u5173SNP\u4e0eHbF\u6c34\u5e73\u7684\u5173\u8054</li> <li>\u5206\u6790\u60a3\u8005\u6837\u672c\u4e2dBCL11A\u8868\u8fbe\u4e0e\u4e34\u5e8a\u75c7\u72b6\u7684\u76f8\u5173\u6027</li> <li>\u4f53\u5916\u57f9\u517b\u60a3\u8005\u6765\u6e90\u7684\u7ea2\u7cfb\u7956\u7ec6\u80de\u8fdb\u884c\u529f\u80fd\u7814\u7a76</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Hemoglobin%20Switching/#_5","title":"\u4e94\u3001\u6570\u636e\u5206\u6790\u4e0e\u6574\u5408","text":"<ol> <li>\u751f\u7269\u4fe1\u606f\u5b66\u5206\u6790</li> <li>\u6d4b\u5e8f\u6570\u636e\u6bd4\u5bf9\u81f3\u53c2\u8003\u57fa\u56e0\u7ec4</li> <li>\u4f7f\u7528DESeq2\u8fdb\u884c\u5dee\u5f02\u8868\u8fbe\u5206\u6790</li> <li>\u57fa\u5e8f\u5bcc\u96c6\u5206\u6790\u548c\u901a\u8def\u5206\u6790</li> <li> <p>\u6574\u5408GWAS\u6570\u636e\u4e0e\u529f\u80fd\u57fa\u56e0\u7ec4\u5b66\u6570\u636e</p> </li> <li> <p>\u7edf\u8ba1\u5206\u6790</p> </li> <li>t\u68c0\u9a8c\u6216ANOVA\u8bc4\u4f30\u7ec4\u95f4\u5dee\u5f02\u663e\u8457\u6027</li> <li>Fisher\u7cbe\u786e\u68c0\u9a8c\u5206\u6790\u57fa\u56e0\u4f4d\u70b9\u5bcc\u96c6</li> <li> <p>\u591a\u91cd\u68c0\u9a8c\u6821\u6b63\u63a7\u5236\u5047\u9633\u6027\u7387</p> </li> <li> <p>\u6570\u636e\u53ef\u89c6\u5316</p> </li> <li>\u4f7f\u7528IGV\u6d4f\u89c8\u5668\u5c55\u793a\u57fa\u56e0\u7ec4\u7ed3\u5408\u4f4d\u70b9</li> <li>\u70ed\u56fe\u663e\u793a\u5dee\u5f02\u8868\u8fbe\u57fa\u56e0</li> <li>\u67f1\u72b6\u56fe\u5c55\u793aHbF\u548cHbA\u6c34\u5e73\u53d8\u5316</li> <li>\u57fa\u56e0\u8c03\u63a7\u7f51\u7edc\u56fe\u6574\u5408\u591a\u7ec4\u5b66\u6570\u636e</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Hemoglobin%20Switching/#_6","title":"\u516d\u3001\u6cbb\u7597\u5e94\u7528\u63a2\u7d22","text":"<ol> <li>\u836f\u7269\u5e72\u9884\u7814\u7a76</li> <li>\u7b5b\u9009BCL11A\u6291\u5236\u5242\u5019\u9009\u5316\u5408\u7269</li> <li>\u8bc4\u4f30\u5c0f\u5206\u5b50\u5316\u5408\u7269\u5bf9\u03b3-\u73e0\u86cb\u767d\u8868\u8fbe\u7684\u5f71\u54cd</li> <li> <p>\u5242\u91cf-\u53cd\u5e94\u5173\u7cfb\u5206\u6790\u548c\u6bd2\u6027\u8bc4\u4f30</p> </li> <li> <p>\u57fa\u56e0\u6cbb\u7597\u7b56\u7565\u5f00\u53d1</p> </li> <li>\u8bbe\u8ba1\u9776\u5411BCL11A\u7684shRNA\u6216gRNA</li> <li>\u6784\u5efa\u6162\u75c5\u6bd2\u6216AAV\u8f7d\u4f53</li> <li> <p>\u5728\u4f53\u5916\u548c\u52a8\u7269\u6a21\u578b\u4e2d\u8bc4\u4f30\u6cbb\u7597\u6548\u679c</p> </li> <li> <p>\u8f6c\u5316\u533b\u5b66\u7814\u7a76</p> </li> <li>\u5efa\u7acb\u9884\u6d4b\u6a21\u578b\u8bc4\u4f30\u5e72\u9884BCL11A\u7684\u6cbb\u7597\u6548\u679c</li> <li>\u8bbe\u8ba1\u4e34\u5e8a\u524d\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u8bc4\u4f30\u65b9\u6848</li> <li>\u5236\u5b9a\u9488\u5bf9\u03b2-\u5730\u4e2d\u6d77\u8d2b\u8840\u548c\u9570\u72b6\u7ec6\u80de\u75c5\u7684\u4e2a\u4f53\u5316\u6cbb\u7597\u7b56\u7565</li> </ol> <p>\u8fd9\u4e00\u7cfb\u7edf\u6027\u7684\u5b9e\u9a8c\u6d41\u7a0b\u4f7f\u7814\u7a76\u4eba\u5458\u80fd\u591f\u5168\u9762\u4e86\u89e3\u8840\u7ea2\u86cb\u767d\u8f6c\u6362\u7684\u5206\u5b50\u673a\u5236\uff0c\u7279\u522b\u662fBCL11A\u5728\u6291\u5236\u80ce\u513f\u8840\u7ea2\u86cb\u767d\u8868\u8fbe\u4e2d\u7684\u4f5c\u7528\uff0c\u5e76\u4e3a\u5f00\u53d1\u9488\u5bf9\u8840\u7ea2\u86cb\u767d\u75c5\u7684\u65b0\u578b\u6cbb\u7597\u7b56\u7565\u63d0\u4f9b\u79d1\u5b66\u57fa\u7840\u3002</p> <ul> <li>Hemoglobin switching refers to the developmental process during fetal development and early infancy: featal hemoglobin (HbF) to adult hemoglobin (HbA)</li> <li>\u5728\u5b50\u5bab\u5185\uff0c\u4e3b\u8981\u7684\u8840\u7ea2\u86cb\u767d\u662f HbF\uff0c\u5b83\u5bf9\u6c27\u6c14\u7684\u4eb2\u548c\u529b\u9ad8\u4e8e HbA\uff0c\u4f7f\u80ce\u513f\u80fd\u591f\u6709\u6548\u5730\u4ece\u6bcd\u4eb2\u7684\u8840\u6db2\u4e2d\u5438\u6536\u6c27\u6c14</li> <li>\u51fa\u751f\u540e\uff0c\u8eab\u4f53\u9010\u6e10\u8f6c\u5411\u4ea7\u751f HbA\uff0c\u8fd9\u662f\u6210\u4eba\u8840\u7ea2\u86cb\u767d\u7684\u4e3b\u8981\u5f62\u5f0f</li> </ul> <p>Summary of Hemoglobin Switching Research</p> <ol> <li> <p>Experimental Purpose    The primary scientific question addressed in this research is the molecular mechanism underlying hemoglobin switching, specifically the transcriptional repression of fetal hemoglobin (HbF) and activation of adult hemoglobin (HbA) during development. Figure 1 (representative of the broader study) investigates how genetic and epigenetic factors regulate this switch, focusing on BCL11A as a key repressor of \u03b3-globin (HbF). The experimental design uses GWAS, CRISPR editing, and chromatin profiling (e.g., CUT&amp;RUN) to directly test BCL11A\u2019s role in \u03b3-globin repression. Figure 2 likely repeats similar designs to validate results across different contexts (e.g., cell types or species) or explore new variables, such as the impact of BCL11A depletion on chromatin accessibility.</p> </li> <li> <p>Model System    The study employs multiple model systems, including:  </p> </li> <li>Human cell lines (e.g., HUDEP-2): These allow in vitro manipulation of erythroid differentiation and gene editing.  </li> <li>Mouse models: BCL11A knockout mice are used to study the phenotypic effects of HbF reactivation in vivo.  </li> <li> <p>Patient-derived cells: Clinical samples from \u03b2-thalassemia and sickle cell disease (SCD) patients validate therapeutic approaches. Advantages: Human cell lines and patient samples ensure translatability, while mice offer genetic tractability. Alternatives like zebrafish or induced pluripotent stem cells (iPSCs) could reduce costs but may lack relevance to human erythropoiesis. Ethical considerations include animal welfare in mouse studies and patient consent for clinical trials.</p> </li> <li> <p>Measurement Approach    Techniques used include:  </p> </li> <li>CUT&amp;RUN: Quantitative analysis of protein-DNA interactions (e.g., BCL11A binding sites).  </li> <li>CRISPR screens: High-throughput identification of functional enhancers in \u03b3-globin regulation.  </li> <li>Luciferase assays: Semi-quantitative assessment of promoter activity.  </li> <li> <p>PRO-seq: Quantitative profiling of nascent transcription rates. Rationale: CUT&amp;RUN provides higher resolution than ChIP-seq, while CRISPR screens enable unbiased discovery. Technical replicates (e.g., multiple gRNA libraries) minimize batch effects, though potential biases include off-target editing or cell culture variability.</p> </li> <li> <p>Group Setting    Experimental groups typically compare:  </p> </li> <li>Controls: Wild-type cells or mock-treated samples.  </li> <li> <p>Treatments: BCL11A knockout, CRISPR-edited cells, or epigenetic modifiers.    Variables controlled include cell type, differentiation stage, and genetic background. Negative controls (e.g., non-targeting gRNAs) ensure specificity. Biological replicates vary (e.g., 3-5 per group), which is generally sufficient for statistical power. A modified design could include dose-response experiments or positive controls (e.g., known \u03b3-globin activators like hydroxyurea).</p> </li> <li> <p>Data Analysis &amp; Presentation </p> </li> <li>Raw data processing: Sequencing reads are aligned to reference genomes; expression levels are normalized (e.g., via DESeq2).  </li> <li>Statistical tests: t-tests, ANOVA, or Fisher\u2019s exact tests evaluate significance. Power is adequate for most experiments, though GWAS relies on large sample sizes.  </li> <li>Visualization: Heatmaps, bar graphs, and genome browser tracks are used to display chromatin occupancy and expression changes. Scaling is generally clear, though some figures might benefit from log transformations for skewed data.  </li> <li>Validation: Results are cross-validated using orthogonal methods (e.g., CUT&amp;RUN confirmed by ChIP-qPCR, luciferase assays, and in vivo mouse studies).  </li> </ol> <p>Conclusion: This research bridges molecular mechanisms of hemoglobin switching with therapeutic development, demonstrating how integrative approaches (GWAS, CRISPR, and chromatin biology) can translate basic science into clinical applications for hemoglobinopathies.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W13.LiuNan%20Pro-seq/","title":"S1.W13.LiuNan Pro seq","text":"<p>PRO-seq\u6280\u672f\u5c31\u662f\u5bf9\u4f20\u7edfRNA-seq\u6280\u672f\u5728\u8fd9\u65b9\u9762\u7684\u6539\u8fdb\uff0c\u5b83\u53ef\u4ee5\u5bcc\u96c6\u5e76\u4e14\u6d4b\u51fa\u521a\u521a\u88abRNA\u805a\u5408\u9176\u8f6c\u5f55\u51fa\u6765\u7684\u65b0\u751fRNA\uff0c\u5e76\u4e14\u7cbe\u5ea6\u8fbe\u5230\u4e00\u4e2a\u78b1\u57fa\u5bf9\u3002 PRO-seq, short for ==Precision Run-On sequencing==, is a technique used to examine gene transcription in cells. It measures the abundance and location of transcriptionally engaged RNA polymerases across the genome. This is done by \"freezing\" the transcription complexes in action and then sequencing the new RNA that is being transcribed. The method allows for the assessment of transcriptional activity with nucleotide precision, which means you can see exactly where the polymerase is and which genes are being actively transcribed, in what direction, and to what extent.</p> <p>PRO-seq is particularly useful when you want to: - Investigate the effects of transcriptional regulation in different conditions or treatments. - Understand the mechanisms of transcription regulation, such as promoter-proximal pausing. - Examine the dynamics of transcription in response to cellular or environmental cues. - Compare the activity of RNA polymerases between different genes or different stages of cell development or differentiation.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/","title":"S1.W14.WangQun Immunotherapy development","text":"<p>\u5f25\u6f2b\u6027\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624(DLBCL)\u7814\u7a76\u7684\u5b9e\u9a8c\u6d41\u7a0b</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#_1","title":"\u4e00\u3001\u5206\u5b50\u5206\u578b\u4e0e\u9884\u540e\u5206\u7c7b","text":"<ol> <li>\u57fa\u56e0\u8868\u8fbe\u8c31\u5206\u6790</li> <li>\u4ece\u6dcb\u5df4\u7624\u7ec4\u7ec7\u6837\u672c\u4e2d\u63d0\u53d6\u603bRNA</li> <li>\u8fdb\u884cRNA\u6d4b\u5e8f\u6216\u57fa\u56e0\u82af\u7247\u5206\u6790</li> <li>\u4f7f\u7528\u5206\u7c7b\u7b97\u6cd5\u5c06\u6837\u672c\u5206\u4e3a\u751f\u53d1\u4e2d\u5fc3B\u7ec6\u80de\u578b(GCB)\u548c\u6d3b\u5316B\u7ec6\u80de\u578b(ABC)</li> <li>\u5e94\u7528NanoString\u6280\u672f\u8fdb\u884c\u4e34\u5e8a\u9a8c\u8bc1</li> <li> <p>\u901a\u8fc7Hans\u514d\u75ab\u7ec4\u5316\u7b97\u6cd5(CD10, BCL6, MUM1)\u8fdb\u884c\u66ff\u4ee3\u5206\u578b</p> </li> <li> <p>\u7a81\u53d8\u8c31\u5206\u6790</p> </li> <li>\u4ece\u80bf\u7624\u548c\u5339\u914d\u7684\u6b63\u5e38\u7ec4\u7ec7\u63d0\u53d6DNA</li> <li>\u8fdb\u884c\u5168\u5916\u663e\u5b50\u6216\u9776\u5411\u6d4b\u5e8f</li> <li>\u5206\u6790\u5e38\u89c1\u9a71\u52a8\u57fa\u56e0(MYD88, CD79B, BCL2, MYC)\u7684\u7a81\u53d8</li> <li>\u8bc4\u4f30\u62f7\u8d1d\u6570\u53d8\u5f02\u548c\u67d3\u8272\u4f53\u91cd\u6392</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#_2","title":"\u4e8c\u3001\u529f\u80fd\u57fa\u56e0\u7ec4\u5b66\u7b5b\u9009","text":"<ol> <li>CRISPR-Cas9\u5168\u57fa\u56e0\u7ec4\u7b5b\u9009</li> <li>\u6784\u5efa\u5305\u542b\u5168\u57fa\u56e0\u7ec4\u9776\u70b9\u7684sgRNA\u6587\u5e93</li> <li>\u5c06\u6587\u5e93\u8f6c\u5bfc\u5165\u7a33\u5b9a\u8868\u8fbeCas9\u7684DLBCL\u7ec6\u80de\u7cfb</li> <li>\u57f9\u517b\u7ec6\u80de14-21\u5929\u8fdb\u884c\u6b63\u8d1f\u9009\u62e9</li> <li>\u63d0\u53d6\u57fa\u56e0\u7ec4DNA\u5e76\u6269\u589esgRNA\u5e8f\u5217</li> <li>\u901a\u8fc7\u9ad8\u901a\u91cf\u6d4b\u5e8f\u5206\u6790sgRNA\u4e30\u5ea6\u53d8\u5316</li> <li> <p>\u4f7f\u7528MAGeCK\u7b49\u7b97\u6cd5\u8bc6\u522b\u5fc5\u9700\u57fa\u56e0(\u5982CARD11, BCL2L1)</p> </li> <li> <p>\u836f\u7269\u654f\u611f\u6027\u7b5b\u9009</p> </li> <li>\u572896\u6216384\u5b54\u677f\u4e2d\u63a5\u79cdDLBCL\u7ec6\u80de</li> <li>\u7528\u4e0d\u540c\u6d53\u5ea6\u7684\u836f\u7269\u5904\u7406(\u5355\u836f\u6216\u7ec4\u5408)</li> <li>\u57f9\u517b48-72\u5c0f\u65f6\u540e\u8bc4\u4f30\u7ec6\u80de\u6d3b\u529b</li> <li>\u8ba1\u7b97IC50\u503c\u548c\u534f\u540c\u6307\u6570</li> <li>\u9a8c\u8bc1\u5173\u952e\u9776\u70b9\u7684\u86cb\u767d\u8d28\u8868\u8fbe\u548c\u901a\u8def\u6fc0\u6d3b</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#_3","title":"\u4e09\u3001\u4e34\u5e8a\u524d\u6a21\u578b\u7cfb\u7edf","text":"<ol> <li>\u7ec6\u80de\u7cfb\u6a21\u578b\u5f00\u53d1</li> <li>\u5efa\u7acb\u4ee3\u8868\u4e0d\u540cDLBCL\u4e9a\u578b\u7684\u7ec6\u80de\u7cfb</li> <li>\u901a\u8fc7CRISPR-Cas9\u6280\u672f\u521b\u5efa\u57fa\u56e0\u6572\u9664\u6216\u6572\u5165\u7ec6\u80de\u7cfb</li> <li>\u4f7f\u7528\u6162\u75c5\u6bd2\u7cfb\u7edf\u8fc7\u8868\u8fbe\u5173\u952e\u57fa\u56e0</li> <li> <p>\u5f00\u53d1\u4e09\u7ef4\u57f9\u517b\u7cfb\u7edf\u6a21\u62df\u80bf\u7624\u5fae\u73af\u5883</p> </li> <li> <p>\u5c0f\u9f20\u6a21\u578b\u5b9e\u9a8c</p> </li> <li>\u5efa\u7acb\u60a3\u8005\u6765\u6e90\u7684\u5f02\u79cd\u79fb\u690d(PDX)\u6a21\u578b:<ul> <li>\u5c06\u60a3\u8005\u80bf\u7624\u7ec4\u7ec7\u79fb\u690d\u5230\u514d\u75ab\u7f3a\u9677\u5c0f\u9f20</li> <li>\u7b49\u5f85\u80bf\u7624\u751f\u957f\u81f3100-200mm\u00b3</li> <li>\u968f\u673a\u5206\u7ec4\u8fdb\u884c\u836f\u7269\u6cbb\u7597</li> <li>\u6d4b\u91cf\u80bf\u7624\u4f53\u79ef\u548c\u5c0f\u9f20\u751f\u5b58\u671f</li> </ul> </li> <li>\u4eba\u6e90\u5316\u5c0f\u9f20\u6a21\u578b\u7528\u4e8e\u514d\u75ab\u6cbb\u7597\u7814\u7a76:<ul> <li>\u91cd\u5efa\u5c0f\u9f20\u514d\u75ab\u7cfb\u7edf</li> <li>\u79fb\u690dDLBCL\u80bf\u7624</li> <li>\u8bc4\u4f30\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u6216CAR-T\u7597\u6cd5\u7684\u7597\u6548</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#_4","title":"\u56db\u3001\u514d\u75ab\u6cbb\u7597\u5f00\u53d1","text":"<ol> <li>CAR-T\u7ec6\u80de\u5de5\u7a0b</li> <li>\u4ece\u5065\u5eb7\u4f9b\u4f53\u5206\u79bb\u5916\u5468\u8840T\u7ec6\u80de</li> <li>\u4f7f\u7528\u6162\u75c5\u6bd2\u8f7d\u4f53\u8f6c\u5bfcCAR\u7ed3\u6784(\u5982\u6297CD19)</li> <li>\u4f53\u5916\u6269\u589eCAR-T\u7ec6\u80de</li> <li>\u8fdb\u884c\u4f53\u5916\u7ec6\u80de\u6bd2\u6027\u8bd5\u9a8c:<ul> <li>\u5c06CAR-T\u7ec6\u80de\u4e0eDLBCL\u9776\u7ec6\u80de\u5171\u57f9\u517b</li> <li>\u6d4b\u91cf\u7279\u5f02\u6027\u88c2\u89e3\u548c\u7ec6\u80de\u56e0\u5b50\u91ca\u653e</li> <li>\u8bc4\u4f30CAR-T\u7ec6\u80de\u6301\u4e45\u6027\u548c\u8017\u7aed\u6807\u5fd7\u7269</li> </ul> </li> <li> <p>\u5728PDX\u6a21\u578b\u4e2d\u9a8c\u8bc1\u4f53\u5185\u6297\u80bf\u7624\u6d3b\u6027</p> </li> <li> <p>\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7814\u7a76</p> </li> <li>\u6d41\u5f0f\u7ec6\u80de\u672f\u5206\u6790\u80bf\u7624\u548c\u514d\u75ab\u7ec6\u80de\u4e0a\u7684PD-1/PD-L1\u8868\u8fbe</li> <li>\u4f7f\u7528\u6297\u4f53\u963b\u65ad\u5b9e\u9a8c\u8bc4\u4f30\u529f\u80fd\u610f\u4e49</li> <li>\u5728\u5c0f\u9f20\u6a21\u578b\u4e2d\u6d4b\u8bd5\u6297PD-1\u6216\u6297CTLA-4\u6297\u4f53\u7684\u7597\u6548</li> <li>\u5206\u6790\u6cbb\u7597\u524d\u540e\u80bf\u7624\u5fae\u73af\u5883\u7684\u53d8\u5316:<ul> <li>\u514d\u75ab\u7ec6\u80de\u6d78\u6da6</li> <li>\u7ec6\u80de\u56e0\u5b50\u8c31</li> <li>T\u7ec6\u80de\u53d7\u4f53\u591a\u6837\u6027</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#_5","title":"\u4e94\u3001\u4e34\u5e8a\u8bd5\u9a8c\u8bbe\u8ba1\u4e0e\u5206\u6790","text":"<ol> <li>\u6cbb\u7597\u53cd\u5e94\u8bc4\u4f30</li> <li>\u57fa\u4e8ePET/CT\u7684Lugano\u6807\u51c6\u8bc4\u4f30:<ul> <li>\u5b8c\u5168\u7f13\u89e3(CR)</li> <li>\u90e8\u5206\u7f13\u89e3(PR)</li> <li>\u7a33\u5b9a\u75c5\u53d8(SD)</li> <li>\u75be\u75c5\u8fdb\u5c55(PD)</li> </ul> </li> <li>\u5faa\u73af\u80bf\u7624DNA(ctDNA)\u76d1\u6d4b:<ul> <li>\u4ece\u60a3\u8005\u8840\u6db2\u4e2d\u63d0\u53d6ctDNA</li> <li>\u4f7f\u7528\u6570\u5b57PCR\u6216NGS\u68c0\u6d4b\u7279\u5f81\u6027\u7a81\u53d8</li> <li>\u8bc4\u4f30\u5fae\u5c0f\u6b8b\u7559\u75c5\u7076(MRD)</li> </ul> </li> <li> <p>\u514d\u75ab\u76d1\u6d4b:</p> <ul> <li>\u6d41\u5f0f\u7ec6\u80de\u672f\u5206\u6790\u5916\u5468\u8840\u514d\u75ab\u7ec6\u80de\u4e9a\u7fa4</li> <li>\u7ec6\u80de\u56e0\u5b50\u6c34\u5e73\u6d4b\u5b9a</li> <li>T\u7ec6\u80de\u529f\u80fd\u8bc4\u4f30</li> </ul> </li> <li> <p>\u751f\u7269\u6807\u5fd7\u7269\u5f00\u53d1</p> </li> <li>\u591a\u91cd\u514d\u75ab\u7ec4\u5316:<ul> <li>\u540c\u65f6\u68c0\u6d4b\u591a\u4e2a\u6807\u5fd7\u7269(CD20, CD3, PD-L1\u7b49)</li> <li>\u5206\u6790\u80bf\u7624\u548c\u514d\u75ab\u7ec6\u80de\u7a7a\u95f4\u5206\u5e03</li> </ul> </li> <li>\u6570\u5b57\u75c5\u7406\u5b66:<ul> <li>\u5168\u5207\u7247\u626b\u63cf</li> <li>AI\u8f85\u52a9\u56fe\u50cf\u5206\u6790</li> <li>\u5b9a\u91cf\u8bc4\u4f30\u80bf\u7624\u5f02\u8d28\u6027</li> </ul> </li> <li>\u6574\u5408\u591a\u7ec4\u5b66\u6570\u636e\u9884\u6d4b\u6cbb\u7597\u53cd\u5e94</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#_6","title":"\u516d\u3001\u6570\u636e\u5206\u6790\u4e0e\u7edf\u8ba1\u65b9\u6cd5","text":"<ol> <li>\u751f\u5b58\u5206\u6790</li> <li>\u6784\u5efaKaplan-Meier\u751f\u5b58\u66f2\u7ebf\u6bd4\u8f83\u4e0d\u540c\u4e9a\u578b(GCB vs ABC)</li> <li>\u4f7f\u7528log-rank\u68c0\u9a8c\u8bc4\u4f30\u5dee\u5f02\u663e\u8457\u6027</li> <li>\u5e94\u7528Cox\u6bd4\u4f8b\u98ce\u9669\u6a21\u578b\u8fdb\u884c\u591a\u53d8\u91cf\u5206\u6790</li> <li> <p>\u8bc4\u4f30\u4e0d\u540c\u6cbb\u7597\u65b9\u6848\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f(PFS)\u548c\u603b\u751f\u5b58\u671f(OS)</p> </li> <li> <p>\u7f51\u7edc\u5206\u6790</p> </li> <li>\u901a\u8def\u5bcc\u96c6\u5206\u6790\u8bc6\u522b\u5931\u8c03\u7684\u751f\u7269\u5b66\u8fc7\u7a0b</li> <li>\u6784\u5efa\u86cb\u767d\u8d28-\u86cb\u767d\u8d28\u76f8\u4e92\u4f5c\u7528\u7f51\u7edc</li> <li>\u6574\u5408\u591a\u7ec4\u5b66\u6570\u636e\u8fdb\u884c\u7cfb\u7edf\u7ea7\u7406\u89e3</li> <li>\u9884\u6d4b\u6f5c\u5728\u7684\u836f\u7269\u9776\u70b9\u548c\u8054\u5408\u6cbb\u7597\u7b56\u7565</li> </ol> <p>\u8fd9\u4e9b\u7efc\u5408\u6027\u5b9e\u9a8c\u65b9\u6cd5\u4f7f\u7814\u7a76\u4eba\u5458\u80fd\u591f\u6df1\u5165\u4e86\u89e3DLBCL\u7684\u5f02\u8d28\u6027,\u8bc6\u522b\u6cbb\u7597\u9776\u70b9,\u5e76\u4e3a\u8fd9\u79cd\u590d\u6742\u75be\u75c5\u5f00\u53d1\u4e2a\u4f53\u5316\u6cbb\u7597\u7b56\u7565\u3002</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#experimental-workflow-for-diffuse-large-b-cell-lymphoma-dlbcl-research","title":"Experimental Workflow for Diffuse Large B-Cell Lymphoma (DLBCL) Research","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#i-molecular-subtyping-and-prognostic-classification","title":"I. Molecular Subtyping and Prognostic Classification","text":"<ol> <li>Gene Expression Profiling</li> <li>Extract total RNA from lymphoma tissue samples</li> <li>Perform RNA sequencing or microarray analysis</li> <li>Apply classification algorithms to categorize samples as germinal center B-cell-like (GCB) or activated B-cell-like (ABC)</li> <li>Validate using NanoString technology for clinical implementation</li> <li> <p>Apply Hans immunohistochemistry algorithm (CD10, BCL6, MUM1) as a surrogate classification method</p> </li> <li> <p>Mutational Landscape Analysis</p> </li> <li>Extract DNA from tumor and matched normal tissue</li> <li>Perform whole exome or targeted sequencing</li> <li>Analyze mutations in common driver genes (MYD88, CD79B, BCL2, MYC)</li> <li>Assess copy number variations and chromosomal rearrangements</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#ii-functional-genomics-screening","title":"II. Functional Genomics Screening","text":"<ol> <li>CRISPR-Cas9 Genome-wide Screening</li> <li>Construct sgRNA library targeting the whole genome</li> <li>Transduce library into Cas9-expressing DLBCL cell lines</li> <li>Culture cells for 14-21 days under positive or negative selection</li> <li>Extract genomic DNA and amplify sgRNA sequences</li> <li>Analyze sgRNA abundance changes by high-throughput sequencing</li> <li> <p>Identify essential genes (e.g., CARD11, BCL2L1) using algorithms like MAGeCK</p> </li> <li> <p>Drug Sensitivity Screening</p> </li> <li>Seed DLBCL cells in 96 or 384-well plates</li> <li>Treat with different drug concentrations (single or combinations)</li> <li>Assess cell viability after 48-72 hours of culture</li> <li>Calculate IC50 values and synergy indices</li> <li>Validate protein expression and pathway activation of key targets</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#iii-preclinical-model-systems","title":"III. Preclinical Model Systems","text":"<ol> <li>Cell Line Model Development</li> <li>Establish cell lines representing different DLBCL subtypes</li> <li>Create gene knockout or knockin cell lines using CRISPR-Cas9</li> <li>Overexpress key genes using lentiviral systems</li> <li> <p>Develop 3D culture systems to mimic tumor microenvironment</p> </li> <li> <p>Mouse Model Experiments</p> </li> <li>Establish patient-derived xenograft (PDX) models:<ul> <li>Implant patient tumor tissue into immunodeficient mice</li> <li>Allow tumors to grow to 100-200mm\u00b3</li> <li>Randomize into treatment groups</li> <li>Measure tumor volume and mouse survival</li> </ul> </li> <li>Humanized mouse models for immunotherapy studies:<ul> <li>Reconstitute mouse immune system</li> <li>Implant DLBCL tumors</li> <li>Evaluate efficacy of checkpoint inhibitors or CAR-T therapies</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#iv-immunotherapy-development","title":"IV. Immunotherapy Development","text":"<ol> <li>CAR-T Cell Engineering</li> <li>Isolate peripheral blood T cells from healthy donors</li> <li>Transduce with lentiviral vectors encoding CAR constructs (e.g., anti-CD19)</li> <li>Expand CAR-T cells in vitro</li> <li>Perform in vitro cytotoxicity assays:<ul> <li>Co-culture CAR-T cells with DLBCL target cells</li> <li>Measure specific lysis and cytokine release</li> <li>Assess CAR-T cell persistence and exhaustion markers</li> </ul> </li> <li> <p>Validate in vivo anti-tumor activity in PDX models</p> </li> <li> <p>Checkpoint Inhibitor Studies</p> </li> <li>Analyze PD-1/PD-L1 expression on tumor and immune cells by flow cytometry</li> <li>Evaluate functional significance using antibody blocking experiments</li> <li>Test anti-PD-1 or anti-CTLA-4 antibodies in mouse models</li> <li>Analyze tumor microenvironment changes before and after treatment:<ul> <li>Immune cell infiltration</li> <li>Cytokine profiles</li> <li>T cell receptor diversity</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#v-clinical-trial-design-and-analysis","title":"V. Clinical Trial Design and Analysis","text":"<ol> <li>Response Assessment</li> <li>PET/CT-based Lugano criteria evaluation:<ul> <li>Complete response (CR)</li> <li>Partial response (PR)</li> <li>Stable disease (SD)</li> <li>Progressive disease (PD)</li> </ul> </li> <li>Circulating tumor DNA (ctDNA) monitoring:<ul> <li>Extract ctDNA from patient blood</li> <li>Detect characteristic mutations using digital PCR or NGS</li> <li>Evaluate minimal residual disease (MRD)</li> </ul> </li> <li> <p>Immune monitoring:</p> <ul> <li>Flow cytometry analysis of peripheral blood immune cell subsets</li> <li>Cytokine level determination</li> <li>T cell function assessment</li> </ul> </li> <li> <p>Biomarker Development</p> </li> <li>Multiplex immunohistochemistry:<ul> <li>Simultaneous detection of multiple markers (CD20, CD3, PD-L1, etc.)</li> <li>Analysis of tumor and immune cell spatial distribution</li> </ul> </li> <li>Digital pathology:<ul> <li>Whole slide scanning</li> <li>AI-assisted image analysis</li> <li>Quantitative assessment of tumor heterogeneity</li> </ul> </li> <li>Integration of multi-omics data to predict treatment response</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W14.WangQun%20Immunotherapy%20development/#vi-data-analysis-and-statistical-methods","title":"VI. Data Analysis and Statistical Methods","text":"<ol> <li>Survival Analysis</li> <li>Generate Kaplan-Meier survival curves comparing different subtypes (GCB vs ABC)</li> <li>Apply log-rank tests to assess significance of differences</li> <li>Use Cox proportional hazards models for multivariate analysis</li> <li> <p>Evaluate progression-free survival (PFS) and overall survival (OS) for different treatment regimens</p> </li> <li> <p>Network Analysis</p> </li> <li>Pathway enrichment analysis to identify dysregulated biological processes</li> <li>Construction of protein-protein interaction networks</li> <li>Integration of multi-omics data for systems-level understanding</li> <li>Prediction of potential drug targets and combination therapy strategies</li> </ol> <p>These comprehensive experimental approaches enable researchers to gain deeper insights into DLBCL heterogeneity, identify therapeutic targets, and develop personalized treatment strategies for this complex disease.</p> <p>1. Experimental Purpose The seminar addresses key scientific questions in DLBCL biology and therapy, focusing on: - Biological Heterogeneity: The differential survival outcomes between germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL subtypes following R-CHOP treatment (implied by survival curves). - Molecular Targets: Identification of essential genes in ABC DLBCL via genome-wide CRISPR screens (e.g., CARD11, BCL2L), and evaluation of combinatorial therapies to overcome resistance. - Immunotherapy Efficacy: Mechanisms of immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1) and CAR-T/CAR-NK cell therapies in preclinical and clinical settings.  </p> <p>2. Model Systems - Cell Lines: Used for CRISPR screens and drug testing (e.g., ABC DLBCL cell lines). Advantages: Cost-effective, genetically tractable. Limitations: Lack of tumor microenvironment complexity. - Mouse Models: Employed to validate checkpoint inhibitor efficacy (e.g., anti-CTLA-4 in melanoma models). Advantages: Recapitulate in vivo immune responses. Limitations: Ethical concerns, high cost. - Clinical Trials: Human patient data (e.g., survival curves, PET/CT scans) to assess CAR-T outcomes. Advantages: Direct translatability. Limitations: Variability in patient responses. - Alternative Models: PDX (patient-derived xenografts) or organoids could enhance translational relevance but are technically challenging and costly.  </p> <p>3. Measurement Approaches - Quantitative Methods:   - Survival analysis (Kaplan-Meier curves, log-rank tests) for clinical outcomes.   - CRISPR screen data analysis (volcano plots, gene set enrichment) to identify essential genes.   - Flow cytometry and immunohistochemistry for biomarker expression (e.g., CD19, PD-L1). - Qualitative Methods:   - Preclinical validation of CAR-T efficacy via microscopy (e.g., tumor cell lysis).   - Immunoblotting to confirm protein expression changes post-treatment. - Rationale: These methods enable precise quantification of gene dependencies, treatment responses, and survival metrics, balancing throughput and accuracy.  </p> <p>4. Group Setting - Preclinical Studies:   - Treatment groups: Drug combinations (e.g., targeted inhibitors + checkpoint blockade).   - Controls: Vehicle-treated or single-agent groups.   - Variables controlled: Tumor type, mouse strain, treatment timing. - Clinical Trials:   - Treatment groups: CAR-T cell infusions (e.g., anti-CD19 CAR-T).   - Controls: Historical controls or standard-of-care (e.g., R-CHOP).   - Variables controlled: Disease stage, prior therapy, age. - Limitations: Small patient cohorts (e.g., 19 GCB vs. 21 ABC patients) may reduce statistical power. Adding dose-response arms or positive controls (e.g., nivolumab for PD-L1+ tumors) could strengthen designs.  </p> <p>5. Data Analysis &amp; Presentation - Statistical Methods:   - Survival data: Log-rank tests, Cox proportional hazards models.   - CRISPR screens: Benjamini-Hochberg correction for false discovery rate.   - Immunotherapy outcomes: Fisher\u2019s exact test for response rates. - Visualization:   - Kaplan-Meier curves with clear labeling of p-values and sample sizes.   - Volcano plots to highlight differentially essential genes.   - PET/CT images to illustrate treatment responses (e.g., CR in liver-infiltrated lymphoma). - Validation: Results are cross-validated using orthogonal methods (e.g., Western blotting for CRISPR-validated targets, murine models for checkpoint inhibitor efficacy).  </p> <p>Key Challenges &amp; Future Directions - Targeted Therapy Resistance: Compensatory pathways (e.g., NF-\u03baB activation) limit single-agent efficacy, necessitating rational combinations. - Immunotherapy Optimization: Enhancing CAR-T persistence (e.g., 4-1BB vs. CD28 signaling domains) and reducing toxicity (e.g., cytokine release syndrome). - Biomarker Development: Identifying predictive markers (e.g., PD-L1 expression, TP53 mutations) to stratify patients for precision medicine.  </p> <p>This seminar underscores the importance of integrating molecular profiling, preclinical modeling, and clinical trial design to advance DLBCL treatment, with a focus on overcoming therapeutic resistance through combinatorial and immune-based strategies.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20%20Flow%20Cytometry%20for%20immunology/","title":"S1.W3.tu.  Flow Cytometry for immunology","text":"<p>Flow cytometry is a powerful laboratory technique that analyzes individual cells as they flow in a fluid stream through a beam of light. This technology simultaneously measures multiple physical and chemical characteristics of thousands of cells per second.</p> <p>At its core, flow cytometry works by suspending cells in a fluid and passing them through a detection apparatus. As cells flow through the system, they're hit with laser beams at specific wavelengths. The cells scatter light and emit fluorescence if they've been labeled with fluorescent markers (typically antibodies targeting specific cellular components).</p> <p>The scattered light provides information about cell size (forward scatter) and internal complexity/granularity (side scatter). Meanwhile, fluorescence detectors measure signals from various fluorescent markers, allowing scientists to identify specific cell types, quantify protein expression, assess cell cycle status, measure enzyme activity, and detect apoptosis.</p> <p>Modern flow cytometers can measure 15-30 parameters simultaneously on each cell, enabling detailed characterization of complex cell populations. The data is typically visualized through dot plots, histograms, and other graphical representations, with various gating strategies used to isolate populations of interest.</p> <p>Flow cytometry has become essential in immunology, hematology, oncology, and cell biology research. It's used clinically for diagnosing blood cancers, monitoring HIV infection, evaluating immunodeficiencies, and matching transplant donors. The technology has evolved to include cell sorting capabilities (FACS), imaging features, and high-throughput adaptations for drug screening and biomarker discovery. </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20%20Flow%20Cytometry%20for%20immunology/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How does treatment X affect the frequency, activation status, and functional profile of immune cell subsets in disease model Y?</li> <li>Design Rationale: Multi-parameter flow cytometry allows simultaneous assessment of multiple cell populations and their activation/functional markers at single-cell resolution</li> <li>Follow-up Studies: Sort identified cell populations for transcriptomic analysis, validate functional changes with in vitro assays, test targeted interventions based on altered immune profiles</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20%20Flow%20Cytometry%20for%20immunology/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human peripheral blood mononuclear cells (PBMCs) from patients with disease Y and matched healthy controls</li> <li>Rationale: PBMCs contain diverse immune cell populations and are readily accessible through minimally invasive procedures, enabling direct assessment of clinically relevant immune changes</li> <li>Alternatives:</li> <li>Mouse models (pros: controlled genetics and environment; cons: species differences)</li> <li>Tissue biopsies (pros: microenvironment context; cons: limited cell numbers, processing artifacts)</li> <li>In vitro stimulated cells (pros: controlled conditions; cons: artificial environment)</li> <li>Ethical Considerations: IRB approval, informed consent, sample de-identification, minimal blood draw volumes</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20%20Flow%20Cytometry%20for%20immunology/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques:</li> <li>Multi-parameter flow cytometry (10-18 colors)</li> <li>Fluorescence minus one (FMO) controls for gating</li> <li>Viability dye to exclude dead cells</li> <li>Compensation beads for spectral overlap correction</li> <li>Technical Replicates: Duplicate staining for key samples</li> <li>Potential Biases:</li> <li>Sample processing delays (standardize time from collection to processing)</li> <li>Antibody batch variations (use same lot throughout study)</li> <li>Instrument calibration drift (daily QC with tracking beads)</li> <li>Manual gating subjectivity (use standardized gating strategy, consider automated approaches)</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20%20Flow%20Cytometry%20for%20immunology/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Experimental: Samples from patients with disease Y receiving treatment X</li> <li>Control 1: Samples from untreated patients with disease Y</li> <li>Control 2: Samples from age/sex-matched healthy donors</li> <li>Control 3: In vitro stimulated samples for positive controls</li> <li>Controlled Variables: Sample processing protocol, antibody concentrations, incubation times, instrument settings</li> <li>Biological Replicates: Minimum 10-20 subjects per group based on power analysis</li> <li>Modified Design: Include longitudinal sampling (pre-treatment, early, and late timepoints) to track dynamic changes in immune populations</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20%20Flow%20Cytometry%20for%20immunology/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: </li> <li>Manual gating in FlowJo or automated clustering (SPADE, viSNE, FlowSOM)</li> <li>Compensation and transformation of fluorescence data</li> <li>Calculation of frequency and mean fluorescence intensity (MFI)</li> <li>Dimensionality reduction for visualization (tSNE, UMAP)</li> <li>Statistical Analysis:</li> <li>Non-parametric tests for population frequencies (Mann-Whitney, Kruskal-Wallis)</li> <li>Multiple comparison correction (Benjamini-Hochberg)</li> <li>Correlation analysis with clinical parameters</li> <li>Multivariate analysis to identify predictive immune signatures</li> <li>Data Presentation:</li> <li>Hierarchical gating trees showing population identification</li> <li>Box plots or violin plots for population frequencies</li> <li>Heatmaps showing marker expression across populations</li> <li>tSNE/UMAP plots colored by marker expression</li> <li>Correlation matrices with clinical parameters</li> <li>Validation Methods:</li> <li>Immunohistochemistry on tissue samples</li> <li>Functional assays (cytokine production, proliferation)</li> <li>RNA-seq of sorted populations</li> <li>Mass cytometry (CyTOF) for higher-dimensional validation</li> <li>Longitudinal follow-up to correlate with clinical outcomes</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20Flow%20cytometry%20in%20Biomedical/","title":"S1.W3.tu. Flow cytometry in Biomedical","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20Flow%20cytometry%20in%20Biomedical/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<p>Flow cytometry addresses fundamental questions in cell biology, such as phenotypic characterization of immune cells, functional analysis of cellular responses, and genetic modification effects. For instance, a typical experiment might investigate how genetic alterations impact T-cell activation by quantifying surface markers like CD4 or CD8. The design directly tests hypotheses through controlled comparisons (e.g., wild-type vs. genetically modified groups), using fluorescent antibodies to identify specific cell subsets. Repeating similar designs in subsequent figures often validates results across tissues (e.g., spleen vs. thymus) or optimizes protocols for different cell types, ensuring robustness and addressing context-specific variability.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20Flow%20cytometry%20in%20Biomedical/#2-model-system","title":"2. Model System","text":"<p>Model Selection: Murine models, particularly transgenic mice, are widely used due to their genetic tractability and immune system homology to humans. They enable in vivo studies of gene function and disease mechanisms.  </p> <p>Alternatives: - Cell Lines: Cost-effective and easy to manipulate but lack in vivo complexity. - Zebrafish: Ethically favorable for early developmental studies but limited translational relevance. - Non-human Primates: Biologically similar to humans but costly and ethically controversial.  </p> <p>Ethical Considerations: Animal studies require adherence to welfare guidelines (e.g., humane euthanasia), while human studies demand strict privacy protection and informed consent. Ethical challenges include minimizing animal use, ensuring data confidentiality, and avoiding biased interpretations.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20Flow%20cytometry%20in%20Biomedical/#3-measurement-approach","title":"3. Measurement Approach","text":"<p>Techniques: Flow cytometry employs quantitative methods to analyze light scatter (cell size/granularity) and fluorescence intensity (protein expression). It is inherently high-throughput and single-cell resolutive.  </p> <p>Method Advantages: - Multiplexing: Simultaneous detection of up to 50 markers. - Viability Assessment: Exclusion of dead cells via dyes like Zombie Aqua. - Speed: Analyzes thousands of cells per second.  </p> <p>Replicates and Biases: - Technical Replicates: Multiple measurements per sample reduce random errors. - Biological Replicates: Typically 10\u201320 samples, though small sizes may compromise statistical power. - Biases: Batch effects minimized through standardized protocols; compensation controls correct spectral overlap.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20Flow%20cytometry%20in%20Biomedical/#4-group-setting","title":"4. Group Setting","text":"<p>Experimental Groups: - Controls: Wild-type or unstained cells. - Treatments: Genetically modified or drug-treated groups - Variables Controlled: Age, sex, and environmental conditions.  </p> <p>Controls: - Negative Controls: Isotype-matched antibodies to assess nonspecific binding. - Positive Controls: Known healthy samples to validate assay performance.  </p> <p>Sample Size: Small cohorts (e.g., n=12 mice) may limit statistical power. Suggested improvements include dose-response groups or matched pairs to enhance precision.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W3.tu.%20Flow%20cytometry%20in%20Biomedical/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<p>Processing: Raw data are analyzed using software like FlowJo, gating cell populations (e.g., CD4+ T cells) and extracting metrics like mean fluorescence intensity (MFI).  </p> <p>Statistics: - Tests: t-tests, ANOVA, or non-parametric methods. - Power Concerns: Small sample sizes increase Type II error risk; larger cohorts or Bayesian approaches are recommended.  </p> <p>Presentation: - Visuals: Dot plots (e.g., CD44 vs. CD62L) and bar graphs. - Clarity: Axis scaling must avoid misleading truncation; color-coding aids interpretation.  </p> <p>Validation: Results should be cross-validated with orthogonal methods (e.g., immunohistochemistry, ELISA) to ensure reproducibility.  </p> <p>Conclusion Flow cytometry\u2019s multiplexing and single-cell capabilities make it indispensable for immunological and translational research. However, challenges like small sample sizes, technical expertise requirements, and ethical considerations demand careful attention. Future advancements may focus on integrating multi-omic data and improving accessibility, ensuring robust and ethically sound applications across biomedical fields.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W5.tu%20WB%20and%20ELISA/","title":"Western Blot (WB)","text":"<p>Western blotting is a laboratory technique used to detect specific proteins in a sample. The process involves several key steps:</p> <ol> <li> <p>Sample preparation: Proteins are extracted from cells or tissues and denatured.</p> </li> <li> <p>Gel electrophoresis: Proteins are separated by size as they migrate through a polyacrylamide gel under an electric field.</p> </li> <li> <p>Transfer: Separated proteins are transferred from the gel to a membrane (typically nitrocellulose or PVDF) using an electric current.</p> </li> <li> <p>Blocking: The membrane is blocked with a protein solution to prevent non-specific antibody binding.</p> </li> <li> <p>Primary antibody incubation: A specific antibody that recognizes the target protein is applied.</p> </li> <li> <p>Secondary antibody incubation: An enzyme-conjugated (typically horseradish peroxidase) secondary antibody that binds to the primary antibody is added.</p> </li> <li> <p>Detection: A substrate that reacts with the enzyme is applied, producing a detectable signal (chemiluminescence, fluorescence, or colorimetric) where the target protein is located.</p> </li> </ol> <p>Western blots provide information about protein molecular weight, expression levels, post-translational modifications, and can confirm protein identity in complex mixtures.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W5.tu%20WB%20and%20ELISA/#elisa-enzyme-linked-immunosorbent-assay","title":"ELISA (Enzyme-Linked Immunosorbent Assay)","text":"<p>ELISA is a plate-based assay technique designed to detect and quantify substances such as peptides, proteins, antibodies, and hormones. The main ELISA formats include:</p> <ol> <li> <p>Direct ELISA: An antigen is immobilized on a plate and detected using an enzyme-linked antibody.</p> </li> <li> <p>Indirect ELISA: The antigen is immobilized, a primary antibody binds to it, and an enzyme-linked secondary antibody detects the primary antibody.</p> </li> <li> <p>Sandwich ELISA: A capture antibody is immobilized, which binds the antigen. A detection antibody then binds to the antigen, followed by an enzyme-linked secondary antibody.</p> </li> <li> <p>Competitive ELISA: Sample antigen competes with a reference antigen for binding to a limited amount of antibody.</p> </li> </ol> <p>The final step in all ELISA formats involves adding a substrate that produces a measurable signal (typically colorimetric) proportional to the amount of target molecule present. The signal is quantified using a plate reader.</p> <p>ELISA offers high sensitivity and specificity, making it valuable for diagnostic applications, including disease screening, allergen detection, and hormone level measurement. It's particularly useful for quantifying proteins in complex mixtures without the need for protein separation. </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W5.tu%20WB%20and%20ELISA/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<p>Case Study 1 addresses the hypothesis that autophagy declines with age by measuring Atg5 protein expression in murine tissues (brain, heart, lungs, kidneys) across different age groups (4\u201372 weeks). The experimental design directly tests this by comparing Atg5 levels via Western Blot, using \u03b2-Actin as a loading control to normalize results.  </p> <p>Case Study 2 investigates IFN\u03b3 production by antigen-specific CD8 T-cells from Listeria-infected mice, aiming to characterize effector properties of novel memory phenotype cells. The repeated design in Figure 2 (stimulation with peptides/CD3/CD28) likely confirms consistency in IFN\u03b3 responses across different activation methods or explores antigen-specific vs. polyclonal stimulation.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W5.tu%20WB%20and%20ELISA/#2-model-system","title":"2. Model System","text":"<p>Both studies use mice as the model system due to their genetic similarity to humans, ethical feasibility, and ease of experimental manipulation (e.g., age-controlled cohorts, cell sorting). Alternatives like cell lines lack in vivo complexity, while non-human primates are costly and ethically restrictive. Ethical considerations include humane euthanasia and minimizing animal suffering, as outlined in protocols.  </p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W5.tu%20WB%20and%20ELISA/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Case Study 1: Western Blot (quantitative) detects protein expression via chemiluminescence. \u03b2-Actin ensures loading consistency. Technical replicates (multiple lanes per sample) reduce variability.  </li> <li>Case Study 2: ELISA (quantitative) measures IFN\u03b3 in cell supernatants. Duplicate/quadruplicate samples control for pipetting errors. Potential biases include plate-to-plate variation, minimized by separate plates per cell type.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W5.tu%20WB%20and%20ELISA/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Case Study 1: Groups are age-segregated (4\u201372 weeks) with tissues as biological replicates. \u03b2-Actin serves as a negative control. Sample size (9 age points) allows trend analysis but may lack power for pairwise comparisons.  </li> <li>Case Study 2: Groups include naive vs. Listeria-infected mice, with stimulation conditions (peptides, CD3/CD28) as variables. Negative controls (unstimulated cells) validate assay specificity. Replicates (duplicates/quadruplicates) improve reliability.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W5.tu%20WB%20and%20ELISA/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Case Study 1: Raw band intensities are normalized to \u03b2-Actin. Statistical analysis (e.g., ANOVA) identifies age-related trends. Results are visualized via Western blot images with labeled lanes.  </li> <li>Case Study 2: OD values from ELISA plates are converted to IFN\u03b3 concentrations. Technical replicates are averaged, and statistical tests (e.g., t-tests) compare groups. Visuals (e.g., bar graphs) highlight differences between cell populations and stimulation conditions.  </li> </ul> <p>Key Considerations: Both studies emphasize the importance of internal controls (\u03b2-Actin, unstimulated cells), technical reproducibility, and hypothesis-driven experimental design. Future work could include dose-response experiments (e.g., varying antigen concentrations) or longitudinal sampling to strengthen conclusions.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/","title":"Summary of Genetic Modification Techniques","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/#traditional-methods","title":"Traditional Methods","text":"<ul> <li>Homologous Recombination: Uses DNA constructs with homologous sequences to target specific genes in embryonic stem cells. Relatively inefficient but precise for gene knockouts and knockins.</li> <li>Pronuclear Injection: Direct injection of DNA into fertilized eggs for random integration of transgenes. Useful for overexpression studies but lacks targeting precision.</li> <li>Gene Trapping: Uses vector insertion to disrupt and report gene expression. Efficient for large-scale mutagenesis screening.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/#site-specific-recombination-systems","title":"Site-Specific Recombination Systems","text":"<ul> <li>Cre/loxP System: Uses Cre recombinase to excise DNA between loxP sites. Enables conditional knockouts when Cre expression is controlled by tissue-specific promoters.</li> <li>Flp/FRT System: Similar to Cre/loxP but uses Flp recombinase and FRT recognition sites. Often used in combination with Cre/loxP for complex genetic manipulations.</li> <li>Inducible Systems: Tet-On/Off and tamoxifen-inducible Cre (CreERT2) provide temporal control of gene expression or deletion.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/#modern-genome-editing","title":"Modern Genome Editing","text":"<ul> <li>CRISPR/Cas9: Revolutionary technique using guide RNAs to direct Cas9 nuclease to specific DNA sequences. Creates precise double-strand breaks for gene knockout, knockin, or base editing. Highly efficient and versatile.</li> <li>CRISPR Base Editors: Modified Cas9 systems fused to deaminases that convert specific nucleotides without double-strand breaks (C\u2192T or A\u2192G).</li> <li>CRISPR Prime Editing: Combines Cas9 with reverse transcriptase to make precise edits without donor DNA templates.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/#rna-interference","title":"RNA Interference","text":"<ul> <li>shRNA/siRNA: Short hairpin or small interfering RNAs that target specific mRNAs for degradation, providing transient or stable knockdown rather than complete knockout.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/#transgenesis-enhancements","title":"Transgenesis Enhancements","text":"<ul> <li>BAC Transgenesis: Uses bacterial artificial chromosomes to incorporate large DNA fragments with regulatory elements for more physiological expression patterns.</li> <li>TARGATT/PhiC31: Site-specific integration systems that reduce position effects by targeting transgenes to predetermined genomic locations.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/#validation-methods","title":"Validation Methods","text":"<ul> <li>PCR/Sequencing: Confirms correct targeting and sequence integrity.</li> <li>Southern Blotting: Verifies genomic integration and copy number.</li> <li>Western Blotting: Confirms protein expression changes.</li> <li>Functional Assays: Tests physiological consequences of genetic modifications.</li> </ul> <p>These techniques have revolutionized biomedical research by enabling precise manipulation of genomes to study gene function, model diseases, and develop therapeutic approaches.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Questions Addressed:  </li> <li>The document explores the use of genetically modified mice to study gene function, tissue-specific expression, developmental timing, molecular pathways, and disease modeling (e.g., understanding disease mechanisms and developing treatments).  </li> <li> <p>Techniques like CRISPR/Cas9 and Cre/loxP are discussed to address how gene disruption affects phenotypes and disease outcomes.  </p> </li> <li> <p>Experimental Design:  </p> </li> <li>Figure 1 (hypothetical) likely tests whether gene knockout recapitulates a disease phenotype. The design uses total knockout mice (e.g., via CRISPR/Cas9) to ablate gene function globally.  </li> <li>Figure 2 (hypothetical) might replicate the design to confirm consistency (e.g., in different genetic backgrounds) or test conditional knockouts in specific tissues.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/#2-model-system","title":"2. Model System","text":"<ul> <li>Choice of Mice:  </li> <li>Relevance: Mice (Mus musculus) are used due to their genetic similarity to humans (99% homologs), rapid reproduction, and inbred strains for reduced variability.  </li> <li> <p>Ease of Manipulation: Sequenced and annotated genomes facilitate precise genetic modifications (e.g., via CRISPR/Cas9).  </p> </li> <li> <p>Alternative Models:  </p> </li> <li>Pros: Rats (larger size), zebrafish (transparency), or cell cultures (lower cost).  </li> <li> <p>Cons: Limited translatability to humans (e.g., zebrafish) or technical challenges (e.g., rat genome editing).  </p> </li> <li> <p>Ethical Considerations:  </p> </li> <li>Animal welfare protocols are implied but not explicitly discussed. Ethical concerns include potential embryonic lethality in knockout models.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques:  </li> <li>Homologous Recombination (traditional) and CRISPR/Cas9 (modern) for gene knockout.  </li> <li> <p>Cre/loxP for conditional knockouts and Tamoxifen-inducible Cre for temporal control.  </p> </li> <li> <p>Method Selection:  </p> </li> <li>CRISPR is favored for speed and efficiency, though it risks off-target effects.  </li> <li> <p>Cre/loxP enables cell-specific targeting but may have leaky expression.  </p> </li> <li> <p>Replicates and Biases:  </p> </li> <li>Biological replicates (e.g., multiple mice per genotype) are implied but not quantified. Technical replicates (e.g., PCR validation of mutations) are standard.  </li> <li>Potential biases include off-target edits (CRISPR) or incomplete recombination (Cre/loxP), mitigated by controls (e.g., wild-type littermates).  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:  </li> <li>Controls: Wild-type (WT), heterozygous, and homozygous knockout mice.  </li> <li> <p>Variables Controlled: Age, sex, and genetic background (via inbred strains).  </p> </li> <li> <p>Negative/Positive Controls:  </p> </li> <li>Negative controls: WT mice or Cre-negative littermates.  </li> <li> <p>Positive controls: Known disease models (e.g., BRCA2 mutations).  </p> </li> <li> <p>Replicates:  </p> </li> <li>Sample sizes are not specified but must meet statistical power (e.g., \u22655 mice/group for phenotypic analysis).  </li> <li>Modified designs could include dose-response experiments or additional Cre driver lines for tissue specificity.  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S1.W8.Laura%20Gene%20modified%20mouse/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing:  </li> <li>Quantitative: Genotyping via PCR, phenotypic scoring (e.g., survival rates).  </li> <li> <p>Qualitative: Histology or immunohistochemistry for tissue-specific expression.  </p> </li> <li> <p>Statistics:  </p> </li> <li> <p>Tests like ANOVA or t-tests are implied but not detailed. Power depends on effect size and sample size.  </p> </li> <li> <p>Data Visualization:  </p> </li> <li> <p>Hypothetical figures (e.g., survival curves, western blots) would show genotype comparisons. Clear scaling and labeling are critical to avoid bias.  </p> </li> <li> <p>Validation:  </p> </li> <li>Results may be confirmed via alternative methods (e.g., RNA-seq for gene expression).  </li> </ul> <p>Key Takeaways: - Mice are a gold-standard model due to genetic tractability and human relevance. - CRISPR/Cas9 and Cre/loxP offer versatile tools but require careful validation. - Ethical and technical considerations (e.g., off-target effects, incomplete recombination) must be addressed in experimental design.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2%20Comprehensive%20Design%20Framework%20for%20Computational%20Methods%20in%20Biomedicine/","title":"S2 Comprehensive Design Framework for Computational Methods in Biomedicine","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2%20Comprehensive%20Design%20Framework%20for%20Computational%20Methods%20in%20Biomedicine/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<p>Scientific Question Formulation: - Problem specificity: Define whether you're addressing a classification problem (e.g., mutation pathogenicity), regression problem (e.g., expression level prediction), clustering task (e.g., cell type identification), or generative challenge (e.g., protein structure prediction) - Data-to-question alignment: Ensure your data type (genomic, transcriptomic, proteomic, clinical) directly informs your question - Hypothesis granularity: Formulate testable computational hypotheses at multiple levels (molecular, cellular, tissue, organism) - Prediction scope: Determine whether your method aims for mechanistic insight, diagnostic application, therapeutic guidance, or prognostic value</p> <p>Iterative Development Strategy: - Benchmark selection: Choose appropriate existing methods to compare against (e.g., SIFT vs. PolyPhen for variant prediction) - Performance metrics prioritization: Decide which metrics matter most (accuracy, precision, recall, F1, AUROC, AUPRC) based on downstream applications - Transfer learning approach: Determine whether to train from scratch or leverage pre-trained models (e.g., protein language models like ESM-2) - Ablation study design: Plan systematic removal of features/components to assess their contribution</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2%20Comprehensive%20Design%20Framework%20for%20Computational%20Methods%20in%20Biomedicine/#2-model-system-selection","title":"2. Model System Selection","text":"<p>Data Source Considerations: - Primary data sources:   - Human clinical data (direct relevance but limited control)   - Patient-derived organoids (3D structure with patient genetics)   - Primary cell cultures (patient-specific but limited lifespan)   - Established cell lines (reproducible but potentially divergent)   - Model organisms (genetic manipulation but evolutionary distance)   - Synthetic data (complete control but potential artificiality)</p> <ul> <li>Multi-omics integration: Determine whether to use single-modality or multi-modal data (genomic + transcriptomic + proteomic + clinical)</li> <li>Temporal dimension: Consider static vs. time-series data based on biological dynamics</li> <li>Spatial resolution: Evaluate bulk vs. single-cell vs. spatial transcriptomics/proteomics approaches</li> </ul> <p>Alternative Data Sources Assessment: - Public database selection: Choose between repositories (GEO, TCGA, GTEx, UK Biobank) based on sample size, annotation quality, and population diversity - Synthetic data generation: Consider GANs or VAEs to augment limited datasets or address privacy concerns - Simulated data application: Evaluate when to use simulated data (e.g., for testing extreme conditions)</p> <p>Ethical Framework Implementation: - Consent granularity: Ensure data usage aligns with original consent parameters - Bias detection protocol: Implement methods to identify and quantify dataset biases - Fairness metrics: Select appropriate fairness measures (demographic parity, equal opportunity, equalized odds) - Interpretability requirements: Balance performance with explainability based on application context</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2%20Comprehensive%20Design%20Framework%20for%20Computational%20Methods%20in%20Biomedicine/#3-measurement-approach","title":"3. Measurement Approach","text":"<p>Methodological Selection: - Algorithm taxonomy:   - Classical machine learning:     - Linear methods (Logistic regression, SVM, elastic net)     - Tree-based methods (Random Forest, XGBoost, LightGBM)     - Probabilistic models (Bayesian networks, Hidden Markov Models)     - Kernel methods (kernel SVM, Gaussian processes)</p> <ul> <li> <p>Deep learning architectures:</p> <ul> <li>Convolutional networks (for image or k-mer data)</li> <li>Recurrent networks (LSTM/GRU for sequential data)</li> <li>Transformer models (for capturing long-range dependencies)</li> <li>Graph neural networks (for interaction networks)</li> <li>Variational autoencoders (for dimensionality reduction)</li> <li>Generative adversarial networks (for synthetic data)</li> <li>Hybrid architectures (CNN-LSTM, CNN-Transformer)</li> </ul> </li> <li> <p>Feature engineering strategies:</p> </li> <li>Manual feature selection based on domain knowledge</li> <li>Automated feature selection (LASSO, recursive feature elimination)</li> <li>Feature embedding (word2vec, doc2vec for biological sequences)</li> <li> <p>Dimensionality reduction (PCA, t-SNE, UMAP)</p> </li> <li> <p>Hyperparameter optimization:</p> </li> <li>Grid search vs. random search vs. Bayesian optimization</li> <li>Learning rate scheduling (step, cosine, one-cycle)</li> <li>Regularization approach (L1, L2, dropout, batch normalization)</li> </ul> <p>Validation Strategy Implementation: - Cross-validation design:   - k-fold vs. stratified k-fold vs. leave-one-out   - Nested cross-validation for hyperparameter tuning   - Patient-wise vs. sample-wise partitioning   - Temporal validation for time-series data</p> <ul> <li>Ensemble methodology:</li> <li>Bagging vs. boosting vs. stacking</li> <li>Model averaging vs. weighted averaging</li> <li>Diversity promotion in ensemble members</li> <li>Heterogeneous vs. homogeneous ensembles</li> </ul> <p>Bias Mitigation Techniques: - Data-level interventions:   - Resampling techniques (SMOTE, ADASYN, Tomek links)   - Synthetic data augmentation (noise addition, SMOTE variants)   - Batch effect correction (ComBat, Harmony, Seurat integration)   - Missing data imputation (KNN, MICE, matrix factorization)</p> <ul> <li>Algorithm-level approaches:</li> <li>Cost-sensitive learning with class weights</li> <li>Focal loss for imbalanced classification</li> <li>Adversarial debiasing during training</li> <li>Fairness constraints as regularization terms</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2%20Comprehensive%20Design%20Framework%20for%20Computational%20Methods%20in%20Biomedicine/#4-group-setting-design","title":"4. Group Setting Design","text":"<p>Experimental Groups Structuring: - Data partitioning strategy:   - Random vs. stratified vs. temporal splits   - Hold-out validation set size (10%, 20%, 30%)   - External validation cohort selection criteria   - Cross-study validation approach</p> <ul> <li>Confounding variable control:</li> <li>Matching algorithms (propensity score, coarsened exact matching)</li> <li>Covariate adjustment in model training</li> <li>Residualization of unwanted variation</li> <li>Causal inference frameworks (potential outcomes, causal graphs)</li> </ul> <p>Control Implementation Strategy: - Negative controls:   - Permutation testing with shuffled labels   - Comparison to theoretical null distributions   - Use of known non-functional variants/sequences   - Scrambled or reversed biological sequences</p> <ul> <li>Computational baselines:</li> <li>Simple heuristic models (GC content, sequence length)</li> <li>Published algorithms as performance floors</li> <li>State-of-the-art methods as performance ceilings</li> <li>Ensemble of existing methods</li> </ul> <p>Replication Strategy Design: - Internal validation:   - Bootstrap resampling with confidence intervals   - Jackknife resampling for influence analysis   - Monte Carlo cross-validation   - Out-of-bag estimates for ensemble methods</p> <ul> <li>External validation:</li> <li>Independent dataset testing protocol</li> <li>Cross-platform validation approach</li> <li>Cross-species validation where applicable</li> <li>Prospective validation planning</li> </ul> <p>Experimental Extensions Planning: - Ablation studies:   - Feature importance quantification (SHAP, LIME)   - Layer-wise relevance propagation for deep networks   - Knockout studies of network components   - Gradient-based attribution methods</p> <ul> <li>Sensitivity analysis:</li> <li>Hyperparameter perturbation tests</li> <li>Training data subsampling curves</li> <li>Noise addition robustness testing</li> <li>Adversarial example generation</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2%20Comprehensive%20Design%20Framework%20for%20Computational%20Methods%20in%20Biomedicine/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<p>Data Processing Pipeline: - Preprocessing protocols:   - Normalization methods (min-max, z-score, quantile, TPM, RPKM)   - Outlier detection and handling (IQR, z-score, isolation forest)   - Quality control metrics and thresholds   - Batch correction algorithms (ComBat, RUV, scVI)</p> <ul> <li>Feature transformation:</li> <li>Log transformation for skewed distributions</li> <li>Power transformations (Box-Cox, Yeo-Johnson)</li> <li>Rank-based inverse normal transformation</li> <li>Non-linear embeddings (UMAP, t-SNE, autoencoders)</li> </ul> <p>Statistical Analysis Framework: - Hypothesis testing selection:   - Parametric tests (t-test, ANOVA, linear regression)   - Non-parametric alternatives (Mann-Whitney, Kruskal-Wallis)   - Permutation-based significance testing   - Bootstrapped confidence intervals</p> <ul> <li>Multiple testing correction:</li> <li>Bonferroni vs. Benjamini-Hochberg vs. q-value</li> <li>Family-wise error rate vs. false discovery rate</li> <li>Adaptive procedures for correlation structure</li> <li> <p>Local FDR estimation methods</p> </li> <li> <p>Effect size quantification:</p> </li> <li>Cohen's d vs. odds ratio vs. hazard ratio</li> <li>Confidence interval calculation methods</li> <li>Minimal clinically important difference threshold</li> <li>Number needed to treat/test calculations</li> </ul> <p>Visualization Standards Implementation: - Plot selection by data type:   - Categorical data: Bar plots, mosaic plots, heatmaps   - Continuous data: Box plots, violin plots, density plots   - Relational data: Scatter plots, bubble plots, contour plots   - Temporal data: Line plots, area charts, horizon plots   - High-dimensional data: PCA plots, t-SNE, UMAP, heatmaps</p> <ul> <li>Visualization best practices:</li> <li>Perceptually uniform color scales (viridis, cividis)</li> <li>Colorblind-friendly palettes with sufficient contrast</li> <li>Consistent scales across comparison figures</li> <li>Appropriate error representation (SE, SD, CI, IQR)</li> <li>Jittered points to show data distribution</li> </ul> <p>Validation Approach Selection: - In silico validation:   - Simulated data with known ground truth   - Cross-species conservation analysis   - Structure-based validation for protein effects   - Literature-derived knowledge bases</p> <ul> <li>Experimental validation:</li> <li>Functional assays (reporter assays, CRISPR screens)</li> <li>Orthogonal measurement technologies</li> <li>Independent cohort replication</li> <li> <p>Prospective clinical validation</p> </li> <li> <p>Deployment validation:</p> </li> <li>A/B testing in clinical decision support</li> <li>User feedback integration</li> <li>Monitoring for performance drift</li> <li>Continuous retraining protocols</li> </ul> <p>By implementing this detailed framework, researchers can develop robust computational methods in biomedicine that maximize scientific validity, technical performance, and translational impact while minimizing bias and ensuring reproducibility.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/","title":"S2.W1.1.Seminar DL for genomic modeling","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#1-translatorner-a-transformer-based-model-for-mrna-translation","title":"1.\u00a0Translatorner: A Transformer-based Model for mRNA Translation","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#experimental-purpose","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand the regulation of mRNA translation and its impact on protein abundance, which is crucial for understanding disease mechanisms. The central dogma of biology (DNA \u2192 RNA \u2192 Protein) is well-known, but the correlation between mRNA and protein levels is not perfect (0.39 to 0.79). The study seeks to model how mRNA translation is regulated and how this regulation affects protein levels.</li> <li>Experimental Design: The study uses a Transformer-based deep learning model (Translatorner) to predict ribosome profiling (translatome) from RNA-seq data and gene sequences. The model is trained on human data and tested on both human and mouse datasets to evaluate its ability to generalize across species.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#model-system","title":"Model System:","text":"<ul> <li>Model System: The study uses human and mouse genomic data. These systems are appropriate because they are well-studied, and the conservation of regulatory mechanisms between humans and mice allows for cross-species validation.</li> <li>Alternative Model Systems: Other model systems like yeast or zebrafish could be used, but they may lack the complexity and relevance to human diseases. However, they are cheaper and easier to manipulate.</li> <li>Ethical Considerations: Using human genomic data requires ethical approval, especially when dealing with patient data. The study likely adheres to ethical guidelines for genomic research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#measurement-approach","title":"Measurement Approach:","text":"<ul> <li>Techniques: The study uses ribosome profiling (Ribo-seq) and RNA-seq data. These are quantitative techniques that measure translation efficiency and mRNA abundance, respectively.</li> <li>Method Choice: Deep learning models (Transformers) were chosen because they can capture long-range dependencies in sequences, which is crucial for understanding translation regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from data normalization or sequencing depth. These are minimized by using standardized protocols and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#group-setting","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The model is trained on human data and tested on both human and mouse data. The groups are defined by cell types (e.g., epithelial cells, brain cells).</li> <li>Negative Controls: The study compares Translatorner with state-of-the-art models (e.g., Riboformer) to ensure that the improvements are not due to overfitting.</li> <li>Biological Replicates: The study uses multiple datasets (e.g., K562, epithelial cells) to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of mRNA affect translation efficiency.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#data-analysis-presentation","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw data from Ribo-seq and RNA-seq are processed using deep learning models. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses Pearson correlation coefficients (PCC) to compare predicted and observed ribosome profiling data.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using cross-species data and in silico mutagenesis, which confirms the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#2-transrbp-modeling-rbp-binding-and-its-interaction-with-m6a","title":"2.\u00a0TransRBP: Modeling RBP Binding and Its Interaction with m6A","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#experimental-purpose_1","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how RNA-binding proteins (RBPs) interact with m6A modifications and how these interactions affect RNA metabolism and disease.</li> <li>Experimental Design: The study develops a deep learning model (TransRBP) to predict RBP binding sites and their interaction with m6A. The model is trained on RNA sequences and tested for its ability to identify disease-related variants that alter RBP binding.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#model-system_1","title":"Model System:","text":"<ul> <li>Model System: The study uses human genomic data, focusing on RBPs and m6A modifications. This system is appropriate because m6A is the most prevalent mRNA modification and plays a critical role in RNA metabolism.</li> <li>Alternative Model Systems: Other systems like yeast or bacteria could be used, but they lack the complexity of m6A regulation seen in higher eukaryotes.</li> <li>Ethical Considerations: Similar to Translatorner, the use of human genomic data requires ethical approval.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#measurement-approach_1","title":"Measurement Approach:","text":"<ul> <li>Techniques: The study uses RNA-seq data and m6A sequencing data. These are quantitative techniques that measure RNA abundance and m6A modifications.</li> <li>Method Choice: Deep learning models (Transformers) were chosen because they can capture complex interactions between RNA sequences and RBPs.</li> <li>Technical Replicates: The study likely uses multiple replicates, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from sequencing errors or incomplete annotation of m6A sites. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#group-setting_1","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The model is trained on RNA sequences and tested for its ability to predict RBP binding sites. The groups are defined by disease types (e.g., Parkinson\u2019s disease, autism).</li> <li>Negative Controls: The study compares TransRBP with existing models to ensure that the improvements are not due to overfitting.</li> <li>Biological Replicates: The study uses multiple datasets to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of m6A affect RBP binding.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#data-analysis-presentation_1","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw data from RNA-seq and m6A sequencing are processed using deep learning models. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses Pearson correlation coefficients (PCC) to compare predicted and observed RBP binding data.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using in silico mutagenesis and experimental data, which confirms the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W1.1.Seminar%20DL%20for%20genomic%20modeling/#general-observations","title":"General Observations:","text":"<ul> <li>Both studies leverage deep learning models (Transformers) to address complex questions in genomics. The models are trained on large datasets and validated using cross-species data and in silico experiments.</li> <li>The studies highlight the importance of model interpretability, using techniques like in silico mutagenesis and gradient-based interpretation to understand the contribution of different input modalities.</li> <li>The results have significant implications for understanding disease mechanisms, particularly in the context of translation regulation and RBP interactions with m6A modifications</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/","title":"S2.W3.2 Structural study of epigenetic regulation in transcription","text":"<p>\u7ec4\u86cb\u767d\u4fee\u9970\u548c\u67d3\u8272\u8d28\u8c03\u63a7\u7684\u7ed3\u6784\u751f\u7269\u5b66\uff1a\u5b9e\u9a8c\u5de5\u4f5c\u6d41\u7a0b</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#_1","title":"\u4e00\u3001\u6837\u54c1\u5236\u5907\u548c\u86cb\u767d\u8d28\u7eaf\u5316","text":"<ol> <li>\u91cd\u7ec4\u86cb\u767d\u8868\u8fbe</li> <li>\u5c06\u7f16\u7801SAGA\u590d\u5408\u7269\u7ec4\u5206(\u5982Gcn5\u3001Ada2\u3001Ada3)\u7684\u57fa\u56e0\u514b\u9686\u5230\u8868\u8fbe\u8f7d\u4f53\u4e2d</li> <li>\u8f6c\u5316\u5230\u5927\u80a0\u6746\u83cc\u8868\u8fbe\u83cc\u682a(BL21(DE3))</li> <li>\u4f7f\u7528IPTG\u8bf1\u5bfc\u86cb\u767d\u8868\u8fbe</li> <li>\u6536\u96c6\u7ec6\u80de\u5e76\u5728\u5929\u7136\u6761\u4ef6\u4e0b\u5236\u5907\u88c2\u89e3\u6db2</li> <li>\u4f7f\u7528\u4eb2\u548c\u5c42\u6790(His\u6807\u7b7e\u3001GST\u6807\u7b7e)\u7eaf\u5316\u86cb\u767d</li> <li> <p>\u901a\u8fc7\u79bb\u5b50\u4ea4\u6362\u548c\u5206\u5b50\u7b5b\u5c42\u6790\u8fdb\u4e00\u6b65\u7eaf\u5316</p> </li> <li> <p>\u6838\u5c0f\u4f53\u7ec4\u88c5</p> </li> <li>\u8868\u8fbe\u5e76\u7eaf\u5316\u91cd\u7ec4\u7ec4\u86cb\u767d(H2A\u3001H2B\u3001H3\u3001H4)</li> <li>\u4ece\u7eaf\u5316\u7684\u7ec4\u86cb\u767d\u4e2d\u91cd\u6298\u53e0\u7ec4\u86cb\u767d\u516b\u805a\u4f53</li> <li>\u5236\u5907\u542b\u6709\u6838\u5c0f\u4f53\u5b9a\u4f4d\u5e8f\u5217\u7684DNA\u7247\u6bb5</li> <li>\u901a\u8fc7\u76d0\u68af\u5ea6\u900f\u6790\u91cd\u6784\u6838\u5c0f\u4f53</li> <li> <p>\u7528\u5929\u7136PAGE\u9a8c\u8bc1\u7ec4\u88c5</p> </li> <li> <p>\u5f15\u5165\u7ec4\u86cb\u767d\u4fee\u9970</p> </li> <li>\u5316\u5b66\u5408\u6210\u4fee\u9970\u7684\u7ec4\u86cb\u767d</li> <li>\u4f7f\u7528\u7eaf\u5316\u7684HATs/HDACs\u8fdb\u884c\u9176\u4fc3\u4fee\u9970</li> <li>\u4f7f\u7528\u5929\u7136\u5316\u5b66\u8fde\u63a5\u6cd5\u6574\u5408\u4fee\u9970\u7684\u7ec4\u86cb\u767d\u5c3e\u90e8</li> <li> <p>\u901a\u8fc7\u8d28\u8c31\u548cWestern blot\u9a8c\u8bc1\u4fee\u9970</p> </li> <li> <p>\u590d\u5408\u7269\u5f62\u6210</p> </li> <li>\u5c06\u7eaf\u5316\u7684SAGA\u590d\u5408\u7269\u4e0e\u4fee\u9970\u7684\u6838\u5c0f\u4f53\u7ed3\u5408</li> <li>\u4f18\u5316\u7f13\u51b2\u6761\u4ef6\u4ee5\u5f62\u6210\u7a33\u5b9a\u590d\u5408\u7269</li> <li>\u901a\u8fc7\u51dd\u80f6\u8fc7\u6ee4\u5c42\u6790\u9a8c\u8bc1\u590d\u5408\u7269\u5f62\u6210</li> <li>\u901a\u8fc7\u5206\u6790\u578b\u8d85\u901f\u79bb\u5fc3\u8bc4\u4f30\u5316\u5b66\u8ba1\u91cf\u6bd4</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#_2","title":"\u4e8c\u3001\u7ed3\u6784\u5206\u6790","text":"<ol> <li>\u51b7\u51bb\u7535\u955c\u6837\u54c1\u5236\u5907\u548c\u6570\u636e\u6536\u96c6</li> <li>\u5c063-4\u03bcl\u7eaf\u5316\u7684\u590d\u5408\u7269\u5e94\u7528\u4e8e\u653e\u7535\u5904\u7406\u7684\u7535\u955c\u7f51\u683c\u4e0a</li> <li>\u5438\u9664\u591a\u4f59\u6db2\u4f53\u5e76\u5728\u6db2\u6001\u4e59\u70f7\u4e2d\u5feb\u901f\u51b7\u51bb</li> <li>\u7b5b\u9009\u7f51\u683c\u4ee5\u8bc4\u4f30\u51b0\u8d28\u91cf\u548c\u9897\u7c92\u5206\u5e03</li> <li>\u5728\u7535\u5b50\u663e\u5fae\u955c(\u5982Titan Krios)\u4e0a\u6536\u96c6\u9ad8\u5206\u8fa8\u7387\u6570\u636e</li> <li>\u4f7f\u7528\u76f4\u63a5\u7535\u5b50\u63a2\u6d4b\u5668\u8bb0\u5f55\u7535\u5f71</li> <li> <p>\u4f7f\u7528\u8fd0\u52a8\u6821\u6b63\u8f6f\u4ef6\u5904\u7406\u6570\u636e</p> </li> <li> <p>\u51b7\u51bb\u7535\u955c\u6570\u636e\u5904\u7406</p> </li> <li>\u8fdb\u884cCTF\u4f30\u8ba1\u548c\u6821\u6b63</li> <li>\u4f7f\u7528\u81ea\u52a8\u548c\u624b\u52a8\u62fe\u53d6\u9009\u62e9\u9897\u7c92</li> <li>\u63d0\u53d6\u9897\u7c92\u5e76\u8fdb\u884c2D\u5206\u7c7b</li> <li>\u751f\u6210\u521d\u59cb3D\u6a21\u578b</li> <li>\u901a\u8fc7\u8fed\u4ee3\u5206\u7c7b\u4f18\u53163D\u7ed3\u6784</li> <li>\u5e94\u7528\u540e\u5904\u7406\u4ee5\u63d0\u9ad8\u5206\u8fa8\u7387</li> <li> <p>\u4f7f\u7528\u5085\u91cc\u53f6\u58f3\u76f8\u5173\u9a8c\u8bc1\u5206\u8fa8\u7387</p> </li> <li> <p>X\u5c04\u7ebf\u6676\u4f53\u5b66(\u9488\u5bf9\u7279\u5b9a\u7ed3\u6784\u57df)</p> </li> <li>\u7b5b\u9009\u5355\u4e2a\u7ed3\u6784\u57df\u7684\u7ed3\u6676\u6761\u4ef6</li> <li>\u4f18\u5316\u6676\u4f53\u751f\u957f\u53c2\u6570</li> <li>\u6536\u83b7\u6676\u4f53\u5e76\u51c6\u5907\u884d\u5c04</li> <li>\u5728\u540c\u6b65\u52a0\u901f\u5668\u8bbe\u65bd\u6536\u96c6\u884d\u5c04\u6570\u636e</li> <li>\u5904\u7406\u884d\u5c04\u6570\u636e\u5e76\u8fdb\u884c\u76f8\u4f4d\u786e\u5b9a</li> <li>\u6784\u5efa\u548c\u4f18\u5316\u539f\u5b50\u6a21\u578b</li> <li> <p>\u9a8c\u8bc1\u6a21\u578b\u8d28\u91cf</p> </li> <li> <p>\u6a21\u578b\u6784\u5efa\u548c\u4f18\u5316</p> </li> <li>\u5c06\u539f\u5b50\u6a21\u578b\u62df\u5408\u5230\u51b7\u51bb\u7535\u955c\u5bc6\u5ea6\u56fe\u4e2d</li> <li>\u6839\u636e\u5b9e\u9a8c\u6570\u636e\u4f18\u5316\u6a21\u578b</li> <li>\u9a8c\u8bc1\u6a21\u578b\u51e0\u4f55\u5f62\u72b6\u548c\u4e0e\u5bc6\u5ea6\u7684\u62df\u5408</li> <li>\u5206\u6790\u86cb\u767d\u8d28-\u86cb\u767d\u8d28\u548c\u86cb\u767d\u8d28-\u6838\u5c0f\u4f53\u754c\u9762</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#_3","title":"\u4e09\u3001\u751f\u5316\u548c\u529f\u80fd\u8868\u5f81","text":"<ol> <li>\u4f53\u5916HAT/HDAC\u6d3b\u6027\u6d4b\u5b9a</li> <li>\u51c6\u5907\u5e95\u7269(\u542b\u672a\u4fee\u9970\u7ec4\u86cb\u767d\u7684\u6838\u5c0f\u4f53)</li> <li>\u4e0e\u7eaf\u5316\u7684SAGA\u590d\u5408\u7269\u6216HDACs\u5b75\u80b2</li> <li>\u901a\u8fc7\u4ee5\u4e0b\u65b9\u6cd5\u68c0\u6d4b\u4e59\u9170\u5316/\u53bb\u4e59\u9170\u5316:<ul> <li>\u653e\u5c04\u6027\u6807\u8bb0\u4e59\u9170\u8f85\u9176A\u7684\u63ba\u5165</li> <li>\u4f7f\u7528\u4fee\u9970\u7279\u5f02\u6027\u6297\u4f53\u8fdb\u884cWestern blot</li> <li>\u8d28\u8c31\u5206\u6790</li> </ul> </li> <li> <p>\u786e\u5b9a\u9176\u52a8\u529b\u5b66\u53c2\u6570(Km, Vmax)</p> </li> <li> <p>\u7ed3\u5408\u4eb2\u548c\u529b\u6d4b\u91cf</p> </li> <li>\u7b49\u6e29\u6ef4\u5b9a\u91cf\u70ed\u6cd5(ITC)\u6d4b\u91cf\u70ed\u529b\u5b66\u53c2\u6570</li> <li>\u8868\u9762\u7b49\u79bb\u5b50\u4f53\u5171\u632f(SPR)\u6d4b\u91cf\u7ed3\u5408\u52a8\u529b\u5b66</li> <li>\u8367\u5149\u5404\u5411\u5f02\u6027\u6d4b\u91cf\u8f83\u5c0f\u7ed3\u6784\u57df\u7684\u76f8\u4e92\u4f5c\u7528</li> <li> <p>\u6bd4\u8f83\u4fee\u9970\u4e0e\u672a\u4fee\u9970\u5e95\u7269\u7684\u7ed3\u5408\u4eb2\u548c\u529b</p> </li> <li> <p>\u7a81\u53d8\u5206\u6790</p> </li> <li>\u8bbe\u8ba1\u5173\u952e\u76f8\u4e92\u4f5c\u7528\u754c\u9762\u7684\u7a81\u53d8</li> <li>\u4f7f\u7528\u5b9a\u70b9\u7a81\u53d8\u4ea7\u751f\u7a81\u53d8\u86cb\u767d</li> <li>\u7eaf\u5316\u7a81\u53d8\u86cb\u767d\u5e76\u8bc4\u4f30\u7ed3\u6784\u5b8c\u6574\u6027</li> <li>\u6d4b\u91cf\u5bf9\u7ed3\u5408\u548c\u9176\u6d3b\u6027\u7684\u5f71\u54cd</li> <li>\u4e0e\u7ed3\u6784\u89c2\u5bdf\u76f8\u5173\u8054</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#_4","title":"\u56db\u3001\u7ec6\u80de\u548c\u57fa\u56e0\u7ec4\u7814\u7a76","text":"<ol> <li>\u7ec6\u80de\u7cfb\u5de5\u7a0b</li> <li>\u4ea7\u751fSAGA\u7ec4\u5206\u7a81\u53d8\u7684\u9175\u6bcd\u83cc\u682a</li> <li>\u4f7f\u7528CRISPR-Cas9\u7f16\u8f91HATs/HDACs\u521b\u5efa\u4eba\u7c7b\u7ec6\u80de\u7cfb</li> <li>\u5f00\u53d1\u8868\u8fbe\u7ec4\u86cb\u767d\u7a81\u53d8\u4f53\u7684\u7ec6\u80de\u7cfb(\u5982K\u2192R\u4ee5\u9632\u6b62\u4e59\u9170\u5316)</li> <li> <p>\u901a\u8fc7Western blot\u548c\u8d28\u8c31\u9a8c\u8bc1\u4fee\u9970</p> </li> <li> <p>\u67d3\u8272\u8d28\u514d\u75ab\u6c89\u6dc0(ChIP)</p> </li> <li>\u5728\u6d3b\u7ec6\u80de\u4e2d\u5c06\u86cb\u767d\u8d28\u4e0eDNA\u4ea4\u8054</li> <li>\u5c06\u67d3\u8272\u8d28\u8d85\u58f0\u5904\u7406\u81f3\u9002\u5f53\u7247\u6bb5\u5927\u5c0f</li> <li>\u4f7f\u7528\u4ee5\u4e0b\u6297\u4f53\u8fdb\u884c\u514d\u75ab\u6c89\u6dc0:<ul> <li>\u4fee\u9970\u7684\u7ec4\u86cb\u767d(\u5982H3K27ac)</li> <li>SAGA\u7ec4\u5206</li> <li>\u8f6c\u5f55\u56e0\u5b50</li> </ul> </li> <li>\u7eaf\u5316DNA\u5e76\u901a\u8fc7qPCR\u6216\u6d4b\u5e8f(ChIP-seq)\u5206\u6790</li> <li> <p>\u7ed8\u5236\u4fee\u9970\u548c\u7ed3\u5408\u7684\u5168\u57fa\u56e0\u7ec4\u5206\u5e03\u56fe</p> </li> <li> <p>\u8f6c\u5f55\u7ec4\u5206\u6790</p> </li> <li>\u4ece\u91ce\u751f\u578b\u548c\u7a81\u53d8\u7ec6\u80de\u4e2d\u63d0\u53d6RNA</li> <li>\u5236\u5907RNA-seq\u6587\u5e93</li> <li>\u6d4b\u5e8f\u5e76\u5206\u6790\u5dee\u5f02\u57fa\u56e0\u8868\u8fbe</li> <li> <p>\u4e0eChIP-seq\u6570\u636e\u76f8\u5173\u8054\uff0c\u94fe\u63a5\u7ec4\u86cb\u767d\u4fee\u9970\u4e0e\u57fa\u56e0\u8c03\u63a7</p> </li> <li> <p>HDAC\u6291\u5236\u5242\u7814\u7a76</p> </li> <li>\u7528\u9009\u62e9\u6027HDAC\u6291\u5236\u5242\u5904\u7406\u7ec6\u80de</li> <li>\u76d1\u6d4b\u7ec4\u86cb\u767d\u4fee\u9970\u6a21\u5f0f\u7684\u53d8\u5316</li> <li>\u5206\u6790\u5bf9\u8f6c\u5f55\u56e0\u5b50\u7ed3\u5408\u7684\u5f71\u54cd</li> <li>\u8bc4\u4f30\u5bf9\u57fa\u56e0\u8868\u8fbe\u7684\u5f71\u54cd</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#_5","title":"\u4e94\u3001\u6570\u636e\u6574\u5408\u4e0e\u5206\u6790","text":"<ol> <li>\u7ed3\u6784\u5206\u6790\u548c\u53ef\u89c6\u5316</li> <li>\u4f7f\u7528PyMOL\u6216Chimera\u751f\u6210\u5206\u5b50\u6a21\u578b</li> <li>\u521b\u5efa\u663e\u793a\u5173\u952e\u76f8\u4e92\u4f5c\u7528\u754c\u9762\u7684\u7535\u5b50\u5bc6\u5ea6\u56fe</li> <li>\u8bc6\u522b\u53c2\u4e0e\u5e95\u7269\u8bc6\u522b\u7684\u5173\u952e\u6b8b\u57fa</li> <li> <p>\u5206\u6790\u5e95\u7269\u7ed3\u5408\u65f6\u7684\u6784\u8c61\u53d8\u5316</p> </li> <li> <p>\u8ba1\u7b97\u5206\u6790</p> </li> <li>\u8fdb\u884c\u5206\u5b50\u52a8\u529b\u5b66\u6a21\u62df</li> <li>\u8ba1\u7b97\u9759\u7535\u8868\u9762\u7535\u4f4d</li> <li>\u6a21\u62df\u7ed3\u5408\u76f8\u4e92\u4f5c\u7528\u7684\u80fd\u91cf\u5b66</li> <li>\u9884\u6d4b\u7a81\u53d8\u6216\u6291\u5236\u5242\u7684\u6548\u679c</li> <li> <p>\u8fdb\u884c\u5206\u5b50\u5bf9\u63a5\u7814\u7a76\u8bc4\u4f30\u5c0f\u5206\u5b50\u7ed3\u5408\u4f4d\u70b9</p> </li> <li> <p>\u7edf\u8ba1\u5206\u6790</p> </li> <li>\u5bf9\u751f\u5316\u6570\u636e\u5e94\u7528\u9002\u5f53\u7684\u7edf\u8ba1\u68c0\u9a8c</li> <li>\u8ba1\u7b97ChIP-seq\u548cRNA-seq\u7ed3\u679c\u7684\u663e\u8457\u6027</li> <li>\u8fdb\u884c\u7ed3\u6784\u7279\u5f81\u4e0e\u529f\u80fd\u7ed3\u679c\u4e4b\u95f4\u7684\u76f8\u5173\u6027\u5206\u6790</li> <li>\u9a8c\u8bc1\u751f\u7269\u5b66\u91cd\u590d\u95f4\u7684\u53ef\u91cd\u590d\u6027</li> <li> <p>\u5e94\u7528\u591a\u53d8\u91cf\u5206\u6790\u8bc6\u522b\u5173\u952e\u8c03\u63a7\u56e0\u7d20</p> </li> <li> <p>\u6570\u636e\u5c55\u793a\u548c\u89e3\u91ca</p> </li> <li>\u521b\u5efa\u663e\u793a\u5173\u952e\u754c\u9762\u7684\u7ed3\u6784\u56fe</li> <li>\u751f\u6210\u6bd4\u8f83\u9176\u6d3b\u6027\u7684\u56fe\u8868</li> <li>\u5f00\u53d1ChIP-seq\u6570\u636e\u7684\u57fa\u56e0\u7ec4\u6d4f\u89c8\u5668\u8f68\u9053</li> <li>\u5c06\u53d1\u73b0\u6574\u5408\u5230\u8f6c\u5f55\u8c03\u63a7\u7684\u673a\u5236\u6a21\u578b\u4e2d</li> <li>\u5236\u4f5c\u793a\u610f\u56fe\u5c55\u793a\u4fee\u9970\u5982\u4f55\u5f71\u54cd\u67d3\u8272\u8d28\u7ed3\u6784</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#_6","title":"\u516d\u3001\u529f\u80fd\u9a8c\u8bc1\u5b9e\u9a8c","text":"<ol> <li>\u4f53\u5916\u8f6c\u5f55\u7cfb\u7edf</li> <li>\u6784\u5efa\u542b\u6709\u6a21\u578b\u542f\u52a8\u5b50\u7684DNA\u6a21\u677f</li> <li>\u51c6\u5907\u6838\u63d0\u53d6\u7269\u6216\u91cd\u7ec4\u8f6c\u5f55\u56e0\u5b50</li> <li>\u5728\u6709/\u65e0\u4fee\u9970\u6838\u5c0f\u4f53\u5b58\u5728\u4e0b\u8fdb\u884c\u4f53\u5916\u8f6c\u5f55</li> <li>\u901a\u8fc7\u5f15\u7269\u5ef6\u4f38\u6216RNA\u6d4b\u5e8f\u5206\u6790\u8f6c\u5f55\u4ea7\u7269</li> <li> <p>\u8bc4\u4f30SAGA\u590d\u5408\u7269\u548c\u4fee\u9970\u5bf9\u8f6c\u5f55\u8d77\u59cb\u548c\u5ef6\u4f38\u7684\u5f71\u54cd</p> </li> <li> <p>\u86cb\u767d\u8d28-\u86cb\u767d\u8d28\u76f8\u4e92\u4f5c\u7528\u9a8c\u8bc1</p> </li> <li>\u8fdb\u884c\u514d\u75ab\u5171\u6c89\u6dc0\u5b9e\u9a8c\u9a8c\u8bc1\u590d\u5408\u7269\u7ec4\u5206\u76f8\u4e92\u4f5c\u7528</li> <li>\u4f7f\u7528\u53cc\u6742\u4ea4\u6216BiFC\u7cfb\u7edf\u5728\u7ec6\u80de\u5185\u9a8c\u8bc1\u76f8\u4e92\u4f5c\u7528</li> <li>\u5e94\u7528FRET\u6216BRET\u6d4b\u91cf\u6d3b\u7ec6\u80de\u4e2d\u7684\u52a8\u6001\u76f8\u4e92\u4f5c\u7528</li> <li> <p>\u901a\u8fc7\u4f53\u5916\u62c9\u4e0b\u5b9e\u9a8c\u786e\u8ba4\u76f4\u63a5\u7ed3\u5408</p> </li> <li> <p>\u67d3\u8272\u8d28\u52a8\u529b\u5b66\u7814\u7a76</p> </li> <li>\u4f7f\u7528\u8367\u5149\u6062\u590d\u540e\u6f02\u767d(FRAP)\u7814\u7a76\u4fee\u9970\u5bf9\u86cb\u767d\u8d28-\u67d3\u8272\u8d28\u7ed3\u5408\u52a8\u529b\u5b66\u7684\u5f71\u54cd</li> <li>\u5e94\u7528\u5355\u5206\u5b50\u8ddf\u8e2a\u6280\u672f\u89c2\u5bdf\u8f6c\u5f55\u56e0\u5b50\u4e0e\u4fee\u9970\u67d3\u8272\u8d28\u7684\u76f8\u4e92\u4f5c\u7528</li> <li>\u8fdb\u884c\u5fae\u6838\u9178\u9176\u6d88\u5316\u5b9e\u9a8c\u8bc4\u4f30\u67d3\u8272\u8d28\u53ef\u53ca\u6027\u7684\u53d8\u5316</li> <li> <p>\u4f7f\u7528Hi-C\u6216\u5faeC\u6280\u672f\u7814\u7a76\u9ad8\u7ea7\u67d3\u8272\u8d28\u7ed3\u6784\u6539\u53d8</p> </li> <li> <p>\u836f\u7269\u5e72\u9884\u7814\u7a76</p> </li> <li>\u4f7f\u7528\u7279\u5f02\u6027HAT\u6216HDAC\u6291\u5236\u5242\u5904\u7406\u7ec6\u80de</li> <li>\u76d1\u6d4b\u7ec4\u86cb\u767d\u4fee\u9970\u6c34\u5e73\u548c\u5206\u5e03\u7684\u53d8\u5316</li> <li>\u5206\u6790\u57fa\u56e0\u8868\u8fbe\u6539\u53d8</li> <li>\u5c06\u7ed3\u6784\u89c1\u89e3\u5e94\u7528\u4e8e\u836f\u7269\u8bbe\u8ba1\u548c\u4f18\u5316</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#_7","title":"\u4e03\u3001\u75be\u75c5\u76f8\u5173\u7814\u7a76","text":"<ol> <li>\u764c\u75c7\u6a21\u578b\u7814\u7a76</li> <li>\u5206\u6790\u764c\u75c7\u7ec6\u80de\u7cfb\u4e2dSAGA\u590d\u5408\u7269\u7ec4\u5206\u7684\u7a81\u53d8</li> <li>\u6bd4\u8f83\u6b63\u5e38\u548c\u764c\u7ec4\u7ec7\u4e2d\u7684\u7ec4\u86cb\u767d\u4fee\u9970\u6a21\u5f0f</li> <li>\u7814\u7a76\u8868\u89c2\u9057\u4f20\u8c03\u63a7\u7d0a\u4e71\u5bf9\u80bf\u7624\u53d1\u751f\u7684\u5f71\u54cd</li> <li> <p>\u8bc4\u4f30\u9776\u5411SAGA\u590d\u5408\u7269\u6216HDACs\u7684\u6cbb\u7597\u7b56\u7565</p> </li> <li> <p>\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u6a21\u578b</p> </li> <li>\u7814\u7a76\u795e\u7ecf\u5143\u4e2d\u7684\u7ec4\u86cb\u767d\u4fee\u9970\u52a8\u6001\u53d8\u5316</li> <li>\u5206\u6790\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u6a21\u578b\u4e2d\u7684\u8868\u89c2\u9057\u4f20\u53d8\u5316</li> <li>\u8bc4\u4f30HDAC\u6291\u5236\u5242\u4f5c\u4e3a\u6cbb\u7597\u795e\u7ecf\u9000\u884c\u6027\u75be\u75c5\u7684\u6f5c\u529b</li> <li> <p>\u5c06\u7ed3\u6784\u89c1\u89e3\u4e0e\u75be\u75c5\u8868\u578b\u76f8\u5173\u8054</p> </li> <li> <p>\u53d1\u80b2\u548c\u7ec6\u80de\u5206\u5316\u7814\u7a76</p> </li> <li>\u7814\u7a76\u7ec6\u80de\u5206\u5316\u8fc7\u7a0b\u4e2d\u7ec4\u86cb\u767d\u4fee\u9970\u7684\u53d8\u5316</li> <li>\u5206\u6790SAGA\u590d\u5408\u7269\u5728\u53d1\u80b2\u4e2d\u7684\u65f6\u7a7a\u8868\u8fbe\u6a21\u5f0f</li> <li>\u8bc4\u4f30\u8868\u89c2\u9057\u4f20\u8c03\u63a7\u5728\u7ec6\u80de\u547d\u8fd0\u51b3\u5b9a\u4e2d\u7684\u4f5c\u7528</li> <li>\u6784\u5efa\u53d1\u80b2\u8fc7\u7a0b\u4e2d\u7684\u8868\u89c2\u9057\u4f20\u666f\u89c2\u56fe\u8c31</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#_8","title":"\u516b\u3001\u5148\u8fdb\u6280\u672f\u5e94\u7528","text":"<ol> <li>\u51b7\u51bb\u7535\u5b50\u65ad\u5c42\u626b\u63cf(Cryo-ET)</li> <li>\u5728\u7ec6\u80de\u5185\u539f\u4f4d\u7814\u7a76\u67d3\u8272\u8d28\u7ed3\u6784\u548c\u4fee\u9970</li> <li>\u83b7\u53d6\u5b8c\u6574\u6838\u5c0f\u4f53\u9635\u5217\u7684\u4e09\u7ef4\u7ed3\u6784</li> <li>\u5206\u6790\u67d3\u8272\u8d28\u7ea4\u7ef4\u4e2d\u7684\u4fee\u9970\u5206\u5e03</li> <li> <p>\u5c06\u4f53\u5916\u7ed3\u6784\u4e0e\u7ec6\u80de\u5185\u73af\u5883\u76f8\u5173\u8054</p> </li> <li> <p>\u65f6\u95f4\u5206\u8fa8\u7ed3\u6784\u7814\u7a76</p> </li> <li>\u4f7f\u7528\u65f6\u95f4\u5206\u8fa8\u51b7\u51bb\u7535\u955c\u6355\u6349\u52a8\u6001\u7ed3\u6784\u53d8\u5316</li> <li>\u7814\u7a76\u9176\u50ac\u5316\u8fc7\u7a0b\u4e2d\u7684\u6784\u8c61\u53d8\u5316</li> <li>\u5206\u6790\u4fee\u9970\u6dfb\u52a0\u6216\u79fb\u9664\u7684\u52a8\u529b\u5b66</li> <li> <p>\u6784\u5efa\u7ed3\u6784\u8f6c\u53d8\u7684\u80fd\u91cf\u666f\u89c2</p> </li> <li> <p>\u6574\u5408\u591a\u7ec4\u5b66\u6570\u636e</p> </li> <li>\u5c06\u7ed3\u6784\u6570\u636e\u4e0e\u57fa\u56e0\u7ec4\u3001\u8f6c\u5f55\u7ec4\u548c\u86cb\u767d\u8d28\u7ec4\u6570\u636e\u6574\u5408</li> <li>\u5f00\u53d1\u8ba1\u7b97\u6a21\u578b\u9884\u6d4b\u4fee\u9970\u5bf9\u57fa\u56e0\u8868\u8fbe\u7684\u5f71\u54cd</li> <li>\u6784\u5efa\u67d3\u8272\u8d28\u4fee\u9970\u548c\u8f6c\u5f55\u8c03\u63a7\u7684\u7cfb\u7edf\u751f\u7269\u5b66\u6a21\u578b</li> <li>\u5e94\u7528\u673a\u5668\u5b66\u4e60\u65b9\u6cd5\u8bc6\u522b\u7ed3\u6784-\u529f\u80fd\u5173\u7cfb\u7684\u6a21\u5f0f</li> </ol> <p>\u8fd9\u4e00\u7efc\u5408\u6027\u5b9e\u9a8c\u5de5\u4f5c\u6d41\u7a0b\u4f7f\u7814\u7a76\u4eba\u5458\u80fd\u591f\u6df1\u5165\u4e86\u89e3\u7ec4\u86cb\u767d\u4fee\u9970\u7684\u7ed3\u6784\u57fa\u7840\u53ca\u5176\u5728\u8f6c\u5f55\u8c03\u63a7\u4e2d\u7684\u4f5c\u7528\uff0c\u4e3a\u57fa\u7840\u8868\u89c2\u9057\u4f20\u673a\u5236\u7814\u7a76\u548c\u6f5c\u5728\u6cbb\u7597\u9776\u70b9\u5f00\u53d1\u63d0\u4f9b\u89c1\u89e3\u3002\u901a\u8fc7\u7ed3\u5408\u5148\u8fdb\u7684\u7ed3\u6784\u751f\u7269\u5b66\u6280\u672f\u4e0e\u529f\u80fd\u57fa\u56e0\u7ec4\u5b66\u65b9\u6cd5\uff0c\u7814\u7a76\u4eba\u5458\u53ef\u4ee5\u63ed\u793a\u67d3\u8272\u8d28\u4fee\u9970\u5982\u4f55\u7cbe\u786e\u8c03\u63a7\u57fa\u56e0\u8868\u8fbe\uff0c\u4ee5\u53ca\u8fd9\u4e9b\u8fc7\u7a0b\u7d0a\u4e71\u5982\u4f55\u5bfc\u81f4\u75be\u75c5\u53d1\u751f\u3002</p> <p>Structural Biology of Histone Modifications and Chromatin Regulation: Experimental Workflow</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#i-sample-preparation-and-protein-purification","title":"I. Sample Preparation and Protein Purification","text":"<ol> <li>Recombinant Protein Expression</li> <li>Clone genes encoding SAGA complex components (e.g., Gcn5, Ada2, Ada3) into expression vectors</li> <li>Transform into E. coli expression strains (BL21(DE3))</li> <li>Induce protein expression with IPTG</li> <li>Harvest cells and prepare lysates under native conditions</li> <li>Purify proteins using affinity chromatography (His-tag, GST-tag)</li> <li> <p>Further purify via ion exchange and size exclusion chromatography</p> </li> <li> <p>Nucleosome Assembly</p> </li> <li>Express and purify recombinant histone proteins (H2A, H2B, H3, H4)</li> <li>Refold histone octamers from purified histones</li> <li>Prepare DNA fragments containing nucleosome positioning sequences</li> <li>Reconstitute nucleosomes by salt gradient dialysis</li> <li> <p>Verify assembly by native PAGE</p> </li> <li> <p>Introduction of Histone Modifications</p> </li> <li>Chemical synthesis of modified histones</li> <li>Enzymatic modification using purified HATs/HDACs</li> <li>Native chemical ligation to incorporate modified histone tails</li> <li> <p>Verify modifications by mass spectrometry and Western blotting</p> </li> <li> <p>Complex Formation</p> </li> <li>Combine purified SAGA complex with modified nucleosomes</li> <li>Optimize buffer conditions for stable complex formation</li> <li>Verify complex formation by gel filtration chromatography</li> <li>Assess stoichiometry by analytical ultracentrifugation</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#ii-structural-analysis","title":"II. Structural Analysis","text":"<ol> <li>Cryo-EM Sample Preparation and Data Collection</li> <li>Apply 3-4\u03bcl of purified complex to glow-discharged EM grids</li> <li>Blot excess liquid and plunge-freeze in liquid ethane</li> <li>Screen grids for ice quality and particle distribution</li> <li>Collect high-resolution data on microscope (e.g., Titan Krios)</li> <li>Record movies with direct electron detector</li> <li> <p>Process data using motion correction software</p> </li> <li> <p>Cryo-EM Data Processing</p> </li> <li>Perform CTF estimation and correction</li> <li>Select particles using automated and manual picking</li> <li>Extract particles and perform 2D classification</li> <li>Generate initial 3D model</li> <li>Refine 3D structure through iterative classification</li> <li>Apply post-processing for resolution enhancement</li> <li> <p>Validate resolution using Fourier shell correlation</p> </li> <li> <p>X-ray Crystallography (for Specific Domains)</p> </li> <li>Screen crystallization conditions for individual domains</li> <li>Optimize crystal growth parameters</li> <li>Harvest crystals and prepare for diffraction</li> <li>Collect diffraction data at synchrotron facility</li> <li>Process diffraction data and perform phase determination</li> <li>Build and refine atomic models</li> <li> <p>Validate model quality</p> </li> <li> <p>Model Building and Refinement</p> </li> <li>Fit atomic models into cryo-EM density maps</li> <li>Refine models against experimental data</li> <li>Validate model geometry and fit to density</li> <li>Analyze protein-protein and protein-nucleosome interfaces</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#iii-biochemical-and-functional-characterization","title":"III. Biochemical and Functional Characterization","text":"<ol> <li>In Vitro HAT/HDAC Activity Assays</li> <li>Prepare substrates (nucleosomes with unmodified histones)</li> <li>Incubate with purified SAGA complex or HDACs</li> <li>Detect acetylation/deacetylation by:<ul> <li>Radiolabeled acetyl-CoA incorporation</li> <li>Western blotting with modification-specific antibodies</li> <li>Mass spectrometry analysis</li> </ul> </li> <li> <p>Determine enzyme kinetics (Km, Vmax)</p> </li> <li> <p>Binding Affinity Measurements</p> </li> <li>Isothermal titration calorimetry (ITC) to measure thermodynamics</li> <li>Surface plasmon resonance (SPR) to measure binding kinetics</li> <li>Fluorescence anisotropy for smaller domain interactions</li> <li> <p>Compare binding affinities for modified vs. unmodified substrates</p> </li> <li> <p>Mutational Analysis</p> </li> <li>Design mutations at key interaction interfaces</li> <li>Generate mutant proteins using site-directed mutagenesis</li> <li>Purify mutant proteins and assess structural integrity</li> <li>Measure effects on binding and enzymatic activity</li> <li>Correlate with structural observations</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#iv-cellular-and-genomic-studies","title":"IV. Cellular and Genomic Studies","text":"<ol> <li>Cell Line Engineering</li> <li>Generate yeast strains with mutations in SAGA components</li> <li>Create human cell lines with CRISPR-Cas9 edited HATs/HDACs</li> <li>Develop cell lines expressing histone mutants (e.g., K\u2192R to prevent acetylation)</li> <li> <p>Verify modifications by Western blotting and mass spectrometry</p> </li> <li> <p>Chromatin Immunoprecipitation (ChIP)</p> </li> <li>Crosslink proteins to DNA in living cells</li> <li>Sonicate chromatin to appropriate fragment size</li> <li>Immunoprecipitate with antibodies against:<ul> <li>Modified histones (e.g., H3K27ac)</li> <li>SAGA components</li> <li>Transcription factors</li> </ul> </li> <li>Purify and analyze DNA by qPCR or sequencing (ChIP-seq)</li> <li> <p>Map genome-wide distribution of modifications and binding</p> </li> <li> <p>Transcriptome Analysis</p> </li> <li>Extract RNA from wild-type and mutant cells</li> <li>Prepare RNA-seq libraries</li> <li>Sequence and analyze differential gene expression</li> <li> <p>Correlate with ChIP-seq data to link histone modifications to gene regulation</p> </li> <li> <p>HDAC Inhibitor Studies</p> </li> <li>Treat cells with selective HDAC inhibitors</li> <li>Monitor changes in histone modification patterns</li> <li>Analyze effects on transcription factor binding</li> <li>Assess impact on gene expression</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#v-data-integration-and-analysis","title":"V. Data Integration and Analysis","text":"<ol> <li>Structural Analysis and Visualization</li> <li>Generate molecular models using PyMOL or Chimera</li> <li>Create electron density maps showing key interaction interfaces</li> <li>Identify critical residues involved in substrate recognition</li> <li> <p>Analyze conformational changes upon substrate binding</p> </li> <li> <p>Computational Analysis</p> </li> <li>Perform molecular dynamics simulations</li> <li>Calculate electrostatic surface potentials</li> <li>Model energetics of binding interactions</li> <li> <p>Predict effects of mutations or inhibitors</p> </li> <li> <p>Statistical Analysis</p> </li> <li>Apply appropriate statistical tests for biochemical data</li> <li>Calculate significance of ChIP-seq and RNA-seq results</li> <li>Perform correlation analysis between structural features and functional outcomes</li> <li> <p>Validate reproducibility across biological replicates</p> </li> <li> <p>Data Presentation and Interpretation</p> </li> <li>Create structural figures showing key interfaces</li> <li>Generate graphs comparing enzymatic activities</li> <li>Develop genome browser tracks for ChIP-seq data</li> <li>Integrate findings into mechanistic models of transcriptional regulation</li> </ol> <p>This comprehensive experimental workflow enables researchers to understand the structural basis of histone modifications and their role in transcriptional regulation, providing insights into fundamental epigenetic mechanisms and potential therapeutic targets.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#1-experimental-purpose","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how\u00a0histone modifications\u00a0(e.g., acetylation, methylation) and\u00a0chromatin structure\u00a0regulate transcription. Specifically, it investigates the structural mechanisms by which histone modifications influence the binding of transcription machinery and the regulation of gene expression.</li> <li>Experimental Design: The study uses\u00a0structural biology techniques\u00a0(e.g., cryo-EM, X-ray crystallography) to determine the molecular structures of key epigenetic regulators, such as\u00a0histone acetyltransferases (HATs)\u00a0and\u00a0histone deacetylases (HDACs), and their interactions with nucleosomes and transcription factors.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#2-model-system","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0yeast\u00a0and\u00a0human cells, as these systems are well-characterized and provide a direct link to eukaryotic transcription regulation. The study focuses on the\u00a0SAGA complex, a well-known HAT complex involved in transcription regulation.</li> <li>Why This System?: Yeast and human cells are appropriate for this study because they allow for the manipulation of specific histone modifications and chromatin structures. The SAGA complex is relevant because it plays a key role in regulating transcription through histone acetylation.</li> <li>Alternative Model Systems: Other model systems like\u00a0bacteria\u00a0or\u00a0plants\u00a0could be used, but they lack the complexity of eukaryotic chromatin and histone modifications.</li> <li>Ethical Considerations: Using human cell lines requires ethical approval, especially when dealing with patient-derived samples. The study likely adheres to ethical guidelines for genomic research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#3-measurement-approach","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>Cryo-electron microscopy (cryo-EM): To determine the structures of epigenetic regulators (e.g., SAGA complex) and their interactions with nucleosomes.</li> <li>X-ray crystallography: To obtain high-resolution structures of specific histone modifications and their interactions with transcription factors.</li> <li>Biochemical assays: To study the functional roles of histone modifications in transcription regulation.</li> <li>Chromatin immunoprecipitation (ChIP): To study the binding of transcription factors to histone-modified chromatin.</li> </ul> </li> <li>Why These Methods?: Cryo-EM and X-ray crystallography were chosen because they allow for the visualization of molecular structures at atomic resolution, which is crucial for understanding the mechanisms of epigenetic regulation. Biochemical assays and ChIP were used to study the functional roles of histone modifications in transcription.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=3 or more) to ensure the robustness of the structural data.</li> <li>Potential Biases: Biases could arise from sample preparation or data interpretation. These are minimized by using standardized protocols and cross-validation with biochemical assays.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#4-group-setting","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Wild-type cells\u00a0vs.\u00a0cells with specific histone modifications: To study the effects of histone modifications on transcription.</li> <li>Cells with intact SAGA complex\u00a0vs.\u00a0cells with SAGA complex mutations: To study the role of the SAGA complex in transcription regulation.</li> <li>Cells treated with HDAC inhibitors\u00a0vs.\u00a0untreated cells: To study the effects of histone deacetylation on transcription.</li> </ul> </li> <li>Negative Controls: Cells without specific histone modifications or with intact SAGA complex serve as negative controls to study the effects of histone modifications and SAGA complex mutations.</li> <li>Biological Replicates: Multiple samples are used in each group (e.g., n=3 or more) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of histone modifications or HDAC inhibitors affect transcription.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#5-data-analysis-presentation","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw structural data from cryo-EM and X-ray crystallography are processed to generate 3D models of the molecular structures. Biochemical and ChIP data are analyzed to study the functional roles of histone modifications in transcription.</li> <li>Statistical Tests: The study uses statistical validation methods (e.g., cross-validation, resolution assessment) to ensure the accuracy of the structural models. Differential binding analysis is performed to identify key transcription factors regulated by histone modifications.</li> <li>Data Presentation: Results are presented using\u00a03D structural models,\u00a0graphs, and\u00a0tables, which are clear and free of misleading scaling. For example, the study uses\u00a0electron density maps\u00a0to show the structures of histone modifications and\u00a0bar graphs\u00a0to compare transcription factor binding.</li> <li>Confirmation: The structural findings are confirmed using\u00a0biochemical assays\u00a0and\u00a0functional studies, which validate the proposed mechanisms of epigenetic regulation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W3.2%20Structural%20study%20of%20epigenetic%20regulation%20in%20transcription/#general-observations","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how\u00a0histone modifications\u00a0and\u00a0chromatin structure\u00a0regulate transcription through the\u00a0SAGA complex\u00a0and other epigenetic regulators.</li> <li>The findings highlight the importance of\u00a0histone acetylation\u00a0and\u00a0deacetylation\u00a0in regulating gene expression and suggest potential therapeutic targets for diseases linked to epigenetic dysregulation.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0epigenetic regulation\u00a0and developing therapies for\u00a0cancer\u00a0and other diseases.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/","title":"S2.W5 GFP reporter model","text":"<p>GFP Reporter Mouse Models: Comprehensive Overview</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#fundamental-principles-of-gfp-reporter-systems","title":"Fundamental Principles of GFP Reporter Systems","text":"<p>GFP (Green Fluorescent Protein) reporter mouse models are genetically engineered mice that express GFP under the control of specific promoters, allowing visualization of gene expression patterns, cell lineages, or biological processes. These models have revolutionized in vivo imaging and cellular tracking.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#types-of-gfp-reporter-strategies","title":"Types of GFP Reporter Strategies","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#1-promoter-driven-reporters","title":"1. Promoter-Driven Reporters","text":"<p>Mechanism: GFP expression is directly controlled by a target gene promoter - Direct Promoter Replacement: GFP replaces the coding sequence of the target gene - Promoter-Only Transgene: GFP is expressed from a transgene containing only the promoter - Knock-in Approach: GFP is inserted at the endogenous locus, preserving regulatory elements</p> <p>Applications: - Monitoring transcriptional activity of specific genes - Identifying cells actively expressing the gene of interest - Studying developmental or stimulus-dependent gene activation</p> <p>Examples: - Sox2-GFP (neural stem cells) - CD11c-GFP (dendritic cells) - GFAP-GFP (astrocytes)</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#2-bicistronic-reporter-systems","title":"2. Bicistronic Reporter Systems","text":"<p>Mechanism: Both the gene of interest and GFP are expressed from a single transcript - IRES (Internal Ribosome Entry Site): Allows translation of two proteins from one mRNA - 2A Peptide Sequences: Self-cleaving peptides creating separate proteins - Fusion Proteins: GFP directly fused to protein of interest (if function is preserved)</p> <p>Applications: - Studying protein expression while maintaining gene function - Correlating fluorescence intensity with protein levels - Tracking cells expressing functional protein</p> <p>Examples: - Foxp3-IRES-GFP (regulatory T cells) - Lgr5-IRES-GFP-CreERT2 (intestinal stem cells) - Cx3cr1-GFP (microglia/macrophages)</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#3-cre-dependent-reporter-systems","title":"3. Cre-Dependent Reporter Systems","text":"<p>Mechanism: GFP expression requires Cre recombinase activity - Floxed Stop Cassette: Removal of stop signal by Cre activates GFP - Recombination-Activated Gene Expression (RAGE): Cre rearranges sequence to enable expression</p> <p>Applications: - Lineage tracing (permanent labeling of cells and descendants) - Conditional gene expression studies - Cell-specific or temporally controlled labeling</p> <p>Examples: - Rosa26-loxP-STOP-loxP-GFP crossed with tissue-specific Cre lines - Ai6 reporter (ZsGreen expression after Cre-mediated recombination)</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#4-biological-process-reporters","title":"4. Biological Process Reporters","text":"<p>Mechanism: GFP expression reports on cellular processes or states - Cell Cycle Reporters: Fluorescence during specific cell cycle phases - Signaling Pathway Reporters: GFP expression upon pathway activation - Cellular Stress Reporters: Fluorescence indicating stress responses</p> <p>Applications: - Monitoring dynamic cellular processes in real-time - Studying pathway activation in disease models - Screening for compounds affecting specific processes</p> <p>Examples: - FUCCI system (fluorescent ubiquitination-based cell cycle indicator) - NF\u03baB-GFP (inflammation/immune signaling) - Hypoxia response element-driven GFP</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#engineering-techniques-for-gfp-reporter-mice","title":"Engineering Techniques for GFP Reporter Mice","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#1-transgenic-approaches","title":"1. Transgenic Approaches","text":"<p>Random Integration: - Microinjection of DNA constructs into pronuclei - Integration occurs at random genomic locations - Multiple copies may integrate as concatemers</p> <p>Advantages/Limitations: - Relatively simple and fast - Position effects may alter expression - Copy number variation between lines</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#2-targeted-knock-in-approaches","title":"2. Targeted Knock-in Approaches","text":"<p>Homologous Recombination in ES Cells: - Traditional method using embryonic stem cells - Precise integration at target locus - Selection markers for identifying correct clones</p> <p>CRISPR/Cas9-Mediated Integration: - Direct zygote manipulation - Faster generation time - Reduced mosaicism with optimized protocols</p> <p>Site-Specific Integration Systems: - PhiC31 integrase - Flp/FRT recombination - TARGATT\u2122 technology for predetermined loci</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#3-bac-transgenesis","title":"3. BAC Transgenesis","text":"<p>Bacterial Artificial Chromosome Modification: - Recombineering of large genomic fragments (150-200kb) - Preserves most regulatory elements - More consistent expression patterns</p> <p>Applications: - Complex gene regulation studies - Genes with distant enhancers - Faithful recapitulation of expression patterns</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#advanced-gfp-variants-and-modifications","title":"Advanced GFP Variants and Modifications","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#1-spectral-variants","title":"1. Spectral Variants","text":"<p>Enhanced GFP (EGFP): - Brighter fluorescence - Improved folding at 37\u00b0C - Codon optimization for mammalian expression</p> <p>Spectral Derivatives: - BFP, CFP, YFP for multicolor imaging - Far-red variants for deeper tissue penetration - Spectrally distinct options for multiplexing</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#2-photomodulatable-fluorescent-proteins","title":"2. Photomodulatable Fluorescent Proteins","text":"<p>Photoactivatable GFP: - Activated by specific wavelength illumination - Enables pulse-chase experiments in vivo - Useful for cellular dynamics studies</p> <p>Photoconvertible Proteins: - Kaede, Dendra2, mEos - Change emission spectrum after illumination - Tracking specific cell populations over time</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#3-destabilized-gfp-variants","title":"3. Destabilized GFP Variants","text":"<p>Mechanism: Addition of degradation sequences - Shorter half-life for dynamic expression studies - More accurate reflection of transcriptional changes - Useful for studying transient gene expression</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#analytical-techniques-for-gfp-reporter-mice","title":"Analytical Techniques for GFP Reporter Mice","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#1-in-vivo-imaging","title":"1. In Vivo Imaging","text":"<p>Intravital Microscopy: - Surgical exposure of tissues - Real-time imaging in anesthetized animals - Cell tracking in native environments</p> <p>Whole-Body Imaging: - IVIS systems for macroscopic fluorescence - Limited by depth penetration - Useful for superficial tissues or strong signals</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#2-ex-vivo-analysis","title":"2. Ex Vivo Analysis","text":"<p>Flow Cytometry and Cell Sorting: - Quantitative analysis of GFP+ cell populations - Multiparameter phenotyping - Isolation of live GFP+ cells for further studies</p> <p>Tissue Section Analysis: - Confocal microscopy of fixed tissues - Co-localization with other markers - Spatial relationships in tissue context</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#3-single-cell-techniques","title":"3. Single-Cell Techniques","text":"<p>Single-Cell RNA Sequencing: - Transcriptome analysis of sorted GFP+ cells - Correlation of GFP expression with gene programs - Discovery of heterogeneity within GFP+ populations</p> <p>Live Cell Imaging: - Ex vivo culture of isolated GFP+ cells - Time-lapse microscopy - Cell behavior and division kinetics</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#applications-in-biomedical-research","title":"Applications in Biomedical Research","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#1-developmental-biology","title":"1. Developmental Biology","text":"<ul> <li>Lineage tracing during embryogenesis</li> <li>Organ formation and morphogenesis</li> <li>Stem cell dynamics in developing tissues</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#2-immunology","title":"2. Immunology","text":"<ul> <li>Immune cell trafficking and localization</li> <li>Response to infection or inflammation</li> <li>Immune cell development and differentiation</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#3-neuroscience","title":"3. Neuroscience","text":"<ul> <li>Neural circuit mapping</li> <li>Activity-dependent gene expression</li> <li>Neurogenesis and neural development</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#4-cancer-research","title":"4. Cancer Research","text":"<ul> <li>Tumor cell tracking and metastasis</li> <li>Cancer stem cell identification</li> <li>Drug response monitoring</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#5-regenerative-medicine","title":"5. Regenerative Medicine","text":"<ul> <li>Stem cell engraftment and differentiation</li> <li>Tissue repair processes</li> <li>Cell-based therapy development</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#limitations-and-considerations","title":"Limitations and Considerations","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#1-technical-limitations","title":"1. Technical Limitations","text":"<ul> <li>Autofluorescence in certain tissues</li> <li>Limited depth penetration of GFP signal</li> <li>Potential toxicity with very high expression</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#2-biological-considerations","title":"2. Biological Considerations","text":"<ul> <li>Potential interference with normal gene function</li> <li>Delayed fluorophore maturation (time lag)</li> <li>Differences between mRNA and protein dynamics</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#3-design-considerations","title":"3. Design Considerations","text":"<ul> <li>Promoter selection and regulatory elements</li> <li>GFP variant selection for specific applications</li> <li>Integration site effects on expression</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2.W5%20GFP%20reporter%20model/#future-directions","title":"Future Directions","text":"<ul> <li>Combining with other genetic tools (optogenetics, CRISPR)</li> <li>Integration with spatial transcriptomics</li> <li>Development of infrared fluorescent proteins for deeper imaging</li> <li>Computational approaches for automated tracking and analysis</li> </ul> <p>GFP reporter mouse models continue to evolve as essential tools in biomedical research, providing unprecedented insights into gene expression, cellular dynamics, and biological processes in the living organism.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/","title":"S2W2.2.Seminar Precision medicine with computational biology","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#1-resa-de-novo-identification-of-expressed-cancer-somatic-mutations","title":"1.\u00a0RESA: De Novo Identification of Expressed Cancer Somatic Mutations","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#experimental-purpose","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to identify somatic mutations in cancer from single-cell RNA sequencing (scRNA-seq) data, which is challenging due to the low abundance of mutations and the complexity of distinguishing them from germline variants and RNA editing events.</li> <li>Experimental Design: The RESA (RNA Editing and Somatic Mutation Annotation) tool is developed to filter out germline variants and RNA editing sites, allowing for the confident identification of somatic mutations. The tool uses joint logistic regression to classify somatic SNVs (single nucleotide variants) based on quality and sequence features.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#model-system","title":"Model System:","text":"<ul> <li>Model System: Human cancer samples are used, as they provide a direct link to human disease and are relevant for precision medicine.</li> <li>Alternative Model Systems: Mouse models or cell lines could be used, but they may not fully capture the complexity of human cancers.</li> <li>Ethical Considerations: Using human cancer samples requires ethical approval, especially when dealing with patient data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#measurement-approach","title":"Measurement Approach:","text":"<ul> <li>Techniques: scRNA-seq is used to measure gene expression and identify somatic mutations. The data are quantitative, allowing for precise identification of low-frequency mutations.</li> <li>Method Choice: RESA was chosen because it can filter out germline variants and RNA editing events, which are common sources of noise in scRNA-seq data.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from sequencing errors or incomplete annotation of RNA editing sites. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#group-setting","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The study compares cancer samples with matched normal samples to identify somatic mutations.</li> <li>Negative Controls: Germline variants and RNA editing sites are used as negative controls to ensure that only somatic mutations are identified.</li> <li>Biological Replicates: Multiple cancer samples are used to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of mutations affect cancer progression.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#data-analysis-presentation","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw scRNA-seq data are processed using RESA to identify somatic mutations. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: Joint logistic regression is used to classify somatic SNVs based on quality and sequence features.</li> <li>Data Presentation: Results are presented using tables and plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using matched normal samples and RNA editing databases, confirming the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#2-magpie-pathogenic-prediction-for-multiple-variant-types","title":"2.\u00a0MAGPIE: Pathogenic Prediction for Multiple Variant Types","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#experimental-purpose_1","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to predict the pathogenicity of multiple types of genetic variants (e.g., frameshift, non-synonymous, splice site) using a machine learning approach.</li> <li>Experimental Design: MAGPIE (Multimodal Analysis Generated Pathogenic Impact Evaluator) uses gradient boosting methods to predict the pathogenicity of variants based on multimodal feature annotations, including functional effects, spatial effects, and conservation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#model-system_1","title":"Model System:","text":"<ul> <li>Model System: Human genomic data are used, as they are directly relevant to human diseases and precision medicine.</li> <li>Alternative Model Systems: Model organisms like mice could be used, but they may not fully capture the complexity of human genetic variation.</li> <li>Ethical Considerations: Using human genomic data requires ethical approval, especially when dealing with patient data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#measurement-approach_1","title":"Measurement Approach:","text":"<ul> <li>Techniques: Variant annotation and machine learning are used to predict pathogenicity. The data are quantitative, allowing for precise predictions.</li> <li>Method Choice: Gradient boosting was chosen because it can handle complex, multimodal data and provide accurate predictions.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from incomplete annotation or imbalanced datasets. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#group-setting_1","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The study compares pathogenic variants with benign variants to train the model.</li> <li>Negative Controls: Benign variants are used as negative controls to ensure that the model can distinguish between pathogenic and non-pathogenic variants.</li> <li>Biological Replicates: Multiple datasets are used to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of variant pathogenicity affect disease outcomes.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#data-analysis-presentation_1","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw variant data are processed using MAGPIE to predict pathogenicity. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: Gradient boosting methods are used to predict pathogenicity based on multimodal feature annotations.</li> <li>Data Presentation: Results are presented using tables and plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using known pathogenic and benign variants, confirming the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#3-sptransformer-tissue-specific-splicing-prediction","title":"3.\u00a0SpTransformer: Tissue-Specific Splicing Prediction","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#experimental-purpose_2","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to predict tissue-specific splicing alterations caused by single nucleotide variants (SNVs) and understand their role in human diseases.</li> <li>Experimental Design: SpTransformer, a Transformer-based deep learning model, is developed to predict splicing alterations in 15 different tissues. The model is trained on RNA-seq data and validated using clinical samples.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#model-system_2","title":"Model System:","text":"<ul> <li>Model System: Human genomic data are used, as they are directly relevant to human diseases and precision medicine.</li> <li>Alternative Model Systems: Model organisms like mice could be used, but they may not fully capture the complexity of human splicing regulation.</li> <li>Ethical Considerations: Using human genomic data requires ethical approval, especially when dealing with patient data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#measurement-approach_2","title":"Measurement Approach:","text":"<ul> <li>Techniques: RNA-seq data are used to measure splicing alterations. The data are quantitative, allowing for precise predictions.</li> <li>Method Choice: Transformers were chosen because they can capture long-range dependencies in sequences, which is crucial for understanding splicing regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from sequencing errors or incomplete annotation of splicing events. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#group-setting_2","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The study compares splicing alterations in different tissues to understand tissue-specific effects.</li> <li>Negative Controls: Non-splicing variants are used as negative controls to ensure that the model can distinguish between splicing and non-splicing events.</li> <li>Biological Replicates: Multiple datasets are used to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of splicing alterations affect tissue function.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#data-analysis-presentation_2","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed using SpTransformer to predict splicing alterations. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses z-scores to define tissue-specific splicing alterations and enrichment analysis to identify disease-related genes.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using clinical samples and RNA-seq data, confirming the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W2.2.Seminar%20Precision%20medicine%20with%20computational%20biology/#general-observations","title":"General Observations:","text":"<ul> <li>The studies leverage computational biology and deep learning to address complex questions in genomics, particularly in the context of cancer, genetic variants, and splicing regulation.</li> <li>The models are trained on large datasets and validated using cross-species data and experimental data, highlighting their robustness and generalizability.</li> <li>The results have significant implications for precision medicine, particularly in the context of cancer diagnosis, genetic variant interpretation, and understanding tissue-specific splicing alterations.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W3%20Antibody%20de%20novo%20design/","title":"S2W3 Antibody de novo design","text":"<ul> <li>Traditional Drug:<ul> <li>High Investment --&gt; Long time consumption --&gt; High risk</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W3%20Antibody%20de%20novo%20design/#antibody","title":"Antibody","text":"<ul> <li>Structure:<ul> <li>Antibodies, also known as immunoglobulins (Igs), are Y-shaped proteins composed of two heavy chains and two light chains, connected by disulfide bonds</li> </ul> </li> <li>Antigen binding<ul> <li>The variable regions (Fv) of the antibody, particularly the six loops called complementarity-determining regions (CDRs), are responsible for binding to specific antigens.</li> </ul> </li> <li>Fab and Fc<ul> <li>Antibodies have two antigen-binding fragments (Fab) and one crystallizable domain (Fc</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W3%20Antibody%20de%20novo%20design/#_1","title":"\u6297\u4f53\u8bbe\u8ba1\u6d41\u7a0b\uff1a\u4ece\u8ba1\u7b97\u8bbe\u8ba1\u5230\u5b9e\u9a8c\u9a8c\u8bc1","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W3%20Antibody%20de%20novo%20design/#_2","title":"\u4e00\u3001\u8ba1\u7b97\u8bbe\u8ba1\u9636\u6bb5","text":"<ol> <li>\u521d\u59cb\u8f93\u5165</li> <li>\u6297\u539f\u7ed3\u6784(\u6676\u4f53\u7ed3\u6784\u6216\u8ba1\u7b97\u9884\u6d4b)</li> <li>\u8868\u4f4d\u8bc6\u522b\u4e0e\u9009\u62e9</li> <li> <p>\u73b0\u6709\u6297\u4f53\u6570\u636e\u5e93\u5206\u6790</p> </li> <li> <p>\u8bbe\u8ba1\u65b9\u6cd5</p> </li> <li>\u4ece\u5934\u8bbe\u8ba1:\u6784\u5efa\u4e3b\u94fe\u2192\u5b8c\u6210\u4fa7\u94fe\u2192\u751f\u6210\u5e8f\u5217</li> <li>\u57fa\u4e8e\u7a81\u53d8\u7684\u4f18\u5316:\u5728\u7ea6\u675f\u641c\u7d22\u7a7a\u95f4\u5185\u7cfb\u7edf\u63a2\u7d22\u7a81\u53d8</li> <li> <p>\u7ed3\u6784\u9884\u6d4b\u5de5\u5177:AlphaFold2, ESM-Fold, AF3, DMFold\u7528\u4e8e\u9a8c\u8bc1/\u9884\u6d4b</p> </li> <li> <p>\u53ef\u5f00\u53d1\u6027\u8bc4\u4f30</p> </li> <li>MPGNN, RF Diffusion (DDPM), SCUBA-D\u8ba1\u7b97\u4eb2\u548c\u529b</li> <li>\u989d\u5916\u6307\u6807:\u7279\u5f02\u6027\u3001\u6d3b\u6027\u3001\u7a33\u5b9a\u6027</li> <li>\u8fed\u4ee3\u4f18\u5316:\u57fa\u4e8e\u8ba1\u7b97\u9884\u6d4b\u7684\u6027\u8d28\u8fdb\u884c\u8fed\u4ee3\u6539\u8fdb</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W3%20Antibody%20de%20novo%20design/#_3","title":"\u4e8c\u3001\u5b9e\u9a8c\u9a8c\u8bc1\u9636\u6bb5","text":"<ol> <li>\u6297\u4f53\u57fa\u56e0\u5408\u6210\u4e0e\u8868\u8fbe</li> <li> <p>\u57fa\u56e0\u5408\u6210</p> <ul> <li>\u4f18\u5316\u5bc6\u7801\u5b50\u4f7f\u7528</li> <li>\u5408\u6210\u91cd\u94fe\u548c\u8f7b\u94fe\u57fa\u56e0</li> <li>\u514b\u9686\u81f3\u9002\u5f53\u8868\u8fbe\u8f7d\u4f53</li> </ul> </li> <li> <p>\u8868\u8fbe\u7cfb\u7edf\u9009\u62e9</p> <ul> <li>\u54fa\u4e73\u52a8\u7269\u7ec6\u80de\u7cfb(HEK293, CHO)</li> <li>\u6746\u72b6\u75c5\u6bd2-\u6606\u866b\u7ec6\u80de\u7cfb\u7edf</li> <li>\u9175\u6bcd\u6216\u5927\u80a0\u6746\u83cc\u7cfb\u7edf(\u9002\u7528\u4e8e\u6297\u4f53\u7247\u6bb5)</li> </ul> </li> <li> <p>\u5c0f\u89c4\u6a21\u8868\u8fbe\u7b5b\u9009</p> <ul> <li>\u77ac\u65f6\u8f6c\u67d3\u4f18\u5316</li> <li>\u8868\u8fbe\u6761\u4ef6\u7b5b\u9009(\u6e29\u5ea6\u3001\u6dfb\u52a0\u5242\u3001\u57f9\u517b\u65f6\u95f4)</li> <li>ELISA\u6216Western blot\u521d\u6b65\u9a8c\u8bc1\u8868\u8fbe</li> </ul> </li> <li> <p>\u6297\u4f53\u86cb\u767d\u7eaf\u5316\u4e0e\u8d28\u63a7</p> </li> <li> <p>\u4eb2\u548c\u5c42\u6790\u7eaf\u5316</p> <ul> <li>\u86cb\u767dA/G\u67f1\u7eaf\u5316(\u9002\u7528\u4e8eFc\u542b\u6297\u4f53)</li> <li>\u6297\u539f\u4eb2\u548c\u67f1(\u9488\u5bf9\u7279\u5b9a\u6297\u4f53)</li> <li>\u6807\u7b7e\u4eb2\u548c\u7eaf\u5316(His\u6807\u7b7e\u3001FLAG\u6807\u7b7e\u7b49)</li> </ul> </li> <li> <p>\u8fdb\u4e00\u6b65\u7eaf\u5316</p> <ul> <li>\u79bb\u5b50\u4ea4\u6362\u5c42\u6790</li> <li>\u5206\u5b50\u7b5b\u5c42\u6790</li> <li>\u758f\u6c34\u76f8\u4e92\u4f5c\u7528\u5c42\u6790</li> </ul> </li> <li> <p>\u8d28\u91cf\u63a7\u5236\u5206\u6790</p> <ul> <li>SDS-PAGE\u548c\u8003\u9a6c\u65af\u84dd\u67d3\u8272</li> <li>\u8d28\u8c31\u5206\u6790\u786e\u8ba4\u5e8f\u5217\u548c\u4fee\u9970</li> <li>\u51dd\u80f6\u8fc7\u6ee4\u5206\u6790\u8bc4\u4f30\u805a\u96c6\u72b6\u6001</li> <li>\u5185\u6bd2\u7d20\u68c0\u6d4b</li> </ul> </li> <li> <p>\u751f\u7269\u7269\u7406\u7279\u6027\u5206\u6790</p> </li> <li> <p>\u7ed3\u6784\u5b8c\u6574\u6027\u9a8c\u8bc1</p> <ul> <li>\u5706\u4e8c\u8272\u8c31(CD)\u5206\u6790\u4e8c\u7ea7\u7ed3\u6784</li> <li>\u5dee\u793a\u626b\u63cf\u91cf\u70ed\u6cd5(DSC)\u6d4b\u5b9a\u70ed\u7a33\u5b9a\u6027</li> <li>\u52a8\u6001\u5149\u6563\u5c04(DLS)\u8bc4\u4f30\u5747\u4e00\u6027\u548c\u805a\u96c6\u503e\u5411</li> </ul> </li> <li> <p>\u7a33\u5b9a\u6027\u6d4b\u8bd5</p> <ul> <li>\u52a0\u901f\u7a33\u5b9a\u6027\u7814\u7a76(\u9ad8\u6e29\u3001pH\u53d8\u5316)</li> <li>\u51bb\u878d\u5faa\u73af\u7a33\u5b9a\u6027</li> <li>\u957f\u671f\u50a8\u5b58\u7a33\u5b9a\u6027</li> </ul> </li> <li> <p>\u4eb2\u548c\u529b\u6d4b\u5b9a</p> <ul> <li>\u8868\u9762\u7b49\u79bb\u5b50\u4f53\u5171\u632f(SPR)\u6d4b\u91cf\u7ed3\u5408\u52a8\u529b\u5b66\u53c2\u6570</li> <li>\u7b49\u6e29\u6ef4\u5b9a\u91cf\u70ed\u6cd5(ITC)\u6d4b\u91cf\u70ed\u529b\u5b66\u53c2\u6570</li> <li>Bio-layer\u5e72\u6d89\u6cd5(BLI)\u5feb\u901f\u7b5b\u9009</li> </ul> </li> <li> <p>\u529f\u80fd\u6d3b\u6027\u9a8c\u8bc1</p> </li> <li> <p>\u6297\u539f\u7ed3\u5408\u7279\u6027</p> <ul> <li>ELISA\u6d4b\u5b9a\u7ed3\u5408\u6d3b\u6027</li> <li>\u7ade\u4e89\u7ed3\u5408\u5b9e\u9a8c\u8bc4\u4f30\u8868\u4f4d\u7279\u5f02\u6027</li> <li>\u4ea4\u53c9\u53cd\u5e94\u6027\u6d4b\u8bd5(\u4e0e\u76f8\u5173\u6297\u539f\u6216\u5176\u4ed6\u7269\u79cd\u540c\u6e90\u7269)</li> </ul> </li> <li> <p>\u7ec6\u80de\u6c34\u5e73\u529f\u80fd\u9a8c\u8bc1</p> <ul> <li>\u6d41\u5f0f\u7ec6\u80de\u672f\u8bc4\u4f30\u7ec6\u80de\u8868\u9762\u6297\u539f\u7ed3\u5408</li> <li>\u514d\u75ab\u8367\u5149\u663e\u5fae\u955c\u89c2\u5bdf\u7ec6\u80de\u5b9a\u4f4d</li> <li>\u7ec6\u80de\u529f\u80fd\u6d4b\u5b9a(\u5982\u4e2d\u548c\u3001\u6291\u5236\u3001\u6fc0\u6d3b\u7b49)</li> </ul> </li> <li> <p>\u6548\u5e94\u529f\u80fd\u6d4b\u8bd5</p> <ul> <li>\u6297\u4f53\u4f9d\u8d56\u6027\u7ec6\u80de\u4ecb\u5bfc\u7684\u7ec6\u80de\u6bd2\u6027(ADCC)\u6d4b\u5b9a</li> <li>\u8865\u4f53\u4f9d\u8d56\u6027\u7ec6\u80de\u6bd2\u6027(CDC)\u6d4b\u5b9a</li> <li>\u6297\u4f53\u4f9d\u8d56\u6027\u7ec6\u80de\u541e\u566c\u4f5c\u7528(ADCP)\u6d4b\u5b9a</li> </ul> </li> <li> <p>\u4f53\u5916\u7597\u6548\u8bc4\u4f30</p> </li> <li> <p>\u4fe1\u53f7\u901a\u8def\u5206\u6790</p> <ul> <li>Western blot\u68c0\u6d4b\u4e0b\u6e38\u4fe1\u53f7\u86cb\u767d\u78f7\u9178\u5316</li> <li>\u8367\u5149\u7d20\u9176\u62a5\u544a\u57fa\u56e0\u6d4b\u5b9a</li> <li>\u78f7\u9178\u5316\u86cb\u767d\u7ec4\u5b66\u5206\u6790</li> </ul> </li> <li> <p>\u529f\u80fd\u6027\u6d4b\u5b9a</p> <ul> <li>\u7ec6\u80de\u589e\u6b96/\u51cb\u4ea1\u6d4b\u5b9a</li> <li>\u7ec6\u80de\u8fc1\u79fb/\u4fb5\u88ad\u6d4b\u5b9a</li> <li>\u7ec6\u80de\u5206\u5316\u6d4b\u5b9a</li> <li>\u75c5\u6bd2\u4e2d\u548c\u6d4b\u5b9a(\u7528\u4e8e\u6297\u75c5\u6bd2\u6297\u4f53)</li> </ul> </li> <li> <p>\u4e09\u7ef4\u6a21\u578b\u7cfb\u7edf</p> <ul> <li>\u7c7b\u5668\u5b98\u57f9\u517b\u7cfb\u7edf</li> <li>\u7ec6\u80de\u7403\u6d4b\u8bd5</li> <li>\u5171\u57f9\u517b\u7cfb\u7edf</li> </ul> </li> <li> <p>\u4f53\u5185\u521d\u6b65\u8bc4\u4f30</p> </li> <li> <p>\u836f\u4ee3\u52a8\u529b\u5b66\u7814\u7a76</p> <ul> <li>\u5c0f\u9f20\u3001\u5927\u9f20\u6216\u975e\u4eba\u7075\u957f\u7c7b\u52a8\u7269\u4e2d\u7684\u534a\u8870\u671f\u6d4b\u5b9a</li> <li>\u7ec4\u7ec7\u5206\u5e03\u7814\u7a76</li> <li>\u6e05\u9664\u673a\u5236\u7814\u7a76</li> </ul> </li> <li> <p>\u521d\u6b65\u7597\u6548\u7814\u7a76</p> <ul> <li>\u9009\u62e9\u9002\u5f53\u75be\u75c5\u6a21\u578b(\u79fb\u690d\u7624\u3001\u8f6c\u57fa\u56e0\u6216\u75be\u75c5\u8bf1\u5bfc\u6a21\u578b)</li> <li>\u5242\u91cf\u63a2\u7d22\u7814\u7a76</li> <li>\u751f\u7269\u6807\u5fd7\u7269\u54cd\u5e94\u8bc4\u4f30</li> </ul> </li> <li> <p>\u521d\u6b65\u5b89\u5168\u6027\u8bc4\u4f30</p> <ul> <li>\u6025\u6027\u6bd2\u6027\u89c2\u5bdf</li> <li>\u7ec6\u80de\u56e0\u5b50\u91ca\u653e\u6d4b\u8bd5</li> <li>\u7ec4\u7ec7\u4ea4\u53c9\u53cd\u5e94\u6027\u7814\u7a76</li> </ul> </li> <li> <p>\u6297\u4f53\u4f18\u5316\u53cd\u9988</p> </li> <li> <p>\u7ed3\u6784-\u529f\u80fd\u5173\u7cfb\u5206\u6790</p> <ul> <li>\u5c06\u5b9e\u9a8c\u6570\u636e\u4e0e\u8ba1\u7b97\u9884\u6d4b\u5bf9\u6bd4</li> <li>\u8bc6\u522b\u5f71\u54cd\u529f\u80fd\u7684\u5173\u952e\u6b8b\u57fa</li> <li>\u5f52\u7eb3\u7ed3\u6784\u51b3\u5b9a\u56e0\u7d20</li> </ul> </li> <li> <p>\u8bbe\u8ba1\u6539\u8fdb</p> <ul> <li>\u57fa\u4e8e\u5b9e\u9a8c\u6570\u636e\u4fee\u6539\u8ba1\u7b97\u6a21\u578b</li> <li>\u8bbe\u8ba1\u65b0\u4e00\u4ee3\u6297\u4f53\u6539\u8fdb\u7279\u5b9a\u6027\u80fd</li> <li>\u4eb2\u548c\u529b\u6210\u719f\u6216\u4eba\u6e90\u5316\u4f18\u5316</li> </ul> </li> <li> <p>\u5236\u5242\u5f00\u53d1\u521d\u6b65\u7814\u7a76</p> <ul> <li>\u7f13\u51b2\u6db2\u7b5b\u9009</li> <li>\u7a33\u5b9a\u5242\u8bc4\u4f30</li> <li>\u51bb\u5e72\u53ef\u884c\u6027\u7814\u7a76</li> </ul> </li> </ol> <p>\u8fd9\u4e00\u7efc\u5408\u6d41\u7a0b\u5c06\u8ba1\u7b97\u8bbe\u8ba1\u4e0e\u4e25\u683c\u7684\u5b9e\u9a8c\u9a8c\u8bc1\u76f8\u7ed3\u5408\uff0c\u786e\u4fdd\u5f00\u53d1\u7684\u6297\u4f53\u4e0d\u4ec5\u5177\u6709\u7406\u60f3\u7684\u7406\u8bba\u7279\u6027\uff0c\u8fd8\u5177\u5907\u5b9e\u9645\u7684\u529f\u80fd\u6d3b\u6027\u548c\u836f\u7269\u5f00\u53d1\u6f5c\u529b\u3002\u901a\u8fc7\u5b9e\u9a8c\u6570\u636e\u53cd\u9988\u5230\u8ba1\u7b97\u6a21\u578b\uff0c\u53ef\u4ee5\u4e0d\u65ad\u4f18\u5316\u8bbe\u8ba1\u7b97\u6cd5\uff0c\u63d0\u9ad8\u9884\u6d4b\u51c6\u786e\u6027\uff0c\u52a0\u901f\u6297\u4f53\u836f\u7269\u7684\u5f00\u53d1\u8fc7\u7a0b\u3002</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W3%20Antibody%20de%20novo%20design/#antibody-design-pipeline-from-computational-design-to-experimental-validation","title":"Antibody Design Pipeline: From Computational Design to Experimental Validation","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W3%20Antibody%20de%20novo%20design/#i-computational-design-phase","title":"I. Computational Design Phase","text":"<ol> <li>Initial Inputs</li> <li>Antigen structure (crystal structure or computational prediction)</li> <li>Epitope identification and selection</li> <li> <p>Analysis of existing antibody databases</p> </li> <li> <p>Design Approaches</p> </li> <li>De novo design: Build main chain \u2192 complete side chains \u2192 generate sequence</li> <li>Mutation-based optimization: Systematic exploration of mutations within constrained search space</li> <li> <p>Structure prediction tools: AlphaFold2, ESM-Fold, AF3, DMFold for validation/prediction</p> </li> <li> <p>Developability Assessment</p> </li> <li>MPGNN, RF Diffusion (DDPM), SCUBA-D for affinity computation</li> <li>Additional metrics: specificity, activity, stability</li> <li>Optimization loop: Iterative refinement based on computationally predicted properties</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W3%20Antibody%20de%20novo%20design/#ii-experimental-validation-phase","title":"II. Experimental Validation Phase","text":"<ol> <li>Antibody Gene Synthesis and Expression</li> <li> <p>Gene Synthesis</p> <ul> <li>Codon optimization</li> <li>Synthesis of heavy and light chain genes</li> <li>Cloning into appropriate expression vectors</li> </ul> </li> <li> <p>Expression System Selection</p> <ul> <li>Mammalian cell lines (HEK293, CHO)</li> <li>Baculovirus-insect cell system</li> <li>Yeast or E. coli systems (for antibody fragments)</li> </ul> </li> <li> <p>Small-Scale Expression Screening</p> <ul> <li>Transient transfection optimization</li> <li>Expression condition screening (temperature, additives, culture time)</li> <li>Preliminary validation by ELISA or Western blot</li> </ul> </li> <li> <p>Antibody Protein Purification and Quality Control</p> </li> <li> <p>Affinity Chromatography</p> <ul> <li>Protein A/G column purification (for Fc-containing antibodies)</li> <li>Antigen affinity columns (for specific antibodies)</li> <li>Tag-based purification (His-tag, FLAG-tag, etc.)</li> </ul> </li> <li> <p>Further Purification</p> <ul> <li>Ion exchange chromatography</li> <li>Size exclusion chromatography</li> <li>Hydrophobic interaction chromatography</li> </ul> </li> <li> <p>Quality Control Analysis</p> <ul> <li>SDS-PAGE and Coomassie blue staining</li> <li>Mass spectrometry for sequence and modification confirmation</li> <li>Gel filtration analysis for aggregation assessment</li> <li>Endotoxin testing</li> </ul> </li> <li> <p>Biophysical Characterization</p> </li> <li> <p>Structural Integrity Verification</p> <ul> <li>Circular dichroism (CD) for secondary structure analysis</li> <li>Differential scanning calorimetry (DSC) for thermal stability</li> <li>Dynamic light scattering (DLS) for homogeneity and aggregation propensity</li> </ul> </li> <li> <p>Stability Testing</p> <ul> <li>Accelerated stability studies (high temperature, pH variations)</li> <li>Freeze-thaw cycle stability</li> <li>Long-term storage stability</li> </ul> </li> <li> <p>Affinity Determination</p> <ul> <li>Surface plasmon resonance (SPR) for binding kinetics parameters</li> <li>Isothermal titration calorimetry (ITC) for thermodynamic parameters</li> <li>Bio-layer interferometry (BLI) for rapid screening</li> </ul> </li> <li> <p>Functional Activity Validation</p> </li> <li> <p>Antigen Binding Characteristics</p> <ul> <li>ELISA for binding activity</li> <li>Competition binding assays for epitope specificity</li> <li>Cross-reactivity testing (with related antigens or homologs from other species)</li> </ul> </li> <li> <p>Cellular-Level Functional Validation</p> <ul> <li>Flow cytometry for cell surface antigen binding</li> <li>Immunofluorescence microscopy for cellular localization</li> <li>Cell-based functional assays (neutralization, inhibition, activation, etc.)</li> </ul> </li> <li> <p>Effector Function Testing</p> <ul> <li>Antibody-dependent cellular cytotoxicity (ADCC) assays</li> <li>Complement-dependent cytotoxicity (CDC) assays</li> <li>Antibody-dependent cellular phagocytosis (ADCP) assays</li> </ul> </li> <li> <p>In Vitro Efficacy Assessment</p> </li> <li> <p>Signaling Pathway Analysis</p> <ul> <li>Western blot for downstream signaling protein phosphorylation</li> <li>Luciferase reporter assays</li> <li>Phospho-proteomics analysis</li> </ul> </li> <li> <p>Functional Assays</p> <ul> <li>Cell proliferation/apoptosis assays</li> <li>Cell migration/invasion assays</li> <li>Cell differentiation assays</li> <li>Viral neutralization assays (for antiviral antibodies)</li> </ul> </li> <li> <p>Three-Dimensional Model Systems</p> <ul> <li>Organoid culture systems</li> <li>Spheroid assays</li> <li>Co-culture systems</li> </ul> </li> <li> <p>Preliminary In Vivo Evaluation</p> </li> <li> <p>Pharmacokinetic Studies</p> <ul> <li>Half-life determination in mice, rats, or non-human primates</li> <li>Tissue distribution studies</li> <li>Clearance mechanism studies</li> </ul> </li> <li> <p>Preliminary Efficacy Studies</p> <ul> <li>Selection of appropriate disease models (xenografts, transgenic, or disease-induced models)</li> <li>Dose exploration studies</li> <li>Biomarker response assessment</li> </ul> </li> <li> <p>Preliminary Safety Assessment</p> <ul> <li>Acute toxicity observations</li> <li>Cytokine release assays</li> <li>Tissue cross-reactivity studies</li> </ul> </li> <li> <p>Antibody Optimization Feedback</p> </li> <li> <p>Structure-Function Relationship Analysis</p> <ul> <li>Comparison of experimental data with computational predictions</li> <li>Identification of key residues affecting function</li> <li>Deduction of structural determinants</li> </ul> </li> <li> <p>Design Improvements</p> <ul> <li>Modification of computational models based on experimental data</li> <li>Design of next-generation antibodies with improved specific properties</li> <li>Affinity maturation or humanization optimization</li> </ul> </li> <li> <p>Preliminary Formulation Development</p> <ul> <li>Buffer screening</li> <li>Stabilizer evaluation</li> <li>Lyophilization feasibility studies</li> </ul> </li> </ol> <p>This comprehensive pipeline integrates computational design with rigorous experimental validation, ensuring that developed antibodies not only possess ideal theoretical characteristics but also demonstrate practical functional activity and drug development potential. By feeding experimental data back into computational models, design algorithms can be continuously optimized, improving prediction accuracy and accelerating the antibody drug development process.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/","title":"Kaplan-Meier\u4f30\u8ba1\u4e0eLog-rank\u68c0\u9a8c\u7684\u6570\u5b66\u539f\u7406\u4e0e\u5e94\u7528","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#kaplan-meier","title":"\u4e00\u3001Kaplan-Meier\u4f30\u8ba1\u7684\u6570\u5b66\u57fa\u7840","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#1","title":"1. \u57fa\u672c\u539f\u7406","text":"<p>Kaplan-Meier\u4f30\u8ba1\u5668\u662f\u4e00\u79cd\u975e\u53c2\u6570\u65b9\u6cd5\uff0c\u7528\u4e8e\u4f30\u8ba1\u5b58\u5728\u53f3\u5ba1\u67e5\u6570\u636e\u65f6\u7684\u751f\u5b58\u51fd\u6570\u3002\u5176\u6838\u5fc3\u601d\u60f3\u662f\u5c06\u751f\u5b58\u6982\u7387\u8868\u793a\u4e3a\u4e00\u7cfb\u5217\u6761\u4ef6\u6982\u7387\u7684\u4e58\u79ef\u3002</p> <p>\u751f\u5b58\u51fd\u6570S(t)\u7684\u5b9a\u4e49\u4e3a\u5728\u65f6\u95f4t\u4e4b\u540e\u4ecd\u672a\u53d1\u751f\u4e8b\u4ef6\u7684\u6982\u7387\uff1a</p> <pre><code>S(t) = P(T &gt; t)\n</code></pre> <p>\u5176\u4e2dT\u662f\u4e8b\u4ef6\u53d1\u751f\u7684\u65f6\u95f4\u3002</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#2","title":"2. \u6570\u5b66\u63a8\u5bfc","text":"<p>\u5047\u8bbe\u6211\u4eec\u6709\u89c2\u5bdf\u5230\u7684\u4e8b\u4ef6\u53d1\u751f\u65f6\u95f4t\u2081 &lt; t\u2082 &lt; ... &lt; t\u2096\uff0cKaplan-Meier\u4f30\u8ba1\u5668\u901a\u8fc7\u4ee5\u4e0b\u6b65\u9aa4\u6784\u5efa\uff1a</p> <ol> <li> <p>\u6761\u4ef6\u6982\u7387\u5206\u89e3\uff1a    \u751f\u5b58\u51fd\u6570\u53ef\u4ee5\u8868\u793a\u4e3a\u8fde\u7eed\u6761\u4ef6\u6982\u7387\u7684\u4e58\u79ef\uff1a    <code>S(t) = P(T &gt; t\u2081) \u00d7 P(T &gt; t\u2082|T &gt; t\u2081) \u00d7 ... \u00d7 P(T &gt; t|T &gt; t\u2c7c)</code>    \u5176\u4e2dt\u2c7c\u662f\u5c0f\u4e8et\u7684\u6700\u5927\u89c2\u5bdf\u65f6\u95f4\u70b9\u3002</p> </li> <li> <p>\u6761\u4ef6\u6982\u7387\u4f30\u8ba1\uff1a    \u5728\u6bcf\u4e2a\u65f6\u95f4\u70b9t\u1d62\uff0c\u6211\u4eec\u4f30\u8ba1\u6761\u4ef6\u6982\u7387\uff1a    <code>P(T &gt; t\u1d62|T &gt; t\u1d62\u208b\u2081) = 1 - d\u1d62/n\u1d62</code>    \u5176\u4e2d\uff1a</p> </li> <li>d\u1d62 = \u5728\u65f6\u95f4t\u1d62\u53d1\u751f\u4e8b\u4ef6\u7684\u6570\u91cf</li> <li> <p>n\u1d62 = \u5728\u65f6\u95f4t\u1d62\u5904\u4e8e\"\u98ce\u9669\u96c6\"\u4e2d\u7684\u5bf9\u8c61\u6570\u91cf\uff08\u5373\u5728t\u1d62\u4e4b\u524d\u65e2\u6ca1\u6709\u53d1\u751f\u4e8b\u4ef6\u4e5f\u6ca1\u6709\u88ab\u5ba1\u67e5\u7684\u5bf9\u8c61\uff09</p> </li> <li> <p>\u4e58\u79ef\u6781\u9650\u4f30\u8ba1\u5668\uff1a    Kaplan-Meier\u4f30\u8ba1\u5668\u7684\u6700\u7ec8\u5f62\u5f0f\u4e3a\uff1a    <code>\u015c(t) = \u220f\u2096:\u209c\u2096\u2264\u209c (1 - d\u2096/n\u2096)</code>    \u8fd9\u662f\u4e00\u4e2a\u9636\u68af\u51fd\u6570\uff0c\u5728\u6bcf\u4e2a\u4e8b\u4ef6\u53d1\u751f\u65f6\u95f4\u70b9\u5904\u4e0b\u964d\uff0c\u5728\u5ba1\u67e5\u65f6\u95f4\u70b9\u4fdd\u6301\u4e0d\u53d8\u3002</p> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#3","title":"3. \u65b9\u5dee\u4f30\u8ba1\u4e0e\u7f6e\u4fe1\u533a\u95f4","text":"<p>Kaplan-Meier\u4f30\u8ba1\u5668\u7684\u65b9\u5dee\u901a\u5e38\u4f7f\u7528Greenwood\u516c\u5f0f\u4f30\u8ba1\uff1a</p> <pre><code>Var[\u015c(t)] = [\u015c(t)]\u00b2 \u00d7 \u2211\u2096:\u209c\u2096\u2264\u209c [d\u2096/(n\u2096\u00d7(n\u2096-d\u2096))]\n</code></pre> <p>95%\u7f6e\u4fe1\u533a\u95f4\u53ef\u4ee5\u901a\u8fc7\u591a\u79cd\u65b9\u6cd5\u6784\u5efa\uff1a</p> <ol> <li> <p>\u7ebf\u6027\u8fd1\u4f3c\uff1a    <code>\u015c(t) \u00b1 1.96 \u00d7 \u221aVar[\u015c(t)]</code></p> </li> <li> <p>\u5bf9\u6570\u53d8\u6362\uff08\u66f4\u5e38\u7528\uff09\uff1a    <code>\u015c(t)^exp(\u00b11.96\u00d7\u03c3/[\u015c(t)\u00d7log(\u015c(t))])</code>    \u5176\u4e2d\u03c3\u662f\u015c(t)\u7684\u6807\u51c6\u8bef\u3002</p> </li> <li> <p>log-log\u53d8\u6362\uff1a    \u57fa\u4e8elog(-log(\u015c(t)))\u7684\u6e10\u8fd1\u6b63\u6001\u6027\uff0c\u63d0\u4f9b\u66f4\u597d\u7684\u8986\u76d6\u6982\u7387\u3002</p> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#4","title":"4. \u4e2d\u4f4d\u751f\u5b58\u65f6\u95f4","text":"<p>\u4e2d\u4f4d\u751f\u5b58\u65f6\u95f4\u662f\u4f7fS(t) = 0.5\u7684\u65f6\u95f4t\uff0c\u5373\uff1a</p> <pre><code>t\u2098\u2091\u2090\u2099 = min{t: \u015c(t) \u2264 0.5}\n</code></pre> <p>\u5f53\u751f\u5b58\u66f2\u7ebf\u672a\u964d\u81f30.5\u4ee5\u4e0b\u65f6\uff0c\u4e2d\u4f4d\u751f\u5b58\u65f6\u95f4\u4e0d\u53ef\u4f30\u8ba1\u3002</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#kaplan-meier_1","title":"\u4e8c\u3001Kaplan-Meier\u66f2\u7ebf\u7684\u89e3\u91ca\u4e0e\u7279\u6027","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#1_1","title":"1. \u66f2\u7ebf\u7279\u6027","text":"<ul> <li>\u9636\u68af\u51fd\u6570\uff1a\u66f2\u7ebf\u5728\u4e8b\u4ef6\u53d1\u751f\u65f6\u4e0b\u964d\uff0c\u5728\u5ba1\u67e5\u65f6\u4e0d\u53d8</li> <li>\u521d\u59cb\u503c\uff1aS(0) = 1\uff08\u5047\u8bbe\u6240\u6709\u5bf9\u8c61\u5728\u7814\u7a76\u5f00\u59cb\u65f6\u90fd\u672a\u53d1\u751f\u4e8b\u4ef6\uff09</li> <li>\u7ec8\u503c\uff1a\u5982\u679c\u6700\u540e\u7684\u89c2\u5bdf\u662f\u4e8b\u4ef6\u800c\u975e\u5ba1\u67e5\uff0c\u5219\u66f2\u7ebf\u53ef\u80fd\u964d\u81f30\uff1b\u5982\u679c\u6700\u540e\u7684\u89c2\u5bdf\u662f\u5ba1\u67e5\uff0c\u5219\u66f2\u7ebf\u4e0d\u4f1a\u8fbe\u52300</li> <li>\u5e73\u53f0\u671f\uff1a\u66f2\u7ebf\u4e2d\u7684\u6c34\u5e73\u6bb5\u8868\u793a\u8be5\u65f6\u95f4\u6bb5\u5185\u672a\u89c2\u5bdf\u5230\u4e8b\u4ef6</li> <li>\u9661\u964d\uff1a\u66f2\u7ebf\u6025\u5267\u4e0b\u964d\u8868\u793a\u4e8b\u4ef6\u5bc6\u96c6\u53d1\u751f</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#2_1","title":"2. \u5ba1\u67e5\u6807\u8bb0","text":"<p>Kaplan-Meier\u66f2\u7ebf\u4e0a\u901a\u5e38\u7528\u7279\u6b8a\u7b26\u53f7\uff08\u5982\"+\"\u6216\u77ed\u5782\u7ebf\uff09\u6807\u8bb0\u5ba1\u67e5\u70b9\uff0c\u8fd9\u4e9b\u6807\u8bb0\u63d0\u4f9b\u4e86\u5173\u4e8e\u6570\u636e\u5b8c\u6574\u6027\u7684\u91cd\u8981\u4fe1\u606f\uff1a</p> <ul> <li>\u5ba1\u67e5\u6807\u8bb0\u7684\u5206\u5e03\u8868\u660e\u7814\u7a76\u7684\u968f\u8bbf\u6a21\u5f0f</li> <li>\u66f2\u7ebf\u672b\u7aef\u5927\u91cf\u5ba1\u67e5\u6807\u8bb0\u63d0\u793a\u968f\u8bbf\u65f6\u95f4\u53ef\u80fd\u4e0d\u8db3</li> <li>\u4e0d\u540c\u7ec4\u522b\u5ba1\u67e5\u6a21\u5f0f\u7684\u5dee\u5f02\u53ef\u80fd\u6697\u793a\u6f5c\u5728\u504f\u501a</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#3_1","title":"3. \u98ce\u9669\u8868","text":"<p>Kaplan-Meier\u56fe\u4e0b\u65b9\u901a\u5e38\u9644\u6709\"\u98ce\u9669\u8868\"(risk table)\uff0c\u663e\u793a\u5404\u65f6\u95f4\u70b9\u4ecd\u5904\u4e8e\u98ce\u9669\u4e2d\u7684\u5bf9\u8c61\u6570\u91cf\uff1a</p> <pre><code>Time:    0    6    12   18   24   30\nAt risk: 100  87   75   54   32   15\n</code></pre> <p>\u98ce\u9669\u8868\u63d0\u4f9b\u4e86\u91cd\u8981\u4e0a\u4e0b\u6587\u4fe1\u606f\uff1a - \u663e\u793a\u6837\u672c\u91cf\u968f\u65f6\u95f4\u51cf\u5c11 - \u5e2e\u52a9\u89e3\u91ca\u66f2\u7ebf\u672b\u7aef\u7684\u4e0d\u786e\u5b9a\u6027\u589e\u52a0 - \u5728\u6bd4\u8f83\u591a\u7ec4\u65f6\u5c24\u4e3a\u91cd\u8981\uff0c\u8868\u660e\u5404\u65f6\u95f4\u70b9\u7684\u7ec4\u95f4\u6837\u672c\u91cf\u5e73\u8861\u60c5\u51b5</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#log-rank","title":"\u4e09\u3001Log-rank\u68c0\u9a8c\u7684\u7edf\u8ba1\u5b66\u539f\u7406","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#1_2","title":"1. \u57fa\u672c\u5047\u8bbe\u4e0e\u601d\u60f3","text":"<p>Log-rank\u68c0\u9a8c\u662f\u6bd4\u8f83\u4e24\u4e2a\u6216\u591a\u4e2a\u751f\u5b58\u66f2\u7ebf\u7684\u975e\u53c2\u6570\u65b9\u6cd5\uff0c\u57fa\u4e8e\u4ee5\u4e0b\u5047\u8bbe\uff1a</p> <ul> <li>\u96f6\u5047\u8bbe(H\u2080)\uff1a\u5404\u7ec4\u7684\u751f\u5b58\u51fd\u6570\u76f8\u540c\uff0c\u5373S\u2081(t) = S\u2082(t) = ... = S\u2096(t)</li> <li>\u66ff\u4ee3\u5047\u8bbe(H\u2081)\uff1a\u81f3\u5c11\u6709\u4e00\u7ec4\u7684\u751f\u5b58\u51fd\u6570\u4e0e\u5176\u4ed6\u7ec4\u4e0d\u540c</li> </ul> <p>\u68c0\u9a8c\u7684\u6838\u5fc3\u601d\u60f3\u662f\uff1a\u5982\u679c\u96f6\u5047\u8bbe\u4e3a\u771f\uff0c\u5219\u5404\u7ec4\u5728\u6bcf\u4e2a\u65f6\u95f4\u70b9\u89c2\u5bdf\u5230\u7684\u4e8b\u4ef6\u6570\u5e94\u4e0e\u671f\u671b\u4e8b\u4ef6\u6570\u63a5\u8fd1\u3002</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#2_2","title":"2. \u6570\u5b66\u6784\u9020","text":"<p>\u8003\u8651\u5728\u6bcf\u4e2a\u89c2\u5bdf\u5230\u4e8b\u4ef6\u7684\u65f6\u95f4\u70b9t\u1d62\uff0c\u6784\u5efa\u5982\u4e0b2\u00d72\u8868\uff08\u4ee5\u4e24\u7ec4\u6bd4\u8f83\u4e3a\u4f8b\uff09\uff1a</p> <pre><code>          \u4e8b\u4ef6    \u65e0\u4e8b\u4ef6    \u98ce\u9669\u96c6\n\u7ec41        O\u2081\u1d62    n\u2081\u1d62-O\u2081\u1d62    n\u2081\u1d62\n\u7ec42        O\u2082\u1d62    n\u2082\u1d62-O\u2082\u1d62    n\u2082\u1d62\n\u603b\u8ba1       d\u1d62      n\u1d62-d\u1d62     n\u1d62\n</code></pre> <p>\u5176\u4e2d\uff1a - O\u2081\u1d62, O\u2082\u1d62 = \u5404\u7ec4\u5728\u65f6\u95f4t\u1d62\u89c2\u5bdf\u5230\u7684\u4e8b\u4ef6\u6570 - n\u2081\u1d62, n\u2082\u1d62 = \u5404\u7ec4\u5728\u65f6\u95f4t\u1d62\u7684\u98ce\u9669\u96c6\u5927\u5c0f - d\u1d62 = \u5728\u65f6\u95f4t\u1d62\u53d1\u751f\u7684\u603b\u4e8b\u4ef6\u6570 - n\u1d62 = \u5728\u65f6\u95f4t\u1d62\u7684\u603b\u98ce\u9669\u96c6\u5927\u5c0f</p> <p>\u5728\u96f6\u5047\u8bbe\u4e0b\uff0cO\u2081\u1d62\u8fd1\u4f3c\u670d\u4ece\u8d85\u51e0\u4f55\u5206\u5e03\uff0c\u5176\u671f\u671b\u503c\u4e3a\uff1a</p> <pre><code>E\u2081\u1d62 = n\u2081\u1d62 \u00d7 (d\u1d62/n\u1d62)\n</code></pre> <p>\u65b9\u5dee\u4e3a\uff1a</p> <pre><code>V\u2081\u1d62 = n\u2081\u1d62 \u00d7 n\u2082\u1d62 \u00d7 d\u1d62 \u00d7 (n\u1d62-d\u1d62) / [n\u1d62\u00b2 \u00d7 (n\u1d62-1)]\n</code></pre>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#3_2","title":"3. \u68c0\u9a8c\u7edf\u8ba1\u91cf\u6784\u9020","text":"<p>Log-rank\u68c0\u9a8c\u7edf\u8ba1\u91cf\u901a\u8fc7\u6c47\u603b\u6240\u6709\u65f6\u95f4\u70b9\u7684\u89c2\u5bdf\u503c\u4e0e\u671f\u671b\u503c\u4e4b\u5dee\uff1a</p> <ol> <li> <p>\u5bf9\u6bcf\u4e2a\u7ec4j\u8ba1\u7b97\uff1a    <code>O\u2c7c = \u2211\u1d62O\u2c7c\u1d62 \uff08\u603b\u89c2\u5bdf\u4e8b\u4ef6\u6570\uff09    E\u2c7c = \u2211\u1d62E\u2c7c\u1d62 \uff08\u603b\u671f\u671b\u4e8b\u4ef6\u6570\uff09</code></p> </li> <li> <p>\u6784\u9020\u68c0\u9a8c\u7edf\u8ba1\u91cf\uff1a    \u5bf9\u4e8e\u4e24\u7ec4\u6bd4\u8f83\uff1a    <code>\u03c7\u00b2 = (O\u2081-E\u2081)\u00b2 / Var(O\u2081-E\u2081)</code>    \u5176\u4e2dVar(O\u2081-E\u2081) = \u2211\u1d62V\u2081\u1d62</p> </li> </ol> <p>\u5bf9\u4e8e\u591a\u7ec4\u6bd4\u8f83\uff08k\u7ec4\uff09\uff1a    <code>\u03c7\u00b2 = U'V\u207b\u00b9U</code>    \u5176\u4e2dU\u662f\u957f\u5ea6\u4e3a(k-1)\u7684\u5411\u91cf\uff0c\u5143\u7d20\u4e3aO\u2c7c-E\u2c7c\uff0cV\u662f(k-1)\u00d7(k-1)\u7684\u534f\u65b9\u5dee\u77e9\u9635\u3002</p> <ol> <li>\u5206\u5e03\uff1a    \u5728\u96f6\u5047\u8bbe\u4e0b\uff0c\u03c7\u00b2\u7edf\u8ba1\u91cf\u8fd1\u4f3c\u670d\u4ece\u81ea\u7531\u5ea6\u4e3a(\u7ec4\u6570-1)\u7684\u5361\u65b9\u5206\u5e03\u3002</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#4-p","title":"4. p\u503c\u89e3\u91ca","text":"<p>Log-rank\u68c0\u9a8c\u7684p\u503c\u8868\u793a\u5728\u96f6\u5047\u8bbe\u4e3a\u771f\u7684\u6761\u4ef6\u4e0b\uff0c\u89c2\u5bdf\u5230\u5f53\u524d\u6216\u66f4\u6781\u7aef\u5dee\u5f02\u7684\u6982\u7387\uff1a</p> <ul> <li>p &lt; 0.05\uff1a\u901a\u5e38\u8ba4\u4e3a\u5b58\u5728\u7edf\u8ba1\u5b66\u663e\u8457\u5dee\u5f02\uff0c\u62d2\u7edd\u96f6\u5047\u8bbe</li> <li>p\u503c\u8d8a\u5c0f\uff0c\u8bc1\u636e\u8d8a\u5f3a\u70c8\u652f\u6301\u7ec4\u95f4\u751f\u5b58\u66f2\u7ebf\u5b58\u5728\u5dee\u5f02</li> <li>p\u503c\u4e0d\u80fd\u544a\u8bc9\u6211\u4eec\u5dee\u5f02\u7684\u5927\u5c0f\u6216\u4e34\u5e8a\u610f\u4e49</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#log-rank_1","title":"\u56db\u3001Log-rank\u68c0\u9a8c\u7684\u53d8\u4f53\u4e0e\u6269\u5c55","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#1-log-rank","title":"1. \u52a0\u6743Log-rank\u68c0\u9a8c","text":"<p>\u6807\u51c6Log-rank\u68c0\u9a8c\u5bf9\u6240\u6709\u65f6\u95f4\u70b9\u8d4b\u4e88\u76f8\u540c\u6743\u91cd\uff0c\u4f46\u5728\u67d0\u4e9b\u60c5\u51b5\u4e0b\uff0c\u6211\u4eec\u53ef\u80fd\u5e0c\u671b\u5f3a\u8c03\u7279\u5b9a\u65f6\u95f4\u6bb5\u7684\u5dee\u5f02\u3002\u52a0\u6743Log-rank\u68c0\u9a8c\u901a\u8fc7\u5f15\u5165\u6743\u91cd\u51fd\u6570W(t)\u5b9e\u73b0\u8fd9\u4e00\u76ee\u7684\uff1a</p> <pre><code>\u03c7\u00b2_w = [\u2211\u1d62W(t\u1d62)(O\u2081\u1d62-E\u2081\u1d62)]\u00b2 / \u2211\u1d62W(t\u1d62)\u00b2V\u2081\u1d62\n</code></pre> <p>\u5e38\u89c1\u7684\u52a0\u6743\u7248\u672c\u5305\u62ec\uff1a</p> <ol> <li>Gehan-Breslow-Wilcoxon\u68c0\u9a8c\uff1a</li> <li>\u6743\u91cdW(t) = n\u1d62\uff08\u98ce\u9669\u96c6\u5927\u5c0f\uff09</li> <li>\u5f3a\u8c03\u65e9\u671f\u5dee\u5f02</li> <li> <p>\u5f53\u5ba1\u67e5\u6a21\u5f0f\u4e0d\u540c\u65f6\u66f4\u7a33\u5065</p> </li> <li> <p>Peto-Peto\u68c0\u9a8c\uff1a</p> </li> <li>\u6743\u91cdW(t) = S\u0303(t)\uff0c\u5176\u4e2dS\u0303(t)\u662f\u4fee\u6539\u7684Kaplan-Meier\u4f30\u8ba1</li> <li>\u5bf9\u665a\u671f\u4e8b\u4ef6\u8f83\u5c11\u4f9d\u8d56</li> <li> <p>\u5bf9\u4e0d\u540c\u5ba1\u67e5\u6a21\u5f0f\u66f4\u7a33\u5065</p> </li> <li> <p>Fleming-Harrington\u68c0\u9a8c\uff1a</p> </li> <li>\u6743\u91cdW(t) = [\u015c(t)]\u1d56[1-\u015c(t)]\u1d4d</li> <li>\u53c2\u6570p,q\u53ef\u8c03\u6574\uff0c\u5f3a\u8c03\u65e9\u671f(p&gt;0,q=0)\u6216\u665a\u671f(p=0,q&gt;0)\u5dee\u5f02</li> <li>\u7075\u6d3b\u6027\u9ad8\uff0c\u9002\u7528\u4e8e\u7279\u5b9a\u7814\u7a76\u95ee\u9898</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#2-log-rank","title":"2. \u5206\u5c42Log-rank\u68c0\u9a8c","text":"<p>\u5f53\u5b58\u5728\u53ef\u80fd\u5f71\u54cd\u751f\u5b58\u7684\u6df7\u6742\u56e0\u7d20\u65f6\uff0c\u5206\u5c42Log-rank\u68c0\u9a8c\u5141\u8bb8\u5728\u63a7\u5236\u8fd9\u4e9b\u56e0\u7d20\u7684\u540c\u65f6\u6bd4\u8f83\u4e3b\u8981\u5206\u7ec4\u56e0\u7d20\u7684\u6548\u5e94\uff1a</p> <ol> <li>\u65b9\u6cd5\uff1a</li> <li>\u5728\u6bcf\u4e2a\u5206\u5c42\u6c34\u5e73\u5185\u5206\u522b\u8ba1\u7b97\u89c2\u5bdf\u503c\u4e0e\u671f\u671b\u503c</li> <li> <p>\u6c47\u603b\u6240\u6709\u5206\u5c42\u7684\u7ed3\u679c</p> </li> <li> <p>\u7edf\u8ba1\u91cf\uff1a    <code>\u03c7\u00b2_stratified = [\u2211\u209b\u2211\u1d62(O\u2081\u1d62\u209b-E\u2081\u1d62\u209b)]\u00b2 / \u2211\u209b\u2211\u1d62V\u2081\u1d62\u209b</code>    \u5176\u4e2ds\u8868\u793a\u5206\u5c42\u6c34\u5e73\u3002</p> </li> <li> <p>\u5e94\u7528\u573a\u666f\uff1a</p> </li> <li>\u591a\u4e2d\u5fc3\u4e34\u5e8a\u8bd5\u9a8c\uff08\u6309\u4e2d\u5fc3\u5206\u5c42\uff09</li> <li>\u5b58\u5728\u5df2\u77e5\u9884\u540e\u56e0\u7d20\uff08\u5982\u75be\u75c5\u5206\u671f\uff09\u65f6</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#kaplan-meierlog-rank_1","title":"\u4e94\u3001Kaplan-Meier\u66f2\u7ebf\u4e0eLog-rank\u68c0\u9a8c\u7684\u5e94\u7528\u8003\u91cf","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#1_3","title":"1. \u6837\u672c\u91cf\u4e0e\u7edf\u8ba1\u68c0\u9a8c\u529b","text":"<p>Log-rank\u68c0\u9a8c\u7684\u68c0\u9a8c\u529b\u53d6\u51b3\u4e8e\uff1a - \u4e8b\u4ef6\u603b\u6570\uff08\u901a\u5e38\u6bd4\u603b\u6837\u672c\u91cf\u66f4\u91cd\u8981\uff09 - \u9884\u671f\u7684\u6548\u5e94\u5927\u5c0f\uff08\u98ce\u9669\u6bd4\uff09 - \u663e\u8457\u6027\u6c34\u5e73\uff08\u901a\u5e38\u4e3a0.05\uff09</p> <p>\u6837\u672c\u91cf\u8ba1\u7b97\u516c\u5f0f\uff1a</p> <pre><code>\u6240\u9700\u4e8b\u4ef6\u6570 = 4 \u00d7 (z_\u03b1/2 + z_\u03b2)\u00b2 / [log(HR)]\u00b2\n</code></pre> <p>\u5176\u4e2d: - z_\u03b1/2 = \u663e\u8457\u6027\u6c34\u5e73\u5bf9\u5e94\u7684z\u503c\uff081.96\u5bf9\u5e94\u03b1=0.05\uff09 - z_\u03b2 = \u68c0\u9a8c\u529b\u5bf9\u5e94\u7684z\u503c\uff080.84\u5bf9\u5e9480%\u68c0\u9a8c\u529b\uff09 - HR = \u9884\u671f\u98ce\u9669\u6bd4</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#2_3","title":"2. \u5047\u8bbe\u9a8c\u8bc1","text":"<p>Log-rank\u68c0\u9a8c\u57fa\u4e8e\u4ee5\u4e0b\u5047\u8bbe\uff1a - \u6bd4\u4f8b\u98ce\u9669\u5047\u8bbe\uff1a\u5404\u7ec4\u7684\u98ce\u9669\u51fd\u6570\u4e4b\u6bd4\u968f\u65f6\u95f4\u4fdd\u6301\u6052\u5b9a - \u72ec\u7acb\u5ba1\u67e5\u5047\u8bbe\uff1a\u5ba1\u67e5\u673a\u5236\u4e0e\u4e8b\u4ef6\u53d1\u751f\u673a\u5236\u76f8\u4e92\u72ec\u7acb - \u7ec4\u95f4\u72ec\u7acb\u6027\uff1a\u4e0d\u540c\u7ec4\u522b\u7684\u89c2\u5bdf\u76f8\u4e92\u72ec\u7acb</p> <p>\u9a8c\u8bc1\u65b9\u6cd5\uff1a - \u7ed8\u5236log(-log(S(t)))\u5bf9log(t)\u7684\u56fe\uff0c\u68c0\u67e5\u66f2\u7ebf\u5e73\u884c\u6027 - \u68c0\u67e5\u5ba1\u67e5\u6a21\u5f0f\u5728\u5404\u7ec4\u95f4\u7684\u5206\u5e03 - \u8bc4\u4f30\u65f6\u95f4\u4f9d\u8d56\u6548\u5e94</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4%20Survival%20Analysis/#3_3","title":"3. \u89e3\u91ca\u9677\u9631\u4e0e\u6ce8\u610f\u4e8b\u9879","text":"<ol> <li>\u5ba1\u67e5\u5904\u7406\uff1a</li> <li>\u5ba1\u67e5\u6570\u636e\u4e0d\u662f\"\u7f3a\u5931\u6570\u636e\"\uff0c\u800c\u662f\u5305\u542b\u90e8\u5206\u4fe1\u606f</li> <li> <p>\u5ffd\u7565\u5ba1\u67e5\u6216\u5c06\u5ba1\u67e5\u89c6\u4e3a\u4e8b\u4ef6\u90fd\u4f1a\u5bfc\u81f4\u4e25\u91cd\u504f\u501a</p> </li> <li> <p>\u4ea4\u53c9\u751f\u5b58\u66f2\u7ebf\uff1a</p> </li> <li>\u5f53\u751f\u5b58\u66f2\u7ebf\u4ea4\u53c9\u65f6\uff0cLog-rank\u68c0\u9a8c\u53ef\u80fd\u65e0\u6cd5\u68c0\u6d4b\u5230\u5dee\u5f02</li> <li>\u4ea4\u53c9\u66f2\u7ebf\u6697\u793a\u8fdd\u53cd\u6bd4\u4f8b\u98ce\u9669\u5047\u8bbe</li> <li> <p>\u8003\u8651\u4f7f\u7528\u52a0\u6743Log-rank\u68c0\u9a8c\u6216\u5206\u6bb5\u5206\u6790</p> </li> <li> <p>\u957f\u5c3e\u6548\u5e94\uff1a</p> </li> <li>\u66f2\u7ebf\u672b\u7aef\u57fa\u4e8e\u5f88\u5c11\u7684\u98ce\u9669\u96c6\uff0c\u4f30\u8ba1\u4e0d\u786e\u5b9a\u6027\u5927</li> <li>\u672b\u7aef\u7684\u770b\u4f3c\u663e\u8457\u5dee\u5f02\u53ef\u80fd\u4ec5\u57fa\u4e8e\u51e0\u4e2a\u4e8b\u4ef6</li> <li> <p>\u5173\u6ce8\u98ce\u9669\u8868\u548c\u7f6e\u4fe1\u533a\u95f4\u5bbd\u5ea6</p> </li> <li> <p>\u591a\u91cd\u6bd4\u8f83\uff1a</p> </li> <li>\u6bd4\u8f83\u591a\u7ec4\u65f6\u9700\u8981\u8003\u8651\u591a\u91cd\u68c0\u9a8c\u6821\u6b63</li> <li> <p>\u5e38\u7528\u65b9\u6cd5\uff1aBonferroni\u6821\u6b63\u3001Holm\u65b9\u6cd5\u3001Hochberg\u65b9\u6cd5</p> </li> <li> <p>\u4e34\u5e8a\u76f8\u5173\u6027\uff1a</p> </li> <li>\u7edf\u8ba1\u663e\u8457\u6027\u4e0d\u7b49\u540c\u4e8e\u4e34\u5e8a\u610f\u4e49</li> <li>\u8bc4\u4f30\u7edd\u5bf9\u5dee\u5f02\uff08\u59825\u5e74\u751f\u5b58\u7387\u5dee\u5f02\uff09\u548c\u4e2d\u4f4d\u751f\u5b58\u65f6\u95f4\u5dee\u5f02</li> <li>\u8003 </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/","title":"S2W4.3 Host microbial Interactions and Lipid Metabolism","text":"<p>\u80a0\u9053\u5fae\u751f\u7269\u8c03\u63a7\u5bbf\u4e3b\u8102\u8d28\u4ee3\u8c22\u7684\u5b9e\u9a8c\u5de5\u4f5c\u6d41\u7a0b</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_1","title":"\u4e00\u3001\u52a8\u7269\u6a21\u578b\u5efa\u7acb\u4e0e\u8868\u5f81","text":"<ol> <li>\u65e0\u83cc(GF)\u5c0f\u9f20\u7fa4\u7ef4\u62a4</li> <li>\u5728\u65e0\u83cc\u9694\u79bb\u5668\u4e2d\u9972\u517b\u5c0f\u9f20\uff0c\u63d0\u4f9b\u9ad8\u538b\u706d\u83cc\u7684\u98df\u7269\u3001\u6c34\u548c\u57ab\u6599</li> <li>\u901a\u8fc7\u5b9a\u671f\u7caa\u4fbf\u91c7\u6837\u548c\u57f9\u517b\u76d1\u6d4b\u65e0\u83cc\u72b6\u6001</li> <li>\u7ef4\u6301\u65e0\u83cc\u7e41\u6b96\u5bf9\u4ee5\u4ea7\u751f\u5b9e\u9a8c\u52a8\u7269</li> <li> <p>\u6309\u5e74\u9f84\u548c\u6027\u522b\u5339\u914d\u5b9e\u9a8c\u5c0f\u9f20(8-12\u5468\u9f84)</p> </li> <li> <p>\u5e38\u89c4(CV)\u5c0f\u9f20\u5bf9\u7167\u7ec4</p> </li> <li>\u5728\u6807\u51c6\u7279\u5b9a\u75c5\u539f\u4f53\u6e05\u9664(SPF)\u6761\u4ef6\u4e0b\u9972\u517b</li> <li>\u4e0e\u65e0\u83cc\u5c0f\u9f20\u5339\u914d\u9057\u4f20\u80cc\u666f\u3001\u5e74\u9f84\u548c\u6027\u522b</li> <li>\u63a7\u5236\u996e\u98df\u7ec4\u6210\u548c\u5582\u517b\u8ba1\u5212</li> <li> <p>\u6536\u96c6\u7caa\u4fbf\u6837\u672c\u8fdb\u884c\u5fae\u751f\u7269\u7ec4\u8868\u5f81</p> </li> <li> <p>\u7ec4\u7ec7\u7279\u5f02\u6027\u57fa\u56e0\u6572\u9664\u6a21\u578b\u6784\u5efa</p> </li> <li>\u751f\u6210\u80a0\u4e0a\u76ae\u7ec6\u80de\u7279\u5f02\u6027\u6572\u9664\u5c0f\u9f20(\u5982Nfil3\u0394IEC\u3001Hdac3\u0394IEC)</li> <li>\u4f7f\u7528Villin-Cre\u91cd\u7ec4\u9176\u7cfb\u7edf\u8fdb\u884cIEC\u7279\u5f02\u6027\u5220\u9664</li> <li>\u901a\u8fc7PCR\u786e\u8ba4\u57fa\u56e0\u578b\uff0c\u901a\u8fc7qPCR/Western blot\u786e\u8ba4\u5220\u9664\u6548\u7387</li> <li>\u5efa\u7acb\u7e41\u6b96\u7fa4\u4ee5\u4ea7\u751f\u5b9e\u9a8c\u5c0f\u9f20\u548c\u540c\u7a9d\u5bf9\u7167\u5c0f\u9f20</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_2","title":"\u4e8c\u3001\u5fae\u751f\u7269\u7ec4\u64cd\u4f5c\u5b9e\u9a8c","text":"<ol> <li>\u7ec6\u83cc\u83cc\u682a\u5206\u79bb\u4e0e\u8868\u5f81</li> <li>\u4ece\u5065\u5eb7\u5c0f\u9f20\u4e2d\u5206\u79bb\u5019\u9009\u83cc\u682a(\u5982\u4e73\u9178\u6746\u83ccPm001)</li> <li>\u8fdb\u884c16S rRNA\u57fa\u56e0\u6d4b\u5e8f\u8fdb\u884c\u5206\u7c7b\u9274\u5b9a</li> <li>\u5168\u57fa\u56e0\u7ec4\u6d4b\u5e8f\u8868\u5f81\u529f\u80fd\u6f5c\u529b</li> <li> <p>\u5efa\u7acb\u7eaf\u57f9\u517b\u5e76\u5236\u5907\u6807\u51c6\u5316\u63a5\u79cd\u7269</p> </li> <li> <p>\u7ec6\u83cc\u704c\u80c3\u7a0b\u5e8f</p> </li> <li>\u5c06\u7ec6\u83cc\u57f9\u517b\u7269\u5236\u5907\u81f3\u7279\u5b9a\u6d53\u5ea6(10^8-10^9 CFU/ml)</li> <li>\u901a\u8fc7\u53e3\u8154\u704c\u80c3\u7ed9\u65e0\u83cc\u5c0f\u9f20\u65bd\u7528200\u03bcl\u7ec6\u83cc\u60ac\u6db2</li> <li>\u5bf9\u7167\u7ec4\u65bd\u7528\u65e0\u83cc\u57f9\u517b\u57fa</li> <li>\u901a\u8fc7\u5b9a\u671f\u7caa\u4fbf\u91c7\u6837\u548cqPCR\u786e\u8ba4\u5b9a\u690d</li> <li> <p>\u5c06\u5c0f\u9f20\u7ef4\u6301\u5728\u5355\u72ec\u9694\u79bb\u5668\u4e2d\u9632\u6b62\u4ea4\u53c9\u6c61\u67d3</p> </li> <li> <p>\u996e\u98df\u5e72\u9884</p> </li> <li>\u914d\u5236\u5bf9\u7167\u996e\u98df(CD)\u548c\u9ad8\u8102\u996e\u98df(HFD)\uff0c\u6210\u5206\u660e\u786e</li> <li>CD: 10%\u8102\u80aa\u300170%\u78b3\u6c34\u5316\u5408\u7269\u300120%\u86cb\u767d\u8d28(\u6309\u70ed\u91cf)</li> <li>HFD: 60%\u8102\u80aa\u300120%\u78b3\u6c34\u5316\u5408\u7269\u300120%\u86cb\u767d\u8d28(\u6309\u70ed\u91cf)</li> <li>\u6839\u636e\u5b9e\u9a8c\u8bbe\u8ba1\u81ea\u7531\u91c7\u98df\u6216\u914d\u5bf9\u5582\u517b</li> <li>\u6bcf\u54682-3\u6b21\u76d1\u6d4b\u98df\u7269\u6444\u5165\u91cf\u548c\u4f53\u91cd</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_3","title":"\u4e09\u3001\u8868\u578b\u548c\u4ee3\u8c22\u8bc4\u4f30","text":"<ol> <li>\u4f53\u6210\u5206\u5206\u6790</li> <li>\u6d4b\u91cf\u6574\u4e2a\u5b9e\u9a8c\u671f\u95f4\u7684\u4f53\u91cd\u53d8\u5316</li> <li>\u8fdb\u884cDEXA\u626b\u63cf\u91cf\u5316\u8102\u80aa\u548c\u7626\u4f53\u91cd</li> <li>\u6d4b\u91cf\u7ec4\u7ec7\u91cd\u91cf(\u809d\u810f\u3001\u9644\u777e\u8102\u80aa\u57ab\u3001\u76ae\u4e0b\u8102\u80aa)</li> <li> <p>\u8ba1\u7b97\u7ec4\u7ec7\u4e0e\u4f53\u91cd\u6bd4\u7387</p> </li> <li> <p>\u8461\u8404\u7cd6\u548c\u80f0\u5c9b\u7d20\u7a33\u6001</p> </li> <li>\u8fdb\u884c\u8461\u8404\u7cd6\u8010\u53d7\u8bd5\u9a8c(GTT): \u7a7a\u81796\u5c0f\u65f6\u540e\u8179\u8154\u6ce8\u5c041-2 g/kg\u8461\u8404\u7cd6</li> <li>\u8fdb\u884c\u80f0\u5c9b\u7d20\u8010\u53d7\u8bd5\u9a8c(ITT): \u7a7a\u81794\u5c0f\u65f6\u540e\u8179\u8154\u6ce8\u5c040.75-1 U/kg\u80f0\u5c9b\u7d20</li> <li>\u6d4b\u91cf\u7a7a\u8179\u8840\u7cd6\u548c\u80f0\u5c9b\u7d20\u6c34\u5e73</li> <li> <p>\u8ba1\u7b97HOMA-IR\u6307\u6570\u8bc4\u4f30\u80f0\u5c9b\u7d20\u62b5\u6297</p> </li> <li> <p>\u8102\u8d28\u4ee3\u8c22\u5206\u6790</p> </li> <li>\u6536\u96c6\u8840\u6e05\u6d4b\u91cf\u7518\u6cb9\u4e09\u916f\u3001\u80c6\u56fa\u9187\u548c\u6e38\u79bb\u8102\u80aa\u9178</li> <li>\u4f7f\u7528\u6c2f\u4eff/\u7532\u9187(2:1)\u63d0\u53d6\u809d\u810f\u8102\u8d28</li> <li>\u4f7f\u7528\u6bd4\u8272\u6cd5\u6d4b\u5b9a\u809d\u810f\u7518\u6cb9\u4e09\u916f\u548c\u80c6\u56fa\u9187</li> <li>\u5bf9\u809d\u810f\u5207\u7247\u8fdb\u884c\u6cb9\u7ea2O\u67d3\u8272\u53ef\u89c6\u5316\u8102\u6ef4</li> <li> <p>\u5728H&amp;E\u67d3\u8272\u7684\u8102\u80aa\u7ec4\u7ec7\u5207\u7247\u4e2d\u6d4b\u91cf\u8102\u80aa\u7ec6\u80de\u5927\u5c0f</p> </li> <li> <p>\u80fd\u91cf\u6d88\u8017\u548c\u4f53\u529b\u6d3b\u52a8</p> </li> <li>\u5c06\u5c0f\u9f20\u7f6e\u4e8e\u4ee3\u8c22\u7b3c\u4e2d\u6d4b\u91cf:<ul> <li>\u6c27\u6c14\u6d88\u8017\u548c\u4e8c\u6c27\u5316\u78b3\u4ea7\u751f</li> <li>\u547c\u5438\u4ea4\u6362\u6bd4(RER)</li> <li>\u4ea7\u70ed\u91cf</li> <li>\u6d3b\u52a8\u91cf</li> <li>\u98df\u7269\u548c\u6c34\u6444\u5165\u91cf</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_4","title":"\u56db\u3001\u5206\u5b50\u548c\u7ec6\u80de\u5206\u6790","text":"<ol> <li>\u8f6c\u5f55\u7ec4\u5206\u6790</li> <li>\u6536\u83b7\u7ec4\u7ec7(\u809d\u810f\u3001\u56de\u80a0\u3001\u7ed3\u80a0)\u5e76\u63d0\u53d6\u603bRNA</li> <li>\u4f7f\u7528Bioanalyzer\u8fdb\u884cRNA\u8d28\u91cf\u63a7\u5236</li> <li>\u5236\u5907RNA-seq\u6587\u5e93\u5e76\u6d4b\u5e8f(Illumina\u5e73\u53f0)</li> <li>\u5206\u6790\u5b9e\u9a8c\u7ec4\u95f4\u5dee\u5f02\u8868\u8fbe\u57fa\u56e0</li> <li>\u8fdb\u884c\u901a\u8def\u5bcc\u96c6\u5206\u6790\u8bc6\u522b\u88ab\u8c03\u63a7\u7684\u751f\u7269\u5b66\u8fc7\u7a0b</li> <li> <p>\u901a\u8fc7RT-qPCR\u9a8c\u8bc1\u5173\u952e\u57fa\u56e0(\u5982Nfil3\u3001Hdac3\u3001Snhg9)</p> </li> <li> <p>\u86cb\u767d\u8868\u8fbe\u5206\u6790</p> </li> <li>\u4f7f\u7528\u9002\u5f53\u88c2\u89e3\u7f13\u51b2\u6db2\u4ece\u7ec4\u7ec7\u4e2d\u63d0\u53d6\u86cb\u767d\u8d28</li> <li>\u901a\u8fc7BCA\u6cd5\u6d4b\u5b9a\u86cb\u767d\u6d53\u5ea6</li> <li>\u5bf9\u5173\u952e\u86cb\u767d(NFIL3\u3001HDAC3)\u8fdb\u884cWestern blot\u5206\u6790</li> <li>\u5bf9\u7ec4\u7ec7\u5207\u7247\u8fdb\u884c\u514d\u75ab\u7ec4\u7ec7\u5316\u5b66\u67d3\u8272</li> <li> <p>\u901a\u8fc7\u514d\u75ab\u5171\u6c89\u6dc0\u5206\u6790\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528</p> </li> <li> <p>\u8868\u89c2\u9057\u4f20\u5b66\u5206\u6790</p> </li> <li>\u5bf9HDAC3\u548c\u5176\u4ed6\u8c03\u8282\u56e0\u5b50\u8fdb\u884c\u67d3\u8272\u8d28\u514d\u75ab\u6c89\u6dc0(ChIP)</li> <li>\u8bc4\u4f30\u76ee\u6807\u57fa\u56e0\u4f4d\u70b9\u7684\u7ec4\u86cb\u767d\u4fee\u9970(H3K27ac\u3001H3K4me3)</li> <li>\u4f7f\u7528\u4e9a\u786b\u9178\u6c22\u76d0\u6d4b\u5e8f\u5206\u6790DNA\u7532\u57fa\u5316\u6a21\u5f0f</li> <li> <p>\u4f7f\u7528ATAC-seq\u7814\u7a76\u67d3\u8272\u8d28\u53ef\u53ca\u6027</p> </li> <li> <p>\u957f\u975e\u7f16\u7801RNA Snhg9\u529f\u80fd\u5206\u6790</p> </li> <li>\u8bbe\u8ba1\u5e76\u9a8c\u8bc1\u9776\u5411Snhg9\u7684siRNA\u6216\u53cd\u4e49\u5be1\u6838\u82f7\u9178</li> <li>\u8f6c\u67d3\u539f\u4ee3\u809d\u7ec6\u80de\u6216\u80a0\u9053\u7c7b\u5668\u5b98</li> <li>\u6d4b\u91cf\u5bf9\u8102\u8d28\u4ee3\u8c22\u57fa\u56e0\u548c\u8102\u8d28\u79ef\u7d2f\u7684\u5f71\u54cd</li> <li>\u8fdb\u884cRNA\u4e0b\u62c9\u5b9e\u9a8c\u9274\u5b9aSnhg9\u86cb\u767d\u7ed3\u5408\u4f19\u4f34</li> <li>\u4f7f\u7528RNA\u8367\u5149\u539f\u4f4d\u6742\u4ea4\u5206\u6790\u4e9a\u7ec6\u80de\u5b9a\u4f4d</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_5","title":"\u4e94\u3001\u5fae\u751f\u7269\u7ec4\u5206\u6790","text":"<ol> <li>16S rRNA\u57fa\u56e0\u6d4b\u5e8f</li> <li>\u4ece\u7caa\u4fbf\u6837\u672c\u4e2d\u63d0\u53d6\u7ec6\u83ccDNA</li> <li>\u6269\u589e16S rRNA\u57fa\u56e0\u7684V3-V4\u533a\u57df</li> <li>\u5236\u5907\u6d4b\u5e8f\u6587\u5e93\u5e76\u8fdb\u884c\u53cc\u7aef\u6d4b\u5e8f</li> <li>\u5206\u6790\u5206\u7c7b\u7ec4\u6210\u548c\u591a\u6837\u6027\u6307\u6807</li> <li> <p>\u6bd4\u8f83\u5b9e\u9a8c\u7ec4\u95f4\u5fae\u751f\u7269\u7fa4\u843d</p> </li> <li> <p>\u5b8f\u57fa\u56e0\u7ec4\u6d4b\u5e8f</p> </li> <li>\u5bf9\u9009\u5b9a\u6837\u672c\u8fdb\u884c\u9e1f\u67aa\u6cd5\u5b8f\u57fa\u56e0\u7ec4\u6d4b\u5e8f</li> <li>\u5206\u6790\u529f\u80fd\u57fa\u56e0\u5185\u5bb9\u548c\u4ee3\u8c22\u901a\u8def</li> <li>\u9274\u5b9a\u53c2\u4e0e\u8102\u8d28\u4ee3\u8c22\u7684\u7ec6\u83cc\u57fa\u56e0</li> <li> <p>\u6bd4\u8f83\u7fa4\u843d\u95f4\u7684\u83cc\u682a\u6c34\u5e73\u5dee\u5f02</p> </li> <li> <p>\u4ee3\u8c22\u7ec4\u5b66\u5206\u6790</p> </li> <li>\u6536\u96c6\u7caa\u4fbf\u3001\u8840\u6e05\u548c\u7ec4\u7ec7\u6837\u672c\u8fdb\u884c\u4ee3\u8c22\u7269\u63d0\u53d6</li> <li>\u8fdb\u884c\u975e\u9776\u5411LC-MS/MS\u6216GC-MS\u5206\u6790</li> <li>\u9274\u5b9a\u7ec6\u83cc\u4ee3\u8c22\u4ea7\u7269(\u5982\u77ed\u94fe\u8102\u80aa\u9178)</li> <li>\u5c06\u4ee3\u8c22\u7269\u6c34\u5e73\u4e0e\u5bbf\u4e3b\u57fa\u56e0\u8868\u8fbe\u548c\u8868\u578b\u76f8\u5173\u8054</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_6","title":"\u516d\u3001\u673a\u5236\u7814\u7a76","text":"<ol> <li>\u80a0\u9053\u7c7b\u5668\u5b98\u57f9\u517b</li> <li>\u4ece\u5b9e\u9a8c\u5c0f\u9f20\u5206\u79bb\u80a0\u9690\u7a9d</li> <li>\u5728Matrigel\u4e2d\u5efa\u7acb3D\u7c7b\u5668\u5b98\u57f9\u517b</li> <li>\u7528\u7ec6\u83cc\u4e0a\u6e05\u6db2\u6216\u7eaf\u5316\u4ee3\u8c22\u7269\u5904\u7406\u7c7b\u5668\u5b98</li> <li> <p>\u5206\u6790\u57fa\u56e0\u8868\u8fbe\u53d8\u5316\u548c\u8102\u8d28\u4ee3\u8c22</p> </li> <li> <p>\u539f\u4ee3\u809d\u7ec6\u80de\u5206\u79bb\u548c\u57f9\u517b</p> </li> <li>\u4ece\u5b9e\u9a8c\u5c0f\u9f20\u5206\u79bb\u539f\u4ee3\u809d\u7ec6\u80de</li> <li>\u5728\u6709\u6216\u65e0\u7ec6\u83cc\u4ee3\u8c22\u7269\u7684\u5b9a\u4e49\u57f9\u517b\u57fa\u4e2d\u57f9\u517b</li> <li>\u6d4b\u91cf\u8102\u8d28\u5408\u6210\u3001\u6c27\u5316\u548c\u79ef\u7d2f</li> <li> <p>\u5206\u6790\u5173\u952e\u4ee3\u8c22\u57fa\u56e0\u7684\u8868\u8fbe</p> </li> <li> <p>\u4f53\u5916\u7ec6\u83cc-\u4e0a\u76ae\u5171\u57f9\u517b</p> </li> <li>\u5efa\u7acb\u5e26\u6709\u80a0\u4e0a\u76ae\u7ec6\u80de\u7684Transwell\u5171\u57f9\u517b\u7cfb\u7edf</li> <li>\u5728\u9876\u7aef\u8154\u5ba4\u6dfb\u52a0\u4e73\u9178\u6746\u83ccPm001\u6216\u5176\u4ed6\u7ec6\u83cc\u83cc\u682a</li> <li>\u5206\u6790\u4e0a\u76ae\u57fa\u56e0\u8868\u8fbe\u548c\u5c4f\u969c\u529f\u80fd</li> <li> <p>\u6d4b\u91cf\u7ec6\u80de\u56e0\u5b50\u548c\u8d8b\u5316\u56e0\u5b50\u4ea7\u751f</p> </li> <li> <p>\u7ec6\u83cc\u4ee3\u8c22\u7269\u9274\u5b9a\u548c\u6d4b\u8bd5</p> </li> <li>\u5206\u79bb\u7ec6\u83cc\u57f9\u517b\u4e0a\u6e05\u6db2</li> <li>\u4f7f\u7528\u8d28\u8c31\u9274\u5b9a\u6d3b\u6027\u4ee3\u8c22\u7269</li> <li>\u5408\u6210\u6216\u7eaf\u5316\u5019\u9009\u4ee3\u8c22\u7269</li> <li>\u6d4b\u8bd5\u5bf9\u4f53\u5916\u548c\u4f53\u5185\u57fa\u56e0\u8868\u8fbe\u548c\u8102\u8d28\u4ee3\u8c22\u7684\u5f71\u54cd</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_7","title":"\u4e03\u3001\u6570\u636e\u6574\u5408\u4e0e\u5206\u6790","text":"<ol> <li>\u7edf\u8ba1\u5206\u6790</li> <li>\u5e94\u7528\u9002\u5f53\u7edf\u8ba1\u68c0\u9a8c(t\u68c0\u9a8c\u3001ANOVA\u53ca\u4e8b\u540e\u68c0\u9a8c)</li> <li>\u63a7\u5236\u591a\u91cd\u6bd4\u8f83(FDR\u6821\u6b63)</li> <li>\u8fdb\u884c\u529f\u6548\u5206\u6790\u786e\u4fdd\u8db3\u591f\u6837\u672c\u91cf</li> <li> <p>\u5bf9\u7eb5\u5411\u6570\u636e\u4f7f\u7528\u7ebf\u6027\u6df7\u5408\u6a21\u578b</p> </li> <li> <p>\u591a\u7ec4\u5b66\u6570\u636e\u6574\u5408</p> </li> <li>\u5173\u8054\u8f6c\u5f55\u7ec4\u3001\u4ee3\u8c22\u7ec4\u548c\u5fae\u751f\u7269\u7ec4\u6570\u636e</li> <li>\u8fdb\u884c\u7f51\u7edc\u5206\u6790\u8bc6\u522b\u5173\u952e\u8c03\u63a7\u67a2\u7ebd</li> <li>\u4f7f\u7528\u673a\u5668\u5b66\u4e60\u65b9\u6cd5\u8bc6\u522b\u9884\u6d4b\u6027\u6807\u8bb0</li> <li> <p>\u751f\u6210\u5fae\u751f\u7269-\u5bbf\u4e3b\u76f8\u4e92\u4f5c\u7528\u7684\u6574\u5408\u6a21\u578b</p> </li> <li> <p>\u901a\u8def\u5efa\u6a21</p> </li> <li>\u5c06\u5dee\u5f02\u8868\u8fbe\u57fa\u56e0\u6620\u5c04\u5230\u4ee3\u8c22\u901a\u8def</li> <li>\u8bc6\u522b\u8fde\u63a5\u5fae\u751f\u7269\u4fe1\u53f7\u4e0e\u8102\u8d28\u4ee3\u8c22\u7684\u8c03\u63a7\u56de\u8def</li> <li>\u5efa\u6a21NFIL3-HDAC3-Snhg9\u8c03\u63a7\u8f74</li> <li> <p>\u57fa\u4e8e\u901a\u8def\u5206\u6790\u9884\u6d4b\u6f5c\u5728\u6cbb\u7597\u9776\u70b9</p> </li> <li> <p>\u53ef\u89c6\u5316\u548c\u5c55\u793a</p> </li> <li>\u751f\u6210\u5dee\u5f02\u8868\u8fbe\u57fa\u56e0\u70ed\u56fe</li> <li>\u521b\u5efa\u8bf4\u660e\u8c03\u63a7\u673a\u5236\u7684\u901a\u8def\u56fe</li> <li>\u5f00\u53d1\u8868\u578b\u6570\u636e\u7684\u6e05\u6670\u56fe\u5f62\u8868\u793a</li> <li>\u51c6\u5907\u6574\u5408\u591a\u79cd\u6570\u636e\u7c7b\u578b\u7684\u7efc\u5408\u56fe\u8868</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_8","title":"\u516b\u3001\u9a8c\u8bc1\u548c\u8f6c\u5316\u7814\u7a76","text":"<ol> <li>\u72ec\u7acb\u9a8c\u8bc1\u961f\u5217</li> <li>\u5728\u72ec\u7acb\u5c0f\u9f20\u961f\u5217\u4e2d\u91cd\u590d\u5173\u952e\u5b9e\u9a8c</li> <li>\u5728\u4e0d\u540c\u5c0f\u9f20\u54c1\u7cfb\u4e2d\u6d4b\u8bd5\u53d1\u73b0\uff0c\u8bc4\u4f30\u901a\u7528\u6027</li> <li>\u7528\u66ff\u4ee3\u6572\u9664\u6a21\u578b\u9a8c\u8bc1(\u5982\u5168\u8eabvs\u7ec4\u7ec7\u7279\u5f02\u6027)</li> <li> <p>\u7528\u591a\u4e2a\u5206\u79bb\u682a\u786e\u8ba4\u7ec6\u83cc\u83cc\u682a\u6548\u5e94</p> </li> <li> <p>\u529f\u80fd\u83b7\u5f97\u6027\u7814\u7a76</p> </li> <li>\u5728\u76f8\u5173\u7ec4\u7ec7\u4e2d\u8fc7\u8868\u8fbeNfil3\u3001Hdac3\u6216Snhg9</li> <li>\u8bc4\u4f30\u5bf9\u8102\u8d28\u4ee3\u8c22\u548c\u80a5\u80d6\u6613\u611f\u6027\u7684\u5f71\u54cd</li> <li>\u5411\u5fae\u751f\u7269\u7fa4\u5931\u8c03\u7684\u5c0f\u9f20\u5f15\u5165\u4e73\u9178\u6746\u83ccPm001</li> <li> <p>\u6d4b\u8bd5\u7ec6\u83cc\u8865\u5145\u662f\u5426\u80fd\u633d\u6551\u4ee3\u8c22\u8868\u578b</p> </li> <li> <p>\u4eba\u7c7b\u76f8\u5173\u6027\u8bc4\u4f30</p> </li> <li>\u5206\u6790\u4eba\u7c7b\u5fae\u751f\u7269\u7ec4\u6570\u636e\u96c6\u4e2d\u4e73\u9178\u6746\u83cc\u4e30\u5ea6</li> <li>\u4e0e\u4eba\u7c7b\u961f\u5217\u4e2d\u7684\u4ee3\u8c22\u53c2\u6570\u76f8\u5173\u8054</li> <li>\u68c0\u67e5\u4eba\u7c7b\u80a0\u9053\u6d3b\u68c0\u4e2dSNHG9\u3001NFIL3\u548cHDAC3\u8868\u8fbe</li> <li> <p>\u4e0e\u4ee3\u8c22\u75be\u75c5\u60a3\u8005\u6570\u636e\u6bd4\u8f83\u53d1\u73b0</p> </li> <li> <p>\u6cbb\u7597\u6f5c\u529b\u63a2\u7d22</p> </li> <li>\u5f00\u53d1\u542b\u4e73\u9178\u6746\u83ccPm001\u7684\u76ca\u751f\u83cc\u914d\u65b9</li> <li>\u6d4b\u8bd5\u5728\u9884\u9632\u548c\u6cbb\u7597\u996e\u98df\u8bf1\u5bfc\u80a5\u80d6\u4e2d\u7684\u6548\u679c</li> <li>\u63a2\u7d22NFIL3-HDAC3-Snhg9\u901a\u8def\u7684\u5c0f\u5206\u5b50\u8c03\u8282\u5242</li> <li>\u8bc4\u4f30\u9776\u5411\u591a\u4e2a\u901a\u8def\u7ec4\u5206\u7684\u7ec4\u5408\u65b9\u6cd5</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_9","title":"\u4e5d\u3001\u9ad8\u7ea7\u673a\u5236\u7814\u7a76","text":"<ol> <li>\u663c\u591c\u8282\u5f8b\u5206\u6790</li> <li>\u68c0\u67e5Nfil3\u3001Hdac3\u548cSnhg9\u7684\u65f6\u95f4\u4f9d\u8d56\u6027\u8868\u8fbe</li> <li>\u572824\u5c0f\u65f6\u5468\u671f\u5185\u591a\u4e2a\u65f6\u95f4\u70b9\u6536\u96c6\u7ec4\u7ec7</li> <li>\u5206\u6790\u5fae\u751f\u7269\u7fa4\u663c\u591c\u53d8\u5316\u548c\u4ee3\u8c22\u7269\u4ea7\u751f</li> <li> <p>\u7814\u7a76\u9650\u65f6\u5582\u517b\u5982\u4f55\u5f71\u54cd\u8be5\u901a\u8def</p> </li> <li> <p>\u514d\u75ab\u7cfb\u7edf\u76f8\u4e92\u4f5c\u7528</p> </li> <li>\u8868\u5f81\u80a0\u9053\u7ec4\u7ec7\u4e2d\u7684\u514d\u75ab\u7ec6\u80de\u7fa4\u4f53</li> <li>\u6d4b\u91cf\u8840\u6e05\u548c\u7ec4\u7ec7\u5300\u6d46\u4e2d\u7684\u7ec6\u80de\u56e0\u5b50\u8c31</li> <li>\u7814\u7a76\u514d\u75ab\u4fe1\u53f7\u5982\u4f55\u5f71\u54cdNFIL3-HDAC3-Snhg9\u8f74</li> <li> <p>\u5728\u514d\u75ab\u7f3a\u9677\u5c0f\u9f20\u6a21\u578b\u4e2d\u6d4b\u8bd5\u8be5\u901a\u8def</p> </li> <li> <p>\u80c6\u6c41\u9178\u4ee3\u8c22\u7814\u7a76</p> </li> <li>\u5206\u6790\u80a0\u9053\u5185\u5bb9\u7269\u548c\u8840\u6e05\u4e2d\u7684\u80c6\u6c41\u9178\u7ec4\u6210</li> <li>\u5206\u6790\u80c6\u6c41\u9178\u5408\u6210\u548c\u8f6c\u8fd0\u57fa\u56e0\u8868\u8fbe</li> <li>\u7814\u7a76\u4e73\u9178\u6746\u83cc\u5982\u4f55\u5f71\u54cd\u80c6\u6c41\u9178\u4ee3\u8c22</li> <li> <p>\u6d4b\u8bd5\u80c6\u6c41\u9178\u53d7\u4f53\u6fc0\u52a8\u5242/\u62ee\u6297\u5242\u5bf9\u901a\u8def\u7684\u5f71\u54cd</p> </li> <li> <p>\u80a0\u9053\u5c4f\u969c\u529f\u80fd\u8bc4\u4f30</p> </li> <li>\u4f7f\u7528FITC-\u8461\u805a\u7cd6\u6d4b\u5b9a\u80a0\u9053\u901a\u900f\u6027</li> <li>\u5206\u6790\u7d27\u5bc6\u8fde\u63a5\u86cb\u767d\u8868\u8fbe\u548c\u5b9a\u4f4d</li> <li>\u7814\u7a76\u5c4f\u969c\u5b8c\u6574\u6027\u5982\u4f55\u5f71\u54cd\u8102\u8d28\u4ee3\u8c22</li> <li>\u6d4b\u8bd5\u4e73\u9178\u6746\u83cc\u662f\u5426\u6539\u5584\u9ad8\u8102\u996e\u98df\u5582\u517b\u5c0f\u9f20\u7684\u5c4f\u969c\u529f\u80fd</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_10","title":"\u5341\u3001\u4e34\u5e8a\u8f6c\u5316\u548c\u672a\u6765\u65b9\u5411","text":"<ol> <li>\u4eba\u7c7b\u521d\u6b65\u7814\u7a76</li> <li>\u8bbe\u8ba1\u5c0f\u89c4\u6a21\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8865\u5145\u4e73\u9178\u6746\u83cc</li> <li>\u9488\u5bf9\u4ee3\u8c22\u7efc\u5408\u5f81\u6216\u975e\u9152\u7cbe\u6027\u8102\u80aa\u809d\u60a3\u8005</li> <li>\u6d4b\u91cf\u8102\u8d28\u8c31\u3001\u8461\u8404\u7cd6\u4ee3\u8c22\u548c\u708e\u75c7\u53d8\u5316</li> <li> <p>\u6536\u96c6\u7caa\u4fbf\u6837\u672c\u8fdb\u884c\u5fae\u751f\u7269\u7ec4\u5206\u6790\u548cSNHG9\u8868\u8fbe\u6d4b\u5b9a</p> </li> <li> <p>**\u751f\u7269\u6807\u5fd7\u7269\u5f00\u53d1</p> </li> <li>\u8bc6\u522b\u4e0e\u901a\u8def\u6fc0\u6d3b\u76f8\u5173\u7684\u5faa\u73af\u751f\u7269\u6807\u5fd7\u7269</li> <li>\u5f00\u53d1\u6d4b\u91cf\u4eba\u4f53\u6837\u672c\u4e2d\u7ec6\u83cc\u4ee3\u8c22\u7269\u7684\u68c0\u6d4b\u65b9\u6cd5</li> <li>\u521b\u5efa\u8bca\u65ad\u9762\u677f\u8bc6\u522b\u53ef\u80fd\u5bf9\u5e72\u9884\u6709\u53cd\u5e94\u7684\u60a3\u8005</li> <li> <p>\u5728\u524d\u77bb\u6027\u4e34\u5e8a\u961f\u5217\u4e2d\u9a8c\u8bc1\u751f\u7269\u6807\u5fd7\u7269</p> </li> <li> <p>\u4e2a\u6027\u5316\u5e72\u9884\u7b56\u7565</p> </li> <li>\u57fa\u4e8e\u57fa\u7ebf\u5fae\u751f\u7269\u7ec4\u7ec4\u6210\u5bf9\u4e2a\u4f53\u8fdb\u884c\u5206\u5c42</li> <li>\u5f00\u53d1\u7b97\u6cd5\u9884\u6d4b\u5bf9\u4e73\u9178\u6746\u83cc\u8865\u5145\u7684\u53cd\u5e94\u8005</li> <li>\u8bbe\u8ba1\u4e2a\u6027\u5316\u996e\u98df\u5efa\u8bae\u4ee5\u652f\u6301\u6709\u76ca\u7ec6\u83cc\u751f\u957f</li> <li> <p>\u6d4b\u8bd5\u7ec4\u5408\u65b9\u6cd5\uff08\u76ca\u751f\u83cc+\u996e\u98df\uff09\u4ee5\u83b7\u5f97\u6700\u5927\u6548\u679c</p> </li> <li> <p>\u957f\u671f\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u76d1\u6d4b</p> </li> <li>\u5efa\u7acb\u957f\u671f\u968f\u8bbf\u534f\u8bae</li> <li>\u76d1\u6d4b\u5fae\u751f\u7269\u7ec4\u64cd\u4f5c\u7684\u6f5c\u5728\u4e0d\u826f\u53cd\u5e94</li> <li>\u8bc4\u4f30\u4ee3\u8c22\u6539\u5584\u7684\u6301\u4e45\u6027</li> <li>\u7814\u7a76\u4e0e\u73b0\u6709\u4ee3\u8c22\u7597\u6cd5\u7ed3\u5408\u7684\u53ef\u80fd\u6027</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_11","title":"\u5341\u4e00\u3001\u673a\u5236\u6df1\u5165\u63a2\u7a76","text":"<ol> <li>\u80a0-\u809d\u8f74\u7814\u7a76</li> <li>\u5206\u6790\u95e8\u9759\u8109\u8840\u6db2\u4e2d\u7684\u4ee3\u8c22\u7269\u8c31</li> <li>\u7814\u7a76\u5fae\u751f\u7269\u4ee3\u8c22\u4ea7\u7269\u5bf9\u809d\u810f\u57fa\u56e0\u8868\u8fbe\u7684\u76f4\u63a5\u5f71\u54cd</li> <li>\u4f7f\u7528\u809d\u7279\u5f02\u6027\u53d7\u4f53\u6572\u9664\u6a21\u578b\u9a8c\u8bc1\u4fe1\u53f7\u901a\u8def</li> <li> <p>\u63a2\u7d22\u80a0\u9053\u83cc\u7fa4\u5bf9\u809d\u810f\u663c\u591c\u8282\u5f8b\u7684\u5f71\u54cd</p> </li> <li> <p>\u68d5\u8272\u8102\u80aa\u7ec4\u7ec7\u548c\u80fd\u91cf\u6d88\u8017</p> </li> <li>\u5206\u6790\u4e73\u9178\u6746\u83ccPm001\u5bf9\u68d5\u8272\u8102\u80aa\u7ec4\u7ec7\u6d3b\u5316\u7684\u5f71\u54cd</li> <li>\u6d4b\u91cfUCP1\u8868\u8fbe\u548c\u7ebf\u7c92\u4f53\u751f\u7269\u5408\u6210</li> <li>\u4f7f\u7528\u70ed\u6210\u50cf\u6280\u672f\u8bc4\u4f30\u4f53\u6e29\u8c03\u8282</li> <li> <p>\u7814\u7a76\u4ea4\u611f\u795e\u7ecf\u7cfb\u7edf\u5728\u5fae\u751f\u7269\u4ecb\u5bfc\u7684\u80fd\u91cf\u6d88\u8017\u4e2d\u7684\u4f5c\u7528</p> </li> <li> <p>\u80a0\u9053\u6fc0\u7d20\u4ecb\u5bfc\u7684\u6548\u5e94</p> </li> <li>\u6d4b\u91cfGLP-1\u3001PYY\u7b49\u80a0\u9053\u6fc0\u7d20\u6c34\u5e73</li> <li>\u5206\u6790L\u7ec6\u80de\u5bf9\u4e73\u9178\u6746\u83cc\u4ee3\u8c22\u7269\u7684\u53cd\u5e94</li> <li>\u4f7f\u7528\u80a0\u9053\u6fc0\u7d20\u53d7\u4f53\u62ee\u6297\u5242\u963b\u65ad\u5b9e\u9a8c</li> <li> <p>\u7814\u7a76\u5fae\u751f\u7269-\u80a0\u9053\u6fc0\u7d20-\u8102\u8d28\u4ee3\u8c22\u8f74</p> </li> <li> <p>\u8111-\u80a0\u8f74\u76f8\u4e92\u4f5c\u7528</p> </li> <li>\u8bc4\u4f30\u8ff7\u8d70\u795e\u7ecf\u5728\u5fae\u751f\u7269\u4fe1\u53f7\u4f20\u5bfc\u4e2d\u7684\u4f5c\u7528</li> <li>\u5206\u6790\u4e0b\u4e18\u8111\u98df\u6b32\u8c03\u8282\u4e2d\u67a2\u7684\u57fa\u56e0\u8868\u8fbe</li> <li>\u7814\u7a76\u5fae\u751f\u7269\u5bf9\u6444\u98df\u884c\u4e3a\u548c\u98df\u6b32\u7684\u5f71\u54cd</li> <li>\u63a2\u7d22\u80a0\u9053\u5fae\u751f\u7269\u4e0e\u4e2d\u67a2\u795e\u7ecf\u7cfb\u7edf\u4e4b\u95f4\u7684\u53cc\u5411\u901a\u4fe1</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_12","title":"\u5341\u4e8c\u3001\u5de5\u7a0b\u5316\u5fae\u751f\u7269\u548c\u9ad8\u7ea7\u5e72\u9884","text":"<ol> <li>\u5de5\u7a0b\u5316\u76ca\u751f\u83cc\u5f00\u53d1</li> <li>\u57fa\u4e8e\u4e73\u9178\u6746\u83ccPm001\u5f00\u53d1\u91cd\u7ec4\u83cc\u682a</li> <li>\u5de5\u7a0b\u5316\u7ec6\u83cc\u8868\u8fbe\u5173\u952e\u4ee3\u8c22\u7269\u6216\u8c03\u8282\u5206\u5b50</li> <li>\u8bbe\u8ba1\u53ef\u63a7\u5236\u7684\u57fa\u56e0\u8868\u8fbe\u7cfb\u7edf</li> <li> <p>\u8bc4\u4f30\u5de5\u7a0b\u5316\u83cc\u682a\u7684\u5b89\u5168\u6027\u548c\u5b9a\u690d\u80fd\u529b</p> </li> <li> <p>\u9776\u5411\u9012\u9001\u7cfb\u7edf</p> </li> <li>\u5f00\u53d1\u4fdd\u62a4\u76ca\u751f\u83cc\u901a\u8fc7\u80c3\u9178\u7684\u9012\u9001\u7cfb\u7edf</li> <li>\u8bbe\u8ba1\u9776\u5411\u7ed3\u80a0\u7684\u7f13\u91ca\u5236\u5242</li> <li>\u63a2\u7d22\u7ec6\u83cc\u5916\u819c\u56ca\u6ce1\u4f5c\u4e3a\u751f\u7269\u6d3b\u6027\u5206\u5b50\u8f7d\u4f53</li> <li> <p>\u6d4b\u8bd5\u53e3\u670d\u548c\u76f4\u80a0\u7ed9\u836f\u9014\u5f84\u7684\u6548\u679c\u6bd4\u8f83</p> </li> <li> <p>\u8054\u5408\u5e72\u9884\u7b56\u7565</p> </li> <li>\u8bc4\u4f30\u76ca\u751f\u83cc\u4e0e\u7279\u5b9a\u81b3\u98df\u7ea4\u7ef4\u7ec4\u5408\u7684\u534f\u540c\u4f5c\u7528</li> <li>\u6d4b\u8bd5\u5fae\u751f\u7269\u5e72\u9884\u4e0e\u4ee3\u8c22\u836f\u7269\u7684\u7ec4\u5408</li> <li>\u63a2\u7d22\u4e0e\u8fd0\u52a8\u6216\u9650\u65f6\u8fdb\u98df\u7684\u7ed3\u5408\u6548\u679c</li> <li> <p>\u5f00\u53d1\u591a\u83cc\u682a\u914d\u65b9\u4ee5\u589e\u5f3a\u529f\u6548\u548c\u7a33\u5065\u6027</p> </li> <li> <p>\u9884\u9632\u7b56\u7565\u5f00\u53d1</p> </li> <li>\u8bbe\u8ba1\u9488\u5bf9\u9ad8\u98ce\u9669\u4eba\u7fa4\u7684\u65e9\u671f\u5e72\u9884\u65b9\u6848</li> <li>\u8bc4\u4f30\u6bcd\u5a74\u5782\u76f4\u4f20\u64ad\u5bf9\u4ee3\u8c22\u5065\u5eb7\u7684\u5f71\u54cd</li> <li>\u7814\u7a76\u513f\u7ae5\u671f\u5fae\u751f\u7269\u5e72\u9884\u5bf9\u6210\u5e74\u671f\u4ee3\u8c22\u75be\u75c5\u7684\u957f\u671f\u5f71\u54cd</li> <li>\u5f00\u53d1\u53ef\u884c\u7684\u516c\u5171\u5065\u5eb7\u5e72\u9884\u63aa\u65bd</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_13","title":"\u5341\u4e09\u3001\u8f6c\u5316\u533b\u5b66\u5e94\u7528","text":"<ol> <li>\u4e34\u5e8a\u8bd5\u9a8c\u6269\u5c55</li> <li>\u8bbe\u8ba1\u591a\u4e2d\u5fc3\u3001\u968f\u673a\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5bf9\u7167\u8bd5\u9a8c</li> <li>\u7eb3\u5165\u591a\u6837\u5316\u60a3\u8005\u7fa4\u4f53\u4ee5\u8bc4\u4f30\u5e7f\u6cdb\u9002\u7528\u6027</li> <li>\u8bc4\u4f30\u4e0d\u540c\u5242\u91cf\u548c\u6cbb\u7597\u6301\u7eed\u65f6\u95f4\u7684\u6548\u679c</li> <li> <p>\u76d1\u6d4b\u957f\u671f\u7597\u6548\u548c\u5b89\u5168\u6027</p> </li> <li> <p>\u7279\u6b8a\u4eba\u7fa4\u7814\u7a76</p> </li> <li>\u8bc4\u4f30\u5728\u513f\u7ae5\u80a5\u80d6\u4e2d\u7684\u5e94\u7528</li> <li>\u7814\u7a76\u5728\u8001\u5e74\u4ee3\u8c22\u7d0a\u4e71\u4e2d\u7684\u6548\u679c</li> <li>\u63a2\u7d22\u5728\u598a\u5a20\u671f\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027</li> <li> <p>\u9488\u5bf9\u4e0d\u540c\u79cd\u65cf\u548c\u5730\u7406\u4eba\u7fa4\u7684\u9002\u5e94\u6027\u7814\u7a76</p> </li> <li> <p>\u5546\u4e1a\u5316\u548c\u53ef\u53ca\u6027</p> </li> <li>\u5f00\u53d1\u7a33\u5b9a\u3001\u6807\u51c6\u5316\u7684\u76ca\u751f\u83cc\u5236\u5242</li> <li>\u4f18\u5316\u751f\u4ea7\u5de5\u827a\u4ee5\u964d\u4f4e\u6210\u672c</li> <li>\u5efa\u7acb\u8d28\u91cf\u63a7\u5236\u6807\u51c6\u548c\u4fdd\u8d28\u671f\u6d4b\u8bd5</li> <li> <p>\u63a2\u7d22\u9002\u5408\u8d44\u6e90\u6709\u9650\u5730\u533a\u7684\u914d\u65b9</p> </li> <li> <p>\u76d1\u7ba1\u548c\u4f26\u7406\u8003\u91cf</p> </li> <li>\u4e0e\u76d1\u7ba1\u673a\u6784\u5408\u4f5c\u5236\u5b9a\u5fae\u751f\u7269\u6cbb\u7597\u7684\u8bc4\u4f30\u6846\u67b6</li> <li>\u89e3\u51b3\u57fa\u56e0\u5de5\u7a0b\u5fae\u751f\u7269\u7684\u5b89\u5168\u6027\u548c\u73af\u5883\u95ee\u9898</li> <li>\u5efa\u7acb\u60a3\u8005\u77e5\u60c5\u540c\u610f\u7684\u6700\u4f73\u5b9e\u8df5</li> <li>\u8003\u8651\u5fae\u751f\u7269\u7ec4\u5e72\u9884\u7684\u957f\u671f\u751f\u6001\u5f71\u54cd</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#_14","title":"\u5341\u56db\u3001\u57fa\u7840\u79d1\u5b66\u62d3\u5c55","text":"<ol> <li>\u5bbf\u4e3b-\u5fae\u751f\u7269\u5171\u8fdb\u5316\u7814\u7a76</li> <li>\u5206\u6790\u4e0d\u540c\u4eba\u7fa4\u4e2d\u4e73\u9178\u6746\u83cc\u8c31\u7cfb\u7684\u8fdb\u5316</li> <li>\u7814\u7a76\u5bbf\u4e3b\u57fa\u56e0\u53d8\u5f02\u4e0e\u5fae\u751f\u7269\u7ec4\u7ec4\u6210\u7684\u76f8\u4e92\u4f5c\u7528</li> <li>\u63a2\u7d22\u4ee3\u8c22\u9002\u5e94\u7684\u5206\u5b50\u673a\u5236</li> <li> <p>\u6784\u5efa\u5bbf\u4e3b-\u5fae\u751f\u7269\u4e92\u4f5c\u7684\u8fdb\u5316\u6a21\u578b</p> </li> <li> <p>\u751f\u6001\u7cfb\u7edf\u52a8\u529b\u5b66</p> </li> <li>\u7814\u7a76\u5fae\u751f\u7269\u7fa4\u843d\u4e2d\u7684\u7269\u79cd\u95f4\u76f8\u4e92\u4f5c\u7528</li> <li>\u5206\u6790\u4e73\u9178\u6746\u83ccPm001\u7684\u751f\u6001\u4f4d\u548c\u7ade\u4e89\u7b56\u7565</li> <li>\u63a2\u7d22\u5fae\u751f\u7269\u7fa4\u7a33\u5b9a\u6027\u548c\u6062\u590d\u529b\u7684\u51b3\u5b9a\u56e0\u7d20</li> <li> <p>\u5efa\u7acb\u9884\u6d4b\u5fae\u751f\u7269\u5e72\u9884\u957f\u671f\u6548\u679c\u7684\u751f\u6001\u6a21\u578b</p> </li> <li> <p>\u5fae\u751f\u7269\u7fa4\u843d\u95f4\u901a\u4fe1</p> </li> <li>\u7814\u7a76\u7ec6\u83cc\u95f4\u6a2a\u5411\u57fa\u56e0\u8f6c\u79fb</li> <li>\u5206\u6790\u7fa4\u4f53\u611f\u5e94\u5206\u5b50\u5728\u4ee3\u8c22\u8c03\u63a7\u4e2d\u7684\u4f5c\u7528</li> <li>\u63a2\u7d22\u83cc\u7fa4-\u771f\u83cc-\u75c5\u6bd2\u76f8\u4e92\u4f5c\u7528</li> <li>\u5f00\u53d1\u9776\u5411\u5fae\u751f\u7269\u95f4\u901a\u4fe1\u7684\u5e72\u9884\u7b56\u7565</li> </ol> <p>\u8fd9\u4e00\u5168\u9762\u7684\u5b9e\u9a8c\u5de5\u4f5c\u6d41\u7a0b\u4f7f\u7814\u7a76\u4eba\u5458\u80fd\u591f\u6df1\u5165\u7814\u7a76\u80a0\u9053\u5fae\u751f\u7269\uff0c\u7279\u522b\u662f\u4e73\u9178\u6746\u83ccPm001\uff0c\u901a\u8fc7NFIL3-HDAC3-Snhg9\u8f74\u8c03\u63a7\u5bbf\u4e3b\u8102\u8d28\u4ee3\u8c22\u7684\u5206\u5b50\u673a\u5236\u3002\u8be5\u65b9\u6cd5\u6574\u5408\u4e86\u591a\u5c42\u6b21\u5206\u6790\u2014\u4ece\u5fae\u751f\u7269\u7ec4\u5230\u8f6c\u5f55\u7ec4\u518d\u5230\u4ee3\u8c22\u8868\u578b\u2014\u63d0\u4f9b\u4e86\u5bbf\u4e3b-\u5fae\u751f\u7269\u76f8\u4e92\u4f5c\u7528\u5728\u4ee3\u8c22\u5065\u5eb7\u4e0e\u75be\u75c5\u4e2d\u7684\u7cfb\u7edf\u7ea7\u7406\u89e3\uff0c\u5e76\u4e3a\u5f00\u53d1\u57fa\u4e8e\u5fae\u751f\u7269\u7684\u6cbb\u7597\u7b56\u7565\u5960\u5b9a\u4e86\u57fa\u7840\u3002</p> <p>Experimental Workflow: Gut Microbiota Regulation of Host Lipid Metabolism</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#i-animal-model-establishment-and-characterization","title":"I. Animal Model Establishment and Characterization","text":"<ol> <li>Germ-Free (GF) Mouse Colony Maintenance</li> <li>House mice in sterile isolators with autoclaved food, water, and bedding</li> <li>Monitor sterility through regular fecal sampling and culture</li> <li>Maintain GF breeding pairs to generate experimental animals</li> <li> <p>Age and sex-match mice for experiments (8-12 weeks old)</p> </li> <li> <p>Conventional (CV) Mouse Controls</p> </li> <li>House mice in standard specific-pathogen-free (SPF) conditions</li> <li>Match genetic background, age, and sex to GF counterparts</li> <li>Control diet composition and feeding schedule</li> <li> <p>Collect fecal samples for microbiome characterization</p> </li> <li> <p>Tissue-Specific Knockout Model Generation</p> </li> <li>Generate intestinal epithelial cell-specific knockouts (e.g., Nfil3\u0394IEC, Hdac3\u0394IEC)</li> <li>Use Villin-Cre recombinase system for IEC-specific deletion</li> <li>Confirm genotypes by PCR and deletion efficiency by qPCR/Western blot</li> <li>Establish breeding colonies to generate experimental and littermate control mice</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#ii-microbiota-manipulation-experiments","title":"II. Microbiota Manipulation Experiments","text":"<ol> <li>Bacterial Strain Isolation and Characterization</li> <li>Isolate candidate strains (e.g., Lactobacillus plantarum Pm001) from healthy mice</li> <li>Perform 16S rRNA gene sequencing for taxonomic identification</li> <li>Whole-genome sequencing to characterize functional potential</li> <li> <p>Establish pure cultures and prepare standardized inocula</p> </li> <li> <p>Bacterial Gavage Procedures</p> </li> <li>Prepare bacterial cultures to defined concentrations (10^8-10^9 CFU/ml)</li> <li>Administer 200\u03bcl bacterial suspension via oral gavage to GF mice</li> <li>For control groups, administer sterile culture medium</li> <li>Establish colonization through regular fecal sampling and qPCR</li> <li> <p>Maintain mice in separate isolators to prevent cross-contamination</p> </li> <li> <p>Dietary Interventions</p> </li> <li>Formulate control diet (CD) and high-fat diet (HFD) with defined composition</li> <li>CD: 10% fat, 70% carbohydrate, 20% protein by calories</li> <li>HFD: 60% fat, 20% carbohydrate, 20% protein by calories</li> <li>Feed mice ad libitum or pair-fed depending on experimental design</li> <li>Monitor food intake and body weight 2-3 times weekly</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#iii-phenotypic-and-metabolic-assessment","title":"III. Phenotypic and Metabolic Assessment","text":"<ol> <li>Body Composition Analysis</li> <li>Measure body weight progression throughout the experiment</li> <li>Perform DEXA scanning for fat and lean mass quantification</li> <li>Measure tissue weights (liver, epididymal fat pad, subcutaneous fat)</li> <li> <p>Calculate tissue-to-body weight ratios</p> </li> <li> <p>Glucose and Insulin Homeostasis</p> </li> <li>Perform glucose tolerance test (GTT): 1-2 g/kg glucose i.p. after 6h fast</li> <li>Conduct insulin tolerance test (ITT): 0.75-1 U/kg insulin i.p. after 4h fast</li> <li>Measure fasting blood glucose and insulin levels</li> <li> <p>Calculate HOMA-IR index for insulin resistance assessment</p> </li> <li> <p>Lipid Metabolism Analysis</p> </li> <li>Collect serum for triglyceride, cholesterol, and free fatty acid measurement</li> <li>Extract liver lipids using chloroform/methanol (2:1) extraction</li> <li>Quantify hepatic triglycerides and cholesterol using colorimetric assays</li> <li>Perform Oil Red O staining on liver sections to visualize lipid droplets</li> <li> <p>Measure adipocyte size in H&amp;E-stained adipose tissue sections</p> </li> <li> <p>Energy Expenditure and Physical Activity</p> </li> <li>House mice in metabolic cages to measure:<ul> <li>Oxygen consumption and CO2 production</li> <li>Respiratory exchange ratio (RER)</li> <li>Heat production</li> <li>Locomotor activity</li> <li>Food and water intake</li> </ul> </li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#iv-molecular-and-cellular-analysis","title":"IV. Molecular and Cellular Analysis","text":"<ol> <li>Transcriptomic Analysis</li> <li>Harvest tissues (liver, ileum, colon) and extract total RNA</li> <li>Perform RNA quality control using Bioanalyzer</li> <li>Prepare RNA-seq libraries and sequence (Illumina platform)</li> <li>Analyze differential gene expression between experimental groups</li> <li>Perform pathway enrichment analysis to identify regulated biological processes</li> <li> <p>Validate key genes (e.g., Nfil3, Hdac3, Snhg9) by RT-qPCR</p> </li> <li> <p>Protein Expression Analysis</p> </li> <li>Extract proteins from tissues using appropriate lysis buffers</li> <li>Quantify protein concentration by BCA assay</li> <li>Perform Western blotting for key proteins (NFIL3, HDAC3)</li> <li>Conduct immunohistochemistry on tissue sections</li> <li> <p>Analyze protein-protein interactions through co-immunoprecipitation</p> </li> <li> <p>Epigenetic Analysis</p> </li> <li>Perform chromatin immunoprecipitation (ChIP) for HDAC3 and other regulators</li> <li>Assess histone modifications (H3K27ac, H3K4me3) at target gene loci</li> <li>Analyze DNA methylation patterns using bisulfite sequencing</li> <li> <p>Investigate chromatin accessibility using ATAC-seq</p> </li> <li> <p>Functional Analysis of lncRNA Snhg9</p> </li> <li>Design and validate siRNAs or antisense oligonucleotides targeting Snhg9</li> <li>Transfect primary hepatocytes or intestinal organoids</li> <li>Measure effects on lipid metabolism genes and lipid accumulation</li> <li>Perform RNA pulldown to identify Snhg9 protein binding partners</li> <li>Analyze subcellular localization using RNA fluorescence in situ hybridization</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#v-microbiome-analysis","title":"V. Microbiome Analysis","text":"<ol> <li>16S rRNA Gene Sequencing</li> <li>Extract bacterial DNA from fecal samples</li> <li>Amplify V3-V4 region of 16S rRNA gene</li> <li>Prepare sequencing libraries and perform paired-end sequencing</li> <li>Analyze taxonomic composition and diversity metrics</li> <li> <p>Compare microbial communities between experimental groups</p> </li> <li> <p>Metagenomic Sequencing</p> </li> <li>Perform shotgun metagenomic sequencing on select samples</li> <li>Analyze functional gene content and metabolic pathways</li> <li>Identify bacterial genes involved in lipid metabolism</li> <li> <p>Compare strain-level differences between communities</p> </li> <li> <p>Metabolomic Analysis</p> </li> <li>Collect fecal, serum, and tissue samples for metabolite extraction</li> <li>Perform untargeted LC-MS/MS or GC-MS analysis</li> <li>Identify bacterial metabolites (e.g., short-chain fatty acids)</li> <li>Correlate metabolite levels with host gene expression and phenotypes</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#vi-mechanistic-studies","title":"VI. Mechanistic Studies","text":"<ol> <li>Intestinal Organoid Culture</li> <li>Isolate intestinal crypts from experimental mice</li> <li>Establish 3D organoid cultures in Matrigel</li> <li>Treat organoids with bacterial supernatants or purified metabolites</li> <li> <p>Analyze gene expression changes and lipid metabolism</p> </li> <li> <p>Primary Hepatocyte Isolation and Culture</p> </li> <li>Isolate primary hepatocytes from experimental mice</li> <li>Culture in defined media with or without bacterial metabolites</li> <li>Measure lipid synthesis, oxidation, and accumulation</li> <li> <p>Analyze expression of key metabolic genes</p> </li> <li> <p>In Vitro Bacterial-Epithelial Co-culture</p> </li> <li>Establish transwell co-culture systems with intestinal epithelial cells</li> <li>Add L. plantarum Pm001 or other bacterial strains to apical compartment</li> <li>Analyze epithelial gene expression and barrier function</li> <li> <p>Measure cytokine and chemokine production</p> </li> <li> <p>Bacterial Metabolite Identification and Testing</p> </li> <li>Fractionate bacterial culture supernatants</li> <li>Identify active metabolites using mass spectrometry</li> <li>Synthesize or purify candidate metabolites</li> <li>Test effects on gene expression and lipid metabolism in vitro and in vivo</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#vii-data-integration-and-analysis","title":"VII. Data Integration and Analysis","text":"<ol> <li>Statistical Analysis</li> <li>Apply appropriate statistical tests (t-tests, ANOVA with post-hoc tests)</li> <li>Control for multiple comparisons (FDR correction)</li> <li>Perform power analysis to ensure adequate sample sizes</li> <li>Use linear mixed models for longitudinal data</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#vii-data-integration-and-analysis-continued","title":"VII. Data Integration and Analysis (continued)","text":"<ol> <li>Multi-Omics Data Integration (continued)</li> <li>Correlate transcriptomic, metabolomic, and microbiome data</li> <li>Perform network analysis to identify key regulatory hubs</li> <li>Use machine learning approaches to identify predictive signatures</li> <li> <p>Generate integrative models of microbiota-host interactions</p> </li> <li> <p>Pathway Modeling</p> </li> <li>Map differentially expressed genes onto metabolic pathways</li> <li>Identify regulatory circuits connecting microbiota signals to lipid metabolism</li> <li>Model the NFIL3-HDAC3-Snhg9 regulatory axis</li> <li> <p>Predict potential therapeutic targets based on pathway analysis</p> </li> <li> <p>Visualization and Presentation</p> </li> <li>Generate heat maps of differentially expressed genes</li> <li>Create pathway diagrams illustrating regulatory mechanisms</li> <li>Develop clear graphical representations of phenotypic data</li> <li>Prepare comprehensive figures integrating multiple data types</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#viii-validation-and-translational-studies","title":"VIII. Validation and Translational Studies","text":"<ol> <li>Independent Validation Cohorts</li> <li>Repeat key experiments in independent mouse cohorts</li> <li>Test findings in different mouse strains to assess generalizability</li> <li>Validate with alternative knockout models (e.g., global vs. tissue-specific)</li> <li> <p>Confirm bacterial strain effects with multiple isolates</p> </li> <li> <p>Gain-of-Function Studies</p> </li> <li>Overexpress Nfil3, Hdac3, or Snhg9 in relevant tissues</li> <li>Assess effects on lipid metabolism and obesity susceptibility</li> <li>Introduce L. plantarum Pm001 to mice with dysbiotic microbiota</li> <li> <p>Test if bacterial supplementation can rescue metabolic phenotypes</p> </li> <li> <p>Human Relevance Assessment</p> </li> <li>Analyze human microbiome datasets for L. plantarum abundance</li> <li>Correlate with metabolic parameters in human cohorts</li> <li>Examine SNHG9, NFIL3, and HDAC3 expression in human intestinal biopsies</li> <li> <p>Compare findings with data from patients with metabolic disorders</p> </li> <li> <p>Therapeutic Potential Exploration</p> </li> <li>Develop probiotic formulations containing L. plantarum Pm001</li> <li>Test efficacy in prevention and treatment of diet-induced obesity</li> <li>Explore small molecule modulators of the NFIL3-HDAC3-Snhg9 pathway</li> <li>Assess combination approaches targeting multiple pathway components</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#ix-advanced-mechanistic-investigations","title":"IX. Advanced Mechanistic Investigations","text":"<ol> <li>Circadian Rhythm Analysis</li> <li>Examine time-dependent expression of Nfil3, Hdac3, and Snhg9</li> <li>Collect tissues at multiple time points across 24-hour cycle</li> <li>Analyze microbiota diurnal variations and metabolite production</li> <li> <p>Investigate how time-restricted feeding affects the pathway</p> </li> <li> <p>Immune System Interactions</p> </li> <li>Characterize immune cell populations in intestinal tissue</li> <li>Measure cytokine profiles in serum and tissue homogenates</li> <li>Investigate how immune signaling affects the NFIL3-HDAC3-Snhg9 axis</li> <li> <p>Test the pathway in immune-deficient mouse models</p> </li> <li> <p>Bile Acid Metabolism Studies</p> </li> <li>Profile bile acid composition in intestinal content and serum</li> <li>Analyze expression of bile acid synthesis and transport genes</li> <li>Investigate how L. plantarum affects bile acid metabolism</li> <li> <p>Test bile acid receptor agonists/antagonists for pathway effects</p> </li> <li> <p>Intestinal Barrier Function Assessment</p> </li> <li>Measure intestinal permeability using FITC-dextran assay</li> <li>Analyze tight junction protein expression and localization</li> <li>Investigate how barrier integrity affects lipid metabolism</li> <li>Test if L. plantarum improves barrier function in HFD-fed mice</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#x-clinical-translation-and-future-directions","title":"X. Clinical Translation and Future Directions","text":"<ol> <li>Pilot Human Studies</li> <li>Design small-scale clinical trials with L. plantarum supplementation</li> <li>Target patients with metabolic syndrome or non-alcoholic fatty liver disease</li> <li>Measure changes in lipid profiles, glucose metabolism, and inflammation</li> <li> <p>Collect fecal samples for microbiome analysis and SNHG9 expression</p> </li> <li> <p>Biomarker Development</p> </li> <li>Identify circulating biomarkers associated with pathway activation</li> <li>Develop assays to measure bacterial metabolites in human samples</li> <li>Create diagnostic panels to identify patients likely to respond to intervention</li> <li> <p>Validate biomarkers in prospective clinical cohorts</p> </li> <li> <p>Personalized Intervention Strategies</p> </li> <li>Stratify individuals based on baseline microbiome composition</li> <li>Develop algorithms to predict responders to L. plantarum supplementation</li> <li>Design personalized dietary recommendations to support beneficial bacteria</li> <li> <p>Test combined approaches (probiotics + diet) for maximal efficacy</p> </li> <li> <p>Long-term Safety and Efficacy Monitoring</p> </li> <li>Establish protocols for long-term follow-up</li> <li>Monitor for potential adverse effects of microbiome manipulation</li> <li>Assess durability of metabolic improvements</li> <li>Investigate potential for combining with existing metabolic therapies</li> </ol> <p>This comprehensive experimental workflow enables researchers to thoroughly investigate the molecular mechanisms by which gut microbiota, particularly L. plantarum Pm001, regulates host lipid metabolism through the NFIL3-HDAC3-Snhg9 axis. The approach integrates multiple levels of analysis\u2014from microbiome to transcriptome to metabolic phenotype\u2014providing a systems-level understanding of host-microbe interactions in metabolic health and disease.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#1-experimental-purpose","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how the gut microbiota regulates host lipid metabolism and how dysbiosis (imbalance in the microbiota) contributes to metabolic disorders such as obesity and diabetes. Specifically, the study investigates the role of\u00a0Nfil3,\u00a0Hdac3, and\u00a0Snhg9\u00a0in mediating the effects of the microbiota on lipid metabolism.</li> <li>Experimental Design: The study uses\u00a0germ-free (GF) mice\u00a0and\u00a0conventional (CV) mice\u00a0to identify key genes regulated by the microbiota. The researchers then use\u00a0gene knockout models\u00a0and\u00a0bacterial gavage\u00a0to study the functional roles of these genes and specific bacterial strains in lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#2-model-system","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0germ-free (GF) mice\u00a0and\u00a0conventional (CV) mice. These models are ideal for studying the effects of the microbiota on host metabolism because GF mice lack a gut microbiota, allowing researchers to isolate the effects of specific bacterial strains.</li> <li>Why This System?: Mice are appropriate for this study because their gut microbiota and lipid metabolism are well-characterized, and they allow for precise genetic manipulation. The use of GF mice is particularly relevant because it enables researchers to study the effects of specific bacterial strains on host metabolism.</li> <li>Alternative Model Systems: Other model systems like\u00a0zebrafish\u00a0or\u00a0Drosophila\u00a0could be used, but they lack the complexity of mammalian lipid metabolism and gut microbiota interactions.</li> <li>Ethical Considerations: Using mice requires ethical approval, especially when dealing with germ-free conditions and dietary interventions. The study likely adheres to ethical guidelines for animal research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#3-measurement-approach","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>RNA sequencing (RNA-seq): To identify genes regulated by the microbiota.</li> <li>Biochemical assays: To measure lipid levels and metabolic activity.</li> <li>Gene knockout models: To study the functional roles of\u00a0Nfil3,\u00a0Hdac3, and\u00a0Snhg9\u00a0in lipid metabolism.</li> <li>Bacterial gavage: To introduce specific bacterial strains (e.g.,\u00a0Lactobacillus plantarum Pm001) into GF mice and study their effects on lipid metabolism.</li> </ul> </li> <li>Why These Methods?: RNA-seq was chosen to identify genes regulated by the microbiota, while biochemical assays were used to measure lipid levels and metabolic activity. Gene knockout models and bacterial gavage were used to study the functional roles of specific genes and bacterial strains.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=3 or more) to ensure the robustness of the data.</li> <li>Potential Biases: Biases could arise from differences in mouse strains or dietary conditions. These are minimized by using standardized protocols and controls.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#4-group-setting","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Germ-free (GF) mice\u00a0vs.\u00a0conventional (CV) mice: To study the effects of the microbiota on lipid metabolism.</li> <li>Gene knockout mice\u00a0(e.g.,\u00a0Nfil3\u0394IEC,\u00a0Hdac3\u0394IEC) vs.\u00a0wild-type mice: To study the functional roles of specific genes in lipid metabolism.</li> <li>Mice treated with specific bacterial strains\u00a0(e.g.,\u00a0Lactobacillus plantarum Pm001) vs.\u00a0control mice: To study the effects of specific bacterial strains on lipid metabolism.</li> </ul> </li> <li>Negative Controls: GF mice and wild-type mice serve as negative controls to study the effects of the microbiota and gene knockouts on lipid metabolism.</li> <li>Biological Replicates: Multiple mice are used in each group (e.g., n=8) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of specific bacterial strains or gene expression affect lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#5-data-analysis-presentation","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed to identify differentially expressed genes. Biochemical data are analyzed to measure lipid levels and metabolic activity.</li> <li>Statistical Tests: The study uses statistical methods (e.g., t-tests, ANOVA) to compare gene expression and lipid levels between groups. Differential expression analysis is performed to identify key genes regulated by the microbiota.</li> <li>Data Presentation: Results are presented using\u00a0graphs\u00a0and\u00a0tables, which are clear and free of misleading scaling. For example, the study uses\u00a0bar graphs\u00a0to compare lipid levels and\u00a0scatter plots\u00a0to show gene expression changes.</li> <li>Confirmation: The findings are confirmed using\u00a0gene knockout models\u00a0and\u00a0bacterial gavage, which validate the role of specific genes and bacterial strains in regulating lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W4.3%20Host-microbial%20Interactions%20and%20Lipid%20Metabolism/#general-observations","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how the gut microbiota regulates host lipid metabolism through specific genes (Nfil3,\u00a0Hdac3, and\u00a0Snhg9).</li> <li>The findings highlight the importance of\u00a0Lactobacillus plantarum Pm001\u00a0in promoting\u00a0Snhg9\u00a0expression and protecting mice from diet-induced obesity.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0microbiota-host interactions\u00a0and developing\u00a0microbiota-based therapies\u00a0for metabolic disorders.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/","title":"Experimental Workflow: IL-33 Regulation of Cold-Induced Thermogenesis","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#i-animal-model-preparation-and-cold-exposure-protocol","title":"I. Animal Model Preparation and Cold Exposure Protocol","text":"<ol> <li>Mouse Strain Selection and Housing</li> <li>Select C57BL/6J mice (8-12 weeks old, both sexes or sex-matched)</li> <li>House in standard conditions (22\u00b0C, 12h light/dark cycle)</li> <li>For germ-free experiments, maintain mice in sterile isolators</li> <li> <p>Acclimate mice to housing conditions for at least 1 week</p> </li> <li> <p>Cold Exposure Protocol</p> </li> <li>Divide mice into experimental groups:<ul> <li>Room temperature controls (22\u00b0C)</li> <li>Acute cold exposure (6\u00b0C for 24-48h)</li> <li>Chronic cold exposure (6\u00b0C for 7-14 days)</li> </ul> </li> <li>Transfer mice to pre-cooled cages with adequate bedding</li> <li>Monitor body temperature using rectal probe thermometer</li> <li> <p>Record food intake and body weight daily</p> </li> <li> <p>Genetic Model Generation</p> </li> <li>Generate cell-specific knockout models:<ul> <li>PDGFR\u03b2-specific Cre mice crossed with IL-33flox/flox</li> <li>CREB conditional knockout mice</li> </ul> </li> <li>Validate knockout efficiency by qPCR and Western blot</li> <li>Generate reporter mice (e.g., IL-33-GFP) for cell tracking. This means that cells actively transcribing the IL-33 gene will also produce GFP, making them fluorescent and detectable by flow cytometry or fluorescence microscopy.</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#ii-adipose-tissue-analysis-and-cell-isolation","title":"II. Adipose Tissue Analysis and Cell Isolation","text":"<ol> <li>Tissue Collection and Processing</li> <li>Euthanize mice according to ethical guidelines</li> <li>Collect inguinal white adipose tissue (iWAT), epididymal WAT, and brown adipose tissue (BAT)</li> <li> <p>Weigh tissues and divide for:</p> <ul> <li>Snap freezing in liquid nitrogen (gene/protein analysis)</li> <li>Fixation in 4% paraformaldehyde (histology)</li> <li>Fresh processing (cell isolation)</li> </ul> </li> <li> <p>Histological Analysis</p> </li> <li>Process fixed tissues for paraffin embedding or OCT-compound frozen sections</li> <li>Section tissues at 5-8\u03bcm thickness</li> <li>Perform H&amp;E staining for morphological analysis</li> <li>Conduct UCP1 immunohistochemistry to identify beige adipocytes</li> <li> <p>Image using light microscopy and quantify beige adipocyte areas</p> </li> <li> <p>Adipose Tissue Fractionation</p> </li> <li>Mince fresh adipose tissue and digest with collagenase</li> <li>Centrifuge to separate floating adipocytes from stromal vascular fraction (SVF)</li> <li>Filter SVF through 70\u03bcm strainer</li> <li>Lyse red blood cells if necessary</li> <li> <p>Count cells using hemocytometer or automated cell counter</p> </li> <li> <p>PDGFR\u03b2+DPP4+ Cell Isolation</p> </li> <li>Stain SVF with fluorescent antibodies:<ul> <li>Anti-PDGFR\u03b2 (CD140b)</li> <li>Anti-DPP4 (CD26)</li> <li>Lineage markers (CD31, CD45) for exclusion</li> </ul> </li> <li>Perform fluorescence-activated cell sorting (FACS)</li> <li>Collect PDGFR\u03b2+DPP4+ and PDGFR\u03b2+DPP4- populations</li> <li>Verify purity by flow cytometry analysis of a sample aliquot</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#iii-molecular-and-cellular-analysis","title":"III. Molecular and Cellular Analysis","text":"<ol> <li>RNA Sequencing and Transcriptome Analysis</li> <li>Extract total RNA from:<ul> <li>Whole adipose tissue samples</li> <li>Sorted PDGFR\u03b2+DPP4+ cells</li> <li>Other relevant cell populations</li> </ul> </li> <li>Assess RNA quality (Bioanalyzer, RNA integrity number &gt;8)</li> <li>Prepare RNA-seq libraries (poly-A selection or ribo-depletion)</li> <li>Perform paired-end sequencing (Illumina platform)</li> <li> <p>Analyze data using standard bioinformatics pipeline:</p> <ul> <li>Quality control and read alignment</li> <li>Differential expression analysis</li> <li>Pathway enrichment analysis</li> <li>Visualization (heatmaps, volcano plots)</li> </ul> </li> <li> <p>Gene Expression Analysis</p> </li> <li>Design primers for key genes (IL-33, UCP1, PGC1\u03b1, CREB, etc.)</li> <li>Perform RT-qPCR on tissue and cell samples</li> <li>Normalize to housekeeping genes (\u03b2-actin, GAPDH)</li> <li>Calculate relative expression using 2^-\u0394\u0394Ct method</li> <li> <p>Validate RNA-seq findings for selected genes</p> </li> <li> <p>Protein Expression Analysis</p> </li> <li>Extract proteins from tissues and cells</li> <li>Quantify protein concentration (BCA assay)</li> <li>Perform Western blotting for:<ul> <li>IL-33 and its receptor ST2</li> <li>UCP1 and other thermogenic markers</li> <li>CREB and phospho-CREB</li> <li>Signaling pathway components</li> </ul> </li> <li> <p>Conduct ELISA to measure IL-33 levels in tissue and serum</p> </li> <li> <p>Flow Cytometry Analysis of Immune Cells</p> </li> <li>Prepare single-cell suspensions from SVF</li> <li>Stain with antibodies for:<ul> <li>ILC2s (Lineage-CD45+KLRG1+ST2+)</li> <li>Eosinophils (CD11b+Siglec-F+)</li> <li>Other immune cell populations</li> </ul> </li> <li>Analyze using multicolor flow cytometry</li> <li>Quantify cell numbers and percentages</li> <li>Assess activation status through marker expression</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#iv-functional-studies-and-mechanistic-investigations","title":"IV. Functional Studies and Mechanistic Investigations","text":"<ol> <li>CRISPR/Cas9 Gene Editing</li> <li>Design sgRNAs targeting CREB binding sites in IL-33 promoter</li> <li>Validate sgRNA efficiency in cell culture</li> <li>Transfect PDGFR\u03b2+DPP4+ cells or use in vivo delivery methods</li> <li>Confirm editing by sequencing and functional assays</li> <li> <p>Assess effects on IL-33 expression and cold response</p> </li> <li> <p>Chromatin Immunoprecipitation (ChIP)</p> </li> <li>Crosslink proteins to DNA in adipose tissue or isolated cells</li> <li>Sonicate chromatin to appropriate fragment size</li> <li>Immunoprecipitate with anti-CREB antibody</li> <li>Purify DNA and perform qPCR for IL-33 promoter regions</li> <li>For genome-wide analysis, perform ChIP-seq</li> <li> <p>Analyze binding sites and motifs using bioinformatics tools</p> </li> <li> <p>In Vitro Cell Culture Studies</p> </li> <li>Establish primary cultures of PDGFR\u03b2+DPP4+ cells</li> <li>Treat cells with:<ul> <li>\u03b2-adrenergic agonists (e.g., isoproterenol)</li> <li>cAMP analogs to mimic cold stimulation</li> <li>CREB inhibitors or activators</li> </ul> </li> <li>Measure IL-33 expression and secretion</li> <li>Perform co-culture experiments with adipocyte precursors</li> <li> <p>Assess effects on adipogenic and thermogenic gene expression</p> </li> <li> <p>In Vivo Functional Assays</p> </li> <li>Perform metabolic cage studies to measure:<ul> <li>Oxygen consumption and CO2 production</li> <li>Energy expenditure</li> <li>Physical activity</li> </ul> </li> <li>Conduct glucose and insulin tolerance tests</li> <li>Measure core body temperature during cold challenge</li> <li>Use infrared thermography to assess heat production</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#v-intervention-studies-and-pathway-validation","title":"V. Intervention Studies and Pathway Validation","text":"<ol> <li>IL-33 Administration and Neutralization</li> <li>Administer recombinant IL-33 to mice at room temperature</li> <li>Neutralize IL-33 using anti-IL-33 antibodies during cold exposure</li> <li> <p>Assess effects on:</p> <ul> <li>Beige adipocyte formation</li> <li>UCP1 expression</li> <li>Thermogenic capacity</li> <li>ILC2 recruitment and activation</li> </ul> </li> <li> <p>ILC2 Depletion and Reconstitution</p> </li> <li>Deplete ILC2s using anti-CD90.2 or genetic approaches</li> <li>Reconstitute with adoptive transfer of sorted ILC2s</li> <li>Evaluate the necessity of ILC2s for IL-33-mediated thermogenesis</li> <li> <p>Analyze downstream mediators (e.g., IL-4, IL-13)</p> </li> <li> <p>Pharmacological Interventions</p> </li> <li>Target CREB pathway using specific inhibitors</li> <li>Modulate \u03b2-adrenergic signaling with agonists/antagonists</li> <li>Assess effects on IL-33 expression and thermogenic remodeling</li> <li> <p>Identify potential therapeutic targets</p> </li> <li> <p>Microbiome Studies (for GF vs. CV comparison)</p> </li> <li>Collect fecal samples for 16S rRNA sequencing</li> <li>Compare microbiome composition between temperature conditions</li> <li>Perform fecal microbiota transplantation experiments</li> <li>Analyze correlations between specific bacterial taxa and IL-33 expression</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#vi-data-integration-and-analysis","title":"VI. Data Integration and Analysis","text":"<ol> <li>Statistical Analysis</li> <li>Apply appropriate statistical tests:<ul> <li>Student's t-test for two-group comparisons</li> <li>ANOVA with post-hoc tests for multiple groups</li> <li>Non-parametric tests for non-normal distributions</li> </ul> </li> <li>Control for multiple comparisons (Benjamini-Hochberg)</li> <li>Ensure adequate power through appropriate sample sizes</li> <li> <p>Present data as mean \u00b1 SEM with individual data points</p> </li> <li> <p>Multi-omics Integration</p> </li> <li>Correlate transcriptomic data with protein expression</li> <li>Integrate ChIP-seq with RNA-seq to identify direct CREB targets</li> <li>Link cellular composition with functional outcomes</li> <li> <p>Develop pathway models of IL-33-mediated thermogenesis</p> </li> <li> <p>Visualization and Presentation</p> </li> <li>Create clear figures showing key findings</li> <li>Use consistent color schemes and labeling</li> <li>Include appropriate controls in all data presentations</li> <li>Develop schematic models summarizing the mechanism</li> </ol> <p>This comprehensive experimental workflow enables detailed investigation of how IL-33 produced by PDGFR\u03b2+DPP4+ cells regulates cold-induced thermogenesis, from the initial cold stimulus to CREB activation, IL-33 production, ILC2 recruitment, and ultimate beige adipocyte formation. The approach integrates multiple techniques spanning molecular biology, cell biology, and physiology to provide a complete understanding of this important metabolic pathway.</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#il-33","title":"\u5b9e\u9a8c\u5de5\u4f5c\u6d41\u7a0b\uff1aIL-33\u8c03\u63a7\u51b7\u8bf1\u5bfc\u4ea7\u70ed","text":""},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#_1","title":"\u4e00\u3001\u52a8\u7269\u6a21\u578b\u51c6\u5907\u548c\u51b7\u66b4\u9732\u65b9\u6848","text":"<ol> <li>\u5c0f\u9f20\u54c1\u7cfb\u9009\u62e9\u4e0e\u9972\u517b</li> <li>\u9009\u62e9C57BL/6J\u5c0f\u9f20(8-12\u5468\u9f84\uff0c\u4e24\u6027\u6216\u6027\u522b\u5339\u914d)</li> <li>\u5728\u6807\u51c6\u6761\u4ef6\u4e0b\u9972\u517b(22\u00b0C\uff0c12\u5c0f\u65f6\u5149\u7167/\u9ed1\u6697\u5468\u671f)</li> <li>\u5bf9\u4e8e\u65e0\u83cc\u5b9e\u9a8c\uff0c\u5c06\u5c0f\u9f20\u7ef4\u6301\u5728\u65e0\u83cc\u9694\u79bb\u5668\u4e2d</li> <li> <p>\u4f7f\u5c0f\u9f20\u9002\u5e94\u9972\u517b\u6761\u4ef6\u81f3\u5c111\u5468</p> </li> <li> <p>\u51b7\u66b4\u9732\u65b9\u6848</p> </li> <li>\u5c06\u5c0f\u9f20\u5206\u4e3a\u5b9e\u9a8c\u7ec4\uff1a<ul> <li>\u5ba4\u6e29\u5bf9\u7167\u7ec4(22\u00b0C)</li> <li>\u6025\u6027\u51b7\u66b4\u9732\u7ec4(6\u00b0C\u6301\u7eed24-48\u5c0f\u65f6)</li> <li>\u6162\u6027\u51b7\u66b4\u9732\u7ec4(6\u00b0C\u6301\u7eed7-14\u5929)</li> </ul> </li> <li>\u5c06\u5c0f\u9f20\u8f6c\u79fb\u5230\u9884\u51b7\u5374\u7684\u7b3c\u5b50\u4e2d\uff0c\u63d0\u4f9b\u8db3\u591f\u57ab\u6599</li> <li>\u4f7f\u7528\u76f4\u80a0\u6e29\u5ea6\u8ba1\u76d1\u6d4b\u4f53\u6e29</li> <li> <p>\u6bcf\u65e5\u8bb0\u5f55\u98df\u7269\u6444\u5165\u91cf\u548c\u4f53\u91cd</p> </li> <li> <p>\u57fa\u56e0\u6a21\u578b\u6784\u5efa</p> </li> <li>\u751f\u6210\u7ec6\u80de\u7279\u5f02\u6027\u6572\u9664\u6a21\u578b\uff1a<ul> <li>PDGFR\u03b2\u7279\u5f02\u6027Cre\u5c0f\u9f20\u4e0eIL-33flox/flox\u4ea4\u914d</li> <li>CREB\u6761\u4ef6\u6027\u6572\u9664\u5c0f\u9f20</li> </ul> </li> <li>\u901a\u8fc7qPCR\u548cWestern blot\u9a8c\u8bc1\u6572\u9664\u6548\u7387</li> <li>\u751f\u6210\u62a5\u544a\u57fa\u56e0\u5c0f\u9f20(\u5982IL-33-GFP)\u7528\u4e8e\u7ec6\u80de\u8ffd\u8e2a</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#_2","title":"\u4e8c\u3001\u8102\u80aa\u7ec4\u7ec7\u5206\u6790\u548c\u7ec6\u80de\u5206\u79bb","text":"<ol> <li>\u7ec4\u7ec7\u6536\u96c6\u548c\u5904\u7406</li> <li>\u6309\u7167\u4f26\u7406\u6307\u5357\u5b89\u4e50\u6b7b\u5c0f\u9f20</li> <li>\u6536\u96c6\u8179\u80a1\u6c9f\u767d\u8272\u8102\u80aa\u7ec4\u7ec7(iWAT)\u3001\u9644\u777e\u767d\u8272\u8102\u80aa\u7ec4\u7ec7\u548c\u68d5\u8272\u8102\u80aa\u7ec4\u7ec7(BAT)</li> <li> <p>\u79f0\u91cd\u7ec4\u7ec7\u5e76\u5206\u4e3a\uff1a</p> <ul> <li>\u6db2\u6c2e\u5feb\u901f\u51b7\u51bb(\u57fa\u56e0/\u86cb\u767d\u5206\u6790)</li> <li>4%\u591a\u805a\u7532\u919b\u56fa\u5b9a(\u7ec4\u7ec7\u5b66)</li> <li>\u65b0\u9c9c\u5904\u7406(\u7ec6\u80de\u5206\u79bb)</li> </ul> </li> <li> <p>\u7ec4\u7ec7\u5b66\u5206\u6790</p> </li> <li>\u5904\u7406\u56fa\u5b9a\u7ec4\u7ec7\u8fdb\u884c\u77f3\u8721\u5305\u57cb\u6216OCT\u51b7\u51bb\u5207\u7247</li> <li>\u5c06\u7ec4\u7ec7\u5207\u7247\u539a\u5ea6\u4e3a5-8\u03bcm</li> <li>\u8fdb\u884cH&amp;E\u67d3\u8272\u8fdb\u884c\u5f62\u6001\u5b66\u5206\u6790</li> <li>\u8fdb\u884cUCP1\u514d\u75ab\u7ec4\u7ec7\u5316\u5b66\u67d3\u8272\u8bc6\u522b\u7c73\u8272\u8102\u80aa\u7ec6\u80de</li> <li> <p>\u4f7f\u7528\u5149\u5b66\u663e\u5fae\u955c\u6210\u50cf\u5e76\u91cf\u5316\u7c73\u8272\u8102\u80aa\u7ec6\u80de\u9762\u79ef</p> </li> <li> <p>\u8102\u80aa\u7ec4\u7ec7\u5206\u79bb</p> </li> <li>\u526a\u788e\u65b0\u9c9c\u8102\u80aa\u7ec4\u7ec7\u5e76\u7528\u80f6\u539f\u9176\u6d88\u5316</li> <li>\u79bb\u5fc3\u5206\u79bb\u6d6e\u6e38\u8102\u80aa\u7ec6\u80de\u548c\u57fa\u8d28\u8840\u7ba1\u90e8\u5206(SVF)</li> <li>\u901a\u8fc770\u03bcm\u6ee4\u7f51\u8fc7\u6ee4SVF</li> <li>\u5fc5\u8981\u65f6\u6eb6\u89e3\u7ea2\u7ec6\u80de</li> <li> <p>\u4f7f\u7528\u8840\u7403\u8ba1\u6570\u5668\u6216\u81ea\u52a8\u7ec6\u80de\u8ba1\u6570\u5668\u8ba1\u6570</p> </li> <li> <p>PDGFR\u03b2+DPP4+\u7ec6\u80de\u5206\u79bb</p> </li> <li>\u7528\u8367\u5149\u6297\u4f53\u67d3\u8272SVF\uff1a<ul> <li>\u6297PDGFR\u03b2(CD140b)</li> <li>\u6297DPP4(CD26)</li> <li>\u8c31\u7cfb\u6807\u8bb0\u7269(CD31, CD45)\u7528\u4e8e\u6392\u9664</li> </ul> </li> <li>\u8fdb\u884c\u8367\u5149\u6fc0\u6d3b\u7ec6\u80de\u5206\u9009(FACS)</li> <li>\u6536\u96c6PDGFR\u03b2+DPP4+\u548cPDGFR\u03b2+DPP4-\u7ec6\u80de\u7fa4</li> <li>\u901a\u8fc7\u6d41\u5f0f\u7ec6\u80de\u672f\u5206\u6790\u6837\u54c1\u7b49\u5206\u9a8c\u8bc1\u7eaf\u5ea6</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#_3","title":"\u4e09\u3001\u5206\u5b50\u548c\u7ec6\u80de\u5206\u6790","text":"<ol> <li>RNA\u6d4b\u5e8f\u548c\u8f6c\u5f55\u7ec4\u5206\u6790</li> <li>\u4ece\u4ee5\u4e0b\u6837\u672c\u63d0\u53d6\u603bRNA\uff1a<ul> <li>\u6574\u4e2a\u8102\u80aa\u7ec4\u7ec7\u6837\u672c</li> <li>\u5206\u9009\u7684PDGFR\u03b2+DPP4+\u7ec6\u80de</li> <li>\u5176\u4ed6\u76f8\u5173\u7ec6\u80de\u7fa4</li> </ul> </li> <li>\u8bc4\u4f30RNA\u8d28\u91cf(Bioanalyzer\uff0cRNA\u5b8c\u6574\u6027\u6570\u503c&gt;8)</li> <li>\u5236\u5907RNA-seq\u6587\u5e93(poly-A\u9009\u62e9\u6216ribo-depletion)</li> <li>\u8fdb\u884c\u53cc\u7aef\u6d4b\u5e8f(Illumina\u5e73\u53f0)</li> <li> <p>\u4f7f\u7528\u6807\u51c6\u751f\u7269\u4fe1\u606f\u5b66\u6d41\u7a0b\u5206\u6790\u6570\u636e\uff1a</p> <ul> <li>\u8d28\u91cf\u63a7\u5236\u548c\u8bfb\u6bb5\u6bd4\u5bf9</li> <li>\u5dee\u5f02\u8868\u8fbe\u5206\u6790</li> <li>\u901a\u8def\u5bcc\u96c6\u5206\u6790</li> <li>\u53ef\u89c6\u5316(\u70ed\u56fe\uff0c\u706b\u5c71\u56fe)</li> </ul> </li> <li> <p>\u57fa\u56e0\u8868\u8fbe\u5206\u6790</p> </li> <li>\u8bbe\u8ba1\u5173\u952e\u57fa\u56e0\u5f15\u7269(IL-33, UCP1, PGC1\u03b1, CREB\u7b49)</li> <li>\u5bf9\u7ec4\u7ec7\u548c\u7ec6\u80de\u6837\u672c\u8fdb\u884cRT-qPCR</li> <li>\u4f7f\u7528\u770b\u5bb6\u57fa\u56e0(\u03b2-actin, GAPDH)\u6807\u51c6\u5316</li> <li>\u4f7f\u75282^-\u0394\u0394Ct\u65b9\u6cd5\u8ba1\u7b97\u76f8\u5bf9\u8868\u8fbe</li> <li> <p>\u9a8c\u8bc1\u9009\u5b9a\u57fa\u56e0\u7684RNA-seq\u53d1\u73b0</p> </li> <li> <p>\u86cb\u767d\u8868\u8fbe\u5206\u6790</p> </li> <li>\u4ece\u7ec4\u7ec7\u548c\u7ec6\u80de\u4e2d\u63d0\u53d6\u86cb\u767d\u8d28</li> <li>\u6d4b\u5b9a\u86cb\u767d\u8d28\u6d53\u5ea6(BCA\u6cd5)</li> <li>\u8fdb\u884c\u4ee5\u4e0bWestern blot\uff1a<ul> <li>IL-33\u53ca\u5176\u53d7\u4f53ST2</li> <li>UCP1\u548c\u5176\u4ed6\u4ea7\u70ed\u6807\u8bb0\u7269</li> <li>CREB\u548c\u78f7\u9178\u5316CREB</li> <li>\u4fe1\u53f7\u901a\u8def\u7ec4\u5206</li> </ul> </li> <li> <p>\u8fdb\u884cELISA\u6d4b\u91cf\u7ec4\u7ec7\u548c\u8840\u6e05\u4e2dIL-33\u6c34\u5e73</p> </li> <li> <p>\u514d\u75ab\u7ec6\u80de\u6d41\u5f0f\u7ec6\u80de\u672f\u5206\u6790</p> </li> <li>\u4eceSVF\u5236\u5907\u5355\u7ec6\u80de\u60ac\u6db2</li> <li>\u7528\u4ee5\u4e0b\u6297\u4f53\u67d3\u8272\uff1a<ul> <li>ILC2s(Lineage-CD45+KLRG1+ST2+)</li> <li>\u55dc\u9178\u6027\u7c92\u7ec6\u80de(CD11b+Siglec-F+)</li> <li>\u5176\u4ed6\u514d\u75ab\u7ec6\u80de\u7fa4</li> </ul> </li> <li>\u4f7f\u7528\u591a\u8272\u6d41\u5f0f\u7ec6\u80de\u672f\u5206\u6790</li> <li>\u91cf\u5316\u7ec6\u80de\u6570\u91cf\u548c\u767e\u5206\u6bd4</li> <li>\u901a\u8fc7\u6807\u8bb0\u7269\u8868\u8fbe\u8bc4\u4f30\u6fc0\u6d3b\u72b6\u6001</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#_4","title":"\u56db\u3001\u529f\u80fd\u7814\u7a76\u548c\u673a\u5236\u8c03\u67e5","text":"<ol> <li>CRISPR/Cas9\u57fa\u56e0\u7f16\u8f91</li> <li>\u8bbe\u8ba1\u9776\u5411IL-33\u542f\u52a8\u5b50\u4e2dCREB\u7ed3\u5408\u4f4d\u70b9\u7684sgRNAs</li> <li>\u5728\u7ec6\u80de\u57f9\u517b\u4e2d\u9a8c\u8bc1sgRNA\u6548\u7387</li> <li>\u8f6c\u67d3PDGFR\u03b2+DPP4+\u7ec6\u80de\u6216\u4f7f\u7528\u4f53\u5185\u9012\u9001\u65b9\u6cd5</li> <li>\u901a\u8fc7\u6d4b\u5e8f\u548c\u529f\u80fd\u6d4b\u5b9a\u786e\u8ba4\u7f16\u8f91</li> <li> <p>\u8bc4\u4f30\u5bf9IL-33\u8868\u8fbe\u548c\u51b7\u54cd\u5e94\u7684\u5f71\u54cd</p> </li> <li> <p>\u67d3\u8272\u8d28\u514d\u75ab\u6c89\u6dc0(ChIP)</p> </li> <li>\u5728\u8102\u80aa\u7ec4\u7ec7\u6216\u5206\u79bb\u7684\u7ec6\u80de\u4e2d\u5c06\u86cb\u767d\u8d28\u4e0eDNA\u4ea4\u8054</li> <li>\u5c06\u67d3\u8272\u8d28\u8d85\u58f0\u5904\u7406\u81f3\u9002\u5f53\u7247\u6bb5\u5927\u5c0f</li> <li>\u7528\u6297CREB\u6297\u4f53\u8fdb\u884c\u514d\u75ab\u6c89\u6dc0</li> <li>\u7eaf\u5316DNA\u5e76\u5bf9IL-33\u542f\u52a8\u5b50\u533a\u57df\u8fdb\u884cqPCR</li> <li>\u5bf9\u4e8e\u5168\u57fa\u56e0\u7ec4\u5206\u6790\uff0c\u8fdb\u884cChIP-seq</li> <li> <p>\u4f7f\u7528\u751f\u7269\u4fe1\u606f\u5b66\u5de5\u5177\u5206\u6790\u7ed3\u5408\u4f4d\u70b9\u548c\u57fa\u5e8f</p> </li> <li> <p>\u4f53\u5916\u7ec6\u80de\u57f9\u517b\u7814\u7a76</p> </li> <li>\u5efa\u7acbPDGFR\u03b2+DPP4+\u7ec6\u80de\u7684\u539f\u4ee3\u57f9\u517b</li> <li>\u7528\u4ee5\u4e0b\u7269\u8d28\u5904\u7406\u7ec6\u80de\uff1a<ul> <li>\u03b2-\u80be\u4e0a\u817a\u7d20\u80fd\u6fc0\u52a8\u5242(\u5982\u5f02\u4e19\u80be\u4e0a\u817a\u7d20)</li> <li>cAMP\u7c7b\u4f3c\u7269\u6a21\u62df\u51b7\u523a\u6fc0</li> <li>CREB\u6291\u5236\u5242\u6216\u6fc0\u6d3b\u5242</li> </ul> </li> <li>\u6d4b\u91cfIL-33\u8868\u8fbe\u548c\u5206\u6ccc</li> <li>\u8fdb\u884c\u4e0e\u8102\u80aa\u7ec6\u80de\u524d\u4f53\u7684\u5171\u57f9\u517b\u5b9e\u9a8c</li> <li> <p>\u8bc4\u4f30\u5bf9\u8102\u80aa\u751f\u6210\u548c\u4ea7\u70ed\u57fa\u56e0\u8868\u8fbe\u7684\u5f71\u54cd</p> </li> <li> <p>\u4f53\u5185\u529f\u80fd\u6d4b\u5b9a</p> </li> <li>\u8fdb\u884c\u4ee3\u8c22\u7b3c\u7814\u7a76\u6d4b\u91cf\uff1a<ul> <li>\u6c27\u6c14\u6d88\u8017\u548cCO2\u4ea7\u751f</li> <li>\u80fd\u91cf\u6d88\u8017</li> <li>\u4f53\u529b\u6d3b\u52a8</li> </ul> </li> <li>\u8fdb\u884c\u8461\u8404\u7cd6\u548c\u80f0\u5c9b\u7d20\u8010\u53d7\u6027\u6d4b\u8bd5</li> <li>\u5728\u51b7\u6311\u6218\u671f\u95f4\u6d4b\u91cf\u6838\u5fc3\u4f53\u6e29</li> <li>\u4f7f\u7528\u7ea2\u5916\u70ed\u6210\u50cf\u8bc4\u4f30\u4ea7\u70ed</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#_5","title":"\u4e94\u3001\u5e72\u9884\u7814\u7a76\u548c\u901a\u8def\u9a8c\u8bc1","text":"<ol> <li>IL-33\u7ed9\u836f\u548c\u4e2d\u548c</li> <li>\u5728\u5ba4\u6e29\u4e0b\u7ed9\u5c0f\u9f20\u65bd\u7528\u91cd\u7ec4IL-33</li> <li>\u5728\u51b7\u66b4\u9732\u671f\u95f4\u4f7f\u7528\u6297IL-33\u6297\u4f53\u4e2d\u548cIL-33</li> <li> <p>\u8bc4\u4f30\u5bf9\u4ee5\u4e0b\u65b9\u9762\u7684\u5f71\u54cd\uff1a</p> <ul> <li>\u7c73\u8272\u8102\u80aa\u7ec6\u80de\u5f62\u6210</li> <li>UCP1\u8868\u8fbe</li> <li>\u4ea7\u70ed\u80fd\u529b</li> <li>ILC2\u62db\u52df\u548c\u6fc0\u6d3b</li> </ul> </li> <li> <p>ILC2\u6e05\u9664\u548c\u91cd\u5efa</p> </li> <li>\u4f7f\u7528\u6297CD90.2\u6216\u57fa\u56e0\u65b9\u6cd5\u6e05\u9664ILC2s</li> <li>\u901a\u8fc7\u5206\u9009\u7684ILC2s\u8fc7\u7ee7\u8f6c\u79fb\u8fdb\u884c\u91cd\u5efa</li> <li>\u8bc4\u4f30ILC2\u5bf9IL-33\u4ecb\u5bfc\u4ea7\u70ed\u7684\u5fc5\u8981\u6027</li> <li> <p>\u5206\u6790\u4e0b\u6e38\u4ecb\u8d28(\u5982IL-4, IL-13)</p> </li> <li> <p>\u836f\u7406\u5b66\u5e72\u9884</p> </li> <li>\u4f7f\u7528\u7279\u5b9a\u6291\u5236\u5242\u9776\u5411CREB\u901a\u8def</li> <li>\u7528\u6fc0\u52a8\u5242/\u62ee\u6297\u5242\u8c03\u8282\u03b2-\u80be\u4e0a\u817a\u7d20\u80fd\u4fe1\u53f7</li> <li>\u8bc4\u4f30\u5bf9IL-33\u8868\u8fbe\u548c\u4ea7\u70ed\u91cd\u5851\u7684\u5f71\u54cd</li> <li> <p>\u786e\u5b9a\u6f5c\u5728\u7684\u6cbb\u7597\u9776\u70b9</p> </li> <li> <p>\u5fae\u751f\u7269\u7ec4\u7814\u7a76(\u7528\u4e8eGF vs CV\u6bd4\u8f83)</p> </li> <li>\u6536\u96c6\u7caa\u4fbf\u6837\u672c\u8fdb\u884c16S rRNA\u6d4b\u5e8f</li> <li>\u6bd4\u8f83\u4e0d\u540c\u6e29\u5ea6\u6761\u4ef6\u4e0b\u7684\u5fae\u751f\u7269\u7ec4\u6210</li> <li>\u8fdb\u884c\u7caa\u4fbf\u5fae\u751f\u7269\u7fa4\u79fb\u690d\u5b9e\u9a8c</li> <li>\u5206\u6790\u7279\u5b9a\u7ec6\u83cc\u7c7b\u7fa4\u4e0eIL-33\u8868\u8fbe\u4e4b\u95f4\u7684\u76f8\u5173\u6027</li> </ol>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#_6","title":"\u516d\u3001\u6570\u636e\u6574\u5408\u548c\u5206\u6790","text":"<ol> <li>\u7edf\u8ba1\u5206\u6790</li> <li>\u5e94\u7528\u9002\u5f53\u7684\u7edf\u8ba1\u68c0\u9a8c\uff1a<ul> <li>\u4e24\u7ec4\u6bd4\u8f83\u4f7f\u7528Student's t\u68c0\u9a8c</li> <li>\u591a\u7ec4\u4f7f\u7528ANOVA\u53ca\u4e8b\u540e\u68c0\u9a8c</li> <li>\u975e\u6b63\u6001\u5206\u5e03\u4f7f\u7528\u975e\u53c2\u6570\u68c0\u9a8c</li> </ul> </li> <li>\u63a7\u5236\u591a\u91cd\u6bd4\u8f83(Benjamini-Hochberg)</li> <li>\u901a\u8fc7\u9002\u5f53\u7684\u6837\u672c\u91cf\u786e\u4fdd\u8db3\u591f\u7684\u7edf\u8ba1\u529f\u6548</li> <li> <p>\u5c06\u6570\u636e\u5448\u73b0\u4e3a\u5747\u503c\u00b1\u6807\u51c6\u8bef\u5dee\uff0c\u5e76\u663e\u793a\u4e2a\u4f53\u6570\u636e\u70b9</p> </li> <li> <p>\u591a\u7ec4\u5b66\u6574\u5408</p> </li> <li>\u5c06\u8f6c\u5f55\u7ec4\u6570\u636e\u4e0e\u86cb\u767d\u8868\u8fbe\u76f8\u5173\u8054</li> <li>\u6574\u5408ChIP-seq\u4e0eRNA-seq\u8bc6\u522b\u76f4\u63a5CREB\u9776\u70b9</li> <li>\u5c06\u7ec6\u80de\u7ec4\u6210\u4e0e\u529f\u80fd\u7ed3\u679c\u8054\u7cfb\u8d77\u6765</li> <li> <p>\u5f00\u53d1IL-33\u4ecb\u5bfc\u4ea7\u70ed\u7684\u901a\u8def\u6a21\u578b</p> </li> <li> <p>\u53ef\u89c6\u5316\u548c\u5c55\u793a</p> </li> <li>\u521b\u5efa\u663e\u793a\u5173\u952e\u53d1\u73b0\u7684\u6e05\u6670\u56fe\u8868</li> <li>\u4f7f\u7528\u4e00\u81f4\u7684\u914d\u8272\u65b9\u6848\u548c\u6807\u7b7e</li> <li>\u5728\u6240\u6709\u6570\u636e\u5c55\u793a\u4e2d\u5305\u542b\u9002\u5f53\u7684\u5bf9\u7167</li> <li>\u5f00\u53d1\u603b\u7ed3\u673a\u5236\u7684\u793a\u610f\u6a21\u578b</li> </ol> <p>\u8fd9\u4e00\u7efc\u5408\u5b9e\u9a8c\u5de5\u4f5c\u6d41\u7a0b\u4f7f\u7814\u7a76\u4eba\u5458\u80fd\u591f\u8be6\u7ec6\u7814\u7a76PDGFR\u03b2+DPP4+\u7ec6\u80de\u4ea7\u751f\u7684IL-33\u5982\u4f55\u8c03\u63a7\u51b7\u8bf1\u5bfc\u4ea7\u70ed\uff0c\u4ece\u6700\u521d\u7684\u51b7\u523a\u6fc0\u5230CREB\u6fc0\u6d3b\u3001IL-33\u4ea7\u751f\u3001ILC2\u62db\u52df\uff0c\u6700\u7ec8\u5f62\u6210\u7c73\u8272\u8102\u80aa\u7ec6\u80de\u3002\u8be5\u65b9\u6cd5\u6574\u5408\u4e86\u8de8\u8d8a\u5206\u5b50\u751f\u7269\u5b66\u3001\u7ec6\u80de\u751f\u7269\u5b66\u548c\u751f\u7406\u5b66\u7684\u591a\u79cd\u6280\u672f\uff0c\u63d0\u4f9b\u4e86\u5bf9\u8fd9\u4e00\u91cd\u8981\u4ee3\u8c22\u901a\u8def\u7684\u5b8c\u6574\u7406\u89e3\u3002</p>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#1-experimental-purpose","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how\u00a0IL-33, a cytokine produced by\u00a0PDGFR\u03b2+DPP4+ cells, regulates cold-induced thermogenesis and the formation of beige adipocytes in white adipose tissue (WAT). Specifically, the study investigates whether IL-33 expression is induced by cold exposure and how it contributes to thermogenic remodeling.</li> <li>Experimental Design: The study uses a combination of\u00a0RNA sequencing (RNA-seq),\u00a0flow cytometry,\u00a0histology, and\u00a0CRISPR/Cas9 gene editing\u00a0to explore the role of IL-33 in cold-induced thermogenesis. The researchers first identify IL-33 as a key player in the process and then investigate the molecular mechanisms underlying its regulation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#2-model-system","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0mouse models, particularly\u00a0PDGFR\u03b2+DPP4+ cells\u00a0in inguinal(\u8179\u80a1\u6c9f\u7684) white adipose tissue (iWAT). These cells are identified as the main source of IL-33 in iWAT. The study also uses\u00a0germ-free (GF)\u00a0and\u00a0conventional (CV)\u00a0mice to study the effects of cold exposure on adipose tissue.</li> <li>Why This System?: Mice are appropriate for this study because they allow for the manipulation of specific cell populations and genes, and their adipose tissue responds to cold exposure in a manner similar to humans. The use of PDGFR\u03b2+DPP4+ cells is relevant because these cells are known to play a role in adipose tissue remodeling.</li> <li>Alternative Model Systems: Other model systems, such as\u00a0cell cultures\u00a0or\u00a0zebrafish, could be used, but they lack the complexity of in vivo adipose tissue remodeling and the interaction between different cell types.</li> <li>Ethical Considerations: Using mice requires ethical approval, especially when dealing with cold exposure and gene editing. The study likely adheres to ethical guidelines for animal research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#3-measurement-approach","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>RNA-seq: To analyze gene expression changes in response to cold exposure.</li> <li>Flow cytometry: To study immune cell populations (e.g., ILC2s,\u4e00\u79cd\u8c03\u8282\u8102\u80aa\u7684\u514d\u75ab\u7ec6\u80de) in adipose tissue.</li> <li>Histology: To visualize beige adipocyte formation in adipose tissue.</li> <li>CRISPR/Cas9: To knock out\u00a0CREB, a transcription factor that regulates IL-33 expression.</li> <li>Chromatin Immunoprecipitation (ChIP): To study the binding of CREB to the IL-33 promoter.</li> </ul> </li> <li>Why These Methods?: RNA-seq was chosen to identify genes regulated by cold exposure, while flow cytometry and histology were used to study the cellular and tissue-level effects of IL-33. CRISPR/Cas9 and ChIP assays were used to investigate the molecular mechanisms of IL-33 regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=4 or more) to ensure the robustness of the data.</li> <li>Potential Biases: Biases could arise from differences in mouse strains or environmental conditions. These are minimized by using standardized protocols and controls.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#4-group-setting","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Cold-exposed mice (6\u00b0C)\u00a0vs.\u00a0room temperature mice (22\u00b0C): To study the effects of cold exposure on IL-33 expression and thermogenic remodeling.</li> <li>PDGFR\u03b2+DPP4+ cells\u00a0vs.\u00a0PDGFR\u03b2+DPP4- cells: To identify the source of IL-33 in iWAT.</li> <li>CREB knockout mice\u00a0vs.\u00a0wild-type mice: To study the role of CREB in regulating IL-33 expression.</li> </ul> </li> <li>Negative Controls: Mice kept at room temperature and wild-type mice serve as negative controls to study the effects of cold exposure and CREB knockout.</li> <li>Biological Replicates: Multiple mice are used in each group (e.g., n=8) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of cold exposure or IL-33 expression affect thermogenic remodeling.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#5-data-analysis-presentation","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed to identify differentially expressed genes. Flow cytometry and histology data are analyzed to study cell populations and tissue remodeling. ChIP assay data are analyzed to study the binding of CREB to the IL-33 promoter.</li> <li>Statistical Tests: The study uses statistical methods (e.g., t-tests, ANOVA) to compare gene expression, cell populations, and transcription factor binding between groups. Differential expression analysis is performed to identify key genes regulated by cold exposure and IL-33.</li> <li>Data Presentation: Results are presented using\u00a0graphs,\u00a0tables, and\u00a0histological images, which are clear and free of misleading scaling. For example, the study uses\u00a0volcano plots\u00a0to show differentially expressed genes and\u00a0bar graphs\u00a0to compare IL-33 expression levels.</li> <li>Confirmation: The findings are confirmed using\u00a0gene knockout models\u00a0(e.g., CREB knockout) and\u00a0functional assays\u00a0(e.g., ChIP assays), which validate the role of IL-33 and CREB in cold-induced thermogenesis.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/experiments_case/S2W5%20Adipose%20tissue%20in%20cold%20thermogenesis/#general-observations","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how\u00a0IL-33, produced by\u00a0PDGFR\u03b2+DPP4+ cells, regulates cold-induced thermogenesis and beige adipocyte formation.</li> <li>The findings highlight the importance of\u00a0CREB\u00a0as a transcription factor that drives IL-33 expression in response to cold exposure.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0cold-induced thermogenesis\u00a0and developing therapies for\u00a0obesity\u00a0and\u00a0metabolic disorders.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/","title":"AI notes for seminar yicheng","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#s2w11-seminar-deep-learning-for-genomics-modeling-and-interpretation","title":"S2.W1.1. Seminar. Deep learning for genomics modeling and interpretation","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#1-translatorner-a-transformer-based-model-for-mrna-translation","title":"1.\u00a0Translatorner: A Transformer-based Model for mRNA Translation","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#experimental-purpose","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand the regulation of mRNA translation and its impact on protein abundance, which is crucial for understanding disease mechanisms. The central dogma of biology (DNA \u2192 RNA \u2192 Protein) is well-known, but the correlation between mRNA and protein levels is not perfect (0.39 to 0.79). The study seeks to model how mRNA translation is regulated and how this regulation affects protein levels.</li> <li>Experimental Design: The study uses a Transformer-based deep learning model (Translatorner) to predict ribosome profiling (translatome) from RNA-seq data and gene sequences. The model is trained on human data and tested on both human and mouse datasets to evaluate its ability to generalize across species.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#model-system","title":"Model System:","text":"<ul> <li>Model System: The study uses human and mouse genomic data. These systems are appropriate because they are well-studied, and the conservation of regulatory mechanisms between humans and mice allows for cross-species validation.</li> <li>Alternative Model Systems: Other model systems like yeast or zebrafish could be used, but they may lack the complexity and relevance to human diseases. However, they are cheaper and easier to manipulate.</li> <li>Ethical Considerations: Using human genomic data requires ethical approval, especially when dealing with patient data. The study likely adheres to ethical guidelines for genomic research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#measurement-approach","title":"Measurement Approach:","text":"<ul> <li>Techniques: The study uses ribosome profiling (Ribo-seq) and RNA-seq data. These are quantitative techniques that measure translation efficiency and mRNA abundance, respectively.</li> <li>Method Choice: Deep learning models (Transformers) were chosen because they can capture long-range dependencies in sequences, which is crucial for understanding translation regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from data normalization or sequencing depth. These are minimized by using standardized protocols and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#group-setting","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The model is trained on human data and tested on both human and mouse data. The groups are defined by cell types (e.g., epithelial cells, brain cells).</li> <li>Negative Controls: The study compares Translatorner with state-of-the-art models (e.g., Riboformer) to ensure that the improvements are not due to overfitting.</li> <li>Biological Replicates: The study uses multiple datasets (e.g., K562, epithelial cells) to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of mRNA affect translation efficiency.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#data-analysis-presentation","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw data from Ribo-seq and RNA-seq are processed using deep learning models. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses Pearson correlation coefficients (PCC) to compare predicted and observed ribosome profiling data.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using cross-species data and in silico mutagenesis, which confirms the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#2-transrbp-modeling-rbp-binding-and-its-interaction-with-m6a","title":"2.\u00a0TransRBP: Modeling RBP Binding and Its Interaction with m6A","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#experimental-purpose_1","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how RNA-binding proteins (RBPs) interact with m6A modifications and how these interactions affect RNA metabolism and disease.</li> <li>Experimental Design: The study develops a deep learning model (TransRBP) to predict RBP binding sites and their interaction with m6A. The model is trained on RNA sequences and tested for its ability to identify disease-related variants that alter RBP binding.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#model-system_1","title":"Model System:","text":"<ul> <li>Model System: The study uses human genomic data, focusing on RBPs and m6A modifications. This system is appropriate because m6A is the most prevalent mRNA modification and plays a critical role in RNA metabolism.</li> <li>Alternative Model Systems: Other systems like yeast or bacteria could be used, but they lack the complexity of m6A regulation seen in higher eukaryotes.</li> <li>Ethical Considerations: Similar to Translatorner, the use of human genomic data requires ethical approval.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#measurement-approach_1","title":"Measurement Approach:","text":"<ul> <li>Techniques: The study uses RNA-seq data and m6A sequencing data. These are quantitative techniques that measure RNA abundance and m6A modifications.</li> <li>Method Choice: Deep learning models (Transformers) were chosen because they can capture complex interactions between RNA sequences and RBPs.</li> <li>Technical Replicates: The study likely uses multiple replicates, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from sequencing errors or incomplete annotation of m6A sites. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#group-setting_1","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The model is trained on RNA sequences and tested for its ability to predict RBP binding sites. The groups are defined by disease types (e.g., Parkinson\u2019s disease, autism).</li> <li>Negative Controls: The study compares TransRBP with existing models to ensure that the improvements are not due to overfitting.</li> <li>Biological Replicates: The study uses multiple datasets to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of m6A affect RBP binding.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#data-analysis-presentation_1","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw data from RNA-seq and m6A sequencing are processed using deep learning models. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses Pearson correlation coefficients (PCC) to compare predicted and observed RBP binding data.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using in silico mutagenesis and experimental data, which confirms the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#general-observations","title":"General Observations:","text":"<ul> <li>Both studies leverage deep learning models (Transformers) to address complex questions in genomics. The models are trained on large datasets and validated using cross-species data and in silico experiments.</li> <li>The studies highlight the importance of model interpretability, using techniques like in silico mutagenesis and gradient-based interpretation to understand the contribution of different input modalities.</li> <li>The results have significant implications for understanding disease mechanisms, particularly in the context of translation regulation and RBP interactions with m6A modifications  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#s2w21-molecular-interactions-from-structure-perspective","title":"S2.W2.1. Molecular interactions from structure perspective","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#s2w22-seminar-empowering-precision-medicine-with-computational-biology","title":"S2.W2.2. Seminar. Empowering precision medicine with computational biology","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#1-resa-de-novo-identification-of-expressed-cancer-somatic-mutations","title":"1.\u00a0RESA: De Novo Identification of Expressed Cancer Somatic Mutations","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#experimental-purpose_2","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to identify somatic mutations in cancer from single-cell RNA sequencing (scRNA-seq) data, which is challenging due to the low abundance of mutations and the complexity of distinguishing them from germline variants and RNA editing events.</li> <li>Experimental Design: The RESA (RNA Editing and Somatic Mutation Annotation) tool is developed to filter out germline variants and RNA editing sites, allowing for the confident identification of somatic mutations. The tool uses joint logistic regression to classify somatic SNVs (single nucleotide variants) based on quality and sequence features.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#model-system_2","title":"Model System:","text":"<ul> <li>Model System: Human cancer samples are used, as they provide a direct link to human disease and are relevant for precision medicine.</li> <li>Alternative Model Systems: Mouse models or cell lines could be used, but they may not fully capture the complexity of human cancers.</li> <li>Ethical Considerations: Using human cancer samples requires ethical approval, especially when dealing with patient data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#measurement-approach_2","title":"Measurement Approach:","text":"<ul> <li>Techniques: scRNA-seq is used to measure gene expression and identify somatic mutations. The data are quantitative, allowing for precise identification of low-frequency mutations.</li> <li>Method Choice: RESA was chosen because it can filter out germline variants and RNA editing events, which are common sources of noise in scRNA-seq data.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from sequencing errors or incomplete annotation of RNA editing sites. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#group-setting_2","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The study compares cancer samples with matched normal samples to identify somatic mutations.</li> <li>Negative Controls: Germline variants and RNA editing sites are used as negative controls to ensure that only somatic mutations are identified.</li> <li>Biological Replicates: Multiple cancer samples are used to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of mutations affect cancer progression.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#data-analysis-presentation_2","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw scRNA-seq data are processed using RESA to identify somatic mutations. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: Joint logistic regression is used to classify somatic SNVs based on quality and sequence features.</li> <li>Data Presentation: Results are presented using tables and plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using matched normal samples and RNA editing databases, confirming the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#2-magpie-pathogenic-prediction-for-multiple-variant-types","title":"2.\u00a0MAGPIE: Pathogenic Prediction for Multiple Variant Types","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#experimental-purpose_3","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to predict the pathogenicity of multiple types of genetic variants (e.g., frameshift, non-synonymous, splice site) using a machine learning approach.</li> <li>Experimental Design: MAGPIE (Multimodal Analysis Generated Pathogenic Impact Evaluator) uses gradient boosting methods to predict the pathogenicity of variants based on multimodal feature annotations, including functional effects, spatial effects, and conservation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#model-system_3","title":"Model System:","text":"<ul> <li>Model System: Human genomic data are used, as they are directly relevant to human diseases and precision medicine.</li> <li>Alternative Model Systems: Model organisms like mice could be used, but they may not fully capture the complexity of human genetic variation.</li> <li>Ethical Considerations: Using human genomic data requires ethical approval, especially when dealing with patient data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#measurement-approach_3","title":"Measurement Approach:","text":"<ul> <li>Techniques: Variant annotation and machine learning are used to predict pathogenicity. The data are quantitative, allowing for precise predictions.</li> <li>Method Choice: Gradient boosting was chosen because it can handle complex, multimodal data and provide accurate predictions.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from incomplete annotation or imbalanced datasets. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#group-setting_3","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The study compares pathogenic variants with benign variants to train the model.</li> <li>Negative Controls: Benign variants are used as negative controls to ensure that the model can distinguish between pathogenic and non-pathogenic variants.</li> <li>Biological Replicates: Multiple datasets are used to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of variant pathogenicity affect disease outcomes.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#data-analysis-presentation_3","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw variant data are processed using MAGPIE to predict pathogenicity. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: Gradient boosting methods are used to predict pathogenicity based on multimodal feature annotations.</li> <li>Data Presentation: Results are presented using tables and plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using known pathogenic and benign variants, confirming the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#3-sptransformer-tissue-specific-splicing-prediction","title":"3.\u00a0SpTransformer: Tissue-Specific Splicing Prediction","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#experimental-purpose_4","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to predict tissue-specific splicing alterations caused by single nucleotide variants (SNVs) and understand their role in human diseases.</li> <li>Experimental Design: SpTransformer, a Transformer-based deep learning model, is developed to predict splicing alterations in 15 different tissues. The model is trained on RNA-seq data and validated using clinical samples.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#model-system_4","title":"Model System:","text":"<ul> <li>Model System: Human genomic data are used, as they are directly relevant to human diseases and precision medicine.</li> <li>Alternative Model Systems: Model organisms like mice could be used, but they may not fully capture the complexity of human splicing regulation.</li> <li>Ethical Considerations: Using human genomic data requires ethical approval, especially when dealing with patient data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#measurement-approach_4","title":"Measurement Approach:","text":"<ul> <li>Techniques: RNA-seq data are used to measure splicing alterations. The data are quantitative, allowing for precise predictions.</li> <li>Method Choice: Transformers were chosen because they can capture long-range dependencies in sequences, which is crucial for understanding splicing regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from sequencing errors or incomplete annotation of splicing events. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#group-setting_4","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The study compares splicing alterations in different tissues to understand tissue-specific effects.</li> <li>Negative Controls: Non-splicing variants are used as negative controls to ensure that the model can distinguish between splicing and non-splicing events.</li> <li>Biological Replicates: Multiple datasets are used to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of splicing alterations affect tissue function.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#data-analysis-presentation_4","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed using SpTransformer to predict splicing alterations. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses z-scores to define tissue-specific splicing alterations and enrichment analysis to identify disease-related genes.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using clinical samples and RNA-seq data, confirming the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#general-observations_1","title":"General Observations:","text":"<ul> <li>The studies leverage computational biology and deep learning to address complex questions in genomics, particularly in the context of cancer, genetic variants, and splicing regulation.</li> <li>The models are trained on large datasets and validated using cross-species data and experimental data, highlighting their robustness and generalizability.</li> <li>The results have significant implications for precision medicine, particularly in the context of cancer diagnosis, genetic variant interpretation, and understanding tissue-specific splicing alterations.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#s2w23-big-data-analysis-dimensionality-reduction","title":"S2.W2.3. Big data analysis - dimensionality reduction","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#s2w31-large-molecule-de-novo-design-using-antibody-as-an-example","title":"S2.W3.1. Large molecule de-novo design, using antibody as an example","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#s2w32-seminar-structural-study-of-epigenetic-regulation-in-transcription","title":"S2.W3.2. Seminar. Structural study of epigenetic regulation in transcription","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#1-experimental-purpose","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how\u00a0histone modifications\u00a0(e.g., acetylation, methylation) and\u00a0chromatin structure\u00a0regulate transcription. Specifically, it investigates the structural mechanisms by which histone modifications influence the binding of transcription machinery and the regulation of gene expression.</li> <li>Experimental Design: The study uses\u00a0structural biology techniques\u00a0(e.g., cryo-EM, X-ray crystallography) to determine the molecular structures of key epigenetic regulators, such as\u00a0histone acetyltransferases (HATs)\u00a0and\u00a0histone deacetylases (HDACs), and their interactions with nucleosomes and transcription factors.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#2-model-system","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0yeast\u00a0and\u00a0human cells, as these systems are well-characterized and provide a direct link to eukaryotic transcription regulation. The study focuses on the\u00a0SAGA complex, a well-known HAT complex involved in transcription regulation.</li> <li>Why This System?: Yeast and human cells are appropriate for this study because they allow for the manipulation of specific histone modifications and chromatin structures. The SAGA complex is relevant because it plays a key role in regulating transcription through histone acetylation.</li> <li>Alternative Model Systems: Other model systems like\u00a0bacteria\u00a0or\u00a0plants\u00a0could be used, but they lack the complexity of eukaryotic chromatin and histone modifications.</li> <li>Ethical Considerations: Using human cell lines requires ethical approval, especially when dealing with patient-derived samples. The study likely adheres to ethical guidelines for genomic research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#3-measurement-approach","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>Cryo-electron microscopy (cryo-EM): To determine the structures of epigenetic regulators (e.g., SAGA complex) and their interactions with nucleosomes.</li> <li>X-ray crystallography: To obtain high-resolution structures of specific histone modifications and their interactions with transcription factors.</li> <li>Biochemical assays: To study the functional roles of histone modifications in transcription regulation.</li> <li>Chromatin immunoprecipitation (ChIP): To study the binding of transcription factors to histone-modified chromatin.</li> </ul> </li> <li>Why These Methods?: Cryo-EM and X-ray crystallography were chosen because they allow for the visualization of molecular structures at atomic resolution, which is crucial for understanding the mechanisms of epigenetic regulation. Biochemical assays and ChIP were used to study the functional roles of histone modifications in transcription.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=3 or more) to ensure the robustness of the structural data.</li> <li>Potential Biases: Biases could arise from sample preparation or data interpretation. These are minimized by using standardized protocols and cross-validation with biochemical assays.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#4-group-setting","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Wild-type cells\u00a0vs.\u00a0cells with specific histone modifications: To study the effects of histone modifications on transcription.</li> <li>Cells with intact SAGA complex\u00a0vs.\u00a0cells with SAGA complex mutations: To study the role of the SAGA complex in transcription regulation.</li> <li>Cells treated with HDAC inhibitors\u00a0vs.\u00a0untreated cells: To study the effects of histone deacetylation on transcription.</li> </ul> </li> <li>Negative Controls: Cells without specific histone modifications or with intact SAGA complex serve as negative controls to study the effects of histone modifications and SAGA complex mutations.</li> <li>Biological Replicates: Multiple samples are used in each group (e.g., n=3 or more) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of histone modifications or HDAC inhibitors affect transcription.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#5-data-analysis-presentation","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw structural data from cryo-EM and X-ray crystallography are processed to generate 3D models of the molecular structures. Biochemical and ChIP data are analyzed to study the functional roles of histone modifications in transcription.</li> <li>Statistical Tests: The study uses statistical validation methods (e.g., cross-validation, resolution assessment) to ensure the accuracy of the structural models. Differential binding analysis is performed to identify key transcription factors regulated by histone modifications.</li> <li>Data Presentation: Results are presented using\u00a03D structural models,\u00a0graphs, and\u00a0tables, which are clear and free of misleading scaling. For example, the study uses\u00a0electron density maps\u00a0to show the structures of histone modifications and\u00a0bar graphs\u00a0to compare transcription factor binding.</li> <li>Confirmation: The structural findings are confirmed using\u00a0biochemical assays\u00a0and\u00a0functional studies, which validate the proposed mechanisms of epigenetic regulation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#general-observations_2","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how\u00a0histone modifications\u00a0and\u00a0chromatin structure\u00a0regulate transcription through the\u00a0SAGA complex\u00a0and other epigenetic regulators.</li> <li>The findings highlight the importance of\u00a0histone acetylation\u00a0and\u00a0deacetylation\u00a0in regulating gene expression and suggest potential therapeutic targets for diseases linked to epigenetic dysregulation.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0epigenetic regulation\u00a0and developing therapies for\u00a0cancer\u00a0and other diseases.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#s2w41-single-cell-spatial-temporal-multi-omics","title":"S2.W4.1. Single-cell spatial-temporal multi-omics","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#s2w42-survival-analysis","title":"S2.W4.2. Survival analysis","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#s2w43-seminar-host-microbial-interactions-and-lipid-metabolism","title":"S2.W4.3. Seminar. Host-microbial Interactions and Lipid Metabolism","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#1-experimental-purpose_1","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how the gut microbiota regulates host lipid metabolism and how dysbiosis (imbalance in the microbiota) contributes to metabolic disorders such as obesity and diabetes. Specifically, the study investigates the role of\u00a0Nfil3,\u00a0Hdac3, and\u00a0Snhg9\u00a0in mediating the effects of the microbiota on lipid metabolism.</li> <li>Experimental Design: The study uses\u00a0germ-free (GF) mice\u00a0and\u00a0conventional (CV) mice\u00a0to identify key genes regulated by the microbiota. The researchers then use\u00a0gene knockout models\u00a0and\u00a0bacterial gavage\u00a0to study the functional roles of these genes and specific bacterial strains in lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#2-model-system_1","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0germ-free (GF) mice\u00a0and\u00a0conventional (CV) mice. These models are ideal for studying the effects of the microbiota on host metabolism because GF mice lack a gut microbiota, allowing researchers to isolate the effects of specific bacterial strains.</li> <li>Why This System?: Mice are appropriate for this study because their gut microbiota and lipid metabolism are well-characterized, and they allow for precise genetic manipulation. The use of GF mice is particularly relevant because it enables researchers to study the effects of specific bacterial strains on host metabolism.</li> <li>Alternative Model Systems: Other model systems like\u00a0zebrafish\u00a0or\u00a0Drosophila\u00a0could be used, but they lack the complexity of mammalian lipid metabolism and gut microbiota interactions.</li> <li>Ethical Considerations: Using mice requires ethical approval, especially when dealing with germ-free conditions and dietary interventions. The study likely adheres to ethical guidelines for animal research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#3-measurement-approach_1","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>RNA sequencing (RNA-seq): To identify genes regulated by the microbiota.</li> <li>Biochemical assays: To measure lipid levels and metabolic activity.</li> <li>Gene knockout models: To study the functional roles of\u00a0Nfil3,\u00a0Hdac3, and\u00a0Snhg9\u00a0in lipid metabolism.</li> <li>Bacterial gavage: To introduce specific bacterial strains (e.g.,\u00a0Lactobacillus plantarum Pm001) into GF mice and study their effects on lipid metabolism.</li> </ul> </li> <li>Why These Methods?: RNA-seq was chosen to identify genes regulated by the microbiota, while biochemical assays were used to measure lipid levels and metabolic activity. Gene knockout models and bacterial gavage were used to study the functional roles of specific genes and bacterial strains.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=3 or more) to ensure the robustness of the data.</li> <li>Potential Biases: Biases could arise from differences in mouse strains or dietary conditions. These are minimized by using standardized protocols and controls.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#4-group-setting_1","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Germ-free (GF) mice\u00a0vs.\u00a0conventional (CV) mice: To study the effects of the microbiota on lipid metabolism.</li> <li>Gene knockout mice\u00a0(e.g.,\u00a0Nfil3\u0394IEC,\u00a0Hdac3\u0394IEC) vs.\u00a0wild-type mice: To study the functional roles of specific genes in lipid metabolism.</li> <li>Mice treated with specific bacterial strains\u00a0(e.g.,\u00a0Lactobacillus plantarum Pm001) vs.\u00a0control mice: To study the effects of specific bacterial strains on lipid metabolism.</li> </ul> </li> <li>Negative Controls: GF mice and wild-type mice serve as negative controls to study the effects of the microbiota and gene knockouts on lipid metabolism.</li> <li>Biological Replicates: Multiple mice are used in each group (e.g., n=8) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of specific bacterial strains or gene expression affect lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#5-data-analysis-presentation_1","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed to identify differentially expressed genes. Biochemical data are analyzed to measure lipid levels and metabolic activity.</li> <li>Statistical Tests: The study uses statistical methods (e.g., t-tests, ANOVA) to compare gene expression and lipid levels between groups. Differential expression analysis is performed to identify key genes regulated by the microbiota.</li> <li>Data Presentation: Results are presented using\u00a0graphs\u00a0and\u00a0tables, which are clear and free of misleading scaling. For example, the study uses\u00a0bar graphs\u00a0to compare lipid levels and\u00a0scatter plots\u00a0to show gene expression changes.</li> <li>Confirmation: The findings are confirmed using\u00a0gene knockout models\u00a0and\u00a0bacterial gavage, which validate the role of specific genes and bacterial strains in regulating lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#general-observations_3","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how the gut microbiota regulates host lipid metabolism through specific genes (Nfil3,\u00a0Hdac3, and\u00a0Snhg9).</li> <li>The findings highlight the importance of\u00a0Lactobacillus plantarum Pm001\u00a0in promoting\u00a0Snhg9\u00a0expression and protecting mice from diet-induced obesity.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0microbiota-host interactions\u00a0and developing\u00a0microbiota-based therapies\u00a0for metabolic disorders.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#s2w51-binary-trees-and-random-forest","title":"S2.W5.1. Binary trees and Random Forest","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#s2w52-seminar-how-to-do-a-scientific-project-step-by-step","title":"S2.W5.2. Seminar. How to Do a Scientific Project Step-by-step","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#1-experimental-purpose_2","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how\u00a0IL-33, a cytokine produced by\u00a0PDGFR\u03b2+DPP4+ cells, regulates cold-induced thermogenesis and the formation of beige adipocytes in white adipose tissue (WAT). Specifically, the study investigates whether IL-33 expression is induced by cold exposure and how it contributes to thermogenic remodeling.</li> <li>Experimental Design: The study uses a combination of\u00a0RNA sequencing (RNA-seq),\u00a0flow cytometry,\u00a0histology, and\u00a0CRISPR/Cas9 gene editing\u00a0to explore the role of IL-33 in cold-induced thermogenesis. The researchers first identify IL-33 as a key player in the process and then investigate the molecular mechanisms underlying its regulation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#2-model-system_2","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0mouse models, particularly\u00a0PDGFR\u03b2+DPP4+ cells\u00a0in inguinal white adipose tissue (iWAT). These cells are identified as the main source of IL-33 in iWAT. The study also uses\u00a0germ-free (GF)\u00a0and\u00a0conventional (CV)\u00a0mice to study the effects of cold exposure on adipose tissue.</li> <li>Why This System?: Mice are appropriate for this study because they allow for the manipulation of specific cell populations and genes, and their adipose tissue responds to cold exposure in a manner similar to humans. The use of PDGFR\u03b2+DPP4+ cells is relevant because these cells are known to play a role in adipose tissue remodeling.</li> <li>Alternative Model Systems: Other model systems, such as\u00a0cell cultures\u00a0or\u00a0zebrafish, could be used, but they lack the complexity of in vivo adipose tissue remodeling and the interaction between different cell types.</li> <li>Ethical Considerations: Using mice requires ethical approval, especially when dealing with cold exposure and gene editing. The study likely adheres to ethical guidelines for animal research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#3-measurement-approach_2","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>RNA-seq: To analyze gene expression changes in response to cold exposure.</li> <li>Flow cytometry: To study immune cell populations (e.g., ILC2s) in adipose tissue.</li> <li>Histology: To visualize beige adipocyte formation in adipose tissue.</li> <li>CRISPR/Cas9: To knock out\u00a0CREB, a transcription factor that regulates IL-33 expression.</li> <li>Chromatin Immunoprecipitation (ChIP): To study the binding of CREB to the IL-33 promoter.</li> </ul> </li> <li>Why These Methods?: RNA-seq was chosen to identify genes regulated by cold exposure, while flow cytometry and histology were used to study the cellular and tissue-level effects of IL-33. CRISPR/Cas9 and ChIP assays were used to investigate the molecular mechanisms of IL-33 regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=4 or more) to ensure the robustness of the data.</li> <li>Potential Biases: Biases could arise from differences in mouse strains or environmental conditions. These are minimized by using standardized protocols and controls.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#4-group-setting_2","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Cold-exposed mice (6\u00b0C)\u00a0vs.\u00a0room temperature mice (22\u00b0C): To study the effects of cold exposure on IL-33 expression and thermogenic remodeling.</li> <li>PDGFR\u03b2+DPP4+ cells\u00a0vs.\u00a0PDGFR\u03b2+DPP4- cells: To identify the source of IL-33 in iWAT.</li> <li>CREB knockout mice\u00a0vs.\u00a0wild-type mice: To study the role of CREB in regulating IL-33 expression.</li> </ul> </li> <li>Negative Controls: Mice kept at room temperature and wild-type mice serve as negative controls to study the effects of cold exposure and CREB knockout.</li> <li>Biological Replicates: Multiple mice are used in each group (e.g., n=8) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of cold exposure or IL-33 expression affect thermogenic remodeling.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#5-data-analysis-presentation_2","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed to identify differentially expressed genes. Flow cytometry and histology data are analyzed to study cell populations and tissue remodeling. ChIP assay data are analyzed to study the binding of CREB to the IL-33 promoter.</li> <li>Statistical Tests: The study uses statistical methods (e.g., t-tests, ANOVA) to compare gene expression, cell populations, and transcription factor binding between groups. Differential expression analysis is performed to identify key genes regulated by cold exposure and IL-33.</li> <li>Data Presentation: Results are presented using\u00a0graphs,\u00a0tables, and\u00a0histological images, which are clear and free of misleading scaling. For example, the study uses\u00a0volcano plots\u00a0to show differentially expressed genes and\u00a0bar graphs\u00a0to compare IL-33 expression levels.</li> <li>Confirmation: The findings are confirmed using\u00a0gene knockout models\u00a0(e.g., CREB knockout) and\u00a0functional assays\u00a0(e.g., ChIP assays), which validate the role of IL-33 and CREB in cold-induced thermogenesis.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/AI%20notes%20for%20seminar_yicheng/#general-observations_4","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how\u00a0IL-33, produced by\u00a0PDGFR\u03b2+DPP4+ cells, regulates cold-induced thermogenesis and beige adipocyte formation.</li> <li>The findings highlight the importance of\u00a0CREB\u00a0as a transcription factor that drives IL-33 expression in response to cold exposure.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0cold-induced thermogenesis\u00a0and developing therapies for\u00a0obesity\u00a0and\u00a0metabolic disorders.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/","title":"Final notes for seminar yicheng","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#s2w11-seminar-deep-learning-for-genomics-modeling-and-interpretation","title":"S2.W1.1. Seminar. Deep learning for genomics modeling and interpretation","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#1-translatorner-a-transformer-based-model-for-mrna-translation","title":"1.\u00a0Translatorner: A Transformer-based Model for mRNA Translation","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#experimental-purpose","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand the regulation of mRNA translation and its impact on protein abundance, which is crucial for understanding disease mechanisms. The central dogma of biology (DNA \u2192 RNA \u2192 Protein) is well-known, but the correlation between mRNA and protein levels is not perfect (0.39 to 0.79). The study seeks to model how mRNA translation is regulated and how this regulation affects protein levels.</li> <li>Experimental Design: The study uses a Transformer-based deep learning model (Translatorner) to predict ribosome profiling (translatome) from RNA-seq data and gene sequences. The model is trained on human data and tested on both human and mouse datasets to evaluate its ability to generalize across species.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#model-system","title":"Model System:","text":"<ul> <li>Model System: The study uses human and mouse genomic data. These systems are appropriate because they are well-studied, and the conservation of regulatory mechanisms between humans and mice allows for cross-species validation.</li> <li>Alternative Model Systems: Other model systems like yeast or zebrafish could be used, but they may lack the complexity and relevance to human diseases. However, they are cheaper and easier to manipulate.</li> <li>Ethical Considerations: Using human genomic data requires ethical approval, especially when dealing with patient data. The study likely adheres to ethical guidelines for genomic research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#measurement-approach","title":"Measurement Approach:","text":"<ul> <li>Techniques: The study uses ribosome profiling (Ribo-seq) and RNA-seq data. These are quantitative techniques that measure translation efficiency and mRNA abundance, respectively.</li> <li>Method Choice: Deep learning models (Transformers) were chosen because they can capture long-range dependencies in sequences, which is crucial for understanding translation regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from data normalization or sequencing depth. These are minimized by using standardized protocols and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#group-setting","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The model is trained on human data and tested on both human and mouse data. The groups are defined by cell types (e.g., epithelial cells, brain cells).</li> <li>Negative Controls: The study compares Translatorner with state-of-the-art models (e.g., Riboformer) to ensure that the improvements are not due to overfitting.</li> <li>Biological Replicates: The study uses multiple datasets (e.g., K562, epithelial cells) to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of mRNA affect translation efficiency.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#data-analysis-presentation","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw data from Ribo-seq and RNA-seq are processed using deep learning models. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses Pearson correlation coefficients (PCC) to compare predicted and observed ribosome profiling data.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using cross-species data and in silico mutagenesis, which confirms the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#2-transrbp-modeling-rbp-binding-and-its-interaction-with-m6a","title":"2.\u00a0TransRBP: Modeling RBP Binding and Its Interaction with m6A","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#experimental-purpose_1","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how RNA-binding proteins (RBPs) interact with m6A modifications and how these interactions affect RNA metabolism and disease.</li> <li>Experimental Design: The study develops a deep learning model (TransRBP) to predict RBP binding sites and their interaction with m6A. The model is trained on RNA sequences and tested for its ability to identify disease-related variants that alter RBP binding.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#model-system_1","title":"Model System:","text":"<ul> <li>Model System: The study uses human genomic data, focusing on RBPs and m6A modifications. This system is appropriate because m6A is the most prevalent mRNA modification and plays a critical role in RNA metabolism.</li> <li>Alternative Model Systems: Other systems like yeast or bacteria could be used, but they lack the complexity of m6A regulation seen in higher eukaryotes.</li> <li>Ethical Considerations: Similar to Translatorner, the use of human genomic data requires ethical approval.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#measurement-approach_1","title":"Measurement Approach:","text":"<ul> <li>Techniques: The study uses RNA-seq data and m6A sequencing data. These are quantitative techniques that measure RNA abundance and m6A modifications.</li> <li>Method Choice: Deep learning models (Transformers) were chosen because they can capture complex interactions between RNA sequences and RBPs.</li> <li>Technical Replicates: The study likely uses multiple replicates, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from sequencing errors or incomplete annotation of m6A sites. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#group-setting_1","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The model is trained on RNA sequences and tested for its ability to predict RBP binding sites. The groups are defined by disease types (e.g., Parkinson\u2019s disease, autism).</li> <li>Negative Controls: The study compares TransRBP with existing models to ensure that the improvements are not due to overfitting.</li> <li>Biological Replicates: The study uses multiple datasets to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of m6A affect RBP binding.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#data-analysis-presentation_1","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw data from RNA-seq and m6A sequencing are processed using deep learning models. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses Pearson correlation coefficients (PCC) to compare predicted and observed RBP binding data.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using in silico mutagenesis and experimental data, which confirms the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#general-observations","title":"General Observations:","text":"<ul> <li>Both studies leverage deep learning models (Transformers) to address complex questions in genomics. The models are trained on large datasets and validated using cross-species data and in silico experiments.</li> <li>The studies highlight the importance of model interpretability, using techniques like in silico mutagenesis and gradient-based interpretation to understand the contribution of different input modalities.</li> <li>The results have significant implications for understanding disease mechanisms, particularly in the context of translation regulation and RBP interactions with m6A modifications  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#s2w21-molecular-interactions-from-structure-perspective","title":"S2.W2.1. Molecular interactions from structure perspective","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#s2w22-seminar-empowering-precision-medicine-with-computational-biology","title":"S2.W2.2. Seminar. Empowering precision medicine with computational biology","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#1-resa-de-novo-identification-of-expressed-cancer-somatic-mutations","title":"1.\u00a0RESA: De Novo Identification of Expressed Cancer Somatic Mutations","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#experimental-purpose_2","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to identify somatic mutations in cancer from single-cell RNA sequencing (scRNA-seq) data, which is challenging due to the low abundance of mutations and the complexity of distinguishing them from germline variants and RNA editing events.</li> <li>Experimental Design: The RESA (RNA Editing and Somatic Mutation Annotation) tool is developed to filter out germline variants and RNA editing sites, allowing for the confident identification of somatic mutations. The tool uses joint logistic regression to classify somatic SNVs (single nucleotide variants) based on quality and sequence features.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#model-system_2","title":"Model System:","text":"<ul> <li>Model System: Human cancer samples are used, as they provide a direct link to human disease and are relevant for precision medicine.</li> <li>Alternative Model Systems: Mouse models or cell lines could be used, but they may not fully capture the complexity of human cancers.</li> <li>Ethical Considerations: Using human cancer samples requires ethical approval, especially when dealing with patient data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#measurement-approach_2","title":"Measurement Approach:","text":"<ul> <li>Techniques: scRNA-seq is used to measure gene expression and identify somatic mutations. The data are quantitative, allowing for precise identification of low-frequency mutations.</li> <li>Method Choice: RESA was chosen because it can filter out germline variants and RNA editing events, which are common sources of noise in scRNA-seq data.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from sequencing errors or incomplete annotation of RNA editing sites. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#group-setting_2","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The study compares cancer samples with matched normal samples to identify somatic mutations.</li> <li>Negative Controls: Germline variants and RNA editing sites are used as negative controls to ensure that only somatic mutations are identified.</li> <li>Biological Replicates: Multiple cancer samples are used to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of mutations affect cancer progression.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#data-analysis-presentation_2","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw scRNA-seq data are processed using RESA to identify somatic mutations. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: Joint logistic regression is used to classify somatic SNVs based on quality and sequence features.</li> <li>Data Presentation: Results are presented using tables and plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using matched normal samples and RNA editing databases, confirming the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#2-magpie-pathogenic-prediction-for-multiple-variant-types","title":"2.\u00a0MAGPIE: Pathogenic Prediction for Multiple Variant Types","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#experimental-purpose_3","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to predict the pathogenicity of multiple types of genetic variants (e.g., frameshift, non-synonymous, splice site) using a machine learning approach.</li> <li>Experimental Design: MAGPIE (Multimodal Analysis Generated Pathogenic Impact Evaluator) uses gradient boosting methods to predict the pathogenicity of variants based on multimodal feature annotations, including functional effects, spatial effects, and conservation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#model-system_3","title":"Model System:","text":"<ul> <li>Model System: Human genomic data are used, as they are directly relevant to human diseases and precision medicine.</li> <li>Alternative Model Systems: Model organisms like mice could be used, but they may not fully capture the complexity of human genetic variation.</li> <li>Ethical Considerations: Using human genomic data requires ethical approval, especially when dealing with patient data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#measurement-approach_3","title":"Measurement Approach:","text":"<ul> <li>Techniques: Variant annotation and machine learning are used to predict pathogenicity. The data are quantitative, allowing for precise predictions.</li> <li>Method Choice: Gradient boosting was chosen because it can handle complex, multimodal data and provide accurate predictions.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from incomplete annotation or imbalanced datasets. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#group-setting_3","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The study compares pathogenic variants with benign variants to train the model.</li> <li>Negative Controls: Benign variants are used as negative controls to ensure that the model can distinguish between pathogenic and non-pathogenic variants.</li> <li>Biological Replicates: Multiple datasets are used to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of variant pathogenicity affect disease outcomes.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#data-analysis-presentation_3","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw variant data are processed using MAGPIE to predict pathogenicity. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: Gradient boosting methods are used to predict pathogenicity based on multimodal feature annotations.</li> <li>Data Presentation: Results are presented using tables and plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using known pathogenic and benign variants, confirming the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#3-sptransformer-tissue-specific-splicing-prediction","title":"3.\u00a0SpTransformer: Tissue-Specific Splicing Prediction","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#experimental-purpose_4","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to predict tissue-specific splicing alterations caused by single nucleotide variants (SNVs) and understand their role in human diseases.</li> <li>Experimental Design: SpTransformer, a Transformer-based deep learning model, is developed to predict splicing alterations in 15 different tissues. The model is trained on RNA-seq data and validated using clinical samples.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#model-system_4","title":"Model System:","text":"<ul> <li>Model System: Human genomic data are used, as they are directly relevant to human diseases and precision medicine.</li> <li>Alternative Model Systems: Model organisms like mice could be used, but they may not fully capture the complexity of human splicing regulation.</li> <li>Ethical Considerations: Using human genomic data requires ethical approval, especially when dealing with patient data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#measurement-approach_4","title":"Measurement Approach:","text":"<ul> <li>Techniques: RNA-seq data are used to measure splicing alterations. The data are quantitative, allowing for precise predictions.</li> <li>Method Choice: Transformers were chosen because they can capture long-range dependencies in sequences, which is crucial for understanding splicing regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from sequencing errors or incomplete annotation of splicing events. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#group-setting_4","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The study compares splicing alterations in different tissues to understand tissue-specific effects.</li> <li>Negative Controls: Non-splicing variants are used as negative controls to ensure that the model can distinguish between splicing and non-splicing events.</li> <li>Biological Replicates: Multiple datasets are used to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of splicing alterations affect tissue function.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#data-analysis-presentation_4","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed using SpTransformer to predict splicing alterations. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses z-scores to define tissue-specific splicing alterations and enrichment analysis to identify disease-related genes.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using clinical samples and RNA-seq data, confirming the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#general-observations_1","title":"General Observations:","text":"<ul> <li>The studies leverage computational biology and deep learning to address complex questions in genomics, particularly in the context of cancer, genetic variants, and splicing regulation.</li> <li>The models are trained on large datasets and validated using cross-species data and experimental data, highlighting their robustness and generalizability.</li> <li>The results have significant implications for precision medicine, particularly in the context of cancer diagnosis, genetic variant interpretation, and understanding tissue-specific splicing alterations.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#s2w23-big-data-analysis-dimensionality-reduction","title":"S2.W2.3. Big data analysis - dimensionality reduction","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#s2w31-large-molecule-de-novo-design-using-antibody-as-an-example","title":"S2.W3.1. Large molecule de-novo design, using antibody as an example","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#s2w32-seminar-structural-study-of-epigenetic-regulation-in-transcription","title":"S2.W3.2. Seminar. Structural study of epigenetic regulation in transcription","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#1-experimental-purpose","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how\u00a0histone modifications\u00a0(e.g., acetylation, methylation) and\u00a0chromatin structure\u00a0regulate transcription. Specifically, it investigates the structural mechanisms by which histone modifications influence the binding of transcription machinery and the regulation of gene expression.</li> <li>Experimental Design: The study uses\u00a0structural biology techniques\u00a0(e.g., cryo-EM, X-ray crystallography) to determine the molecular structures of key epigenetic regulators, such as\u00a0histone acetyltransferases (HATs)\u00a0and\u00a0histone deacetylases (HDACs), and their interactions with nucleosomes and transcription factors.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#2-model-system","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0yeast\u00a0and\u00a0human cells, as these systems are well-characterized and provide a direct link to eukaryotic transcription regulation. The study focuses on the\u00a0SAGA complex, a well-known HAT complex involved in transcription regulation.</li> <li>Why This System?: Yeast and human cells are appropriate for this study because they allow for the manipulation of specific histone modifications and chromatin structures. The SAGA complex is relevant because it plays a key role in regulating transcription through histone acetylation.</li> <li>Alternative Model Systems: Other model systems like\u00a0bacteria\u00a0or\u00a0plants\u00a0could be used, but they lack the complexity of eukaryotic chromatin and histone modifications.</li> <li>Ethical Considerations: Using human cell lines requires ethical approval, especially when dealing with patient-derived samples. The study likely adheres to ethical guidelines for genomic research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#3-measurement-approach","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>Cryo-electron microscopy (cryo-EM): To determine the structures of epigenetic regulators (e.g., SAGA complex) and their interactions with nucleosomes.</li> <li>X-ray crystallography: To obtain high-resolution structures of specific histone modifications and their interactions with transcription factors.</li> <li>Biochemical assays: To study the functional roles of histone modifications in transcription regulation.</li> <li>Chromatin immunoprecipitation (ChIP): To study the binding of transcription factors to histone-modified chromatin.</li> </ul> </li> <li>Why These Methods?: Cryo-EM and X-ray crystallography were chosen because they allow for the visualization of molecular structures at atomic resolution, which is crucial for understanding the mechanisms of epigenetic regulation. Biochemical assays and ChIP were used to study the functional roles of histone modifications in transcription.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=3 or more) to ensure the robustness of the structural data.</li> <li>Potential Biases: Biases could arise from sample preparation or data interpretation. These are minimized by using standardized protocols and cross-validation with biochemical assays.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#4-group-setting","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Wild-type cells\u00a0vs.\u00a0cells with specific histone modifications: To study the effects of histone modifications on transcription.</li> <li>Cells with intact SAGA complex\u00a0vs.\u00a0cells with SAGA complex mutations: To study the role of the SAGA complex in transcription regulation.</li> <li>Cells treated with HDAC inhibitors\u00a0vs.\u00a0untreated cells: To study the effects of histone deacetylation on transcription.</li> </ul> </li> <li>Negative Controls: Cells without specific histone modifications or with intact SAGA complex serve as negative controls to study the effects of histone modifications and SAGA complex mutations.</li> <li>Biological Replicates: Multiple samples are used in each group (e.g., n=3 or more) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of histone modifications or HDAC inhibitors affect transcription.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#5-data-analysis-presentation","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw structural data from cryo-EM and X-ray crystallography are processed to generate 3D models of the molecular structures. Biochemical and ChIP data are analyzed to study the functional roles of histone modifications in transcription.</li> <li>Statistical Tests: The study uses statistical validation methods (e.g., cross-validation, resolution assessment) to ensure the accuracy of the structural models. Differential binding analysis is performed to identify key transcription factors regulated by histone modifications.</li> <li>Data Presentation: Results are presented using\u00a03D structural models,\u00a0graphs, and\u00a0tables, which are clear and free of misleading scaling. For example, the study uses\u00a0electron density maps\u00a0to show the structures of histone modifications and\u00a0bar graphs\u00a0to compare transcription factor binding.</li> <li>Confirmation: The structural findings are confirmed using\u00a0biochemical assays\u00a0and\u00a0functional studies, which validate the proposed mechanisms of epigenetic regulation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#general-observations_2","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how\u00a0histone modifications\u00a0and\u00a0chromatin structure\u00a0regulate transcription through the\u00a0SAGA complex\u00a0and other epigenetic regulators.</li> <li>The findings highlight the importance of\u00a0histone acetylation\u00a0and\u00a0deacetylation\u00a0in regulating gene expression and suggest potential therapeutic targets for diseases linked to epigenetic dysregulation.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0epigenetic regulation\u00a0and developing therapies for\u00a0cancer\u00a0and other diseases.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#s2w41-single-cell-spatial-temporal-multi-omics","title":"S2.W4.1. Single-cell spatial-temporal multi-omics","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#s2w42-survival-analysis","title":"S2.W4.2. Survival analysis","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#s2w43-seminar-host-microbial-interactions-and-lipid-metabolism","title":"S2.W4.3. Seminar. Host-microbial Interactions and Lipid Metabolism","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#1-experimental-purpose_1","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how the gut microbiota regulates host lipid metabolism and how dysbiosis (imbalance in the microbiota) contributes to metabolic disorders such as obesity and diabetes. Specifically, the study investigates the role of\u00a0Nfil3,\u00a0Hdac3, and\u00a0Snhg9\u00a0in mediating the effects of the microbiota on lipid metabolism.</li> <li>Experimental Design: The study uses\u00a0germ-free (GF) mice\u00a0and\u00a0conventional (CV) mice\u00a0to identify key genes regulated by the microbiota. The researchers then use\u00a0gene knockout models\u00a0and\u00a0bacterial gavage\u00a0to study the functional roles of these genes and specific bacterial strains in lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#2-model-system_1","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0germ-free (GF) mice\u00a0and\u00a0conventional (CV) mice. These models are ideal for studying the effects of the microbiota on host metabolism because GF mice lack a gut microbiota, allowing researchers to isolate the effects of specific bacterial strains.</li> <li>Why This System?: Mice are appropriate for this study because their gut microbiota and lipid metabolism are well-characterized, and they allow for precise genetic manipulation. The use of GF mice is particularly relevant because it enables researchers to study the effects of specific bacterial strains on host metabolism.</li> <li>Alternative Model Systems: Other model systems like\u00a0zebrafish\u00a0or\u00a0Drosophila\u00a0could be used, but they lack the complexity of mammalian lipid metabolism and gut microbiota interactions.</li> <li>Ethical Considerations: Using mice requires ethical approval, especially when dealing with germ-free conditions and dietary interventions. The study likely adheres to ethical guidelines for animal research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#3-measurement-approach_1","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>RNA sequencing (RNA-seq): To identify genes regulated by the microbiota.</li> <li>Biochemical assays: To measure lipid levels and metabolic activity.</li> <li>Gene knockout models: To study the functional roles of\u00a0Nfil3,\u00a0Hdac3, and\u00a0Snhg9\u00a0in lipid metabolism.</li> <li>Bacterial gavage: To introduce specific bacterial strains (e.g.,\u00a0Lactobacillus plantarum Pm001) into GF mice and study their effects on lipid metabolism.</li> </ul> </li> <li>Why These Methods?: RNA-seq was chosen to identify genes regulated by the microbiota, while biochemical assays were used to measure lipid levels and metabolic activity. Gene knockout models and bacterial gavage were used to study the functional roles of specific genes and bacterial strains.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=3 or more) to ensure the robustness of the data.</li> <li>Potential Biases: Biases could arise from differences in mouse strains or dietary conditions. These are minimized by using standardized protocols and controls.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#4-group-setting_1","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Germ-free (GF) mice\u00a0vs.\u00a0conventional (CV) mice: To study the effects of the microbiota on lipid metabolism.</li> <li>Gene knockout mice\u00a0(e.g.,\u00a0Nfil3\u0394IEC,\u00a0Hdac3\u0394IEC) vs.\u00a0wild-type mice: To study the functional roles of specific genes in lipid metabolism.</li> <li>Mice treated with specific bacterial strains\u00a0(e.g.,\u00a0Lactobacillus plantarum Pm001) vs.\u00a0control mice: To study the effects of specific bacterial strains on lipid metabolism.</li> </ul> </li> <li>Negative Controls: GF mice and wild-type mice serve as negative controls to study the effects of the microbiota and gene knockouts on lipid metabolism.</li> <li>Biological Replicates: Multiple mice are used in each group (e.g., n=8) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of specific bacterial strains or gene expression affect lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#5-data-analysis-presentation_1","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed to identify differentially expressed genes. Biochemical data are analyzed to measure lipid levels and metabolic activity.</li> <li>Statistical Tests: The study uses statistical methods (e.g., t-tests, ANOVA) to compare gene expression and lipid levels between groups. Differential expression analysis is performed to identify key genes regulated by the microbiota.</li> <li>Data Presentation: Results are presented using\u00a0graphs\u00a0and\u00a0tables, which are clear and free of misleading scaling. For example, the study uses\u00a0bar graphs\u00a0to compare lipid levels and\u00a0scatter plots\u00a0to show gene expression changes.</li> <li>Confirmation: The findings are confirmed using\u00a0gene knockout models\u00a0and\u00a0bacterial gavage, which validate the role of specific genes and bacterial strains in regulating lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#general-observations_3","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how the gut microbiota regulates host lipid metabolism through specific genes (Nfil3,\u00a0Hdac3, and\u00a0Snhg9).</li> <li>The findings highlight the importance of\u00a0Lactobacillus plantarum Pm001\u00a0in promoting\u00a0Snhg9\u00a0expression and protecting mice from diet-induced obesity.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0microbiota-host interactions\u00a0and developing\u00a0microbiota-based therapies\u00a0for metabolic disorders.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#s2w51-binary-trees-and-random-forest","title":"S2.W5.1. Binary trees and Random Forest","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#s2w52-seminar-how-to-do-a-scientific-project-step-by-step","title":"S2.W5.2. Seminar. How to Do a Scientific Project Step-by-step","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#1-experimental-purpose_2","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how\u00a0IL-33, a cytokine produced by\u00a0PDGFR\u03b2+DPP4+ cells, regulates cold-induced thermogenesis and the formation of beige adipocytes in white adipose tissue (WAT). Specifically, the study investigates whether IL-33 expression is induced by cold exposure and how it contributes to thermogenic remodeling.</li> <li>Experimental Design: The study uses a combination of\u00a0RNA sequencing (RNA-seq),\u00a0flow cytometry,\u00a0histology, and\u00a0CRISPR/Cas9 gene editing\u00a0to explore the role of IL-33 in cold-induced thermogenesis. The researchers first identify IL-33 as a key player in the process and then investigate the molecular mechanisms underlying its regulation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#2-model-system_2","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0mouse models, particularly\u00a0PDGFR\u03b2+DPP4+ cells\u00a0in inguinal(\u8179\u80a1\u6c9f\u7684) white adipose tissue (iWAT). These cells are identified as the main source of IL-33 in iWAT. The study also uses\u00a0germ-free (GF)\u00a0and\u00a0conventional (CV)\u00a0mice to study the effects of cold exposure on adipose tissue.</li> <li>Why This System?: Mice are appropriate for this study because they allow for the manipulation of specific cell populations and genes, and their adipose tissue responds to cold exposure in a manner similar to humans. The use of PDGFR\u03b2+DPP4+ cells is relevant because these cells are known to play a role in adipose tissue remodeling.</li> <li>Alternative Model Systems: Other model systems, such as\u00a0cell cultures\u00a0or\u00a0zebrafish, could be used, but they lack the complexity of in vivo adipose tissue remodeling and the interaction between different cell types.</li> <li>Ethical Considerations: Using mice requires ethical approval, especially when dealing with cold exposure and gene editing. The study likely adheres to ethical guidelines for animal research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#3-measurement-approach_2","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>RNA-seq: To analyze gene expression changes in response to cold exposure.</li> <li>Flow cytometry: To study immune cell populations (e.g., ILC2s,\u4e00\u79cd\u8c03\u8282\u8102\u80aa\u7684\u514d\u75ab\u7ec6\u80de) in adipose tissue.</li> <li>Histology: To visualize beige adipocyte formation in adipose tissue.</li> <li>CRISPR/Cas9: To knock out\u00a0CREB, a transcription factor that regulates IL-33 expression.</li> <li>Chromatin Immunoprecipitation (ChIP): To study the binding of CREB to the IL-33 promoter.</li> </ul> </li> <li>Why These Methods?: RNA-seq was chosen to identify genes regulated by cold exposure, while flow cytometry and histology were used to study the cellular and tissue-level effects of IL-33. CRISPR/Cas9 and ChIP assays were used to investigate the molecular mechanisms of IL-33 regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=4 or more) to ensure the robustness of the data.</li> <li>Potential Biases: Biases could arise from differences in mouse strains or environmental conditions. These are minimized by using standardized protocols and controls.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#4-group-setting_2","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Cold-exposed mice (6\u00b0C)\u00a0vs.\u00a0room temperature mice (22\u00b0C): To study the effects of cold exposure on IL-33 expression and thermogenic remodeling.</li> <li>PDGFR\u03b2+DPP4+ cells\u00a0vs.\u00a0PDGFR\u03b2+DPP4- cells: To identify the source of IL-33 in iWAT.</li> <li>CREB knockout mice\u00a0vs.\u00a0wild-type mice: To study the role of CREB in regulating IL-33 expression.</li> </ul> </li> <li>Negative Controls: Mice kept at room temperature and wild-type mice serve as negative controls to study the effects of cold exposure and CREB knockout.</li> <li>Biological Replicates: Multiple mice are used in each group (e.g., n=8) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of cold exposure or IL-33 expression affect thermogenic remodeling.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#5-data-analysis-presentation_2","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed to identify differentially expressed genes. Flow cytometry and histology data are analyzed to study cell populations and tissue remodeling. ChIP assay data are analyzed to study the binding of CREB to the IL-33 promoter.</li> <li>Statistical Tests: The study uses statistical methods (e.g., t-tests, ANOVA) to compare gene expression, cell populations, and transcription factor binding between groups. Differential expression analysis is performed to identify key genes regulated by cold exposure and IL-33.</li> <li>Data Presentation: Results are presented using\u00a0graphs,\u00a0tables, and\u00a0histological images, which are clear and free of misleading scaling. For example, the study uses\u00a0volcano plots\u00a0to show differentially expressed genes and\u00a0bar graphs\u00a0to compare IL-33 expression levels.</li> <li>Confirmation: The findings are confirmed using\u00a0gene knockout models\u00a0(e.g., CREB knockout) and\u00a0functional assays\u00a0(e.g., ChIP assays), which validate the role of IL-33 and CREB in cold-induced thermogenesis.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/Final%20notes%20for%20seminar_yicheng/#general-observations_4","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how\u00a0IL-33, produced by\u00a0PDGFR\u03b2+DPP4+ cells, regulates cold-induced thermogenesis and beige adipocyte formation.</li> <li>The findings highlight the importance of\u00a0CREB\u00a0as a transcription factor that drives IL-33 expression in response to cold exposure.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0cold-induced thermogenesis\u00a0and developing therapies for\u00a0obesity\u00a0and\u00a0metabolic disorders.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/","title":"IBMS\u603b\u7ed3\u590d\u4e60 yicheng","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#how-the-tutorial-ask-us-to-think","title":"How the tutorial ask us to think...","text":"<ul> <li>\u9996\u5148\uff0cHypothesis/ Experimental purpose and question\uff1f<ul> <li>Model\u8bbe\u8ba1\u76f8\u5173--&gt; Model system\u662f\u4ec0\u4e48\uff1fCells/ Animals/ human population? Why Do they chose the model? Are there ethic to be considered?<ul> <li>--&gt; Group setting:<ul> <li>Negative control?</li> <li>Positive control?</li> <li>Internal Control for normalisation?</li> <li>biological replicates?</li> <li>How to control the variables/ factors?</li> </ul> </li> </ul> </li> <li>--&gt; Measurement approaches\u662f\u4ec0\u4e48\uff1fPCR, WB, IF, IHC, Sequencing....?<ul> <li>Are there technical replicates?</li> <li>Why to choose this approach?</li> </ul> </li> <li>\u7ed3\u679c\u76f8\u5173--&gt; Experimental output: image/ counts/ numbers<ul> <li>Data process?</li> <li>Quantitative or qualitative?</li> <li>Statistical approaches?</li> </ul> </li> </ul> </li> <li>Pilot experiment: (Critical thinking part)<ul> <li>\u662f\u6307\u5728\u8fdb\u884c\u5927\u89c4\u6a21\u8bd5\u9a8c\u524d\u8fdb\u884c\u7684\u5148\u5bfc\u7684\u5c0f\u89c4\u6a21\u7684\u6d4b\u8bd5\u8bd5\u9a8c\uff0c\u9a8c\u8bc1\u53ef\u884c\u6027</li> <li>Can the data be ==reproduced== independently?</li> <li>Can they reproduce previous findings?</li> <li>Awareness of potential bias?</li> <li>Can the results be validated by an alternative approach?</li> <li>How would you design it?</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#_1","title":"\u5b9e\u9a8c\u8bbe\u8ba1\u539f\u5219","text":"<ul> <li>\u8fd9\u7c7b\u9898\u76ee\u53ef\u80fd\u662f\u8ba9\u6211\u4eec\u89e3\u51b3\u4e00\u4e2a\u751f\u7269\u5b66\u95ee\u9898\uff0c\u9700\u8981\u6211\u4eec\u8bbe\u8ba1\u5b9e\u9a8c\u6d41\u7a0b\u548c\u7528\u5230\u7684\u6280\u672f</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#1","title":"1. \u9996\u5148\u660e\u786e\u5b9e\u9a8c\u76ee\u7684\uff0c\u6838\u5fc3\u95ee\u9898","text":"<ul> <li>To determine/ validate ....</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#2","title":"2. \u6280\u672f\u9009\u62e9/\u6280\u672f\u7684\u8be6\u7ec6\u60c5\u51b5","text":"<ul> <li>\u57fa\u56e0\u7f16\u8f91\u548c\u8c03\u63a7\u6280\u672f<ul> <li>CRISPR/Cas 9</li> <li>CRISPRi/a</li> <li>RNAi/siRNA</li> </ul> </li> <li>\u5206\u5b50\u751f\u7269\u5b66\u6280\u672f<ul> <li>Western Blot</li> <li>Co-IP</li> </ul> </li> <li>\u57fa\u56e0\u8868\u8fbe\u5206\u6790<ul> <li>Luciferase Assay</li> <li>RT-qPCR</li> <li>RNA-seq</li> <li>Ribosome Profilling</li> </ul> </li> <li>\u67d3\u8272\u8d28\u4e0e\u8868\u89c2\u9057\u4f20\u5b66\u6280\u672f<ul> <li>Chromosome Conformation Capture (3C)</li> <li>ATAC-seq</li> <li>ChIP-seq</li> </ul> </li> <li>\u86cb\u767d\u8d28\u76f8\u4e92\u4f5c\u7528<ul> <li>PIP netork analysis</li> <li>Cross-linking MS</li> </ul> </li> <li>\u9057\u4f20\u5173\u8054\u548c\u7edf\u8ba1\u6a21\u578b<ul> <li>GWAS</li> <li>eQTL</li> <li>Logistic regression model</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#3-control-group-setting","title":"3. Control group setting","text":"<ul> <li>Positive control<ul> <li>\u5b9e\u9a8c\u4e2d\u4f7f\u7528\u5df2\u77e5\u4f1a\u4ea7\u751f\u9884\u671f\u6548\u679c\u7684\u6837\u672c\u6216\u8005\u6761\u4ef6</li> <li>Including a known enhancer region as positive control</li> </ul> </li> <li>Negative control<ul> <li>\u5b9e\u9a8c\u4e2d\u4f7f\u7528\u4e0d\u4f1a\u4ea7\u751f\u76ee\u6807\u6548\u5e94\uff08\u4e00\u822c\u800c\u8a00\u7684\uff09control group</li> </ul> </li> <li>Internal control<ul> <li>\u5185\u90e8\u5bf9\u7167\u662f\u5728\u540c\u4e00\u4e2a\u6837\u672c\u4e2d\u6d4b\u91cf\u7684\u53c2\u8003\u56e0\u7d20\uff0c\u7528\u4e8e\u6807\u51c6\u5316\u5b9e\u9a8c\u7ed3\u679c\u3002</li> <li>Normalize Western blot results using beta-actin as a loading control</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#4-results-and-analysis","title":"4. Results and analysis","text":"<ul> <li>What is the expected result? And how this can solve our problem</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#5-things-to-be-noticed-and-optimization","title":"5. Things to be noticed and optimization","text":"<ul> <li>What could be the limitation?</li> <li>How can we improve?</li> </ul> <p>Question 3. [25 points] The integration of different omics to identify markers for a complex disease ultimately leads to the correlation of molecular events. In one of the simplest scenarios the outcome could be the correlation between two proteins.</p> <p>Suppose a proteomic study found that Kinase X highly correlated with the phosphorylation of protein B in your model tissue. Briefly, describe at least two experiments (in vitro and in cell) with their corresponding controls, that you would need to do to verify the observed correlation.</p> <ul> <li>\u5206\u6790\uff1a\u9700\u8981\u8bc1\u660eKinase X\u548cprotein B phospohrylation\u7684\u5173\u7cfb<ul> <li>\u9700\u8981\u8bbe\u8ba1\u4e24\u4e2a\u5b9e\u9a8c\uff0cin cell and in vitro</li> </ul> </li> <li>in vitro: \u9700\u8981\u5c06\u7eaf\u5316\u7684Kinase X\u4e0eprotein B\u5728\u542b\u6709ATP\u7684\u7f13\u51b2\u6db2\u4e2d\u6df7\u5408\u5b75\u80b2\uff1b</li> <li></li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#_2","title":"\u57fa\u56e0\u8c03\u63a7\u548c\u8868\u89c2\u9057\u4f20\u5b66","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#_3","title":"\u86cb\u767d\u8d28\u529f\u80fd\u4e0e\u76f8\u4e92\u4f5c\u7528","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#_4","title":"\u9057\u4f20\u5173\u8054\u548c\u591a\u7ec4\u5b66\u5206\u6790","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#_5","title":"\u8f6c\u5316\u533b\u5b66\u4e0e\u4e34\u5e8a\u5e94\u7528","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/IBMS%E6%80%BB%E7%BB%93%E5%A4%8D%E4%B9%A0_yicheng/#_6","title":"\u6279\u5224\u6027\u601d\u7ef4\uff0c\u6570\u636e\u89e3\u8bfb","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/","title":"MY notes for slides yicheng","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w11-introduction-to-experimental-design","title":"S1.W1.1. Introduction to experimental design","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w12-experimental-design-i-elements-of-experimental-design","title":"S1.W1.2. Experimental design I: Elements of experimental design","text":"<ul> <li>Replicates<ul> <li>techinical replicate: \u540c\u4e00\u6d4b\u8bd5\u65b9\u6cd5\u591a\u6d4b\u51e0\u6b21</li> <li>biological replicate: \u591a\u4e2a\u4e2a\u4f53/\u6837\u672c</li> <li>method replicate: \u4e0d\u540c\u5b9e\u9a8c\u65b9\u6cd5\u91cd\u65b0\u9a8c\u8bc1\u540c\u4e2a\u5b9e\u9a8c\u76ee\u7684</li> </ul> </li> <li>Randomisation and Stratification<ul> <li>If you can (and want to), fix a variable</li> <li>If you do not fix a variable, stratify it</li> <li>If you can neither fix nor stratify a variable, randomise it.</li> </ul> </li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w13-bioethics-i-scientific-integrity","title":"S1.W1.3. Bioethics I: Scientific integrity","text":"<ul> <li>5 principles:<ul> <li>1.Truthfulness (Trustworthiness/Honesty)</li> <li>2.Diligence (You did what you claim to have done + did it properly!)</li> <li>3.Objectivity (No conflict of interest - Political/Economic/ Commercial/Bias)</li> <li>4.Circumspection (Avoid over-optimism and exaggeration, \u201cWe think\u201d vs \u201cwe hope\u201d the data shows x.)</li> <li>5.Collegiality (Equal treatment of data regardless of status of authors + all who contributed are credited).</li> </ul> </li> <li>Hawthorne Effect: \u6307\u4eba\u4eec\u5728\u88ab\u89c2\u5bdf\u6216\u7814\u7a76\u65f6\uff0c\u5176\u884c\u4e3a\u4f1a\u53d1\u751f\u6539\u53d8</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w21-bioethics-ii-animal-experimentation","title":"S1.W2.1. Bioethics II: Animal Experimentation","text":"<ul> <li>Mouse model limitations<ul> <li>Rats lack gall bladders</li> <li>Vitamin C is vital for only a few vertebrate species (notably humans and guinea pigs).</li> <li>Of the 19 non-inhalation carcinogens that cause cancer in humans \u2013 only 7 do so in mice or rats.</li> </ul> </li> <li>Developmental Areas, \u53ef\u4ee5\u56de\u8bfe\u4ef6\u770b</li> <li>The 3 R\u2019s Principle</li> <li>Types of animal protectionist\uff0c\u53ef\u4ee5\u56de\u8bfe\u4ef6\u770b</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w22-experimental-design-ii","title":"S1.W2.2. Experimental design II","text":"<ul> <li>Accuracy: \u6d4b\u5f97\u771f\u5b9e\u3001\u6b63\u786e\u6570\u636e\u7684\u80fd\u529b, \u5bf9\u5e94Systematic error</li> <li>Precision: \u826f\u597d\u7684\u53ef\u91cd\u590d\u6027 (Reproducibility), \u5bf9\u5e94Random error</li> <li>Sensitivity: TP / (TP + FN)</li> <li>Specificity: TN / (TN + FP)</li> <li>Power of a hypothesis test: the probability that the test correctly rejects the null hypothesis (H0)</li> <li>Type I error: \"false positive\", \u6307\u5f53\u539f\u5047\u8bbe\uff08H0\u200b\uff09\u5b9e\u9645\u4e0a\u662f\u6b63\u786e\u7684\uff0c\u4f46\u6211\u4eec\u5374\u9519\u8bef\u5730\u62d2\u7edd\u4e86; \u72af\u7b2c\u4e00\u7c7b\u9519\u8bef\u7684\u6982\u7387\u5373\u4e3a\u03b1 (\u81ea\u5df1\u8bbe\u7684significance level)</li> <li>Type II error: \"false negative\", \u6307\u539f\u5047\u8bbe\uff08H0\u200b\uff09\u5b9e\u9645\u4e0a\u662f\u9519\u8bef\u7684\uff0c\u4f46\u6211\u4eec\u5374\u6ca1\u6709\u62d2\u7edd, \u72af\u7b2c\u4e8c\u7c7b\u9519\u8bef\u7684\u6982\u7387\u5373\u4e3a\u03b2, 1-\u03b2\u5c31\u662fPower</li> <li>Effect size: a number measuring the strength of the relationship between two variables in a population, or a sample-based estimate of that quantity. Its significance depends of the sample size</li> <li>Internal Standard\uff08\u5185\u6807\uff09\u662f\u4e00\u79cd\u5206\u6790\u5316\u5b66\u6280\u672f\uff0c\u5e38\u7528\u4e8e\u5b9a\u91cf\u5206\u6790\u3002\u5b83\u662f\u6307\u5728\u6837\u54c1\u4e2d\u52a0\u5165\u4e00\u4e2a\u5df2\u77e5\u6d53\u5ea6\u7684\u5316\u5408\u7269\uff08\u5185\u6807\u7269\uff09\uff0c\u8fd9\u4e2a\u5316\u5408\u7269\u4e0e\u76ee\u6807\u5206\u6790\u7269\u5728\u5316\u5b66\u6027\u8d28\u4e0a\u76f8\u4f3c\uff0c\u4f46\u5728\u6837\u54c1\u4e2d\u5e76\u4e0d\u5b58\u5728\uff0c\u4e5f\u53ef\u4ee5\u4e0e\u76ee\u6807\u5206\u6790\u7269\u5206\u79bb\u5f00\u6765\u3002\u901a\u8fc7\u6bd4\u8f83\u76ee\u6807\u5206\u6790\u7269\u548c\u5185\u6807\u7269\u7684\u5cf0\u9762\u79ef\u6216\u9ad8\u5ea6\uff0c\u5e76\u7ed3\u5408\u5185\u6807\u7269\u8d28\u7684\u5df2\u77e5\u6d53\u5ea6\uff0c\u5c31\u53ef\u4ee5\u8ba1\u7b97\u51fa\u88ab\u5206\u6790\u7269\u7684\u542b\u91cf\uff0c\u8fd9\u53ef\u4ee5\u63d0\u9ad8\u5206\u6790\u7ed3\u679c\u7684\u7cbe\u786e\u6027\u548c\u51c6\u786e\u6027\uff0c\u7279\u522b\u662f\u5728\u6837\u54c1\u7684\u5904\u7406\u548c\u6d4b\u91cf\u8fc7\u7a0b\u4e2d\u53ef\u80fd\u5bfc\u81f4\u7684\u635f\u5931\u548c\u53d8\u5316\u3002</li> <li>Significant Figures\uff08\u6709\u6548\u6570\u5b57\uff09\u662f\u6307\u4e00\u4e2a\u6570\u503c\u4e2d\u80fd\u8868\u793a\u5176\u7cbe\u786e\u6027\u7684\u6570\u5b57\u4f4d\u6570\u3002\u6709\u6548\u6570\u5b57\u5305\u62ec\u6240\u6709\u5df2\u77e5\u7684\u6570\u5b57\u53ca\u6700\u540e\u4e00\u4e2a\u4e0d\u786e\u5b9a\u7684\u6570\u5b57\u3002\u5b83\u5173\u7cfb\u5230\u6d4b\u91cf\u7ed3\u679c\u7684\u7cbe\u786e\u6027\u548c\u4e0d\u786e\u5b9a\u6027\u3002\u4f8b\u5982\uff0c\u5728\u6570\u503c 0.00456\u4e2d\uff0c\u6709\u6548\u6570\u5b57\u4e3a3\uff084\u30015\u548c6\uff09\uff0c\u800c\u5728\u6570\u503c 100.0\u4e2d\uff0c\u6709\u6548\u6570\u5b57\u4e3a4\uff081\u30010\u30010\u548c\u5c0f\u6570\u70b9\u540e\u7684\u4e00\u4f4d0\uff09\u3002</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w31-experimental-design-iii-experimental-bias","title":"S1.W3.1. Experimental design III: Experimental bias","text":"<ul> <li>Bias: \u6240\u6709\u9020\u6210Systematic error\u7684\u56e0\u7d20<ul> <li>Survivorship Bias (e.g.)</li> <li>Sampling/Ascertainment/Selection bias\uff1a\u9009\u53d6\u6837\u672c\u7684\u65b9\u5f0f\u4e0d\u6070\u5f53</li> <li>Experimenter bias\uff1a\u5b9e\u9a8c\u8005\u53d7\u81ea\u8eab\u671f\u671b\u3001\u504f\u597d\u7b49\u4e3b\u89c2\u56e0\u7d20\u5f71\u54cd</li> <li>Reporting Bias\uff1a\u9009\u62e9\u6027\u62a5\u544a\u6216\u4e0d\u5ba2\u89c2\u63cf\u8ff0\u89e3\u91ca</li> <li>Biased Model Systems\uff1a\u6a21\u578b\u81ea\u8eab\u5c40\u9650\u3001\u4e0d\u5408\u7406\u5047\u8bbe\u6216\u6570\u636e\u8f93\u5165\u504f\u5dee\u7b49</li> <li>Publication Bias\uff1a\u5b66\u672f\u671f\u520a\u503e\u5411\u4e8e\u53d1\u8868\u663e\u8457\u7ed3\u679c\u7814\u7a76\uff0c\u5bfc\u81f4\u5df2\u53d1\u8868\u7814\u7a76\u4e0d\u80fd\u5168\u9762\u53cd\u6620\u9886\u57df\u771f\u5b9e\u60c5\u51b5\u800c\u4ea7\u751f\u7684\u504f\u5dee\u3002</li> </ul> </li> <li>\u5982\u4f55\u8bbe\u8ba1unbiased\u7684\u5b9e\u9a8c\uff1f\u53ef\u4ee5\u53c2\u8003\u8bfe\u4ef6\u4f8b\u5b50</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w51-experimental-design-iv-types","title":"S1.W5.1. Experimental design IV: Types","text":"<ul> <li>Completely randomised design: \u5c06\u5b9e\u9a8c\u5bf9\u8c61\u5b8c\u5168\u968f\u673a\u5730\u5206\u914d\u5230\u4e0d\u540c\u5904\u7406\u7ec4</li> <li>Randomised complete block design: \u5c06\u5b9e\u9a8c\u5bf9\u8c61\u6309\u6027\u8d28\u76f8\u540c\u6216\u76f8\u8fd1\u5206\u4e3a\u82e5\u5e72\u533a\u7ec4\uff0c\u518d\u5c06\u6bcf\u4e2a\u533a\u7ec4\u5185\u7684\u5bf9\u8c61\u968f\u673a\u5206\u914d\u5230\u4e0d\u540c\u5904\u7406\u7ec4</li> <li>Split-plot design: \u5c06\u5b9e\u9a8c\u5355\u5143\u5206\u4e3a\u4e3b\u533a\u548c\u526f\u533a\uff0c\u5206\u522b\u5b89\u6392\u4e0d\u540c\u5904\u7406\u56e0\u7d20</li> <li>Randomised Control Trial: \u5c06\u7814\u7a76\u5bf9\u8c61\u968f\u673a\u5206\u914d\u5230\u5e72\u9884\u7ec4\u548c\u5bf9\u7167\u7ec4\uff0c\u4ee5\u8bc4\u4f30\u5e72\u9884\u63aa\u65bd\u6548\u679c<ul> <li>Placebo: \u4e00\u79cd\u4e2d\u7acb\u7684\u63a7\u5236\u5e72\u9884\uff0c\u4f46\u53ef\u4ee5\u4e0e\u79ef\u6781\u6548\u679c\uff08\u5b89\u6170\u5242\u6548\u5e94\uff09\u76f8\u5173\u8054\u3002</li> <li>Nocebo: \u4e00\u79cd\u8d1f\u9762\u7684\u63a7\u5236\u5e72\u9884\uff0c\u53d7\u8bd5\u8005\u4f1a\u7ecf\u5386\u8d1f\u9762\u5f71\u54cd</li> <li>Hawthorne effect: \u5b9e\u9a8c\u5bf9\u8c61\u7684\u884c\u4e3a\u4f1a\u968f\u7740\u88ab\u89c2\u5bdf\u800c\u6539\u53d8</li> <li>Demand characteristics: \u7531\u53d7\u8bd5\u8005\u731c\u6d4b\u7814\u7a76\u76ee\u7684\u5e76\u91c7\u53d6\u76f8\u5e94\u884c\u52a8\u800c\u4ea7\u751f\u7684\u6548\u5e94</li> <li>\u2018Screw-you\u2019 effect: \u5b9e\u9a8c\u5bf9\u8c61\u7684\u884c\u4e3a\u53ef\u80fd\u4f1a\u7834\u574f\u5b9e\u9a8c\u8005\u7684\u76ee\u7684</li> </ul> </li> <li>Cohort Studies<ul> <li>Retrospective (\u56de\u987e\u6027): \u901a\u8fc7\u56de\u987e\u8fc7\u53bb\u7684\u66b4\u9732\u548c\u75be\u75c5\u53d1\u751f\u60c5\u51b5\uff0c\u5206\u6790\u66b4\u9732\u56e0\u7d20\u4e0e\u75be\u75c5\u5173\u7cfb</li> <li>Prospective (\u524d\u77bb\u6027): \u4ece\u73b0\u5728\u5f00\u59cb\u8ffd\u8e2a\u89c2\u5bdf\u4e0d\u540c\u66b4\u9732\u7ec4\u7684\u7814\u7a76\u5bf9\u8c61\uff0c\u4ee5\u786e\u5b9a\u75be\u75c5\u53d1\u751f\u60c5\u51b5\u53ca\u4e0e\u66b4\u9732\u56e0\u7d20\u5173\u7cfb</li> </ul> </li> <li>Cross-Over design: \u8ba9\u7814\u7a76\u5bf9\u8c61\u5728\u4e0d\u540c\u65f6\u671f\u5148\u540e\u63a5\u53d7\u4e0d\u540c\u5904\u7406\uff0c\u4ee5\u6bd4\u8f83\u4e0d\u540c\u5904\u7406\u6548\u679c</li> <li>Cross-sectional: \u5728\u67d0\u4e00\u7279\u5b9a\u65f6\u95f4\u70b9\u5bf9\u7814\u7a76\u5bf9\u8c61\u7684\u7279\u5f81\u548c\u75be\u75c5\u72b6\u51b5\u8fdb\u884c\u8c03\u67e5</li> <li>Longitudinal: \u5bf9\u540c\u4e00\u7ec4\u7814\u7a76\u5bf9\u8c61\u5728\u8f83\u957f\u65f6\u95f4\u5185\u8fdb\u884c\u8ddf\u8e2a\uff0c\u89c2\u5bdf\u5176\u53d8\u5316</li> <li>Meta-analyses: \u7efc\u5408\u591a\u4e2a\u540c\u7c7b\u7814\u7a76\u7ed3\u679c\uff0c\u8fdb\u884c\u5b9a\u91cf\u5206\u6790\u4ee5\u5f97\u51fa\u66f4\u5177\u666e\u904d\u6027\u7ed3\u8bba</li> <li>Multi-batch analyses: \u5bf9\u591a\u4e2a\u6279\u6b21\u7684\u6570\u636e\u8fdb\u884c\u5206\u6790\uff0c\u4ee5\u8003\u8651\u6279\u6b21\u6548\u5e94\u5e76\u83b7\u5f97\u66f4\u53ef\u9760\u7ed3\u679c</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w71-experimental-design-v-interpolationextrapolation-and-mixed-effects-models","title":"S1.W7.1. Experimental design V: interpolation/extrapolation and mixed effects models","text":"<ul> <li>Interpolation: Constructing new data points within the range of known data</li> <li>Extrapolation: Applying your model to calculate values outside of the range of observed data sample</li> <li>Mixed effects models: \u7edf\u8ba1\u6a21\u578b\uff0c\u540c\u65f6\u5305\u542b\u56fa\u5b9a\u6548\u5e94\u548c\u968f\u673a\u6548\u5e94\uff0c\u7528\u4e8e\u5206\u6790\u5177\u6709\u5c42\u6b21\u7ed3\u6784\u6216\u805a\u7c7b\u7ed3\u6784\u7684\u6570\u636e\uff0c\u80fd\u5728\u8003\u8651\u4e2a\u4f53\u5dee\u5f02\u7b49\u968f\u673a\u56e0\u7d20\u7684\u540c\u65f6\uff0c\u7814\u7a76\u56fa\u5b9a\u56e0\u7d20\u5bf9\u54cd\u5e94\u53d8\u91cf\u7684\u5f71\u54cd</li> <li>Random effects model: \u5c06\u4e2a\u4f53\u6216\u7fa4\u4f53\u7684\u6548\u5e94\u89c6\u4e3a\u968f\u673a\u53d8\u91cf\uff0c\u5f3a\u8c03\u4ece\u603b\u4f53\u4e2d\u62bd\u53d6\u7684\u6837\u672c\u6240\u5177\u6709\u7684\u968f\u673a\u6027\uff0c\u66f4\u9002\u5408\u4e8e\u7814\u7a76\u4e2a\u4f53\u6216\u7fa4\u4f53\u95f4\u7684\u5dee\u5f02\u53ca\u53d8\u5316\uff0c\u4ee5\u53ca\u603b\u4f53\u7279\u5f81\u3002</li> <li>Nested design: \u4e00\u79cd\u5b9e\u9a8c\u8bbe\u8ba1\u65b9\u6cd5\uff0c\u6307\u7684\u662f\u4e00\u4e2a\u56e0\u5b50\uff08\u5982\u7ec6\u80de\uff09\u88ab\u5305\u542b\u6216\u5d4c\u5957\u5728\u53e6\u4e00\u4e2a\u56e0\u5b50\uff08\u5982\u80f0\u817a\uff09\u4e2d\uff0c\u4e14\u4e0d\u540c\u7ec4\u7684\u5d4c\u5957\u5bf9\u8c61\u5f7c\u6b64\u72ec\u7acb\uff0c\u4e0d\u80fd\u8de8\u7ec4\u6bd4\u8f83\u3002\u4e3b\u8981\u4f5c\u7528\uff1a\u7528\u6765\u533a\u5206\u4e0d\u540c\u6765\u6e90\u7684\u53d8\u5f02\uff0c\u6bd4\u5982\u533a\u5206\u57fa\u56e0\u578b\u7684\u5dee\u5f02\u3001\u80f0\u817a\u4e4b\u95f4\u7684\u5dee\u5f02\u3001\u4ee5\u53ca\u7ec6\u80de\u4e4b\u95f4\u7684\u5dee\u5f02\u3002</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w81-models-of-genetically-modified-mice-animals","title":"S1.W8.1. Models of genetically modified mice / animals","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w82-sex-differences-in-disease-susceptibility-and-drug-response","title":"S1.W8.2. Sex differences in disease susceptibility and drug response","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w83-recap-of-statistical-models-and-dealing-with-interactions","title":"S1.W8.3. Recap of statistical models and dealing with interactions","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w91-ensuring-reproducible-research-reporting-and-sharing-code-protocols-and-data","title":"S1.W9.1. Ensuring reproducible research, reporting and sharing code, protocols and data","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w101-introduction-to-experimental-design-framework","title":"S1.W10.1. Introduction to experimental design framework","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w102-seminar","title":"S1.W10.2. Seminar.","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w111-working-with-discrete-data-contingency-tables-2-test-fishers-exact-test","title":"S1.W11.1. Working with discrete data - contingency tables, \u03c72-test - Fisher's exact test","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w112-seminar","title":"S1.W11.2. Seminar.","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w121-seminar","title":"S1.W12.1. Seminar.","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w131-working-with-discrete-and-bounded-data-logistic-and-binomial-regression","title":"S1.W13.1. Working with discrete and bounded data - logistic and binomial regression","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w132-seminar","title":"S1.W13.2. Seminar.","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w141-introduction-to-machine-learning-1classification-clustering-dimensionality-reduction","title":"S1.W14.1. Introduction to machine learning 1(classification, clustering, dimensionality reduction)","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w142-introduction-to-machine-learning-2supervised-learning-cross-validation-evaluating-classification-performance","title":"S1.W14.2. Introduction to machine learning 2(supervised learning, cross validation, evaluating classification performance)","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s1w143-seminar","title":"S1.W14.3. Seminar.","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s2w11-seminar-deep-learning-for-genomics-modeling-and-interpretation","title":"S2.W1.1. Seminar. Deep learning for genomics modeling and interpretation","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#1-translatorner-a-transformer-based-model-for-mrna-translation","title":"1.\u00a0Translatorner: A Transformer-based Model for mRNA Translation","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#experimental-purpose","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand the regulation of mRNA translation and its impact on protein abundance, which is crucial for understanding disease mechanisms. The central dogma of biology (DNA \u2192 RNA \u2192 Protein) is well-known, but the correlation between mRNA and protein levels is not perfect (0.39 to 0.79). The study seeks to model how mRNA translation is regulated and how this regulation affects protein levels.</li> <li>Experimental Design: The study uses a Transformer-based deep learning model (Translatorner) to predict ribosome profiling (translatome) from RNA-seq data and gene sequences. The model is trained on human data and tested on both human and mouse datasets to evaluate its ability to generalize across species.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#model-system","title":"Model System:","text":"<ul> <li>Model System: The study uses human and mouse genomic data. These systems are appropriate because they are well-studied, and the conservation of regulatory mechanisms between humans and mice allows for cross-species validation.</li> <li>Alternative Model Systems: Other model systems like yeast or zebrafish could be used, but they may lack the complexity and relevance to human diseases. However, they are cheaper and easier to manipulate.</li> <li>Ethical Considerations: Using human genomic data requires ethical approval, especially when dealing with patient data. The study likely adheres to ethical guidelines for genomic research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#measurement-approach","title":"Measurement Approach:","text":"<ul> <li>Techniques: The study uses ribosome profiling (Ribo-seq) and RNA-seq data. These are quantitative techniques that measure translation efficiency and mRNA abundance, respectively.</li> <li>Method Choice: Deep learning models (Transformers) were chosen because they can capture long-range dependencies in sequences, which is crucial for understanding translation regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from data normalization or sequencing depth. These are minimized by using standardized protocols and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#group-setting","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The model is trained on human data and tested on both human and mouse data. The groups are defined by cell types (e.g., epithelial cells, brain cells).</li> <li>Negative Controls: The study compares Translatorner with state-of-the-art models (e.g., Riboformer) to ensure that the improvements are not due to overfitting.</li> <li>Biological Replicates: The study uses multiple datasets (e.g., K562, epithelial cells) to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of mRNA affect translation efficiency.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#data-analysis-presentation","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw data from Ribo-seq and RNA-seq are processed using deep learning models. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses Pearson correlation coefficients (PCC) to compare predicted and observed ribosome profiling data.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using cross-species data and in silico mutagenesis, which confirms the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#2-transrbp-modeling-rbp-binding-and-its-interaction-with-m6a","title":"2.\u00a0TransRBP: Modeling RBP Binding and Its Interaction with m6A","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#experimental-purpose_1","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how RNA-binding proteins (RBPs) interact with m6A modifications and how these interactions affect RNA metabolism and disease.</li> <li>Experimental Design: The study develops a deep learning model (TransRBP) to predict RBP binding sites and their interaction with m6A. The model is trained on RNA sequences and tested for its ability to identify disease-related variants that alter RBP binding.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#model-system_1","title":"Model System:","text":"<ul> <li>Model System: The study uses human genomic data, focusing on RBPs and m6A modifications. This system is appropriate because m6A is the most prevalent mRNA modification and plays a critical role in RNA metabolism.</li> <li>Alternative Model Systems: Other systems like yeast or bacteria could be used, but they lack the complexity of m6A regulation seen in higher eukaryotes.</li> <li>Ethical Considerations: Similar to Translatorner, the use of human genomic data requires ethical approval.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#measurement-approach_1","title":"Measurement Approach:","text":"<ul> <li>Techniques: The study uses RNA-seq data and m6A sequencing data. These are quantitative techniques that measure RNA abundance and m6A modifications.</li> <li>Method Choice: Deep learning models (Transformers) were chosen because they can capture complex interactions between RNA sequences and RBPs.</li> <li>Technical Replicates: The study likely uses multiple replicates, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from sequencing errors or incomplete annotation of m6A sites. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#group-setting_1","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The model is trained on RNA sequences and tested for its ability to predict RBP binding sites. The groups are defined by disease types (e.g., Parkinson\u2019s disease, autism).</li> <li>Negative Controls: The study compares TransRBP with existing models to ensure that the improvements are not due to overfitting.</li> <li>Biological Replicates: The study uses multiple datasets to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of m6A affect RBP binding.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#data-analysis-presentation_1","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw data from RNA-seq and m6A sequencing are processed using deep learning models. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses Pearson correlation coefficients (PCC) to compare predicted and observed RBP binding data.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using in silico mutagenesis and experimental data, which confirms the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#general-observations","title":"General Observations:","text":"<ul> <li>Both studies leverage deep learning models (Transformers) to address complex questions in genomics. The models are trained on large datasets and validated using cross-species data and in silico experiments.</li> <li>The studies highlight the importance of model interpretability, using techniques like in silico mutagenesis and gradient-based interpretation to understand the contribution of different input modalities.</li> <li>The results have significant implications for understanding disease mechanisms, particularly in the context of translation regulation and RBP interactions with m6A modifications  </li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s2w21-molecular-interactions-from-structure-perspective","title":"S2.W2.1. Molecular interactions from structure perspective","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s2w22-seminar-empowering-precision-medicine-with-computational-biology","title":"S2.W2.2. Seminar. Empowering precision medicine with computational biology","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#1-sptransformer-tissue-specific-splicing-prediction","title":"1.\u00a0SpTransformer: Tissue-Specific Splicing Prediction","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#experimental-purpose_2","title":"Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to predict tissue-specific splicing alterations caused by single nucleotide variants (SNVs) and understand their role in human diseases.</li> <li>Experimental Design: SpTransformer, a Transformer-based deep learning model, is developed to predict splicing alterations in 15 different tissues. The model is trained on RNA-seq data and validated using clinical samples.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#model-system_2","title":"Model System:","text":"<ul> <li>Model System: Human genomic data are used, as they are directly relevant to human diseases and precision medicine.</li> <li>Alternative Model Systems: Model organisms like mice could be used, but they may not fully capture the complexity of human splicing regulation.</li> <li>Ethical Considerations: Using human genomic data requires ethical approval, especially when dealing with patient data.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#measurement-approach_2","title":"Measurement Approach:","text":"<ul> <li>Techniques: RNA-seq data are used to measure splicing alterations. The data are quantitative, allowing for precise predictions.</li> <li>Method Choice: Transformers were chosen because they can capture long-range dependencies in sequences, which is crucial for understanding splicing regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates to ensure robustness, though the exact number is not specified.</li> <li>Potential Biases: Biases could arise from sequencing errors or incomplete annotation of splicing events. These are minimized by using high-quality datasets and cross-validation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#group-setting_2","title":"Group Setting:","text":"<ul> <li>Experimental Groups: The study compares splicing alterations in different tissues to understand tissue-specific effects.</li> <li>Negative Controls: Non-splicing variants are used as negative controls to ensure that the model can distinguish between splicing and non-splicing events.</li> <li>Biological Replicates: Multiple datasets are used to ensure generalizability.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of splicing alterations affect tissue function.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#data-analysis-presentation_2","title":"Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed using SpTransformer to predict splicing alterations. The data are quantitative, and the model outputs are compared with experimental data.</li> <li>Statistical Tests: The study uses z-scores to define tissue-specific splicing alterations and enrichment analysis to identify disease-related genes.</li> <li>Data Presentation: Results are presented using scatter plots and enrichment plots, which are clear and free of misleading scaling.</li> <li>Confirmation: The model's predictions are validated using clinical samples and RNA-seq data, confirming the robustness of the results.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#general-observations_1","title":"General Observations:","text":"<ul> <li>The studies leverage computational biology and deep learning to address complex questions in genomics, particularly in the context of cancer, genetic variants, and splicing regulation.</li> <li>The models are trained on large datasets and validated using cross-species data and experimental data, highlighting their robustness and generalizability.</li> <li>The results have significant implications for precision medicine, particularly in the context of cancer diagnosis, genetic variant interpretation, and understanding tissue-specific splicing alterations.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s2w23-big-data-analysis-dimensionality-reduction","title":"S2.W2.3. Big data analysis - dimensionality reduction","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s2w31-large-molecule-de-novo-design-using-antibody-as-an-example","title":"S2.W3.1. Large molecule de-novo design, using antibody as an example","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s2w32-seminar-structural-study-of-epigenetic-regulation-in-transcription","title":"S2.W3.2. Seminar. Structural study of epigenetic regulation in transcription","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#1-experimental-purpose","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how\u00a0histone modifications\u00a0(e.g., acetylation, methylation) and\u00a0chromatin structure\u00a0regulate transcription. Specifically, it investigates the structural mechanisms by which histone modifications influence the binding of transcription machinery and the regulation of gene expression.</li> <li>Experimental Design: The study uses\u00a0structural biology techniques\u00a0(e.g., cryo-EM, X-ray crystallography) to determine the molecular structures of key epigenetic regulators, such as\u00a0histone acetyltransferases (HATs)\u00a0and\u00a0histone deacetylases (HDACs), and their interactions with nucleosomes and transcription factors.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#2-model-system","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0yeast\u00a0and\u00a0human cells, as these systems are well-characterized and provide a direct link to eukaryotic transcription regulation. The study focuses on the\u00a0SAGA complex, a well-known HAT complex involved in transcription regulation.</li> <li>Why This System?: Yeast and human cells are appropriate for this study because they allow for the manipulation of specific histone modifications and chromatin structures. The SAGA complex is relevant because it plays a key role in regulating transcription through histone acetylation.</li> <li>Alternative Model Systems: Other model systems like\u00a0bacteria\u00a0or\u00a0plants\u00a0could be used, but they lack the complexity of eukaryotic chromatin and histone modifications.</li> <li>Ethical Considerations: Using human cell lines requires ethical approval, especially when dealing with patient-derived samples. The study likely adheres to ethical guidelines for genomic research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#3-measurement-approach","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>Cryo-electron microscopy (cryo-EM): To determine the structures of epigenetic regulators (e.g., SAGA complex) and their interactions with nucleosomes.</li> <li>X-ray crystallography: To obtain high-resolution structures of specific histone modifications and their interactions with transcription factors.</li> <li>Biochemical assays: To study the functional roles of histone modifications in transcription regulation.</li> <li>Chromatin immunoprecipitation (ChIP): To study the binding of transcription factors to histone-modified chromatin.</li> </ul> </li> <li>Why These Methods?: Cryo-EM and X-ray crystallography were chosen because they allow for the visualization of molecular structures at atomic resolution, which is crucial for understanding the mechanisms of epigenetic regulation. Biochemical assays and ChIP were used to study the functional roles of histone modifications in transcription.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=3 or more) to ensure the robustness of the structural data.</li> <li>Potential Biases: Biases could arise from sample preparation or data interpretation. These are minimized by using standardized protocols and cross-validation with biochemical assays.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#4-group-setting","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Wild-type cells\u00a0vs.\u00a0cells with specific histone modifications: To study the effects of histone modifications on transcription.</li> <li>Cells with intact SAGA complex\u00a0vs.\u00a0cells with SAGA complex mutations: To study the role of the SAGA complex in transcription regulation.</li> <li>Cells treated with HDAC inhibitors\u00a0vs.\u00a0untreated cells: To study the effects of histone deacetylation on transcription.</li> </ul> </li> <li>Negative Controls: Cells without specific histone modifications or with intact SAGA complex serve as negative controls to study the effects of histone modifications and SAGA complex mutations.</li> <li>Biological Replicates: Multiple samples are used in each group (e.g., n=3 or more) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of histone modifications or HDAC inhibitors affect transcription.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#5-data-analysis-presentation","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw structural data from cryo-EM and X-ray crystallography are processed to generate 3D models of the molecular structures. Biochemical and ChIP data are analyzed to study the functional roles of histone modifications in transcription.</li> <li>Statistical Tests: The study uses statistical validation methods (e.g., cross-validation, resolution assessment) to ensure the accuracy of the structural models. Differential binding analysis is performed to identify key transcription factors regulated by histone modifications.</li> <li>Data Presentation: Results are presented using\u00a03D structural models,\u00a0graphs, and\u00a0tables, which are clear and free of misleading scaling. For example, the study uses\u00a0electron density maps\u00a0to show the structures of histone modifications and\u00a0bar graphs\u00a0to compare transcription factor binding.</li> <li>Confirmation: The structural findings are confirmed using\u00a0biochemical assays\u00a0and\u00a0functional studies, which validate the proposed mechanisms of epigenetic regulation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#general-observations_2","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how\u00a0histone modifications\u00a0and\u00a0chromatin structure\u00a0regulate transcription through the\u00a0SAGA complex\u00a0and other epigenetic regulators.</li> <li>The findings highlight the importance of\u00a0histone acetylation\u00a0and\u00a0deacetylation\u00a0in regulating gene expression and suggest potential therapeutic targets for diseases linked to epigenetic dysregulation.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0epigenetic regulation\u00a0and developing therapies for\u00a0cancer\u00a0and other diseases.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s2w41-single-cell-spatial-temporal-multi-omics","title":"S2.W4.1. Single-cell spatial-temporal multi-omics","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s2w42-survival-analysis","title":"S2.W4.2. Survival analysis","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s2w43-seminar-host-microbial-interactions-and-lipid-metabolism","title":"S2.W4.3. Seminar. Host-microbial Interactions and Lipid Metabolism","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#1-experimental-purpose_1","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how the gut microbiota regulates host lipid metabolism and how dysbiosis (imbalance in the microbiota) contributes to metabolic disorders such as obesity and diabetes. Specifically, the study investigates the role of\u00a0Nfil3,\u00a0Hdac3, and\u00a0Snhg9\u00a0in mediating the effects of the microbiota on lipid metabolism.</li> <li>Experimental Design: The study uses\u00a0germ-free (GF) mice\u00a0and\u00a0conventional (CV) mice\u00a0to identify key genes regulated by the microbiota. The researchers then use\u00a0gene knockout models\u00a0and\u00a0bacterial gavage\u00a0to study the functional roles of these genes and specific bacterial strains in lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#2-model-system_1","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0germ-free (GF) mice\u00a0and\u00a0conventional (CV) mice. These models are ideal for studying the effects of the microbiota on host metabolism because GF mice lack a gut microbiota, allowing researchers to isolate the effects of specific bacterial strains.</li> <li>Why This System?: Mice are appropriate for this study because their gut microbiota and lipid metabolism are well-characterized, and they allow for precise genetic manipulation. The use of GF mice is particularly relevant because it enables researchers to study the effects of specific bacterial strains on host metabolism.</li> <li>Alternative Model Systems: Other model systems like\u00a0zebrafish\u00a0or\u00a0Drosophila\u00a0could be used, but they lack the complexity of mammalian lipid metabolism and gut microbiota interactions.</li> <li>Ethical Considerations: Using mice requires ethical approval, especially when dealing with germ-free conditions and dietary interventions. The study likely adheres to ethical guidelines for animal research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#3-measurement-approach_1","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>RNA sequencing (RNA-seq): To identify genes regulated by the microbiota.</li> <li>Biochemical assays: To measure lipid levels and metabolic activity.</li> <li>Gene knockout models: To study the functional roles of\u00a0Nfil3,\u00a0Hdac3, and\u00a0Snhg9\u00a0in lipid metabolism.</li> <li>Bacterial gavage: To introduce specific bacterial strains (e.g.,\u00a0Lactobacillus plantarum Pm001) into GF mice and study their effects on lipid metabolism.</li> </ul> </li> <li>Why These Methods?: RNA-seq was chosen to identify genes regulated by the microbiota, while biochemical assays were used to measure lipid levels and metabolic activity. Gene knockout models and bacterial gavage were used to study the functional roles of specific genes and bacterial strains.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=3 or more) to ensure the robustness of the data.</li> <li>Potential Biases: Biases could arise from differences in mouse strains or dietary conditions. These are minimized by using standardized protocols and controls.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#4-group-setting_1","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Germ-free (GF) mice\u00a0vs.\u00a0conventional (CV) mice: To study the effects of the microbiota on lipid metabolism.</li> <li>Gene knockout mice\u00a0(e.g.,\u00a0Nfil3\u0394IEC,\u00a0Hdac3\u0394IEC) vs.\u00a0wild-type mice: To study the functional roles of specific genes in lipid metabolism.</li> <li>Mice treated with specific bacterial strains\u00a0(e.g.,\u00a0Lactobacillus plantarum Pm001) vs.\u00a0control mice: To study the effects of specific bacterial strains on lipid metabolism.</li> </ul> </li> <li>Negative Controls: GF mice and wild-type mice serve as negative controls to study the effects of the microbiota and gene knockouts on lipid metabolism.</li> <li>Biological Replicates: Multiple mice are used in each group (e.g., n=8) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of specific bacterial strains or gene expression affect lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#5-data-analysis-presentation_1","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed to identify differentially expressed genes. Biochemical data are analyzed to measure lipid levels and metabolic activity.</li> <li>Statistical Tests: The study uses statistical methods (e.g., t-tests, ANOVA) to compare gene expression and lipid levels between groups. Differential expression analysis is performed to identify key genes regulated by the microbiota.</li> <li>Data Presentation: Results are presented using\u00a0graphs\u00a0and\u00a0tables, which are clear and free of misleading scaling. For example, the study uses\u00a0bar graphs\u00a0to compare lipid levels and\u00a0scatter plots\u00a0to show gene expression changes.</li> <li>Confirmation: The findings are confirmed using\u00a0gene knockout models\u00a0and\u00a0bacterial gavage, which validate the role of specific genes and bacterial strains in regulating lipid metabolism.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#general-observations_3","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how the gut microbiota regulates host lipid metabolism through specific genes (Nfil3,\u00a0Hdac3, and\u00a0Snhg9).</li> <li>The findings highlight the importance of\u00a0Lactobacillus plantarum Pm001\u00a0in promoting\u00a0Snhg9\u00a0expression and protecting mice from diet-induced obesity.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0microbiota-host interactions\u00a0and developing\u00a0microbiota-based therapies\u00a0for metabolic disorders.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s2w51-binary-trees-and-random-forest","title":"S2.W5.1. Binary trees and Random Forest","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#s2w52-seminar-how-to-do-a-scientific-project-step-by-step","title":"S2.W5.2. Seminar. How to Do a Scientific Project Step-by-step","text":""},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#1-experimental-purpose_2","title":"1.\u00a0Experimental Purpose:","text":"<ul> <li>Scientific Question: The study aims to understand how\u00a0IL-33, a cytokine produced by\u00a0PDGFR\u03b2+DPP4+ cells, regulates cold-induced thermogenesis and the formation of beige adipocytes in white adipose tissue (WAT). Specifically, the study investigates whether IL-33 expression is induced by cold exposure and how it contributes to thermogenic remodeling.</li> <li>Experimental Design: The study uses a combination of\u00a0RNA sequencing (RNA-seq),\u00a0flow cytometry,\u00a0histology, and\u00a0CRISPR/Cas9 gene editing\u00a0to explore the role of IL-33 in cold-induced thermogenesis. The researchers first identify IL-33 as a key player in the process and then investigate the molecular mechanisms underlying its regulation.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#2-model-system_2","title":"2.\u00a0Model System:","text":"<ul> <li>Model System: The study primarily uses\u00a0mouse models, particularly\u00a0PDGFR\u03b2+DPP4+ cells\u00a0in inguinal white adipose tissue (iWAT). These cells are identified as the main source of IL-33 in iWAT. The study also uses\u00a0germ-free (GF)\u00a0and\u00a0conventional (CV)\u00a0mice to study the effects of cold exposure on adipose tissue.</li> <li>Why This System?: Mice are appropriate for this study because they allow for the manipulation of specific cell populations and genes, and their adipose tissue responds to cold exposure in a manner similar to humans. The use of PDGFR\u03b2+DPP4+ cells is relevant because these cells are known to play a role in adipose tissue remodeling.</li> <li>Alternative Model Systems: Other model systems, such as\u00a0cell cultures\u00a0or\u00a0zebrafish, could be used, but they lack the complexity of in vivo adipose tissue remodeling and the interaction between different cell types.</li> <li>Ethical Considerations: Using mice requires ethical approval, especially when dealing with cold exposure and gene editing. The study likely adheres to ethical guidelines for animal research.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#3-measurement-approach_2","title":"3.\u00a0Measurement Approach:","text":"<ul> <li>Techniques: The study employs several techniques:<ul> <li>RNA-seq: To analyze gene expression changes in response to cold exposure.</li> <li>Flow cytometry: To study immune cell populations (e.g., ILC2s) in adipose tissue.</li> <li>Histology: To visualize beige adipocyte formation in adipose tissue.</li> <li>CRISPR/Cas9: To knock out\u00a0CREB, a transcription factor that regulates IL-33 expression.</li> <li>Chromatin Immunoprecipitation (ChIP): To study the binding of CREB to the IL-33 promoter.</li> </ul> </li> <li>Why These Methods?: RNA-seq was chosen to identify genes regulated by cold exposure, while flow cytometry and histology were used to study the cellular and tissue-level effects of IL-33. CRISPR/Cas9 and ChIP assays were used to investigate the molecular mechanisms of IL-33 regulation.</li> <li>Technical Replicates: The study likely uses multiple replicates (e.g., n=4 or more) to ensure the robustness of the data.</li> <li>Potential Biases: Biases could arise from differences in mouse strains or environmental conditions. These are minimized by using standardized protocols and controls.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#4-group-setting_2","title":"4.\u00a0Group Setting:","text":"<ul> <li>Experimental Groups: The study compares several groups:<ul> <li>Cold-exposed mice (6\u00b0C)\u00a0vs.\u00a0room temperature mice (22\u00b0C): To study the effects of cold exposure on IL-33 expression and thermogenic remodeling.</li> <li>PDGFR\u03b2+DPP4+ cells\u00a0vs.\u00a0PDGFR\u03b2+DPP4- cells: To identify the source of IL-33 in iWAT.</li> <li>CREB knockout mice\u00a0vs.\u00a0wild-type mice: To study the role of CREB in regulating IL-33 expression.</li> </ul> </li> <li>Negative Controls: Mice kept at room temperature and wild-type mice serve as negative controls to study the effects of cold exposure and CREB knockout.</li> <li>Biological Replicates: Multiple mice are used in each group (e.g., n=8) to ensure reproducibility.</li> <li>Modified Group Design: A dose-response experiment could be added to study how varying levels of cold exposure or IL-33 expression affect thermogenic remodeling.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#5-data-analysis-presentation_2","title":"5.\u00a0Data Analysis &amp; Presentation:","text":"<ul> <li>Data Processing: Raw RNA-seq data are processed to identify differentially expressed genes. Flow cytometry and histology data are analyzed to study cell populations and tissue remodeling. ChIP assay data are analyzed to study the binding of CREB to the IL-33 promoter.</li> <li>Statistical Tests: The study uses statistical methods (e.g., t-tests, ANOVA) to compare gene expression, cell populations, and transcription factor binding between groups. Differential expression analysis is performed to identify key genes regulated by cold exposure and IL-33.</li> <li>Data Presentation: Results are presented using\u00a0graphs,\u00a0tables, and\u00a0histological images, which are clear and free of misleading scaling. For example, the study uses\u00a0volcano plots\u00a0to show differentially expressed genes and\u00a0bar graphs\u00a0to compare IL-33 expression levels.</li> <li>Confirmation: The findings are confirmed using\u00a0gene knockout models\u00a0(e.g., CREB knockout) and\u00a0functional assays\u00a0(e.g., ChIP assays), which validate the role of IL-33 and CREB in cold-induced thermogenesis.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yc/MY%20notes%20for%20slides_yicheng/#general-observations_4","title":"General Observations:","text":"<ul> <li>The study provides a detailed understanding of how\u00a0IL-33, produced by\u00a0PDGFR\u03b2+DPP4+ cells, regulates cold-induced thermogenesis and beige adipocyte formation.</li> <li>The findings highlight the importance of\u00a0CREB\u00a0as a transcription factor that drives IL-33 expression in response to cold exposure.</li> <li>The results have significant implications for understanding the molecular basis of\u00a0cold-induced thermogenesis\u00a0and developing therapies for\u00a0obesity\u00a0and\u00a0metabolic disorders.</li> </ul>"},{"location":"IBMS3/Yiru/detailed/from_yicheng/","title":"IBMS3 / detailed / from_yicheng","text":"<p>Files in <code>from_yicheng</code>:</p> <ul> <li>AI notes for seminar_yicheng.md</li> <li>Final notes for seminar_yicheng.md</li> <li>IBMS\u603b\u7ed3\u590d\u4e60_yicheng.md</li> <li>MY notes for slides_yicheng.md</li> </ul>"},{"location":"IBMS4/","title":"IBMS4","text":""},{"location":"IBMS4/#external-links","title":"External links","text":"<ul> <li>Hal (2024-2025): https://drive.google.com/file/d/1XcHq_gENuok68vWcGgfdZlpxAXnygs9J/view?usp=sharing</li> </ul>"},{"location":"ICMB1/","title":"ICMB1","text":""},{"location":"ICMB1/#external-links","title":"External links","text":"<ul> <li>Hal (2021-2022): https://drive.google.com/file/d/1-F9q2f747vj1VniamqBVrcKYt_Fn5iH0/view?usp=sharing</li> </ul>"},{"location":"IFBS2/","title":"IFBS2","text":"<p>Files contributed:</p> <ul> <li>ZIP packages are hosted externally. See: \u601d\u7ef4\u5bfc\u56feIFBS_lxr</li> </ul>"},{"location":"IFBS2/#external-links","title":"External links","text":"<ul> <li>Hal (2022-2023): https://drive.google.com/file/d/1lgH-OKJ_kiLtY1RT4h6Taky-VZNVfUoA/view?usp=sharing</li> </ul>"},{"location":"IID_4/","title":"IID_4","text":""},{"location":"IID_4/#contributors","title":"Contributors","text":"<ul> <li>Yiru: notes</li> </ul>"},{"location":"IID_4/#files","title":"Files","text":"<ul> <li>Browse Yiru notes: Yiru/</li> </ul>"},{"location":"IID_4/#external-links","title":"External links","text":"<ul> <li>Hal (2024-2025): https://drive.google.com/file/d/1croWrQe1agk-zbvIklNjL-roso30TlZ_/view?usp=sharing</li> </ul>"},{"location":"IID_4/Yiru/","title":"IID_4","text":"<p>Files:</p> <ul> <li>NotebookLLM_Topic_1.pdf</li> <li>NotebookLLm_Topic_3.pdf</li> <li>NotebookLLM_Topic_4.pdf</li> <li>NotebookLLM_Topic_5_EVA.pdf</li> <li>Topic 0 basic concept of immunology.md</li> <li>Topic 1 Innate Immune system.md</li> <li>Topic 1.5 Trained Innate Immunity.md</li> <li>Topic 10 what I need to know for exam.md</li> <li>Topic 11 Macrophage.md</li> <li>Topic 12 Diseases.md</li> <li>Topic 2 Inflammation algorithm.md</li> <li>Topic 3 T-Cell.md</li> <li>Topic 4 ILC, Innate lymphoid cells.md</li> <li>Topic 5 B cell.md</li> <li>Topic 6 Auto-immune disease.md</li> <li>Topic 7 System exhaustion and cytokine storms.md</li> <li>Topic 8 Immunometablism.md</li> <li>Topic 9 monoclonal antibodies.md</li> </ul>"},{"location":"IID_4/Yiru/Topic%200%20basic%20concept%20of%20immunology/","title":"Topic 0 basic concept of immunology","text":""},{"location":"IID_4/Yiru/Topic%200%20basic%20concept%20of%20immunology/#i-the-sentinels-first-responders-innate-immune-cells","title":"I. The Sentinels &amp; First Responders (Innate Immune Cells)","text":"<p>These cells act as the body's rapid response team. They do not require prior sensitization and rely on Pattern Recognition Receptors (PRRs) to detect general danger signals.</p>"},{"location":"IID_4/Yiru/Topic%200%20basic%20concept%20of%20immunology/#1-macrophages-monocytes","title":"1. Macrophages &amp; Monocytes","text":"<ul> <li>The Logic: They function as both waste management (phagocytosis) and alarm systems (cytokine release). They dictate the local environment's \"tone\" (inflammatory vs. healing).</li> <li>Key Features:<ul> <li>Origin: Monocytes circulate in blood and differentiate into macrophages in tissues (e.g., Kupffer cells in liver, microglia in brain).</li> <li>Polarization (The Decision Makers): They can switch phenotypes based on signals:<ul> <li>M1 (Classically Activated): Pro-inflammatory; kill pathogens and tumor cells.</li> <li>M2 (Alternatively Activated): Anti-inflammatory; promote tissue repair and healing.</li> </ul> </li> </ul> </li> <li>Connection Mechanism: They act as Antigen-Presenting Cells (APCs), processing pathogens and presenting them to T cells via MHC II molecules to initiate the adaptive response.</li> </ul>"},{"location":"IID_4/Yiru/Topic%200%20basic%20concept%20of%20immunology/#2-dendritic-cells-dcs-the-master-bridge","title":"2. Dendritic Cells (DCs) \u2014 The Master Bridge","text":"<ul> <li>The Logic: DCs are the central information hub connecting innate and adaptive immunity. They are the only cells capable of activating naive T cells, effectively \"teaching\" the adaptive system what to attack.</li> <li>Key Features:<ul> <li>Subtypes:<ul> <li>Myeloid DCs (mDCs): Focus on antigen processing and presentation.</li> <li>Plasmacytoid DCs (pDCs): Specialized in producing massive amounts of Type I Interferons (antiviral).<ul> <li>Type I IFN $\\alpha$ and $\\beta$: induce an antiviral state<ul> <li>Normally, cells produce IFN only when detecting non-self nucleic acids, which means viral DNA/RNA<ul> <li>DNA sensing: ==cGAS-STING== pathway</li> <li>RNA sensing: receptor like ==TLR3/7/8, RIG-I and MDA5== detect viral RNA</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>Connection Mechanism (The 3-Signal Hypothesis): DCs activate T cells through three distinct signals:<ol> <li>Recognition: Presenting antigen (pMHC) to the T Cell Receptor (TCR).</li> <li>Costimulation: Surface molecules (CD80/86) binding to CD28 on T cells (prevents anergy).</li> <li>Differentiation: Releasing cytokines (e.g., IL-12) to determine if the T cell becomes Th1, Th2, etc.</li> </ol> </li> </ul>"},{"location":"IID_4/Yiru/Topic%200%20basic%20concept%20of%20immunology/#3-granulocytes-the-heavy-infantry","title":"3. Granulocytes (The Heavy Infantry)","text":"<ul> <li>Neutrophils: The most abundant early responders. They engulf bacteria and release \"nets\" (NETs) to trap pathogens. They bridge mechanisms by performing Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) when antibodies are present.</li> <li>Eosinophils: Specialized for killing parasites (too large to eat) by releasing toxic granules. They also act as APCs to modulate responses.</li> <li>Basophils &amp; Mast Cells: Crucial for allergic responses and defense against parasites. They express IgE receptors; when IgE binds, they degranulate (release histamine).</li> </ul>"},{"location":"IID_4/Yiru/Topic%200%20basic%20concept%20of%20immunology/#4-natural-killer-nk-cells","title":"4. Natural Killer (NK) Cells","text":"<ul> <li>The Logic: They provide surveillance against \"internal\" threats (viruses, cancer) that try to hide. Unlike T cells, they kill cells missing \"self\" markers (MHC I).</li> <li>Connection Mechanism:<ul> <li>ADCC: They bind to antibodies (IgG) coating a target cell via CD16 receptors and destroy it.</li> <li>Crosstalk: They secrete IFN-$\\gamma$ to activate macrophages and promote Th1 differentiation, pushing the adaptive system toward a cellular response.  </li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%200%20basic%20concept%20of%20immunology/#ii-the-blur-innate-like-lymphocytes","title":"II. The \"Blur\" (Innate-like Lymphocytes)","text":"<p>These cells share characteristics of both systems, acting as a rapid bridge with limited memory but semi-specific recognition. - NKT Cells: T cells that express NK markers. They recognize lipids (not proteins) presented by CD1 molecules and rapidly secrete cytokines (Th1/Th2) to tune the immune response. - $\\gamma\\delta$ T Cells: Found in mucosal tissues (skin, gut). They recognize stress signals directly without MHC presentation, acting as a barrier defense. - Innate Lymphoid Cells (ILCs): Mirror the functions of T helper cells but lack T cell receptors.     - ILC1 $\\approx$ Th1 (Viruses/Bacteria).     - ILC2 $\\approx$ Th2 (Parasites/Allergy).     - ILC3 $\\approx$ Th17 (Fungi/Extracellular bacteria).</p>"},{"location":"IID_4/Yiru/Topic%200%20basic%20concept%20of%20immunology/#iii-the-specialized-effectors-adaptive-immune-cells","title":"III. The Specialized Effectors (Adaptive Immune Cells)","text":"<p>These cells provide specific, high-affinity recognition and long-term memory. They are activated only after receiving \"permission\" and instructions from the Innate system.</p>"},{"location":"IID_4/Yiru/Topic%200%20basic%20concept%20of%20immunology/#1-t-lymphocytes-the-coordinators-assassins","title":"1. T Lymphocytes \u2014 The Coordinators &amp; Assassins","text":"<ul> <li>CD4+ Helper T Cells (The Generals): They do not kill; they direct the war.<ul> <li>Th1: Induced by IL-12 (from innate cells); activates Macrophages and CD8+ T cells (Cellular Immunity).</li> <li>Th2: Induced by IL-4; helps B cells produce antibodies (Humoral Immunity).</li> <li>Th17: Induced by IL-6/TGF-$\\beta$; recruits Neutrophils for bacterial/fungal defense.</li> <li>Tregs: Suppress the immune response to prevent autoimmune damage and maintain tolerance.</li> </ul> </li> <li>CD8+ Cytotoxic T Cells (The Assassins): Recognize specific antigens on infected/tumor cells via MHC I and induce apoptosis (cell death) via perforin/granzymes.</li> <li>Connection Mechanism: T cells rely on the Cancer-Immunity Cycle logic: release of antigen $\\to$ presentation by DCs $\\to$ priming T cells $\\to$ trafficking to tumor $\\to$ killing target.</li> </ul>"},{"location":"IID_4/Yiru/Topic%200%20basic%20concept%20of%20immunology/#2-b-lymphocytes-the-factories","title":"2. B Lymphocytes \u2014 The Factories","text":"<ul> <li>The Logic: B cells recognize soluble antigens directly. Once activated (usually with T cell help), they transform into factories (Plasma Cells).</li> <li>Subtypes:<ul> <li>B1 Cells (Innate-like): Found in body cavities; produce \"natural antibodies\" (IgM) without T cell help; no memory.    </li> <li>B2 Cells (Classic Adaptive): Require T cell help; undergo class switching (IgM $\\to$ IgG/IgA/IgE) and high-affinity maturation in Germinal Centers.</li> <li>Plasma Cells: The effector form that pumps out thousands of antibody molecules per second.  </li> <li>Memory B Cells: Long-lived sentinels that respond rapidly upon reinfection.</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%200%20basic%20concept%20of%20immunology/#iv-the-logic-of-interaction-crosstalk","title":"IV. The Logic of Interaction (Crosstalk)","text":"<p>The article emphasizes that these systems are not separate; they form a single integrated network.</p> <ol> <li>Innate $\\to$ Adaptive (Initiation):<ul> <li>Innate cells (DCs/Macrophages) detect pathogens via PRRs (TLRs, NLRs).</li> <li>They present antigens and secrete specific cytokines (e.g., IL-12 vs IL-4) which dictate whether the Adaptive system launches a Th1 (cellular) or Th2 (humoral) response.       </li> </ul> </li> <li>Adaptive $\\to$ Innate (Enhancement):<ul> <li>Antibodies (Adaptive) coat pathogens (Opsonization), making them \"tasty\" for Macrophages (Innate) to eat.</li> <li>Th1 Cells (Adaptive) release IFN-$\\gamma$, which \"supercharges\" Macrophages (Innate) to kill bacteria they have ingested.</li> </ul> </li> <li>Trained Immunity (The New Paradigm):<ul> <li>Unlike traditional views, innate cells (Monocytes/NKs) can have a form of memory. Through epigenetic and metabolic reprogramming (\"Trained Immunity\"), they react more strongly to secondary infections, bridging the gap between non-specific and specific immunity.</li> </ul> </li> </ol>"},{"location":"IID_4/Yiru/Topic%201%20Innate%20Immune%20system/","title":"Topic 1 Innate Immune system","text":"<ul> <li>Learn: 3.1 and 3.2</li> <li>Core idea: the immune system treats pathogens as specific input (pathogen-associated molecular patterns, PAMPs), and different inputs trigger different signalling pathways, which may cause cell death</li> <li>Pattern recognition receptors (PRRs), recognise PAMPs or molecules from damaged cells (DAMPs)<ul> <li>TLRs, Toll-like receptors: surface or endosomal sensor<ul> <li>Example: TLR4 detects LPS (which is a kind of bacteria)</li> <li>Pathway: <ul> <li></li> <li>Dimerized TLRs --&gt; MyD88 --&gt; IRAKs --&gt; TRAF6 --&gt; NF-$\\kappa$B (a kind of transcription factor) --&gt; transcription of pro-inflammatory cytokines<ul> <li>Pro-inflammatory cytokines are signaling molecules secreted by immune cells that promote and regulate inflammation to fight infection. They are crucial for the immune response but can also cause tissue damage if their levels are too high or chronic. Key examples include TNF-\u03b1, IL-1, and IL-6.</li> </ul> </li> </ul> </li> </ul> </li> <li>RLRs, RIG-I-like Receptors: cytosolic sensors<ul> <li></li> <li>Input is Viral RNA (released inside cell)</li> <li>Pathway: viral RNA --&gt; RIG-I --&gt; MAVS (mitochondrial adaptor) --&gt; IRF3 --&gt; Type I interferons and inflammatory cytokines</li> </ul> </li> </ul> </li> <li> <p>The inflammasome</p> <ul> <li>cytosolic multiprotein complexes of the innate immune system responsible for the activation of inflammatory response and cell death</li> <li>MLRP3 inflammasome <ul> <li>A multi-protein complex, NLRP3 (sensor) + ASC (adaptor) + Caspase-1 (Effector)</li> <li>priming and activation: singal 1 and 2<ul> <li>Signal 1, Priming: TLR activation activates NF-$\\kappa$B</li> <li>Signal 2, Activation: Disturbance in the cell, specifically K+ efflux, ROS, or crystals</li> <li>Results<ul> <li>Caspase-1 Activation: It acts as molecular scissors.</li> <li>Cytokine Release: Cleaves Pro-IL-1$\\beta$ and Pro-IL-18 into active forms.</li> <li>Pyroptosis: Cleaves Gasdermin D (GSDMD), which punches pores in the cell membrane to release the cytokines and kill the cell<ul> <li>Pyroptosis rely on GSDMD, which will activate IL-1$\\beta$ and IL-18 maturation and cell lysis</li> </ul> </li> </ul> </li> <li>In the Canonical NLRP3 Pathway, the order is strict: Signal 1 must happen before Signal 2 for a successful immune response.</li> </ul> </li> </ul> </li> </ul> </li> <li> <p>Cell death: silent death (Apoptosis) and lytic death (Necroptosis and pyroptosis)</p> <ul> <li>Apoptosis: non-lytic, membrane stays intact<ul> <li></li> <li>Intrinsic pathway:<ul> <li>response to internal stimuli, like biochemical stress, DNA damage, and withgrawal of growth factors</li> <li>mitochondrial stress --&gt; ==BAX/ BAK== pore formation (MOMP) --&gt; Cytochrome c release --&gt; Apoptosome --&gt; Caspase-9 --&gt; Caspase-3</li> <li>Bcl-2 family protein act as protecotrs blocking BAX/BAK</li> <li></li> </ul> </li> <li>Extrinsic pathway<ul> <li>initiated by external stimuli, primarily through the binding of ligands to death receptors on the cell surface</li> <li>Death receptor --&gt; FADD --&gt; Caspase-8 --&gt; Caspase-3</li> </ul> </li> </ul> </li> <li>Necroptosis<ul> <li>When it happens: only when Caspase-8 is inhibited (like by virus)</li> <li>Machinery<ul> <li>RIPK1 recruits RIPK3 via the RHIM domain</li> <li>They form a complex called the necrosome</li> <li>RIPK3 phosphorylates MLKL</li> </ul> </li> <li>Phosphorylated MLKL oligomerizes and moves to the plasma membrane to form pores, causing the cell to burst.</li> </ul> </li> </ul> </li> <li>Caspase-8 is the Key switch<ul> <li>Active Caspase-8 can cleave RIPK1 and RIPK3, destorying the necroptosis machinery. ==Result = Apoptosis==</li> <li>Inactivate Caspase-8: RIPK1 and RIPK3 accumulate and phosphorylate MLKL. ==Result = Necroptosis==</li> </ul> </li> </ul> Feature Apoptosis Necroptosis Pyroptosis Primary Trigger Intrinsic: Cellular stress (DNA damage, oxidative stress) sensed by Bcl-2 family. Extrinsic: Death Receptor ligation (e.g., FasL, TNF)2. Receptor Activation + Caspase Inhibition: TNFR1 or TLR activation in the presence of Caspase-8 inhibition (e.g., by viral proteins or drugs). Inflammasome Activation: Sensing of PAMPs/DAMPs (e.g., LPS, ATP, Crystals) by sensors like NLRP3, AIM2, or NLRC. Caspase Involvement Caspase-Dependent: \u2022 Initiators: Caspase-8 (extrinsic) or Caspase-9 (intrinsic) . \u2022 Executioners: Caspase-3, -7. Caspase-Independent: Occurs only when Caspase-8 is inactivated. Relies on kinases RIPK1 and RIPK3 Caspase-Dependent: Relies on \"Inflammatory Caspases\": \u2022 Caspase-1 (Canonical) 8. \u2022 Caspase-4/5/11 (Non-canonical). Key Effector Mechanism MOMP: Mitochondrial Outer Membrane Permeabilization via BAX/BAK MLKL Pores: Phosphorylated MLKL oligomerizes and translocates to the plasma membrane to form pores GSDMD Pores: Caspase-1 cleaves Gasdermin D, forming pores that release IL-1\u03b2/IL-18. Outcome Non-Inflammatory (Silent): Cell shrinks, membrane remains intact (initially), formation of apoptotic bodies, phagocytosis 13. Pro-Inflammatory (Lytic): Cell swells and bursts, releasing DAMPs. Often used as a backup anti-viral defense. Pro-Inflammatory (Lytic): Cell bursts, releasing mature cytokines (IL-1\u03b2, IL-18) and DAMPs. ### Key Logic Checks for Exam: <ol> <li> <p>The Caspase-8 Switch: If Caspase-8 is active $\\rightarrow$ Apoptosis. If Caspase-8 is blocked $\\rightarrow$ Necroptosis 16.</p> </li> <li> <p>The Pore Formers: Necroptosis uses MLKL; Pyroptosis uses GSDMD (Gasdermin D). Both cause lysis, but GSDMD is specifically linked to IL-1$\\beta$ release.</p> </li> <li> <p>Mitochondria: Apoptosis is heavily defined by mitochondrial permeabilization (MOMP), whereas Necroptosis and Pyroptosis focus on plasma membrane permeabilization</p> </li> <li> <p>Also,  why Pyroptosis is inflammatory (GSDMD pores) while Apoptosis is silent?</p> <ul> <li>inflammation means a system: detecting PAMP or DAMP; then effector cells secrete cytokines and chemokines</li> <li>So the key point is that, pyroptosis would cause membrane to be broken via GSDMD pores --&gt; ==DAMPs will go out (like ATP, DNA)== --&gt; altert to system </li> <li>But instead, apoptosis will let the cell die as a whole --&gt; content contained in Apoptotic bodies --&gt; cleaning up old cells, no response</li> </ul> </li> </ol>"},{"location":"IID_4/Yiru/Topic%201%20Innate%20Immune%20system/#more-about-complement-proteins","title":"More about: complement proteins","text":"<ul> <li>innate immunology system. they have the ability to activate in a domino-like chain reaction called a cascade --&gt; enhance the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism</li> </ul>"},{"location":"IID_4/Yiru/Topic%201%20Innate%20Immune%20system/#classical-pathway","title":"Classical pathway","text":"<ul> <li>After a antibody bind to bacteria <ul> <li>Complement protien C1 bind to antibody</li> <li>C4 binds to C1</li> <li>C2 binds to  C4</li> <li>C3 binds to C2 --&gt; C3 split up, C3a moves away, C3b remains</li> <li>C5b binds to C3b, C5a moves away</li> <li>...until C9</li> <li>==C3a and C5a== are chemotactic factor --&gt; enhance inflammatory response</li> </ul> </li> <li>MAC formation: membrane attack complex, formed by C5b, C6-C9, break off from the chain<ul> <li>Na+ and H2O flow into cell --&gt; cause cell lysis</li> </ul> </li> <li>So now C3b expose; macrophage bind to C3b with C3b receptor --&gt; cause phagosytosis</li> </ul>"},{"location":"IID_4/Yiru/Topic%201%20Innate%20Immune%20system/#alternative-pathway","title":"Alternative pathway","text":"<ul> <li>C3b bind to bacteria membrane antigen directly; followed by C5b, C6-9</li> <li>C5b-C9 can also form MAC and break off; C3b bind macrophage directly</li> </ul>"},{"location":"IID_4/Yiru/Topic%201%20Innate%20Immune%20system/#lectin-pathway","title":"Lectin pathway","text":"<ul> <li>start with C4 bind to a kind of sugar on antibody; other no difference</li> </ul>"},{"location":"IID_4/Yiru/Topic%201%20Innate%20Immune%20system/#more-about-toll-like-receptor-and-interferon","title":"More about Toll-like receptor and interferon","text":"<ul> <li>when the cell is damaged:<ul> <li>transcript factor IRF will activate the expression IFN(interferon)</li> <li>IFN has three types<ul> <li>$\\alpha$</li> <li>$\\beta$</li> <li>$\\gamma$</li> </ul> </li> <li>IFN $\\alpha$ and $\\beta$ can be released, to warn other cells to produce protein kinase R --&gt; damage the RNA of virus --&gt; prevent the infection of nearby health cells</li> </ul> </li> <li>When macrophage get the signal of virus:<ul> <li>release IFN alpha and beta</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%201.5%20Trained%20Innate%20Immunity/","title":"Topic 1.5 Trained Innate Immunity","text":""},{"location":"IID_4/Yiru/Topic%201.5%20Trained%20Innate%20Immunity/#epigenetic-reprogramming-is-the-key-for-innate-immune-memory","title":"Epigenetic reprogramming is the key for innate immune memory","text":"<ul> <li>Chromatin go through changes</li> <li>Then, immunity related gene expression increase <ul> <li> <ol> <li>Chromatin Status: promoter region of immunity related to immunity open</li> </ol> </li> <li> <ol> <li>Histone modification: H3K4me3, H3K27ac, H3K27me3</li> </ol> </li> <li> <ol> <li>DNA methylation: fDNA methylation level in promoter region decrease</li> </ol> </li> </ul> </li> <li></li> </ul>"},{"location":"IID_4/Yiru/Topic%201.5%20Trained%20Innate%20Immunity/#metabolic-reprogramming","title":"Metabolic reprogramming","text":"<ul> <li>After training, metabolic pathway change from oxidative phosphorylation to glycolysis</li> </ul>"},{"location":"IID_4/Yiru/Topic%201.5%20Trained%20Innate%20Immunity/#central-and-peripheral-innate-immune-memory","title":"Central and peripheral innate immune memory","text":"Comparison Dimension Central Innate Immune Memory Peripheral Innate Immune Memory Core Trained Cells Hematopoietic Stem Cells (HSCs) and myeloid progenitors (e.g., CMP, GMP) in the bone marrow Tissue-resident immune cells (e.g., tissue-resident macrophages, lung/spleen macrophages), NK cells, epidermal stem cells Training Inducer Target Inducers (e.g., BCG, \u03b2-glucan) reach the bone marrow through systemic circulation Inducers act directly on immune cells in peripheral tissues (e.g., lungs, skin, spleen) Memory Transmission Heritable to daughter cells: Trained HSCs/progenitors differentiate into \"pre-trained\" monocytes/neutrophils, which are transported to peripheral tissues via blood circulation Non-heritable to distant cells: Memory is limited to locally trained tissue-resident cells Functional Scope Systemic protection: Enhances the responsiveness of immune cells throughout the body to infections Localized protection: Strengthens immune defense in specific tissues (e.g., lungs, skin) Experimental Evidence Adoptive transfer of bone marrow cells from BCG-immunized mice (Kaufman et al., Cell 2018) LPS-induced lung tissue-resident innate immunity (Cell Reports 2024) <ul> <li>==Central innate immune== memory relies on bone marrow hematopoietic stem cells (HSCs) and myeloid progenitors, achieves systemic protection through heritable epigenetic reprogramming (with trained traits passed to daughter cells), </li> <li>while ==peripheral innate immune memory ==depends on tissue-resident cells (e.g., tissue-resident macrophages, NK cells), realizes localized defense via non-heritable local epigenetic/metabolic reprogramming (memory limited to local tissues) .</li> </ul>"},{"location":"IID_4/Yiru/Topic%2010%20what%20I%20need%20to%20know%20for%20exam/","title":"Topic 10 what I need to know for exam","text":""},{"location":"IID_4/Yiru/Topic%2010%20what%20I%20need%20to%20know%20for%20exam/#cell-markers","title":"Cell markers","text":"<ul> <li>T cell's<ul> <li>CD3 (general), CD4(helper),CD8(Cytotoxic)</li> <li>CD44(high in effector or memory)</li> <li>CD62L(high in naive, low in effector)</li> </ul> </li> <li>B cells'<ul> <li>CD19,CD20</li> <li>Plasma cells (often CD138+, CD19 low)</li> <li>Naive B cells (lgD+, lgM+)</li> </ul> </li> <li>Neutrophils: Ly6G</li> <li>Monocyte/macrophages: CD11b, Ly6C</li> <li>pDCs: major producers of Type I interferons</li> </ul>"},{"location":"IID_4/Yiru/Topic%2010%20what%20I%20need%20to%20know%20for%20exam/#overview-of-cytokines","title":"Overview of Cytokines","text":"<ul> <li>Cytokines are signalling proteins that help control inflammation in body</li> <li>Types<ul> <li>Chemokines CXCL: which can direct immune cells toward infection part</li> <li>Interferons- IFN: Interferons signal cells to put up their defenses against viruses invading your body.</li> <li>Interleukins: IL-xx</li> <li>Tumor necrosis factor (TNF): regulate inflammation in your body. TNF also signals to immune cells that kill tumor cells</li> <li>Colony-stimulating factors (CSF): CSF signals hematopoietic stem cells to develop into specific cell types</li> <li>...</li> </ul> </li> <li>==Pro-inflammatory and anti-inflammatory== cytokines<ul> <li>pro: trigger inflammation. Coordinate body's immune response to fend off attackers, like germs<ul> <li>IL-1 (Interleukin-1): causes Fever and activates blood vessels to let immune cells enter tissue.</li> <li>IL-6 (Interleukin-6): causes the liver to produce Acute Phase Proteins (like CRP). It also causes fever.</li> <li>TNF-$\\alpha$ (Tumor Necrosis Factor alpha): activates endothelial cells (blood vessel walls) and increases permeability. Excessive release can cause septic shock.</li> </ul> </li> <li>anti: lessen inflammation. Prevent an excessive immune respones that can lead to tissue damage<ul> <li>IL-10 (Interleukin-10): The primary \"shut down\" signal. It inhibits activated macrophages and reduces the production of the pro-inflammatory cytokines above.</li> <li>TGF-$\\beta$ (Transforming Growth Factor beta): Promotes tissue repair (wound healing) and suppresses T-cell activation.</li> </ul> </li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%2010%20what%20I%20need%20to%20know%20for%20exam/#damps-and-pamps","title":"DAMPs and PAMPs","text":"<ul> <li>PAMP: <ul> <li>Lipids/Carbohydrates: LPS, peptidoglycan</li> <li>Nucleic Acids: dsRNA, ssRNA, Unmethylated CpG DNA</li> </ul> </li> <li>DAMPs<ul> <li>intracellular proteins: S100 proteins; HMGB1</li> <li>ATP</li> <li>Uric Acid</li> <li>Self-DNA/RNA</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%2010%20what%20I%20need%20to%20know%20for%20exam/#others","title":"Others","text":"<ul> <li>Housekeeping genes: Actin or GAPDH</li> <li>ISGs (interferon stimulated genes): Mx1, Isg15, Rsad2, Irf7</li> </ul>"},{"location":"IID_4/Yiru/Topic%2011%20Macrophage/","title":"Topic 11 Macrophage","text":"<ul> <li>Origin: <ul> <li>==Microglia==: most tissue-resident macrophages, including microglia, originate from the Tolk Sac during embryonic development. not bone marrow</li> <li>==Monocyte==: Derived from bone marrow --&gt; develop to macrophage when needed</li> </ul> </li> <li>Macrophage depend on CSF1R (Colony Stimulating factor 1 receptor) for survival<ul> <li>Ligands 1: CSF-1, the general ligand</li> <li>Ligand 2: IL-34, for brain and Skin local macrophages</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%2011%20Macrophage/#in-brain","title":"In brain","text":"<ul> <li>Microglia contribute to ==Synaptic pruning==: eat the weak connections between neural cells to refine the circuits; in a healthy brain, this is during infant</li> <li>Mechanism: complement Cascade<ul> <li>Step 1 (Tagging): The neuron marks a weak synapse with C1q (\"Eat me\").</li> <li>Step 2 (Opsonization): C1q triggers C3, which coats the synapse.</li> <li>Step 3 (Engulfment): Microglia express the receptor CR3 (also called CD11b/CD18). CR3 locks onto C3 and engulfs the synapse.</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%2011%20Macrophage/#autism-asd","title":"Autism -ASD","text":"<ul> <li>Under-Pruning Hypothesis: lack of pruning will cause Autism</li> <li>If a mother gets a severe infection or inflammation during pregnancy, and let high level of IL-6 cross the placenta: incorrectly prune</li> </ul>"},{"location":"IID_4/Yiru/Topic%2011%20Macrophage/#alzheimers-disease","title":"Alzheimer's Disease","text":"<ul> <li>The protective phase<ul> <li>Microglia can clear Amyloid-beta plaques</li> <li>ApoE can help microglia to recognize it.</li> </ul> </li> <li>The destructive phase<ul> <li>Synaptic Pruning ==Reactivation==: the previous microglia synaptic pruning activated again</li> <li>Microglia start eating healthy synapses causing memory loss.</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%2012%20Diseases/","title":"Topic 12 Diseases","text":"Disease Key immune cells Major molecular / immune mechanisms Simple symptoms Classic / established therapies Psoriasis Dendritic cells, Th17/Th1 cells, keratinocytes, neutrophils IL-23/IL-17 axis \u2192 keratinocyte hyperproliferation; TNF signaling Well-demarcated scaly erythematous plaques (skin) Topical steroids, phototherapy, methotrexate/cyclosporine; biologics (anti-TNF, anti-IL-17, anti-IL-23) Multiple Sclerosis (MS) Autoreactive CD4 (Th1/Th17), CD8 T cells, B cells, microglia, macrophages Autoimmune demyelination in CNS; blood\u2013brain barrier breach; complement &amp; cytotoxicity Relapses of focal neuro deficits, sensory/motor impairment, visual problems High-dose corticosteroids (relapses), disease-modifying therapies: interferon-\u03b2, S1P modulators, anti-CD20 (rituximab/ocrelizumab), natalizumab Crohn\u2019s Disease Innate immune cells, Th1/Th17, B cells, macrophages Barrier dysfunction, dysregulated mucosal immunity (NOD2, IL-12/23, TNF); chronic transmural inflammation Abdominal pain, diarrhea, weight loss, fistulas Aminosalicylates (limited), corticosteroids (induction), immunomodulators (azathioprine), anti-TNF, anti-IL-12/23 HIV \u2192 AIDS CD4\u207a T cells (primary target), macrophages, dendritic cells Lentiviral infection \u2192 progressive CD4 depletion, immune deficiency, opportunistic infections Lymphadenopathy \u2192 opportunistic infections, weight loss, chronic fever Combination antiretroviral therapy (ART); opportunistic infection prophylaxis SLE (systemic lupus erythematosus) B cells, plasmablasts, Tfh, plasmacytoid DCs, complement Autoantibodies (anti-dsDNA), immune complexes \u2192 complement activation; type I IFN signature Malar rash, arthritis, nephritis, cytopenias, photosensitivity Hydroxychloroquine, corticosteroids, immunosuppressants (azathioprine, mycophenolate), biologics (belimumab), supportive care Aicardi\u2013Gouti\u00e8res Syndrome (AGS) Microglia, innate immune sensors, plasmacytoid DCs Genetic defects in nucleic acid metabolism \u2192 chronic type I interferonopathy (sensing of self-nucleic acids) Early onset encephalopathy, intracranial calcifications, developmental delay Supportive; immunomodulation (JAK inhibitors) and symptomatic care (experimental) COPA syndrome T cells, B cells, innate immune cells Defect in ER-Golgi transport \u2192 autoimmune/autoinflammatory phenotype often with elevated type I IFN Interstitial lung disease, arthritis, autoimmunity Immunosuppression (steroids, calcineurin inhibitors), targeted approaches (JAK inhibitors); lung transplant in severe ILD Alzheimer\u2019s disease (microglia-related aspects) Microglia, complement components, astrocytes Microglial activation, complement-mediated synapse pruning, TREM2 pathway; chronic neuroinflammation Progressive memory loss, cognitive decline Symptomatic drugs (AChE inhibitors, memantine); anti-amyloid / anti-tau immunotherapies (experimental); symptomatic/supportive care Autism Spectrum Disorder (ASD) \u2014 microglia associations Microglia (proposed role), peripheral immune cells (associations) Associations of neuroimmune dysregulation in some cases (microglial activation/inflammation) \u2014 heterogeneous and incompletely understood Social-communication deficits, restricted/repetitive behaviors Behavioral therapies (ABA), developmental interventions; no standard immunotherapy (research ongoing) Sepsis Innate immune cells (neutrophils, macrophages), endothelial cells, lymphocytes Dysregulated host response to infection \u2192 excessive cytokines, coagulopathy, immune paralysis/sequential hypo-inflammation Fever/hypothermia, tachycardia, hypotension, organ dysfunction Early antibiotics, source control, fluid resuscitation, vasopressors, organ support; adjunctive immunomodulation selective in trials COVID-19 (severe) Epithelial cells, innate immune cells, T cells, neutrophils Viral infection with possible hyperinflammation (cytokine storm), coagulopathy, impaired antiviral immunity Fever, cough, dyspnea \u2192 hypoxemia, ARDS in severe cases Antivirals (where approved), dexamethasone for severe disease, supportive care, monoclonal antibodies (prophylaxis/early disease), vaccines (preventive) Rheumatic Fever Cross-reactive T/B cells, antibodies Molecular mimicry after Group A strep \u2192 immune cross-reaction against heart/striatum \u2192 carditis Fever, migratory polyarthritis, carditis, chorea (Sydenham) Eradicate streptococcal infection (penicillin), anti-inflammatory therapy (aspirin, steroids), long-term prophylaxis Rheumatoid Arthritis (RA) Synovial macrophages, fibroblast-like synoviocytes, Th17, B cells (autoantibodies RF/ACPA) Autoantibody-associated chronic synovitis; TNF, IL-6, IL-1 pathways; joint erosion mediated by osteoclasts Symmetric peripheral polyarthritis, morning stiffness, joint erosions NSAIDs, glucocorticoids (bridging), DMARDs (methotrexate), biologics (anti-TNF, anti-IL-6, anti-CD20) Rheumatic Heart Disease (RHD) Result of post-streptococcal immune injury (T/B cells) Chronic valvular damage from immune cross-reactivity after rheumatic fever Valvular regurgitation/stenosis, heart failure, arrhythmias Secondary prophylaxis (penicillin), medical management of heart failure; valve repair/replacement surgery Guillain\u2013Barr\u00e9 syndrome (GBS) Peripheral nerve-targeting antibodies, complement, macrophages Autoimmune peripheral demyelination (often post-infection); anti-ganglioside antibodies in subtypes \u2192 complement &amp; macrophage-mediated injury Rapidly progressive ascending weakness, areflexia, possible respiratory failure IV immunoglobulin (IVIG) or plasmapheresis, supportive respiratory care, rehab Cancer (immune aspects) Cytotoxic CD8 T cells, NK cells, tumor-associated macrophages, Tregs, MDSCs Immune evasion (PD-L1, CTLA-4, antigen loss), chronic inflammation, immunosuppressive tumor microenvironment Variable by tumor type \u2014 mass effect, organ-specific symptoms, constitutional symptoms Surgery, chemo, radiotherapy; immunotherapies: checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA-4), CAR-T, cytokine therapies, targeted small molecules"},{"location":"IID_4/Yiru/Topic%202%20Inflammation%20algorithm/","title":"Topic 2 Inflammation algorithm","text":"<ul> <li>Learn 3.2, 10.2</li> <li>Review key point in Topic 1:<ul> <li>Innate immune system have two ports to detect different types of pathogens</li> <li>TLRs (Toll-like receptors) --&gt; detect things outside membrane --&gt; release pro-inflammatory cytokines like TNF, IL-6</li> <li>RLRs (RIG-I-like receptors) --&gt; detect internal virus --&gt; release Type I interferons, in antiviral state</li> </ul> </li> <li> <p>inflammasome Logic</p> <ul> <li>in a word: the NLRP3 inflammasome requires a Two-factor authentication to fire, two-signals are reuqired<ul> <li>Signal 1: priming (permission)<ul> <li>Trigger: PAMPs hit TLRs</li> <li>Process: NF-kB activation</li> <li>Result: Transcription of the raw materials ==NLRP3== and ==Pro-IL-1$\\beta$== produced</li> </ul> </li> <li>Signal 2: activation (Execution)<ul> <li>Trigger: cellular homeostasis breach<ul> <li>Main reason: Potassium efflux</li> <li>others: ATP binding P2X7 channels, pore-forming toxins</li> </ul> </li> <li>Process: <ul> <li> <ol> <li>K+ drops</li> </ol> </li> <li> <ol> <li>NLRP3 oligomerizes</li> </ol> </li> <li> <ol> <li>Recruits ASC (adaptor)</li> </ol> </li> <li> <ol> <li>Recruits Pro-Caspase-1</li> </ol> </li> </ul> </li> <li>Result: form active ==Caspase-1== enzyme</li> </ul> </li> </ul> </li> <li>Event: pyroptosis<ul> <li>Cytokine processing: ==Caspase-1== cleaves ==Pro-IL-1$\\beta$ and Pro-IL-18== into active forms</li> <li>Cell lysis: Caspase-1 cleaves GSDMD<ul> <li>The N-terminal of GSDMD punches pores in the cell membrane</li> <li>Outcome: release of cytokines + cell death</li> </ul> </li> </ul> </li> </ul> </li> <li> <p>Non-Canonical inflammasome</p> <ul> <li>Sensor changes: Caspase-11 in mice; Caspase-4/5 in human</li> <li>Trigger changes: They detect intracellular LPS, bypassing TLR4</li> <li>Outcome: still, cleave GSDMD and cause pyroptosis, and then activate NLRP3</li> </ul> </li> <li> <p>Regulation system</p> <ul> <li>Inhibitor: Bile Acids</li> <li>Pathway: TGR5 receptor --&gt; cAMP --&gt; PKA --&gt; inhibit NLRP3</li> <li>Process: PKA phosphorylates NLRP3, preventing it from assembling. This creates a \"ubiquitination brake\" .</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%202%20Inflammation%20algorithm/#take-home-logic-for-exam","title":"Take home logic for exam:","text":"<ol> <li> <p>Dependencies: You can see <code>if self.primed == False: return</code>. This is the Two-Signal Model.</p> </li> <li> <p>Regulation: You can see <code>if self.pka_active: return</code>. This is the Bile Acid Checkpoint.</p> </li> <li> <p>Pathology: You can see <code>ORF3a</code> forcing the <code>assemble</code> function directly. This is COVID-19 or other kind of virus that can trigger signal 2</p> </li> </ol>"},{"location":"IID_4/Yiru/Topic%203%20T-Cell/","title":"Topic 3 T Cell","text":""},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#1-t-cell-development-the-education-phase","title":"1. T Cell Development (The \"Education\" Phase)","text":"<ul> <li> <p>Origin: Starts in the Red Bone Marrow as a T cell precursor.</p> </li> <li> <p>Migration: Travels to the Thymus (primary lymphoid organ).</p> <ul> <li>Mechanism: Thymus releases chemotactic agents (e.g., thymosin) to attract T cell precursors.</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#step-1-receptor-formation-gene-shuffling","title":"Step 1: Receptor Formation (Gene Shuffling)","text":"<ul> <li> <p>Trigger: Chemotactic agents bind to the naive T cell's receptor.</p> </li> <li> <p>Action: Activates RAG1 and RAG2 (Recombination-Activating Genes).</p> </li> <li> <p>Result: These recombinases shuffle DNA segments to create a unique TCR (T Cell Receptor).</p> <ul> <li>Goal: Create a receptor specific for one unique antigen (Note: TCRs bind Antigen-MHC complexes, not antibodies directly).</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#step-2-lineage-commitment-the-double-positive-stage","title":"Step 2: Lineage Commitment (The \"Double Positive\" Stage)","text":"<ul> <li> <p>T cells initially express both CD4 and CD8 (Double Positive).</p> </li> <li> <p>CD8: Binds to MHC Class I.</p> </li> <li> <p>CD4: Binds to MHC Class II.</p> </li> </ul>"},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#step-3-the-exams-selection-process","title":"Step 3: The Exams (Selection Process)","text":"<ol> <li> <p>Positive Selection (The \"Competence\" Test):</p> <ul> <li> <p>Question: Can this TCR recognize my own MHC molecules?</p> </li> <li> <p>Process: Thymic epithelial cells present MHC.</p> </li> <li> <p>Pass: TCR binds MHC with moderate affinity (Survival signal received).</p> </li> <li> <p>Fail: No binding $\\rightarrow$ Death by Neglect (Apoptosis).</p> </li> </ul> </li> <li> <p>Negative Selection (The \"Loyalty\" Test):</p> <ul> <li> <p>Question: Does this TCR attack \"self\" tissues?</p> </li> <li> <p>Process: Thymic cells present \"self-peptides\" on MHC.</p> </li> <li> <p>Fail: High-affinity binding to self $\\rightarrow$ Clonal Deletion (Apoptosis triggered by FAS ligand released by thymic cells).</p> </li> <li> <p>Pass: Low/No binding to self $\\rightarrow$ Survives.</p> </li> </ul> </li> </ol>"},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#step-4-final-maturation-choice","title":"Step 4: Final Maturation &amp; Choice","text":"<ul> <li> <p>The Choice:</p> <ul> <li> <p>Upregulate CD4, Downregulate CD8 $\\rightarrow$ T Helper Cell (Th) $\\rightarrow$ Secondary Lymphoid Organs.</p> </li> <li> <p>Upregulate CD8, Downregulate CD4 $\\rightarrow$ T Cytotoxic Cell (Tc) $\\rightarrow$ Secondary Lymphoid Organs.</p> </li> </ul> </li> <li> <p>The Exception (Treg):</p> <ul> <li> <p>Some self-reactive CD4+ cells are not killed but diverted to become Natural Tregs.</p> </li> <li> <p>Location: Occurs mainly in Hassall\u2019s Corpuscles in the thymus.</p> </li> <li> <p>Mechanism: Upregulate CD25 and FoxP3 (dependent on IL-2).</p> </li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#2-classification-cheat-sheet","title":"2. Classification Cheat Sheet","text":""},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#a-the-rule-of-8","title":"A. The \"Rule of 8\"","text":"<ul> <li> <p>CD4 x MHC II = 8 (Helpers talk to Generals/APCs).</p> </li> <li> <p>CD8 x MHC I = 8 (Killers check Civilians/Nucleated cells).</p> </li> </ul>"},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#b-cd4-helper-t-lineages","title":"B. CD4+ Helper T Lineages","text":"<p>Input Cytokines $\\rightarrow$ Master Transcription Factor $\\rightarrow$ Output Cytokines</p> Lineage Input (Induction) Master Switch Output (Effector) Main Function Th1 IL-12, IFN-$\\gamma$ T-bet IFN-$\\gamma$, TNF Intracellular Defense: Viruses, bacteria inside macrophages. Th2 IL-4 GATA3 IL-4, IL-5, IL-13 Extracellular Defense: Parasites (Worms), Allergy. Th17 Mouse: TGF-$\\beta$ + IL-6 Human: TGF-$\\beta$ + IL-1$\\beta$ + IL-6 ROR$\\gamma$t IL-17, IL-22 Mucosal Defense: Fungi, Extracellular bacteria. Autoimmunity driver. Treg TGF-$\\beta$, IL-2 FoxP3 TGF-$\\beta$, IL-10 Suppression: Immune tolerance, preventing autoimmunity. Tfh IL-6, IL-21 Bcl6 IL-21 B Cell Help: Antibody production."},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#c-unconventional-t-cells","title":"C. Unconventional T Cells","text":"Cell Type Recognition Target Key Feature NKT Cells Lipids on CD1d Bridge Innate/Adaptive. Rapid cytokine release. $\\gamma\\delta$ T Cells Stress Signals &amp; Phosphoantigens No MHC required. Barrier defense (Skin/Gut)."},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#3-cell-mediated-immunity-the-killers","title":"3. Cell-Mediated Immunity (The Killers)","text":"<p>This is the detailed section you requested on how cells kill.</p>"},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#a-cytotoxic-t-lymphocytes-ctls","title":"A. Cytotoxic T Lymphocytes (CTLs)","text":"<ul> <li> <p>Identity: CD8+, Adaptive Immunity.</p> </li> <li> <p>Target: Virus-infected cells, Tumor cells, Intracellular bacteria.</p> </li> <li> <p>Recognition: TCR binds to specific Antigen + MHC Class I.</p> </li> <li> <p>Mechanism of Killing:</p> <ol> <li> <p>Perforin/Granzyme Pathway (Main):</p> <ul> <li> <p>CTL releases granules.</p> </li> <li> <p>Perforin: Punches holes (pores) in the target cell membrane.</p> </li> <li> <p>Granzymes: Enter through holes and activate Caspases inside the target.</p> </li> <li> <p>Result: Apoptosis (clean cell suicide).</p> </li> </ul> </li> <li> <p>Fas Ligand (FasL) Pathway:</p> <ul> <li> <p>CTL expresses FasL on its surface.</p> </li> <li> <p>Binds to Fas receptor (CD95) on the target cell.</p> </li> <li> <p>Result: Triggers the \"Death Domain\" signal cascade $\\rightarrow$ Apoptosis.</p> </li> </ul> </li> </ol> </li> </ul>"},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#b-natural-killer-nk-cells","title":"B. Natural Killer (NK) Cells","text":"<ul> <li> <p>Identity: Innate Lymphoid Cell (No TCR), Innate Immunity.</p> </li> <li> <p>Target: Cells trying to \"hide\" from CTLs by removing MHC I, or stressed cells.</p> </li> <li> <p>Recognition (The \"Missing Self\" Hypothesis):</p> <ul> <li> <p>Inhibitory Receptor: Binds to Normal MHC Class I. If detected $\\rightarrow$ \"Don't Kill.\"</p> </li> <li> <p>Activating Receptor: Binds to Stress Ligands (e.g., MICA/MICB) on infected cells.</p> </li> <li> <p>Trigger: Low MHC I + High Stress Signal = KILL.</p> </li> </ul> </li> <li> <p>Mechanism: Uses Perforin and Granzymes (same as CTL).</p> </li> <li> <p>ADCC (Antibody-Dependent Cell-mediated Cytotoxicity):</p> <ul> <li> <p>NK cells have CD16 (Fc Receptor).</p> </li> <li> <p>If a target is coated in antibodies (IgG), CD16 binds the antibody tail.</p> </li> <li> <p>Result: NK cell degranulates and kills the target.</p> </li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%203%20T-Cell/#tregs","title":"Tregs","text":"<ul> <li>Immune tolerance, preventing autoimmunity.</li> <li>access a unique transcription factor called FOXP3</li> <li>Further subtypes<ul> <li>natural Tregs (nTregs): in peripheral immune tolerance</li> <li>induced Tregs (iTregs): naive T cells; control inflammation</li> </ul> </li> <li>Produce anti-inflammatory cytokines: IL-10 and TGF-$\\beta$ <ul> <li>inhibit other immune cells; cause the cytolysis of activated T cells</li> </ul> </li> <li>Metabolic regulation<ul> <li>reduce the level of glucose and amino acids that is necessary for other immune cells</li> </ul> </li> <li>Moderate DC cells<ul> <li>prevent DC cells --&gt; prevent other immune cells</li> </ul> </li> <li>Regulating cancer and infections<ul> <li>suppressing the immune cells --&gt; targeting cancer cells</li> <li>prevent immune mediated damage to host tissue and promote immune tolerance</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%204%20ILC%2C%20Innate%20lymphoid%20cells/","title":"Topic 4 ILC, Innate lymphoid cells","text":"<pre><code>- What is ILC?\n- Innate lymphoid cells are the innate counterparts to T cells. \n- They have similiar T cell functions but ==lack== the specific T cell receptor\n- Why do we need ILCs if we have T cells?\n    - ==Speed==: ILCs have rapid response, as a part of innate immunity. They respond immediately to alarm signals (such as cytokines)\n    - ==Location==: ILCs are **tissue-resident** -- Which means it stationed at barrier surfaces like skin, gut, lungs; while naive T cells circulate through lymphoid organs and must be recruited to the tissue after infection starts\n    - ==Specificity==: non-specific, which means it can response to any stress signals and cytokines\n</code></pre> <ul> <li>Classification<ul> <li></li> </ul> </li> </ul> ILC Type Group T Cell Counterpart Primary Function NK Cell Group 1 CD8+ CTL Cytotoxicity (Killing) 1111 ILC1 Group 1 Th1 Inflammation (IFN-$\\gamma$) 2222 ILC2 Group 2 Th2 Immunity to parasites, allergy 3333 ILC3 Group 3 Th17 / Th22 Mucosal homeostasis (extracellular bacteria) 4444 LTi Cell Group 3 (None/Unique) Lymphoid Organogenesis (Building lymph nodes) 55 <ul> <li>Group 1: <ul> <li>==Activated== by IL-12, IL-18</li> <li>==regulated== by T-bet for ILC1, and Eomes for NK cell</li> <li>==release== IFN-$\\gamma$ , TNF</li> <li>NK cell<ul> <li>They are the innate counterpart to CD8+ Cytotoxic T Cells. Their primary job is cytotoxicity\u2014killing infected or stressed cells directly using granules (perforin/granzymes).</li> <li>Kill Mechanism:<ul> <li>the balance: NK cells have both ==activating receptors== (to kill) and ==inhibitory receptor== (not kill)</li> <li>MHC Class I: healthy cells express MHC Class I --&gt; bind inhibitory receptor of Nk cell</li> <li>Missing MHC Class I: activating receptor --&gt; kill this cell</li> </ul> </li> </ul> </li> </ul> </li> <li>Helper-like ILCs (ILC1, ILC2, ILC3)<ul> <li>These are the innate counterparts to CD4+ Helper T Cells (Th1, Th2, Th17). They primarily secrete cytokines to direct the immune response rather than killing cells directly.</li> </ul> </li> <li>Group 2:<ul> <li>==Activated== by \"Alarmins\" from damaged epithelium: IL-25, IL-33, TSLP.</li> <li>==regulated== by GATA3</li> <li>==release== IL-4, IL-5, IL-13</li> </ul> </li> <li>Group 3:<ul> <li>Activated by IL-23, IL-1$\\beta$</li> <li>==regulated== ROR$\\gamma$</li> <li>==release== IL-17, Il-22</li> <li>LTi are special; they are essential for the formation of secondary lymphoid organs (like lymph nodes and Peyer's patches) during development.</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%204%20ILC%2C%20Innate%20lymphoid%20cells/#plasticity-of-ilcs","title":"Plasticity of ILCs","text":"<ul> <li>ILCs can change their phenotypes in response to the environment</li> <li>ILCs can switch their groups, examples<ul> <li>Crohn's Disease: helper-like ILC3s can transfer to inflammatory ILC1s</li> <li>COPD: ILC2s can switch to ILC1s producing IFN-$\\gamma$</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%205%20B%20cell/","title":"Topic 5 B cell","text":"<ul> <li> <p>B cell here main contribute to humoral immunity</p> </li> <li>B cells are produced in lymph node<ul> <li>Naive B-lymphocyte go through recombination (like T cell), by receiving circulating free lgD antigen (by random chance) --&gt; BCRs</li> <li>--&gt; activated B cell --&gt; receptor-mediated endocytosis --&gt; pull antigen in</li> <li>--&gt; In B cell, antigen produce an endosome, and B cell produce specific MHC2 that can bind to the antigen --&gt; MHC2 expose to membrane, the B lymphocyte is activated</li> </ul> </li> <li>In T cell side:<ul> <li>macrophage will have MHC-2 (antigen specific) and MHC-1</li> <li>How it interact with Naive T helper cell<ul> <li>Signal 1: T cell receptor (TCR) --&gt; bind to antigen gotten by MHC2 &amp; CD4 protein --&gt; bind to MHC2</li> <li>Signal 2: macrophage have long protein B7 that can bind the CD28 in T helper cell</li> <li>Signal 3: Macrophage secrete IL-1,  IL-1 bind to T helper<ul> <li>Signal 1 +  Signal 2 + Signal 3 --&gt; costimulation<ul> <li>T cell activated --&gt; T helper secrete IL-2 --&gt; can bind and activate T cell too --&gt;==IL-4==, ==IL-5== secretion --&gt; make the T cell to Th2 cell</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>Why T cell side matters to B cell? --&gt; cause clonal expansion<ul> <li>IL-4 released by T helper cell --&gt; activate B lymphocyte --&gt; proliferation of B cell (with special BCRs)</li> <li>IL-5 function after the clonal expansion --&gt; B cell start to differentiation <ul> <li>--&gt; memory B cells with BCR</li> <li>--&gt; plasma cells /effector B cells</li> </ul> </li> <li>IL-5 and IL-6 activate plasma cells--&gt; secrete ==antibodies== (specific to antigen)</li> </ul> </li> <li>Then antibodies can beat antigens<ul> <li>Neutralization: anitbody bind to the antigens on the surface of bacteria or virus</li> <li>Precipitation: bind to circulating free antigens, and cause them to have precipitation</li> <li>Lysis: produce protein that can cause the bacteria to lysis</li> <li>Attract macrophages: antibody could produce proteins that attract the macrophage to kill the antibody</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%205%20B%20cell/#b-cell-tolerance","title":"B cell Tolerance","text":"<ul> <li> <p>B cell will have VDJ recombination process to produce BCR, which is random --&gt; will produce B cells that recognize self-antigens</p> <ul> <li>==Solution==: quality control system called tolerance</li> </ul> </li> <li> <p>Central Tolerance: Bone marrow; before B cells enter the blood, it must prove it is not dangerous</p> <ul> <li>Stage: Immature B cells, expressing lgM on surface</li> <li>Self-antigen Test:<ul> <li>protein, DNA, cell surface markers</li> <li>Possible outcomes:<ul> <li>if B cell doesn't bind to any self-antigen<ul> <li>--&gt; to the spleen to complete maturation</li> </ul> </li> <li>else if B cell binds tightly to a self-antigen<ul> <li>--&gt; stop B cell moving from marrow; this triggers Receptor editing, RAG reactivation<ul> <li>the cell keeps the RAG1 and RAG2 genes activated</li> <li>it deletes the existing light chain and rearranges a new one</li> <li>In other word, it creates a new BCR with a new specificity</li> <li>if pass: Survival and  export to periphery</li> <li>else (still have auto-reactive): cell tries again or dies</li> </ul> </li> <li>Die: Clonal deletion (apoptosis)<ul> <li>the cell activates the intrinsic apoptotic pathway</li> </ul> </li> </ul> </li> <li>else if weak reaction<ul> <li>The B cell binds weakly or to a soluble self-antigen</li> <li>Cell becomes permanent non-responsiveness and die due to competition in the periphery</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>Peripheral tolerance (as backup system)<ul> <li>Location in spleen, lymph nodes, and circulation</li> <li>Stage: Transitional and mature B cells</li> <li>Mechanisms of removal:<ul> <li> <ol> <li>Follicular exclusion: auto-reactive B cells are chemically excluded form the Follicles, which will let them die</li> </ol> </li> <li> <ol> <li>Resource Competition </li> <li>B cells compete for a critical survival cytokine called ==BAFF== (B cell activating factor)</li> <li>Normal B cells are better at capturing BAFF</li> </ol> </li> <li> <ol> <li>Lack of T cell help</li> <li>For a B cell to fully activate and cause damage, it usually needs confirmation signal from a helper T cell</li> <li>If a B cell presents a self-antigen to a T cell, but the T cell (which has its own tolerance checks) does not recognize it, the B cell receives no help (no CD40L signal).<ul> <li>Key Mechanism of B cell: Linked Recognition<ul> <li>B cells do not just show exactly what they bound to on the outside</li> <li>But they will cut the peptide and then present the parts, to T cells TCR </li> </ul> </li> </ul> </li> </ol> </li> </ul> </li> </ul> </li> </ul> Feature Central Tolerance Peripheral Tolerance Location Bone Marrow 26 Spleen / Lymph Nodes 27 B Cell Stage Immature B Cell (IgM+) 28 Transitional / Mature B Cell 29 Primary Trigger Binding to self-antigen in marrow 30 Binding to self-antigen in periphery Key Mechanism 1 Receptor Editing: RAG reactivation to change receptor 31313131 Anergy: Functional unresponsiveness 32 Key Mechanism 2 Clonal Deletion: Apoptosis via Bim 33 Follicular Exclusion: Denied entry to survival niches 34 Key Mechanism 3 Anergy: If antigen is soluble/weak Starvation: Competition for BAFF 35"},{"location":"IID_4/Yiru/Topic%206%20Auto-immune%20disease/","title":"Topic 6 Auto immune disease","text":""},{"location":"IID_4/Yiru/Topic%206%20Auto-immune%20disease/#crohns-disease","title":"Crohn's disease","text":"<ul> <li>==Symptoms==: bloody diarrhea, abdominal pain, weight loss, failure to thrive in young; effects beyond just gut</li> <li>NOD2 \u529f\u80fd\u7f3a\u5931\u53d8\u5f02\u00a0\u2192 \u65e0\u6cd5\u8bc6\u522b MDP \u2192 DC \u5931\u63a7\uff08\u8fc7\u5ea6\u6fc0\u6d3b Th1/Th17\uff09+ \u6f58\u6c0f\u7ec6\u80de\u5931\u804c\uff08\u83cc\u7fa4\u5931\u8c03 + \u5c4f\u969c\u6f0f\u6d1e\uff09\u2192 \u514d\u75ab\u7cfb\u7edf\u653b\u51fb\u80a0\u9053\u5171\u751f\u83cc \u2192 \u6162\u6027\u708e\u75c7 \u2192 \u514b\u7f57\u6069\u75c5\u3002</li> <li>caused by Th1 / Th17 CD4+ cell intermediated response; can cause inflammation anywhere in whole GI tract<ul> <li>CD4+ T cells , IFNg, IL-12, IL-23 are all elevated in Crohn's disease</li> <li>Could be caused by ==deficient regulatory activity== or ==excess effector function==</li> </ul> </li> <li>Immune response to commensal bacteria; Gut bacteria are the antigen in Crohn's disease</li> </ul>"},{"location":"IID_4/Yiru/Topic%206%20Auto-immune%20disease/#multiple-sclerosis","title":"Multiple Sclerosis","text":"<ul> <li>defined as an autoimmune disease where the body's immune system mistakenly attacks its own tissues</li> <li>Attacker: Autoreactive ==lymphocytes==, immune cells</li> <li>Target: ==myelin sheath== of the central nervous system (CNS)</li> <li>Consequence: destruction of myelin; progressive loss of neurons<ul> <li>vision problems and fatigue</li> </ul> </li> <li>==Hallmark==<ul> <li>Oligoclonal bands (OCBs) in the cerebrospinal fluid (CSF)</li> <li>What they are: These are specific antibodies (immunoglobulins) found in the spinal fluid but not in the blood.</li> <li>OCBs expansion --&gt; local clonal expansion of B cells, in CNS</li> </ul> </li> <li>==Trigger==<ul> <li>While MS is autoimmune, the slides present strong evidence that it is triggered by a viral infection, specifically Epstein-Barr Virus (EBV)</li> <li>Molecular Mimicry: a viral protein looks similiar to a human brain protein, immune system confused<ul> <li>The immune system creates antibodies to fight the EBV protein EBNA1</li> <li>Self-antigen: These same antibodies cross-react with a human protein called GlialCAM, which is found in the brain (glial cells).</li> <li>B cell will be the key attacker; CD9+ T cell will mistakenly recognize GlialCAM as a threat</li> </ul> </li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%206%20Auto-immune%20disease/#sle-systemic-lupus-erythematosus","title":"SLE: systemic Lupus Erythematosus","text":"<ul> <li>a kind of systemic autoimmune disease; which means, unlike MS that only effect CNS, SLE is a multi-system disease</li> <li>Attacker: auto-reactive B cells</li> <li>Target: the whole body; highlight skin, joints, kidney, heart, and brain</li> <li> <p>==Hallmark==: production of high-affinity autoantibodies; particularly those that target components of the cell nucleus (anti-nuclear antibodies)</p> </li> <li> <p>Primary mechanism:</p> <ul> <li>SLE results from a breakdown in B cell tolerance<ul> <li>Central Tolerance: eliminates self-reactive B cells in the bone marrow. In SLE, this process is defective, allowing more autoreactive cells to escape into the body.</li> <li>Peripheral Tolerance: In SLE, all of these are impaired</li> </ul> </li> <li>Immune complex deposition<ul> <li>SLE is not caused by the antibodies directly attacking the organs. Instead, it is a consequence of forming immune complexes.</li> <li>Autoantibody production: defective B cell tolerance leads to the production of autoantibodies against nuclear antigens like DNA and RNA</li> <li>normal cell death --&gt; RNA/ DNA release in blood --&gt; antibody binds to them (antigen) --&gt; form large antibody-antigen complexes</li> <li>Inflammation &amp; Damage: The deposited complexes trigger a Type III hypersensitivity reaction. They activate the complement system and recruit inflammatory cells like neutrophils, leading to widespread tissue damage and vasculitis.</li> </ul> </li> </ul> </li> <li> <p>TLR &amp; Interferon Loop</p> <ul> <li>this could amplifies the autoimmune response</li> <li>TLRs on B cells and DCs recognize pathogen-derived DNA and RNA. <ul> <li>in SLE, they mistakenly bind to the patient's own DNA/RNA that is part of the immune complexes</li> <li>--&gt; after self-antigen binds to B cell, which will further drive B cell to produce more antibody</li> <li>--&gt; after self-antigen binds to plasmacytoid dendritic cells bind to the complexes, they produce massive amounts of type I ==interferon== </li> <li>The Interferon Signature: This chronic production of Type I IFN is a key feature of SLE. It promotes inflammation, activates more dendritic cells, and enhances the survival and activation of autoreactive T and B cells, further fueling the disease.</li> </ul> </li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%206%20Auto-immune%20disease/#ags-aicardi-goutieres-syndrome","title":"AGS: Aicardi-Goutieres Syndrome","text":"<ul> <li>Definition: A mimic of congenital viral infection; caused by aberrant innate immune activation</li> <li>Mutation: cleaning up nucleic acids; when these enzymes fail, self DNA/RNA accumulates --&gt; trigger the sensors via cGAS/STING pathway --&gt; cause the release of IFN --&gt; autoimmune disease</li> </ul>"},{"location":"IID_4/Yiru/Topic%206%20Auto-immune%20disease/#copa-syndrome","title":"COPA Syndrome","text":"<ul> <li>Mutation: a defect in intracellular trafficking (Golgi-to-ER), The STING protein normally recycles, but now the transportation fails<ul> <li>Which will cause the STINg protein stuck in an activate state, leading to constitutive IFN production</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%207%20System%20exhaustion%20and%20cytokine%20storms/","title":"Topic 7 System exhaustion and cytokine storms","text":"<ul> <li>Here is the organized content for Day 7: Viral Hijacking &amp; Collapse, structured with logic and details based on your provided slides. \u4ee5\u4e0b\u662f\u7b2c\u4e03\u5929\u300a\u75c5\u6bd2\u52ab\u6301\u4e0e\u5d29\u6e83 \u300b\u7684\u6709\u5e8f\u5185\u5bb9\uff0c\u57fa\u4e8e\u60a8\u63d0\u4f9b\u7684\u5e7b\u706f\u7247\uff0c\u7ed3\u6784\u5408\u7406\u4e14\u7ec6\u8282\u4e30\u5bcc\u3002</li> </ul>"},{"location":"IID_4/Yiru/Topic%207%20System%20exhaustion%20and%20cytokine%20storms/#1-the-paradox-microbial-translocation-in-hiv","title":"**1. The Paradox: Microbial Translocation in HIV","text":"<ol> <li>\u6096\u8bba\uff1aHIV \u4e2d\u7684\u5fae\u751f\u7269\u6613\u4f4d**</li> </ol> <p>Logic: In HIV, the immune system is activated not just by the virus itself, but by a \"leak\" in the gut caused by early viral damage. This creates a vicious cycle where immune deficiency drives further immune activation. \u903b\u8f91\uff1a \u5728 HIV \u4e2d\uff0c\u514d\u75ab\u7cfb\u7edf\u4e0d\u4ec5\u88ab\u75c5\u6bd2\u6fc0\u6d3b\uff0c\u8fd8\u901a\u8fc7\u65e9\u671f\u75c5\u6bd2\u635f\u4f24\u5bfc\u81f4\u7684\u80a0\u9053\u201c\u6cc4\u6f0f\u201d\u6fc0\u6d3b\u3002\u8fd9\u5f62\u6210\u4e86\u4e00\u4e2a\u6076\u6027\u5faa\u73af\uff0c\u514d\u75ab\u7f3a\u9677\u53c8\u63a8\u52a8\u4e86\u514d\u75ab\u6fc0\u6d3b\u3002</p> <ul> <li> <p>The Trigger (Gut Th17 Loss):     \u89e6\u53d1\u70b9\uff08\u7b2c17\u8282\u5185\u5fc3\u6d41\u5931\uff09\uff1a</p> <ul> <li> <p>During the acute phase of HIV infection, the virus rapidly depletes CD4+ T cells in the Gut Associated Lymphoid Tissue (GALT), a major viral reservoir.     \u5728 HIV \u611f\u67d3\u7684\u6025\u6027\u671f\uff0c\u75c5\u6bd2\u4f1a\u8fc5\u901f\u6d88\u8017\u80a0\u9053\u76f8\u5173\u6dcb\u5df4\u7ec4\u7ec7\uff08GALT\uff09\u4e2d\u7684 CD4+ T \u7ec6\u80de\uff0cGALT \u662f\u75c5\u6bd2\u7684\u4e3b\u8981\u50a8\u5b58\u5e93\u3002</p> </li> <li> <p>Specifically, there is a massive loss of Th17 cells in the gut mucosa. Th17 cells are crucial for maintaining the mucosal barrier; they recruit neutrophils and support epithelial integrity.     \u5177\u4f53\u6765\u8bf4\uff0c\u80a0\u9053\u9ecf\u819c\u4e2d Th17 \u7ec6\u80de\u5927\u91cf\u6d41\u5931\u3002Th17 \u7ec6\u80de\u5bf9\u4e8e\u7ef4\u6301\u9ecf\u819c\u5c4f\u969c\u81f3\u5173\u91cd\u8981;\u5b83\u4eec\u62db\u52df\u4e2d\u6027\u7c92\u7ec6\u80de\u5e76\u652f\u6301\u4e0a\u76ae\u5b8c\u6574\u6027\u3002</p> </li> </ul> </li> <li> <p>The Leak (LPS Translocation):     \u6cc4\u6f0f\uff08LPS \u6613\u4f4d\uff09\uff1a</p> <ul> <li> <p>The depletion of Th17 cells leads to reduced neutrophil activity, decreased IgA secretion, and the loss of tight junctions between enterocytes (gut lining cells).     Th17 \u7ec6\u80de\u7684\u8017\u7aed\u5bfc\u81f4\u4e2d\u6027\u7c92\u7ec6\u80de\u6d3b\u6027\u4e0b\u964d\uff0cIgA \u5206\u6ccc\u51cf\u5c11\uff0c\u4ee5\u53ca\u80a0\u7ec6\u80de\uff08\u80a0\u9ecf\u819c\u7ec6\u80de\uff09\u4e4b\u95f4\u7684\u7d27\u5bc6\u8fde\u63a5\u4e27\u5931 \u3002</p> </li> <li> <p>This \"leaky gut\" allows microbial products from the gut lumen to cross into the systemic circulation. Key products include Lipopolysaccharide (LPS), peptidoglycan, and flagellin.     \u8fd9\u79cd\u201c\u80a0\u6f0f\u201d\u4f7f\u80a0\u9053\u5185\u7684\u5fae\u751f\u7269\u4ea7\u7269\u8fdb\u5165\u5168\u8eab\u5faa\u73af\u3002\u4e3b\u8981\u4ea7\u54c1\u5305\u62ec\u8102\u591a\u7cd6\uff08LPS\uff09\u3001 \u80bd\u805a\u7cd6\u548c\u97ad\u6bdb\u7d20\u3002</p> </li> </ul> </li> <li> <p>The Consequence (Systemic Inflammation):     \u540e\u679c\uff08\u5168\u8eab\u6027\u708e\u75c7\uff09\uff1a</p> <ul> <li> <p>```</p> <ul> <li>These translocated microbial products are sensed by innate immune receptors (like TLR4 for LPS) on monocytes and dendritic cells. ```</li> </ul> </li> <li> <p>This sensing triggers signaling pathways (NF-kB) that release pro-inflammatory cytokines (IL-6, TNF, IL-1\u03b2), driving systemic chronic inflammation even when viral load is suppressed.     \u8fd9\u79cd\u611f\u77e5\u89e6\u53d1\u4fe1\u53f7\u901a\u8def\uff08NF-kB\uff09\uff0c\u91ca\u653e\u4fc3\u708e\u7ec6\u80de\u56e0\u5b50\uff08IL-6\u3001TNF\u3001IL-1\u03b2\uff09\uff0c\u5373\u4f7f\u75c5\u6bd2\u8f7d\u91cf\u88ab\u6291\u5236\uff0c\u4e5f\u4f1a\u5f15\u53d1\u5168\u8eab\u6027\u6162\u6027\u708e\u75c7 \u3002</p> </li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%207%20System%20exhaustion%20and%20cytokine%20storms/#2-cell-death-abortive-hiv-infection-pyroptosis","title":"**2. Cell Death: Abortive HIV Infection &amp; Pyroptosis","text":"<ol> <li>\u7ec6\u80de\u6b7b\u4ea1\uff1a\u6d41\u4ea7\u6027 HIV \u611f\u67d3\u4e0e\u7126\u51cb\u4ea1**</li> </ol> <p>Logic: Most CD4 T cells that die in HIV infection are not productively infected. They die because they sense the virus trying to enter and trigger a \"suicide\" alarm to stop it. \u903b\u8f91\uff1a \u5927\u591a\u6570\u5728 HIV \u611f\u67d3\u4e2d\u6b7b\u4ea1\u7684 CD4 T \u7ec6\u80de_\u5e76\u672a_\u88ab\u6709\u6548\u611f\u67d3\u3002\u4ed6\u4eec\u6b7b\u4e8e\u611f\u77e5\u75c5\u6bd2\u8bd5\u56fe\u8fdb\u5165\u5e76\u89e6\u53d1\u201c\u81ea\u6740\u201d\u8b66\u62a5\u4ee5\u963b\u6b62\u75c5\u6bd2\u3002</p> <ul> <li> <p>Abortive Infection:\u00a0\u00a0\u6d41\u4ea7\u6027\u611f\u67d3\uff1a</p> <ul> <li> <p>Only a minority of CD4 T cells are successfully infected (productive infection). However, the majority of dying cells are \"bystander\" quiescent CD4 T cells where the infection is abortive.     \u53ea\u6709\u5c11\u6570 CD4 T \u7ec6\u80de\u6210\u529f\u611f\u67d3\uff08\u751f\u4ea7\u6027\u611f\u67d3\uff09\u3002\u7136\u800c\uff0c\u5927\u591a\u6570\u6b7b\u4ea1\u7ec6\u80de\u662f\u201c\u65c1\u89c2\u8005\u201d\u9759\u6b62\u578b CD4 T \u7ec6\u80de\uff0c\u611f\u67d3\u662f\u6d41\u4ea7\u6027\u7684 \u3002</p> </li> <li> <p>In these cells, the virus enters, but reverse transcription fails to complete, leaving incomplete cytosolic viral DNA transcripts.     \u75c5\u6bd2\u8fdb\u5165\u8fd9\u4e9b\u7ec6\u80de\u540e\uff0c\u9006\u8f6c\u5f55\u672a\u80fd\u5b8c\u6210\uff0c\u5bfc\u81f4\u7ec6\u80de\u8d28\u75c5\u6bd2 DNA \u8f6c\u5f55\u672c\u4e0d\u5b8c\u6574\u3002</p> </li> </ul> </li> <li> <p>The Sensor (IFI16):\u00a0\u00a0\u4f20\u611f\u5668\uff08IFI16\uff09\uff1a</p> <ul> <li>These accumulated viral DNA fragments are detected by intracellular sensors, specifically IFI16.     \u8fd9\u4e9b\u79ef\u7d2f\u7684\u75c5\u6bd2 DNA \u7247\u6bb5\u88ab\u7ec6\u80de\u5185\u4f20\u611f\u5668\u68c0\u6d4b\uff0c\u7279\u522b\u662f IFI16\u3002</li> </ul> </li> <li> <p>The Execution (Pyroptosis):     \u5904\u51b3\uff08\u706b\u7130\u8df3\u8dc3\uff09\uff1a</p> <ul> <li> <p>```</p> <ul> <li>Sensing via IFI16 triggers the inflammasome (involving Caspase-1). ```</li> </ul> </li> <li> <p>This leads to Pyroptosis, a highly inflammatory form of cell death. Unlike silent apoptosis, pyroptosis causes the cell to swell and burst, releasing inflammatory cytokines like IL-1\u03b2 and IL-18 into the surrounding tissue, which attracts more cells to be infected and die.     \u8fd9\u5bfc\u81f4\u4e86\u7126\u78f7\u9041\u5f62 \uff0c\u8fd9\u662f\u4e00\u79cd\u9ad8\u5ea6\u708e\u75c7\u6027\u7684\u7ec6\u80de\u6b7b\u4ea1\u5f62\u5f0f\u3002\u4e0e\u65e0\u58f0\u51cb\u4ea1\u4e0d\u540c\uff0c\u70ed\u51cb\u4ea1\u4f1a\u5bfc\u81f4\u7ec6\u80de\u80bf\u80c0\u7834\u88c2\uff0c\u91ca\u653e\u708e\u75c7\u6027\u7ec6\u80de\u56e0\u5b50\u5982 IL-1\u03b2 \u548c IL-18 \u5230\u5468\u56f4\u7ec4\u7ec7\uff0c\u5438\u5f15\u66f4\u591a\u7ec6\u80de\u88ab\u611f\u67d3\u5e76\u6b7b\u4ea1\u3002</p> </li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%207%20System%20exhaustion%20and%20cytokine%20storms/#3-exhaustion-the-pd-1-phenotype","title":"**3. Exhaustion: The PD-1 Phenotype","text":"<ol> <li>\u75b2\u52b3\uff1aPD-1 \u8868\u578b**</li> </ol> <p>Logic: When T cells are forced to fight a chronic infection without rest, they lose their ability to function and put up \"stop\" signs to prevent over-activation. \u903b\u8f91\uff1a \u5f53 T \u7ec6\u80de\u88ab\u8feb\u5728\u6ca1\u6709\u4f11\u606f\u7684\u60c5\u51b5\u4e0b\u4e0e\u6162\u6027\u611f\u67d3\u4f5c\u6597\u4e89\u65f6\uff0c\u5b83\u4eec\u5931\u53bb\u4e86\u529f\u80fd\uff0c\u5e76\u53d1\u51fa\u201c\u505c\u6b62\u201d\u4fe1\u53f7\u4ee5\u9632\u6b62\u8fc7\u5ea6\u6d3b\u5316\u3002</p> <ul> <li> <p>Definition of Exhaustion:     \u75b2\u52b3\u7684\u5b9a\u4e49\uff1a</p> <ul> <li>In chronic conditions like HIV, constant antigen stimulation drives T cells into a state of exhaustion, where they lose effector functions such as cytokine secretion and cytotoxicity.     \u5728\u827e\u6ecb\u75c5\u7b49\u6162\u6027\u75be\u75c5\u4e2d\uff0c\u6301\u7eed\u7684\u6297\u539f\u523a\u6fc0\u4f1a\u4f7f T \u7ec6\u80de\u8fdb\u5165\u75b2\u52b3\u72b6\u6001\uff0c\u5931\u53bb\u7ec6\u80de\u56e0\u5b50\u5206\u6ccc\u548c\u7ec6\u80de\u6bd2\u6027\u7b49\u6548\u5e94\u529f\u80fd\u3002</li> </ul> </li> <li> <p>The Phenotype (PD-1):\u00a0\u00a0\u8868\u578b\uff08PD-1\uff09\uff1a</p> <ul> <li> <p>Exhausted T cells typically express high levels of the inhibitory receptor PD-1 (Programmed Cell Death Protein 1).     \u8017\u5c3d\u7684 T \u7ec6\u80de\u901a\u5e38\u8868\u8fbe\u8f83\u9ad8\u6c34\u5e73\u7684\u6291\u5236\u6027\u53d7\u4f53 PD-1\uff08\u7a0b\u5e8f\u6027\u7ec6\u80de\u6b7b\u4ea1\u86cb\u767d 1\uff09\u3002</p> </li> <li> <p>The slides show a direct correlation: higher viral loads correlate with higher PD-1 expression on HIV-specific CD8+ T cells.     \u5207\u7247\u663e\u793a\u4e86\u76f4\u63a5\u76f8\u5173\u6027\uff1a\u75c5\u6bd2\u8f7d\u91cf\u8d8a\u9ad8\uff0cHIV \u7279\u5f02\u6027 CD8+ T \u7ec6\u80de\u4e0a PD-1 \u8868\u8fbe\u8d8a\u9ad8\u3002</p> </li> <li> <p>Blocking PD-1 (or its ligand PD-L1) can restore the function of these T cells, proving that this pathway actively suppresses the immune response.     \u963b\u65ad PD-1\uff08\u6216\u5176\u914d\u4f53 PD-L1\uff09\u53ef\u4ee5\u6062\u590d\u8fd9\u4e9b T \u7ec6\u80de\u7684\u529f\u80fd\uff0c\u8bc1\u660e\u8be5\u901a\u8def\u80fd\u79ef\u6781\u6291\u5236\u514d\u75ab\u53cd\u5e94\u3002</p> </li> <li> <p>Note: While TIM-3 is often co-expressed with PD-1 in exhaustion, your provided slides focus specifically on PD-1 data.     \u6ce8\u610f\uff1a\u867d\u7136 TIM-3 \u5e38\u4e0e PD-1 \u5728\u7a77\u5c3d\u65f6\u5e76\u5217\uff0c\u4f46\u4f60\u63d0\u4f9b\u7684\u5e7b\u706f\u7247\u7279\u522b\u5173\u6ce8 PD-1 \u6570\u636e\u3002</p> </li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%207%20System%20exhaustion%20and%20cytokine%20storms/#4-crisis-the-mechanism-of-sepsis","title":"**4. Crisis: The Mechanism of Sepsis","text":"<ol> <li>\u5371\u673a\uff1a\u8d25\u8840\u75c7\u7684\u673a\u5236**</li> </ol> <p>Logic: Sepsis is a chaotic collapse where the immune response itself, rather than the pathogen, causes lethal organ damage through a \"storm\" of signals. \u903b\u8f91\uff1a \u8d25\u8840\u75c7\u662f\u4e00\u79cd\u6df7\u4e71\u7684\u5d29\u6e83\uff0c\u514d\u75ab\u53cd\u5e94\u672c\u8eab\u800c\u975e\u75c5\u539f\u4f53\u901a\u8fc7\u201c\u98ce\u66b4\u201d\u4fe1\u53f7\u5f15\u53d1\u81f4\u547d\u5668\u5b98\u635f\u4f24\u3002</p> <ul> <li> <p>The Trigger (Cytokine Storm):     \u89e6\u53d1\u70b9\uff08\u7ec6\u80de\u56e0\u5b50\u98ce\u66b4\uff09\uff1a</p> <ul> <li> <p>```</p> <ul> <li>Sepsis begins with an excessive host response to infection (bacterial, viral, etc.). ```</li> </ul> </li> <li> <p>Pathogen Associated Molecular Patterns (PAMPs) trigger TLR4 and NF-\u03baB signaling, launching a Cytokine Storm (IL-1, IL-6, TNF). Interferons (IFN) act as amplifiers, speeding up this hyper-inflammation.     \u75c5\u539f\u4f53\u76f8\u5173\u5206\u5b50\u6a21\u5f0f\uff08PAMPs\uff09\u89e6\u53d1 TLR4 \u548c NF-\u03baB \u4fe1\u53f7\uff0c\u5f15\u53d1\u7ec6\u80de\u56e0\u5b50\u98ce\u66b4 \uff08IL-1\u3001IL-6\u3001TNF\uff09\u3002 \u5e72\u6270\u7d20\uff08IFN\uff09\u5145\u5f53\u653e\u5927\u5668\uff0c\u52a0\u901f\u8fd9\u79cd\u8d85\u53d1\u708e\u3002</p> </li> </ul> </li> <li> <p>The Collapse (Vasodilation &amp; Coagulation):     \u8840\u7ba1\u6e83\u7f29\uff08\u8840\u7ba1\u6269\u5f20\u4e0e\u51dd\u8840\uff09\uff1a</p> <ul> <li> <p>This storm triggers widespread endotheliopathy (damage to blood vessel lining) and microthrombosis (tiny blood clots), leading to coagulopathy.     \u8fd9\u573a\u98ce\u66b4\u5f15\u53d1\u5e7f\u6cdb\u7684\u5185\u76ae\u75c5\u53d8\uff08\u8840\u7ba1\u5185\u819c\u635f\u4f24\uff09\u548c\u5fae\u8840\u6813\uff08\u5fae\u5c0f\u8840\u6813\uff09\uff0c\u8fdb\u800c\u5f15\u53d1\u51dd\u8840\u529f\u80fd\u969c\u788d\u3002</p> </li> <li> <p>The systemic inflammatory response causes a massive drop in blood pressure (Septic Shock), necessitating the use of vasopressors to maintain blood flow.     \u5168\u8eab\u6027\u708e\u75c7\u53cd\u5e94\u4f1a\u5bfc\u81f4\u8840\u538b\u5927\u5e45\u4e0b\u964d\uff08\u8d25\u8840\u6027\u4f11\u514b\uff09\uff0c\u56e0\u6b64\u9700\u8981\u4f7f\u7528\u8840\u7ba1\u6269\u5f20\u5242\u6765\u7ef4\u6301\u8840\u6d41\u3002</p> </li> </ul> </li> <li> <p>The End Result (Organ Failure):     \u6700\u7ec8\u7ed3\u679c\uff08\u5668\u5b98\u8870\u7aed\uff09\uff1a</p> <ul> <li>The combination of low blood pressure (hypoperfusion) and clotting leads to multi-organ damage, commonly affecting the kidneys (requiring dialysis), liver, lungs (ARDS), and heart.     \u4f4e\u8840\u538b\uff08\u704c\u6ce8\u4e0d\u8db3\uff09\u4e0e\u8840\u6813\u5f62\u6210\u7684\u7ed3\u5408\u5bfc\u81f4\u591a\u5668\u5b98\u635f\u4f24 \uff0c\u901a\u5e38\u5f71\u54cd\u80be\u810f\uff08\u9700\u900f\u6790\uff09\u3001\u809d\u810f\u3001\u80ba\u90e8\uff08ARDS\uff09\u548c\u5fc3\u810f\u3002</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%208%20Immunometablism/","title":"Topic 8 Immunometablism","text":"<ul> <li> <p>Immunemetabolism: is about interpolay between metabolism and imunology, divided into systemic immunometablism and cellular immunometabolism</p> </li> <li> <p>Major metabolic pathways</p> <ul> <li>Glycolysis: converts glucose to pyruvate for quick energy and biosynthetic</li> <li>TCA cycle (krebs cycle): produce precursors for amino acids and lipids</li> <li>Lipid metabolism: <ul> <li>==FAS==: fatty acid synthesis for membrane and signals</li> <li>==FAO==: fatty acid oxidation for energy</li> </ul> </li> </ul> </li> <li> <p>T cell</p> <ul> <li>Naive T cells<ul> <li>Maintain metabolic quiescence</li> </ul> </li> <li>T cell activation<ul> <li>undergo metabolic reprogramming</li> <li>Key Pathway: The CD28-PI3K-AKT-mTORC1 axis is the central regulator, driving glucose uptake and glycolysis</li> <li>transcription factors: drive glycolysis and glutaminolysis, and lipid metabolism</li> <li>Mitochondrial Changes: rapid glycolysis; mitochondrial support nucleotide synthesis</li> </ul> </li> </ul> </li> <li> <p>Macrophage metabolism: Polarization dictates metabolic phenotype</p> <ul> <li>M1 Macrophages (pro-informmatory)<ul> <li>Characterized by enhanced glycolysis and the pentose phosphate pathway (PPP) to support ROS (Reactive Oxygen Species, which can help to antimicrobial role) production and nucleotide synthesis.</li> </ul> </li> <li>M2 macrophages ( anti-inflammatory/ repair)<ul> <li>Rely on OXPHOS and fatty acid oxidation (FAO). Glycolysis is not necessary for M2 polarization.</li> </ul> </li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%208%20Immunometablism/#metabolites-act-as-epigenetic-regulators","title":"Metabolites Act as Epigenetic Regulators","text":"<p>This is the central mechanistic link presented in the slides. Metabolic intermediates leave the mitochondria and directly alter the epigenome, turning genes on or off.</p>"},{"location":"IID_4/Yiru/Topic%209%20monoclonal%20antibodies/","title":"Topic 9 monoclonal antibodies","text":"<ul> <li>Monoclonal antibodies are a kind of therapeutic class; targeting cancer, autoimmune diseases, and infectious diseases</li> <li>Antibody Structure: <ul> <li>consists of variable light (V_L) and heavy (V_H) chains</li> <li>Constant regions (C_L, C_H)</li> <li>and CDRs: determine binding specificity</li> </ul> </li> <li>How it works<ul> <li>Antagonisms: Blocking receptor-ligand interactions</li> <li>CDC-Complement-dependent cytotoxicity: inducing cell lysis via the complement system </li> <li>ADCC- Antibody dependent cellular cytotoxicity: recruiting effector cells (like NK cells) to kill targets</li> <li>Signaling: inducing direct signaling pathways</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%209%20monoclonal%20antibodies/#mabs-suppressing-inflammation","title":"mAbs -- Suppressing inflammation","text":"<ul> <li>this function could be the way to treat autoimmune diseases</li> <li>Example: In MS, activated T-cells (Th1, Th17) and B-cells cross the blood-brain barrier, attacking neurons and oligodendrocytes.<ul> <li>Anti-CD20: targets B cells</li> <li>Anti-CD52: Depletes T and B cells</li> <li>Anti-Integrin: Blocks entry into the brain</li> <li>Anti-CD25: targets activated T cells</li> </ul> </li> <li>Systemic Lupus Erythematosus<ul> <li>Characterized by \"butterfly rash\" and systemic organ damage caused by autoantibodies. The process is driven by ==apoptotic== material activating dendritic cells (DCs), which then stimulate T and B cells.</li> <li>Target Cytokines: Anti-IFN$\\alpha/\\beta$ and anti-TNF$\\alpha$.</li> <li>Target Co-stimulation: Anti-CD40L to block T-cell help.</li> <li>B-cell survival: Anti-BAFF antibodies to reduce autoantibody production.</li> <li>Could also, expand the active Tregs, to release anti-inflammatory cytokines</li> </ul> </li> </ul>"},{"location":"IID_4/Yiru/Topic%209%20monoclonal%20antibodies/#mabs-stimulating-enhance-inflammation","title":"mAbs -- Stimulating, enhance inflammation","text":"<ul> <li>Example: mAbs are used to drive the immune system to attack tumors, counteracting the immunosupressive tumor microenvironment</li> <li>In cancer: suppression of cytotoxic CD8+ T cells, by reducing MHC expression, increasing inhibitory molecules ==PD-L1==, increasing suppressor cells like ==Tregs and M2 macrophages==</li> <li>mAbs block inhibitory signals to ==restore T-cell cytotoxicity==:<ul> <li>Anti-PD-L1: block interaction between the tumor and the T cell</li> <li>Anti-CTLA-4: block the inhibitory signalling during T cell activation</li> </ul> </li> </ul>"},{"location":"IN3_full/","title":"IN","text":"<p>Files contributed:</p> <ul> <li>ZIP packages are hosted externally. See: IN_lxfwyqlxr</li> </ul>"},{"location":"MATH1/","title":"MATH","text":""},{"location":"MATH1/#external-links","title":"External links","text":"<ul> <li>Calculus (2021-2022): https://drive.google.com/file/d/1KUHEEFDBXyBm7Oh1rY_DLn2DcPFOQed7/view?usp=sharing</li> <li>Statistics (2021-2022): https://drive.google.com/file/d/1vnRG-aoylkFqrY6-cSYmbtZSIeNBYlim/view?usp=sharing</li> </ul>"},{"location":"MBE3/","title":"MBE3","text":""},{"location":"MBE3/#contributors","title":"Contributors","text":"<ul> <li>Yiru: notes</li> <li>Xiaoran_etal: additional materials</li> </ul>"},{"location":"MBE3/#files","title":"Files","text":"<ul> <li>Browse Yiru notes: Yiru/</li> <li>Browse Xiaoran_etal materials: Xiaoran_etal/</li> </ul>"},{"location":"MBE3/#external-links","title":"External links","text":"<ul> <li>Hal (2023-2024): https://drive.google.com/file/d/1GC6xVmn8OFAWXFWk_nmLOwHJy7hro2DJ/view?usp=sharing</li> </ul>"},{"location":"MBE3/Yiru/","title":"MBE3","text":"<p>Files:</p> <ul> <li>MBE Chromosome structure detection.md</li> <li>MBE CRISPR screen disease gene factor.md</li> <li>MBE CRISPR_screen_drug_resistence.md</li> <li>MBE DNA assessment.md</li> <li>MBE Epigenetic sequencing.md</li> <li>MBE Epigenome Engineering Discussion.md</li> <li>MBE Gene editing.md</li> <li>MBE Gene expression analysis technologies.md</li> <li>MBE mRNA visualization and analysis technologies.md</li> <li>MBE Protein assessment.md</li> <li>MBE Protein-DNA interaction.md</li> <li>MBE RNA assessment.md</li> <li>MBE RNA editing-based RNA-seq.md</li> <li>MBE RNA-seq.md</li> </ul>"},{"location":"MBE3/Yiru/MBE%20CRISPR%20screen%20disease%20gene%20factor/","title":"MBE CRISPR screen disease gene factor","text":""},{"location":"MBE3/Yiru/MBE%20CRISPR%20screen%20disease%20gene%20factor/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Which human genes are essential for virus X infection and replication?</li> <li>Design Rationale: Genome-wide CRISPR screen enables identification of host dependency factors required for viral entry, replication, assembly, or release</li> <li>Follow-up Studies: Investigate mechanism of top hits, develop small molecule inhibitors targeting key host factors, test for broad-spectrum activity against related viruses</li> </ul>"},{"location":"MBE3/Yiru/MBE%20CRISPR%20screen%20disease%20gene%20factor/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cell line susceptible to virus X infection (e.g., Huh7 cells for hepatitis C virus)</li> <li>Rationale: Permissive cell lines that support complete viral lifecycle while maintaining high Cas9 editing efficiency provide ideal platform for identifying host factors</li> <li>Alternatives:</li> <li>Primary human cells (pros: physiological relevance; cons: difficult to scale, variable editing)</li> <li>Immortalized cells from target organs (pros: tissue-specific factors; cons: may have altered cellular pathways)</li> <li>Reporter virus systems (pros: biosafety, high-throughput; cons: may miss late-stage factors)</li> <li>Ethical Considerations: Biosafety protocols for viral work, cell line authentication, appropriate containment levels</li> </ul>"},{"location":"MBE3/Yiru/MBE%20CRISPR%20screen%20disease%20gene%20factor/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques:</li> <li>Lentiviral delivery of genome-wide sgRNA library to Cas9-expressing cells</li> <li>Viral challenge with optimized MOI</li> <li>Cell survival/death assay or FACS-based sorting of infected vs. uninfected cells</li> <li>Next-generation sequencing of sgRNA abundance pre/post-selection</li> <li>Technical Replicates: Duplicate NGS library preparations, multiple infection timepoints</li> <li>Potential Biases:</li> <li>Viral stock variations (standardize preparation, titration)</li> <li>Infection efficiency differences (optimize viral MOI)</li> <li>Cell death from Cas9 toxicity (include essential gene controls)</li> <li>Off-target effects (use libraries with minimal predicted off-targets)</li> </ul>"},{"location":"MBE3/Yiru/MBE%20CRISPR%20screen%20disease%20gene%20factor/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: sgRNA library-transduced cells infected with virus X</li> <li>Control 1: Uninfected sgRNA library cells (baseline sgRNA distribution)</li> <li>Control 2: Non-targeting sgRNA library with viral infection</li> <li>Control 3: Time-matched uninfected cells for growth-related effects</li> <li>Controlled Variables: Cell density, viral dose, infection duration, sgRNA library coverage</li> <li>Biological Replicates: 3-4 independent library transductions and viral challenges</li> <li>Modified Design: Include CRISPR screens with multiple viral strains to identify strain-specific vs. conserved host factors</li> </ul>"},{"location":"MBE3/Yiru/MBE%20CRISPR%20screen%20disease%20gene%20factor/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: </li> <li>sgRNA read counting from sequencing data</li> <li>Normalization to library depth</li> <li>Enrichment/depletion calculation relative to uninfected controls</li> <li>Gene-level significance using MAGeCK or similar algorithms</li> <li>Statistical Analysis:</li> <li>False discovery rate control for multiple testing</li> <li>Comparison with published essential gene datasets</li> <li>Pathway and network analysis of hits</li> <li>Comparison with known viral interactors from proteomics data</li> <li>Data Presentation:</li> <li>Manhattan plots of gene significance across the genome</li> <li>Cellular pathway maps highlighting hit clusters</li> <li>Validation data for top hits showing infection rates with individual knockouts</li> <li>Comparison with previous genetic screens or interactome studies</li> <li>Validation Methods:</li> <li>Individual gene knockout confirmation</li> <li>Viral replication assays with knockout cell lines</li> <li>Rescue experiments with cDNA expression</li> <li>Protein-protein interaction studies with viral components</li> <li>Small molecule inhibition of identified pathways</li> </ul>"},{"location":"MBE3/Yiru/MBE%20CRISPR_screen_drug_resistence/","title":"Experimental Design: Genome-Wide CRISPR Screen for Drug Resistance Mechanisms","text":""},{"location":"MBE3/Yiru/MBE%20CRISPR_screen_drug_resistence/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Which genes, when knocked out, confer resistance to drug X in cancer cell line Y?</li> <li>Design Rationale: Genome-wide CRISPR-Cas9 knockout screen allows unbiased identification of genes whose loss enables cell survival under drug selection pressure</li> <li>Follow-up Studies: Validate top hits with individual knockouts, investigate mechanism of resistance for key genes, test combinations of drug X with inhibitors targeting resistance pathways</li> </ul>"},{"location":"MBE3/Yiru/MBE%20CRISPR_screen_drug_resistence/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cancer cell line relevant to drug X's therapeutic application (e.g., A375 melanoma cells for BRAF inhibitor screen)</li> <li>Rationale: Cancer cell lines provide stable Cas9 expression, consistent growth, and clinically relevant drug responses while enabling high-throughput screening</li> <li>Alternatives:</li> <li>Patient-derived xenografts (pros: better clinical relevance; cons: more variable, complex, expensive)</li> <li>Primary patient cells (pros: direct clinical relevance; cons: limited expansion, variable Cas9 efficiency)</li> <li>Immortalized non-cancer cells (pros: define cancer-specific vs. general mechanisms; cons: may lack disease context)</li> <li>Ethical Considerations: Cell line authentication, appropriate biosafety practices, responsible use of patient-derived materials if applicable</li> </ul>"},{"location":"MBE3/Yiru/MBE%20CRISPR_screen_drug_resistence/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques:</li> <li>Lentiviral delivery of genome-wide gRNA library</li> <li>Next-generation sequencing of gRNA abundance</li> <li>Drug dose-response assays for validation</li> <li>Western blotting and RT-qPCR for mechanism studies</li> <li>Technical Replicates: Duplicate NGS library preparations</li> <li>Potential Biases:</li> <li>Variable Cas9 editing efficiency (use cells with validated high Cas9 activity)</li> <li>Lentiviral MOI variations (maintain &gt;500x library coverage throughout)</li> <li>gRNA design efficiency differences (use validated libraries with multiple guides per gene)</li> <li>PCR amplification bias (minimize PCR cycles, use UMIs if possible)</li> </ul>"},{"location":"MBE3/Yiru/MBE%20CRISPR_screen_drug_resistence/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Treatment: Cells with gRNA library exposed to drug X at IC70-IC90 concentration</li> <li>Control 1: Cells with gRNA library without drug treatment (T0 reference)</li> <li>Control 2: Cells with gRNA library grown in parallel without drug (time-matched control)</li> <li>Control 3: Cells with non-targeting gRNA library with drug treatment</li> <li>Controlled Variables: Cell passage number, Cas9 expression level, library coverage, drug concentration, treatment duration</li> <li>Biological Replicates: 3-4 independent infections and selections</li> <li>Modified Design: Include multiple drug concentrations to identify dose-dependent resistance mechanisms, or combine with CRISPRa screen to identify both loss- and gain-of-function resistance mechanisms</li> </ul>"},{"location":"MBE3/Yiru/MBE%20CRISPR_screen_drug_resistence/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: </li> <li>gRNA counting from raw NGS reads</li> <li>Normalization for sequencing depth</li> <li>Guide-level fold-change calculation (treatment vs. control)</li> <li>Gene-level enrichment scores using algorithms like MAGeCK or BAGEL</li> <li>Statistical Analysis:</li> <li>False discovery rate correction for multiple hypothesis testing</li> <li>Robust rank aggregation for combining multiple guides per gene</li> <li>Gene set enrichment analysis for pathway-level insights</li> <li>Principal component analysis to assess replicate consistency</li> <li>Data Presentation:</li> <li>Volcano plots showing gene enrichment/depletion significance</li> <li>Ranked bar charts of top hits with statistical significance</li> <li>Pathway enrichment bubble plots</li> <li>Validation data for selected hits showing individual knockout phenotypes</li> <li>Network visualization of functionally related hits</li> <li>Validation Methods:</li> <li>Individual CRISPR knockout of top hits</li> <li>Rescue experiments with cDNA expression</li> <li>Dose-response curves with and without gene knockout</li> <li>Combinatorial drug testing targeting resistance pathways</li> <li>Protein-protein interaction studies to elucidate mechanisms</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/","title":"MBE Chromosome structure detection","text":""},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How does three-dimensional genome organization influence gene regulation and cellular function?</li> <li>Design Rationale: Chromosome conformation capture technologies reveal spatial organization of chromatin, regulatory interactions, and topological domains</li> <li>Follow-up Studies: Correlation with gene expression, epigenetic marks, functional validation of regulatory interactions, dynamic changes during development or disease</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, primary cells, tissue samples, embryos</li> <li>Rationale: These systems provide sufficient material for capturing chromatin interactions while maintaining native nuclear architecture</li> <li>Alternatives:</li> <li>In vitro nuclear preparations (pros: enriched nuclei; cons: potential disruption of architecture)</li> <li>Single-cell approaches (pros: cellular heterogeneity; cons: technical noise)</li> <li>Tissue sections (pros: spatial context; cons: fixation artifacts)</li> <li>Ethical Considerations: Standard considerations for cell and tissue sources, potential insights into disease mechanisms</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>Crosslinking to preserve chromatin interactions</li> <li>Restriction enzyme digestion</li> <li>Proximity ligation of interacting fragments</li> <li>DNA purification and analysis</li> <li>Technical Replicates: Multiple libraries recommended due to complexity of protocols</li> <li>Potential Biases:</li> <li>Restriction enzyme bias (site distribution)</li> <li>Crosslinking efficiency variations</li> <li>PCR amplification bias</li> <li>Mapping biases in repetitive regions</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples under experimental condition of interest</li> <li>Control 1: Untreated/baseline samples</li> <li>Control 2: Technical controls (random ligation controls)</li> <li>Control 3: Biological reference samples for normalization</li> <li>Controlled Variables: Cell cycle stage, fixation conditions, cell density</li> <li>Biological Replicates: Minimum 2-3 biological replicates; more for heterogeneous samples</li> <li>Modified Design: Time-course analysis, cell type comparisons, treatment effects</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Interaction matrix generation</li> <li>Normalization for technical biases</li> <li>Identification of significant interactions</li> <li>Domain calling (TADs, compartments)</li> <li>Presentation Approaches:</li> <li>Heatmaps at various resolutions</li> <li>Virtual 4C plots for specific viewpoints</li> <li>Circos plots for genome-wide interactions</li> <li>3D models of chromatin folding</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature 3C (Chromosome Conformation Capture) 4C (Circular Chromosome Conformation Capture) 5C (Carbon Copy Chromosome Conformation Capture) Hi-C Primary Application One-to-one interactions One-to-all interactions Many-to-many interactions All-to-all interactions Scope Focused (few loci) Viewpoint-centric Regional (multiple loci) Genome-wide Resolution High (restriction fragment) High at viewpoint High within region Variable (10kb-1Mb) Coverage Limited (targeted) Genome-wide from viewpoint Selected regions Genome-wide Throughput Low Medium High for target regions Very high Input Material Low (millions of cells) Low to moderate Moderate High (millions of cells) Complexity Low Moderate High Very high Cost Low Moderate Moderate to high High Sequencing Depth Low (targeted) Moderate High for covered regions Very high Analysis Complexity Simple Moderate Moderate to high Very high Best For \u2022 Testing specific interactions\u2022 Validating predictions\u2022 Focused hypothesis testing\u2022 Quantitative comparison \u2022 Single locus regulation\u2022 Enhancer-promoter mapping\u2022 Identifying all contacts for a region\u2022 Detailed viewpoint analysis \u2022 Regulatory landscapes\u2022 Complex locus organization\u2022 Multiple candidate interactions\u2022 Medium-scale mapping \u2022 Global architecture\u2022 TAD identification\u2022 Compartment analysis\u2022 Comprehensive interaction maps Limitations \u2022 Limited to predefined regions\u2022 Labor-intensive for multiple loci\u2022 No global context\u2022 Primer design challenges \u2022 Limited to single viewpoint\u2022 Uneven coverage away from viewpoint\u2022 Complex library preparation\u2022 Viewpoint bias \u2022 Limited to predefined regions\u2022 Primer design complexity\u2022 Coverage gaps\u2022 Labor-intensive design \u2022 Lower resolution\u2022 High sequencing costs\u2022 Complex computational analysis\u2022 High cell input requirements"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Hypothesis Generation:</li> <li>Begin with Hi-C for global chromosome architecture</li> <li> <p>Identify domains, compartments, and potential regulatory hubs</p> </li> <li> <p>Focused Investigation:</p> </li> <li>Use 4C to explore all interactions from key regulatory elements</li> <li>Apply 5C to comprehensively map interactions across candidate regions</li> <li> <p>Validate specific interactions with 3C for quantitative assessment</p> </li> <li> <p>Functional Validation:</p> </li> <li>Correlate interactions with gene expression data</li> <li>Integrate with epigenetic marks (ChIP-seq, ATAC-seq)</li> <li> <p>Perform genetic perturbation of interaction sites</p> </li> <li> <p>Integrated Approach: Design multi-platform studies for comprehensive characterization:</p> </li> <li>Hi-C to map global architecture and identify domains</li> <li>4C to explore key regulatory elements in detail</li> <li>5C to comprehensively analyze complex regulatory regions</li> <li>3C to validate and quantify specific interactions of interest</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#8-technology-specific-considerations","title":"8. Technology-Specific Considerations","text":""},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#3c-chromosome-conformation-capture","title":"3C (Chromosome Conformation Capture)","text":"<ul> <li>Design Considerations:</li> <li>Primer design critical for efficiency and specificity</li> <li>Control for primer efficiency with BAC templates</li> <li> <p>Quantitative PCR for accurate interaction measurement</p> </li> <li> <p>Applications:</p> </li> <li>Validation of predicted interactions</li> <li>Quantitative comparison between conditions</li> <li> <p>Focused analysis of specific regulatory elements</p> </li> <li> <p>Variations:</p> </li> <li>Real-time PCR vs. traditional PCR detection</li> <li>Multiplexed 3C for multiple simultaneous interactions</li> <li>Nested 3C for improved specificity</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#4c-circular-chromosome-conformation-capture","title":"4C (Circular Chromosome Conformation Capture)","text":"<ul> <li>Design Considerations:</li> <li>Viewpoint selection critical (regulatory elements, promoters)</li> <li>Secondary restriction enzyme choice affects resolution</li> <li> <p>Inverse PCR conditions optimization important</p> </li> <li> <p>Applications:</p> </li> <li>Enhancer-promoter interaction mapping</li> <li>Identifying novel regulatory contacts</li> <li> <p>Comparing interaction profiles between conditions</p> </li> <li> <p>Variations:</p> </li> <li>4C-seq with high-throughput sequencing</li> <li>r3C-seq with reduced complexity</li> <li>e4C with enhanced sensitivity</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#5c-carbon-copy-chromosome-conformation-capture","title":"5C (Carbon Copy Chromosome Conformation Capture)","text":"<ul> <li>Design Considerations:</li> <li>Primer design complexity (hundreds of primers)</li> <li>Balanced primer pool important for even coverage</li> <li> <p>Optimization of multiplex PCR conditions</p> </li> <li> <p>Applications:</p> </li> <li>Comprehensive mapping of complex loci</li> <li>Regulatory landscapes of developmental genes</li> <li> <p>Comparing multiple regions simultaneously</p> </li> <li> <p>Variations:</p> </li> <li>5C with next-generation sequencing</li> <li>Targeted 5C for specific pathways</li> <li>Condition-specific 5C designs</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#hi-c","title":"Hi-C","text":"<ul> <li>Design Considerations:</li> <li>Biotin incorporation efficiency</li> <li>Streptavidin bead enrichment optimization</li> <li> <p>Sequencing depth vs. resolution trade-off</p> </li> <li> <p>Applications:</p> </li> <li>Global chromatin organization</li> <li>Topologically associating domain (TAD) identification</li> <li>A/B compartment analysis</li> <li> <p>Long-range interaction discovery</p> </li> <li> <p>Variations:</p> </li> <li>In situ Hi-C for improved signal-to-noise</li> <li>Capture Hi-C for targeted regions</li> <li>Micro-C with micrococcal nuclease for nucleosome-level resolution</li> <li>HiChIP/PLAC-seq for protein-centric interactions</li> <li>Single-cell Hi-C for cellular heterogeneity</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Chromosome%20structure%20detection/#9-integration-with-other-technologies","title":"9. Integration with Other Technologies","text":"<ul> <li>Epigenomic Integration:</li> <li>ChIP-seq data to correlate interactions with histone marks</li> <li>ATAC-seq to identify accessible regions at interaction sites</li> <li> <p>DNA methylation data to assess regulatory potential</p> </li> <li> <p>Transcriptomic Integration:</p> </li> <li>RNA-seq to correlate interactions with gene expression</li> <li>eQTL analysis to link genetic variation to interaction changes</li> <li> <p>Nascent RNA analysis for direct regulatory effects</p> </li> <li> <p>Imaging Validation:</p> </li> <li>DNA FISH to validate specific interactions</li> <li>Super-resolution microscopy for fine-scale organization</li> <li>Live-cell imaging for dynamic changes</li> </ul> <p>This integrated framework provides researchers with a structured approach to selecting and combining chromosome conformation capture technologies. The complementary use of these methods, from genome-wide to locus-specific, enables a comprehensive understanding of chromatin architecture and its functional implications in gene regulation.</p>"},{"location":"MBE3/Yiru/MBE%20DNA%20assessment/","title":"MBE DNA assessment","text":""},{"location":"MBE3/Yiru/MBE%20DNA%20assessment/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Is gene X present, altered, or differentially expressed in condition Y compared to controls?</li> <li>Design Rationale: DNA detection and quantification techniques allow identification of specific sequences, structural variations, and abundance changes</li> <li>Follow-up Studies: Functional validation of detected variants, expression analysis, correlation with phenotypic outcomes</li> </ul>"},{"location":"MBE3/Yiru/MBE%20DNA%20assessment/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human tissue samples from patients with condition Y and matched controls</li> <li>Rationale: Patient-derived samples provide direct clinical relevance while allowing sufficient DNA extraction for multiple analytical approaches</li> <li>Alternatives:</li> <li>Cell lines (pros: abundant material, controlled conditions; cons: may not reflect in vivo context)</li> <li>Animal models (pros: controlled genetics; cons: species differences)</li> <li>Synthetic DNA (pros: precise control; cons: lacks biological context)</li> <li>Ethical Considerations: IRB approval, informed consent, sample de-identification, responsible data sharing</li> </ul>"},{"location":"MBE3/Yiru/MBE%20DNA%20assessment/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>High-quality DNA extraction</li> <li>Appropriate sample storage</li> <li>Consistent quantification methods</li> <li>Inclusion of reference standards</li> <li>Technical Replicates: Triplicate measurements for each sample and technique</li> <li>Potential Biases:</li> <li>Sample quality variations (standardize extraction protocols)</li> <li>Batch effects (include inter-run calibrators)</li> <li>Amplification bias (optimize primer design)</li> <li>Probe specificity (validate with known controls)</li> </ul>"},{"location":"MBE3/Yiru/MBE%20DNA%20assessment/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples from subjects with condition Y</li> <li>Control 1: Matched samples from healthy subjects</li> <li>Control 2: Positive controls with known sequence variants</li> <li>Control 3: Negative controls (no template controls)</li> <li>Controlled Variables: DNA quantity, quality metrics, reagent lots, instrument calibration</li> <li>Biological Replicates: Minimum 20-30 subjects per group for adequate statistical power</li> <li>Modified Design: Include family members for hereditary conditions or longitudinal sampling for progressive conditions</li> </ul>"},{"location":"MBE3/Yiru/MBE%20DNA%20assessment/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Quality control metrics</li> <li>Normalization to reference genes/sequences</li> <li>Statistical comparison between groups</li> <li>Correlation with clinical parameters</li> <li>Presentation Approaches:</li> <li>Gel/blot images with size markers</li> <li>Amplification curves and threshold cycles</li> <li>Quantitative comparisons with error bars</li> <li>Correlation plots with clinical outcomes</li> </ul>"},{"location":"MBE3/Yiru/MBE%20DNA%20assessment/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature PCR qPCR Southern Blotting Primary Use Qualitative detection of specific sequences Precise quantification of target DNA Detection of specific sequences and structural variations Sensitivity Moderate (detects ~10-100 copies) High (detects 1-10 copies) Moderate (50-100 ng of genomic DNA) Specificity Good, primer-dependent Very good, primer and probe-dependent Excellent, especially for complex rearrangements Quantification Semi-quantitative at best Highly quantitative Semi-quantitative Throughput High High Low Time Required 2-3 hours 2-3 hours 1-3 days Cost Low Moderate High Equipment Basic thermal cycler qPCR instrument Multiple specialized equipment Technical Expertise Basic Moderate Advanced Best For \u2022 Rapid presence/absence detection\u2022 Genotyping\u2022 Initial screening\u2022 Amplifying targets for sequencing \u2022 Precise copy number quantification\u2022 Gene expression studies\u2022 Pathogen load determination\u2022 Allelic discrimination \u2022 Complex structural variations\u2022 Large insertions/deletions\u2022 Repetitive sequence analysis\u2022 Confirming ambiguous PCR results Limitations \u2022 Limited quantification\u2022 Potential for false positives\u2022 Size constraints \u2022 Limited fragment size information\u2022 Requires careful assay design\u2022 Potential amplification bias \u2022 Labor intensive\u2022 Low throughput\u2022 Requires large DNA amounts\u2022 Radioactive hazards (for some probes)"},{"location":"MBE3/Yiru/MBE%20DNA%20assessment/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Initial Screening: Use standard PCR for rapid, cost-effective detection of target sequences</li> <li>Precise Quantification: Follow with qPCR for accurate measurement of differences between groups</li> <li>Structural Validation: Employ Southern blotting to confirm complex structural variations or repetitive sequence changes</li> <li>Integrated Approach: Use all three methods for comprehensive characterization of important targets:</li> <li>PCR to rapidly screen multiple samples</li> <li>qPCR to precisely quantify differences</li> <li>Southern blotting to validate structural context and complex variations</li> </ul> <p>This multi-technique approach provides complementary data that overcomes the limitations of any single method while maximizing confidence in results for critical findings.</p>"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/","title":"Experimental Design: Epigenetic Analysis Technologies","text":""},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How do epigenetic modifications regulate gene expression and chromatin structure in different biological contexts?</li> <li>Design Rationale: Epigenetic sequencing techniques reveal DNA methylation patterns, histone modifications, chromatin accessibility, nucleosome positioning, and RNA modifications</li> <li>Follow-up Studies: Integration with transcriptome data, functional validation of regulatory elements, epigenetic editing, developmental trajectory analysis</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, primary cells, tissue samples, embryos, patient biopsies</li> <li>Rationale: These systems provide sufficient material while maintaining native epigenetic landscapes relevant to development or disease</li> <li>Alternatives:</li> <li>In vitro differentiation models (pros: controlled progression; cons: artificial conditions)</li> <li>Animal models (pros: developmental context; cons: species differences)</li> <li>Patient-derived xenografts (pros: human relevance; cons: altered microenvironment)</li> <li>Ethical Considerations: Informed consent for human samples, developmental stage considerations, transgenerational effects</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>Careful sample preservation to maintain epigenetic marks</li> <li>Cross-linking conditions optimization</li> <li>Antibody validation for IP-based methods</li> <li>Appropriate enzymatic digestion parameters</li> <li>Technical Replicates: Multiple replicates to account for technical variability in enzymatic or antibody-based methods</li> <li>Potential Biases:</li> <li>Antibody specificity (validate with knockout controls)</li> <li>Enzymatic bias (optimize digestion conditions)</li> <li>PCR duplication (use UMIs when possible)</li> <li>GC content bias (normalize in computational analysis)</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples from experimental condition of interest</li> <li>Control 1: Matched untreated/baseline samples</li> <li>Control 2: Technical controls (input DNA, IgG controls for IP methods)</li> <li>Control 3: Spike-in controls for quantitative comparisons</li> <li>Controlled Variables: Cell cycle stage, developmental time point, tissue processing method</li> <li>Biological Replicates: Minimum 3 biological replicates; more for heterogeneous samples</li> <li>Modified Design: Time-course analysis, multiple cell types, disease progression stages</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Quality control metrics (library complexity, mapping rates)</li> <li>Peak calling or methylation calling algorithms</li> <li>Differential analysis between conditions</li> <li>Integration with gene expression data</li> <li>Presentation Approaches:</li> <li>Genome browser tracks for visual comparison</li> <li>Heatmaps centered on features of interest</li> <li>Metaplots showing average profiles around features</li> <li>Enrichment analyses for functional interpretation</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#6-technique-comparison-dna-methylation-and-chromatin-structure","title":"6. Technique Comparison - DNA Methylation and Chromatin Structure","text":"Feature Bisulfite Sequencing MeDIP-seq ChIP-seq ATAC-seq MNase-seq Primary Target DNA methylation DNA methylation Protein-DNA interactions Chromatin accessibility Nucleosome positioning Resolution Single-base 100-300 bp 150-300 bp &lt;50 bp Single-nucleosome Coverage Genome-wide Enriched regions Protein binding sites Accessible regions Nucleosome-occupied Sensitivity Very high Moderate Moderate to high High Moderate Specificity Very high Antibody-dependent Antibody-dependent High High Input Material 50-500 ng 100-1000 ng 1-10 million cells 50,000-100,000 cells 1-5 million cells Cost High Moderate Moderate to high Moderate Moderate Technical Complexity High Moderate Moderate to high Low to moderate Moderate to high Best For \u2022 Comprehensive methylome\u2022 Single-CpG resolution\u2022 Quantitative analysis\u2022 Allele-specific methylation \u2022 Cost-effective methylation\u2022 Low input samples\u2022 Enriched methylated regions\u2022 Hypermethylated regions \u2022 Histone modifications\u2022 Transcription factor binding\u2022 Enhancer mapping\u2022 Protein-DNA interactions \u2022 Global accessibility\u2022 Low cell numbers\u2022 Regulatory element mapping\u2022 Footprinting \u2022 Nucleosome positioning\u2022 Chromatin structure\u2022 Linker regions\u2022 Phasing analysis Limitations \u2022 Incomplete conversion\u2022 Cannot distinguish 5mC from 5hmC\u2022 PCR bias\u2022 High sequencing cost \u2022 Low resolution\u2022 Qualitative rather than quantitative\u2022 Antibody specificity\u2022 CpG density bias \u2022 Antibody quality dependent\u2022 High cell input\u2022 Background signal\u2022 Indirect binding detection \u2022 Mitochondrial contamination\u2022 Tn5 sequence bias\u2022 Fragment size selection\u2022 Cellular heterogeneity \u2022 Digestion variability\u2022 High cell input\u2022 Complex analysis\u2022 Enzyme accessibility bias"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#7-technique-comparison-chromatin-accessibility-and-rna-modifications","title":"7. Technique Comparison - Chromatin Accessibility and RNA Modifications","text":"Feature DNase-seq FAIRE-seq Small RNA-seq m6A-seq Primary Target Open chromatin Open regulatory regions Small non-coding RNAs RNA methylation Resolution 50-150 bp 200-300 bp Single-base 100-200 bp Coverage Accessible regions Nucleosome-depleted Small RNA population Modified transcripts Sensitivity High Moderate High Moderate Specificity High Moderate Very high Antibody-dependent Input Material 1-10 million cells 1-5 million cells 100-1000 ng RNA 100-300 \u03bcg RNA Cost Moderate Low to moderate Moderate High Technical Complexity Moderate to high Moderate Moderate High Best For \u2022 Regulatory elements\u2022 Transcription factor footprints\u2022 Cell-type specific elements\u2022 Enhancer mapping \u2022 Active regulatory regions\u2022 Nucleosome depletion\u2022 Complementary to DNase-seq\u2022 Simple protocol \u2022 miRNA profiling\u2022 piRNA discovery\u2022 siRNA characterization\u2022 Non-coding RNA regulation \u2022 RNA modification maps\u2022 Epitranscriptome analysis\u2022 mRNA regulation\u2022 Modification dynamics Limitations \u2022 High cell input\u2022 Enzyme efficiency\u2022 Sensitivity to conditions\u2022 Complex analysis \u2022 Lower signal-to-noise\u2022 Variable efficiency\u2022 Lower resolution\u2022 Limited sensitivity \u2022 Size selection bias\u2022 Adapter ligation bias\u2022 Secondary structure effects\u2022 Quantification challenges \u2022 Antibody specificity\u2022 IP efficiency\u2022 Low resolution\u2022 High input requirements"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#8-complementary-usage-strategy","title":"8. Complementary Usage Strategy","text":"<ul> <li>DNA Methylation Analysis: </li> <li>Use bisulfite sequencing for comprehensive, single-base resolution methylation mapping</li> <li> <p>Employ MeDIP-seq for cost-effective screening of methylated regions</p> </li> <li> <p>Chromatin Structure Analysis:</p> </li> <li>Apply ATAC-seq for global accessibility with low input requirements</li> <li>Use DNase-seq for detailed footprinting of transcription factor binding</li> <li>Implement MNase-seq for precise nucleosome positioning</li> <li> <p>Utilize FAIRE-seq as a complementary approach for open chromatin</p> </li> <li> <p>Protein-DNA Interactions:</p> </li> <li>Employ ChIP-seq for mapping specific histone modifications and transcription factor binding</li> <li> <p>Integrate with accessibility data to identify functional binding events</p> </li> <li> <p>RNA Regulation:</p> </li> <li>Use Small RNA-seq to profile regulatory non-coding RNAs</li> <li> <p>Apply m6A-seq to map RNA modifications affecting transcript processing and stability</p> </li> <li> <p>Integrated Approach: Design multi-platform studies for comprehensive epigenetic characterization:</p> </li> <li>Bisulfite sequencing to establish DNA methylation landscape</li> <li>ChIP-seq for key histone modifications (H3K4me3, H3K27me3, H3K27ac, etc.)</li> <li>ATAC-seq to map accessible chromatin regions</li> <li>Integration with transcriptome data to correlate epigenetic features with gene expression</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#9-technology-specific-considerations","title":"9. Technology-Specific Considerations","text":""},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#dna-methylation-methods","title":"DNA Methylation Methods","text":"<ul> <li>Bisulfite Sequencing:</li> <li>Variants include WGBS (whole genome), RRBS (reduced representation), and targeted approaches</li> <li>Alternative methods (oxBS-seq, TAB-seq) can distinguish 5mC from 5hmC</li> <li> <p>Non-bisulfite methods (TAPS, EM-seq) reduce DNA degradation</p> </li> <li> <p>MeDIP-seq:</p> </li> <li>Antibody selection critical (5mC vs. 5hmC specificity)</li> <li>Quantification requires normalization for CpG density</li> <li>Cost-effective for large-scale comparative studies</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#chromatin-accessibility-methods","title":"Chromatin Accessibility Methods","text":"<ul> <li>ATAC-seq:</li> <li>Optimization for cell number and transposition conditions</li> <li>Single-cell protocols available for heterogeneous samples</li> <li> <p>Mitochondrial filtering essential in analysis</p> </li> <li> <p>DNase-seq:</p> </li> <li>Enzyme concentration titration critical for optimal results</li> <li>Digital genomic footprinting possible with deep sequencing</li> <li> <p>Higher input requirements than ATAC-seq</p> </li> <li> <p>MNase-seq:</p> </li> <li>Digestion conditions affect nucleosome detection</li> <li>Can reveal subnucleosomal particles with light digestion</li> <li> <p>Paired-end sequencing recommended for precise positioning</p> </li> <li> <p>FAIRE-seq:</p> </li> <li>Simplest protocol but lower signal-to-noise ratio</li> <li>Complements protein-based methods</li> <li>Useful for samples where crosslinking is challenging</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#protein-dna-interactions","title":"Protein-DNA Interactions","text":"<ul> <li>ChIP-seq:</li> <li>Antibody validation critical (specificity, lot testing)</li> <li>Fixation conditions affect efficiency</li> <li>Spike-in normalization recommended for quantitative comparisons</li> <li>Variants include CUT&amp;RUN and CUT&amp;Tag for lower input requirements</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenetic%20sequencing/#rna-modification-methods","title":"RNA Modification Methods","text":"<ul> <li>Small RNA-seq:</li> <li>Size selection critically important</li> <li>Adapter design affects capture efficiency</li> <li> <p>Special considerations for highly modified RNAs</p> </li> <li> <p>m6A-seq:</p> </li> <li>IP efficiency varies between experiments</li> <li>Single-base resolution variants available (miCLIP)</li> <li>Integration with RNA structure data enhances interpretation</li> </ul> <p>This integrated framework provides researchers with a comprehensive approach to epigenetic analysis, enabling the selection of appropriate technologies based on research questions, sample availability, and resource constraints. The complementary use of multiple methods strengthens findings by overcoming the limitations of individual approaches.</p>"},{"location":"MBE3/Yiru/MBE%20Epigenome%20Engineering%20Discussion/","title":"MBE Epigenome Engineering Discussion","text":""},{"location":"MBE3/Yiru/MBE%20Epigenome%20Engineering%20Discussion/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Epigenome engineering explores how specific epigenetic modifications affect gene expression and cellular function without altering DNA sequence. The experimental design directly tests this by using CRISPR-dCas9 fused to epigenetic enzymes to target precise genomic locations.</li> <li>Repeated Designs: Researchers often repeat similar designs to test different epigenetic modifiers (DNMT3A vs TET for methylation/demethylation), target different genomic regions, or study effects across different cell types to understand context-dependent regulation.</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenome%20Engineering%20Discussion/#2-model-system","title":"2. Model System","text":"<ul> <li>Current Systems: Commonly uses cell culture models (e.g., HEK293, iPSCs, cancer cell lines) which allow for efficient transfection of CRISPR components and controlled experimental conditions.</li> <li>Alternatives: Mouse models offer in vivo context but are more complex and expensive. Organoids provide 3D tissue-like environments but with increased variability. Drosophila or zebrafish can be used for developmental studies.</li> <li>Ethical Considerations: Cell line work has minimal ethical concerns, though patient-derived cells require proper consent. Animal models raise standard animal welfare considerations.</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenome%20Engineering%20Discussion/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques: Combines sequencing approaches (BS-seq, ChIP-seq, RNA-seq, ATAC-seq) providing quantitative measurements of epigenetic marks, chromatin accessibility, and gene expression changes.</li> <li>Method Selection: These methods offer genome-wide coverage and quantitative precision compared to alternatives like immunofluorescence or PCR-based approaches.</li> <li>Technical Replicates: Multiple sequencing reads per genomic region serve as technical replicates, with quality filters applied to ensure reliable signal detection.</li> <li>Potential Biases: Off-target binding of dCas9, variable transfection efficiency, and cell-cycle effects can introduce biases, minimized through proper controls and normalization.</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenome%20Engineering%20Discussion/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups: Typically includes dCas9-enzyme treated samples versus controls (untreated, dCas9-only without enzyme, or catalytically dead enzyme).</li> <li>Negative Controls: dCas9 without effector domains, non-targeting gRNAs, and catalytically inactive enzyme fusions serve as negative controls.</li> <li>Biological Replicates: 3-4 biological replicates are standard, generally sufficient for statistical power in controlled cell culture experiments.</li> <li>Modified Design: Adding time-course measurements would reveal dynamics and persistence of epigenetic modifications; testing combinatorial modifications would explore synergistic effects.</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Epigenome%20Engineering%20Discussion/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: Raw sequencing data undergoes quality filtering, alignment to reference genome, and normalization before quantifying epigenetic changes at target sites.</li> <li>Statistical Tests: Differential modification analysis uses tools like DESeq2 or edgeR, with multiple testing correction (FDR) to identify significant changes.</li> <li>Data Presentation: Results typically appear as genome browser tracks, heatmaps of modification patterns across targets, and correlation plots between epigenetic changes and gene expression.</li> <li>Validation Methods: Findings are confirmed through orthogonal techniques like targeted bisulfite sequencing, ChIP-qPCR, and functional assays (luciferase reporters, phenotypic readouts) to establish causal relationships.</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/","title":"MBE Gene editing","text":""},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How do specific genes or regulatory elements contribute to cellular function, development, and disease?</li> <li>Design Rationale: Gene editing and expression modulation technologies enable precise manipulation of the genome and gene expression to establish causality</li> <li>Follow-up Studies: Phenotypic analysis, mechanistic investigations, therapeutic applications, genetic interaction mapping</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, primary cells, organoids, model organisms, patient-derived cells</li> <li>Rationale: These systems allow genetic manipulation while maintaining relevant biological context for functional analysis</li> <li>Alternatives:</li> <li>In vitro biochemical systems (pros: mechanistic detail; cons: lack cellular context)</li> <li>Ex vivo tissue cultures (pros: tissue architecture; cons: limited viability)</li> <li>In vivo models (pros: physiological relevance; cons: delivery challenges, ethical considerations)</li> <li>Ethical Considerations: Off-target effects, germline editing concerns, animal welfare, consent for human cells</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>Validation of editing efficiency</li> <li>Off-target analysis</li> <li>Phenotypic readouts</li> <li>Molecular characterization</li> <li>Technical Replicates: Multiple transfection/transduction experiments, multiple edited clones</li> <li>Potential Biases:</li> <li>Delivery method efficiency</li> <li>Cell type-specific editing outcomes</li> <li>Clonal selection artifacts</li> <li>Off-target effects</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Cells/organisms with targeted genetic modification</li> <li>Control 1: Wild-type/unmodified cells</li> <li>Control 2: Mock-treated cells (transfection reagents only)</li> <li>Control 3: Non-targeting guide RNA or scrambled siRNA controls</li> <li>Controlled Variables: Cell passage number, transfection conditions, selection methods</li> <li>Biological Replicates: Minimum 3 independent editing experiments; multiple clones for stable modifications</li> <li>Modified Design: Multiplexed editing, inducible systems, combinatorial modifications</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Editing efficiency quantification</li> <li>Off-target analysis</li> <li>Expression level verification</li> <li>Phenotypic measurements</li> <li>Presentation Approaches:</li> <li>Sequencing traces showing edits</li> <li>Western blots/qPCR for expression changes</li> <li>Phenotypic assay results</li> <li>Off-target analysis plots</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#6-technique-comparison-genome-editing-methods","title":"6. Technique Comparison - Genome Editing Methods","text":"Feature Homologous Recombination ZFNs (Zinc Finger Nucleases) TALENs CRISPR-Cas9 Mechanism Endogenous DNA repair Engineered nuclease + DNA repair Engineered nuclease + DNA repair RNA-guided nuclease + DNA repair Design Complexity High (homology arms) Very high (protein engineering) High (protein assembly) Low (guide RNA design) Efficiency Very low (0.1-1%) Moderate (1-10%) Moderate (1-10%) High (1-90%, system-dependent) Specificity Very high High Very high Moderate to high (guide-dependent) Size of Edit Unlimited (replacement) Small to large Small to large Small to large Multiplexing Difficult Difficult Difficult Easy Time to Implement Months Months Weeks to months Days to weeks Cost High Very high High Low Best For \u2022 Precise gene replacement\u2022 Knock-in of large sequences\u2022 Clean modifications\u2022 ES cell modifications \u2022 Targeted gene disruption\u2022 Editing in specific contexts\u2022 When high specificity is critical\u2022 Historic datasets \u2022 Highly specific editing\u2022 Modification of methylated regions\u2022 Alternative to CRISPR\u2022 Reduced off-target concerns \u2022 Rapid genetic screening\u2022 Multiplexed editing\u2022 Versatile applications\u2022 Complex genetic manipulations Limitations \u2022 Extremely low efficiency\u2022 Labor intensive\u2022 Limited to dividing cells\u2022 Complex construct design \u2022 Difficult protein design\u2022 Limited targeting range\u2022 High cost\u2022 Technical expertise required \u2022 Complex assembly\u2022 Large protein size limits delivery\u2022 Time-consuming design\u2022 Lower efficiency than CRISPR \u2022 Off-target concerns\u2022 PAM site requirements\u2022 Delivery challenges for large Cas9\u2022 Immune responses in vivo"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#7-technique-comparison-expression-modulation-methods","title":"7. Technique Comparison - Expression Modulation Methods","text":"Feature RNAi CRISPRi CRISPRa Gene Overexpression Epigenome Engineering Mechanism mRNA degradation Transcriptional repression Transcriptional activation Increased gene dosage Modification of epigenetic marks Target mRNA DNA (promoters/enhancers) DNA (promoters/enhancers) Coding sequence DNA/histones Effect Level Post-transcriptional Transcriptional Transcriptional Post-transcriptional Transcriptional Duration Transient (siRNA)Stable (shRNA) Stable while expressed Stable while expressed Variable (transient to stable) Potentially heritable Completeness Partial knockdown Near-complete silencing possible Variable activation Controlled by promoter/enhancer Variable and context-dependent Specificity Moderate (off-targets) High (guide-dependent) High (guide-dependent) Very high (gene-specific) High (site-specific) Ease of Design Easy Easy Moderate Easy Moderate to complex Best For \u2022 Rapid gene inhibition\u2022 Transient effects\u2022 Dose-dependent studies\u2022 Non-coding RNAs \u2022 Gene silencing\u2022 Regulatory element analysis\u2022 Non-coding regions\u2022 Stable repression \u2022 Upregulating endogenous genes\u2022 Enhancer activation\u2022 Screening enhancers\u2022 Complex gene regulation \u2022 Rescue experiments\u2022 Protein function studies\u2022 Dominant effects\u2022 Dose-response analysis \u2022 Chromatin state manipulation\u2022 Imprinting studies\u2022 Heritable modifications\u2022 Regulatory element analysis Limitations \u2022 Incomplete knockdown\u2022 Off-target effects\u2022 Variable efficiency\u2022 Interferon responses \u2022 Requires continuous expression\u2022 Variable across genomic contexts\u2022 Limited to accessible regions\u2022 Delivery challenges \u2022 Context-dependent efficiency\u2022 Chromatin state dependent\u2022 Limited by endogenous potential\u2022 Delivery challenges \u2022 Non-physiological levels\u2022 Ectopic expression artifacts\u2022 Toxicity concerns\u2022 Delivery limitations \u2022 Context-dependent effects\u2022 Complex readouts\u2022 Variable stability\u2022 Technical complexity"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#8-complementary-usage-strategy","title":"8. Complementary Usage Strategy","text":"<ul> <li>Gene Function Analysis:</li> <li>Use CRISPR-Cas9 for complete gene knockout</li> <li>Apply RNAi for dose-dependent or transient knockdown</li> <li> <p>Implement gene overexpression for rescue experiments</p> </li> <li> <p>Regulatory Element Analysis:</p> </li> <li>Employ CRISPRi to silence specific regulatory elements</li> <li>Use CRISPRa to activate enhancers or promoters</li> <li> <p>Apply epigenome engineering to modify chromatin states</p> </li> <li> <p>Therapeutic Development:</p> </li> <li>CRISPR-Cas9 for correction of pathogenic mutations</li> <li>RNAi for targeting disease-causing gene products</li> <li> <p>Gene overexpression for replacement of deficient proteins</p> </li> <li> <p>Integrated Approach: Design multi-platform studies for comprehensive characterization:</p> </li> <li>CRISPR-Cas9 to generate complete knockouts for core phenotypic analysis</li> <li>RNAi for temporal or partial inhibition studies</li> <li>CRISPRi/a for regulatory element mapping</li> <li>Overexpression for structure-function and rescue studies</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#9-technology-specific-considerations","title":"9. Technology-Specific Considerations","text":""},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#crispr-cas9-system","title":"CRISPR-Cas9 System","text":"<ul> <li>Guide RNA Design:</li> <li>Optimize for on-target efficiency and minimal off-targets</li> <li>Consider chromatin accessibility at target site</li> <li> <p>Account for PAM requirements of specific Cas variants</p> </li> <li> <p>Delivery Methods:</p> </li> <li>Plasmid transfection (simple, transient)</li> <li>Viral vectors (efficient, stable integration)</li> <li> <p>RNP delivery (rapid, reduced off-targets)</p> </li> <li> <p>Variants and Adaptations:</p> </li> <li>Cas9 nickase for reduced off-targets</li> <li>High-fidelity Cas9 variants (SpCas9-HF1, eSpCas9)</li> <li>Cas12a/Cpf1 for alternative PAM requirements</li> <li>Base editors for precise nucleotide changes</li> <li>Prime editors for targeted insertions and deletions</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#rnai-technology","title":"RNAi Technology","text":"<ul> <li>Design Considerations:</li> <li>siRNA vs. shRNA selection based on duration needs</li> <li>Seed region optimization to reduce off-targets</li> <li> <p>Pooled vs. individual siRNAs</p> </li> <li> <p>Validation Approaches:</p> </li> <li>Multiple independent siRNAs targeting different regions</li> <li>Rescue experiments with RNAi-resistant constructs</li> <li>Dose-response analysis</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#crispri-and-crispra","title":"CRISPRi and CRISPRa","text":"<ul> <li>Component Selection:</li> <li>dCas9 fusion partners (KRAB, VP64, p65, HSF1)</li> <li>Guide RNA positioning relative to TSS</li> <li> <p>Single guides vs. multiple guides for synergistic effects</p> </li> <li> <p>Applications:</p> </li> <li>Tiling of regulatory regions to map functional elements</li> <li>Multiplexed activation/repression for pathway analysis</li> <li>Inducible systems for temporal control</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#gene-overexpression","title":"Gene Overexpression","text":"<ul> <li>Vector Selection:</li> <li>Viral (lentivirus, AAV, adenovirus) based on cell type</li> <li>Inducible promoters for controlled expression</li> <li> <p>Tagged constructs for tracking and purification</p> </li> <li> <p>Considerations:</p> </li> <li>Expression level optimization</li> <li>Codon optimization for efficient translation</li> <li>Subcellular targeting signals if needed</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20editing/#epigenome-engineering","title":"Epigenome Engineering","text":"<ul> <li>Effector Domains:</li> <li>DNA methyltransferases (DNMT3A, DNMT3B)</li> <li>Histone modifiers (p300, LSD1, EZH2)</li> <li> <p>Combinations for synergistic effects</p> </li> <li> <p>Target Selection:</p> </li> <li>CpG islands for DNA methylation</li> <li>Promoters vs. enhancers</li> <li>Boundary elements and insulators</li> </ul> <p>This comprehensive framework provides researchers with a structured approach to selecting and implementing gene editing and expression modulation technologies. The complementary use of these methods enables precise dissection of gene function and regulatory mechanisms in diverse biological contexts.</p>"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/","title":"MBE Gene expression analysis technologies","text":""},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How do gene expression patterns vary across conditions, cell types, or spatial locations within tissues?</li> <li>Design Rationale: Transcriptome analysis techniques reveal comprehensive gene expression profiles, alternative splicing events, and spatial distribution of transcripts</li> <li>Follow-up Studies: Functional validation of differentially expressed genes, pathway analysis, biomarker identification, therapeutic target discovery</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, tissue samples, patient biopsies, single-cell suspensions</li> <li>Rationale: These systems provide RNA of sufficient quality and quantity while maintaining biological relevance</li> <li>Alternatives:</li> <li>In vitro cell models (pros: controlled conditions, homogeneity; cons: may not reflect in vivo complexity)</li> <li>Animal models (pros: system-level responses; cons: species differences, ethical considerations)</li> <li>Organoids (pros: 3D structure, cell-cell interactions; cons: incomplete tissue architecture)</li> <li>Ethical Considerations: Patient consent for clinical samples, minimizing animal use, responsible data sharing and privacy</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>High-quality RNA extraction and preservation</li> <li>RNA integrity verification</li> <li>Library preparation optimization</li> <li>Inclusion of spike-in controls</li> <li>Technical Replicates: Multiple technical replicates for microarrays; sequencing depth considerations for RNA-seq approaches</li> <li>Potential Biases:</li> <li>RNA degradation (use RIN scores to assess quality)</li> <li>Batch effects (include batch controls)</li> <li>PCR amplification bias (UMIs for single-cell approaches)</li> <li>3' bias in degraded samples (assess coverage uniformity)</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples from experimental condition of interest</li> <li>Control 1: Matched untreated/baseline samples</li> <li>Control 2: Technical controls (spike-ins, housekeeping genes)</li> <li>Control 3: Biological reference standards when available</li> <li>Controlled Variables: RNA quality, batch processing, sequencing platform, analysis pipeline</li> <li>Biological Replicates: Minimum 3-5 biological replicates per condition; higher numbers for heterogeneous samples</li> <li>Modified Design: Time-course analysis, dose-response relationships, multiple tissue regions</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Quality control metrics (read depth, mapping rates, coverage)</li> <li>Normalization strategies appropriate to technique</li> <li>Differential expression analysis with statistical thresholds</li> <li>Pathway and functional enrichment analysis</li> <li>Presentation Approaches:</li> <li>Heatmaps for expression patterns</li> <li>Volcano plots for significance visualization</li> <li>PCA/t-SNE/UMAP for dimensionality reduction</li> <li>Spatial maps for regional expression patterns</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature Microarray RNA-seq Single-cell RNA-seq Long-read Sequencing Spatial Transcriptomics Primary Use Global gene expression profiling Comprehensive transcriptome analysis Cell-type specific expression patterns Full-length transcript analysis Spatial mapping of gene expression Sensitivity Moderate (limited dynamic range) High (wide dynamic range) Moderate (limited by dropout effects) Moderate (lower throughput) Moderate (depends on platform) Specificity Good for known transcripts Excellent for known and novel transcripts Good for abundant transcripts Excellent for isoform discrimination Good for targeted gene panels Quantification Relative abundance through hybridization Digital counts of transcript abundance Digital counts at single-cell resolution Accurate isoform quantification Regional expression quantification Throughput High (thousands of genes) Very high (entire transcriptome) High (thousands of cells) Moderate (fewer reads, longer lengths) Moderate (spatial resolution trade-off) Resolution Gene-level only Gene and transcript-level Single-cell Full transcript structure Tissue region/cell location Cost Low to moderate Moderate High High Very high RNA Input Required 50-500 ng 10-1000 ng Single-cell (pg range) 50-1000 ng Tissue sections Technical Expertise Moderate Moderate to advanced Advanced Advanced Very advanced Best For \u2022 Well-characterized systems\u2022 Large sample comparisons\u2022 Cost-effective screening\u2022 Established gene sets \u2022 Discovering novel transcripts\u2022 Detecting rare transcripts\u2022 Alternative splicing analysis\u2022 Comprehensive profiling \u2022 Heterogeneous samples\u2022 Rare cell type identification\u2022 Developmental trajectories\u2022 Cellular diversity studies \u2022 Isoform identification\u2022 Fusion transcript detection\u2022 Complex structural variants\u2022 Complete transcript sequences \u2022 Tissue architecture analysis\u2022 Cell-cell communication\u2022 Niche-specific expression\u2022 Disease boundary mapping Limitations \u2022 Limited to known sequences\u2022 Cross-hybridization issues\u2022 Narrow dynamic range\u2022 No novel transcript discovery \u2022 Complex data analysis\u2022 Computational requirements\u2022 Short-read assembly challenges\u2022 Batch effects \u2022 Low RNA capture efficiency\u2022 High dropout rates\u2022 Expensive per sample\u2022 Limited splicing information \u2022 Lower throughput\u2022 Higher error rates\u2022 More expensive\u2022 Specialized analysis required \u2022 Limited gene coverage\u2022 Resolution constraints\u2022 Expensive technology\u2022 Complex data integration"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Initial Profiling: Use microarrays for cost-effective screening of known genes across many samples</li> <li>Comprehensive Analysis: Follow with RNA-seq for in-depth transcriptome characterization including novel transcripts</li> <li>Heterogeneity Assessment: Apply single-cell RNA-seq to dissect cellular subpopulations and rare cell types</li> <li>Structural Validation: Employ long-read sequencing to resolve complex isoforms and structural variants</li> <li>Contextual Understanding: Integrate spatial transcriptomics to map expression patterns within tissue architecture</li> <li>Integrated Approach: Design multi-platform studies for comprehensive characterization:</li> <li>RNA-seq for global transcriptome profiling</li> <li>Single-cell RNA-seq to resolve cellular heterogeneity</li> <li>Long-read sequencing to characterize full-length transcripts of interest</li> <li>Spatial transcriptomics to map key findings to tissue context</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#8-technology-specific-considerations","title":"8. Technology-Specific Considerations","text":""},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#microarray","title":"Microarray","text":"<ul> <li>Design Optimization: Probe selection affects specificity and coverage</li> <li>Hybridization Conditions: Critical for signal-to-noise ratio</li> <li>Data Normalization: Essential for cross-array comparisons</li> <li>Legacy Data: Valuable historical datasets available for meta-analysis</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#rna-seq","title":"RNA-seq","text":"<ul> <li>Library Preparation: Stranded vs. unstranded, poly(A) selection vs. ribo-depletion</li> <li>Sequencing Depth: Tailored to research question (15-30M reads for differential expression)</li> <li>Read Length: Longer reads improve mapping and transcript assembly</li> <li>Spike-in Controls: Essential for absolute quantification</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#single-cell-rna-seq","title":"Single-cell RNA-seq","text":"<ul> <li>Cell Isolation: Dissociation protocols affect cell representation</li> <li>Droplet vs. Well-based: Trade-off between cell number and coverage depth</li> <li>Doublet Rate: Quality control to remove multi-cell captures</li> <li>Computational Deconvolution: Advanced algorithms for cell type identification</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#long-read-sequencing","title":"Long-read Sequencing","text":"<ul> <li>Platform Selection: PacBio (higher accuracy) vs. Oxford Nanopore (longer reads)</li> <li>Error Correction: Critical for accurate transcript annotation</li> <li>Hybrid Approaches: Combining with short-read data for error correction</li> <li>Direct RNA Sequencing: Captures native modifications but with lower throughput</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Gene%20expression%20analysis%20technologies/#spatial-transcriptomics","title":"Spatial Transcriptomics","text":"<ul> <li>Resolution Range: From tissue regions to subcellular localization</li> <li>Coverage vs. Resolution: Trade-off between gene number and spatial detail</li> <li>Image Integration: Correlating expression with histological features</li> <li>Cell Type Deconvolution: Computational methods to resolve mixed signals</li> </ul> <p>This integrated framework provides a comprehensive approach to transcriptome analysis, leveraging the strengths of each technology while addressing their individual limitations. The complementary use of these methods enables researchers to build a multi-dimensional understanding of gene expression across biological systems.</p>"},{"location":"MBE3/Yiru/MBE%20Protein%20assessment/","title":"MBE Protein assessment","text":"<ul> <li>\u8868\u8fbe\u5c42\u9762\uff1aWestern Blotting\uff08WB\uff09\u548c ELISA \u9002\u5408\u68c0\u6d4b\u86cb\u767d\u8d28\u4e30\u5ea6\u53d8\u5316\u6216\u7ffb\u8bd1\u540e\u4fee\u9970\uff08PTM\uff09\u3002</li> <li>\u76f8\u4e92\u4f5c\u7528\u5c42\u9762\uff1aCo-IP\u3001Pull-Down \u548c\u8d28\u8c31\uff08MS\uff09\u7528\u4e8e\u89e3\u6790\u86cb\u767d\u590d\u5408\u7269\u7ec4\u6210\u3002</li> <li>\u52a8\u6001\u5c42\u9762\uff1aFRET \u53ef\u5b9e\u65f6\u76d1\u6d4b\u6d3b\u7ec6\u80de\u4e2d\u86cb\u767d\u4e92\u4f5c\u7684\u65f6\u7a7a\u52a8\u6001\u3002</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein%20assessment/#_1","title":"\u6280\u672f\u4e92\u8865\u6027\u793a\u4f8b","text":"<ul> <li>WB \u2192 Co-IP \u2192 MS\uff1a     \u5148\u7528 WB \u786e\u8ba4\u86cb\u767d\u8868\u8fbe\u6c34\u5e73\uff0c\u518d\u901a\u8fc7 Co-IP \u5bcc\u96c6\u590d\u5408\u7269\uff0c\u6700\u540e\u7528 MS \u9274\u5b9a\u4e92\u4f5c\u86cb\u767d\u3002</li> <li>Pull-Down \u2192 FRET\uff1a     \u4f53\u5916\u9a8c\u8bc1\u76f4\u63a5\u4e92\u4f5c\u540e\uff0c\u7528 FRET \u5728\u6d3b\u7ec6\u80de\u4e2d\u9a8c\u8bc1\u52a8\u6001\u8fc7\u7a0b\u3002</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein%20assessment/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: Are specific proteins expressed, modified, or forming complexes under particular cellular conditions?</li> <li>Design Rationale: Protein analysis techniques enable detection, quantification, and characterization of protein-protein interactions critical for understanding cellular pathways</li> <li>Follow-up Studies: Functional validation of protein interactions, structure-function analysis, development of targeted interventions</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein%20assessment/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, tissue lysates, purified protein preparations</li> <li>Rationale: These systems provide sufficient protein yield while maintaining native conformations and interactions</li> <li>Alternatives:</li> <li>In vitro reconstituted systems (pros: defined components; cons: may lack cellular context)</li> <li>In vivo animal models (pros: physiological relevance; cons: complex background, ethical considerations)</li> <li>Patient samples (pros: clinical relevance; cons: limited availability, heterogeneity)</li> <li>Ethical Considerations: Responsible antibody production, ethical sourcing of biological materials, data reproducibility</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein%20assessment/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>Optimized protein extraction methods</li> <li>Appropriate buffer conditions to maintain native interactions</li> <li>Validated antibodies or detection reagents</li> <li>Inclusion of appropriate controls</li> <li>Technical Replicates: Minimum triplicate measurements for quantitative assessments</li> <li>Potential Biases:</li> <li>Antibody cross-reactivity (validate with knockouts/knockdowns)</li> <li>Extraction efficiency variations (standardize protocols)</li> <li>Artificial interactions during lysis (crosslinking strategies)</li> <li>Overexpression artifacts (use endogenous levels when possible)</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein%20assessment/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples from treatment conditions of interest</li> <li>Control 1: Untreated/baseline samples</li> <li>Control 2: Negative controls (non-specific antibodies, irrelevant proteins)</li> <li>Control 3: Positive controls (known interactors or expression levels)</li> <li>Controlled Variables: Protein concentration, lysis conditions, incubation times, detection parameters</li> <li>Biological Replicates: Minimum 3-5 independent experiments for statistical validity</li> <li>Modified Design: Include time-course analysis, dose-response relationships, or genetic perturbations</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein%20assessment/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Normalization to loading controls or reference proteins</li> <li>Statistical comparison between experimental conditions</li> <li>Quantification of band intensities or signal strength</li> <li>Correlation with functional outcomes</li> <li>Presentation Approaches:</li> <li>Representative blot/gel images with molecular weight markers</li> <li>Quantitative graphs with error bars</li> <li>Network diagrams for interaction studies</li> <li>Co-localization images for spatial information</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein%20assessment/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature Western Blotting Co-IP Pull-Down Assay Mass Spectrometry FRET ELISA Primary Use Protein detection and semi-quantification Endogenous protein-protein interactions Direct protein-protein binding Comprehensive protein identification and quantification Real-time protein interactions in living cells Sensitive protein quantification Sensitivity Moderate (nanogram range) Moderate (depends on antibody) Moderate (depends on bait affinity) High (picogram range) Moderate (requires sufficient fluorophore expression) Very high (picogram to femtogram range) Specificity Good, antibody-dependent Good, antibody-dependent Good, depends on bait purity Very good with proper controls Good for direct interactions (&lt;10nm) Excellent (sandwich format) Quantification Semi-quantitative Qualitative to semi-quantitative Qualitative to semi-quantitative Highly quantitative with proper controls Quantitative for interaction dynamics Highly quantitative Throughput Low to moderate Low Low High Low to moderate High Time Required 1-2 days 1-2 days 1-2 days 2-3 days (including analysis) Hours to days (construct preparation) Hours Cost Moderate Moderate Moderate High High (equipment) Moderate Equipment Gel apparatus, transfer system, imaging Basic lab equipment Basic lab equipment Mass spectrometer, LC system Specialized fluorescence microscope Plate reader Technical Expertise Moderate Moderate Moderate Advanced Advanced Basic to moderate Best For \u2022 Protein expression levels\u2022 Post-translational modifications\u2022 Confirming specific proteins\u2022 Relative comparison between conditions \u2022 Endogenous protein complexes\u2022 Verification of interactions\u2022 Identifying components of complexes\u2022 Native interaction conditions \u2022 Direct binding partners\u2022 Testing specific interactions\u2022 In vitro confirmation\u2022 Domain mapping \u2022 Unbiased interaction discovery\u2022 Comprehensive proteome analysis\u2022 PTM identification\u2022 Complex composition \u2022 Real-time interaction kinetics\u2022 Spatial localization of interactions\u2022 Conformational changes\u2022 Living cell studies \u2022 Precise protein quantification\u2022 Biomarker detection\u2022 High-throughput screening\u2022 Clinical samples Limitations \u2022 Limited quantification\u2022 Antibody availability\u2022 Single protein focus\u2022 Size limitations \u2022 Non-specific binding\u2022 Transient interactions may be missed\u2022 Requires good antibodies\u2022 Indirect interactions indistinguishable \u2022 Artificial conditions\u2022 Overexpression artifacts\u2022 May miss weak interactions\u2022 Limited to binary interactions \u2022 Expensive equipment\u2022 Complex data analysis\u2022 Sample preparation critical\u2022 Low abundance proteins challenging \u2022 Requires protein tagging\u2022 Background fluorescence\u2022 Limited to close interactions\u2022 Complex setup \u2022 Limited to soluble proteins\u2022 Antibody pair requirement\u2022 Limited structural information\u2022 No interaction details"},{"location":"MBE3/Yiru/MBE%20Protein%20assessment/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Expression Analysis: Begin with Western blotting to confirm protein expression and basic modifications</li> <li>Interaction Screening: Use Co-IP or pull-down assays to identify potential interacting partners</li> <li>Comprehensive Mapping: Apply mass spectrometry for unbiased identification of complex components</li> <li>Dynamic Analysis: Employ FRET to study real-time interaction kinetics in living cells</li> <li>Quantitative Assessment: Utilize ELISA for precise quantification of specific proteins</li> <li>Integrated Approach: Combine techniques for robust validation:</li> <li>Western blotting to confirm protein expression</li> <li>Co-IP to identify native protein complexes</li> <li>Pull-down to verify direct interactions</li> <li>Mass spectrometry to comprehensively map interaction networks</li> <li>FRET to validate interactions in living cells</li> <li>ELISA to precisely quantify changes in protein abundance</li> </ul> <p>This multi-technique strategy leverages the strengths of each method while compensating for individual limitations, providing a comprehensive understanding of protein interactions that is critical for elucidating cellular pathways and disease mechanisms.</p>"},{"location":"MBE3/Yiru/MBE%20Protein-DNA%20interaction/","title":"MBE Protein DNA interaction","text":""},{"location":"MBE3/Yiru/MBE%20Protein-DNA%20interaction/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: What are the genomic binding sites of transcription factor X, and how do these binding patterns change in response to condition Y?</li> <li>Design Rationale: Protein-DNA interaction techniques reveal where regulatory proteins bind across the genome, helping elucidate gene regulation mechanisms</li> <li>Follow-up Studies: Functional validation of binding sites, correlation with gene expression changes, investigation of co-factors and chromatin modifications</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein-DNA%20interaction/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cell lines expressing the transcription factor of interest, with and without exposure to condition Y</li> <li>Rationale: Cell lines provide controlled experimental conditions, consistent expression of the factor, and sufficient material for multiple analytical approaches</li> <li>Alternatives:</li> <li>Primary cells (pros: physiological relevance; cons: limited material, variability)</li> <li>Animal tissues (pros: in vivo context; cons: species differences)</li> <li>In vitro reconstituted systems (pros: defined components; cons: lacks chromatin context)</li> <li>Ethical Considerations: Cell line authentication, appropriate antibody validation, responsible data sharing</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein-DNA%20interaction/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>Protein expression verification</li> <li>Antibody validation</li> <li>Appropriate controls for each technique</li> <li>Consistent sample processing</li> <li>Technical Replicates: Duplicate or triplicate experiments for each condition</li> <li>Potential Biases:</li> <li>Antibody specificity (validate with knockout/knockdown)</li> <li>Crosslinking efficiency (optimize protocols)</li> <li>Fragmentation bias (control fragment size distribution)</li> <li>Sequencing depth variation (normalize appropriately)</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein-DNA%20interaction/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Cells expressing transcription factor X in condition Y</li> <li>Control 1: Cells expressing transcription factor X in baseline condition</li> <li>Control 2: Cells lacking transcription factor X (knockout/knockdown)</li> <li>Control 3: Technique-specific controls (IgG, input DNA, etc.)</li> <li>Controlled Variables: Cell density, treatment conditions, protein expression levels, sample processing</li> <li>Biological Replicates: Minimum 2-3 independent experiments</li> <li>Modified Design: Include time-course or dose-response elements to capture dynamic binding changes</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein-DNA%20interaction/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Peak/binding site identification</li> <li>Motif analysis</li> <li>Genomic feature annotation</li> <li>Comparison between conditions</li> <li>Presentation Approaches:</li> <li>Genome browser tracks</li> <li>Heatmaps of binding intensity</li> <li>Motif logos</li> <li>Venn diagrams of binding site overlap</li> </ul>"},{"location":"MBE3/Yiru/MBE%20Protein-DNA%20interaction/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature ChIP-seq Footprinting EMSA CUT&amp;RUN Primary Use Genome-wide mapping of protein binding sites High-resolution analysis of protein-DNA contacts Verification of direct protein-DNA interactions High-resolution mapping with minimal sample input Genomic Scale Genome-wide Limited regions Single locus Genome-wide Resolution 100-300 bp 1-10 bp ~20-30 bp 10-50 bp Required Sample High (millions of cells) Moderate (thousands to millions) Low (recombinant protein and oligos) Very low (hundreds to thousands of cells) Antibody Needed Yes No No (can use for supershifts) Yes In vivo Relevance High (captures native chromatin) Moderate to high Low (in vitro binding) High (native chromatin) Throughput High Low Low High Time Required 2-3 days 1-2 days 4-6 hours 1-2 days Technical Difficulty Moderate to high High Low to moderate Moderate Equipment Needs Sequencer, sonicator/fragmenter Sequencer or capillary electrophoresis Electrophoresis equipment Sequencer Best For \u2022 Global binding patterns\u2022 Discovering new targets\u2022 Comparative analysis across conditions\u2022 Integration with other genomic data \u2022 Precise binding site determination\u2022 Visualizing multiple factors at one locus\u2022 Determining occupancy levels\u2022 Characterizing binding dynamics \u2022 Confirming direct binding\u2022 Testing binding affinity\u2022 Evaluating sequence specificity\u2022 Identifying protein complexes (supershifts) \u2022 Rare cell types\u2022 Highly specific factor mapping\u2022 Low background profiling\u2022 High resolution binding maps Limitations \u2022 Antibody quality dependence\u2022 High cell number requirement\u2022 Crosslinking artifacts\u2022 Limited resolution \u2022 Limited to accessible regions\u2022 Labor intensive\u2022 Technically challenging\u2022 Limited throughput \u2022 In vitro conditions\u2022 Single locus at a time\u2022 Semi-quantitative\u2022 May not reflect chromatin context \u2022 Relatively new technique\u2022 Limited antibody compatibility\u2022 Specialized protocol optimization\u2022 Data analysis challenges"},{"location":"MBE3/Yiru/MBE%20Protein-DNA%20interaction/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":""},{"location":"MBE3/Yiru/MBE%20Protein-DNA%20interaction/#sequential-approach","title":"Sequential Approach","text":"<ol> <li>ChIP-seq for Global Discovery:</li> <li>Perform first to identify genome-wide binding patterns</li> <li>Reveals overall distribution (promoters, enhancers, etc.)</li> <li> <p>Identifies condition-specific binding changes</p> </li> <li> <p>CUT&amp;RUN for High-Resolution Validation:</p> </li> <li>Follow up on key regions with higher resolution</li> <li>Validate findings with lower cell numbers</li> <li> <p>Reduce background and increase signal-to-noise</p> </li> <li> <p>Footprinting for Base-Level Resolution:</p> </li> <li>Apply to critical regulatory regions</li> <li>Determine exact nucleotide contacts</li> <li> <p>Identify binding of multiple factors at regulatory hubs</p> </li> <li> <p>EMSA for Biochemical Validation:</p> </li> <li>Confirm direct binding to specific sequences</li> <li>Test affinity of variants or mutants</li> <li>Identify co-factor requirements</li> </ol>"},{"location":"MBE3/Yiru/MBE%20Protein-DNA%20interaction/#optimal-application-scenarios","title":"Optimal Application Scenarios","text":"<ul> <li>Novel Factor with Unknown Targets: Start with ChIP-seq for broad discovery</li> <li>Limited Sample Availability: Use CUT&amp;RUN as primary approach</li> <li>Complex Regulatory Region: Apply footprinting for detailed architecture</li> <li>Mutation Impact Assessment: Use EMSA to test sequence variants</li> <li>Comprehensive Analysis: Combine techniques for multi-level validation:</li> <li>ChIP-seq \u2192 identify binding regions</li> <li>CUT&amp;RUN \u2192 refine binding sites</li> <li>Footprinting \u2192 determine exact contacts</li> <li>EMSA \u2192 biochemically validate direct interactions</li> </ul> <p>This integrated approach leverages the strengths of each technique while compensating for individual limitations, providing comprehensive characterization of protein-DNA interactions from genome-wide patterns to specific base contacts.</p>"},{"location":"MBE3/Yiru/MBE%20RNA%20assessment/","title":"MBE RNA assessment","text":""},{"location":"MBE3/Yiru/MBE%20RNA%20assessment/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How does gene X expression change in response to condition Y, and what transcript variants are present?</li> <li>Design Rationale: RNA detection techniques allow quantification of expression levels and characterization of transcript structures in different conditions</li> <li>Follow-up Studies: Protein expression correlation, functional validation of transcript variants, mechanistic investigation of expression changes</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA%20assessment/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cell lines exposed to condition Y (e.g., drug treatment, stress, differentiation signal)</li> <li>Rationale: Cell lines provide controlled experimental conditions, reproducible responses, and sufficient RNA yield for multiple analytical approaches</li> <li>Alternatives:</li> <li>Patient tissues (pros: clinical relevance; cons: variability, limited availability)</li> <li>Animal models (pros: in vivo context; cons: species differences)</li> <li>Organoids (pros: 3D tissue architecture; cons: technical complexity)</li> <li>Ethical Considerations: Cell line authentication, appropriate handling of patient materials if used, responsible data sharing</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA%20assessment/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>High-quality RNA extraction with RNase inhibition</li> <li>DNase treatment to remove genomic contamination</li> <li>RNA integrity assessment (e.g., Bioanalyzer RIN scores)</li> <li>Reference gene selection for normalization</li> <li>Technical Replicates: Triplicate measurements for each sample and technique</li> <li>Potential Biases:</li> <li>RNA degradation (rapid processing, quality controls)</li> <li>Reverse transcription efficiency variation (consistent protocols)</li> <li>Amplification bias (optimize primer design)</li> <li>Batch effects (include inter-run calibrators)</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA%20assessment/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Cells exposed to condition Y (multiple timepoints)</li> <li>Control 1: Untreated cells (time-matched)</li> <li>Control 2: Positive controls (known expression changes)</li> <li>Control 3: No-template and no-RT controls</li> <li>Controlled Variables: RNA quantity, integrity metrics, reagent lots, treatment conditions</li> <li>Biological Replicates: Minimum 3-5 independent experiments</li> <li>Modified Design: Include dose-response or time-course elements to capture dynamic expression changes</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA%20assessment/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Quality control metrics</li> <li>Normalization to reference genes</li> <li>Statistical comparison between conditions</li> <li>Visualization of expression changes</li> <li>Presentation Approaches:</li> <li>Gel/blot images with size markers</li> <li>Amplification curves and threshold cycles</li> <li>Fold-change calculations with error bars</li> <li>Time-course or dose-response plots</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA%20assessment/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature RT-PCR Northern Blotting Primary Use Sensitive detection and semi-quantification of specific RNA transcripts Visualization and size determination of specific RNA transcripts Sensitivity Very high (can detect &lt;100 copies) Moderate (requires ~5-10 \u03bcg total RNA) Specificity Good, primer-dependent Excellent, especially for transcript size variants Quantification Semi-quantitative (endpoint PCR)Highly quantitative (real-time RT-qPCR) Semi-quantitative Transcript Size Info Limited (primer-dependent) Excellent (directly visualizes transcript size) Throughput High Low Time Required 3-5 hours 1-2 days Cost Low to moderate High Equipment PCR thermocycler (or qPCR instrument) Multiple specialized equipment Technical Expertise Basic to moderate Advanced RNA Input Required Low (ng range) High (\u03bcg range) Best For \u2022 Highly sensitive detection\u2022 High-throughput screening\u2022 Small sample amounts\u2022 Quantitative expression analysis (RT-qPCR)\u2022 Specific splice variant detection \u2022 Transcript size determination\u2022 Detection of novel transcript variants\u2022 Visualization of RNA processing\u2022 Confirming transcript integrity\u2022 Detecting multiple transcripts with one probe Limitations \u2022 Limited transcript size information\u2022 Cannot detect novel variants\u2022 Potential for genomic DNA contamination\u2022 Reverse transcription variability \u2022 Labor intensive\u2022 Low throughput\u2022 Requires large RNA amounts\u2022 Less sensitive\u2022 Potential RNA degradation during procedure"},{"location":"MBE3/Yiru/MBE%20RNA%20assessment/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Initial Expression Analysis: Use RT-PCR/RT-qPCR for sensitive, high-throughput screening of expression changes across many samples and conditions</li> <li>Transcript Validation: Follow with Northern blotting for critical genes to:</li> <li>Confirm actual transcript size</li> <li>Detect unexpected transcript variants</li> <li>Validate full-length mRNA integrity</li> <li> <p>Identify processing intermediates</p> </li> <li> <p>Integrated Approach:</p> </li> <li>RT-qPCR for rapid quantification across many samples and timepoints</li> <li>Northern blotting for detailed characterization of transcript structure for key findings</li> <li>Use Northern results to design improved RT-PCR primers for specific variants</li> <li>Follow up with specialized techniques (RNA-seq, 5'/3' RACE) based on initial findings</li> </ul> <p>This complementary approach leverages the sensitivity and throughput of RT-PCR with the structural information provided by Northern blotting, providing a more complete picture of gene expression changes than either technique alone.</p>"},{"location":"MBE3/Yiru/MBE%20RNA%20editing-based%20RNA-seq/","title":"MBE RNA editing based RNA seq","text":""},{"location":"MBE3/Yiru/MBE%20RNA%20editing-based%20RNA-seq/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: What are the direct RNA targets and precise binding sites of RNA-binding protein X in living cells?</li> <li>Design Rationale: Fusion of RNA-binding protein (RBP) to an RNA editing enzyme (APOBEC) creates a chimeric protein that marks RNA binding sites with C-to-U conversions, detectable by RNA-seq without crosslinking artifacts</li> <li>Follow-up Studies: Motif analysis of binding sites, functional validation of key targets, structural studies of RBP-RNA interactions, comparison with other RBP mapping techniques (CLIP-seq)</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA%20editing-based%20RNA-seq/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary System: Human cell line relevant to RBP function (e.g., neuronal cells for neuron-specific RBPs, cancer cells for cancer-relevant RBPs)</li> <li>Rationale: Cell lines provide controlled expression of the RBP-APOBEC fusion, high RNA yield, and consistent experimental conditions</li> <li>Alternatives:</li> <li>Primary cells (pros: physiological relevance; cons: transfection challenges, variability)</li> <li>Mouse models with inducible RBP-APOBEC (pros: in vivo context; cons: complex, expensive)</li> <li>In vitro transcribed RNAs (pros: defined sequences; cons: lacks cellular context)</li> <li>Ethical Considerations: Cell line authentication, appropriate biosafety practices, responsible use of genetic modification tools</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA%20editing-based%20RNA-seq/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Techniques:</li> <li>Doxycycline-inducible expression of RBP-APOBEC fusion</li> <li>RNA extraction with DNase treatment</li> <li>Strand-specific RNA-seq with high depth</li> <li>C-to-U editing site identification</li> <li>Technical Replicates: Duplicate RNA-seq libraries</li> <li>Potential Biases:</li> <li>Expression level variations of RBP-APOBEC (use inducible system with titrated expression)</li> <li>Off-target editing (include catalytically inactive APOBEC control)</li> <li>RNA degradation artifacts (optimize RNA extraction protocol)</li> <li>Sequence context preferences of APOBEC (account for in computational analysis)</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA%20editing-based%20RNA-seq/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Cells expressing RBP-APOBEC fusion</li> <li>Control 1: Cells expressing catalytically inactive APOBEC fusion (deaminase mutant)</li> <li>Control 2: Cells expressing APOBEC only (no RBP)</li> <li>Control 3: Cells expressing GFP-APOBEC (non-specific RNA binding)</li> <li>Control 4: Uninduced cells (baseline editing)</li> <li>Controlled Variables: Induction time, expression level, RNA quality, sequencing depth</li> <li>Biological Replicates: 3-4 independent inductions and RNA preparations</li> <li>Modified Design: Include time-course of induction to capture kinetics of editing, or RBP mutants with altered RNA-binding specificity</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA%20editing-based%20RNA-seq/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Data Processing: </li> <li>Read alignment to reference genome</li> <li>C-to-U conversion identification</li> <li>Background filtering using controls</li> <li>Peak calling to identify significant binding sites</li> <li>Motif discovery in binding regions</li> <li>Statistical Analysis:</li> <li>Statistical significance of editing sites above background</li> <li>Enrichment analysis for RNA types and cellular compartments</li> <li>Correlation with RBP expression levels</li> <li>Comparison with known binding motifs or CLIP-seq data</li> <li>Data Presentation:</li> <li>Genome browser tracks showing editing sites</li> <li>Metagene plots of binding distribution across transcript regions</li> <li>Motif logos for identified binding sequences</li> <li>Venn diagrams comparing targets with other datasets</li> <li>Functional enrichment maps of target RNAs</li> <li>Validation Methods:</li> <li>RT-qPCR validation of editing at selected sites</li> <li>CLIP-seq or RIP-seq for orthogonal validation</li> <li>Functional assays for key targets (e.g., minigene reporters)</li> <li>Mutagenesis of binding sites to confirm direct interaction</li> <li>RNA structure probing to assess structural context of binding</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA-seq/","title":"MBE RNA seq","text":""},{"location":"MBE3/Yiru/MBE%20RNA-seq/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How do gene expression patterns vary across conditions, cell types, or spatial locations within tissues?</li> <li>Design Rationale: Transcriptome analysis techniques reveal comprehensive gene expression profiles, alternative splicing events, and spatial distribution of transcripts</li> <li>Follow-up Studies: Functional validation of differentially expressed genes, pathway analysis, biomarker identification, therapeutic target discovery</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA-seq/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, tissue samples, patient biopsies, single-cell suspensions</li> <li>Rationale: These systems provide RNA of sufficient quality and quantity while maintaining biological relevance</li> <li>Alternatives:</li> <li>In vitro cell models (pros: controlled conditions, homogeneity; cons: may not reflect in vivo complexity)</li> <li>Animal models (pros: system-level responses; cons: species differences, ethical considerations)</li> <li>Organoids (pros: 3D structure, cell-cell interactions; cons: incomplete tissue architecture)</li> <li>Ethical Considerations: Patient consent for clinical samples, minimizing animal use, responsible data sharing and privacy</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA-seq/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>High-quality RNA extraction and preservation</li> <li>RNA integrity verification</li> <li>Library preparation optimization</li> <li>Inclusion of spike-in controls</li> <li>Technical Replicates: Multiple technical replicates for microarrays; sequencing depth considerations for RNA-seq approaches</li> <li>Potential Biases:</li> <li>RNA degradation (use RIN scores to assess quality)</li> <li>Batch effects (include batch controls)</li> <li>PCR amplification bias (UMIs for single-cell approaches)</li> <li>3' bias in degraded samples (assess coverage uniformity)</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA-seq/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples from experimental condition of interest</li> <li>Control 1: Matched untreated/baseline samples</li> <li>Control 2: Technical controls (spike-ins, housekeeping genes)</li> <li>Control 3: Biological reference standards when available</li> <li>Controlled Variables: RNA quality, batch processing, sequencing platform, analysis pipeline</li> <li>Biological Replicates: Minimum 3-5 biological replicates per condition; higher numbers for heterogeneous samples</li> <li>Modified Design: Time-course analysis, dose-response relationships, multiple tissue regions</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA-seq/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Quality control metrics (read depth, mapping rates, coverage)</li> <li>Normalization strategies appropriate to technique</li> <li>Differential expression analysis with statistical thresholds</li> <li>Pathway and functional enrichment analysis</li> <li>Presentation Approaches:</li> <li>Heatmaps for expression patterns</li> <li>Volcano plots for significance visualization</li> <li>PCA/t-SNE/UMAP for dimensionality reduction</li> <li>Spatial maps for regional expression patterns</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA-seq/#6-technique-comparison","title":"6. Technique Comparison","text":"Feature Microarray RNA-seq Single-cell RNA-seq Long-read Sequencing Spatial Transcriptomics Primary Use Global gene expression profiling Comprehensive transcriptome analysis Cell-type specific expression patterns Full-length transcript analysis Spatial mapping of gene expression Sensitivity Moderate (limited dynamic range) High (wide dynamic range) Moderate (limited by dropout effects) Moderate (lower throughput) Moderate (depends on platform) Specificity Good for known transcripts Excellent for known and novel transcripts Good for abundant transcripts Excellent for isoform discrimination Good for targeted gene panels Quantification Relative abundance through hybridization Digital counts of transcript abundance Digital counts at single-cell resolution Accurate isoform quantification Regional expression quantification Throughput High (thousands of genes) Very high (entire transcriptome) High (thousands of cells) Moderate (fewer reads, longer lengths) Moderate (spatial resolution trade-off) Resolution Gene-level only Gene and transcript-level Single-cell Full transcript structure Tissue region/cell location Cost Low to moderate Moderate High High Very high RNA Input Required 50-500 ng 10-1000 ng Single-cell (pg range) 50-1000 ng Tissue sections Technical Expertise Moderate Moderate to advanced Advanced Advanced Very advanced Best For \u2022 Well-characterized systems\u2022 Large sample comparisons\u2022 Cost-effective screening\u2022 Established gene sets \u2022 Discovering novel transcripts\u2022 Detecting rare transcripts\u2022 Alternative splicing analysis\u2022 Comprehensive profiling \u2022 Heterogeneous samples\u2022 Rare cell type identification\u2022 Developmental trajectories\u2022 Cellular diversity studies \u2022 Isoform identification\u2022 Fusion transcript detection\u2022 Complex structural variants\u2022 Complete transcript sequences \u2022 Tissue architecture analysis\u2022 Cell-cell communication\u2022 Niche-specific expression\u2022 Disease boundary mapping Limitations \u2022 Limited to known sequences\u2022 Cross-hybridization issues\u2022 Narrow dynamic range\u2022 No novel transcript discovery \u2022 Complex data analysis\u2022 Computational requirements\u2022 Short-read assembly challenges\u2022 Batch effects \u2022 Low RNA capture efficiency\u2022 High dropout rates\u2022 Expensive per sample\u2022 Limited splicing information \u2022 Lower throughput\u2022 Higher error rates\u2022 More expensive\u2022 Specialized analysis required \u2022 Limited gene coverage\u2022 Resolution constraints\u2022 Expensive technology\u2022 Complex data integration"},{"location":"MBE3/Yiru/MBE%20RNA-seq/#7-complementary-usage-strategy","title":"7. Complementary Usage Strategy","text":"<ul> <li>Initial Profiling: Use microarrays for cost-effective screening of known genes across many samples</li> <li>Comprehensive Analysis: Follow with RNA-seq for in-depth transcriptome characterization including novel transcripts</li> <li>Heterogeneity Assessment: Apply single-cell RNA-seq to dissect cellular subpopulations and rare cell types</li> <li>Structural Validation: Employ long-read sequencing to resolve complex isoforms and structural variants</li> <li>Contextual Understanding: Integrate spatial transcriptomics to map expression patterns within tissue architecture</li> <li>Integrated Approach: Design multi-platform studies for comprehensive characterization:</li> <li>RNA-seq for global transcriptome profiling</li> <li>Single-cell RNA-seq to resolve cellular heterogeneity</li> <li>Long-read sequencing to characterize full-length transcripts of interest</li> <li>Spatial transcriptomics to map key findings to tissue context</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA-seq/#8-technology-specific-considerations","title":"8. Technology-Specific Considerations","text":""},{"location":"MBE3/Yiru/MBE%20RNA-seq/#microarray","title":"Microarray","text":"<ul> <li>Design Optimization: Probe selection affects specificity and coverage</li> <li>Hybridization Conditions: Critical for signal-to-noise ratio</li> <li>Data Normalization: Essential for cross-array comparisons</li> <li>Legacy Data: Valuable historical datasets available for meta-analysis</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA-seq/#rna-seq","title":"RNA-seq","text":"<ul> <li>Library Preparation: Stranded vs. unstranded, poly(A) selection vs. ribo-depletion</li> <li>Sequencing Depth: Tailored to research question (15-30M reads for differential expression)</li> <li>Read Length: Longer reads improve mapping and transcript assembly</li> <li>Spike-in Controls: Essential for absolute quantification</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA-seq/#single-cell-rna-seq","title":"Single-cell RNA-seq","text":"<ul> <li>Cell Isolation: Dissociation protocols affect cell representation</li> <li>Droplet vs. Well-based: Trade-off between cell number and coverage depth</li> <li>Doublet Rate: Quality control to remove multi-cell captures</li> <li>Computational Deconvolution: Advanced algorithms for cell type identification</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA-seq/#long-read-sequencing","title":"Long-read Sequencing","text":"<ul> <li>Platform Selection: PacBio (higher accuracy) vs. Oxford Nanopore (longer reads)</li> <li>Error Correction: Critical for accurate transcript annotation</li> <li>Hybrid Approaches: Combining with short-read data for error correction</li> <li>Direct RNA Sequencing: Captures native modifications but with lower throughput</li> </ul>"},{"location":"MBE3/Yiru/MBE%20RNA-seq/#spatial-transcriptomics","title":"Spatial Transcriptomics","text":"<ul> <li>Resolution Range: From tissue regions to subcellular localization</li> <li>Coverage vs. Resolution: Trade-off between gene number and spatial detail</li> <li>Image Integration: Correlating expression with histological features</li> <li>Cell Type Deconvolution: Computational methods to resolve mixed signals</li> </ul> <p>This integrated framework provides a comprehensive approach to transcriptome analysis, leveraging the strengths of each technology while addressing their individual limitations. The complementary use of these methods enables researchers to build a multi-dimensional understanding of gene expression across biological systems.</p>"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/","title":"MBE mRNA visualization and analysis technologies","text":""},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#1-experimental-purpose","title":"1. Experimental Purpose","text":"<ul> <li>Scientific Question: How are mRNAs localized, transported, and regulated through interactions with proteins in cells and tissues?</li> <li>Design Rationale: RNA visualization and interaction analysis techniques reveal spatial distribution, dynamics, and protein-binding properties of transcripts</li> <li>Follow-up Studies: Functional validation of RNA localization patterns, characterization of RNA-protein regulatory networks, investigation of RNA transport mechanisms</li> </ul>"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#2-model-system","title":"2. Model System","text":"<ul> <li>Primary Systems: Cell lines, primary cells, tissue sections, organoids, model organisms</li> <li>Rationale: These systems allow observation of native RNA distribution and dynamics while providing sufficient material for biochemical analyses</li> <li>Alternatives:</li> <li>In vitro reconstituted systems (pros: defined components; cons: artificial context)</li> <li>Fixed vs. live specimens (trade-off between spatial resolution and dynamic information)</li> <li>Transgenic models (pros: tagged RNAs; cons: potential artifacts from tagging)</li> <li>Ethical Considerations: Minimal invasiveness for live imaging, fixation protocols, genetic manipulation considerations</li> </ul>"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#3-measurement-approach","title":"3. Measurement Approach","text":"<ul> <li>Common Elements:</li> <li>RNA preservation during sample preparation</li> <li>Probe/tag specificity validation</li> <li>Signal-to-noise optimization</li> <li>Appropriate controls for non-specific binding</li> <li>Technical Replicates: Multiple fields of view, technical replicates for biochemical methods</li> <li>Potential Biases:</li> <li>Probe accessibility in structured RNAs</li> <li>Fixation artifacts in FISH approaches</li> <li>Tag-induced alterations in RNA behavior</li> <li>Crosslinking efficiency variations in CLIP methods</li> </ul>"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#4-group-setting","title":"4. Group Setting","text":"<ul> <li>Experimental Groups:</li> <li>Test: Samples under experimental condition of interest</li> <li>Control 1: Untreated/baseline samples</li> <li>Control 2: Technical controls (non-specific probes, IgG controls for IP)</li> <li>Control 3: Competing or blocking controls to validate specificity</li> <li>Controlled Variables: Cell cycle stage, cell density, fixation conditions, imaging parameters</li> <li>Biological Replicates: Minimum 3 biological replicates; more for heterogeneous samples</li> <li>Modified Design: Time-course analysis, drug treatments, genetic perturbations</li> </ul>"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#5-data-analysis-presentation","title":"5. Data Analysis &amp; Presentation","text":"<ul> <li>Common Analysis Elements: </li> <li>Image segmentation and quantification</li> <li>Colocalization analysis</li> <li>Tracking of RNA movement in live cells</li> <li>Binding site identification and motif analysis</li> <li>Presentation Approaches:</li> <li>Representative images with scale bars</li> <li>Quantitative measurements of localization or binding</li> <li>Tracking plots for dynamic studies</li> <li>Genome browser tracks for binding site data</li> </ul>"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#6-technique-comparison-visualization-methods","title":"6. Technique Comparison - Visualization Methods","text":"Feature FISH Molecular Beacon MCP-MS2 System Molecular Dyes (HBC) Primary Application Fixed cell/tissue RNA localization Specific RNA detection Live cell RNA dynamics Live cell RNA tracking Detection Principle Hybridization with labeled probes Conformational change upon hybridization MS2 stem-loops bound by fluorescent MCP Fluorescence activation upon RNA binding Temporal Resolution Snapshot (fixed) Real-time possible Real-time Real-time Spatial Resolution High (20-200 nm with super-resolution) Moderate Moderate (diffraction-limited) Moderate to high Multiplexing Capability High (10-1000s with sequential FISH) Moderate (spectral limitations) Limited (few spectrally distinct FPs) Limited (spectral limitations) Single Molecule Detection Yes (smFISH) Yes Yes Variable Live Cell Compatibility No (fixed samples) Yes Yes Yes Sample Preparation Fixation, permeabilization Minimal (cell-permeable probes) Genetic engineering required Cell-permeable dyes Technical Complexity Moderate to high Moderate High (construct design) Moderate Best For \u2022 Precise spatial mapping\u2022 Tissue sections\u2022 Quantitative analysis\u2022 Multiple RNA targets \u2022 Rapid RNA detection\u2022 Homogeneous assays\u2022 Real-time monitoring\u2022 Specific sequence detection \u2022 RNA trafficking\u2022 Real-time dynamics\u2022 Long-term imaging\u2022 Single molecule tracking \u2022 Dynamic RNA tracking\u2022 No genetic modification\u2022 Global RNA visualization\u2022 Rapid implementation Limitations \u2022 Fixed samples only\u2022 Background fluorescence\u2022 Probe accessibility\u2022 Time-consuming protocol \u2022 Probe design complexity\u2022 Background issues\u2022 Limited to accessible regions\u2022 Signal strength \u2022 Requires genetic modification\u2022 Potential functional interference\u2022 Limited multiplexing\u2022 Tag size effects \u2022 Limited specificity\u2022 Variable binding properties\u2022 Potential toxicity\u2022 Off-target interactions"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#7-technique-comparison-rna-protein-interaction-methods","title":"7. Technique Comparison - RNA-Protein Interaction Methods","text":"Feature RIP CLIP RNA Editing-Based RNA-seq Primary Application RNA-protein interactions Precise protein binding sites RNA-protein interactions in vivo Detection Principle Immunoprecipitation of RNP complexes UV crosslinking and immunoprecipitation Detecting RNA editing events at protein binding sites Resolution Transcript-level Nucleotide-level Near nucleotide-level Crosslinking Optional (native RIP) Required (UV crosslinking) Not required (detects natural editing) Stringency Lower (potential for reassociation) Higher (covalent bonds) High (detects in vivo events) Input Material Moderate (millions of cells) High (millions of cells) Moderate to high Complexity Low to moderate High Very high Bioinformatic Analysis Moderate Complex Very complex Best For \u2022 Initial screening\u2022 Strong interactions\u2022 Global RNA partners\u2022 Simple implementation \u2022 Precise binding sites\u2022 Motif discovery\u2022 Direct interactions\u2022 Regulatory element mapping \u2022 Natural binding events\u2022 In vivo interactions\u2022 No crosslinking artifacts\u2022 Novel binding site discovery Limitations \u2022 Indirect binding detection\u2022 Reassociation artifacts\u2022 Lower resolution\u2022 Background binding \u2022 UV crosslinking bias\u2022 Complex protocol\u2022 High input requirements\u2022 Crosslinking efficiency \u2022 Limited to editing sites\u2022 Complex data analysis\u2022 Lower efficiency\u2022 Requires deep sequencing"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#8-complementary-usage-strategy","title":"8. Complementary Usage Strategy","text":"<ul> <li>Spatial Analysis:</li> <li>Use FISH for high-resolution mapping in fixed samples</li> <li>Apply molecular beacons for specific sequence detection</li> <li> <p>Implement MCP-MS2 or molecular dyes for live-cell dynamics</p> </li> <li> <p>Interaction Analysis:</p> </li> <li>Begin with RIP for global RNA partners of a protein</li> <li>Follow with CLIP for precise binding site mapping</li> <li> <p>Validate with RNA editing-based approaches for in vivo confirmation</p> </li> <li> <p>Combined Approaches:</p> </li> <li>Correlate localization patterns with binding protein distribution</li> <li>Link binding sites to functional outcomes in gene expression</li> <li> <p>Integrate with structural information for mechanistic insights</p> </li> <li> <p>Integrated Approach: Design multi-platform studies for comprehensive characterization:</p> </li> <li>FISH to map spatial distribution of target RNAs</li> <li>Live imaging (MCP-MS2 or dyes) to track dynamic behavior</li> <li>CLIP to identify protein binding sites on RNAs of interest</li> <li>Functional validation through perturbation of identified elements</li> </ul>"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#9-technology-specific-considerations","title":"9. Technology-Specific Considerations","text":""},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#fish-approaches","title":"FISH Approaches","text":"<ul> <li>Single Molecule FISH (smFISH):</li> <li>Multiple short probes for single transcript detection</li> <li>Quantitative analysis possible with spot counting</li> <li> <p>Super-resolution variants (STORM, STED) for nanoscale localization</p> </li> <li> <p>Multiplexed FISH:</p> </li> <li>Sequential hybridization for increased targets (seqFISH)</li> <li>Combinatorial labeling strategies (MERFISH)</li> <li>Expansion microscopy for improved resolution</li> </ul>"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#live-cell-rna-imaging","title":"Live Cell RNA Imaging","text":"<ul> <li>MCP-MS2 System:</li> <li>Requires genetic modification of target RNA</li> <li>MS2 stem-loops can affect RNA behavior</li> <li> <p>Enables long-term tracking of specific transcripts</p> </li> <li> <p>Molecular Dyes:</p> </li> <li>Various chemical structures with different properties</li> <li>Can target specific RNA features or global RNA</li> <li>Potential for photoactivation or photoswitching</li> </ul>"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#rna-protein-interaction-methods","title":"RNA-Protein Interaction Methods","text":"<ul> <li>RIP Variants:</li> <li>Native vs. crosslinked conditions</li> <li>RIP-Chip or RIP-Seq for genome-wide analysis</li> <li> <p>Tandem affinity purification for increased specificity</p> </li> <li> <p>CLIP Variants:</p> </li> <li>HITS-CLIP: High-throughput sequencing of CLIP</li> <li>PAR-CLIP: Photoactivatable ribonucleoside-enhanced CLIP</li> <li>iCLIP: Individual-nucleotide resolution CLIP</li> <li>eCLIP: Enhanced CLIP with improved efficiency</li> </ul>"},{"location":"MBE3/Yiru/MBE%20mRNA%20visualization%20and%20analysis%20technologies/#rna-editing-based-approaches","title":"RNA Editing-Based Approaches","text":"<ul> <li>Types of Editing:</li> <li>A-to-I editing most common (ADAR enzymes)</li> <li>C-to-U editing (APOBEC enzymes)</li> <li> <p>Requires careful analysis to distinguish from sequencing errors</p> </li> <li> <p>Analysis Considerations:</p> </li> <li>Comparison to genomic sequence essential</li> <li>Statistical models for identifying true editing events</li> <li>Integration with RNA structure prediction</li> </ul> <p>This comprehensive framework provides researchers with a structured approach to selecting and combining RNA visualization and interaction analysis techniques. The integration of spatial, temporal, and molecular information enables a deeper understanding of RNA biology in cellular contexts.</p>"},{"location":"MI2/","title":"MI2","text":""},{"location":"MI2/#contributors","title":"Contributors","text":"<ul> <li>Yue: PDF materials</li> </ul>"},{"location":"MI2/#files","title":"Files","text":"<ul> <li>Browse Yue PDFs: Yue/</li> </ul>"},{"location":"PoN3/","title":"PoN3","text":""},{"location":"PoN3/#contributors","title":"Contributors","text":"<ul> <li>Yiru: notes</li> <li>Yue: PDF materials</li> </ul>"},{"location":"PoN3/#files","title":"Files","text":"<ul> <li>Browse Yiru notes: Yiru/</li> <li>Browse Yue PDFs: Yue/</li> </ul>"},{"location":"PoN3/#external-links","title":"External links","text":"<ul> <li>Hal (2023-2024): https://drive.google.com/file/d/1DXCndsKcLVPyI3PtXEGB4igvw_cncc89/view?usp=sharing</li> </ul>"},{"location":"PoN3/Yiru/","title":"PoN3","text":"<p>Files and subfolders:</p> <ul> <li>1.1 Introduction and Refresh.md</li> <li>1.2 Presynaptic release.md</li> <li>10.1, 2 Neurodegenerative disease.md</li> <li>10.2 Neurodegeneration disease- Parkinson's disease and Prion disease.md</li> <li>12.1 Brain and spinal cord of movement control.md</li> <li>13.2 Social neuroscience- Theory of mid, empathy, mirror neurons and aggression.md</li> <li>2.1 Long- term plasticity.md</li> <li>2.2 Synaptic plasticity.md</li> <li>3.1 GABAergic inhibitory function.md</li> <li>3.2 Interneuron Diversity.md</li> <li>4.2 Learning and memory.md</li> <li>5.1 Attention and emotion.md</li> <li>6.1 Rewards, punishment, reinforcement learning.md</li> <li>6.2 Schemas and decision making.md</li> <li>7.1 Neuroimaging.md</li> <li>7.2 Mood, habits, and addiction.md</li> <li>final_exam/</li> </ul>"},{"location":"PoN3/Yiru/1.1%20Introduction%20and%20Refresh/","title":"1.1 Introduction and Refresh","text":""},{"location":"PoN3/Yiru/1.1%20Introduction%20and%20Refresh/#overview-of-basic-concepts","title":"Overview of basic concepts","text":"<ul> <li>Brain, complex system with $10^{11}$ neurons and $10^{14}$ synapses</li> <li> <p>Cellular components</p> <ul> <li>Neurons: information in/out</li> <li>Glia: structural and functional support to neurons</li> <li>Others, like blood vessels, immune cells</li> </ul> </li> <li> <p>structure of euron</p> <ul> <li>CEll membrane</li> <li>Cell body (soma)</li> <li>In Axon<ul> <li>Dendrite</li> <li>Node of Ranvier</li> <li>Myelin sheath</li> <li>Synaptic end bulds</li> <li>Axon terminal</li> <li>Oligodenfrocyte</li> </ul> </li> </ul> </li> <li>Resting Potential: due to $Na+$ and K+ balance<ul> <li>\u7406\u89e3\uff1a\u7ec6\u80de\u5916\u7684Na\u591a\uff0c\u7ec6\u80de\u5185\u7684K\u591a\uff0c\u53ef\u80fd\u51fa\u4e8e\u79bb\u5b50\u6570\u91cf\u7684\u539f\u56e0\uff0c\u901a\u5e38\u5bf9\u4e8eK\u5b58\u5728\u4e24\u4e2a\u529b\uff1aElectronic gradient and Chemical gradient. Chemical gradient will equal to Electronic gradient under resting balance: CG give K a force point into cell, and EG give K a force point into out. (\u5916\u6b63\u5185\u8d1f\uff0c\u5438\u5f15K\u5f80\u7ec6\u80de\u5916)</li> <li>\u901a\u5e38\uff0cresting potential\u662f-70mv\u3002\u6211\u4eec\u79f0\u8fd9\u6837\u5185\u5916\u7535\u538b\u4e0d\u5e73\u8861\u7684\u72b6\u6001\u7684\u7ec6\u80de\u4e3aelectrically polarized</li> </ul> </li> <li>Action Potentials: send electroinc<ul> <li>\u5f53\u7535\u538b\u5dee\u8fbe\u5230threshold potential, \u5c31\u4f1a\u5f15\u8d77:depolarize</li> <li>\u8fd9\u4e2a\u8fc7\u7a0b\u901a\u5e38\u662f\u7531\u4e8e\u6536\u5230\u5916\u754c\u523a\u6fc0\uff0c\u6bd4\u5982\u76f8\u90bb\u7684\u7535\u4f4d\u53d8\u5316\uff0c\u7a81\u89e6\u63a5\u53d7\u5230\u4e86\u5316\u5b66\u53d7\u4f53</li> <li>\u603b\u4e4b\uff0c\u7535\u4f4d\u5dee\u9010\u6e10\u4ece\u5185\u8d1f\u5916\u6b63\u53d8\u6210\u5185\u8d1f\u5916\u6b63\uff08voltage-gated sodium channels\u6253\u5f00\uff09\uff0c\u4e5f\u5373\u662fdepolarization;\u7136\u540e\uff0c\u53c8\u4ece\u5185\u8d1f\u5916\u6b63\u9010\u6e10\u53d8\u6210\u5185\u6b63\u5916\u8d1f\uff08voltage-gted potassium channels\u6253\u5f00\uff09,\u5373\u662frepolarization and hyperpolarization phase</li> </ul> </li> <li>Saltatory conduction<ul> <li>action potential propagated through its axon</li> <li>Propagated doesn\u2019t decrease or affect the quality of action potential</li> <li>\u52a8\u4f5c\u7535\u4f4d\u672c\u8eab\u4e0d\u4f1a\u79fb\u52a8\uff0c\u800c\u662f\u5f15\u53d1\u4e0b\u4e00\u4e2a\u795e\u7ecf\u5143\u819c\u90e8\u5206\u7684\u52a8\u4f5c\u7535\u4f4d</li> <li>\u7531\u4e8e\u524d\u4e00\u4e2a\u795e\u7ecf\u819c\u5904\u7684refactory period \uff0c\u52a8\u4f5c\u7535\u4f4d\u53ea\u80fd\u5411\u524d\u4f20\u64ad</li> <li>jumping information</li> </ul> </li> <li> <p>Neuronal communication</p> <ul> <li>Synapse: a structure allowing a neuron to pass an electrical or chemical signal to a target cell<ul> <li>Electrical <ul> <li>between groups of neurons that need to be synchronized</li> </ul> </li> <li> <p>Chemical</p> <ul> <li>Neurons separated by a cleft</li> <li> <p>slower response but more modifiable</p> </li> <li> <p>Neurontransmitters</p> <ul> <li>Monoamines<ul> <li>Dopamine</li> <li>Serotonin</li> <li>Can be stimulatory or inhibitory</li> </ul> </li> <li>Neuropeptides<ul> <li>AVP, GHRH, GnRH</li> </ul> </li> <li>Purines<ul> <li>Act through purinergic receptors</li> </ul> </li> <li>Gas<ul> <li>NO, hydrogen sulfite, Carbon monoxide</li> <li>Fast acting, can also modifying proteins</li> </ul> </li> <li>Aminoacids<ul> <li>MOst common neurotransmitters: Glu and GABA</li> <li>GABA for inhibitory<ul> <li>cause inhibitory postsynaptic potential (IPSP)<ul> <li>\u8fd9\u662f\u56e0\u4e3a\u5f00\u653e\u4e86Cl- channel\u2014&gt; cause the more negative potential, making it harder to be activated </li> </ul> </li> </ul> </li> <li>Glumate for excitatoy<ul> <li>Glumate recepotros: NMDA-R and AMPA-R, related to ligand-gated ion channels</li> <li>G-protein coupled receptors</li> <li>The receptor will make excitatory postsynaptic potential<ul> <li>\u5f00\u653e\u94a0\u94be\u901a\u9053\uff1b\u4f1a\u4f7f\u5f97\u7ec6\u80de\u7535\u4f4d\u66f4\u52a0\u63a5\u8fd1resting potential, making it more likely to be activated</li> </ul> </li> </ul> </li> <li>Summation<ul> <li>Multiple EPSP lead to summed depolarisation and action potential firing</li> <li>IPSP can counteract EPSP summation and prevent action potential firing</li> </ul> </li> <li>Glycine is generally inhibitory</li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li> <p>Glia: 50% of the cells in the brain</p> <ul> <li>Derived from same progenitors as neurons</li> <li></li> <li>Multiple types<ul> <li>Microglia: immune cells, protect it against injury and disease</li> <li>Macroglia<ul> <li>Astrocytes: \u661f\u5f62\u80f6\u8d28\u7ec6\u80de\u3002</li> <li>Maintain the environment around synapses</li> <li>Modulate neurons communication</li> </ul> </li> <li>Oligodendrocytes<ul> <li>Produce fatty substance called myelin, become myelin sheath</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/1.2%20Presynaptic%20release/","title":"1.2 Presynaptic release","text":""},{"location":"PoN3/Yiru/1.2%20Presynaptic%20release/#synaptic-strength","title":"Synaptic strength","text":"<ul> <li>Amplitude = n x p x a<ul> <li>n = number of release sites<ul> <li>number of terminals or release sites</li> </ul> </li> <li>a = quantal amplitude<ul> <li>\u662f\u5355\u4e2avesicle\u5bf9\u4e8e\u7a81\u89e6\u540e\u795e\u7ecf\u5143\u7684\u5f71\u54cd</li> </ul> </li> <li>p = probability of release<ul> <li>determined by $Ca^{2+}$ and proportion of synapses with docked vesicles\uff1b\u5747\u662f\u6b63\u6bd4\u5173\u7cfb<ul> <li>\u4ec0\u4e48\u662fdocked vesicle: near the membrane of presynaptic, ready to fuse and release</li> </ul> </li> </ul> </li> </ul> </li> <li>Paired Pulse Ratios<ul> <li>\u5177\u4f53\u5b9a\u4e49\u662f\u7b2c\u4e8c\u4e2a\u8109\u51b2\u5f15\u8d77\u7684postsynaptic reponse \u548c\u7b2c\u4e00\u4e2a\u5f15\u8d77\u7684\u7684\u6bd4\u503c</li> <li>\u56e0\u4e3ano change in number of release sites, and no change i quantal amplitude, so PPR can be used to calculate the change in release probability<ul> <li>Paired-pulse depression<ul> <li>\u7b2c\u4e00\u6b21\u5267\u70c8\uff0cvesicle\u51cf\u5c11\uff0c\u7b2c\u4e8c\u6b21\u91ca\u653e\u6982\u7387\u964d\u4f4e</li> <li>high initial release probability often leads to paried-pulse depression</li> </ul> </li> <li>Paired- pulse facilitation<ul> <li>Low initial release probability often leads to paried-pulse facilitation; increased $Ca^{2+}$ can cause facilitation</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/1.2%20Presynaptic%20release/#techniques-for-studying-short-term-plasticity","title":"Techniques for studying short-term plasticity","text":"<ul> <li>Short-term plasticity:\u77ed\u671f\u5185\u7a81\u89e6\u4f20\u9012\u6548\u7387\u7684\u53d8\u5316</li> </ul>"},{"location":"PoN3/Yiru/1.2%20Presynaptic%20release/#1-filed-recordings","title":"1. filed recordings","text":"<ul> <li>\u6d4b\u91cf\u7684\u662f\u4e00\u4e2a\u8303\u56f4\u5185\u7684\u7ec6\u80de\u7fa4\u4f53\u7684\u5e73\u5747\u7684activity\u548c\u7535\u538b\u53d8\u5316</li> <li>\u653e\u7f6e\u5728\u795e\u7ecf\u5143\u5468\u56f4</li> </ul>"},{"location":"PoN3/Yiru/1.2%20Presynaptic%20release/#2-patch-clamp-recording","title":"2. Patch clamp recording","text":"<ul> <li>\u603b\u7684\u5206\u4e3a\u4e24\u5927\u7c7b\uff0c\u6216\u8005\u8bf4\u6d4b\u91cf\u6a21\u5f0f\uff1aVoltage clamp and Current clamp<ul> <li>Voltage clamp:\u63a7\u5236\u819c\u7535\u4f4d\u5728\u4e00\u4e2a\u7279\u5b9a\u7684\u503c\uff0c\u8bb0\u5f55\u7ef4\u6301\u8fd9\u4e2a\u76ee\u6807\u7535\u538b\u6240\u6ce8\u5165\u7684\u7535\u6d41</li> <li>Current clamp: \u5411\u7814\u7a76\u5bf9\u8c61\u6ce8\u5165\u7cbe\u786ed\u7684\u7535\u6d41\uff0c\u4ece\u800c\u8bb0\u5f55\u7535\u538b\u7684\u53d8\u5316</li> </ul> </li> <li> <p>\u8fd9\u4e24\u4e2a\u6a21\u5f0f\u90fd\u6709\u4e0d\u540c\u7684\u6280\u672f</p> <ul> <li>cell-attached patch clamp recordings<ul> <li>\u53ea\u5c06clamp \u56fa\u5b9a\u5728\u7ec6\u80de\u819c\u5916\uff0c\u7136\u540e\u8fdb\u884c\u6d4b\u91cf</li> </ul> </li> <li>Whole-cell patch clamp recordings<ul> <li>\u7535\u6c60\u5185\u6db2\u548c\u80de\u5185\u6db2\u76f4\u63a5\u76f8\u901a\uff0c\u5b9e\u73b0\u5bf9\u4e8e\u6574\u4e2a\u7ec6\u80de\u819c\u4e0a\u6240\u6709\u79bb\u5b50\u901a\u9053\u7535\u6d3b\u52a8\u7684\u603b\u548c\u7684\u8bb0\u5f55</li> </ul> </li> <li>Paired recording: allow recording of synapses of known origin and action potential timing<ul> <li>\u540c\u65f6\u8868\u5f81\u4e24\u4e2a\u76f8\u5173\u8054\u7684\u795e\u7ecf\u5143</li> </ul> </li> </ul> </li> <li> <p>Time-course of short-term plasticity</p> <ul> <li>\u968f\u7740\u6b21\u6570\u548c\u65f6\u95f4\u589e\u52a0\uff0cfacilitation\u7684\u5f3a\u5ea6\u964d\u4f4e</li> </ul> </li> <li>Post-Tetanic potentiation<ul> <li>\u662f\u4e00\u79cdshort plasticity\u73b0\u8c61</li> <li>high frequency presynaptic firing leads to larger, longer-lasting potentiation also mediated by increased release</li> <li>\u5bfc\u81f4\u795e\u7ecf\u9012\u8d28\u7684\u4f20\u9012\u589e\u52a0\uff0c\u6301\u7eed\u4e00\u5c0f\u6bb5\u65f6\u95f4</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/1.2%20Presynaptic%20release/#presynaptic-modulation","title":"Presynaptic Modulation","text":"<ul> <li>Gi-linked GPCRs receptors, regulating by inhibiting synaptic vesicle fusion<ul> <li>GABA_B receptors and A1 adenosine receptors present at a high proportion of central presynaptic terminals </li> </ul> </li> <li>Presynaptic modulation can come from different sources, including:<ul> <li>Autoreceptors: receptors on the same presynaptic terminal that respond to the neurotransmitter, released by that same neuron<ul> <li>often related to paired-pulse depression</li> </ul> </li> <li>Heteroreceptors: respond to  neurontransmitters released by a different neuron; </li> <li>Circulating molecules: Hormones like adenosine can act on presynaptic receptors to regulate neurotransmitter release</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/1.2%20Presynaptic%20release/#measure-of-probability-of-release-p_r","title":"Measure of probability of release (P_r)","text":"<ul> <li>Conclude from paired pulse ratios<ul> <li>High initial release probability often leads to paired-pulse depression</li> <li>Low initial release probability often leads to paired-pulse facilitation</li> </ul> </li> <li>Coefficient of variation: determine if a change in synaptic strength is pre- or post- synaptic<ul> <li>Pre: affecting neurotransmitter release probability<ul> <li>Higher release probability --&gt; less variability, lower CV</li> <li>Lower release probability --&gt; more variability, higher CV</li> </ul> </li> <li>Post: if synaptic strength changes due to modifications in postsynaptic receptors, the variability in response amplitude remains relatively stable</li> </ul> </li> <li>2-Photon Glutamate Uncaging:<ul> <li>\u7cbe\u786e\u63a7\u5236Glutamate\u7684\u91ca\u653e\u65f6\u95f4\u548c\u4f4d\u7f6e\u5c3a\u5ea6</li> <li>\u53ef\u4ee5\u9009\u62e9\u7279\u5b9a\u7684\u5355\u4e2a\u7a81\u89e6\u8fdb\u884cglutamate\u91ca\u653e\u800c\u4e0d\u4f1a\u5f71\u54cd\u5468\u56f4\u7684\u7a81\u89e6</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/10.1%2C%202%20Neurodegenerative%20disease/","title":"10.1, 2 Neurodegenerative disease","text":"<ul> <li>Neurodegenerative disease can cause different symptoms, due to the different region of degradation</li> </ul>"},{"location":"PoN3/Yiru/10.1%2C%202%20Neurodegenerative%20disease/#alzheimers-disease","title":"Alzheimer's disease","text":"<p>Alzheimer\u2019s disease (AD) is defined by brain deposition of numerous amyloid plaques and neurofibrillary tangles. - Mainly due to two type of disordered misfolded proteins     - Tau: neurofibrillary     - Amyloid plaques (Amyloid $\\beta, A\\beta$) - Symptoms:     - Memory loss     - Disorientation in time and space     - Difficulty in interpreting images and distances     - Poor judgement     - Lack of engagement at work and social activities     - Problems in oral and written expression     - Changes of humor and personality     - Also contains varaible clinical subtypes:         - Memory syndrome: typical AD         - Language syndrome: logogenic variant of AD         - Visual syndrome: Posterior variant of AD         - Frontal syndrome: frontal varaint of AD</p> <ul> <li> <p>Phases of amyloid-$\\beta$ deposition in AD</p> <ul> <li>no AD or non-AD dementia --&gt; pre_AD dementia --&gt; symptomatic AD</li> <li></li> </ul> </li> <li> <p>==Braak stages==</p> <ul> <li></li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/10.1%2C%202%20Neurodegenerative%20disease/#tau-microtubule-associated-protein","title":"Tau: microtubule-associated protein","text":"<ul> <li>there are six isoforms of tau </li> <li>The formation of tau neurofibrillary tangels<ul> <li></li> <li>Tau \u4e3b\u8981\u548c\u78f7\u9178\u5316\u6709\u5173\uff0c\u4f1a\u5bfc\u81f4microtubule\u7684\u805a\u96c6</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/10.1%2C%202%20Neurodegenerative%20disease/#ads-biomarkers","title":"AD's biomarkers","text":""},{"location":"PoN3/Yiru/10.1%2C%202%20Neurodegenerative%20disease/#1-pet-positron-emission","title":"1. PET: Positron emission","text":"<ul> <li> <p>PET is a non-invasive imaging tech </p> </li> <li> <p>using radioactive compounds that bind fibrillary A\u03b2 or tau.</p> </li> </ul>"},{"location":"PoN3/Yiru/10.1%2C%202%20Neurodegenerative%20disease/#2-cerebrospinal-fluid-csf-biomarkers","title":"2. Cerebrospinal Fluid (CSF) biomarkers","text":"<p>CSF is collected via lumbar puncture and provides direct insight into brain biochemistry:</p> <ul> <li>Amyloid-\u03b242: Decreases in CSF as it accumulates in brain plaques</li> <li>Total tau and phosphorylated tau: Increase with neuronal damage and tangle formation</li> <li>A\u03b242/A\u03b240 ratio: Improves diagnostic accuracy over A\u03b242 alone</li> <li>Neurofilament light chain (NfL): Indicates neuronal damage (though not specific to AD)</li> </ul>"},{"location":"PoN3/Yiru/10.1%2C%202%20Neurodegenerative%20disease/#3-blood-biomarkers","title":"3. Blood biomarkers","text":"<p>Recent advances have enabled less invasive blood tests:</p> <ul> <li>Plasma p-tau181 and p-tau217: Highly specific for AD pathology</li> <li>Plasma A\u03b242/A\u03b240 ratio: Correlates with brain amyloid burden</li> <li>Plasma NfL: Reflects neurodegeneration but isn't AD-specific</li> <li>GFAP (Glial Fibrillary Acidic Protein): Indicates astrocytic activation</li> </ul>"},{"location":"PoN3/Yiru/10.2%20Neurodegeneration%20disease-%20Parkinson%27s%20disease%20and%20Prion%20disease/","title":"10.2 Neurodegeneration disease  Parkinson's disease and Prion disease","text":""},{"location":"PoN3/Yiru/10.2%20Neurodegeneration%20disease-%20Parkinson%27s%20disease%20and%20Prion%20disease/#parkinsons-disease","title":"Parkinson's disease","text":"<ul> <li>Pd is the second most common neurodegenerative disease after AD<ul> <li>symptoms include shaking, rigidity, slowness, and difficulty with walking.</li> <li>Primaru cause<ul> <li>dopamine neurons death</li> </ul> </li> </ul> </li> <li> <p>Main feature: Lewy bodies, composed of $\\alpha-$ synuclein</p> </li> <li> <p>Two groups of PD patients:</p> <ul> <li>Body-first PD<ul> <li>derived from enteric nervous system</li> <li>more systemetical</li> </ul> </li> <li>Brain-first PD<ul> <li>derived from brain directly </li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/10.2%20Neurodegeneration%20disease-%20Parkinson%27s%20disease%20and%20Prion%20disease/#ascending-pathological-process","title":"Ascending pathological process","text":"<ul> <li>The progress direction of brain in PD is from down to up</li> <li> </li> <li> <p>Mitochodrial dysfunction is central to the pathogenesis of Parkinson's disease</p> </li> </ul>"},{"location":"PoN3/Yiru/10.2%20Neurodegeneration%20disease-%20Parkinson%27s%20disease%20and%20Prion%20disease/#parkinsons-disease-treatment","title":"Parkinson's disease Treatment","text":"<ul> <li>L-dopa<ul> <li>Because loss of dopamine neurons--&gt; decline in dopamine release --&gt; PD</li> <li>So a kind of treatment is to deliver L-dopa (can cross BBB; can convert to dopamine)</li> </ul> </li> <li>Deep brain stimulation(DBS)<ul> <li>Using electrodes: stimulate neurons and axons in specific nuclei</li> <li>DBS is designed to compensate for the alteration of the basal ganglia circuit dynamics in PD</li> </ul> </li> <li>Cell-replacement therapy<ul> <li>Dopamine neurons: transplanted into the host stratum and release dopamine</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/10.2%20Neurodegeneration%20disease-%20Parkinson%27s%20disease%20and%20Prion%20disease/#prion-disease","title":"Prion disease","text":"<ul> <li> <p>called mad cow disease</p> <ul> <li>can cause animal's and human's disease</li> </ul> </li> <li> <p>caused by propagation of protein-induced protein conformational change</p> </li> <li></li> </ul>"},{"location":"PoN3/Yiru/10.2%20Neurodegeneration%20disease-%20Parkinson%27s%20disease%20and%20Prion%20disease/#huntingtons-disease","title":"Huntington's disease","text":""},{"location":"PoN3/Yiru/10.2%20Neurodegeneration%20disease-%20Parkinson%27s%20disease%20and%20Prion%20disease/#-caused-by-poly-q-disease","title":"-  caused by poly-Q disease","text":""},{"location":"PoN3/Yiru/12.1%20Brain%20and%20spinal%20cord%20of%20movement%20control/","title":"12.1 Brain and spinal cord of movement control","text":""},{"location":"PoN3/Yiru/12.1%20Brain%20and%20spinal%20cord%20of%20movement%20control/#hierarchy-of-control-levels-in-central-motor-system","title":"Hierarchy of control levels in central motor system","text":"<ul> <li>The highest level: areas of neocortex and basal ganglia of the forebrain</li> <li>The middle level: represented by the motor cortex and cerebellum</li> <li>The lowest levels: represented by the brain stem and spinal cord </li> </ul>"},{"location":"PoN3/Yiru/12.1%20Brain%20and%20spinal%20cord%20of%20movement%20control/#movement-controlled-by-brain-and-spinal-cord","title":"Movement controlled by brain and spinal cord","text":"<ul> <li>Key components for arm movement<ul> <li>the joints</li> <li>skeletal muscles</li> <li>nerves</li> </ul> </li> <li>Each muscle fiber is innervated by a single motor axon<ul> <li>organised by neuromuscular junction</li> <li>Each motor neuron may synapse with multiple muscle fibers </li> </ul> </li> <li> <p>Two types of neurons in motor control</p> <ul> <li>Lower motor neurons<ul> <li>the motor neurons whose cell bodies are located in the ==anterior horn of the spinal cord or brainstem cranial nerve nuclei==, and whose axons project to make connections with muscles at the neuromuscular junctions</li> </ul> </li> <li>Upper motor neurons<ul> <li>controlled by motor region of the cerebral cortex or in the brainstem and carry motor information down to the lower motor neurons</li> </ul> </li> </ul> </li> <li> <p>Motor unit and motor pool</p> <ul> <li>Alpha motor neurons <ul> <li>Directly trigger the generation of force by muscles</li> <li>One alpha motor neurons + all the muscle fibers --&gt; motor unit, elementary component of motor control</li> <li>==Motor neuron pool==: The collection of alpha motor neurons that innervates a single muscle</li> </ul> </li> <li>Gamma motor neurons<ul> <li>Intrafusal muscle fibers (\u68ad\u5185\u808c\u7ea4\u7ef4)</li> <li>The tension in intrafusal can control the sensitivity of muscle spindles</li> <li>independently targeted by descending pathways, thereby regulating muscle spindle sensitivity</li> </ul> </li> <li>Alpha-Gamma coactivation during voluntary movements<ul> <li>To ensure that the muscle spindles remain taut and can accurately detect changes in muscle length</li> </ul> </li> </ul> </li> <li> <p>Spindle can detect the changes in muscle length, which is a part of somatic sensory system and proprioception (how our body is positioned and moving in space)</p> </li> </ul>"},{"location":"PoN3/Yiru/12.1%20Brain%20and%20spinal%20cord%20of%20movement%20control/#myotatic-reflex-stretch-reflex","title":"Myotatic reflex (Stretch reflex)","text":"<ul> <li>the stretch reflex is a monosynaptic reflex <ul> <li>regulates muscle length, through neuronal stimulation at the muscle spindle</li> </ul> </li> <li>the knee-jerk reflex<ul> <li>tap the tendon beneath the kneecap --&gt; stretches the quadriceps muscle of your thigh --&gt; contracts and causes the leg to extend</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/12.1%20Brain%20and%20spinal%20cord%20of%20movement%20control/#flexor-and-extensors","title":"Flexor and extensors","text":"<ul> <li> <p>Flexor muscles:</p> <ul> <li>Decrease the angle between bones at a joint </li> <li>Biceps brachii(\u80b1\u4e8c\u5934\u808c): Flexes the elbow </li> </ul> </li> <li> <p>Extensor muscles: </p> <ul> <li>increase the angle between bones at a joint (straightening the elbow or knee)</li> </ul> </li> <li>Open arm --&gt; flexors relax and extensors contract</li> <li>Close arm --&gt; extensors relax and flexors contract</li> </ul>"},{"location":"PoN3/Yiru/12.1%20Brain%20and%20spinal%20cord%20of%20movement%20control/#reciprocal-inhibition","title":"Reciprocal inhibition","text":"<ul> <li>When you move a joint, two groups of muscles work together: agonists (the prime movers) and antagonists (the opposing muscles). For smooth movement, when one contracts, the other must relax.</li> <li>Inhibitory interneurons would prevent the contraction of antagonist muscle (flexor)</li> </ul>"},{"location":"PoN3/Yiru/12.1%20Brain%20and%20spinal%20cord%20of%20movement%20control/#withdrawal-reflex-flexor-reflex-and-crossed-extensor-reflex","title":"Withdrawal reflex (flexor reflex) and crossed-extensor reflex","text":"<ul> <li> <p>The withdrawal reflex (flexor reflex) is your body's immediate response to pain:</p> <ul> <li>\u7c7b\u4f3c\u4e8e\u6761\u4ef6\u53cd\u5c04</li> <li>Step on tack --&gt; pain fibers send signal to spinal cord</li> <li>--&gt; interneurons branch to different spinal cord segments</li> <li>--&gt; motor fibers in several segments are activaated </li> <li>--&gt; lift foot off to tack </li> </ul> </li> <li> <p>The crossed-extensor reflex works alongside the withdrawal reflex to maintain balance</p> <ul> <li>While one limb withdraws from pain, the opposite limb must support your body weight</li> <li>The same apin signal would triggers withdrawal crosses to the opposite side of spinal cord</li> <li>This prevents you from falling when you suddenly lift one foot</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/12.1%20Brain%20and%20spinal%20cord%20of%20movement%20control/#brian-mechanisms-in-controlling-motor-programs","title":"Brian mechanisms in controlling motor programs","text":""},{"location":"PoN3/Yiru/12.1%20Brain%20and%20spinal%20cord%20of%20movement%20control/#-","title":"-","text":"<p> - These tracts are organized in two major functional systems: 1. Pyramidal System\u00a0(Corticospinal tracts)     - Direct pathways from cortex to spinal motor neurons     - Responsible for voluntary, skilled movements     - Phylogenetically newer system     - Damage results in specific motor deficits 2. Extrapyramidal System\u00a0(Rubrospinal and Tectospinal tracts, among others)     - Indirect pathways involving subcortical nuclei     - Controls posture, muscle tone, and automatic movements     - Phylogenetically older system     - Provides background support for pyramidal system</p>"},{"location":"PoN3/Yiru/13.2%20Social%20neuroscience-%20Theory%20of%20mid%2C%20empathy%2C%20mirror%20neurons%20and%20aggression/","title":"13.2 Social neuroscience  Theory of mid, empathy, mirror neurons and aggression","text":""},{"location":"PoN3/Yiru/13.2%20Social%20neuroscience-%20Theory%20of%20mid%2C%20empathy%2C%20mirror%20neurons%20and%20aggression/#theory-of-mind","title":"Theory of mind","text":"<ul> <li>Awareness that other individuals have mental states that are different from our own</li> <li>Develops in humans around 4-5 years of age</li> </ul>"},{"location":"PoN3/Yiru/13.2%20Social%20neuroscience-%20Theory%20of%20mid%2C%20empathy%2C%20mirror%20neurons%20and%20aggression/#empathy","title":"Empathy","text":"<ul> <li>ability to share another person's feelings</li> <li>Types of empathy feeling<ul> <li>Personal distress<ul> <li>when witnessing someone's suffering causes your own discomfort</li> </ul> </li> <li>Sympathy<ul> <li>Can feel concern or sorrow for someone but don't about shared feeling like personal distress</li> </ul> </li> </ul> </li> <li>Cognitive empathy: knowing<ul> <li>understanding another person's perspective intellectually</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/13.2%20Social%20neuroscience-%20Theory%20of%20mid%2C%20empathy%2C%20mirror%20neurons%20and%20aggression/#aggression","title":"Aggression","text":"<ul> <li>Definition: behaviour aimed at harming or injuring another living being<ul> <li>Physical aggression</li> <li>Relational aggression</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/13.2%20Social%20neuroscience-%20Theory%20of%20mid%2C%20empathy%2C%20mirror%20neurons%20and%20aggression/#mirror-neurons","title":"Mirror neurons","text":"<ul> <li>Mirror neurons are specialized brain cells that activate both when you perform an action and when you observe someone else performing the same action.</li> <li>Activity in some brain areas in MRI study both if a participant experienced pain and if they saw a loved one experience pain</li> </ul> <p>Regarding human studies: - Most human \"mirror neuron\" research uses fMRI or EEG, which measure broader neural activity rather than individual neurons - We can't directly observe single neuron activity in humans the way researchers did with monkeys - What's often called \"mirror system activity\" in humans may involve various neural networks</p> <p>On explaining empathy: - Mirror neurons likely contribute to empathy but aren't sufficient to explain it - Empathy involves multiple processes including emotion regulation, perspective-taking, and contextual understanding - People with autism, sometimes characterized by empathy differences, don't consistently show mirror system deficits</p> <p>Methodological issues: - Correlational rather than causal evidence dominates the field - Difficult to isolate mirror neuron activity from other neural processes - Risk of reverse inference (assuming mental states from brain activation)</p> <p>Cause-and-effect questions:</p> <ul> <li>Does mirror neuron activity cause empathy, or might empathic tendencies enhance mirror system development?</li> <li>Individual differences in empathy can't be reduced to mirror neuron function alone</li> </ul> <p>The mirror neuron hypothesis for empathy represents an intriguing but oversimplified explanation for complex social-cognitive abilities that likely involve numerous brain systems working together.</p>"},{"location":"PoN3/Yiru/2.1%20Long-%20term%20plasticity/","title":"2.1 Long  term plasticity","text":""},{"location":"PoN3/Yiru/2.1%20Long-%20term%20plasticity/#learn-about-glutamate-transmitter-system","title":"Learn about glutamate transmitter system","text":"<ul> <li>Glutamate --&gt; get into vesicles --&gt;release - -&gt; retakes by Astrocyte </li> <li>NMDA: high calcium permeability </li> <li>Glutamate released from presynaptic neuron, bind to NMDA and AMPA<ul> <li>slight stimulation only activate AMPA receptor\uff0c $Na+$</li> <li>\u7531\u4e8e\u5728\u4f4e\u53bb\u6781\u5316\u7684\u60c5\u51b5\uff0cNMDA\u88abMg\u5835\u585e\uff0c\u56e0\u6b64EPSP\u7531AMPA\u4e3b\u5bfc</li> <li>\u5f53\u53d1\u751f\u66f4\u5927\u53bb\u6781\u5316\uff0cMg\u79bb\u5f00NMDA\uff0cNMDA\u53d1\u6325\u4f5c\u7528--&gt; \u5141\u8bb8$Na+$\uff0c$Ca^{2+}$ </li> <li>$Ca^{2+}$\u53d1\u6325\u4f5c\u7528\uff0c\u5f15\u53d1\u4e0b\u6587\u7684LTP</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/2.1%20Long-%20term%20plasticity/#ltp","title":"LTP","text":"<ul> <li>LTP: Long-term potentiation, \u957f\u65f6\u7a0b\u589e\u5f3a<ul> <li>\u5728\u7279\u5b9a\u7684\u795e\u7ecf\u56de\u8def\u4e2d\uff0c\u5f53\u7a81\u89e6\u524d\u795e\u7ecf\u5143\u6536\u5230\u77ed\u6682\u9ad8\u9891\u523a\u6fc0\u540e (like Tetanus)\uff0c\u7a81\u89e6\u4f20\u9012\u6548\u7387\u548c\u5f3a\u5ea6\u4f1a\u663e\u8457\u589e\u5f3a\uff0c\u5e76\u4e14\u8fd9\u79cd\u589e\u5f3a\u53ef\u4ee5\u6301\u7eed\u6570\u5c0f\u65f6\u751a\u81f3\u6570\u5929</li> </ul> </li> <li>LTP happens between: <ul> <li>Pre-synaptic CA3 schaefer collateral neurons</li> <li>Post-synaptic CA1 region of the hippocampus</li> </ul> </li> <li>LTP is synapse specific: \u5728\u540c\u4e00\u4e2a\u795e\u7ecf\u5143\u4e0a\uff0c\u67d0\u4e00\u4e2a\u7a81\u89e6\u7684LTP\u6fc0\u6d3b\u4e5f\u662f\u7279\u5f02\u6027\u7684</li> </ul>"},{"location":"PoN3/Yiru/2.1%20Long-%20term%20plasticity/#ltp-induction","title":"LTP induction","text":"<ul> <li>\u662f\u6307\u5f15\u53d1LTP\u521d\u59cb\u4fe1\u53f7\u7684\u7ea7\u8054\u53cd\u5e94\uff0c\u5305\u62ec</li> <li>Pre synaptic neuron release glutamate --&gt; </li> <li>AMPA receptor and NMDA receptor in Post-synaptic neuron --&gt; </li> <li>$Ca^{2+}$ influx through NMDARs-&gt; </li> <li>$Ca^{2+}$ binds to calmodulin and together they activate CaMKII triggering autophosphorylation and sustained activation-&gt; </li> <li> <p>CaMKII phosphorylates various targets leading to LTP</p> <ul> <li>through high-frequent potential summation, EPSP build up</li> <li>$Ca^{2+}$\u5f15\u53d1AMPA\u53d7\u4f53\u7684\u78f7\u9178\u5316\uff0c\u4ece\u800cAMPA\u53d7\u4f53\u63d2\u5165\u7a81\u89e6\u819c</li> <li>\u5bf9\u4e8eNMDAR\u901a\u5e38\u589e\u5f3a\u4e0d\u5927</li> </ul> </li> <li> <p>Silent Synapse\uff1a\u8fd9\u79cd\u7a81\u89e6\u57fa\u672c\u90fd\u662f\u53ea\u6709NMDAR\uff0c\u800c\u6ca1\u6709\u80fd\u591f\u5feb\u901f\u53cd\u5e94\u7684AMPAR</p> <ul> <li>\u5982\u679c\u7ed9\u4e88\u5f3a\u70c8\u7684\u53bb\u6781\u5316\uff0c\u80fd\u591f\u89e3\u9664NMDA\u53d7\u4f53\u4e0a\u7684\u9541\u79bb\u5b50\u963b\u65ad</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/2.1%20Long-%20term%20plasticity/#ltp-expression","title":"LTP expression","text":"<ul> <li>\u662f\u6307\u7ef4\u6301\u7a81\u51fa\u589e\u5f3a\u7684\u957f\u671f\u673a\u5236</li> <li>\u5b9e\u9a8c\u73b0\u8c61\uff1aPaired-pulse Ratio is unchanged\uff0cLTP\u5f62\u6210\u540e\uff0c\u77ed\u65f6\u95f4\u5185\u8fde\u7eed\u7ed9\u4e88\u4e24\u6b21\u523a\u6fc0\u65f6\u7b2c\u4e8c\u6b21\u53cd\u5e94\u4e0e\u7b2c\u4e00\u6b21\u53cd\u5e94\u7684\u6bd4\u503c\u4e0d\u53d8\uff1b\u56e0\u6b64LTP\u4e3b\u8981\u662f\u540e\u7a81\u89e6\u8868\u8fbe</li> </ul>"},{"location":"PoN3/Yiru/2.1%20Long-%20term%20plasticity/#ca2","title":"$Ca^{2+}$ \u7684\u4f5c\u7528","text":"<ul> <li>$Ca^{2+}$ \u5728\u7ec6\u80de\u5185\u626e\u6f14\u8005\u91cd\u8981\u7684\u4fe1\u53f7\u5206\u5b50\u89d2\u8272\uff0c$Ca^{2+}$\u8fdb\u5165\u7ec6\u80de\u540e\uff0c\u4f1a\u548c\u9499\u8c03\u86cb\u767dCaM\u7ed3\u5408\uff0c\u5f62\u6210$Ca^{2+}$/CaM\u590d\u5408\u7269</li> <li>Presynaptic glutamate release, \u7136\u540e$Ca^{2+}$ influx into NMDARs</li> <li>In CAMKII, Calcium-calmodulin-dependent kinase II , \u4e00\u4e2a\u6b8b\u57fa\u4f1a\u53d1\u751fautophosphorylation, \u4ece\u800c\u4ece\u5931\u6d3b\u72b6\u6001\u8f6c\u5411\u6d3b\u6027\u72b6\u6001,\u5e76\u4e14\u53ef\u4ee5\u957f\u671f\u4fdd\u6301\u81ea\u4f53\u6d3b\u6027</li> </ul>"},{"location":"PoN3/Yiru/2.1%20Long-%20term%20plasticity/#mossy-fibre-ltp","title":"Mossy Fibre LTP","text":"<ul> <li>\u548c\u7ecf\u5178\u7684CA1\u533aLTP\u6709\u6240\u533a\u522b<ul> <li>\u8bf1\u5bfc\u673a\u5236\u4e0d\u540c\uff1aMossy fibre LTP is NMDAR-independent<ul> <li>Induction via: presynaptic PKA, through release machinery</li> <li>\u4f9d\u8d56presynaptic $Ca^{2+}$ channel\u800c\u4e0d\u662fpost-synaptic $Ca^{2+}$ channel</li> <li></li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/2.2%20Synaptic%20plasticity/","title":"2.2 Synaptic plasticity","text":""},{"location":"PoN3/Yiru/2.2%20Synaptic%20plasticity/#spike-timing-dependent-plasticity-stdp","title":"Spike-timing dependent plasticity, STDP","text":"<ul> <li>\u63cf\u8ff0\u4e86\u795e\u7ecf\u5143\u4e4b\u95f4\u7684\u7a81\u89e6\u5f3a\u5ea6\u5982\u4f55\u6839\u636e\u524d\u540espike\u7684\u76f8\u5bf9\u65f6\u95f4\u800c\u6539\u53d8<ul> <li>pre-spike before post-spike--&gt; cause LTP</li> <li>post-spike before pre-spike --&gt; cause LTD</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/2.2%20Synaptic%20plasticity/#ltd","title":"LTD","text":"<ul> <li>Because of other stimulation other than presynaptic stimulation, the postsynaptic will be activated before pre synaptic --&gt;</li> <li>Low level of $Ca^{2+}$ will get into post synapse through NMDARs--&gt;</li> <li>cause activation of phosphatases, and removal of AMPARs, make it harder for later action potential</li> <li>\u6240\u4ee5\u8bf4\uff0c$Ca^{2+}$\u7684\u6d53\u5ea6\u4e0d\u540c\uff0c\u5bf9\u4e8e\u8bb0\u5fc6\u7684\u5f71\u54cd\u4e0d\u540c</li> </ul>"},{"location":"PoN3/Yiru/2.2%20Synaptic%20plasticity/#ltp","title":"LTP","text":"<ul> <li>does LTP = memory?<ul> <li>blocking LTP prevents learning</li> <li>Learning induces LTP</li> <li>Reversing LTP removes memories</li> <li>Inducing LTP produces memories</li> <li>So: LTP is very likely involved in memory formation though other processes also likely to contribute</li> </ul> </li> <li>induction of LTP --&gt; new spine and synapse formation</li> <li>experience may result in remapping</li> </ul>"},{"location":"PoN3/Yiru/2.2%20Synaptic%20plasticity/#plateau-potential","title":"Plateau potential","text":"<ul> <li>\u6301\u7eed\u65f6\u95f4\u6570\u767e\u6beb\u79d2\u5230\u79d2\u7ea7\u7684\u53bb\u6781\u5316\u72b6\u6001\uff0c\u7535\u4f4d\u76f8\u5bf9\u7a33\u5b9a\uff0c\u5448\u73b0\u51fa\u5e73\u53f0\u5316\u72b6\u6001\u3002</li> </ul>"},{"location":"PoN3/Yiru/3.1%20GABAergic%20inhibitory%20function/","title":"3.1 GABAergic inhibitory function","text":""},{"location":"PoN3/Yiru/3.1%20GABAergic%20inhibitory%20function/#gaba","title":"GABA","text":"<ul> <li>Glutamic Acid Decarboxylase, GAD \u662f\u4e00\u79cd\u91cd\u8981\u7684\u9176\uff0c\u50ac\u5316\u8c37\u6c28\u9178\u8f6c\u5316\u4e3aGABA</li> <li>GABA get into vesicle via GABA transporter, VGAT</li> <li>GABA released to clef</li> <li></li> <li>GABAergic Synapses\u7684\u5206\u5e03\uff1a<ul> <li>all excitatory synapses on spines</li> <li>but inhibitory synapses on spines, dendritic shafts and soma (even on axon)</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/3.1%20GABAergic%20inhibitory%20function/#gaba_a-receptor","title":"GABA_A receptor","text":"<ul> <li>\u51e0\u4e2a\u672c\u8bfe\u91cd\u8981\u7684\u79bb\u5b50\u901a\u9053<ul> <li>$Na+$-K+ ATPase\uff1a\u5c063\u4e2a$Na+$\u6cf5\u51fa\u7ec6\u80de\u5916\uff0c\u540c\u65f6\u5c062\u4e2aK+\u6cf5\u5165\u7ec6\u80de\u5185</li> <li>KCC2\uff1aK+-Cl+\u516c\u5141\u9898</li> <li>GABA_A Receptor</li> </ul> </li> <li>Concept of reversal potential:\u53cd\u8f6c\u7535\u4f4d\u662f\u6307\u79bb\u5b50\u901a\u9053\u5f00\u653e\u65f6\uff0c\u79bb\u5b50\u51c0\u6d41\u52a8\u65b9\u5411\u6539\u53d8\u7684\u819c\u7535\u4f4d\u503c<ul> <li>Three steps of reversal potential<ul> <li>Leaving: negative charge repels negative ions: more ions leave than enter</li> <li>Balance: negative charge balances the concentration gradient </li> <li>Entering: negative charge too small to overcome the concentration gradient</li> </ul> </li> </ul> </li> <li>Inhibitory postsynaptic potential (IPSP)<ul> <li>\u8868\u73b0\u4e3a\uff1ahyperpolarization </li> <li>\u901a\u8fc7voltage clamp \u6d4b\u91cf</li> </ul> </li> <li>Inhibitory postsynaptic current (IPSC)<ul> <li>GABA\u7b49\u6291\u5236\u6027\u795e\u7ecf\u9012\u8d28\u6fc0\u6d3bCl\u79bb\u5b50\u901a\u9053\u65f6\u5019\uff0c\u4ea7\u751f\u7684Cl\u5185\u6d41\u7535\u538b\u7b49</li> <li>Current clamp\u6d4b\u91cf</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/3.1%20GABAergic%20inhibitory%20function/#gaba_b-receptor","title":"GABA_B receptor","text":"<ul> <li>A kind of G_linked GCPRs</li> <li>can cause hyperpolarization, and slower IPSP than GABA_A</li> <li>the beta and gamma of GABA_B receptor can cause the open of inward rectifying potassium channel, and thus K+ move outwards</li> <li></li> </ul>"},{"location":"PoN3/Yiru/3.1%20GABAergic%20inhibitory%20function/#_1","title":"3.1 GABAergic inhibitory function","text":"<ul> <li>\u548cinhibition\u7c7b\u4f3c\uff0c\u4f46\u662f\u8868\u73b0\u5f62\u5f0f\u662f\u5206\u6d41\u7684\u5f62\u5f0f </li> <li>\u4ece\u76f4\u89c9\u4e0a\u6765\u8bf4\uff0cGABA\u7684\u5f00\u653e\u540c\u65f6\u4fc3\u8fdb\u4e86\u6b63\u7535\u8377\u5411\u5916</li> <li>When postsynaptic receptors area activated, membrane conductance increases</li> <li>This incraese in conductance reduces membrane resistance</li> <li>\u5206\u6d41\u6291\u5236\uff0c\u8868\u73b0\u4e3alocal drop in membrane resistance or membrane hyperpolarization</li> </ul>"},{"location":"PoN3/Yiru/3.1%20GABAergic%20inhibitory%20function/#model-of-gabaergic-neurons","title":"Model of GABAergic Neurons","text":"<ul> <li>Principal cells(black): main output of a brain area<ul> <li>including in striatum and cerebellum</li> </ul> </li> <li>Interneurons(red): connect between cells in the same area </li> </ul>"},{"location":"PoN3/Yiru/3.1%20GABAergic%20inhibitory%20function/#forms-of-inhibition","title":"Forms of inhibition","text":"<p> - Feedforward     - Information --&gt; inhibitory cell     - At the same time: information --&gt; postsynaptic targets     - soon: inhibitory cell --&gt; postsynaptic - Feedback     - Postsynaptic targets --&gt; inhibitory cell --&gt; postsynaptic targets     - \u8fd9\u6837\u7684\u6291\u5236\u6027\u795e\u7ecf\u5143\u6709\u5229\u4e8e\u9632\u6b62\u8fc7\u5ea6\u5174\u594b\uff0c\u7ef4\u6301\u7f51\u7edc\u7a33\u5b9a - Tonic inhibition     - \u6301\u7eed\u7684\u6291\u5236\uff0c\u8fd9\u79cd\u6291\u5236\u901a\u5e38\u901a\u8fc7\u7ec6\u80de\u5916GABA\uff08\u03b3-\u6c28\u57fa\u4e01\u9178\uff09\u4f5c\u7528\u4e8e\u9ad8\u4eb2\u548c\u529b\u7684extrasynaptic GABAA\u53d7\u4f53\u4e9a\u578b\u5b9e\u73b0 - Lateral inhibition     - \u540c\u4e00\u4e2apopulation\u4e2d\uff0c\u6d3b\u8dc3\u7684\u795e\u7ecf\u5143\u6291\u5236\u5176\u90bb\u8fd1\u795e\u7ecf\u5143\uff0c\u589e\u5f3a\u5bf9\u6bd4\u5ea6\u5e76\u63d0\u9ad8\u4fe1\u53f7\u7684\u7a7a\u95f4\u6216\u65f6\u95f4\u5206\u8fa8\u7387</p>"},{"location":"PoN3/Yiru/3.2%20Interneuron%20Diversity/","title":"3.2 Interneuron Diversity","text":"<ul> <li>Cell types of interneurons varies<ul> <li>Because like in hippocampus region of brain, have many kinds of interneurons, with different functions<ul> <li></li> </ul> </li> </ul> </li> <li> <p>Why we need inhibition?</p> <ul> <li> <p>\u63a7\u5236AP\u65f6\u95f4</p> <ul> <li>Feedforward inhibition: \u51cf\u5c11\u4e86excitatory time window     </li> </ul> </li> <li> <p>\u9632\u6b62\u8fc7\u5ea6\u5174\u594b\u5bfc\u81f4\u7684 Seizures</p> </li> <li>Reducing the impcat of specific excitatory inputs</li> <li>Disinhibition</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/3.2%20Interneuron%20Diversity/#where-should-the-inhibitory-synapses-be","title":"Where should the inhibitory synapses be","text":"<ul> <li>Synapses on dendrites: \u8c03\u8282\u5174\u594b\u6027\u8f93\u5165\u7684\u6574\u5408</li> <li>Synapses on distal dendritic tuftS</li> <li>Synapses on soma and proximal dendrites (basket cells)</li> </ul>"},{"location":"PoN3/Yiru/3.2%20Interneuron%20Diversity/#fast-spiking-cell","title":"Fast-Spiking cell","text":"<ul> <li>Fast-spiking \u7279\u6027\u4f7f\u5f97\u7ec6\u80de\u53ef\u4ee5\u9ad8\u6548\u7684\u4ea7\u751f\u9ad8\u9891\u52a8\u4f5c\u7535\u4f4d\uff1b\u8fd9\u4e9b\u7279\u6027\u548c\u7ec6\u80de\u7684\u751f\u7406\u529f\u80fd\u5bc6\u5207\u76f8\u5173</li> <li>Threshold Depolarisation: have lower AP threshold</li> <li>Faster Repolarisation: \u5feb\u901f\u653e\u7535\u7ec6\u80de\u7684repolarisation\u8fc7\u7a0b\u975e\u5e38\u5feb\uff0c\u8fd9\u4e3b\u8981\u5f52\u529f\u4e8ekV3.1,\u53ef\u4ee5\u8fc5\u901f\u5173\u95ed\u7684\u94be\u901a\u9053<ul> <li>\u56e0\u6b64\u8fd9\u80fd\u8ba9\u7ec6\u80de\u5728\u77ed\u65f6\u95f4\u5185\u6062\u590d\u5230\u9759\u606f\u7535\u4f4d\uff0c\u4ece\u800c\u80fd\u591f\u5feb\u901f\u5730\u518d\u6b21\u4ea7\u751f\u52a8\u4f5c\u7535\u4f4d</li> </ul> </li> <li>Intrinsic properties</li> <li></li> <li>\u8fd9\u4e9b\u7279\u6027\uff0c\u4f7f\u5f97\u5feb\u901f\u653e\u70b9\u7684interneuron \u53ef\u4ee5\u5feb\u901f\u8c03\u8282\u4e0b\u6e38\u795e\u7ecf\u5143</li> </ul>"},{"location":"PoN3/Yiru/3.2%20Interneuron%20Diversity/#preventing-runaway-excitation","title":"Preventing runaway excitation","text":"<ul> <li>\u91cd\u65b0\u7406\u89e3paied-pulse facilitation:<ul> <li>\u5f53initial relese probability low, the activation will increase the $Ca^{2+}$ , and channels, which will facilitate neurotransmitter release</li> </ul> </li> <li>Compare PV basket cell and CCk containing cell<ul> <li>parvalbumin basket cell \u662f\u5feb\u901f\u653e\u7535\u7684\u6291\u5236\u6027interneuron<ul> <li>\u4f9d\u8d56P/Q type calcium channel, which can accumulate $Ca^{2+}$ fast --&gt; increase the release of neurontransmitter</li> </ul> </li> <li>Cholecystokinin Containing cell<ul> <li>\u4e5f\u662f\u4e00\u7c7binterneuron\uff0c\u4f46\u662f\u4e3b\u8981\u662f\u4f4e\u9891\u523a\u6fc0\u4e0b\u53cd\u5e94\uff08\u6b63\u5e38\uff09</li> <li>\u5728\u9ad8\u9891\u523a\u6fc0\u4e0b\u91ca\u653e\u6982\u7387\u4f4e\uff08PPD\uff09</li> <li>Can cause asynchronous GABA release gives diffuse envelope of inhibition  PV\u9633\u6027\u7bee\u72b6\u7ec6\u80de\u548cCCK\u9633\u6027\u7ec6\u80de\u5728\u9632\u6b62\u795e\u7ecf\u5143\u8fc7\u5ea6\u5174\u594b\u4e2d\u53d1\u6325\u91cd\u8981\u4f5c\u7528\u3002PV\u9633\u6027\u7bee\u72b6\u7ec6\u80de\u901a\u8fc7\u5feb\u901f\u6291\u5236\u548c\u540c\u6b65\u5316\u673a\u5236\uff0c\u786e\u4fdd\u795e\u7ecf\u7f51\u7edc\u5728\u9ad8\u9891\u6d3b\u52a8\u671f\u95f4\u7684\u7a33\u5b9a\u6027\u3002CCK\u9633\u6027\u7ec6\u80de\u5219\u901a\u8fc7\u6301\u7eed\u6291\u5236\u548c\u5f02\u6b65\u5316\u673a\u5236\uff0c\u7ef4\u6301\u795e\u7ecf\u7f51\u7edc\u5728\u4f4e\u9891\u6d3b\u52a8\u671f\u95f4\u7684\u7a33\u5b9a\u6027\u3002\u8fd9\u79cd\u4e92\u8865\u673a\u5236\u786e\u4fdd\u4e86\u795e\u7ecf\u7f51\u7edc\u5728\u4e0d\u540c\u65f6\u95f4\u5c3a\u5ea6\u4e0a\u90fd\u80fd\u6709\u6548\u5730\u9632\u6b62\u8fc7\u5ea6\u5174\u594b\uff0c\u4ece\u800c\u7ef4\u6301\u795e\u7ecf\u6d3b\u52a8\u7684\u7a33\u5b9a\u6027\u548c\u7cbe\u786e\u6027</li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/3.2%20Interneuron%20Diversity/#disinhibition","title":"Disinhibition","text":"<ul> <li>Interneuron can stop other interneuron to inhibit principal cell</li> <li>Example:<ul> <li>M1 (motor cortex) will send activation to S1 (somatosensory)</li> <li>these activation will activate interneurons that have VIP</li> <li>VIP-containing interneurons will inhibit somatostatin</li> <li>\u6240\u4ee5\u8fd9\u91cc\u5f62\u6210\u4e86\u6291\u5236 \u6291\u5236\u795e\u7ecf\u5143\u7684\u8fc7\u7a0b</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/4.2%20Learning%20and%20memory/","title":"4.2 Learning and memory","text":""},{"location":"PoN3/Yiru/4.2%20Learning%20and%20memory/#hippocampus-and-entorhinal-cortex","title":"Hippocampus and entorhinal cortex","text":"<p> - In hippocampus     - CA1, CA2, CA3 region and DG</p>"},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/","title":"5.1 Attention and emotion","text":""},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/#attention","title":"Attention","text":"<ul> <li> <p>Dorsolateral prefrontal cortex in human: </p> <ul> <li>for attention; function and more in general high cognitive processes</li> </ul> </li> <li> <p>Attractor networks: labile (unstable) state to stable state</p> </li> <li>And this will cause the increased firing rates for the winning population and decreased firing rates for the losing populations</li> <li>\u4e5f\u5c31\u662f\u8bf4\uff0c\u6ce8\u610f\u529b\u9ad8\u7684\u5bf9\u8c61\u5bf9\u5e94\u7684\u533a\u57df\u4f1a\u6709\u76f8\u5bf9\u66f4\u9ad8\u7684firing rate</li> </ul>"},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/#neurotransmitters","title":"Neurotransmitters","text":"<ul> <li>Acetilcholine, Ach<ul> <li>Attention related: the cortically projecting cholinergic system, arising in the basal forebrain (BF)</li> </ul> </li> <li>Dopamine, DA<ul> <li>DA is strongly linked to reward signalling and the economic decision variable of utility</li> <li>supporting prefrontal spatial working memory signals</li> </ul> </li> <li>Noradrenaline, Na<ul> <li>NA system form locus coeruleus (a region)</li> <li>NA in PFC region (prefrontal cortex), involved in top-down control, like attention, working memory</li> <li>NA in sensory cortex, involved in bottom-up state control</li> </ul> </li> <li>Serotonin<ul> <li>the abnormal serotonin system related to many diseases </li> <li>\u5f3a\u8feb\u75c7\uff0c\u5e7f\u6cdb\u6027\u7126\u8651\u969c\u788d</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/#attention-deficit","title":"Attention deficit","text":"<ul> <li>Caused by inherited effects(mostly) and environment</li> <li>Treatment<ul> <li>MPH, increase the level of DA, NE in profrontal cortex</li> <li>LDX, increase the activity of DA</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/#brain-waves","title":"Brain waves","text":"<ol> <li>Delta\uff08\u03b4\uff0c0.5\u20133 Hz\uff09 \u72b6\u6001\uff1a\u6df1\u5ea6\u65e0\u68a6\u7761\u7720\u3001\u6df1\u5ea6\u653e\u677e\uff0c\u662f\u8eab\u4f53\u81ea\u7136\u7597\u6108\u3001\u52a0\u901f\u4fee\u590d\u7684\u72b6\u6001\uff0c\u4e5f\u7528\u4e8e\u7761\u7720\u969c\u788d\u6cbb\u7597\uff0c\u4ee3\u8868\u6700\u9ad8\u7ea7\u522b\u7684\u653e\u677e\u4e0e\u6062\u590d\u3002 \u7279\u70b9\uff1a\u9891\u7387\u6700\u4f4e\uff0c\u6ce2\u5e45\u6700\u9ad8\u3002</li> <li>Theta\uff08\u03b8\uff0c4\u20137 Hz\uff09 \u72b6\u6001\uff1a\u6df1\u5ea6\u653e\u677e\u3001\u51a5\u60f3\u3001\u5feb\u901f\u773c\u52a8\u7761\u7720\uff08REM\uff09\uff0c\u5173\u8054\u521b\u4f24\u4fee\u590d\u3001\u514b\u670d\u6210\u763e\uff0c\u5e38\u89c1\u4e8e\u767d\u65e5\u68a6\u3001\u5fc3\u7406\u610f\u8c61\uff0c\u5904\u4e8e\u534a\u6e05\u9192\u534a\u6f5c\u610f\u8bc6\u7684\u8fc7\u6e21\u72b6\u6001\u3002 \u7279\u70b9\uff1a\u4f34\u968f\u4e59\u9170\u80c6\u78b1\u5206\u6ccc\u589e\u52a0\uff0c\u6ce2\u5e45\u4e2d\u7b49\u3002</li> <li>Alpha\uff08\u03b1\uff0c8\u201312 Hz\uff09 \u72b6\u6001\uff1a\u653e\u677e\u7684\u5927\u8111\u72b6\u6001\uff0c\u6d89\u53ca\u88ab\u52a8\u6ce8\u610f\u529b\u3001\u521b\u9020\u529b\uff0c\u4e5f\u4e0e\u6e05\u9192\u5e73\u9759\u3001\u8f7b\u5ea6\u51a5\u60f3\u76f8\u5173\uff0c\u662f\u8fdb\u5165\u6f5c\u610f\u8bc6\u7684 \u201c\u9608\u503c\u72b6\u6001\u201d\u3002 \u7279\u70b9\uff1a\u4f34\u968f\u8840\u6e05\u7d20\u5206\u6ccc\u589e\u52a0\uff0c\u9891\u7387\u548c\u6ce2\u5e45\u8f83\u9ad8\u3002</li> <li>Beta\uff08\u03b2\uff0c13\u201330 Hz\uff09 \u72b6\u6001\uff1a\u6d3b\u8dc3\u5fd9\u788c\u7684\u601d\u7ef4\uff0c\u65e2\u53ef\u80fd\u5bf9\u5e94\u7126\u8651 / \u538b\u529b\uff0c\u4e5f\u662f\u6b63\u5e38\u601d\u8003\u3001\u89e3\u51b3\u95ee\u9898\u3001\u6e05\u9192\u8b66\u89c9\u7684\u72b6\u6001\uff0c\u4e0e\u4e13\u6ce8\u6ce8\u610f\u529b\u76f8\u5173\uff0c\u4eba\u7c7b\u591a\u6570\u65f6\u95f4\u5904\u4e8e\u6b64\u72b6\u6001\u3002 \u7279\u70b9\uff1a\u9891\u7387\u9ad8\uff0c\u6ce2\u5e45\u4f4e\u3002</li> <li>Gamma\uff08\u03b3\uff0c31\u2013120 Hz\uff09 \u72b6\u6001\uff1a\u5168\u8111\u534f\u540c\u6d3b\u52a8\uff0c\u4e0e\u9ad8\u6548\u5b66\u4e60\u3001\u95ee\u9898\u89e3\u51b3\u3001\u9ad8\u5ea6\u4e13\u6ce8\u76f8\u5173\uff0c\u8fd8\u6d89\u53ca\u611f\u5b98\u6574\u5408\uff08\u5982\u55c5\u89c9\u3001\u89c6\u89c9\u3001\u542c\u89c9\uff09\u3001\u8ba4\u77e5\u529f\u80fd\u53ca\u6781\u5ea6\u6e05\u9192\u3002 \u7279\u70b9\uff1a\u9891\u7387\u6700\u9ad8\uff0c\u6ce2\u5e45\u4f4e\u3002 </li> </ol>"},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/#limbic-system","title":"Limbic system","text":"<ul> <li>\u8fb9\u7f18\u7cfb\u7edf\uff1b\u8d1f\u8d23\u5904\u7406emotions, memory, homeostasis, motivations</li> <li> </li> <li> <p>\u8fd9\u4e2a\u7cfb\u7edf\u5305\u62ec\uff1a</p> <ul> <li>amygdala: fear and emotion center</li> <li>hypothalamic nuclei: involved in homeostasis, like hunger, satiety, thermoregulation, and sleep onset</li> <li>olfactory</li> <li>Septal nuclei: \u53c2\u4e0e\u60c5\u7eea </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/#more-about-amygdala","title":"More about amygdala","text":""},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/#summary-of-amygdala-knowledge","title":"Summary of Amygdala Knowledge","text":""},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/#1-core-functions","title":"1. Core Functions","text":"<ul> <li>Emotion &amp; Behavior Regulation: Regulates anxiety, aggression, fear conditioning; processes fear/aversive stimuli and appetitive stimuli (food, sex, drugs). Involved in emotional memory consolidation and social cognition.  </li> <li>Memory Modulation: Activation modulates the acquisition and consolidation of emotion-related memories.  </li> </ul>"},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/#2-internal-structural-division","title":"2. Internal Structural Division","text":"<ul> <li>Basolateral nucleus (BLA): Cortical-like structure in dorsal amygdala, regulating behavioral and physiological responses to stress.  </li> <li>Central amygdala (CeA): Critical for physiological responses to stressors (fearful stimuli, stressful stimuli, drug-related stimuli).  </li> <li>Bed nucleus of the stria terminalis (BNST, extended amygdala): Participates in anxiety and stress processing.  </li> <li>Lateral nucleus (LA): In fear conditioning, receives conditioned stimulus (CS) and unconditioned stimulus (US) from thalamic and cortical regions of auditory/somatosensory systems. Facilitates plasticity in \"trigger\" and \"storage\" cells.  </li> </ul>"},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/#3-fear-conditioning-mechanism","title":"3. Fear Conditioning Mechanism","text":"<ul> <li>Signal Transmission: CS and US are relayed to LA. CS inputs enter LA\u2019s dorsal subregion, interacting with US to induce neuronal plasticity.  </li> <li>Information Conduction: CS information transmits through LA to central nucleus (CE) for fear response integration.  </li> </ul>"},{"location":"PoN3/Yiru/5.1%20Attention%20and%20emotion/#4-cellular-composition-features","title":"4. Cellular Composition Features","text":"<ul> <li>BLA &amp; sCLR: Resemble cerebral cortex. Mainly pyramidal-like spiny glutamatergic projection neurons, with sparse spiny GABAergic interneurons (parvalbumin (PV)-containing neurons, somatostatin (SOM) neurons).  </li> <li>Ce &amp; Me nuclei: Resemble striatum/globus pallidus. Most neurons in CeL are highly branched spiny GABAergic neurons (like medium spiny neurons in striatum).  </li> <li>Centromedial extended amygdala (Ce, Me, BNST): Characterized by high expression of several neuropeptides.</li> </ul>"},{"location":"PoN3/Yiru/6.1%20Rewards%2C%20punishment%2C%20reinforcement%20learning/","title":"6.1 Rewards, punishment, reinforcement learning","text":""},{"location":"PoN3/Yiru/6.1%20Rewards%2C%20punishment%2C%20reinforcement%20learning/#reward-prediction-errors","title":"Reward Prediction errors","text":"<ul> <li>RPEs<ul> <li>\u6307\u5b9e\u9645\u83b7\u5f97\u7684\u5956\u52b1\u548c\u9884\u671f\u5956\u52b1\u4e4b\u95f4\u7684\u5dee\u5f02</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/6.1%20Rewards%2C%20punishment%2C%20reinforcement%20learning/#lateral-habenula-negative-reward-signals","title":"Lateral habenula: negative reward signals","text":"<ul> <li>No reward, or negative RPE --&gt; lateral habenula frequency increase, dopamine neural activity decrease</li> <li>Positive RPE --&gt; dopamine neural activity increase</li> </ul>"},{"location":"PoN3/Yiru/6.1%20Rewards%2C%20punishment%2C%20reinforcement%20learning/#blocking-effect","title":"Blocking effect","text":"<ul> <li>When a conditioned stimulus has been established, if we add another stimulus, it is hard to establish this as new conditioned stimulus</li> </ul>"},{"location":"PoN3/Yiru/6.1%20Rewards%2C%20punishment%2C%20reinforcement%20learning/#reforcement-leanring","title":"Reforcement leanring","text":"<ul> <li>Q-value: expected cumulative future reward, which can be received if at state st action at is performed. $$Q\\left(s_{t}, a_{t}\\right)=E\\left[r(t)+\\gamma r(t+1)+\\gamma^{2} r(t+2)+... | s_{t}, a_{t}\\right]$$</li> </ul>"},{"location":"PoN3/Yiru/6.1%20Rewards%2C%20punishment%2C%20reinforcement%20learning/#the-exploration-exploitation-dilemma","title":"The Exploration-exploitation dilemma","text":"<ul> <li>Exploitation: <ul> <li>harvesting max, rewards</li> </ul> </li> <li>Exploration<ul> <li>harvesting information, may lead to even higher rewards</li> </ul> </li> <li>\u591a\u79cd\u7b56\u7565\u6a21\u62df\u8fd9\u79cd\u56f0\u5883<ul> <li>Greedy strategy<ul> <li>always choose the best reward</li> </ul> </li> <li>$\\epsilon$ -greedy strategy<ul> <li>\u4e00\u5b9a\u7684\u6982\u7387\u9009\u62e9\u6700\u4f18\u7ed3\u679c\uff0c\u4e00\u5c0f\u70b9\u6982\u7387\u9009\u62e9\u5176\u4ed6\u7ed3\u679c\uff08\u63a2\u7d22\uff09</li> </ul> </li> <li>Optimistic greedy<ul> <li>start with Q values that are too big</li> </ul> </li> <li>Softmax action selection<ul> <li>\u901a\u8fc7softmax\u51fd\u6570\u786e\u5b9a\u9009\u62e9\u63a2\u7d22\u6216\u8005\u4fdd\u5b88\u7684\u6982\u7387</li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/6.2%20Schemas%20and%20decision%20making/","title":"6.2 Schemas and decision making","text":""},{"location":"PoN3/Yiru/6.2%20Schemas%20and%20decision%20making/#schema","title":"Schema","text":"<ul> <li> <p>An organized pattern of knowledge and behavior</p> </li> <li> <p>Psychological schemas can facilitate learning and consolidation of new memories</p> <ul> <li>Schemas learning happenes in hippocampal </li> <li>Happens gradually, helps leanring new associations, and new associations are rapidly transfered to neocortex</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/7.1%20Neuroimaging/","title":"MRI, DTI, EEG, MEG, fMRI, MVPA","text":""},{"location":"PoN3/Yiru/7.1%20Neuroimaging/#structural-magnetic-resonance-imaging-mri","title":"Structural magnetic resonance imaging (MRI)","text":"<ul> <li>MRI is detecting content of hydrogen atoms in tissue<ul> <li>It will detect the radio frequency signal of resonance frequency</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/7.1%20Neuroimaging/#diffusion-tensor-imaging-dti","title":"Diffusion Tensor Imaging (DTI)","text":"<ul> <li>DTI measures the direction and magnitude of water diffusion in the brain<ul> <li>in isotropic and anisotropic environments</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/7.1%20Neuroimaging/#electroencephalography","title":"ElectroEncephaloGraphy","text":"<ul> <li>Non-invasive, Can detect the spontaneous electrical activity of the brain<ul> <li>Which represent the postsynaptic potentials of pyramidal neurons in the neocortex and allocortex</li> <li>Can not detect activity in deep brain structures</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/7.1%20Neuroimaging/#magnetoencephalography","title":"MagnetoEncephaloGraphy","text":"<ul> <li>Signal derives from net effect of ionic currents during synaptic transmission</li> </ul>"},{"location":"PoN3/Yiru/7.1%20Neuroimaging/#comparison-eeg-meg-fmri","title":"Comparison: EEG, MEG, fMRI","text":"<ul> <li>Cost: EEG &lt; MEG/ fMRI</li> <li>Spatial resolution: EEG &lt; MEG &lt; fMRI</li> <li>Temporal resolution: fMRI &lt; EEG/ MEG<ul> <li>\u8bf4\u660eEEG\u548cMEG\u80fd\u591f\u66f4\u5feb\u5730\u6355\u6349\u795e\u7ecf\u6d3b\u52a8\u7684\u53d8\u5316\uff0c\u800cfMRI\u7684\u65f6\u95f4\u5206\u8fa8\u7387\u4f4e</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/7.1%20Neuroimaging/#functional-magnetic-resonance-imaging","title":"Functional Magnetic Resonance imaging","text":"<ul> <li>BOLD (blood oxygenation level dependent effect)<ul> <li>\u901a\u8fc7\u8840\u6c27\u60c5\u51b5\uff0c\u5206\u6790\u4ee3\u8c22\uff0c\u6d3b\u52a8\u7b49\u60c5\u51b5</li> <li>\u5e76\u4e0d\u80fd\u76f4\u63a5\u548cneural activity\u76f8\u5173\uff0c\u53ea\u80fdcorrelated to it</li> </ul> </li> <li>fMRI\u7684\u5173\u952e\u6982\u5ff5\uff1a<ul> <li>Voxels\uff1a\u4e09\u7ef4\u7a7a\u95f4\u7684\u4f53\u79ef\u50cf\u7d20</li> <li>planes: like coronal plane, horizontal plane, Sagittal plane</li> <li>\u901a\u8fc7\u53c2\u8003\u6807\u51c6\u5316\u7684\u5750\u6807\u7cfb\u7edf\uff0c\u786e\u5b9a\u4e0d\u540c\u533a\u57df\u7684\u4f4d\u7f6e\uff1a<ul> <li>Montreal Neurological Institute space (152 normal scans, average)</li> <li>Talairach space: one dissected and photographed brain ![[\u622a\u5c4f2025-03-31 10.32.33.png]]</li> </ul> </li> </ul> </li> <li>\u7edf\u8ba1\u63a8\u65ad<ul> <li>Betas: can be calculated from raw data, which represents the activity strength of specific regions <ul> <li>calculated by generalized linear model</li> <li>Beta\u503c\u4ee3\u8868\u4e86\u5927\u8111\u533a\u57df\u5bf9\u7279\u5b9a\u6761\u4ef6\u7684\u6fc0\u6d3b\u5f3a\u5ea6</li> <li>\u8fd9\u4e9b\u68c0\u9a8c\u5e2e\u52a9\u786e\u5b9a\u4e86\u5927\u8111\u533a\u57df\u5728\u7279\u5b9a\u4efb\u52a1\u4e2d\u663e\u8457\u6d3b\u8dc3</li> </ul> </li> <li>Two types of corrections:<ul> <li>Whole brain correction</li> <li>Small volume correction</li> </ul> </li> </ul> </li> <li>Two analysis method in fMRI<ul> <li>Mass-univariate approach<ul> <li>conventional</li> <li>Data is smoothed and averaged across subjects</li> <li>Can analyze groups differences voxel by voxel, based on average activity level</li> </ul> </li> <li>Multi-voxel pattern analysis (MVPA)<ul> <li>\u884c\u4e3a\u9884\u6d4b\u57fa\u4e8e\u5c40\u90e8\u6216\u8005\u5168\u5c40</li> <li>\u4e24\u79cd\u4e0d\u540c\u7684\u523a\u6fc0\u53ef\u80fd\u6fc0\u6d3b\u76f8\u540c\u7684\u8111\u533a(\u5e73\u5747\u6d3b\u52a8\u76f8\u4f3c)\uff0c\u4f46\u6fc0\u6d3b\u6a21\u5f0f\u4e0d\u540c\uff0cMVPA\u80fd\u591f\u533a\u5206\u8fd9\u4e9b\u6a21\u5f0f\u5e76\u5c06\u5176\u4e0e\u4e0d\u540c\u7684\u8ba4\u77e5\u72b6\u6001\u6216\u523a\u6fc0\u5173\u8054\u8d77\u6765\u3002</li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/7.2%20Mood%2C%20habits%2C%20and%20addiction/","title":"7.2 Mood, habits, and addiction","text":""},{"location":"PoN3/Yiru/7.2%20Mood%2C%20habits%2C%20and%20addiction/#happiness","title":"Happiness","text":"<ul> <li>Related to <ul> <li>Reward prediction errors</li> <li>certain rewards</li> <li>expected values</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/7.2%20Mood%2C%20habits%2C%20and%20addiction/#habits","title":"Habits","text":"<ul> <li>Fundamentals<ul> <li>Learned,\u540e\u5929\u4e60\u5f97</li> <li>fast, efficient: \u6267\u884c\u65f6\u65e0\u9700\u590d\u6742\u601d\u8003</li> <li>Require little cognitive resources: \u4e60\u60ef\u5f62\u6210\u540e\u65e0\u9700\u5360\u7528\u592a\u591a\u5927\u8111\u601d\u8003\u8d44\u6e90</li> <li>hard to change</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/7.2%20Mood%2C%20habits%2C%20and%20addiction/#drug-addiction","title":"Drug addiction","text":"<ul> <li>will mess up the reward system we mentioned in happiness</li> <li>drugs of abuse<ul> <li>risk factors for addiction<ul> <li>Chronic stress</li> <li>history of psychological trauma</li> <li>neuropsychiatric disorders</li> <li>behavioural genetic traits</li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/7.2%20Mood%2C%20habits%2C%20and%20addiction/#tutorial-7","title":"Tutorial 7","text":"<ul> <li>Post-traumatic stress disorder (PTSD)<ul> <li>people with a range of reactions after experiencing or witnessing a traumatic event. </li> <li>People who have PTSD may continue to feel stressed or frightened, even though they are not in danger</li> <li>Disgnosis: their symptoms last for an extended period after a traumatic event and begin to interfere with aspects of daily life,</li> </ul> </li> <li>Anxiety:<ul> <li>feel extremely worried or nervous more frequently about these and other things</li> </ul> </li> <li>Depression<ul> <li>The symptoms range from mild to severe and can disrupt a person\u2019s ability to carry out everyday activities.</li> <li>Genetic and environment related to this disorder</li> </ul> </li> <li>Bipolar disorder<ul> <li>manic-depressive illness</li> <li>People with bipolar disorder often experience <ul> <li>periods of extremely \u201cup,\u201d elated, irritable, or energized behavior\u00a0(known as manic episodes)</li> <li>and very \u201cdown,\u201d sad, indifferent, or hopeless periods (known as depressive episodes).</li> </ul> </li> </ul> </li> <li>Schizophrenia<ul> <li>mental disorder, characterized by hallucinations, delusions</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/","title":"PoN3 / final_exam","text":"<p>Files:</p> <ul> <li>Experiments Summary.md</li> <li>Overall review.md</li> </ul>"},{"location":"PoN3/Yiru/final_exam/Experiments%20Summary/","title":"Experiments Summary","text":"<p>Theme 1: Introduction and Synaptic Plasticity</p> <ol> <li> <p>Electrophysiological Recordings (General - often Patch Clamp: Voltage Clamp &amp; Current Clamp)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>AMPA/NMDA Receptor Properties: Rise time, decay time of currents (EPSCs), ion permeability (by changing ion concentrations and measuring reversal potentials), voltage-dependent Mg2+ block (for NMDARs by varying holding potential).</p> </li> <li> <p>Synaptic Strength/Amplitude (EPSCs/EPSPs): The magnitude of the postsynaptic current or potential change. This is the fundamental readout for plasticity.</p> </li> <li> <p>Quantal Amplitude (a): Amplitude of response to a single vesicle release (often measured via miniature EPSC analysis or statistical methods).</p> </li> <li> <p>Postsynaptic Potentials (PSPs): Voltage changes (EPSPs, IPSPs) in response to synaptic input (measured in current clamp).</p> </li> </ul> </li> </ul> </li> <li> <p>Paired-Pulse Experiments (PPR)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Initial Probability of Release (p): Inferred from the Paired-Pulse Ratio (PPR = Amplitude of 2nd response / Amplitude of 1st response).</p> <ul> <li> <p>PPR &lt; 1 (depression) suggests high initial 'p'.</p> </li> <li> <p>PPR &gt; 1 (facilitation) suggests low initial 'p'.</p> </li> </ul> </li> <li> <p>Short-Term Plasticity Dynamics: Nature and magnitude of facilitation or depression.</p> </li> <li> <p>Locus of LTP/LTD Expression (Indirect): Changes (or lack thereof) in PPR after LTP/LTD induction can suggest pre- vs. postsynaptic mechanisms.</p> </li> </ul> </li> </ul> </li> <li> <p>Tetanic Stimulation / High-Frequency Stimulation (HFS)</p> <ul> <li> <p>Values Tested/Induced:</p> <ul> <li> <p>Induction of Post-Tetanic Potentiation (PTP): A short-term increase in synaptic strength.</p> </li> <li> <p>Induction of NMDAR-Dependent Long-Term Potentiation (LTP): A long-lasting increase in synaptic strength.</p> </li> <li> <p>Presynaptic Calcium Accumulation (Indirectly): HFS leads to significant Ca2+ buildup, which is a value being manipulated/observed.</p> </li> </ul> </li> </ul> </li> <li> <p>Low-Frequency Stimulation (LFS) (e.g., 1-5 Hz)</p> <ul> <li> <p>Values Tested/Induced:</p> <ul> <li> <p>Induction of NMDAR-Dependent Long-Term Depression (LTD): A long-lasting decrease in synaptic strength.</p> </li> <li> <p>Modest, Prolonged Intracellular Ca2+ Elevation (Indirectly): LFS leads to a different Ca2+ dynamic than HFS.</p> </li> </ul> </li> </ul> </li> <li> <p>Coefficient of Variation (CV) Analysis (1/CV\u00b2)</p> <ul> <li>Values Tested:<ul> <li>Locus of Synaptic Change (Pre- vs. Postsynaptic): Changes in 1/CV\u00b2 (inversely related to variance) can distinguish between presynaptic (changes in 'n' or 'p') and postsynaptic (changes in 'a') mechanisms of plasticity, as 1/CV\u00b2 is proportional to n*p.</li> </ul> </li> </ul> </li> <li> <p>Photon Glutamate Uncaging (especially Two-Photon Excitation)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Postsynaptic Receptor Sensitivity/Number: Directly probes the responsiveness of postsynaptic receptors by bypassing presynaptic release.</p> </li> <li> <p>Locus of LTP/LTD Expression (Direct):</p> <ul> <li> <p>If natural (evoked) response increases but uncaging response doesn't change \u2192 presynaptic LTP.</p> </li> <li> <p>If both natural and uncaging responses increase \u2192 postsynaptic LTP.</p> </li> </ul> </li> </ul> </li> </ul> </li> <li> <p>Advanced Imaging (e.g., Calcium Imaging, Fluorescent Vesicle Reporters)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Presynaptic Calcium Concentration/Dynamics: Real-time changes in [Ca2+]i.</p> </li> <li> <p>Vesicle Trafficking Parameters: Docking, fusion rates, size of vesicle pools (readily releasable pool, reserve pool).</p> </li> <li> <p>Structural Changes: Synapse size, spine morphology.</p> </li> </ul> </li> </ul> </li> </ol> <p>Theme 2: Inhibitory Synaptic Transmission</p> <ol> <li> <p>Electrophysiology (Current Clamp / Voltage Clamp)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Reversal Potential (E_ion, specifically E_Cl for GABA-A, E_K for GABA-B): The membrane potential at which there's no net flow of the specific ion. Crucial for determining if GABA is hyperpolarizing, shunting, or depolarizing.</p> </li> <li> <p>Inhibitory Postsynaptic Currents (IPSCs): Amplitude, kinetics (rise/decay) of GABA-A and GABA-B mediated currents.</p> </li> <li> <p>Inhibitory Postsynaptic Potentials (IPSPs): Amplitude, duration, and effect on membrane potential (hyperpolarization, shunting).</p> </li> <li> <p>Neuronal Excitability: How IPSPs affect the likelihood of action potential firing.</p> </li> <li> <p>Shunting Inhibition: Measured by observing the reduction in an EPSP's amplitude or depolarizing effect when co-activated with an IPSP near the resting potential.</p> </li> </ul> </li> </ul> </li> <li> <p>Pharmacological Manipulation (using specific receptor agonists/antagonists)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Contribution of specific receptor subtypes (GABA-A vs. GABA-B) to inhibition: By blocking one type and observing the remaining current/potential.</p> </li> <li> <p>Modulation of KCC2 function: Drugs affecting KCC2 can alter E_Cl and thus GABA's effect, which can be measured electrophysiologically.</p> </li> </ul> </li> </ul> </li> <li> <p>Paired-Pulse Experiments (at inhibitory synapses)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Initial GABA Release Probability (p_GABA): Similar to excitatory synapses, PPR at inhibitory synapses can indicate high or low initial p_GABA.</p> </li> <li> <p>Short-Term Plasticity of Inhibitory Transmission: Facilitation or depression of IPSCs/IPSPs.</p> </li> </ul> </li> </ul> </li> <li> <p>Optogenetic/Chemogenetic Manipulation of Interneuron Subtypes (e.g., PV, CCK, VIP, SST cells)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Specific Role of Interneuron Subtypes in Circuit Function: By selectively activating/silencing them and recording from target neurons (e.g., principal cells or other interneurons).</p> </li> <li> <p>Connectivity Patterns: Mapping inputs and outputs of specific interneuron types.</p> </li> <li> <p>Impact on Network Oscillations: How specific interneurons contribute to rhythms like gamma.</p> </li> </ul> </li> </ul> </li> </ol> <p>Theme 3: Learning and Memory (Many experiments overlap with Theme 1, as synaptic plasticity is a core mechanism)</p> <ol> <li> <p>Behavioral Paradigms (e.g., Morris water maze, fear conditioning, novel object recognition)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Memory Formation/Acquisition: Learning curves, time to criterion.</p> </li> <li> <p>Memory Recall/Retrieval: Performance on a test phase (e.g., time in target quadrant, freezing behavior).</p> </li> <li> <p>Memory Extinction/Consolidation: Changes in memory strength over time or with new learning.</p> </li> <li> <p>Working Memory Capacity/Duration: Performance on tasks requiring active maintenance and manipulation of information (e.g., delayed non-match to sample).</p> </li> </ul> </li> </ul> </li> <li> <p>Engram Tagging &amp; Manipulation (e.g., c-fos based, activity-dependent reporters + opto/chemogenetics)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Necessity of Engram Cells for Recall: Silencing tagged cells and observing impaired memory.</p> </li> <li> <p>Sufficiency of Engram Cells for Recall: Activating tagged cells and observing memory recall/expression (e.g., artificial fear memory).</p> </li> <li> <p>Excitability of Neurons for Engram Allocation: Correlating pre-learning excitability with likelihood of being part of an engram.</p> </li> </ul> </li> </ul> </li> <li> <p>In Vivo Electrophysiology (Single-unit, Multi-unit, LFP recordings in behaving animals)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Place Cell Firing Fields: Location-specific firing of hippocampal neurons.</p> </li> <li> <p>Grid Cell Firing Patterns: Hexagonal firing patterns in MEC.</p> </li> <li> <p>Neuronal Firing Rate Changes with Learning/Attention: Correlation between task performance/attention and neuronal activity.</p> </li> <li> <p>Memory Reactivation/Replay (during sleep/rest): Coordinated firing sequences mirroring waking experience.</p> </li> <li> <p>Neural Correlates of Attention: Increased firing for attended stimuli, decreased for unattended; changes in synchrony/oscillations.</p> </li> </ul> </li> </ul> </li> <li> <p>Lesion Studies / Pharmacological Inactivation of Brain Regions (e.g., Hippocampus, mPFC, Amygdala)</p> <ul> <li> <p>Values Tested:</p> <ul> <li>Necessity of a Brain Region for Specific Memory Types/Processes: Observing deficits in learning/memory after inactivation.</li> </ul> </li> </ul> </li> <li> <p>EEG/LFP Recordings</p> <ul> <li> <p>Values Tested:</p> <ul> <li>Brain Wave Frequencies and Power (Delta, Theta, Alpha, Beta, Gamma): Correlation with behavioral states (sleep, wakefulness, attention, task performance), memory consolidation processes.</li> </ul> </li> </ul> </li> </ol> <p>Theme 5: Development and Neurodevelopmental Disorders</p> <ol> <li> <p>Ocular Dominance Plasticity Paradigms (e.g., Monocular Deprivation - MD)</p> <ul> <li> <p>Values Tested (using techniques below):</p> <ul> <li> <p>Shift in Ocular Dominance: The relative strength of input from the open vs. deprived eye to visual cortex neurons.</p> </li> <li> <p>Extent of LTD at Deprived Eye Synapses / LTP at Open Eye Synapses.</p> </li> </ul> </li> </ul> </li> <li> <p>Recording Techniques for ODP:</p> <ul> <li> <p>Single-Unit Extracellular Recordings (in visual cortex):</p> <ul> <li>Value Tested: Firing rate responses of individual neurons to visual stimuli presented to each eye separately; calculation of Ocular Dominance Index (ODI).</li> </ul> </li> <li> <p>Calcium Fluorescence Imaging (in visual cortex):</p> <ul> <li>Value Tested: Population activity (Ca2+ transients) in response to monocular/binocular visual stimuli over time.</li> </ul> </li> <li> <p>Visually-Evoked Potentials (VEPs):</p> <ul> <li>Value Tested: Gross electrical response of visual cortex to stimulation of each eye.</li> </ul> </li> </ul> </li> <li> <p>Pharmacological/Genetic Manipulation during Critical Periods</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Role of Specific Molecules (e.g., GABA, NMDA receptor subunits, LTD machinery) in opening/closing critical periods or mediating ODP: By blocking/enhancing their function and observing effects on ODP.</p> </li> <li> <p>Chloride Reversal Potential (E_Cl) changes: Measured electrophysiologically to track GABAergic maturation.</p> </li> </ul> </li> </ul> </li> <li> <p>Dark Rearing Experiments (Metaplasticity)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Baseline Plasticity State: How experience (or lack thereof) alters the subsequent capacity for LTP/LTD induction.</p> </li> <li> <p>NMDA Receptor Subunit Composition: Biochemical analysis.</p> </li> </ul> </li> </ul> </li> <li> <p>Animal Models of Neurodevelopmental Disorders (e.g., genetic KOs/KIs, pharmacological models like NMDAR hypofunction for Schizophrenia, PTZ for epilepsy)</p> <ul> <li> <p>Values Tested (using electrophysiology, EEG, behavioral tests):</p> <ul> <li> <p>Gamma Oscillation Power/Coherence: Often impaired in schizophrenia models.</p> </li> <li> <p>PV Interneuron Function/Number/Connectivity: Histology, electrophysiology.</p> </li> <li> <p>Excitatory/Inhibitory Balance: Measured via synaptic currents or network activity.</p> </li> <li> <p>Seizure Threshold/Severity: In epilepsy models.</p> </li> <li> <p>KCC2 Expression/Function: Biochemical or electrophysiological assessment (E_Cl).</p> </li> <li> <p>Cognitive/Behavioral Deficits: Relevant to human symptoms.</p> </li> </ul> </li> </ul> </li> </ol> <p>Theme 6: Neurodegeneration</p> <ol> <li> <p>Biomarker Assays:</p> <ul> <li> <p>PET Imaging (with specific radiotracers):</p> <ul> <li>Value Tested: Brain load/distribution of fibrillary A\u03b2 plaques or tau tangles.</li> </ul> </li> <li> <p>Cerebrospinal Fluid (CSF) Analysis:</p> <ul> <li>Value Tested: Levels of A\u03b242, A\u03b242/A\u03b240 ratio, total tau (t-tau), phosphorylated tau (p-tau), Neurofilament light chain (NfL).</li> </ul> </li> <li> <p>Blood Biomarker Tests:</p> <ul> <li>Value Tested: Plasma levels of p-tau181, p-tau217, A\u03b242/A\u03b240 ratio, NfL, GFAP.</li> </ul> </li> </ul> </li> <li> <p>Neuropathological Staging (Post-mortem or in animal models using histology/immunohistochemistry)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Density and Distribution of Pathological Proteins: Amyloid plaques (Thal phases), neurofibrillary tangles (Braak stages), Lewy bodies, TDP-43 inclusions, prion plaques.</p> </li> <li> <p>Neuronal Loss/Dysfunction in Specific Regions.</p> </li> </ul> </li> </ul> </li> <li> <p>Genetic Testing (for familial forms or risk alleles)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Presence of Mutations: In APP, PSEN1, PSEN2 (familial AD), HTT (Huntington's CAG repeats), PINK1/Parkin (PD).</p> </li> <li> <p>ApoE Genotype (\u03b52, \u03b53, \u03b54): Risk factor for late-onset AD.</p> </li> </ul> </li> </ul> </li> <li> <p>Animal Models of Neurodegenerative Diseases (transgenic, knock-in, toxin-induced, protein seed injection)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Rate of Pathological Protein Aggregation &amp; Spread.</p> </li> <li> <p>Degree of Neuronal Dysfunction/Loss.</p> </li> <li> <p>Severity of Behavioral/Motor Deficits (e.g., cognitive tests for AD models, motor tests for PD models).</p> </li> <li> <p>Mitochondrial Function: Assays for respiratory chain activity, ROS production, mitophagy.</p> </li> </ul> </li> </ul> </li> <li> <p>Real-Time Quaking-Induced Conversion (RT-QuIC)</p> <ul> <li> <p>Values Tested:</p> <ul> <li>Presence and Seeding Activity of Misfolded Proteins (PrPSc, \u03b1-synuclein, tau) in biological samples (CSF, skin): Provides diagnostic value by amplifying these specific aggregates.</li> </ul> </li> </ul> </li> <li> <p>Deep Brain Stimulation (DBS) (as a treatment that underwent experimental testing)</p> <ul> <li> <p>Values Tested (during clinical trials/optimization):</p> <ul> <li> <p>Improvement in Motor Scores (e.g., UPDRS for PD).</p> </li> <li> <p>Optimal Stimulation Parameters (frequency, amplitude, location).</p> </li> </ul> </li> </ul> </li> <li> <p>Cell-Replacement Therapy Studies (preclinical and clinical trials)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Graft Survival and Integration.</p> </li> <li> <p>Restoration of Neurotransmitter Levels (e.g., dopamine in PD).</p> </li> <li> <p>Functional Motor/Cognitive Improvement.</p> </li> </ul> </li> </ul> </li> </ol> <p>Theme 7: Motor and Sensory Neuroscience</p> <ol> <li> <p>Electrophysiology of Sensory Receptors (e.g., Photoreceptors in retina)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Receptor Potential: Graded potential change in response to stimulus (e.g., light hyperpolarizing photoreceptors).</p> </li> <li> <p>Signal Transduction Cascade Activity: e.g., levels of cGMP in photoreceptors.</p> </li> <li> <p>Neurotransmitter Release Modulation: e.g., reduced glutamate release from hyperpolarized photoreceptors.</p> </li> </ul> </li> </ul> </li> <li> <p>Electromyography (EMG)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Muscle Activity/Contraction Strength &amp; Timing.</p> </li> <li> <p>Motor Unit Action Potentials (MUAPs): To define motor units.</p> </li> </ul> </li> </ul> </li> <li> <p>Nerve Conduction Studies / Motor Evoked Potentials (MEPs)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Integrity and Conduction Velocity of Motor/Sensory Nerves.</p> </li> <li> <p>Excitability of Corticospinal Tract (using Transcranial Magnetic Stimulation - TMS to elicit MEPs).</p> </li> </ul> </li> </ul> </li> <li> <p>Reflex Testing (e.g., tapping patellar tendon for myotatic reflex)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Reflex Latency and Amplitude.</p> </li> <li> <p>Integrity of Monosynaptic/Polysynaptic Reflex Arcs.</p> </li> <li> <p>Muscle Spindle Sensitivity.</p> </li> </ul> </li> </ul> </li> <li> <p>Animal Models of Movement Disorders (e.g., MPTP model for Parkinson's)</p> <ul> <li> <p>Values Tested:</p> <ul> <li> <p>Degree of Dopamine Neuron Loss (for PD models).</p> </li> <li> <p>Severity of Motor Deficits (bradykinesia, rigidity, tremor).</p> </li> <li> <p>Activity Changes in Basal Ganglia Nuclei (via electrophysiology or c-fos mapping).</p> </li> </ul> </li> </ul> </li> </ol> <p>This list covers a wide range of experimental approaches. The specific \"value\" being tested often depends on the precise experimental design and the question being asked, but this gives a good overview based on your notes.</p>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/","title":"Overall review","text":""},{"location":"PoN3/Yiru/final_exam/Overall%20review/#theme-1-introduction-and-synaptic-plasticity","title":"Theme 1: Introduction and Synaptic plasticity","text":""},{"location":"PoN3/Yiru/final_exam/Overall%20review/#basic-potential-knowledge","title":"Basic potential knowledge","text":""},{"location":"PoN3/Yiru/final_exam/Overall%20review/#glutamate-transmitter-system","title":"Glutamate transmitter system","text":"<ul> <li>==Glutamate==<ul> <li>The primary excitatory neurotransmitter</li> </ul> </li> <li>Glutamate transmission<ul> <li>Glutamate is packaged into vesicles in presynaptic terminals</li> <li>After release, glutamate is primarily cleared (retake) by astrocytes through transporters</li> <li>This astrocytic uptake is crucial for preventing over excitotoxicity</li> </ul> </li> <li>Glutamate receptor<ul> <li>in Presynaptic terminals:<ul> <li>mGluRs and kainate receptors<ul> <li>as autoreceptors that modulate neurotransmitter</li> </ul> </li> </ul> </li> <li>In Postsynaptic terminals:</li> <li>NMDA receptors:<ul> <li>Slow rise and decay</li> <li>high calcium permeability and voltage-dependent magnesium block</li> </ul> </li> <li>AMPA receptors:<ul> <li>fast rise and decay</li> <li>AMPARs mediate most of the rapid excitatory synaptic signaling in the brain, responding to glutamate within milliseconds</li> </ul> </li> <li>At resting potential, NMDA receptors are blocked by Mg2+; initial slight stimulation activates AMPA receptors --&gt; $Na+$ influx</li> <li>Stronger depolarization removes Mg2+ block from NMDA receptors, and then NMDA allows both $Na+$ and $Ca^{2+}$ influx</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#presynaptic-release-and-synaptic-plasticity","title":"Presynaptic release and synaptic plasticity","text":"<ul> <li>Definition of Presynaptic release: is the process, a neuron releases neuotransmitters from synaptic vesicles into the synaptic cleft to communicate with another neuron.</li> <li>Presynaptic release is a primary target for ==synaptic plasticity ==mechanisms<ul> <li>Controlled by:<ul> <li>Calcium signaling: The primary trigger for vesicle fusion</li> <li>Vesicle trafficking: Controls availability of release-ready vesicles</li> <li>Modulatory systems: Fine-tune release probability<ul> <li>G protein coupleed receptors</li> <li>autoreceptors: feedback control</li> </ul> </li> </ul> </li> </ul> </li> </ul> <p>Synaptic strength of synaptic plasticity - Amplitude = n x p x a     - n = number of release sites         - number of terminals or release sites     - a = quantal amplitude         - \u662f\u5355\u4e2avesicle\u5bf9\u4e8e\u7a81\u89e6\u540e\u795e\u7ecf\u5143\u7684\u5f71\u54cd     - p = probability of release         - determined by $Ca^{2+}$ and proportion of synapses with docked vesicles\uff1b\u5747\u662f\u6b63\u6bd4\u5173\u7cfb             - \u4ec0\u4e48\u662fdocked vesicle: near the membrane of presynaptic, ready to fuse and release - This means the strength of a connection depends on how many release sites exist (n), how likely each is to release (p), and how strong each quantum's effect is (a)</p> <p>Paired Pulse ratios - When you stimulate a neuron twice in quick succession, the second response is affected by the first     - Paired pulse depression         - If the first stimulus depletes available vesicles, the second response is smaller (depression)     - Paired pulse facilitation         - If the first stimulus leaves residual calcium, the second response is larger (facilitation) - The p (inital state of release probability could be inferred from this ratio)</p> <p>Short-term plasticity (seconds to minutes) - Facilitation occurs when calcium accumulates in the terminal, increasing release probability for subsequent stimuli - Depression happens when readily-releasable vesicles are depleted, reducing probability temporarily - ==Post-Tetanic potentiation==:     - represents a longer-lasting enhancement of release after intense stimulation     - during tetanus, calcium accumulation; after tetanus, residual calcium would increase probability of vesicle fusion</p> <ul> <li>How to detect these changes?<ul> <li>Paired-pulse experiments: Reveal initial state and short-term dynamics</li> <li>Coefficient of variation analysis: Distinguishes pre vs. postsynaptic changes</li> <li>Advanced imaging: Directly visualizes presynaptic function</li> <li>Photon Glutamate Uncaging<ul> <li>Scientists use a special form of glutamate that's chemically \"caged\" (inactive) until exposed to light. </li> <li>Then Two-photon excitation: Using a special infrared laser that only activates the compound when two photons hit simultaneously</li> <li>This creates a tiny activation spot (less than 1 micron - smaller than a single synapse)</li> <li>If you induce LTP at a synapse and then:<ul> <li>Natural responses increase BUT uncaging responses don't change \u2192 presynaptic mechanism</li> <li>Both natural AND uncaging responses increase \u2192 postsynaptic mechanism</li> </ul> </li> </ul> </li> </ul> </li> </ul> <p>Long-term plasticity (hours to days) - Presynaptic LTP/LTD can involve persistent changes in release machinery,calcium handling, or terminal size - These changes alter the baseline probability of neurotransmitter release</p> <ul> <li> <p>LTP: long term potentiation</p> <ul> <li>NMDAR-dependent LTP<ul> <li> <ol> <li>Initial activation: High-frequency stimulation pre- and postsynaptic activity causes glutamate release from presynaptic terminals</li> </ol> </li> <li>AMPA receptor activation: Glutamate binds to AMPARs, allowing Na\u207a influx and initial depolarization of the postsynaptic membrane</li> <li>NMDA receptor unblocking: The depolarization removes Mg\u00b2\u207a ions that normally block NMDA receptors at resting potential</li> <li>Calcium influx: With Mg\u00b2\u207a block removed, NMDA receptors allow Ca\u00b2\u207a entry into the postsynaptic cell</li> <li>Calcium as second messenger: The rapid rise in intracellular Ca\u00b2\u207a triggers several signaling cascades:<ul> <li>Ca\u00b2\u207a binds to calmodulin, forming Ca\u00b2\u207a/calmodulin complexes</li> <li>Ca\u00b2\u207a/calmodulin activates CaMKII (calcium/calmodulin-dependent protein kinase II)</li> <li>CaMKII undergoes autophosphorylation at Thr286, becoming persistently active</li> <li>AMPA receptor move to membrane</li> </ul> </li> </ul> </li> <li>LTP expression: maintain enhanced synaptic strength after LTP has been induced<ul> <li>related to postsynaptic modifications<ul> <li>increased AMPA receptor</li> </ul> </li> <li>unchanged paired-pulse ratio after LTP suggests that expression is primarily postsynaptic in classical NMDAR-dependent LTP.</li> </ul> </li> <li>==Mossy Fibre LTP==<ul> <li>Different from NMDAR-dependent LTP</li> <li>Presynaptic mechanism: depends on presynaptic $Ca^{2+}$ entry through voltage-gated calcium channels</li> <li>cAMP-PKA pathway: Elevated Ca\u00b2\u207a activates adenylyl cyclase, increasing cAMP and activating PKA</li> <li>Results in enhanced glutamate release rather than changes in postsynaptic sensiticity</li> </ul> </li> </ul> </li> <li> <p>LTD: long term depression</p> <ul> <li>synaptic weakening</li> <li>crucial for information storage, memory refinement, and preventing network saturation.</li> <li>NMDAR-dependent LTD<ul> <li>Induction with low-frequency stimulation, typically 1-5 Hz</li> <li>Modest, prolonged elevation of intracellular $Ca^{2+}$ ; Lower $Ca^{2+}$ levels than LTP</li> <li>This will cause: Activation of phosphatases, and cause dephosphorylation of AMPA receptors, and inhibition of CaMKII activity</li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#theme-2-inhibitory-synaptic-transmission","title":"Theme 2: Inhibitory Synaptic transmission","text":"<ul> <li>Why we need inhibition?<ul> <li> <ol> <li>precise control of action potential timing</li> <li>like feedforward inhibition</li> </ol> </li> <li> <ol> <li>Preventing Pathological over-excitation</li> <li>lack of inhibition would cause ==Seizures==</li> </ol> </li> <li> <ol> <li>modulating the impact of specific excitatory inputs</li> <li>Inhibition can selectively dampen or gate certain excitatory pathways</li> </ol> </li> <li> <ol> <li>Enabling complex circuit operations like disinihibition</li> <li>can inhibit other inhibition neurons</li> </ol> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#gaba","title":"GABA","text":"<ul> <li>Glutamic Acid Decarboxylase(GAD) is a enzyme that can convert Glutamate into ==GABA==<ul> <li>GABA: primary inhibitory neurotransmitter in the central nervous system</li> <li>reduce neuronal activity (calming effect)</li> </ul> </li> <li>Two types of Synapses<ul> <li>Excitatory Synapses<ul> <li>presynaptic neuron: glutamatergic neurons</li> <li>Postsynaptic neuron</li> </ul> </li> <li>Inhibitory synapses<ul> <li>Presynaptic neuron: ==GABAergic neurons==--&gt; synthesize GABA</li> <li>GABA then transported into synaptic nesicles, and this packaging is mediated by Vesicular GABA transporter (VGAT)</li> <li>Then release into the synaptic cleft</li> </ul> </li> </ul> </li> <li>When a GABAergic neuron fires an action potential, the depolarization of the presynaptic terminal triggers the influx of $Ca^{2+}$ --&gt; GABA release to cleft</li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#reversal-potential","title":"Reversal potential","text":"<ul> <li>Represent a balance between the electrical gradient and the chemical concentration gradient</li> <li> <p>The reversal potential for an ion is the membrane potential at which there is no net flow of that ion across the membrane, even if channels permeable to it are open. GABA-A Receptors: Fast, Direct Chloride-Mediated Inhibition</p> </li> <li> <p>Type:\u00a0GABA-A receptors are\u00a0fast-acting, ligand-gated ion channels, also known as ionotropic receptors.</p> </li> <li> <p>Mechanism:\u00a0When GABA binds directly to the GABA-A receptor, the integral ion channel opens. This channel is primarily permeable to\u00a0chloride ions (Cl\u207b).</p> </li> <li> <p>Role of KCC2 and Chloride Gradient:\u00a0In mature neurons, the\u00a0K\u207a-Cl\u207b-cotransporter (KCC2)\u00a0actively pumps Cl\u207b ions\u00a0out of the cell. This action maintains a\u00a0low intracellular Cl\u207b concentration, setting the reversal potential for chloride (E_Cl) at a value typically more negative than the action potential threshold (and often near or slightly more negative than the resting membrane potential).</p> </li> <li>Effect of Activation:<ul> <li>Because intracellular Cl\u207b is kept low by KCC2, when GABA-A receptors open, Cl\u207b ions flow\u00a0into the cell\u00a0down their electrochemical gradient.</li> <li>This influx of negatively charged Cl\u207b ions generates an\u00a0Inhibitory Postsynaptic Current (IPSC).</li> <li>The IPSC leads to an\u00a0Inhibitory Postsynaptic Potential (IPSP), where the inside of the neuron becomes more negative (hyperpolarization) or is \"clamped\" near E_Cl, making it harder for the neuron to reach the threshold for firing an action potential. IPSPs (voltage changes) are measured using current clamp electrophysiology.</li> <li>This results in rapid inhibition.</li> </ul> </li> <li> </li> <li>If AMPA and GABA-A open together: the EPSP caused by AMPA would be shunting inhibited by GABA-A<ul> <li>lower potential, because the potential would be used to resist GABA-A IPSP</li> <li>GABA-A offer a existing path for positive channel moved from AMPA to leave</li> </ul> </li> </ul> <p>GABA-B Receptors: Slow, G-Protein Mediated Potassium-Dependent Inhibition - Type:\u00a0GABA-B receptors are\u00a0metabotropic receptors, specifically\u00a0G_i/o protein-coupled receptors (GPCRs). They mediate slower and more prolonged inhibitory effects. - Mechanism:     1. Unlike GABA-A receptors, GABA-B receptors do not form an ion channel themselves.     2. When GABA binds, the receptor activates an associated\u00a0G protein\u00a0located on the inner surface of the cell membrane.     3. The activated G protein splits into its subunits (G\u03b1_i/o and G\u03b2\u03b3).     4. These subunits then interact with downstream effector proteins. - Effect of Activation (Postsynaptic):     - A primary postsynaptic effect involves the\u00a0G\u03b2\u03b3 subunit directly activating G-protein-gated inwardly rectifying K\u207a (GIRK) channels\u00a0(as depicted in the image).     - Since K\u207a concentration is much higher inside the cell than outside, opening these channels allows\u00a0K\u207a ions to flow outwards.     - This efflux of positive charge causes the membrane potential to move towards the very negative K\u207a reversal potential (E_K), resulting in\u00a0hyperpolarization\u00a0and a slow IPSP.</p> <ul> <li>Slower Time Course:\u00a0The multi-step cascade (GABA binding \u2192 G protein activation \u2192 subunit dissociation \u2192 subunit interaction with effector/channel) means that the onset of GABA-B receptor effects is significantly slower (tens to hundreds of milliseconds) and longer-lasting (seconds) compared to the immediate response of GABA-A receptors.</li> <li>Other Effects (Presynaptic &amp; Biochemical):\u00a0GABA-B receptors can also be located presynaptically where G\u03b2\u03b3 can inhibit Ca\u00b2\u207a channels, reducing neurotransmitter release. The G\u03b1_i subunit can inhibit adenylyl cyclase, reducing cAMP levels and modulating cellular functions over longer timescales (as suggested by the\u00a0adenylyl cyclase\u00a0part of your image).  </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#shunting-inhibition","title":"Shunting inhibition","text":""},{"location":"PoN3/Yiru/final_exam/Overall%20review/#model-of-gabaergic-neurons","title":"MODEL of GABAergic Neurons","text":"<ul> <li>Principal Cells:<ul> <li>The main output neurons of a specific brain region.</li> <li>They collect and process information within their area and then send signals out to other brain regions</li> </ul> </li> <li>Interneurons<ul> <li>These neurons make connections within the same brain area. </li> <li>Can inhibiting bearby principal cells or other interneurons</li> <li>GABAergic Nature: Many, if not most, interneurons are GABAergic. They are crucial for shaping the activity patterns within a brain region, preventing over-excitation, and refining signals.</li> </ul> </li> <li>Forms of inhibition<ul> <li> <ol> <li>Feedforward Inhibition (Top-Left in image):</li> <li>Mechanism:<ol> <li>An incoming excitatory signal (e.g., from another brain area) arrives.</li> <li>This signal splits: one branch excites the main target neuron (e.g., a principal cell).</li> <li>The\u00a0other\u00a0branch excites an inhibitory interneuron.</li> <li>This interneuron then\u00a0quickly\u00a0fires and inhibits the\u00a0same\u00a0main target neuron that just received the direct excitation.</li> </ol> </li> <li>Effect:\u00a0This creates a narrow window of opportunity for the target neuron to fire. The initial excitation might make it fire, but the subsequent inhibition quickly shuts it down or prevents prolonged firing. It helps to make the timing of neuronal responses more precise</li> <li>Image:\u00a0The input (blue arrow) activates both the Excitatory cell (E, in black) and the Inhibitory cell (I, in red). The I cell then inhibits the E cell.</li> </ol> </li> <li> <ol> <li>Feedback Inhibition (Top-Right in image):</li> <li>Mechanism:<ol> <li>A target neuron (e.g., a principal cell) becomes active and fires.</li> <li>This firing\u00a0excites\u00a0a nearby inhibitory interneuron.</li> <li>The activated interneuron then fires and sends an inhibitory signal\u00a0back\u00a0to the original target neuron (or a population of similar neurons).</li> </ol> </li> <li>Effect:\u00a0This acts like a negative feedback loop. \"Such inhibitory neurons are beneficial for preventing over-excitation and maintaining network stability.\" It helps to prevent runaway excitation, dampens activity after a neuron has fired, and can contribute to generating rhythmic activity.</li> <li>Image:\u00a0The E cell activates the I cell, which then inhibits the E cell.</li> </ol> </li> <li> <ol> <li>Tonic inhibition</li> <li>provides a constant background level of inhibition, setting the overall excitability</li> <li>Extracellular GABA:\u00a0There's a low, ambient concentration of GABA present in the space\u00a0outside\u00a0of synapses.</li> <li>Extrasynaptic Receptors:\u00a0Neurons have GABA-A receptors located\u00a0outside\u00a0the synaptic cleft (extrasynaptic) that are highly sensitive to GABA. These receptors bind to the ambient GABA.</li> <li>Image:\u00a0Shows ambient GABA molecules (small dots) influencing the neuron, representing this constant background inhibition.</li> </ol> </li> <li> <ol> <li>Lateral Inhibition</li> <li>When one neuron (or a small group of neurons) becomes highly active, it activates inhibitory interneurons that then suppress the activity of adjacent, less active neurons.</li> <li>This mechanism sharpens the representation of sensory information by making the \"winner\" (most active neuron) stand out more clearly against its \"quieter\" neighbors. </li> </ol> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#interneuron-cell-types-and-diversity","title":"Interneuron: cell types and diversity","text":"<ul> <li>Different brain region have different interneuron subtypes</li> <li>Where should the inhibitory synapses be?<ul> <li>Synapses on dendrites: modulate the integration of excitatory inputs</li> <li>Synapses on distal dendritic </li> <li>Synapses on soma and proximal dendrites: basket cells</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#fast-spiking-cell","title":"Fast-spiking cell","text":"<ul> <li>are major class of inhibitory interneurons, and their electrophysiological property is:<ul> <li>their ability to fire action potentials at very high frequencies with little or no slowing down (adaptation).<ul> <li> <ol> <li>Have a relative low threshold for firing an action potential --&gt; ready to be fired</li> </ol> </li> <li> <ol> <li>Faster repolarization: FS cells have specific types of potassium channels, notably\u00a0KV 3.1 channels. </li> <li>When the cell depolarizes, these channels open quickly allowing K+ ions to rush out, rapidly repolarizing the membrane</li> </ol> </li> </ul> </li> </ul> </li> <li>Fast-spiking interneuron-Mediated IPSCs (inhibitory postsynaptic currents) have fast kinetics<ul> <li>When an FS cell releases GABA onto a target neuron, the resulting inhibitory current is rapid in its onset and decay</li> </ul> </li> <li></li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#preventing-runaway-excitation","title":"Preventing runaway excitation","text":"<ul> <li>Short-term plasticity<ul> <li>Paired-Pulse depression <ul> <li>If an interneuron has a high initial probability of releasing GABA, repeated activation might lead to less GABA release per action potential</li> </ul> </li> <li>Paired-pulse facilitation<ul> <li>If an interneuron has a low initial probability of release, repeated activation can lead to\u00a0more\u00a0GABA release (e.g., due to residual calcium buildup). Interneurons with\u00a0facilitating inputs\u00a0become stronger as network activity increases.</li> </ul> </li> </ul> </li> <li>Two type of cell types<ul> <li>Parvalbumin (PV) basket cells<ul> <li>Inhibitory interneuron</li> <li>Provide a\u00a0fast, strong, immediate brake\u00a0on network activity. Their high initial release probability ensures a rapid and potent inhibitory effect.</li> <li>Often have P/Q-type Ca2+ channels and nanodomain signaling, leading to fast, reliable, and often depressing or robust (non-facilitating) synapses. They are good for strong, fast feedback inhibition.</li> </ul> </li> <li>Cholecystokinin(CCK) basket cells<ul> <li>Provide a\u00a0more graded and building form of inhibition\u00a0that strengthens as network activity persists or increases.</li> <li>Prevent hyper-excitation</li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#disinhibition","title":"Disinhibition:","text":"<ul> <li>Example : Long-range inputs (e.g., from motor cortex M1 to somatosensory cortex S1) can preferentially activate\u00a0VIP (Vasoactive Intestinal Polypeptide)-containing interneurons.<ul> <li>VIP interneurons often target other interneurons, particularly SST-containing interneurons (which, as we saw, target dendrites).</li> <li>So, M1 activates VIP cells in S1 \u2192 VIP cells inhibit SST cells in S1 \u2192 SST cells are less able to inhibit the dendrites of S1 principal cells \u2192 dendrites of S1 principal cells are\u00a0disinhibited\u00a0and more responsive to other excitatory inputs</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#theme-3-leaning-and-memory","title":"Theme 3: Leaning and memory","text":""},{"location":"PoN3/Yiru/final_exam/Overall%20review/#categorize-memories","title":"Categorize memories","text":"<p>A. By Content &amp; Conscious Awareness (Qualitative Classification)     1.  Declarative Memory (Explicit Memory):         *   Definition: Memories that can be consciously recalled and \"declared\" (facts, events).         * Like episodic memory:\u60c5\u666f\u5f0f\u7684         * Which could be expressed easily     2.  Non-Declarative Memory (Implicit/Procedural Memory):         *   Definition: Memories expressed through performance without conscious awareness or recollection.         - Which is more likely to be performed instead of expressed B. By Duration (Temporal Classification)     3.  Immediate Memory:         *   Duration: Fractions of a second to seconds.         *   Characteristics: Large capacity, rapid decay without attention.     4.  Short-Term Memory (STM):         *   Duration: Seconds to minutes.         *   Characteristics: Limited capacity, requires rehearsal for maintenance.         *   ==Working Memor==y (a key component/type of STM):             *   Definition: Actively holding and manipulating information to plan and carry out behavior (e.g., mental arithmetic, following complex instructions).             *   Putative Location: Medial Prefrontal Cortex (mPFC) involvement     5.  Long-Term Memory (LTM):         *   Duration: Days to years, potentially a lifetime.         *   Characteristics: Vast capacity, relatively stable but can be modified.         *   mPFC Role: Also involved in the recall of remote (older) long-term memories (Lee et al., 2022).</p>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#structural-brain-causing-declarative-memory","title":"Structural brain, causing declarative memory","text":"<p>A. Key Anatomical Structures:     1.  Medial Temporal Lobe (MTL): A collection of structures crucial for declarative memory formation.     2.  Hippocampus (within the MTL):         *   Overall Role: Essential for forming new declarative memories (especially episodic) and spatial navigation.         *   Internal Circuitry: e.g., The \"Trisynaptic Loop\" (EC \u2192 DG \u2192 CA3 \u2192 CA1).         *   Subregions (Cornu Ammonis - CA): Involved in binding elements of an experience, conscious recollection.         *   Debate on LTM storage:             *   Standard Model of Systems Consolidation: Hippocampus is temporary for LTM; memories eventually become independent and stored in the cortex.             *   Multiple Trace Theory: Hippocampus is always needed for recalling detailed episodic LTMs.     3.  Entorhinal Cortex (EC) (gateway to the Hippocampus):         *   Medial Entorhinal Cortex (MEC): Contains Grid Cells (fire in hexagonal patterns creating a \"cognitive map\" for spatial navigation).         *   Lateral Entorhinal Cortex (LEC): Processes multisensory information (olfactory, visual etc.), coding contextual elements for episodic memory.     4.  Dentate Gyrus (DG) (within the Hippocampus):         *   Primary Role: Critical for Pattern Separation (distinguishing similar memories).         *   Unique Feature: Site of Adult Neurogenesis (birth of new neurons in adulthood).</p>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#cellular-and-network-mechanisms","title":"Cellular and network mechanisms","text":"<p>A. Neural Plasticity: The Brain's Ability to Change     1.  Concept (Santiago Ramon y Cajal, 1890s): Learning involves changes in the connections between neurons.</p> <p>B. Engrams: The Physical Trace of Memory     2.  Definition: The hypothetical physical/biochemical change in the brain that represents a memory.     3. Preferential allocation: Neurons with higher excitability at the time of learning are more likely to become part of engram for that memory     4.  Mechanism: Involves specific populations of neurons (\"engram neurons\") activated during learning and reactivated during recall. Linked to dendritic spine changes.     5. Silencing them prevents recall, and activating them can trigger recall </p> <p>C. Specialized Cells for Spatial Memory &amp; Navigation:     1.  Place Cells (in the Hippocampus):         *   Discovery: O'Keefe &amp; Dostrovsky, 1971.         *   Function: Fire when an animal is in a specific location (\"place field\"), contributing to a \"cognitive map.\"         *   Stability: GABAergic CA1 place cells can be more stable than glutamatergic ones across context changes.     2.  Grid Cells (in the Medial Entorhinal Cortex):         *   Function: Fire in a hexagonal pattern as an animal navigates, providing a metric for space.         *   Interaction: Input from grid cells likely contributes to the formation of place fields in the hippocampus.</p> <p>D. Pattern Separation (in the Dentate Gyrus):     1.  Function: The ability to distinguish between similar inputs or experiences, encoding them as distinct memories. Prevents interference.</p> <p>E. Adult Neurogenesis (in the Dentate Gyrus):     1.  Function: The birth of new neurons in adulthood, potentially contributing to learning, pattern separation, and memory flexibility.</p>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#the-influence-of-sleep-on-memory","title":"The influence of sleep on memory","text":"<p>A.  Consolidation Enhancement: Sleep plays a critical role in strengthening and reorganizing memories. B.  Key Processes During Sleep:     1.  Memory Reactivation/Replay: Neural patterns of recent experiences are replayed in the hippocampus and prefrontal cortex.     2.  Context Generalization: Sleep can help generalize learned responses (e.g., fear) to similar contexts.     3.  Synaptic Plasticity Modulation: Sleep oscillations (e.g., slow waves, spindles) coordinate changes at synapses, refining memory traces.     4.  Experience-Driven Maturation: The efficiency of sleep-dependent consolidation can improve with experience.</p>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#attention-and-emotion","title":"Attention and emotion","text":"<ul> <li>Where cause attention<ul> <li>The medial prefrontal cortex in rodents</li> <li>The dorsolateral prefrontal cortex in human </li> <li>Related to ==working memory ==(holding and manipulating information relevant to the current task); and preparatory attention (preparing to focus on an upcoming stimulus or task) </li> </ul> </li> <li></li> <li>Neuronal correlates of attention<ul> <li> <ol> <li>Changes in firing rates</li> <li>Increased Firing: Neurons representing attended locations, features, or objects generally show increased firing rates.</li> <li>Decreased Firing (Suppression): Neurons representing unattended locations or features can show decreased activity.</li> </ol> </li> <li> <ol> <li>Attractor networks</li> <li>Attention might involve neural networks shifting from labile sates to stable attractor states</li> <li>In these stable states, the \"winning\" neuronal population (representing the focus of attention) shows increased firing, while \"losing\" populations (representing unattended stimuli) show decreased firing.</li> </ol> </li> </ul> </li> <li>Attention related neurotransmitter<ul> <li> <ol> <li>Acetilcholine, Ach</li> <li>Role: Arousal, attention, learning, memory.</li> <li>Increased Ach can improve attention</li> <li>Essential for spatial working memory</li> </ol> </li> <li> <ol> <li>Dopamine (DA)</li> <li>Role: Reward signaling, decision-making, spatial working memory, spatial attention, target selection.</li> <li>Clinical relevance: ADHD, schizophrenia, Parkinson's </li> </ol> </li> <li> <ol> <li>Noradrenaline, NA</li> <li>More complex; In PFC region, involved in top-down control, attention, working memory via \u03b12 receptors in PFC</li> <li>In sensory cortex, involved in bottom-up state control</li> </ol> </li> <li> <ol> <li>Serotonin (5-HT)</li> <li>Role: Learning, memory, executive functioning.</li> <li>Reduced 5-HT could impair LTM and decision-making but may enhance focused attention and not affect working memory</li> </ol> </li> </ul> </li> <li>Attention deficit<ul> <li>Caused by inherited effects and environment</li> </ul> </li> <li>Bottom-Up attention: External stimulus<ul> <li>Fast, from senses</li> <li>Automatic</li> </ul> </li> <li>Top-down attention: internal goals and intentions<ul> <li>Goal-directed</li> <li>From mind downwards</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#brain-waves","title":"Brain waves","text":"<p> - From fastest wave to slowest wave:     - ==Gamma==: binding and peak performance wave; fastest frequency, associated with high-level information processing, intense focus, and the binding of sensory information into a coherent perception     - ==Beta==: the active&amp; alert wave; Associated with\u00a0active wakefulness, alertness, focused attention, and active thinking/problem-solving.     - ==Alpha==: The relaxed and reflective wave; Characterizes a state of relaxed wakefulness, often with eye closed, reduce sensory processing         - bridge between active thought and deeper relaxation/drowsiness     - ==Theta==: memory wave; Associated with\u00a0drowsiness, light sleep (including REM sleep), deep relaxation, and processes like memory consolidation and creative insight.     - ==Delta==: deep sleep and restoration wave; Slowest frequency, dominant during\u00a0deep, dreamless (non-REM) sleep, essential for physical restoration and healing.</p>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#limbic-system","title":"Limbic system","text":"<p>Contains: - Amygdala: fear and emotion center - Hypothalamic nuclei: Homeostasis - Olfactory bulb: smell - Septal nuclei: emotional related - Nucleus accumbens: reward, motivation - hippocamapl formation: memory - Cingulate cortex: emotional processing, motivation, decision-making - Areas of basal Ganglia - Ventral tegmental area (VTA): reward, motivation - Limbic midbrain areas: pain modulation, defensive behaviours</p> <ul> <li>Focusing on Amygdala<ul> <li>Kluver-Bucy syndrome, loss of amygdala will cause loss of emotional reactivity hypersexuality, oral fixation</li> <li>Key subnuclei:<ul> <li>Lateral nucleus (LA)<ul> <li>Receives sensory input from thalamus and cortex</li> <li>Process realtionship of events</li> </ul> </li> <li>Basolateral Nucleus (BLA)<ul> <li>Regulates behavioral and physiological responses to stress</li> <li>Composed mainly of glutamatergic projection neurons and GABAergic interneurons</li> </ul> </li> <li>Central Nucleus (CE)<ul> <li>Crucial for physiological responses to stressors (fearful stimuli, stress, drug-related stimuli)</li> <li>Outputs from LA project here to drive fear responses.</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#theme-5-development-and-neurodevelopmental-disorders","title":"Theme 5: Development and neurodevelopmental disorders","text":""},{"location":"PoN3/Yiru/final_exam/Overall%20review/#critical-periods-in-brain-development","title":"Critical periods in brain development","text":"<ul> <li>A discrete period of time during development when normal sensory experience is required for the brain to develop properly<ul> <li>Sensitive period for experience-dependent brain development</li> <li>Example: brain visual development is about from 6 months to about 5 years of age. Normal visual input during this time is crucial for the development of visual pathways</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#ocular-dominance-plasticity","title":"ocular dominance plasticity","text":"<ul> <li>A key model for studying critical periods, particularly in the visual cortex. </li> <li>It refers to the change in neuronal responses in the visual cortex to input from one eye relative to the other due to ==altered visual experience==</li> <li>Key: shift in ocular dominance; if one eye is deprived of normal input during the critical period, the synapses carrying signals from that eye waken, while synapses from the open eye may strengthen</li> <li></li> <li>Role of ODP:<ul> <li>Related to LTD of the synapses connected to the deprived eye</li> <li>ODP results in LTD, blocking LTD blocks ODP</li> <li>==Recording techniques==<ul> <li>Single unit extracellular recordings: allow for many individual recordings to assess neuronal firing</li> <li>Calcium fluorescence imaging: enables continuous recording from the same cells over time </li> <li>Visually-evoked potentials (VEPs): measure electrical responses in the brain to visual stimuli</li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#role-of-gabaergic-inhibition-in-timing-critical-periods","title":"Role of GABAergic inhibition in timing critical periods","text":"<ul> <li>Development shift in GABA action: in young age of animal, GABA neurotransmitter can be somehow excitatory</li> <li>The maturation of GABAergic inhibition is a key factor defining the timing (opening and closing) of critical periods.<ul> <li>Chloride Reversal Potential:\u00a0Changes from depolarized (excitatory) in young neurons to more hyperpolarized (inhibitory) in mature neurons</li> </ul> </li> <li>The time of inhibition development should be 'just right'</li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#metaplasticity","title":"Metaplasticity:","text":"<p>The \"plasticity of plasticity.\" Changes in the brain that alter its capacity for subsequent synaptic plasticity. - Example:\u00a0Dark rearing can shift the balance of plasticity towards potentiation (LTP). This might be related to changes in NMDA receptor subunit composition (e.g., a reduction in GluN2A-containing NMDARs).     - NMDA Receptors:\u00a0Composed of different subunits (e.g., GluN1, GluN2A, GluN2B). The subunit composition affects receptor properties and can change during development and with experience.</p>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#neurodevelopment-disorders-schizophrenia-and-epilepsy","title":"Neurodevelopment disorders: schizophrenia and epilepsy","text":"<ul> <li>Network oscillations<ul> <li>Synchronized activity:\u00a0Neural oscillations are rhythmic, synchronized patterns of electrical activity across populations of neurons.</li> <li>IPSPs can synchronize firing: <ul> <li>Before IPSP: individual neurons in a population will tend to fire more asynchronously </li> <li>After small IPSP:<ul> <li>Can reset and delay with inhibition effects</li> </ul> </li> </ul> </li> <li>How inhibition synchronizes<ul> <li>ING, interneuron Gamma<ul> <li>In a group of interneuron, they would auto- and intra- regulation to be sybchronized</li> </ul> </li> <li>PING, Pyramidal-interneuron Gamma<ul> <li>Excitatory pyramidal cells (+) fire, exciting inhibitory interneurons (-).</li> <li>These interneurons then fire and broadly inhibit the pyramidal cells.</li> <li>As the inhibition wears off, the pyramidal cells recover and become more likely to fire again, restarting the cycle.</li> </ul> </li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#1-schizophrenia","title":"1. Schizophrenia","text":"<ul> <li>One of the most common serious mental health conditions, </li> <li>Hallucinations, delusions; speaking little, lack of pleasure in life</li> <li>Cognitive symptoms<ul> <li>Poor executive function</li> <li>Trouble focusing</li> <li>Working memory deficit</li> </ul> </li> <li>Remove PV induces Schizophrenia</li> <li>Parvalbumin-containing (PV) interneurons  seems to be impaired in Schizophrenia case<ul> <li>PV responsible for feedforward inhibition</li> <li>reduction in PV +ve neurons: physically fewer PV interneurons</li> <li>reduction in PV +ve boutons: Boutons are the presynaptic terminals where neurotransmitters (in this case, GABA from PV neurons) are released. A reduction in PV-positive boutons means that even if the PV neuron cell bodies are present, their ability to form synaptic connections and release GABA onto target neurons is compromised.</li> <li>reduction in GABA-A receptor<ul> <li>targeted by PV interneurons</li> </ul> </li> <li>NMDAR hypofunction may act via PV interneurons<ul> <li>NMDA receptors are glutamate receptors for excitatory neurotransmission and synaptic plasticity. PV interneuron contains NMDA receptors</li> <li>When NMDA hypofunction<ul> <li>PV interneurons receive less excitatory drive from principal neurons or other excitatory inputs.</li> <li>This reduced excitation leads to decreased firing of PV interneurons.</li> <li>Consequently, PV interneurons release less GABA</li> </ul> </li> </ul> </li> </ul> </li> <li>PV containing basket cells, fire on every cycle of gamma oscillation <ul> <li>drive high-frequency oscillations like gamma</li> </ul> </li> <li>==Synchronizing gamma oscillations are impaired in schizophrenia:==<ul> <li>Clinical Relevance:\u00a0This is a critical link. The evidence you listed previously (reduced PV neurons, boutons, GABAA \u03b11 receptors, NMDAR hypofunction affecting PV cells) all point to a deficit in PV interneuron function.</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#2-epilepsy-seizure","title":"2. Epilepsy seizure","text":"<ul> <li>Definition: abnormal excessive or synchronous activity in the brain</li> <li>Main cause: lack of inhibition while too much excitation<ul> <li>can be induced by glutamate agonists</li> <li>May be caused by:<ul> <li>Mutations in GABA-related genes --&gt; GABA dysfunction</li> <li>Changes in GABA in non-genetic epilepsy</li> <li>GABA-A receptor mutations</li> </ul> </li> </ul> </li> <li>Initial epilepsy seizure would lead to more seizure<ul> <li>Initial seizure reduce KCC2 expression </li> <li>KCC2 is responsible for the exclude Cl from cell--&gt;keep Cl- level in a lower level </li> <li>So if lack of KCC2, intracellular Cl- level would increase, so GABA will somehow become a less inhibitory or even excitatory neurotransmitter--&gt; more likely to over excitation</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#theme-6-neurodegeneration","title":"Theme 6: Neurodegeneration","text":"<ul> <li>Definition: Progressive loss of nerve structure and function</li> <li>Misfolded proteins is a big problem<ul> <li>Alzheimer's disease<ul> <li>Neurofibrillary tangles (tau)</li> <li>Amyloid plaques</li> </ul> </li> <li>Parkinson's disease<ul> <li>Lewy body </li> </ul> </li> <li>Amyotrophic lateral sclerosis<ul> <li>TDP-43 inclusion body (TDP-43 protein)</li> </ul> </li> <li>Prion disease<ul> <li>Prion plaque</li> </ul> </li> <li>Huntington's disease<ul> <li>huntington inclusion body (Huntingtin)</li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#1-alzheimers-disease","title":"1. Alzheimer's disease","text":"<p>Defined by brain deposition of ==numerous amyloid plaques== and ==neurofibrillary tangles==  - Neurofibrillary tangles: aggregation of tau protein     - Tau was hyperphosphorylated - Based on different variant of AD, can have multiple syndromes</p> <ul> <li>Amyloid-beta: cleaved from Amyloid precursor protien (APP)</li> <li>Microtubule-Associated protein Tau<ul> <li>have 6 isoforms, but contribute to AD tau aggregates equally</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#ads-biomarkers","title":"AD's biomarkers","text":""},{"location":"PoN3/Yiru/final_exam/Overall%20review/#1-pet-positron-emission","title":"1. PET: Positron emission","text":"<ul> <li> <p>PET is a non-invasive imaging tech </p> </li> <li> <p>using radioactive compounds that bind fibrillary A\u03b2 or tau.</p> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#2-cerebrospinal-fluid-csf-biomarkers","title":"2. Cerebrospinal Fluid (CSF) biomarkers","text":"<p>CSF is collected via lumbar puncture and provides direct insight into brain biochemistry:</p> <ul> <li>Amyloid-\u03b242: Decreases in CSF as it accumulates in brain plaques</li> <li>Total tau and phosphorylated tau: Increase with neuronal damage and tangle formation</li> <li>A\u03b242/A\u03b240 ratio: Improves diagnostic accuracy over A\u03b242 alone</li> <li>Neurofilament light chain (NfL): Indicates neuronal damage (though not specific to AD)</li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#3-blood-biomarkers","title":"3. Blood biomarkers","text":"<p>Recent advances have enabled less invasive blood tests:</p> <ul> <li>Plasma p-tau181 and p-tau217: Highly specific for AD pathology</li> <li>Plasma A\u03b242/A\u03b240 ratio: Correlates with brain amyloid burden</li> <li>Plasma NfL: Reflects neurodegeneration but isn't AD-specific</li> <li>GFAP (Glial Fibrillary Acidic Protein): Indicates astrocytic activation</li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#neuropathological-phases-of-amyloid-deposition-in-ad","title":"Neuropathological phases of amyloid-\u03b2 deposition in AD","text":"<ul> <li>Thal phase<ul> <li>Thal phase 1: basal temporal and orbitofrontal neocortex</li> <li>Thal phase 2/3: throughout the neocortex, amygdala ... most section of brain</li> <li>Thal phase 4/5: mesencephalon, lower brainstem, and cerebellar cortex</li> </ul> </li> <li>Braak stages<ul> <li>Braak stage I/II: near locus coeruleus</li> <li>Braak stage III/IV: hippocampal formation and ome parts of neocortex</li> <li>Braak stage V/VI: large parts of the  </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#cause-of-ad","title":"Cause of AD","text":"<ul> <li>Key factor: ==the accumulation of A$\\beta$ ==is a critical, early, and causal event in the cascade of pathological changes that lead to Alzheimer's disease</li> <li>Mutations in Familial AD<ul> <li> <ol> <li>APP (Amyloid precursor protein) mutaiton</li> <li>APP gene is located on Chromosome 21, and the mutations happen near the secretase cleavage sites</li> <li>This will increase the production of A$\\beta$</li> </ol> </li> <li> <ol> <li>PSEN1 and PSEN2 genes</li> <li>Similar to APP mutations,\u00a0these mutations directly lead to an increased production of the A\u03b242 peptide</li> </ol> </li> </ul> </li> <li>Down Syndrome with early onset AD<ul> <li>they have three copies of APP gene so have more A$\\beta$</li> </ul> </li> <li>For those late-onset AD (not Familial AD)<ul> <li>ApoE \u03b54 allel as a major risk factor </li> <li>ApoE is involved in cholesterol transport but also plays a role in A\u03b2 aggregation and clearance. ApoE  \u03b54 is a kind of less effective form of ApoE so may cause aggregation</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#2-parkinsons-disease","title":"2. Parkinson's disease","text":"<ul> <li>Primary cause: the death of dopamine neurons in a midbrain</li> <li> <p>PD affects movement control, and the symptoms include shaking, rigidly, slowness, and difficulty with walking</p> </li> <li> <p>Key protein disorder: ==Lewy bodies==</p> <ul> <li>The main protein componenet of Lewy bidy is alpha-synuclein; misfolded alpha-synuclein will aggregates to form these insoluble Lewy </li> </ul> </li> <li>Body first and brain-first PD:<ul> <li>Braak stage of PD<ul> <li></li> </ul> </li> <li>Developing from down to up brain: <ul> <li>From enteric nervous system (nervous system of the gut); synuclein detection of skin is positive</li> </ul> </li> <li>Developing from brain to body:<ul> <li>From olfactory buld; synuclein detection of skin is negative</li> </ul> </li> </ul> </li> <li>Mitochondial dysfunction is a core mechanism in PD<ul> <li>Mutations:\u00a0Loss-of-function mutations in PINK1 or Parkin impair this quality control system. Damaged, dysfunctional mitochondria accumulate, leading to oxidative stress, energy deficits, and neuronal death, particularly in vulnerable dopamine neurons. This is a major cause of early-onset, recessive PD.</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#treatment-of-parkinsons-disease","title":"Treatment of Parkinson's disease","text":"<ul> <li> <ol> <li>L-DOPA, the precurosor of dopamine: repleace the dopamine. </li> </ol> </li> <li> <ol> <li>Deep brain stimulation (DBS): Continuous high-frequency electrical stimulation is delivered to basal ganglia targets --&gt; improve motor performances</li> </ol> </li> <li> <ol> <li>Cell-replacement therapy: To replace the lost dopamine neurons with new healthy ones; </li> <li>Transplanting fetal dopaminergic precursor cells, or more recently, dopamine neurons derived from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), into the striatum</li> </ol> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#3-prion-disease","title":"3. Prion disease","text":"<ul> <li>The disease is caused by Prion protein<ul> <li>The Prion protein undergoes a misfolding event, and become insoluble --&gt; will aggregation (PrP_sC)</li> </ul> </li> <li>==Protein-induced propagation==: once a abnormal prion protein form, it can convert more and more normal prion protein into abnormal form.</li> <li>Pathological Consequences:\u00a0The accumulation of these misfolded, aggregated PrP<sup>Sc</sup>\u00a0proteins leads to:<ul> <li>Neuronal dysfunction and death.</li> <li>Formation of amyloid plaques (in some prion diseases).</li> <li>Spongiform encephalopathy (the brain develops a characteristic sponge-like appearance due to the formation of numerous tiny holes, or vacuoles, in the tissue).</li> <li>Progressive and invariably fatal neurodegeneration.</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#disease-model-with-prion-like-disease","title":"Disease model with prion-like disease","text":"<ul> <li>Shared mechanics: Protein conformational change, which could cause misfolding; and further, this could lead to aggregation</li> <li> <p>Like AD, PD, Prion disease: Can build animal model with lab-made aggregated protein seeds to lead disease development</p> </li> <li> <p>Detection of disease-specific misfolded proteins</p> <ul> <li>Real-time quaking-induced coversion (RT-QulC)<ul> <li>disease-specific misfolded protein \"seeds\" (like prion protein, alpha-synuclein, or tau) in patient samples\u00a0(e.g., cerebrospinal fluid) by amplifying them through seeded aggregation.</li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#4-huntingtons-disease","title":"4. Huntington's disease","text":"<ul> <li>Cause: an expansion of CAG trinucleotide repeat in exon 1 of the Huntingtin gene (HTT)<ul> <li>lead to an abnormally long polyglutamine (polyQ) tract in the huntingtin protein</li> </ul> </li> <li>Mutated huntingtin protein would misfold, and aggregate</li> <li>Mechanism of Toxicity (PolyQ):<ul> <li>Gain-of-Function:\u00a0The expanded polyQ tract confers new, toxic properties on the huntingtin protein.</li> <li>Loss-of-Function:\u00a0The normal functions of the huntingtin protein (which are important for neuronal health, e.g., in intracellular transport, transcription) might also be impaired.</li> <li>Disruption of Interacting Proteins:\u00a0The expanded polyQ tract can abnormally interact with a multitude of other cellular proteins, disrupting their normal functions. This explains why different polyQ diseases (caused by polyQ expansions in different genes) have different symptoms \u2013 the specific \"host protein\" context matters.</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#5-amyotrophic-lateral-sclerosis","title":"5. Amyotrophic lateral sclerosis","text":"<ul> <li>Cause is not clear</li> <li>Pathology: selective motor neuron degeneration</li> <li>Key related genes<ul> <li>TDP-43: In ALS conditions, both mutant and wild-type TDP-43 accumulate in cytoplasmic inclusion bodies. (aggregation)</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#theme-7-motor-and-sensory-neuroscience","title":"Theme 7: Motor and sensory neuroscience","text":"<ul> <li>All sensory system shared common tasks<ul> <li>sensory stimuli --&gt; electrical signals</li> <li>Optimization of detection</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#visual-system","title":"Visual system","text":""},{"location":"PoN3/Yiru/final_exam/Overall%20review/#eye-and-retina","title":"Eye and retina","text":"<ul> <li>Retina has a layerd structure with specific cell types in each layer</li> <li> <p>The eye projects the visual scene onto the retina\u2019s photoreceptors</p> <ul> <li>Light activates rhodopsin--&gt;G-protein signaling --&gt; decraese of cyclic-GMP level</li> <li>--&gt; hyperpolarize the photoreceptors, reducing glutamate release </li> </ul> </li> <li> <p>How do Rods and cones detect light signals</p> <ul> <li>Light activates rhodopsin (a kind of G-protein-coupled receptor)</li> <li>This will cause greater amplification of the phototransduction cascade, and are used mostly for ==night vision==</li> <li>Cones recover more rapidly and have a larger adaptation range, and serve daylight vision and motion vision</li> <li>The presence of different kinds of cones with opsins that confer different spectral sensitivities-- short-, medium- and long- wavelength for trichromatic primates including humans, enables color vision</li> </ul> </li> <li> <p>Two types of cells in receptive fields: OFF and ON bipolar cells</p> <ul> <li>Light --&gt; Hyperpolarization cones --&gt; less glutamate release<ul> <li>--&gt; ==ionotropic glutamate recepto==r is less active --&gt; fewer cations enter bipolar cell --&gt; OFF biplolar cell is hyperpolarized</li> <li>--&gt; Metabotropic glutamate receptor is less active --&gt; inhibitory G proteins are less active --&gt; cation channels are less inhibited--&gt; ON bipolar cell is depolarized</li> </ul> </li> <li>Bipolar cells acquire their center\u2013surround receptive field through lateral inhibition of horizontal cells</li> </ul> </li> </ul> <p>Light \u2192 Photoreceptor Hyperpolarization (\u2193Glutamate) \u2192 1.\u00a0Direct Pathway (Center):  \u2192\u00a0OFF Bipolar:\u00a0(Ionotropic GluR) \u2192 Hyperpolarization (if light) \u2192 Modulates Glutamate release to OFF-Center RGC  \u2192\u00a0ON Bipolar:\u00a0(Metabotropic GluR6) \u2192 Depolarization (if light) \u2192 Modulates Glutamate release to ON-Center RGC 2.\u00a0Lateral Pathway (Surround via Horizontal Cells): * Photoreceptors also modulate Horizontal Cells \u2192 Horizontal Cells provide inhibitory feedback to (surround) photoreceptors (and sometimes directly to bipolars) \u2192 This feedback antagonizes the center response.</p>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#movement-control","title":"Movement Control","text":""},{"location":"PoN3/Yiru/final_exam/Overall%20review/#management-system-hierarchy-of-control","title":"Management system: Hierarchy of control","text":"<ul> <li>The highest level: think and plan<ul> <li>Neocortex</li> <li>Basla ganglia</li> </ul> </li> <li>The middle level: tactics and execution<ul> <li>Motor cortex and cerebellum</li> </ul> </li> <li>Lowest level: execution and local operation<ul> <li>Brainstem</li> <li>Spinal cord</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#movement-with-mucle-and-neuron","title":"Movement with mucle and neuron","text":"<ul> <li>Key components for arm movement<ul> <li>the joints</li> <li>skeletal muscles</li> <li>nerves: transmit signals from the brain and spinal cord to muscle</li> </ul> </li> <li>Motor Neurons: The Messengers<ul> <li>Lower Motor Neurons (LMNs): The \"Front-Line Workers\"<ul> <li>Location:\u00a0Cell bodies in the anterior horn of the spinal cord or brainstem cranial nerve nuclei.</li> <li>Job:\u00a0Their axons project\u00a0directly\u00a0to skeletal muscles, forming\u00a0neuromuscular junctions. When an LMN fires, the muscle fibers it connects to contract. They are the\u00a0final common pathway\u00a0for all motor commands.</li> </ul> </li> <li>Upper Motor Neurons (UMNs): The \"Supervisors\"<ul> <li>Location:\u00a0Cell bodies in the motor regions of the cerebral cortex or brainstem.</li> <li>Job:\u00a0They\u00a0control\u00a0the LMNs. They send signals\u00a0down\u00a0to the LMNs (or interneurons that connect to LMNs) to initiate, modify, or stop movement.</li> </ul> </li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#motor-units-and-motor-pools","title":"Motor units and motor pools","text":"<ul> <li> <p>Alpha motor neurons</p> <ul> <li>LLMs</li> <li>==Motor Units==: ONE alpha motor neuron + ALL the muscle fibers it innervates. This is the\u00a0elementary component of motor control. Small motor units (few fibers per neuron) allow for fine control</li> <li>Motor Neuron Pool:\u00a0The collection of ALL alpha motor neurons that innervate a\u00a0single muscle.</li> </ul> </li> <li> <p>Gamma motor neurons</p> <ul> <li>They adjust the tension of intrafusal fibers. This doesn't cause major muscle contraction for movement but is crucial for\u00a0regulating the sensitivity of muscle spindles.</li> </ul> </li> <li> <p>Alpha-Gamma Coactivation</p> <ul> <li>During voluntary movements, both alpha and gamma motor neurons are activated simultaneously. Alpha neurons cause the main muscle (extrafusal fibers) to contract, and gamma neurons cause the intrafusal fibers within the spindle to contract.</li> <li>Spindle can detect the changes in muscle length</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#automatic-response-of-reflexes","title":"Automatic response of reflexes","text":"<ul> <li>Myotatic reflex (Stretch reflex): like knee-jerk<ul> <li> <ol> <li>Sudden stretch of a muscle (e.g., tapping the patellar tendon stretches the quadriceps).</li> </ol> </li> <li>Muscle spindles in the stretched muscle are activated.</li> <li>Sensory neurons from the spindle send a signal directly to the spinal cord.</li> <li>In the spinal cord, these sensory neurons make a\u00a0monosynaptic\u00a0(single synapse) connection with alpha motor neurons that innervate the\u00a0same\u00a0muscle.</li> <li>The alpha motor neurons are activated, causing the stretched muscle to contract.</li> <li>==To resist sudden stretching (lengthening) of a muscle and help maintain muscle tone and posture.==</li> </ul> </li> <li>Reciprocal inhibition<ul> <li>only one of Flexor and extensor would contract, and another one must relax</li> <li>Inhibitory interneurons would prevent the contraction of antagonist muscle</li> </ul> </li> <li>Withdrawal reflex <ul> <li>Immediate response to pain: step on pin and then motor fibers in several segments are activated, so lift foot off to pin</li> </ul> </li> <li>Crossed-extensor reflex<ul> <li>Maintain balance, after withdrawal reflex</li> <li>While one foot withdraws from pain, the other one must support the body, so the signal would cross to the opposite side of spinal cord</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#controling-motor-systems","title":"Controling motor systems","text":"<ul> <li>Cortical neurons send axonal projections via multiple tracts to various brain regions</li> <li>==Pyramidal system==<ul> <li>Contain Corticospinal tracts</li> <li>Responsible for voluntary, skilled movements</li> </ul> </li> <li>Extrapyramidal system<ul> <li>Rubrospinal and tectospinal tracts, among others</li> <li>Controls posture, muscle tone and automatic movements</li> </ul> </li> </ul>"},{"location":"PoN3/Yiru/final_exam/Overall%20review/#movement-disorders","title":"Movement disorders","text":"<ul> <li>Basal ganglia<ul> <li>Help to facilitate movement that are required, and inhibit unwanted movement</li> </ul> </li> <li>Two pathways of modulation of  basal ganglia<ul> <li>Direct Pathway: MSIT, more motor activity in movement<ul> <li>M: Motor cortex</li> <li>S: Striatum</li> <li>I: Internus</li> <li>T: Thalamus</li> </ul> </li> <li>Indirect pathway: MS==EN==IT, more motor activity of unwanted movement<ul> <li>E: Externus</li> <li>N: Nucleus</li> </ul> </li> <li>\u9996\u5c3e\u6fc0\u6d3b</li> <li>\u4e2d\u95f4\u6291\u5236\u5356\u51fa\u4e86N</li> </ul> </li> <li>Parkinson's disease<ul> <li>related to the loss of dopaminergic neurons in the substantia nigra pars compacta (SNs)</li> <li>Problem:<ul> <li>defects in the both direct and indirect pathway, leading to less wanted and unwanted movement</li> <li>Direct pathway: Dopamine is crucial for inhibiting the internus (I). Lack of Dopamine will lead to increased inhibition of the thalmus (T), resulting in reduced motor activity and inhibition</li> </ul> </li> </ul> </li> <li>Huntinton's disease</li> </ul>"},{"location":"Year1/","title":"Year 1","text":"<p>Courses (Year 1):</p> <ul> <li>CHEM1: CHEM1/</li> <li>IBI1: IBI1/</li> <li>IBMS1: IBMS1/</li> <li>ICMB1: ICMB1/</li> <li>MATH1: MATH1/</li> </ul>"},{"location":"Year2/","title":"Year 2","text":"<p>Courses (Year 2):</p> <ul> <li>ADS2: ADS2/</li> <li>BG2: BG2/</li> <li>BaO2: BaO2/</li> <li>DST2: DST2/</li> <li>GP2: GP2/</li> <li>IFBS2: IFBS2/</li> <li>MI2: MI2/</li> </ul>"},{"location":"Year3/","title":"Year 3","text":"<p>Courses (Year 3):</p> <ul> <li>BMI3: BMI3/</li> <li>CBSB3: CBSB3/</li> <li>IBMS3: IBMS3/</li> <li>IN3: IN3/</li> <li>MBE3: MBE3/</li> <li>PoN3: PoN3/</li> </ul>"},{"location":"Year4/","title":"Year 4","text":"<p>Courses (Year 4):</p> <ul> <li>BIA4: BIA4/</li> <li>IBMS4: IBMS4/</li> <li>IID_4: IID_4/</li> </ul>"},{"location":"zip_contents/","title":"ZIP Contents Overview","text":"<p>This folder contains per-zip detail pages.</p> <p>Note: ZIP files are hosted externally (not stored in this Git repo).</p> <p>Google Drive folder (all uploads): https://drive.google.com/drive/folders/1_ttbZASdiHPW9xt0GSjVjFHF5MAPk2fv?usp=drive_link</p>"},{"location":"zip_contents/#xiaoran_etal","title":"Xiaoran_etal","text":"<ul> <li><code>BG\u5bfc\u56fe\u5408\u96c6_lxrwyqlxf.zip</code> \u2014 detail: BG\u5bfc\u56fe\u5408\u96c6_lxrwyqlxf</li> <li><code>\u601d\u7ef4\u5bfc\u56feIFBS_lxr.zip</code> \u2014 detail: \u601d\u7ef4\u5bfc\u56feIFBS_lxr</li> <li><code>IN_lxfwyqlxr.zip</code> \u2014 detail: IN_lxfwyqlxr</li> <li><code>MBE_lxrwyalxf.zip</code> \u2014 detail: MBE_lxrwyalxf</li> <li><code>pon\u590d\u4e60\u8d44\u6599_lxrwyqlxf.zip</code> \u2014 detail: pon\u590d\u4e60\u8d44\u6599_lxrwyqlxf</li> </ul>"},{"location":"zip_contents/#yiru","title":"Yiru","text":"<p>These are consolidated zips created from each <code>Yiru</code> folder. They are intended for upload to Zenodo/Google Drive and are not stored in git.</p> <ul> <li><code>BG2_sum_Yiru.zip</code></li> <li><code>Code_Cheatsheet_Yiru.zip</code></li> <li><code>GP2_sum_Yiru.zip</code></li> <li><code>IBMS3_full_Yiru.zip</code></li> <li><code>IID_4_full_Yiru.zip</code></li> <li><code>MBE3_sum_Yiru.zip</code></li> <li><code>PoN3_full_Yiru.zip</code></li> </ul> <p>After you upload these to Zenodo, paste the Zenodo DOI or file links into the corresponding per-zip detail pages or into <code>ZJE_Collection/ZIPS_INDEX.md</code>.</p>"},{"location":"zip_contents/#yue","title":"Yue","text":"<ul> <li><code>BaO\uff08\u975e\u5b8c\u6574\uff09.pdf</code></li> <li><code>IFBStheme34_tutorialquestion.pdf</code></li> <li><code>IFBS\uff08theme34).zip</code></li> <li><code>pon.zip</code> \u2014 detail: pon</li> <li><code>MI\uff08\u975e\u5b8c\u6574\uff09.pdf</code></li> </ul> <p>If you want, I can automatically insert the Zenodo links into these detail pages after you upload. Paste the Zenodo URLs here when ready.</p>"},{"location":"zip_contents/BG2_sum_Yiru/","title":"Contents of BG2_sum_Yiru.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>BG2_sum/Collection of disease.pdf</li> <li>BG2_sum/Collection of technology.pdf</li> <li>BG2_sum/calculation.pdf</li> <li>BG2_sum/index.md</li> </ul>"},{"location":"zip_contents/BG%E5%AF%BC%E5%9B%BE%E5%90%88%E9%9B%86_lxrwyqlxf/","title":"Contents of BG\u5bfc\u56fe\u5408\u96c6_lxrwyqlxf.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>\u2561\u255d\u2550\u255d/1 Genetic variation.pdf</li> <li>\u2561\u255d\u2550\u255d/1 Genetic variation.xmind</li> <li>\u2561\u255d\u2550\u255d/10 Developmental Genetics.pdf</li> <li>\u2561\u255d\u2550\u255d/10 Developmental Genetics.xmind</li> <li>\u2561\u255d\u2550\u255d/11  Study Gene Function and Model Human Diseases in Post-Genome Era.xmind</li> <li>\u2561\u255d\u2550\u255d/11 Study Gene Function and Model Human Diseases in Post-Genome Era.pdf</li> <li>\u2561\u255d\u2550\u255d/12 Genetic Testing.pdf</li> <li>\u2561\u255d\u2550\u255d/12 Genetic Testing.xmind</li> <li>\u2561\u255d\u2550\u255d/13 Genetic testing and risk assessment for complex diseases.pdf</li> <li>\u2561\u255d\u2550\u255d/13 Genetic testing and risk assessment for complex diseases.xmind</li> <li>\u2561\u255d\u2550\u255d/14 Genetic Treatment Approaches &amp; Gene Therapy.pdf</li> <li>\u2561\u255d\u2550\u255d/14 Genetic Treatment Approaches &amp; Gene Therapy.xmind</li> <li>\u2561\u255d\u2550\u255d/2 patterns of inheritance.pdf</li> <li>\u2561\u255d\u2550\u255d/3 Maternal inheritance and mitochondrial disease.pdf</li> <li>\u2561\u255d\u2550\u255d/3 Maternal inheritance and mitochondrial disease.xmind</li> <li>\u2561\u255d\u2550\u255d/4 Multifactorial Diseases.pdf</li> <li>\u2561\u255d\u2550\u255d/5 Cell Division and Chromosomes.pdf</li> <li>\u2561\u255d\u2550\u255d/5 Cell Division and Chromosomes.xmind</li> <li>\u2561\u255d\u2550\u255d/6 The Human Genome.xmind</li> <li>\u2561\u255d\u2550\u255d/7  Population genetics.xmind</li> <li>\u2561\u255d\u2550\u255d/8 Cancer Genetics and Genomics.pdf</li> <li>\u2561\u255d\u2550\u255d/8 Cancer Genetics and Genomics.xmind</li> <li>\u2561\u255d\u2550\u255d/9 Sequencing techniques and discovery.pdf</li> <li>\u2561\u255d\u2550\u255d/9 Sequencing techniques and discovery.xmind</li> </ul>"},{"location":"zip_contents/Code_Cheatsheet_Yiru/","title":"Contents of Code_Cheatsheet_Yiru.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>Code_Cheatsheet/JAVA_Sum_yiru.pdf</li> <li>Code_Cheatsheet/R\u6570\u636e\u79d1\u5b66 ( etc.) (Z-Library).pdf</li> <li>Code_Cheatsheet/SQL-cheat-sheet.pdf</li> <li>Code_Cheatsheet/base-r-cheat-sheet.pdf</li> <li>Code_Cheatsheet/data-visualization.pdf</li> <li>Code_Cheatsheet/java-cheat-sheet-comprehensive-guide.pdf</li> </ul>"},{"location":"zip_contents/GP2_sum_Yiru/","title":"Contents of GP2_sum_Yiru.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>GP2_sum/GP\u63d0\u7eb2.pdf</li> <li>GP2_sum/index.md</li> </ul>"},{"location":"zip_contents/IBMS3_full_Yiru/","title":"Contents of IBMS3_full_Yiru.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>IBMS3_full/Experimental Design &amp; Ethics.pdf</li> <li>IBMS3_full/IBMS Dry Lab \u7b54\u9898\u603b\u7ed3.pdf</li> <li>IBMS3_full/IBMS Wet Lab \u7b54\u9898\u603b\u7ed3.pdf</li> <li>IBMS3_full/detailed/.DS_Store</li> <li>IBMS3_full/detailed/0. Model selection.md</li> <li>IBMS3_full/detailed/1. Experiment Methods.md</li> <li>IBMS3_full/detailed/2. Group settings.md</li> <li>IBMS3_full/detailed/4. Statistical analysis; Computational methods.md</li> <li>IBMS3_full/detailed/4.5 Visualization.md</li> <li>IBMS3_full/detailed/5. Ethics.md</li> <li>IBMS3_full/detailed/6. Critical thinking.md</li> <li>IBMS3_full/detailed/experiments_case/EXTRA DREADD, neuronal method.md</li> <li>IBMS3_full/detailed/experiments_case/EXTRA FUCCI.md</li> <li>IBMS3_full/detailed/experiments_case/EXTRA Fluorescence Polarization.md</li> <li>IBMS3_full/detailed/experiments_case/EXTRA eQTL.md</li> <li>IBMS3_full/detailed/experiments_case/MBE CRISPR screen disease gene factor.md</li> <li>IBMS3_full/detailed/experiments_case/MBE CRISPR_screen_drug_resistence.md</li> <li>IBMS3_full/detailed/experiments_case/MBE Chromosome structure detection.md</li> <li>IBMS3_full/detailed/experiments_case/MBE DNA assessment.md</li> <li>IBMS3_full/detailed/experiments_case/MBE Epigenetic sequencing.md</li> <li>IBMS3_full/detailed/experiments_case/MBE Epigenome Engineering Discussion.md</li> <li>IBMS3_full/detailed/experiments_case/MBE Gene editing.md</li> <li>IBMS3_full/detailed/experiments_case/MBE Gene expression analysis technologies.md</li> <li>IBMS3_full/detailed/experiments_case/MBE Protein assessment.md</li> <li>IBMS3_full/detailed/experiments_case/MBE Protein-DNA interaction.md</li> <li>IBMS3_full/detailed/experiments_case/MBE RNA assessment.md</li> <li>IBMS3_full/detailed/experiments_case/MBE RNA editing-based RNA-seq.md</li> <li>IBMS3_full/detailed/experiments_case/MBE RNA-seq.md</li> <li>IBMS3_full/detailed/experiments_case/MBE mRNA visualization and analysis technologies.md</li> <li>IBMS3_full/detailed/experiments_case/S1 Antisense oligonucleotides.md</li> <li>IBMS3_full/detailed/experiments_case/S1.W10.ChenDi Aging research in C elegans.md</li> <li>IBMS3_full/detailed/experiments_case/S1.W12.LiangGong Long read sequencing, Genomic Structural Variation.md</li> <li>IBMS3_full/detailed/experiments_case/S1.W13.LiuNan Dual-Luciferase reporter assay.md</li> <li>IBMS3_full/detailed/experiments_case/S1.W13.LiuNan GWAS.md</li> <li>IBMS3_full/detailed/experiments_case/S1.W13.LiuNan Hemoglobin Switching.md</li> <li>IBMS3_full/detailed/experiments_case/S1.W13.LiuNan Pro-seq.md</li> <li>IBMS3_full/detailed/experiments_case/S1.W14.WangQun Immunotherapy development.md</li> <li>IBMS3_full/detailed/experiments_case/S1.W3.tu.  Flow Cytometry for immunology.md</li> <li>IBMS3_full/detailed/experiments_case/S1.W3.tu. Flow cytometry in Biomedical.md</li> <li>IBMS3_full/detailed/experiments_case/S1.W5.tu WB and ELISA.md</li> <li>IBMS3_full/detailed/experiments_case/S1.W8.Laura Gene modified mouse.md</li> <li>IBMS3_full/detailed/experiments_case/S2 Comprehensive Design Framework for Computational Methods in Biomedicine.md</li> <li>IBMS3_full/detailed/experiments_case/S2.W1.1.Seminar DL for genomic modeling.md</li> <li>IBMS3_full/detailed/experiments_case/S2.W3.2 Structural study of epigenetic regulation in transcription.md</li> <li>IBMS3_full/detailed/experiments_case/S2.W5 GFP reporter model.md</li> <li>IBMS3_full/detailed/experiments_case/S2W2.2.Seminar Precision medicine with computational biology.md</li> <li>IBMS3_full/detailed/experiments_case/S2W3 Antibody de novo design.md</li> <li>IBMS3_full/detailed/experiments_case/S2W4 Survival Analysis.md</li> <li>IBMS3_full/detailed/experiments_case/S2W4.3 Host-microbial Interactions and Lipid Metabolism.md</li> <li>IBMS3_full/detailed/experiments_case/S2W5 Adipose tissue in cold thermogenesis.md</li> <li>IBMS3_full/detailed/experiments_case/index.md</li> <li>IBMS3_full/detailed/from_yc/AI notes for seminar_yicheng.md</li> <li>IBMS3_full/detailed/from_yc/Final notes for seminar_yicheng.md</li> <li>IBMS3_full/detailed/from_yc/IBMS\u603b\u7ed3\u590d\u4e60_yicheng.md</li> <li>IBMS3_full/detailed/from_yc/MY notes for slides_yicheng.md</li> <li>IBMS3_full/detailed/from_yicheng/index.md</li> <li>IBMS3_full/detailed/index.md</li> <li>IBMS3_full/detailed/\u4e00\u5b9e\u9a8c\u65b9\u6cd5\u901f\u67e5.md</li> <li>IBMS3_full/index.md</li> <li>IBMS3_full/\u4e00\u5b9e\u9a8c\u65b9\u6cd5\u901f\u67e5.pdf</li> <li>IBMS3_full/\u8003\u524d\u6574\u7406(1).pdf</li> </ul>"},{"location":"zip_contents/IFBS%EF%BC%88theme34%29/","title":"Contents of IFBS\uff08theme34).zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>IFBS/IFBS theme3_\u6d88\u5316\u5438\u6536\u8fc7\u7a0b.pdf</li> <li>IFBS/IFBS theme3_\u6d88\u5316\u5668\u5b981.pdf</li> <li>IFBS/IFBS theme3_\u6d88\u5316\u7cfb\u7edf2.pdf</li> <li>IFBS/IFBS theme4\uff08\u975e\u5b8c\u6574\uff09.pdf</li> </ul>"},{"location":"zip_contents/IID_4_full_Yiru/","title":"Contents of IID_4_full_Yiru.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>IID_4_full/NotebookLLM_Topic_1.pdf</li> <li>IID_4_full/NotebookLLM_Topic_4.pdf</li> <li>IID_4_full/NotebookLLM_Topic_5_EVA.pdf</li> <li>IID_4_full/NotebookLLm_Topic_3.pdf</li> <li>IID_4_full/Topic 0 basic concept of immunology.md</li> <li>IID_4_full/Topic 1 Innate Immune system.md</li> <li>IID_4_full/Topic 1.5 Trained Innate Immunity.md</li> <li>IID_4_full/Topic 10 what I need to know for exam.md</li> <li>IID_4_full/Topic 11 Macrophage.md</li> <li>IID_4_full/Topic 12 Diseases.md</li> <li>IID_4_full/Topic 2 Inflammation algorithm.md</li> <li>IID_4_full/Topic 3 T-Cell.md</li> <li>IID_4_full/Topic 4 ILC, Innate lymphoid cells.md</li> <li>IID_4_full/Topic 5 B cell.md</li> <li>IID_4_full/Topic 6 Auto-immune disease.md</li> <li>IID_4_full/Topic 7 System exhaustion and cytokine storms.md</li> <li>IID_4_full/Topic 8 Immunometablism.md</li> <li>IID_4_full/Topic 9 monoclonal antibodies.md</li> <li>IID_4_full/index.md</li> </ul>"},{"location":"zip_contents/IN_lxfwyqlxr/","title":"Contents of IN_lxfwyqlxr.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>in/1.1 1.2 Epidemiology.xmind</li> <li>in/2.1 Candida spp..xmind</li> <li>in/2.2 Cryptococcus neoformans.xmind</li> <li>in/2.3 Antifungal Resistance \u2013 A global threat.xmind</li> <li>in/3.1 3.2 3.3 Virulence mechanisms and immune evasion(1).xmind</li> <li>in/3.1-3.3Virulence mechanisms and immune evasion.xmind</li> <li>in/4.1 respiratory viruses.docx</li> <li>in/4.1 respiratory viruses.pdf</li> <li>in/4.2 Gastrointestinal viruses.xmind</li> <li>in/4.3 5.1 5.2.docx</li> <li>in/4.3 Herpesviruses-\u6a2a.pdf</li> <li>in/4.3 Herpesviruses.pdf</li> <li>in/5.1 Innate_Immune_Control_of_Viruses_Review.docx</li> <li>in/5.1 innate immune system.pdf</li> <li>in/5.2 vaccines.pdf</li> <li>in/5.3 antiviral drugs.pdf</li> <li>in/6.1 HIV.xmind</li> <li>in/6.2 Viral Hepatitis.docx</li> <li>in/6.2 Viral Hepatitis.pdf</li> <li>in/6.3 emerging viruses.pdf</li> <li>in/7.1 Arboviruses.xmind</li> <li>in/7.2 Viral Vectors and Gene Therapy.xmind</li> <li>in/7.3.docx</li> <li>in/8.1-11.3.docx</li> <li>in/8.1-8.3.docx</li> <li>in/Bacteria.xmind</li> <li>in/Fungal Infection.xmind</li> <li>in/IN_\u8003\u524d\u8bb0\u5fc6.docx</li> <li>in/Practical.xmind</li> <li>in/\u590d\u5236\u5468\u671f.docx</li> <li>in/\u75b1\u75b9\u75c5\u6bd2\u590d\u4e60\u8d44\u6599.docx</li> <li>in/\u75c5\u6bd2.pdf</li> <li>in/\u75c5\u6bd2\u6574\u7406.pdf</li> </ul>"},{"location":"zip_contents/MBE3_sum_Yiru/","title":"Contents of MBE3_sum_Yiru.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>MBE3_sum/MBE CRISPR screen disease gene factor.md</li> <li>MBE3_sum/MBE CRISPR_screen_drug_resistence.md</li> <li>MBE3_sum/MBE Chromosome structure detection.md</li> <li>MBE3_sum/MBE DNA assessment.md</li> <li>MBE3_sum/MBE Epigenetic sequencing.md</li> <li>MBE3_sum/MBE Epigenome Engineering Discussion.md</li> <li>MBE3_sum/MBE Gene editing.md</li> <li>MBE3_sum/MBE Gene expression analysis technologies.md</li> <li>MBE3_sum/MBE Protein assessment.md</li> <li>MBE3_sum/MBE Protein-DNA interaction.md</li> <li>MBE3_sum/MBE RNA assessment.md</li> <li>MBE3_sum/MBE RNA editing-based RNA-seq.md</li> <li>MBE3_sum/MBE RNA-seq.md</li> <li>MBE3_sum/MBE mRNA visualization and analysis technologies.md</li> <li>MBE3_sum/index.md</li> </ul>"},{"location":"zip_contents/MBE_lxrwyalxf/","title":"Contents of MBE_lxrwyalxf.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>MBE/Key points - tp lxr.docx</li> <li>MBE/Key points-\u7b80\u5316\u7248\u5173\u952e\u4fe1\u606f.docx</li> <li>MBE/Techniques\u6574\u7406-lxr.docx</li> <li>MBE/\u8bfe\u4e0aSAQ.docx</li> </ul>"},{"location":"zip_contents/PoN3_full_Yiru/","title":"Contents of PoN3_full_Yiru.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>PoN3_full/1.1 Introduction and Refresh.md</li> <li>PoN3_full/1.2 Presynaptic release.md</li> <li>PoN3_full/10.1, 2 Neurodegenerative disease.md</li> <li>PoN3_full/10.2 Neurodegeneration disease- Parkinson's disease and Prion disease.md</li> <li>PoN3_full/12.1 Brain and spinal cord of movement control.md</li> <li>PoN3_full/13.2 Social neuroscience- Theory of mid, empathy, mirror neurons and aggression.md</li> <li>PoN3_full/2.1 Long- term plasticity.md</li> <li>PoN3_full/2.2 Synaptic plasticity.md</li> <li>PoN3_full/3.1 GABAergic inhibitory function.md</li> <li>PoN3_full/3.2 Interneuron Diversity.md</li> <li>PoN3_full/4.2 Learning and memory.md</li> <li>PoN3_full/5.1 Attention and emotion.md</li> <li>PoN3_full/6.1 Rewards, punishment, reinforcement learning.md</li> <li>PoN3_full/6.2 Schemas and decision making.md</li> <li>PoN3_full/7.1 Neuroimaging.md</li> <li>PoN3_full/7.2 Mood, habits, and addiction.md</li> <li>PoN3_full/final_exam/.DS_Store</li> <li>PoN3_full/final_exam/Experiments Summary.md</li> <li>PoN3_full/final_exam/Overall review.md</li> <li>PoN3_full/final_exam/index.md</li> <li>PoN3_full/index.md</li> </ul>"},{"location":"zip_contents/pon/","title":"Contents of pon.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>pon/pon angelica.pdf</li> <li>pon/pon gedi.pdf</li> <li>pon/pon\u7b14\u8bb0.pdf</li> <li>pon/theme NDD.pdf</li> </ul>"},{"location":"zip_contents/pon%E5%A4%8D%E4%B9%A0%E8%B5%84%E6%96%99_lxrwyqlxf/","title":"Contents of pon\u590d\u4e60\u8d44\u6599_lxrwyqlxf.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>pon\u590d\u4e60\u8d44\u6599/1.1 Neuroscience.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/1.2 Presynaptic Release.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/10.1 10.2+13.1  Neuronal Diseases.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/11.1 visual system.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/12.1 Spinal and brain mechanisms ofmovement control.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/12.1 movement control.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/13.2 Social Neuroscience.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/2.1 Expression Mechanisms of Long-Term Plasticity.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/2.2 Plasticity_and_Learning_Summary.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/2.2 Synaptic Plasticity and Learning in the Brain.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/3.1 Inhibitory Function.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/3.1Inhibitory_Function_Lecture_Summary.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/3.2.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/4.1 Learning and Memory.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/4.2.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/5.1 Attention and Emotion.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/6.1 6.2.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/7.1 Neuroimaging.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/7.2 Mood, Habits and Addiction.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/8.1 Critical period plasticity.pptx</li> <li>pon\u590d\u4e60\u8d44\u6599/8.1 Critical periods.pdf</li> <li>pon\u590d\u4e60\u8d44\u6599/8.1 Critical_Periods.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/8.2 NeurodevelopmentalDisorders.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/9.1 Inhibitory dysfunction in schizophrenia and epilepsy.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/pon\u75be\u75c5.docx</li> </ul>"},{"location":"zip_contents/%E6%80%9D%E7%BB%B4%E5%AF%BC%E5%9B%BEIFBS_lxr/","title":"Contents of \u601d\u7ef4\u5bfc\u56feIFBS_lxr.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.12-1.16 Urinary System.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.2-1.3 The heart.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.4 Blood Pressure.pdf</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.5 control of blood flow.pdf</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.6 1.7 Fluid balance and cardiovascular function.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.8 Haemostasis.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.9-1.11 Lung.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.1-2.3+\u6700\u540e\u4e00\u8282.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.10 2.12\u8fd0\u52a8l\u9aa8\u9abc\u808c\u8089\u7cfb\u7edf.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.11smooth muscle.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.4-2.5 The integumentarysystem(1).xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.4-2.5 The integumentarysystem.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.6 Calcium and phosphate handling in the kidney.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.7-2.8 bone structure, composition, function, remodeling.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.9 Skeletal Muscle.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/\u5012\u6570\u7b2c\u4e8c\u8282 \u9499\u78f7disorder.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.1 Glucose metabolism and Energy balance.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.10 Absorption of fluid electrolytes vitamins and iron.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.13 Skeletal muscle metabolism.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.14-3.16 Energy homeostasis.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.3 stomach.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.4 Small intestine .xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.5-6liver.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.7-3.9 Digestion and Absorption of lipid, proteins, and CHO.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme4/4.2-4.4 HPO axis and prolactin.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme4/4.5-4.6 4.8 4.11 homeostasis and HPA axis.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme4/4.7 4.10 4.12 System functions.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme4/4.9 4.13 GIT adaptations.xmind</li> </ul>"},{"location":"zip_contents/Xiaoran_etal/BG%E5%AF%BC%E5%9B%BE%E5%90%88%E9%9B%86_lxrwyqlxf/","title":"Contents of BG\u5bfc\u56fe\u5408\u96c6_lxrwyqlxf.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>\u2561\u255d\u2550\u255d/1 Genetic variation.pdf</li> <li>\u2561\u255d\u2550\u255d/1 Genetic variation.xmind</li> <li>\u2561\u255d\u2550\u255d/10 Developmental Genetics.pdf</li> <li>\u2561\u255d\u2550\u255d/10 Developmental Genetics.xmind</li> <li>\u2561\u255d\u2550\u255d/11  Study Gene Function and Model Human Diseases in Post-Genome Era.xmind</li> <li>\u2561\u255d\u2550\u255d/11 Study Gene Function and Model Human Diseases in Post-Genome Era.pdf</li> <li>\u2561\u255d\u2550\u255d/12 Genetic Testing.pdf</li> <li>\u2561\u255d\u2550\u255d/12 Genetic Testing.xmind</li> <li>\u2561\u255d\u2550\u255d/13 Genetic testing and risk assessment for complex diseases.pdf</li> <li>\u2561\u255d\u2550\u255d/13 Genetic testing and risk assessment for complex diseases.xmind</li> <li>\u2561\u255d\u2550\u255d/14 Genetic Treatment Approaches &amp; Gene Therapy.pdf</li> <li>\u2561\u255d\u2550\u255d/14 Genetic Treatment Approaches &amp; Gene Therapy.xmind</li> <li>\u2561\u255d\u2550\u255d/2 patterns of inheritance.pdf</li> <li>\u2561\u255d\u2550\u255d/3 Maternal inheritance and mitochondrial disease.pdf</li> <li>\u2561\u255d\u2550\u255d/3 Maternal inheritance and mitochondrial disease.xmind</li> <li>\u2561\u255d\u2550\u255d/4 Multifactorial Diseases.pdf</li> <li>\u2561\u255d\u2550\u255d/5 Cell Division and Chromosomes.pdf</li> <li>\u2561\u255d\u2550\u255d/5 Cell Division and Chromosomes.xmind</li> <li>\u2561\u255d\u2550\u255d/6 The Human Genome.xmind</li> <li>\u2561\u255d\u2550\u255d/7  Population genetics.xmind</li> <li>\u2561\u255d\u2550\u255d/8 Cancer Genetics and Genomics.pdf</li> <li>\u2561\u255d\u2550\u255d/8 Cancer Genetics and Genomics.xmind</li> <li>\u2561\u255d\u2550\u255d/9 Sequencing techniques and discovery.pdf</li> <li>\u2561\u255d\u2550\u255d/9 Sequencing techniques and discovery.xmind</li> </ul>"},{"location":"zip_contents/Xiaoran_etal/IN_lxfwyqlxr/","title":"Contents of IN_lxfwyqlxr.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>in/1.1 1.2 Epidemiology.xmind</li> <li>in/2.1 Candida spp..xmind</li> <li>in/2.2 Cryptococcus neoformans.xmind</li> <li>in/2.3 Antifungal Resistance \u2013 A global threat.xmind</li> <li>in/3.1 3.2 3.3 Virulence mechanisms and immune evasion(1).xmind</li> <li>in/3.1-3.3Virulence mechanisms and immune evasion.xmind</li> <li>in/4.1 respiratory viruses.docx</li> <li>in/4.1 respiratory viruses.pdf</li> <li>in/4.2 Gastrointestinal viruses.xmind</li> <li>in/4.3 5.1 5.2.docx</li> <li>in/4.3 Herpesviruses-\u6a2a.pdf</li> <li>in/4.3 Herpesviruses.pdf</li> <li>in/5.1 Innate_Immune_Control_of_Viruses_Review.docx</li> <li>in/5.1 innate immune system.pdf</li> <li>in/5.2 vaccines.pdf</li> <li>in/5.3 antiviral drugs.pdf</li> <li>in/6.1 HIV.xmind</li> <li>in/6.2 Viral Hepatitis.docx</li> <li>in/6.2 Viral Hepatitis.pdf</li> <li>in/6.3 emerging viruses.pdf</li> <li>in/7.1 Arboviruses.xmind</li> <li>in/7.2 Viral Vectors and Gene Therapy.xmind</li> <li>in/7.3.docx</li> <li>in/8.1-11.3.docx</li> <li>in/8.1-8.3.docx</li> <li>in/Bacteria.xmind</li> <li>in/Fungal Infection.xmind</li> <li>in/IN_\u8003\u524d\u8bb0\u5fc6.docx</li> <li>in/Practical.xmind</li> <li>in/\u590d\u5236\u5468\u671f.docx</li> <li>in/\u75b1\u75b9\u75c5\u6bd2\u590d\u4e60\u8d44\u6599.docx</li> <li>in/\u75c5\u6bd2.pdf</li> <li>in/\u75c5\u6bd2\u6574\u7406.pdf</li> </ul>"},{"location":"zip_contents/Xiaoran_etal/MBE_lxrwyalxf/","title":"Contents of MBE_lxrwyalxf.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>MBE/Key points - tp lxr.docx</li> <li>MBE/Key points-\u7b80\u5316\u7248\u5173\u952e\u4fe1\u606f.docx</li> <li>MBE/Techniques\u6574\u7406-lxr.docx</li> <li>MBE/\u8bfe\u4e0aSAQ.docx</li> </ul>"},{"location":"zip_contents/Xiaoran_etal/pon%E5%A4%8D%E4%B9%A0%E8%B5%84%E6%96%99_lxrwyqlxf/","title":"Contents of pon\u590d\u4e60\u8d44\u6599_lxrwyqlxf.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>pon\u590d\u4e60\u8d44\u6599/1.1 Neuroscience.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/1.2 Presynaptic Release.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/10.1 10.2+13.1  Neuronal Diseases.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/11.1 visual system.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/12.1 Spinal and brain mechanisms ofmovement control.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/12.1 movement control.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/13.2 Social Neuroscience.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/2.1 Expression Mechanisms of Long-Term Plasticity.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/2.2 Plasticity_and_Learning_Summary.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/2.2 Synaptic Plasticity and Learning in the Brain.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/3.1 Inhibitory Function.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/3.1Inhibitory_Function_Lecture_Summary.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/3.2.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/4.1 Learning and Memory.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/4.2.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/5.1 Attention and Emotion.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/6.1 6.2.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/7.1 Neuroimaging.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/7.2 Mood, Habits and Addiction.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/8.1 Critical period plasticity.pptx</li> <li>pon\u590d\u4e60\u8d44\u6599/8.1 Critical periods.pdf</li> <li>pon\u590d\u4e60\u8d44\u6599/8.1 Critical_Periods.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/8.2 NeurodevelopmentalDisorders.xmind</li> <li>pon\u590d\u4e60\u8d44\u6599/9.1 Inhibitory dysfunction in schizophrenia and epilepsy.docx</li> <li>pon\u590d\u4e60\u8d44\u6599/pon\u75be\u75c5.docx</li> </ul>"},{"location":"zip_contents/Xiaoran_etal/%E6%80%9D%E7%BB%B4%E5%AF%BC%E5%9B%BEIFBS/","title":"Contents of \u601d\u7ef4\u5bfc\u56feIFBS.zip","text":"<p>Download: hosted externally (see the Google Drive folder linked from Zips Index).</p> <ul> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.12-1.16 Urinary System.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.2-1.3 The heart.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.4 Blood Pressure.pdf</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.5 control of blood flow.pdf</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.6 1.7 Fluid balance and cardiovascular function.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.8 Haemostasis.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme1/1.9-1.11 Lung.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.1-2.3+\u6700\u540e\u4e00\u8282.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.10 2.12\u8fd0\u52a8l\u9aa8\u9abc\u808c\u8089\u7cfb\u7edf.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.11smooth muscle.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.4-2.5 The integumentarysystem(1).xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.4-2.5 The integumentarysystem.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.6 Calcium and phosphate handling in the kidney.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.7-2.8 bone structure, composition, function, remodeling.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/2.9 Skeletal Muscle.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme2/\u5012\u6570\u7b2c\u4e8c\u8282 \u9499\u78f7disorder.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.1 Glucose metabolism and Energy balance.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.10 Absorption of fluid electrolytes vitamins and iron.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.13 Skeletal muscle metabolism.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.14-3.16 Energy homeostasis.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.3 stomach.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.4 Small intestine .xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.5-6liver.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme3/3.7-3.9 Digestion and Absorption of lipid, proteins, and CHO.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme4/4.2-4.4 HPO axis and prolactin.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme4/4.5-4.6 4.8 4.11 homeostasis and HPA axis.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme4/4.7 4.10 4.12 System functions.xmind</li> <li>\u601d\u7ef4\u5bfc\u56feIFBS/theme4/4.9 4.13 GIT adaptations.xmind</li> </ul>"}]}